Seleigline	O
-	O
idnuced	O
posutral	B-Disease
hypotnesion	I-Disease
in	O
Parknison	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
:	O
a	O
lonigtudinal	O
sutdy	O
on	O
the	O
effects	O
of	O
durg	O
withdraawl	O
.	O

OBJECTVIES	O
:	O
The	O
Unietd	O
Knigdom	O
Prakinson	B-Disease
'	I-Disease
s	I-Disease
Diesase	I-Disease
Reserach	O
Gorup	O
(	O
UKDPRG	O
)	O
tiral	O
found	O
an	O
icnreased	O
mrotality	O
in	O
pateints	O
with	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
(	O
PD	B-Disease
)	O
randomiezd	O
to	O
receive	O
10	O
mg	O
seleigline	O
per	O
day	O
and	O
L	O
-	O
dpoa	O
comapred	O
with	O
those	O
taking	O
L	O
-	O
dpoa	O
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
tehrapy	O
with	O
sleegiline	O
and	O
L	O
-	O
dpoa	O
was	O
associated	O
with	O
selective	O
ssytolic	B-Disease
otrhostatic	I-Disease
hyptoension	I-Disease
which	O
was	O
abolished	O
by	O
withdarwal	O
of	O
sleegiline	O
.	O

This	O
unwanted	O
effcet	O
on	O
postuarl	O
blood	O
perssure	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autonmoic	O
faiulre	O
.	O

The	O
aims	O
of	O
this	O
stduy	O
were	O
to	O
confirm	O
our	O
previous	O
findnigs	O
in	O
a	O
separate	O
cohrot	O
of	O
patietns	O
and	O
to	O
determine	O
the	O
tmie	O
cousre	O
of	O
the	O
cardoivascular	O
consequecnes	O
of	O
stopping	O
selgeiline	O
in	O
the	O
expectaiton	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechnaisms	O
by	O
which	O
the	O
durg	O
causes	O
orthosttaic	B-Disease
hpyotension	I-Disease
.	O

METHODS	O
:	O
The	O
cardoivascular	O
repsonses	O
to	O
standnig	O
and	O
haed	O
-	O
up	O
tlit	O
were	O
studied	O
repeatedly	O
in	O
PD	B-Disease
patinets	O
receiving	O
selegliine	O
and	O
as	O
the	O
durg	O
was	O
withdrawn	O
.	O

RSEULTS	O
:	O
Haed	O
-	O
up	O
tlit	O
caused	O
ssytolic	B-Disease
orthosttaic	I-Disease
hypotensoin	I-Disease
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	B-Disease
patietns	O
on	O
seleigline	O
,	O
one	O
of	O
whom	O
lsot	O
consicousness	O
with	O
unrecordbale	O
bolod	O
perssures	O
.	O

A	O
lesser	O
dgeree	O
of	O
orthosttaic	B-Disease
hypotnesion	I-Disease
occurred	O
with	O
stnading	O
.	O

Orhtostatic	B-Disease
hpyotension	I-Disease
was	O
ameloirated	O
4	O
dyas	O
after	O
withdrwaal	O
of	O
selegiilne	O
and	O
totally	O
abolished	O
7	O
dyas	O
after	O
disconitnuation	O
of	O
the	O
durg	O
.	O

Stopping	O
selegilnie	O
also	O
significantly	O
rdeuced	B-Disease
the	I-Disease
supnie	I-Disease
systloic	I-Disease
and	I-Disease
diatsolic	I-Disease
blood	I-Disease
prsesures	I-Disease
consistent	O
with	O
a	O
previously	O
undescribed	O
spuine	O
perssor	O
aciton	O
.	O

CONCLSUION	O
:	O
This	O
stduy	O
confirms	O
our	O
previous	O
fidning	O
that	O
selegilnie	O
in	O
comibnation	O
with	O
L	O
-	O
dpoa	O
is	O
associated	O
with	O
selective	O
orthosattic	B-Disease
hypotnesion	I-Disease
.	O

The	O
possibilities	O
that	O
these	O
cardiovsacular	O
fidnings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inihbition	O
of	O
monoaimne	O
oixdase	O
or	O
of	O
amhpetamine	O
and	O
metampheatmine	O
are	O
discussed	O
.	O

Further	O
studeis	O
on	O
efefcts	O
of	O
irrigation	O
soltuions	O
on	O
rat	O
baldders	O
.	O

Further	O
sutdies	O
on	O
the	O
effcets	O
of	O
certain	O
irirgating	O
fulids	O
on	O
the	O
rat	O
bladder	O
for	O
18	O
hours	O
are	O
reported	O
.	O

The	O
resluts	O
have	O
shown	O
that	O
the	O
degradaiton	O
proudct	O
p	O
-	O
cholooraniline	O
is	O
not	O
a	O
significant	O
facotr	O
in	O
chlorhxeidine	O
-	O
diglucoante	O
associated	O
erosvie	O
cystiits	B-Disease
.	O

A	O
high	O
precentage	O
of	O
kaanmycin	O
-	O
colitsin	O
and	O
pvoidone	O
-	O
iodnie	O
irrigations	O
were	O
associated	O
with	O
erosvie	O
cysttiis	B-Disease
and	O
suggested	O
a	O
possible	O
complicatoin	O
with	O
huamn	O
usgae	O
.	O

Picloxyidne	O
irriagtions	O
appeared	O
to	O
have	O
a	O
loewr	O
inciednce	O
of	O
eorsive	O
cystiits	B-Disease
but	O
further	O
sutdies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
rceommended	O
for	O
use	O
in	O
urloogical	O
procedrues	O
.	O

Effcets	O
of	O
tertandrine	O
and	O
fnagchinoline	O
on	O
experiemntal	O
throbmosis	B-Disease
in	O
mcie	O
and	O
huamn	O
platleet	B-Disease
aggregatoin	I-Disease
.	O

Tterandrine	O
(	O
TET	O
)	O
and	O
fangchionline	O
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analgoues	O
with	O
a	O
bisebnzylisoquinoline	O
strucutre	O
.	O

The	O
present	O
sutdy	O
was	O
undertaken	O
to	O
investiagte	O
the	O
effetcs	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimetnal	O
thromboiss	B-Disease
inudced	O
by	O
collaegn	O
plus	O
epinephirne	O
(	O
EP	O
)	O
in	O
mcie	O
,	O
and	O
platleet	B-Disease
agrgegation	I-Disease
and	O
blood	B-Disease
coauglation	I-Disease
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
stduy	O
,	O
the	O
adimnistration	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mcie	O
showed	O
the	O
inhibtiion	O
of	O
trhombosis	B-Disease
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalciylic	O
aicd	O
(	O
ASA	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
poistive	O
conrtol	O
,	O
showed	O
only	O
30	O
%	O
inihbition	O
.	O

In	O
the	O
vitro	O
huamn	O
platleet	B-Disease
aggregations	I-Disease
idnuced	O
by	O
the	O
agoinsts	O
used	O
in	O
tetss	O
,	O
TET	O
and	O
FAN	O
showed	O
the	O
inhibitoins	O
dsoe	O
dependently	O
.	O

In	O
addition	O
,	O
neither	O
TET	O
nor	O
FAN	O
showed	O
any	O
antcioagulation	O
activtiies	O
in	O
the	O
mesaurement	O
of	O
the	O
acitvated	O
partail	O
thromboplasitn	O
tmie	O
(	O
ATPT	O
)	O
,	O
prothrobmin	O
tmie	O
(	O
PT	O
)	O
and	O
throbmin	O
tmie	O
(	O
TT	O
)	O
using	O
hmuan	O
-	O
ctirated	O
plamsa	O
.	O

These	O
rseults	O
suggest	O
that	O
antithrobmosis	O
of	O
TET	O
and	O
FAN	O
in	O
mcie	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antipaltelet	O
aggregatoin	O
atcivities	O
.	O

Angoiedema	B-Disease
due	O
to	O
ACE	O
inhibitros	O
:	O
common	O
and	O
iandequately	O
daignosed	O
.	O

The	O
estimaetd	O
incidecne	O
of	O
angiodeema	B-Disease
during	O
angitoensin	O
-	O
converting	O
enzmye	O
(	O
ACE	O
)	O
inhibiotr	O
treatmnet	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patinets	O
.	O

This	O
potentially	O
serious	O
advrese	O
effect	O
is	O
often	O
preceded	O
by	O
minor	O
manifesttaions	O
that	O
may	O
serve	O
as	O
a	O
wanring	O
.	O

Cocanie	O
-	O
inudced	O
mood	B-Disease
dsiorder	I-Disease
:	O
prevalnece	O
rtaes	O
and	O
psychaitric	B-Disease
sympotms	O
in	O
an	O
outaptient	O
cocanie	O
-	O
depenednt	O
sapmle	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
comprae	O
prevaelnce	O
rtaes	O
and	O
smyptom	O
pattenrs	O
of	O
DSM	O
substacne	O
-	O
inudced	O
and	O
other	O
mood	B-Disease
disroders	I-Disease
.	O

243	O
coacine	O
-	O
depenednt	O
outpateints	O
with	O
cocanie	O
-	O
indcued	O
mood	B-Disease
disodrer	I-Disease
(	O
CMID	B-Disease
)	O
,	O
other	O
mood	B-Disease
disordres	I-Disease
,	O
or	O
no	O
mood	B-Disease
disodrer	I-Disease
were	O
comapred	O
on	O
meausres	O
of	O
psychiatirc	B-Disease
sympotms	O
.	O

The	O
prevalecne	O
rtae	O
for	O
CMID	B-Disease
was	O
12	O
%	O
at	O
basleine	O
.	O

Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagnsois	O
of	O
CMID	B-Disease
did	O
not	O
substantially	O
affect	O
rtaes	O
of	O
the	O
other	O
dperessive	B-Disease
diosrders	I-Disease
.	O

Paitents	O
with	O
CMID	B-Disease
had	O
symtpom	O
sveerity	O
lveels	O
between	O
those	O
of	O
pateints	O
with	O
and	O
without	O
a	O
mood	B-Disease
disodrer	I-Disease
.	O

These	O
fidnings	O
suggest	O
some	O
valdiity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diagnoiss	O
of	O
CMID	B-Disease
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
spceification	O
and	O
repliaction	O
.	O

Efefct	O
of	O
fcuoidan	O
treatemnt	O
on	O
collaegnase	O
-	O
inudced	O
inrtacerebral	B-Disease
hemorrhage	I-Disease
in	O
rtas	O
.	O

Inflammatroy	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
barin	B-Disease
daamge	I-Disease
following	O
iscehmic	B-Disease
storke	I-Disease
.	O

Intracerebarl	B-Disease
heomrrhage	I-Disease
is	O
associated	O
with	O
more	O
inflamamtion	B-Disease
than	O
ischeimc	B-Disease
srtoke	I-Disease
.	O

We	O
tseted	O
the	O
slufated	O
polysaccahride	O
fcuoidan	O
,	O
which	O
has	O
been	O
reported	O
to	O
redcue	O
inflmamatory	O
barin	B-Disease
daamge	I-Disease
,	O
in	O
a	O
rat	O
moedl	O
of	O
intraceerbral	B-Disease
hemrorhage	I-Disease
inudced	O
by	O
injetcion	O
of	O
bacetrial	O
collagensae	O
into	O
the	O
caduate	O
nuclues	O
.	O

Rtas	O
were	O
tretaed	O
with	O
seven	O
day	O
intravenuos	O
infsuion	O
of	O
fcuoidan	O
(	O
30	O
microgarms	O
h	O
-	O
1	O
)	O
or	O
vheicle	O
.	O

The	O
hematmoa	B-Disease
was	O
asesssed	O
in	O
vivo	O
by	O
mganetic	O
resonnace	O
imagnig	O
.	O

Mtoor	O
behvaior	O
,	O
passive	O
avodiance	O
,	O
and	O
skileld	O
forelmib	O
functoin	O
were	O
tetsed	O
repeatedly	O
for	O
six	O
wekes	O
.	O

Fuciodan	O
-	O
treaetd	O
rtas	O
exhibited	O
eviednce	O
of	O
impaierd	B-Disease
blood	I-Disease
cltoting	I-Disease
and	O
hemoidlution	B-Disease
,	O
had	O
larger	O
hmeatomas	B-Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammatoin	B-Disease
in	O
the	O
vicinity	O
of	O
the	O
hmeatoma	B-Disease
after	O
three	O
dyas	O
.	O

They	O
showed	O
significantly	O
more	O
rpaid	O
imprvoement	O
of	O
mootr	O
functoin	O
in	O
the	O
first	O
week	O
following	O
hemorrhgae	B-Disease
and	O
better	O
mmeory	O
reetntion	O
in	O
the	O
passvie	O
aovidance	O
tset	O
.	O

Aucte	O
wihte	B-Disease
matter	I-Disease
eedma	I-Disease
and	O
evenutal	O
neurnoal	B-Disease
lsos	I-Disease
in	O
the	O
stritaum	O
adjcaent	O
to	O
the	O
heamtoma	B-Disease
did	O
not	O
differ	O
between	O
the	O
two	O
gorups	O
.	O

Ivnestigation	O
of	O
more	O
specific	O
atni	O
-	O
inflmamatory	O
agetns	O
and	O
hemodiluitng	O
aegnts	O
are	O
warranted	O
in	O
intracerebarl	B-Disease
hemorhrage	I-Disease
.	O

Recurarizatoin	O
in	O
the	O
reocvery	O
room	O
.	O

A	O
csae	O
of	O
recurarizaiton	O
in	O
the	O
recoevry	O
room	O
is	O
reported	O
.	O

Accumulation	O
of	O
atracuirum	O
in	O
the	O
intraveonus	O
line	O
led	O
to	O
recuarrization	O
after	O
fluhsing	O
the	O
line	O
in	O
the	O
recovrey	O
room	O
.	O

A	O
respirtaory	B-Disease
arrest	I-Disease
with	O
seevre	O
desaturtaion	B-Disease
and	O
bradycadria	B-Disease
occurred	O
.	O

Cicrumstances	O
leading	O
to	O
this	O
evnet	O
and	O
the	O
mechansims	O
enabling	O
a	O
nueromuscular	B-Disease
blockdae	I-Disease
to	O
occur	O
,	O
following	O
the	O
amdinistration	O
of	O
a	O
small	O
dsoe	O
of	O
relxaant	O
,	O
are	O
discussed	O
.	O

The	O
haemodyanmic	O
effcets	O
of	O
prpoofol	O
in	O
combinatoin	O
with	O
ephedirne	O
in	O
edlerly	O
paitents	O
(	O
ASA	O
gorups	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasoidlator	O
and	O
negatvie	O
inotorpic	O
effetcs	O
of	O
propfool	O
are	O
disadvantages	O
in	O
frial	O
eldrely	O
patietns	O
.	O

We	O
investigaetd	O
the	O
saftey	O
and	O
efficcay	O
of	O
adding	O
different	O
dsoes	O
of	O
ephedrnie	O
to	O
prpoofol	O
in	O
order	O
to	O
obutnd	O
the	O
hypotenisve	B-Disease
respnose	O
.	O

The	O
haemdoynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephderine	O
to	O
200	O
mg	O
of	O
propfool	O
were	O
compraed	O
to	O
conrtol	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patietns	O
over	O
60	O
yaers	O
persenting	O
for	O
gneito	O
-	O
urianry	O
sugrery	O
.	O

The	O
addition	O
of	O
epherdine	O
to	O
porpofol	O
appears	O
to	O
be	O
an	O
effcetive	O
metohd	O
of	O
obutnding	O
the	O
hpyotensive	B-Disease
rseponse	O
to	O
propoofl	O
at	O
all	O
dsoes	O
used	O
in	O
this	O
stduy	O
.	O

However	O
,	O
marked	O
tachycadria	B-Disease
associated	O
with	O
the	O
use	O
of	O
epherdine	O
in	O
cmobination	O
with	O
propfool	O
occurred	O
in	O
the	O
majority	O
of	O
ptaients	O
,	O
occasionally	O
reaching	O
high	O
leevls	O
in	O
inidvidual	O
patinets	O
.	O

Due	O
to	O
the	O
rsik	O
of	O
this	O
tcahycardia	B-Disease
inudcing	O
myocradial	B-Disease
ischeima	I-Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
eledrly	O
pateints	O
of	O
any	O
of	O
the	O
epehdrine	O
/	O
prpoofol	O
/	O
mixtuers	O
studied	O
.	O

Gemictabine	O
plus	O
vinorebline	O
in	O
nosnmall	B-Disease
clel	I-Disease
lnug	I-Disease
carcinmoa	I-Disease
patinets	O
age	O
70	O
yaers	O
or	O
odler	O
or	O
patietns	O
who	O
cannot	O
receive	O
csiplatin	O
.	O

Oncoapz	O
Coopeartive	O
Gruop	O
.	O

BACKGRONUD	O
:	O
Although	O
the	O
prevlaence	O
of	O
nonsmlal	B-Disease
clel	I-Disease
lnug	I-Disease
carcnioma	I-Disease
(	O
NSLCC	B-Disease
)	O
is	O
high	O
among	O
edlerly	O
pateints	O
,	O
few	O
dtaa	O
are	O
available	O
regarding	O
the	O
efifcacy	O
and	O
toxiicty	B-Disease
of	O
cheomtherapy	O
in	O
this	O
gruop	O
of	O
patietns	O
.	O

Recent	O
reprots	O
indicate	O
that	O
single	O
aegnt	O
tehrapy	O
with	O
vniorelbine	O
(	O
VNB	O
)	O
or	O
gemictabine	O
(	O
GEM	O
)	O
may	O
obtain	O
a	O
respnose	O
rtae	O
of	O
20	O
-	O
30	O
%	O
in	O
eldelry	O
patinets	O
,	O
with	O
accepatble	O
toxciity	B-Disease
and	O
imrpovement	O
in	O
symptmos	O
and	O
quailty	O
of	O
lfie	O
.	O

In	O
the	O
current	O
stduy	O
the	O
efficcay	O
and	O
toxictiy	B-Disease
of	O
the	O
combiantion	O
of	O
GEM	O
and	O
VNB	O
in	O
edlerly	O
ptaients	O
with	O
adavnced	O
NCSLC	B-Disease
or	O
those	O
with	O
some	O
contraindciation	O
to	O
receiving	O
cisplaitn	O
were	O
asssesed	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
paitents	O
with	O
advacned	O
NSLCC	B-Disease
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
yeras	O
and	O
11	O
were	O
age	O
<	O
70	O
yaers	O
but	O
who	O
had	O
some	O
contraindicaiton	O
to	O
receiving	O
cisplaitn	O
.	O

All	O
patinets	O
were	O
evalauble	O
for	O
resopnse	O
and	O
toxiicty	B-Disease
.	O

Teratment	O
was	O
comprised	O
of	O
VNB	O
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	O
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Dyas	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
dyas	O
.	O

Patietns	O
received	O
a	O
minimum	O
of	O
three	O
coruses	O
unless	O
progressive	O
dsiease	O
was	O
detceted	O
.	O

RESLUTS	O
:	O
One	O
hundred	O
sixty	O
-	O
five	O
cousres	O
were	O
adminsitered	O
,	O
with	O
a	O
mdeian	O
of	O
3	O
.	O

6	O
cuorses	O
per	O
paitent	O
.	O

The	O
overall	O
respnose	O
rtae	O
was	O
26	O
%	O
(	O
95	O
%	O
confdience	O
itnerval	O
,	O
15	O
-	O
41	O
%	O
)	O
.	O

Two	O
pateints	O
attained	O
a	O
complete	O
resopnse	O
(	O
4	O
%	O
)	O
and	O
11	O
pateints	O
(	O
22	O
%	O
)	O
achieved	O
a	O
partail	O
resposne	O
.	O

Eastren	O
Cooperatvie	O
Oncoolgy	O
Gorup	O
preformance	O
stauts	O
imprvoed	O
in	O
35	O
%	O
of	O
those	O
paitents	O
with	O
an	O
initial	O
value	O
>	O
0	O
,	O
whereas	O
releif	O
of	O
at	O
least	O
1	O
sypmtom	O
without	O
woresning	O
of	O
other	O
sympotms	O
was	O
noted	O
in	O
27	O
patietns	O
(	O
55	O
%	O
)	O
.	O

The	O
medain	O
tmie	O
to	O
progresison	O
was	O
16	O
weeks	O
and	O
the	O
1	O
-	O
yaer	O
surviavl	O
rtae	O
was	O
33	O
%	O
.	O

Txoicity	B-Disease
was	O
mlid	O
.	O

Six	O
ptaients	O
(	O
12	O
%	O
)	O
had	O
Wolrd	O
Helath	O
Organziation	O
Grdae	O
3	O
-	O
4	O
neutorpenia	B-Disease
,	O
2	O
paitents	O
(	O
4	O
%	O
)	O
had	O
Garde	O
3	O
-	O
4	O
thromboyctopenia	B-Disease
,	O
and	O
2	O
paitents	O
(	O
4	O
%	O
)	O
had	O
Grdae	O
3	O
neurtooxicity	B-Disease
.	O

Three	O
patinets	O
with	O
seevre	O
nuetropenia	B-Disease
(	O
6	O
%	O
)	O
deid	O
of	O
sepiss	B-Disease
.	O

The	O
meidan	O
age	O
of	O
those	O
pateints	O
developing	O
Grdae	O
3	O
-	O
4	O
neurtopenia	B-Disease
was	O
significantly	O
hgiher	O
than	O
that	O
of	O
the	O
remaining	O
patinets	O
(	O
75	O
yaers	O
vs	O
.	O
72	O
yaers	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

CNOCLUSIONS	O
:	O
The	O
combintaion	O
of	O
GEM	O
and	O
VNB	O
is	O
modeartely	O
acitve	O
and	O
well	O
tolearted	O
except	O
in	O
pateints	O
age	O
>	O
/	O
=	O
75	O
yeras	O
.	O

This	O
age	O
gorup	O
had	O
an	O
incresaed	O
rsik	O
of	O
myelousppression	B-Disease
.	O

Therefore	O
the	O
prpohylactic	O
use	O
of	O
garnulocyte	O
-	O
colnoy	O
stimulaitng	O
fatcor	O
should	O
be	O
considered	O
with	O
this	O
treatmnet	O
.	O

New	O
chemotherpay	O
combintaions	O
with	O
higehr	O
actviity	O
and	O
lwoer	O
toxictiy	B-Disease
are	O
needed	O
for	O
eldelry	O
ptaients	O
with	O
advanecd	O
NSLCC	B-Disease
.	O

A	O
selective	O
dopaimne	O
D4	O
rceeptor	O
antagoinst	O
,	O
NRA0160	O
:	O
a	O
perclinical	O
neuropharmacolgoical	O
proifle	O
.	O

NRA0160	O
,	O
5	O
-	O
[	O
2	O
-	O
(	O
4	O
-	O
(	O
3	O
-	O
fulorobenzylidene	O
)	O
ppieridin	O
-	O
1	O
-	O
yl	O
)	O
ehtyl	O
]	O
-	O
4	O
-	O
(	O
4	O
-	O
fluoropehnyl	O
)	O
thizaole	O
-	O
2	O
-	O
carboaxmide	O
,	O
has	O
a	O
high	O
affiinty	O
for	O
huamn	O
colned	O
doapmine	O
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
recetpors	O
,	O
with	O
Ki	O
valeus	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	O
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
dopamnie	O
D4	O
.	O
2	O
recepotr	O
copmared	O
with	O
the	O
huamn	O
colned	O
dopaimne	O
D2L	O
recepotr	O
.	O

NRA0160	O
has	O
negligbile	O
affiinty	O
for	O
the	O
hmuan	O
cloend	O
dopamnie	O
D3	O
recepotr	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotnoin	O
(	O
5	O
-	O
HT	O
)	O
2A	O
receptros	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alhpa1	O
adrenocetpor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
and	O
colzapine	O
atnagonized	O
locomtoor	O
hyperactviity	B-Disease
idnuced	O
by	O
methamphteamine	O
(	O
MAP	O
)	O
in	O
mcie	O
.	O

NRA0160	O
and	O
clozapnie	O
antgaonized	O
MAP	O
-	O
idnuced	O
stereoytped	O
beahvior	O
in	O
mcie	O
,	O
although	O
their	O
efefcts	O
did	O
not	O
exceed	O
50	O
%	O
inhibitoin	O
,	O
even	O
at	O
the	O
highest	O
dsoe	O
given	O
.	O

NRA0160	O
and	O
cloazpine	O
significantly	O
induecd	O
catlaepsy	B-Disease
in	O
rtas	O
,	O
although	O
their	O
effcets	O
did	O
not	O
exceed	O
50	O
%	O
induciton	O
even	O
at	O
the	O
highest	O
dsoe	O
given	O
.	O

NRA0160	O
and	O
clozaipne	O
significantly	O
rveersed	O
the	O
dirsuption	O
of	O
perpulse	O
ihnibition	O
(	O
PPI	O
)	O
in	O
rtas	O
produced	O
by	O
apomorphnie	O
.	O

NRA0160	O
and	O
clozapnie	O
significantly	O
shotrened	O
the	O
pehncyclidine	O
(	O
PCP	O
)	O
-	O
induecd	O
prolonegd	O
siwmming	O
ltaency	O
in	O
rtas	O
in	O
a	O
waetr	O
mzae	O
tsak	O
.	O

These	O
finidngs	O
suggest	O
that	O
NRA0160	O
may	O
have	O
unqiue	O
antipsyhcotic	O
activiites	O
without	O
the	O
libaility	O
of	O
mtoor	O
side	O
effects	O
typical	O
of	O
classical	O
atnipsychotics	O
.	O

Wrafarin	O
-	O
inudced	O
aretry	B-Disease
caclification	I-Disease
is	O
accelreated	O
by	O
gorwth	O
and	O
viatmin	O
D	O
.	O

The	O
present	O
sutdies	O
demonstrate	O
that	O
gorwth	O
and	O
vitmain	O
D	O
treatmnet	O
enhacne	O
the	O
extent	O
of	O
artrey	B-Disease
caclification	I-Disease
in	O
rtas	O
given	O
sufficient	O
doess	O
of	O
Wrafarin	O
to	O
inhbiit	O
gmama	O
-	O
carobxylation	O
of	O
martix	O
Gla	O
prtoein	O
,	O
a	O
calcifiaction	B-Disease
inhibiotr	O
known	O
to	O
be	O
expresesd	O
by	O
smooth	O
mucsle	O
cells	O
and	O
macrohpages	O
in	O
the	O
atrery	O
wlal	O
.	O

The	O
first	O
series	O
of	O
experimnets	O
examined	O
the	O
influnece	O
of	O
age	O
and	O
gorwth	O
sttaus	O
on	O
aretry	B-Disease
calcifiaction	I-Disease
in	O
Warfairn	O
-	O
terated	O
rtas	O
.	O

Treatmnet	O
for	O
2	O
wekes	O
with	O
Warfairn	O
caused	O
massive	O
fcoal	O
calicfication	B-Disease
of	I-Disease
the	I-Disease
atrery	I-Disease
meida	O
in	O
20	O
-	O
day	O
-	O
old	O
rtas	O
and	O
less	O
exetnsive	O
foacl	O
calcifictaion	B-Disease
in	O
42	O
-	O
day	O
-	O
old	O
rtas	O
.	O

In	O
contrast	O
,	O
no	O
artrey	B-Disease
caclification	I-Disease
could	O
be	O
dteected	O
in	O
10	O
-	O
motnh	O
-	O
old	O
audlt	O
rtas	O
even	O
after	O
4	O
wekes	O
of	O
Wafrarin	O
treamtent	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
grwoth	O
to	O
Warfairn	O
-	O
idnuced	O
artrey	B-Disease
caclification	I-Disease
in	O
aniamls	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rtas	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
lbiitum	O
deit	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
deit	O
that	O
maintains	O
weihgt	O
but	O
prevents	O
gorwth	O
.	O

Concrurent	O
treatemnt	O
of	O
both	O
dieatry	O
gorups	O
with	O
Warfrain	O
produced	O
massive	O
fcoal	O
calciifcation	B-Disease
of	I-Disease
the	I-Disease
artrey	I-Disease
meida	O
in	O
the	O
ad	O
liibtum	O
-	O
fed	O
rtas	O
but	O
no	O
deetctable	O
aretry	B-Disease
clacification	I-Disease
in	O
the	O
restricted	O
-	O
deit	O
,	O
grwoth	O
-	O
inhbiited	O
gorup	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
associatoin	O
between	O
atrery	B-Disease
clacification	I-Disease
and	O
grotwh	O
sattus	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
stduy	O
,	O
there	O
was	O
a	O
reltaionship	O
between	O
hgiher	O
seurm	O
phospahte	O
and	O
susecptibility	O
to	O
artrey	B-Disease
calcifiaction	I-Disease
,	O
with	O
30	O
%	O
higehr	O
levles	O
of	O
sreum	O
phopshate	O
in	O
yuong	O
,	O
ad	O
libiutm	O
-	O
fed	O
rtas	O
comapred	O
with	O
either	O
of	O
the	O
gropus	O
that	O
was	O
reisstant	O
to	O
Warfairn	O
-	O
idnuced	O
aretry	B-Disease
calcifiaction	I-Disease
,	O
ie	O
,	O
the	O
10	O
-	O
motnh	O
-	O
old	O
rtas	O
and	O
the	O
restricted	O
-	O
deit	O
,	O
grotwh	O
-	O
inhiibted	O
yuong	O
rtas	O
.	O

This	O
obsevration	O
suggests	O
that	O
increaesd	O
suscetpibility	O
to	O
Wrafarin	O
-	O
induecd	O
artrey	B-Disease
clacification	I-Disease
could	O
be	O
related	O
to	O
hihger	O
sreum	O
phsophate	O
lveels	O
.	O

The	O
second	O
set	O
of	O
experiemnts	O
examined	O
the	O
possible	O
snyergy	O
between	O
vitmain	O
D	O
and	O
Wrafarin	O
in	O
artrey	B-Disease
calicfication	I-Disease
.	O

High	O
doess	O
of	O
vtiamin	O
D	O
are	O
known	O
to	O
cause	O
caclification	B-Disease
of	I-Disease
the	I-Disease
artrey	I-Disease
meida	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
dyas	O
.	O

High	O
dsoes	O
of	O
the	O
vitaimn	O
K	O
antgaonist	O
Warfairn	O
are	O
also	O
known	O
to	O
cause	O
calicfication	B-Disease
of	I-Disease
the	I-Disease
aretry	I-Disease
mdeia	O
,	O
but	O
at	O
treatmnet	O
times	O
of	O
2	O
wekes	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

In	O
the	O
current	O
stduy	O
,	O
we	O
investigaetd	O
the	O
synegry	O
between	O
these	O
2	O
treatmnets	O
and	O
found	O
that	O
concrurent	O
Wrafarin	O
adimnistration	O
dramatically	O
inrceased	O
the	O
extent	O
of	O
calcifciation	B-Disease
in	O
the	O
meida	O
of	O
vitaimn	O
D	O
-	O
treaetd	O
rtas	O
at	O
3	O
and	O
4	O
dyas	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
viatmin	O
D	O
dsoe	O
on	O
atrery	B-Disease
calcifciation	I-Disease
and	O
the	O
effcet	O
of	O
vitaimn	O
D	O
dsoe	O
on	O
the	O
eleavtion	O
of	O
sreum	O
calicum	O
,	O
which	O
suggests	O
that	O
vtiamin	O
D	O
may	O
inudce	O
aretry	B-Disease
calciifcation	I-Disease
through	O
its	O
effect	O
on	O
seurm	O
calicum	O
.	O

Because	O
Warfairn	O
traetment	O
had	O
no	O
effcet	O
on	O
the	O
eleavtion	O
in	O
seurm	O
calicum	O
produced	O
by	O
vtiamin	O
D	O
,	O
the	O
synegry	O
between	O
Warafrin	O
and	O
vtiamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hpyothesis	O
that	O
Warfrain	O
inhibtis	O
the	O
atcivity	O
of	O
mtarix	O
Gla	O
portein	O
as	O
a	O
calcifiaction	B-Disease
inhibiotr	O
.	O

High	O
lveels	O
of	O
matirx	O
Gla	O
protien	O
are	O
found	O
at	O
siets	O
of	O
atrery	B-Disease
caclification	I-Disease
in	O
rtas	O
tretaed	O
with	O
vitmain	O
D	O
plus	O
Warafrin	O
,	O
and	O
chmeical	O
anaylsis	O
showed	O
that	O
the	O
proetin	O
that	O
accumulated	O
was	O
indeed	O
not	O
gmama	O
-	O
carboyxlated	O
.	O

These	O
obseravtions	O
indicate	O
that	O
although	O
the	O
gamma	O
-	O
carboxyglutaamte	O
rseidues	O
of	O
martix	O
Gla	O
protien	O
are	O
apparently	O
required	O
for	O
its	O
funciton	O
as	O
a	O
calcifiaction	B-Disease
inhiibtor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulaiton	O
at	O
calciifcation	B-Disease
siets	O
.	O

Tset	O
codnitions	O
inlfuence	O
the	O
repsonse	O
to	O
a	O
durg	O
challenge	O
in	O
roednts	O
.	O

These	O
sutdies	O
were	O
conducted	O
to	O
examine	O
the	O
differetnial	O
rseponse	O
to	O
a	O
durg	O
challenge	O
under	O
varied	O
experimenatl	O
tset	O
conditinos	O
routinely	O
employed	O
to	O
stduy	O
durg	O
-	O
idnuced	O
behavioarl	O
and	O
neurophysiologcial	O
rseponses	O
in	O
rdoents	O
.	O

Apomrophine	O
,	O
a	O
nonselective	O
doapmine	O
agonsit	O
,	O
was	O
selected	O
due	O
to	O
its	O
bpihasic	O
beahvioral	O
efefcts	O
,	O
its	O
ability	O
to	O
idnuce	O
hypothremia	B-Disease
,	O
and	O
to	O
produce	O
distinct	O
chagnes	O
to	O
dpoamine	O
turonver	O
in	O
the	O
rdoent	O
barin	O
.	O

From	O
such	O
experimnets	O
there	O
is	O
eivdence	O
that	O
charactreization	O
and	O
deetction	O
of	O
apomorhpine	O
-	O
induecd	O
atcivity	O
in	O
rdoents	O
critically	O
depends	O
upon	O
the	O
tset	O
condiitons	O
employed	O
.	O

In	O
rtas	O
,	O
deetction	O
of	O
apmoorphine	O
-	O
idnuced	O
hyepractivity	B-Disease
was	O
facilitated	O
by	O
a	O
peirod	O
of	O
acclimatization	O
to	O
the	O
tset	O
condtiions	O
.	O

Moreover	O
,	O
tset	O
conidtions	O
can	O
imapct	O
upon	O
other	O
physiologcial	O
rseponses	O
to	O
apoomrphine	O
such	O
as	O
durg	O
-	O
indcued	O
hypothremia	B-Disease
.	O

In	O
mcie	O
,	O
apomoprhine	O
produced	O
qualtiatively	O
different	O
resposnes	O
under	O
novel	O
conidtions	O
when	O
compraed	O
to	O
those	O
beahviors	O
elicited	O
in	O
the	O
hmoe	O
tset	O
cgae	O
.	O

Durg	O
-	O
idnuced	O
gorss	O
actiivty	O
coutns	O
were	O
incresaed	O
in	O
the	O
novel	O
expolratory	O
box	O
only	O
,	O
while	O
maesures	O
of	O
setreotypic	O
behaivor	O
were	O
similar	O
in	O
both	O
.	O

By	O
contrast	O
,	O
apoomrphine	O
-	O
induecd	O
locoomtion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
epxloratory	O
box	O
.	O

Dpoamine	O
turnvoer	O
rtaios	O
(	O
DPOAC	O
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lwoer	O
in	O
those	O
anmials	O
expoesd	O
to	O
the	O
exploraotry	O
box	O
when	O
cmopared	O
to	O
their	O
hmoe	O
cgae	O
counterparts	O
.	O

However	O
,	O
apomrophine	O
-	O
idnuced	O
reducitons	O
in	O
striaatl	O
dopamnie	O
tunrover	O
were	O
deetcted	O
in	O
both	O
novel	O
and	O
hmoe	O
cgae	O
enivronments	O
.	O

The	O
implications	O
of	O
these	O
findnigs	O
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
psychopharmcaological	O
challenge	O
tsets	O
in	O
rodnets	O
.	O

Hemloysis	B-Disease
of	O
huamn	O
eyrthrocytes	O
inudced	O
by	O
tmaoxifen	O
is	O
related	O
to	O
disrutpion	O
of	O
membrnae	O
srtucture	O
.	O

Tamxoifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrogeinc	O
durg	O
most	O
widely	O
prescriebd	O
in	O
the	O
cheomtherapy	O
of	O
bresat	B-Disease
canecr	I-Disease
,	O
indcues	O
chagnes	O
in	O
nromal	O
disciod	O
shpae	O
of	O
erythroyctes	O
and	O
heomlytic	B-Disease
aneima	I-Disease
.	O

This	O
work	O
evalutaes	O
the	O
efefcts	O
of	O
TAM	O
on	O
isoalted	O
hmuan	O
erythorcytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mehcanisms	O
on	O
TAM	O
-	O
inudced	O
hemoyltic	B-Disease
aneima	I-Disease
and	O
the	O
involevment	O
of	O
bimoembranes	O
in	O
its	O
cyotstatic	O
aciton	O
mechanimss	O
.	O

TAM	O
induecs	O
hemolsyis	B-Disease
of	O
eyrthrocytes	O
as	O
a	O
funciton	O
of	O
concentratoin	O
.	O

The	O
etxension	O
of	O
hemloysis	B-Disease
is	O
varaible	O
with	O
ertyhrocyte	O
sampels	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	O
induecs	O
total	O
hemoylsis	B-Disease
of	O
all	O
tesetd	O
suspnesions	O
.	O

Despite	O
induicng	O
extensvie	O
eryhtrocyte	O
lyiss	O
,	O
TAM	O
does	O
not	O
shift	O
the	O
osomtic	O
fragliity	O
curevs	O
of	O
erythrocyets	O
.	O

The	O
hemolyitc	B-Disease
effcet	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrtaions	O
of	O
aplha	O
-	O
tocpoherol	O
(	O
aplha	O
-	O
T	O
)	O
and	O
alhpa	O
-	O
tocohperol	O
aceatte	O
(	O
alhpa	O
-	O
TAc	O
)	O
(	O
inactivtaed	O
fucntional	O
hydroyxl	O
)	O
indicating	O
that	O
TAM	O
-	O
inudced	O
hmeolysis	B-Disease
is	O
not	O
related	O
to	O
oxiadtive	O
memrbane	O
daamge	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
abesnce	O
of	O
oxyegn	O
consupmtion	O
and	O
hmeoglobin	O
oxdiation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	O
-	O
induecd	O
heomlysis	B-Disease
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	O
inhbiits	O
the	O
peroxiadtion	O
of	O
hmuan	O
eyrthrocytes	O
indcued	O
by	O
APAH	O
,	O
thus	O
ruling	O
out	O
TAM	O
-	O
idnuced	O
clel	O
oxidatvie	O
srtess	O
.	O

Hemolsyis	B-Disease
caused	O
by	O
TAM	O
was	O
not	O
preceded	O
by	O
the	O
leaakge	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colliod	O
-	O
omsotic	O
tpye	O
mehcanism	O
of	O
hemolsyis	B-Disease
,	O
according	O
to	O
the	O
effects	O
on	O
osmtoic	O
frgaility	O
cruves	O
.	O

However	O
,	O
TAM	O
indcues	O
rleease	O
of	O
periphearl	O
protiens	O
of	O
memrbane	O
-	O
cyotskeleton	O
and	O
cyotsol	O
proetins	O
essentially	O
bonud	O
to	O
bnad	O
3	O
.	O

Either	O
alhpa	O
-	O
T	O
or	O
aplha	O
-	O
TAc	O
icnreases	O
membarne	O
pacikng	O
and	O
prevents	O
TAM	O
pratition	O
into	O
moedl	O
membarnes	O
.	O

These	O
effcets	O
suggest	O
that	O
the	O
portection	O
from	O
hemloysis	B-Disease
by	O
tcoopherols	O
is	O
related	O
to	O
a	O
decraesed	O
TAM	O
incoropration	O
in	O
cnodensed	O
membraens	O
and	O
the	O
sturctural	O
daamge	O
of	O
the	O
erytrhocyte	O
membrnae	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	O
-	O
induecd	O
hemolsyis	B-Disease
resluts	O
from	O
a	O
strcutural	O
perturbatoin	O
of	O
red	O
clel	O
membrnae	O
,	O
leading	O
to	O
chnages	O
in	O
the	O
frameowrk	O
of	O
the	O
erythroctye	O
membarne	O
and	O
its	O
cytosekleton	O
caused	O
by	O
its	O
high	O
partitoin	O
in	O
the	O
mebmrane	O
.	O

These	O
defetcs	O
explain	O
the	O
anbormal	O
erytrhocyte	O
shpae	O
and	O
decresaed	O
mechancial	O
satbility	O
promoted	O
by	O
TAM	O
,	O
resulting	O
in	O
hemoltyic	B-Disease
aenmia	I-Disease
.	O

Additionally	O
,	O
since	O
mmebrane	O
lekaage	O
is	O
a	O
final	O
satge	O
of	O
cytotxoicity	O
,	O
the	O
disurption	O
of	O
the	O
srtuctural	O
charactersitics	O
of	O
biomemrbanes	O
by	O
TAM	O
may	O
contribute	O
to	O
the	O
mulitple	O
mechanimss	O
of	O
its	O
anitcancer	O
actoin	O
.	O

Cahnges	O
of	O
sdoium	O
and	O
ATP	O
affniities	O
of	O
the	O
cardaic	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPsae	O
during	O
and	O
after	O
nitirc	O
oixde	O
deifcient	O
hypertenison	B-Disease
.	O

In	O
the	O
cardiovascualr	O
sysetm	O
,	O
NO	O
is	O
involved	O
in	O
the	O
regluation	O
of	O
a	O
variety	O
of	O
functoins	O
.	O

Inhiibtion	O
of	O
NO	O
sytnhesis	O
inudces	O
sustianed	O
hypertensoin	B-Disease
.	O

In	O
several	O
mdoels	O
of	O
hyperetnsion	B-Disease
,	O
eelvation	O
of	O
intracelullar	O
soidum	O
lveel	O
was	O
documenetd	O
in	O
cadriac	O
tisuse	O
.	O

To	O
assess	O
the	O
molecualr	O
basis	O
of	O
disturbacnes	O
in	O
transmembraenous	O
tranpsort	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
resopnse	O
of	O
cradiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATaPse	O
to	O
NO	O
-	O
dfeicient	O
hypetrension	B-Disease
indcued	O
in	O
rtas	O
by	O
NO	O
-	O
synhtase	O
inhibtiion	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nirto	O
-	O
L	O
-	O
argniine	O
mehtyl	O
esetr	O
(	O
L	O
-	O
NMAE	O
)	O
for	O
4	O
four	O
weeks	O
.	O

After	O
4	O
-	O
week	O
adminisrtation	O
of	O
L	O
-	O
NMAE	O
,	O
the	O
systoilc	O
blood	O
perssure	O
(	O
SBP	O
)	O
incresaed	O
by	O
36	O
%	O
.	O

Two	O
wekes	O
after	O
terminating	O
the	O
teratment	O
,	O
the	O
SBP	O
recovreed	O
to	O
conrtol	O
value	O
.	O

When	O
actviating	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPsae	O
with	O
its	O
subtsrate	O
ATP	O
,	O
no	O
cahnges	O
in	O
Km	O
and	O
Vamx	O
vaules	O
were	O
observed	O
in	O
NO	O
-	O
defciient	O
rtas	O
.	O

During	O
activatoin	O
with	O
Na	O
+	O
,	O
the	O
Vamx	O
remained	O
uncahnged	O
,	O
however	O
the	O
K	O
(	O
Na	O
)	O
icnreased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
porfound	O
dcerease	O
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
bidning	O
stie	O
in	O
NO	O
-	O
deifcient	O
rtas	O
.	O

After	O
recovrey	O
from	O
hypertesnion	B-Disease
,	O
the	O
acitvity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
APTase	O
inrceased	O
,	O
due	O
to	O
hgiher	O
affniity	O
of	O
the	O
ATP	O
-	O
binidng	O
stie	O
,	O
as	O
revaeled	O
from	O
the	O
loewred	O
Km	O
value	O
for	O
ATP	O
.	O

The	O
K	O
(	O
Na	O
)	O
value	O
for	O
Na	O
+	O
returned	O
to	O
conrtol	O
value	O
.	O

Inhiibtion	O
of	O
NO	O
-	O
snythase	O
indcued	O
a	O
reversible	O
hypertesnion	B-Disease
accompanied	O
by	O
depressed	B-Disease
Na	O
+	O
-	O
exrtusion	O
from	O
caridac	O
clels	O
as	O
a	O
consequence	O
of	O
deteroirated	O
Na	O
+	O
-	O
binidng	O
proeprties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPsae	O
.	O

After	O
reocvery	O
of	O
blood	O
pressrue	O
to	O
cnotrol	O
vlaues	O
,	O
the	O
extrusoin	O
of	O
Na	O
+	O
from	O
cardaic	O
clels	O
was	O
normalized	O
,	O
as	O
reevaled	O
by	O
restoraiton	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
APTase	O
atcivity	O
.	O

Efefcts	O
of	O
long	O
-	O
term	O
prerteatment	O
with	O
isoporterenol	O
on	O
bromocrpitine	O
-	O
indcued	O
tcahycardia	B-Disease
in	O
consicous	O
rtas	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptnie	O
-	O
indcued	O
tachyacrdia	B-Disease
,	O
which	O
persisted	O
after	O
adrenalcetomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
cnetral	O
dpoamine	O
D2	O
recetpor	O
atcivation	O
and	O
(	O
ii	O
)	O
reudced	O
by	O
5	O
-	O
day	O
isporoterenol	O
pretretament	O
,	O
supporting	O
therefore	O
the	O
hypothseis	O
that	O
this	O
efefct	O
is	O
dpeendent	O
on	O
sympathteic	O
ouftlow	O
to	O
the	O
haert	O
.	O

This	O
sutdy	O
was	O
conducted	O
to	O
examine	O
whether	O
prologned	O
pertreatment	O
with	O
iosproterenol	O
could	O
abolsih	O
bormocriptine	O
-	O
induecd	O
tacyhcardia	B-Disease
in	O
consciuos	O
rtas	O
.	O

Isoprotereonl	O
preteratment	O
for	O
15	O
dyas	O
caused	O
cardaic	B-Disease
hyeprtrophy	I-Disease
without	O
afefcting	O
baseilne	O
bolod	O
prsesure	O
and	O
haert	O
rtae	O
.	O

In	O
contorl	O
rtas	O
,	O
inrtavenous	O
bormocriptine	O
(	O
150	O
mcirog	O
/	O
kg	O
)	O
induecd	O
significant	O
hypotnesion	B-Disease
and	O
tachycadria	B-Disease
.	O

Broomcriptine	O
-	O
induecd	O
hypotesnion	B-Disease
was	O
unaffected	O
by	O
isoproteernol	O
pretraetment	O
,	O
while	O
tacyhcardia	B-Disease
was	O
reevrsed	O
to	O
significant	O
bardycardia	B-Disease
,	O
an	O
effcet	O
that	O
was	O
partly	O
reudced	O
by	O
i	O
.	O
v	O
.	O
domperiodne	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
cadriac	O
vaagl	O
nor	O
sympathteic	O
tnoe	O
was	O
altreed	O
by	O
isoprotreenol	O
preteratment	O
.	O

In	O
isoltaed	O
prefused	O
herat	O
preaprations	O
from	O
isoprtoerenol	O
-	O
prtereated	O
rtas	O
,	O
the	O
isoproetrenol	O
-	O
indcued	O
mxaimal	O
inrcease	O
in	O
lfet	O
ventrciular	O
systloic	O
pressrue	O
was	O
significantly	O
reduecd	O
,	O
cmopared	O
with	O
sailne	O
-	O
prerteated	O
rtas	O
(	O
the	O
E5C0	O
of	O
the	O
isporoterenol	O
-	O
idnuced	O
incraese	O
in	O
lfet	O
ventrciular	O
systloic	O
perssure	O
was	O
enhacned	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

These	O
resluts	O
show	O
that	O
15	O
-	O
day	O
isoprtoerenol	O
pertreatment	O
not	O
only	O
abolished	O
but	O
reveresd	O
bromocirptine	O
-	O
idnuced	O
tahcycardia	B-Disease
to	O
bradycadria	B-Disease
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cadriac	O
btea	O
-	O
adernoceptor	O
desnesitization	O
rather	O
than	O
to	O
impairemnt	O
of	O
autonoimc	O
regualtion	O
of	O
the	O
herat	O
.	O

They	O
suggest	O
that	O
,	O
in	O
nomral	O
concsious	O
rtas	O
,	O
the	O
centarl	O
tachycradia	B-Disease
of	O
brmoocriptine	O
appears	O
to	O
predominate	O
and	O
to	O
msak	O
the	O
bradycadria	B-Disease
of	O
this	O
agnoist	O
at	O
periphearl	O
dopmaine	O
D2	O
recepotrs	O
.	O

A	O
dveelopmental	O
anlaysis	O
of	O
colnidine	O
'	O
s	O
effetcs	O
on	O
cardaic	O
rtae	O
and	O
ultraosund	O
porduction	O
in	O
ifnant	O
rtas	O
.	O

Under	O
cotnrolled	O
conditinos	O
,	O
infnat	O
rtas	O
eimt	O
ultrsaonic	O
vocalizaitons	O
during	O
extreme	O
clod	O
expsoure	O
and	O
after	O
admniistration	O
of	O
the	O
aplha	O
(	O
2	O
)	O
adrenocepotr	O
aognist	O
,	O
cloniidne	O
.	O

Previous	O
investigatoins	O
have	O
determined	O
that	O
,	O
in	O
resposne	O
to	O
clnoidine	O
,	O
ultrasuond	O
prdouction	O
increaess	O
through	O
the	O
2nd	O
-	O
week	O
postaprtum	O
and	O
derceases	O
thereafter	O
.	O

Given	O
that	O
sypmathetic	O
nerual	O
doimnance	O
exhibits	O
a	O
similar	O
develpomental	O
pattren	O
,	O
and	O
given	O
that	O
colnidine	O
inudces	O
sympatehtic	O
witdhrawal	O
and	O
bradycradia	B-Disease
,	O
we	O
hypothesized	O
that	O
cloindine	O
'	O
s	O
deveolpmental	O
effcets	O
on	O
cradiac	O
rtae	O
and	O
ultarsound	O
produciton	O
would	O
mriror	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
exepriment	O
,	O
the	O
effetcs	O
of	O
cloniidne	O
administratoin	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
cadriac	O
rtae	O
and	O
ultarsound	O
porduction	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
day	O
-	O
old	O
rtas	O
.	O

Age	O
-	O
related	O
chanegs	O
in	O
ultrasuond	O
prdouction	O
corresponded	O
with	O
chanegs	O
in	O
cardiovsacular	O
vraiables	O
,	O
including	O
basleine	O
cadriac	O
rtae	O
and	O
colnidine	O
-	O
induecd	O
bradycadria	B-Disease
.	O

This	O
expreiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypotehsis	O
that	O
ultarsound	O
proudction	O
is	O
the	O
aocustic	O
by	O
-	O
prodcut	O
of	O
a	O
phyisological	O
mnaeuver	O
that	O
compensates	O
for	O
clondiine	O
'	O
s	O
detirmental	O
effects	O
on	O
cardoivascular	O
fnuction	O
.	O

Rceurrent	O
use	O
of	O
newer	O
oarl	O
contracetpives	O
and	O
the	O
rsik	O
of	O
vneous	B-Disease
thromboemoblism	I-Disease
.	O

The	O
epidemiloogical	O
stuides	O
that	O
asssesed	O
the	O
rsik	O
of	O
vneous	B-Disease
thromboemoblism	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
newer	O
oarl	O
contracetpives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patetrns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
tmie	O
uesrs	O
,	O
repetaers	O
and	O
switchres	O
.	O

Dtaa	O
from	O
a	O
Transntaional	O
csae	O
-	O
cnotrol	O
sutdy	O
were	O
used	O
to	O
assess	O
the	O
rsik	O
of	O
VTE	B-Disease
for	O
the	O
latter	O
pattrens	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duratoin	O
of	O
use	O
.	O

Over	O
the	O
preiod	O
1993	O
-	O
1996	O
,	O
551	O
caess	O
of	O
VTE	B-Disease
were	O
identifeid	O
in	O
Geramny	O
and	O
the	O
UK	O
along	O
with	O
2066	O
cnotrols	O
.	O

Totlas	O
of	O
128	O
caess	O
and	O
650	O
cotnrols	O
were	O
aanlysed	O
for	O
repaet	O
use	O
and	O
135	O
caess	O
and	O
622	O
contrlos	O
for	O
switching	O
patetrns	O
.	O

The	O
adjusted	O
rtae	O
rtaio	O
of	O
VTE	B-Disease
for	O
rpeeat	O
uesrs	O
of	O
third	O
geenration	O
OC	O
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repaet	O
uesrs	O
of	O
second	O
genertaion	O
plils	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
switchres	O
from	O
second	O
to	O
third	O
gneeration	O
pills	O
relative	O
to	O
swtichers	O
from	O
third	O
to	O
second	O
genertaion	O
plils	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
generatoin	O
agnets	O
are	O
associated	O
with	O
equvialent	O
rsiks	O
of	O
VTE	B-Disease
when	O
the	O
same	O
aegnt	O
is	O
used	O
repeatedly	O
after	O
interrutpion	O
peirods	O
or	O
when	O
usres	O
are	O
switched	O
between	O
the	O
two	O
genreations	O
of	O
plils	O
.	O

These	O
analyess	O
suggest	O
that	O
the	O
hihger	O
rsik	O
observed	O
for	O
the	O
newer	O
OC	O
in	O
other	O
studeis	O
may	O
be	O
the	O
result	O
of	O
inadequtae	O
copmarisons	O
of	O
plil	O
uesrs	O
with	O
different	O
pattenrs	O
of	O
plil	O
use	O
.	O

Dfiferential	O
effetcs	O
of	O
systemically	O
admiinstered	O
ketaimne	O
and	O
liodcaine	O
on	O
dyanmic	O
and	O
staitc	O
hyperaglesia	B-Disease
induecd	O
by	O
intardermal	O
capasicin	O
in	O
huamns	O
.	O

We	O
have	O
examined	O
the	O
effcet	O
of	O
systeimc	O
administartion	O
of	O
keatmine	O
and	O
lidociane	O
on	O
bursh	O
-	O
eovked	O
(	O
dynaimc	O
)	O
pian	B-Disease
and	O
pucntate	O
-	O
evkoed	O
(	O
sttaic	O
)	O
hyperlagesia	B-Disease
indcued	O
by	O
capsaciin	O
.	O

In	O
a	O
rnadomized	O
,	O
double	O
-	O
bilnd	O
,	O
palcebo	O
-	O
controleld	O
,	O
crossoevr	O
stduy	O
,	O
we	O
studied	O
12	O
volutneers	O
in	O
three	O
experimetns	O
.	O

Capasicin	O
100	O
microgarms	O
was	O
inejcted	O
intrdaermally	O
on	O
the	O
vloar	O
foerarm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
inufsion	O
of	O
kteamine	O
(	O
blous	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infuison	O
of	O
7	O
micrgorams	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocanie	O
5	O
mg	O
kg	O
-	O
1	O
or	O
sailne	O
for	O
50	O
min	O
.	O

Infuison	O
started	O
15	O
min	O
after	O
injeciton	O
of	O
capsaciin	O
.	O

The	O
following	O
were	O
maesured	O
:	O
sopntaneous	O
pian	B-Disease
,	O
pian	B-Disease
eovked	O
by	O
pucntate	O
and	O
bursh	O
stiumli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brsuh	O
-	O
eovked	O
and	O
pnuctate	O
-	O
evoekd	O
hyperlagesia	B-Disease
.	O

Keatmine	O
redcued	O
both	O
the	O
aera	O
of	O
bursh	O
-	O
eovked	O
and	O
puncttae	O
-	O
evoekd	O
hypearlgesia	B-Disease
significantly	O
and	O
it	O
tended	O
to	O
rdeuce	O
bursh	O
-	O
evkoed	O
pian	B-Disease
.	O

Lidcoaine	O
redcued	O
the	O
aera	O
of	O
puncatte	O
-	O
eovked	O
hpyeralgesia	B-Disease
significantly	O
.	O

It	O
tended	O
to	O
reudce	O
VAS	O
scoers	O
of	O
spontanoeus	O
pian	B-Disease
but	O
had	O
no	O
effcet	O
on	O
eovked	O
pian	B-Disease
.	O

The	O
dfiferential	O
effcets	O
of	O
keatmine	O
and	O
ldiocaine	O
on	O
staitc	O
and	O
dnyamic	O
hyepralgesia	B-Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hpyeralgesia	B-Disease
are	O
mediated	O
by	O
separate	O
mecahnisms	O
and	O
have	O
a	O
distinct	O
pharmacloogy	O
.	O

Developemnt	O
of	O
apmoorphine	O
-	O
idnuced	O
aggerssive	B-Disease
behavoir	I-Disease
:	O
cmoparison	O
of	O
adlut	O
mlae	O
and	O
femlae	O
Witsar	O
rtas	O
.	O

The	O
deveolpment	O
of	O
apmoorphine	O
-	O
induecd	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
daliy	O
)	O
aggresisve	B-Disease
beahvior	I-Disease
of	O
adlut	O
mlae	O
and	O
femlae	O
Wisatr	O
rtas	O
obtained	O
from	O
the	O
same	O
breeedr	O
was	O
studied	O
in	O
two	O
consecutvie	O
stes	O
.	O

In	O
mlae	O
animlas	O
,	O
repaeted	O
apomorphnie	O
tretament	O
idnuced	O
a	O
gardual	O
deveolpment	O
of	O
aggressive	B-Disease
bheavior	I-Disease
as	O
evidenced	O
by	O
the	O
increaesd	O
intenisty	O
of	O
aggerssiveness	B-Disease
and	O
sohrtened	O
latnecy	O
before	O
the	O
first	O
attcak	O
toward	O
the	O
oppoennt	O
.	O

In	O
fmeale	O
rtas	O
,	O
only	O
a	O
waek	O
tendency	O
toward	O
aggrsesiveness	B-Disease
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
stduy	O
demonstrates	O
gneder	O
difefrences	O
in	O
the	O
developemnt	O
of	O
the	O
apomorphnie	O
-	O
induecd	O
aggrsesive	B-Disease
beahvior	I-Disease
and	O
indicates	O
that	O
the	O
feamle	O
rtas	O
do	O
not	O
fill	O
the	O
validatoin	O
cirteria	O
for	O
use	O
in	O
this	O
metohd	O
.	O

Intracranail	B-Disease
aenurysms	I-Disease
and	O
coacine	B-Disease
aubse	I-Disease
:	O
aanlysis	O
of	O
porgnostic	O
indiactors	O
.	O

OJBECTIVE	O
:	O
The	O
outcmoe	O
of	O
subarachonid	B-Disease
hemorrahge	I-Disease
associated	O
with	O
coacine	B-Disease
absue	I-Disease
is	O
reportedly	O
poor	O
.	O

However	O
,	O
no	O
stduy	O
in	O
the	O
literautre	O
has	O
reported	O
the	O
use	O
of	O
a	O
staitstical	O
moedl	O
to	O
anlayze	O
the	O
vairables	O
that	O
infulence	O
outocme	O
.	O

METHODS	O
:	O
A	O
reveiw	O
of	O
admissions	O
during	O
a	O
6	O
-	O
yaer	O
preiod	O
rveealed	O
14	O
paitents	O
with	O
cocanie	O
-	O
related	O
aneruysms	B-Disease
.	O

This	O
gorup	O
was	O
compraed	O
with	O
a	O
cotnrol	O
gruop	O
of	O
135	O
ptaients	O
with	O
ruptrued	B-Disease
aenurysms	I-Disease
and	O
no	O
hisotry	O
of	O
coacine	B-Disease
aubse	I-Disease
.	O

Age	O
at	O
presnetation	O
,	O
tmie	O
of	O
icuts	O
after	O
intoxicatoin	O
,	O
Hunt	O
and	O
Hses	O
grdae	O
of	O
subarachonid	B-Disease
hemorrhgae	I-Disease
,	O
szie	O
of	O
the	O
anuerysm	B-Disease
,	O
lcoation	O
of	O
the	O
anuerysm	B-Disease
,	O
and	O
the	O
Glasogw	O
Otucome	O
Sacle	O
scroe	O
were	O
asssesed	O
and	O
cmopared	O
.	O

RESLUTS	O
:	O
The	O
pateints	O
in	O
the	O
sutdy	O
gorup	O
were	O
significantly	O
younegr	O
than	O
the	O
patinets	O
in	O
the	O
cotnrol	O
gorup	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

In	O
patinets	O
in	O
the	O
stduy	O
gorup	O
,	O
all	O
aneursyms	B-Disease
were	O
located	O
in	O
the	O
anteiror	O
criculation	O
.	O

The	O
majority	O
of	O
these	O
anuerysms	B-Disease
were	O
smaller	O
than	O
those	O
of	O
the	O
contorl	O
gorup	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
diffreences	O
in	O
mrotality	O
and	O
mobridity	O
between	O
the	O
two	O
gropus	O
were	O
not	O
significant	O
.	O

Hunt	O
and	O
Hses	O
garde	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predcitors	O
of	O
outcmoe	O
for	O
the	O
patinets	O
with	O
cocanie	O
-	O
related	O
anuerysms	B-Disease
.	O

COCNLUSION	O
:	O
Cocanie	O
use	O
predispoesd	O
aneurymsal	B-Disease
rputure	I-Disease
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aenurysms	B-Disease
.	O

Contrary	O
to	O
the	O
pbulished	O
literatrue	O
,	O
this	O
gruop	O
did	O
reasonably	O
well	O
with	O
aggressive	O
mangaement	O
.	O

Effcet	O
of	O
intrvaenous	O
nimdoipine	O
on	O
bolod	O
pressure	O
and	O
outcmoe	O
after	O
aucte	B-Disease
storke	I-Disease
.	O

BCAKGROUND	O
AND	O
PUPROSE	O
:	O
The	O
Intraveonus	O
Nmiodipine	O
Wset	O
Eurpoean	O
Storke	B-Disease
Tiral	O
(	O
INWSET	O
)	O
found	O
a	O
crorelation	O
between	O
nimodipnie	O
-	O
indcued	O
reductoin	B-Disease
in	I-Disease
blood	I-Disease
pressrue	I-Disease
(	O
BP	O
)	O
and	O
an	O
unfavoralbe	O
outcmoe	O
in	O
aucte	B-Disease
strkoe	I-Disease
.	O

We	O
sought	O
to	O
confirm	O
this	O
crorelation	O
with	O
and	O
without	O
adjustemnt	O
for	O
porgnostic	O
varibales	O
and	O
to	O
inevstigate	O
outocme	O
in	O
subgorups	O
with	O
incraesing	O
leevls	O
of	O
BP	B-Disease
rdeuction	I-Disease
.	O

METHODS	O
:	O
Paitents	O
with	O
a	O
cilnical	O
diagnsois	O
of	O
ishcemic	B-Disease
srtoke	I-Disease
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placbeo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dsoe	O
)	O
niomdipine	O
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dsoe	O
)	O
nimoidpine	O
(	O
n	O
=	O
94	O
)	O
.	O

The	O
correlaiton	O
between	O
avergae	O
BP	O
change	O
during	O
the	O
first	O
2	O
dyas	O
and	O
the	O
outocme	O
at	O
day	O
21	O
was	O
analzyed	O
.	O

RESUTLS	O
:	O
Two	O
hundred	O
sixty	O
-	O
five	O
patinets	O
were	O
included	O
in	O
this	O
aanlysis	O
(	O
n	O
=	O
92	O
,	O
93	O
,	O
and	O
80	O
for	O
placbeo	O
,	O
low	O
dsoe	O
,	O
and	O
high	O
dsoe	O
,	O
respectively	O
)	O
.	O

Nimodiipne	O
teratment	O
resulted	O
in	O
a	O
statitsically	O
significant	O
reudction	B-Disease
in	I-Disease
sytsolic	I-Disease
BP	I-Disease
(	O
SBP	O
)	O
and	O
disatolic	O
BP	O
(	O
DBP	O
)	O
from	O
baesline	O
compaerd	O
with	O
placbeo	O
during	O
the	O
first	O
few	O
dyas	O
.	O

In	O
mlutivariate	O
anaylsis	O
,	O
a	O
significant	O
corerlation	O
between	O
DBP	B-Disease
reductoin	I-Disease
and	O
worsennig	O
of	O
the	O
nuerological	O
scroe	O
was	O
found	O
for	O
the	O
high	O
-	O
dsoe	O
gorup	O
(	O
btea	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Patinets	O
with	O
a	O
DBP	B-Disease
reudction	I-Disease
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dsoe	O
gruop	O
had	O
a	O
significantly	O
incresaed	O
adjusted	O
OR	O
for	O
the	O
componud	O
outocme	O
vraiable	O
detah	B-Disease
or	O
depnedency	O
(	O
Barhtel	O
Idnex	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
detah	B-Disease
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
comapred	O
with	O
all	O
placbeo	O
ptaients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
correlaiton	O
between	O
SBP	O
change	O
and	O
otucome	O
.	O

CONCULSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduciton	O
was	O
associated	O
with	O
neurloogical	O
woresning	O
after	O
the	O
intravenuos	O
adimnistration	O
of	O
high	O
-	O
dsoe	O
nimdoipine	O
after	O
aucte	B-Disease
storke	I-Disease
.	O

For	O
low	O
-	O
dsoe	O
nimodipnie	O
,	O
the	O
resutls	O
were	O
not	O
conclusive	O
.	O

These	O
resluts	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroproetctive	O
property	O
of	O
nimdoipine	O
.	O

Neontaal	O
pyrdioxine	O
responsvie	O
convulsoins	B-Disease
due	O
to	O
isoniaizd	O
threapy	O
.	O

A	O
17	O
-	O
day	O
-	O
old	O
inafnt	O
on	O
isnoiazid	O
threapy	O
13	O
mg	O
/	O
kg	O
dialy	O
from	O
brith	O
because	O
of	O
materanl	O
tubecrulosis	B-Disease
was	O
admitetd	O
after	O
4	O
dyas	O
of	O
clnoic	B-Disease
fits	I-Disease
.	O

No	O
underlying	O
ifnective	O
or	O
biochemiacl	O
cause	O
could	O
be	O
found	O
.	O

The	O
fits	B-Disease
cesaed	O
within	O
4	O
hours	O
of	O
administeirng	O
intraumscular	O
pyirdoxine	O
,	O
suggesting	O
an	O
aetoilogy	O
of	O
pyirdoxine	O
defiicency	O
secondary	O
to	O
iosniazid	O
medicatoin	O
.	O

Ketamnie	O
sdeation	O
for	O
the	O
redcution	O
of	O
chlidren	O
'	O
s	O
fractuers	B-Disease
in	O
the	O
emeregncy	O
departmnet	O
.	O

BAKCGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
reusrgence	O
in	O
the	O
utilziation	O
of	O
ketamnie	O
,	O
a	O
uinque	O
anestheitc	O
,	O
for	O
emergecny	O
-	O
deaprtment	O
proecdures	O
requiring	O
sedatoin	O
.	O

The	O
purpose	O
of	O
the	O
present	O
stduy	O
was	O
to	O
examine	O
the	O
saefty	O
and	O
efifcacy	O
of	O
ketaimne	O
for	O
sedtaion	O
in	O
the	O
treatemnt	O
of	O
chlidren	O
'	O
s	O
fracutres	B-Disease
in	O
the	O
eemrgency	O
departmnet	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
cihldren	O
(	O
aevrage	O
age	O
,	O
5	O
.	O
3	O
yaers	O
;	O
range	O
,	O
twelve	O
monhts	O
to	O
ten	O
yeras	O
and	O
ten	O
mnoths	O
)	O
who	O
underwent	O
colsed	O
redutcion	O
of	O
an	O
isoltaed	O
fratcure	B-Disease
or	O
disloaction	B-Disease
in	O
the	O
emeregncy	O
departmnet	O
at	O
a	O
leevl	O
-	O
I	O
taruma	B-Disease
cenetr	O
were	O
prospectively	O
evlauated	O
.	O

Ketamnie	O
hydrohcloride	O
was	O
amdinistered	O
intravenoulsy	O
(	O
at	O
a	O
dsoe	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
bdoy	O
wieght	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patinets	O
and	O
itnramuscularly	O
(	O
at	O
a	O
dsoe	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
bdoy	O
weihgt	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

A	O
borad	O
-	O
certified	O
emergecny	O
physicain	O
skileld	O
in	O
airawy	O
managemnet	O
supervised	O
admniistration	O
of	O
the	O
ansethetic	O
,	O
and	O
the	O
patinets	O
were	O
monitroed	O
by	O
a	O
registeerd	O
nusre	O
.	O

Any	O
pian	B-Disease
during	O
the	O
redutcion	O
was	O
rated	O
by	O
the	O
orthoapedic	O
suregon	O
terating	O
the	O
paitent	O
according	O
to	O
the	O
Childern	O
'	O
s	O
Hosiptal	O
of	O
Eatsern	O
Ontraio	O
Pian	B-Disease
Sacle	O
(	O
CEHOPS	O
)	O
.	O

RSEULTS	O
:	O
The	O
avearge	O
tmie	O
from	O
intraveonus	O
administrtaion	O
of	O
keatmine	O
to	O
manipultaion	O
of	O
the	O
fracutre	B-Disease
or	O
dislocatoin	B-Disease
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
mintues	O
)	O
,	O
and	O
the	O
avreage	O
tmie	O
from	O
inrtamuscular	O
administratoin	O
to	O
manipultaion	O
was	O
four	O
mintues	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
miuntes	O
)	O
.	O

The	O
avreage	O
socre	O
according	O
to	O
the	O
Chlidren	O
'	O
s	O
Hopsital	O
of	O
Esatern	O
Ontraio	O
Pian	B-Disease
Sclae	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
miniaml	O
or	O
no	O
pian	B-Disease
during	O
farcture	B-Disease
reudction	O
.	O

Adqeuate	O
frcature	B-Disease
reductoin	O
was	O
obtained	O
in	O
111	O
of	O
the	O
cihldren	O
.	O

Ninety	O
-	O
nine	O
percent	O
(	O
sixty	O
-	O
eight	O
)	O
of	O
the	O
sixty	O
-	O
nine	O
paretns	O
present	O
during	O
the	O
reudction	O
were	O
pleaesd	O
with	O
the	O
sedtaion	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation	O
.	O

Ptaency	O
of	O
the	O
airawy	O
and	O
indeepndent	O
respirtaion	O
were	O
maintained	O
in	O
all	O
of	O
the	O
pateints	O
.	O

Bolod	O
perssure	O
and	O
haert	O
rtae	O
remained	O
satble	O
.	O

Minor	O
side	O
effcets	O
included	O
nuasea	B-Disease
(	O
thirteen	O
paitents	O
)	O
,	O
eemsis	B-Disease
(	O
eight	O
of	O
the	O
thirteen	O
pateints	O
with	O
nasuea	B-Disease
)	O
,	O
clumisness	B-Disease
(	O
evident	O
as	O
ataixc	B-Disease
moveemnts	I-Disease
in	O
ten	O
pateints	O
)	O
,	O
and	O
dyspohric	B-Disease
reaciton	I-Disease
(	O
one	O
patinet	O
)	O
.	O

No	O
long	O
-	O
term	O
seqeulae	O
were	O
noted	O
,	O
and	O
no	O
patietns	O
had	O
hlalucinations	B-Disease
or	O
nigthmares	O
.	O

CONCLUSINOS	O
:	O
Ketamnie	O
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adeqaute	O
sedaiton	O
to	O
effectively	O
facilitate	O
the	O
reduciton	O
of	O
chlidren	O
'	O
s	O
fracutres	B-Disease
in	O
the	O
emergnecy	O
deparmtent	O
at	O
our	O
institutoin	O
.	O

Keatmine	O
should	O
only	O
be	O
used	O
in	O
an	O
envrionment	O
such	O
as	O
the	O
eemrgency	O
dpeartment	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitornig	O
is	O
used	O
and	O
borad	O
-	O
certified	O
pyhsicians	O
siklled	O
in	O
airawy	O
managemnet	O
are	O
directly	O
involved	O
in	O
the	O
crae	O
of	O
the	O
pateint	O
.	O

Cyclospoirne	O
and	O
tacrolmius	O
-	O
associated	O
trhombotic	B-Disease
mciroangiopathy	I-Disease
.	O

The	O
develpoment	O
of	O
thrombtoic	B-Disease
mciroangiopathy	I-Disease
(	O
TMA	B-Disease
)	O
associated	O
with	O
the	O
use	O
of	O
cyclospoirne	O
has	O
been	O
well	O
documneted	O
.	O

Treamtents	O
have	O
included	O
discontinuaiton	O
or	O
redcution	O
of	O
cyclopsorine	O
dsoe	O
with	O
or	O
without	O
concrurent	O
palsma	O
exchagne	O
,	O
palsma	O
infsuion	O
,	O
anticoagultaion	O
,	O
and	O
itnravenous	O
immunogloublin	O
G	O
ifnusion	O
.	O

However	O
,	O
for	O
recipeints	O
of	O
oragn	O
trasnplantation	O
,	O
removing	O
the	O
inciitng	O
aegnt	O
is	O
not	O
without	O
the	O
attendant	O
rsik	O
of	O
prceipitating	O
aucte	O
rejetcion	O
and	O
garft	O
lsos	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emegrence	O
of	O
tcarolimus	O
as	O
a	O
potent	O
immunousppressive	O
aegnt	O
with	O
mcehanisms	O
of	O
actoin	O
virtually	O
iedntical	O
to	O
those	O
of	O
cylcosporine	O
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacroilmus	O
has	O
been	O
reported	O
to	O
be	O
a	O
vaible	O
therpaeutic	O
option	O
in	O
the	O
setting	O
of	O
cycolsporine	O
-	O
inudced	O
TMA	B-Disease
.	O

With	O
the	O
more	O
widespread	O
applictaion	O
of	O
tacroliums	O
in	O
oragn	O
tranpslantation	O
,	O
tacrloimus	O
-	O
associated	O
TMA	B-Disease
has	O
also	O
been	O
recognized	O
.	O

However	O
,	O
litreature	O
regarding	O
the	O
incidnece	O
of	O
the	O
rceurrence	O
of	O
TMA	B-Disease
in	O
pateints	O
exopsed	O
sequentially	O
to	O
cyclsoporine	O
and	O
tacrolmius	O
is	O
limtied	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
a	O
lviing	O
doonr	O
rneal	O
transpalnt	O
reciipent	O
who	O
developed	O
cyclospoirne	O
-	O
indcued	O
TMA	B-Disease
that	O
responded	O
to	O
the	O
withdrwaal	O
of	O
cyclopsorine	O
in	O
conjunciton	O
with	O
plasmapehresis	O
and	O
frseh	O
forzen	O
plsama	O
replcaement	O
therpay	O
.	O

Introduction	O
of	O
tacrloimus	O
as	O
an	O
atlernative	O
immunosuppressive	O
aegnt	O
resulted	O
in	O
the	O
recurernce	O
of	O
TMA	B-Disease
and	O
the	O
subsequent	O
lsos	O
of	O
the	O
reanl	O
allgoraft	O
.	O

Paitents	O
who	O
are	O
switched	O
from	O
cycolsporine	O
to	O
tcarolimus	O
or	O
vice	O
versa	O
should	O
be	O
closely	O
mointored	O
for	O
the	O
sgins	O
and	O
smyptoms	O
of	O
rceurrent	O
TMA	B-Disease
.	O

Anlagesic	O
effect	O
of	O
inrtavenous	O
ketmaine	O
in	O
cacner	B-Disease
paitents	O
on	O
morhpine	O
thearpy	O
:	O
a	O
ranodmized	O
,	O
contorlled	O
,	O
double	O
-	O
bilnd	O
,	O
crossover	O
,	O
double	O
-	O
dsoe	O
stduy	O
.	O

Pian	B-Disease
not	O
respnosive	O
to	O
morpihne	O
is	O
often	O
problematic	O
.	O

Ainmal	O
and	O
cliincal	O
studeis	O
have	O
suggested	O
that	O
N	O
-	O
metyhl	O
-	O
D	O
-	O
aspatrate	O
(	O
NDMA	O
)	O
antgaonists	O
,	O
such	O
as	O
keatmine	O
,	O
may	O
be	O
effective	O
in	O
imrpoving	O
oipoid	O
analgseia	O
in	O
difficult	O
pian	B-Disease
syndormes	O
,	O
such	O
as	O
neuroapthic	B-Disease
pian	I-Disease
.	O

A	O
slow	O
bouls	O
of	O
subhynpotic	O
doess	O
of	O
kteamine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
canecr	B-Disease
pateints	O
whose	O
pian	B-Disease
was	O
unreleived	O
by	O
morpihne	O
in	O
a	O
randomzied	O
,	O
double	O
-	O
blnid	O
,	O
corssover	O
,	O
double	O
-	O
dsoe	O
sutdy	O
.	O

Pian	B-Disease
itnensity	O
on	O
a	O
0	O
to	O
10	O
nuemrical	O
scale	O
;	O
nauesa	B-Disease
and	O
vomiitng	B-Disease
,	O
drowsniess	O
,	O
confusoin	B-Disease
,	O
and	O
dry	B-Disease
motuh	I-Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mnii	O
-	O
Metnal	O
Satte	O
Examinatoin	O
(	O
MSME	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arteiral	O
prsesure	O
were	O
recorded	O
before	O
admniistration	O
of	O
durgs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minuets	O
(	O
T30	O
)	O
,	O
60	O
miuntes	O
(	O
T60	O
)	O
,	O
120	O
miuntes	O
(	O
T210	O
)	O
,	O
and	O
180	O
minuets	O
(	O
T810	O
)	O
.	O

Ketaimne	O
,	O
but	O
not	O
sailne	O
soltuion	O
,	O
significantly	O
redcued	O
the	O
pian	B-Disease
itnensity	O
in	O
almost	O
all	O
the	O
patinets	O
at	O
both	O
doess	O
.	O

This	O
efefct	O
was	O
more	O
relevnat	O
in	O
patietns	O
traeted	O
with	O
hihger	O
dsoes	O
.	O

Hallucniations	B-Disease
occurred	O
in	O
4	O
ptaients	O
,	O
and	O
an	O
upnleasant	O
sesnation	O
(	O
"	O
empty	O
haed	O
"	O
)	O
was	O
also	O
reported	O
by	O
2	O
paitents	O
.	O

These	O
epiosdes	O
rveersed	O
after	O
the	O
admniistration	O
of	O
diaezpam	O
1	O
mg	O
itnravenously	O
.	O

Signifiacnt	O
incraeses	O
in	O
droswiness	O
were	O
reported	O
in	O
pateints	O
terated	O
with	O
ketamnie	O
in	O
both	O
gorups	O
and	O
were	O
more	O
marked	O
with	O
ketaimne	O
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
difference	O
in	O
MSME	O
was	O
observed	O
at	O
T30	O
in	O
patietns	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
kteamine	O
.	O

Ketaimne	O
can	O
imporve	O
moprhine	O
anlagesia	O
in	O
difficult	O
pian	B-Disease
syndrmoes	O
,	O
such	O
as	O
neuropatihc	B-Disease
pian	I-Disease
.	O

However	O
,	O
the	O
occrurence	O
of	O
cenrtal	O
advrese	O
efefcts	O
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
higehr	O
doess	O
.	O

This	O
osbervation	O
should	O
be	O
tetsed	O
in	O
sutdies	O
of	O
porlonged	O
ketmaine	O
administraiton	O
.	O

Paclitxael	O
,	O
cislpatin	O
,	O
and	O
gemcitabnie	O
comibnation	O
chemotherpay	O
within	O
a	O
multidisciplniary	O
threapeutic	O
approach	O
in	O
metastaitc	O
nonsamll	B-Disease
clel	I-Disease
lnug	I-Disease
carcinmoa	I-Disease
.	O

BACGKROUND	O
:	O
Cispaltin	O
-	O
based	O
chmeotherapy	O
cobminations	O
imporve	O
qaulity	O
of	O
lfie	O
and	O
sruvival	O
in	O
adavnced	O
nonmsall	B-Disease
clel	I-Disease
lnug	I-Disease
cracinoma	I-Disease
(	O
NSLCC	B-Disease
)	O
.	O

The	O
eemrgence	O
of	O
new	O
actvie	O
drgus	O
might	O
translate	O
into	O
more	O
effcetive	O
rgeimens	O
for	O
the	O
teratment	O
of	O
this	O
dsiease	O
.	O

METHODS	O
:	O
The	O
objecitve	O
of	O
this	O
stduy	O
was	O
to	O
determine	O
the	O
fesaibility	O
,	O
respnose	O
rtae	O
,	O
and	O
txoicity	B-Disease
of	O
a	O
paclitaexl	O
,	O
cispltain	O
,	O
and	O
gmecitabine	O
cobmination	O
to	O
traet	O
metasttaic	O
NCSLC	B-Disease
.	O

Thirty	O
-	O
five	O
consecutvie	O
cehmotherapy	O
-	O
niave	O
paitents	O
with	O
Satge	O
IV	O
NSLCC	B-Disease
and	O
an	O
Eastren	O
Copoerative	O
Oncolgoy	O
Gorup	O
pefrormance	O
sttaus	O
of	O
0	O
-	O
2	O
were	O
tretaed	O
with	O
a	O
cmobination	O
of	O
paclitaexl	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
inrtavenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cispaltin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravneously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemictabine	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenoulsy	O
in	O
30	O
miuntes	O
)	O
on	O
Dyas	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Although	O
responidng	O
paitents	O
were	O
shceduled	O
to	O
receive	O
consolidtaion	O
radiotehrapy	O
and	O
24	O
pateints	O
received	O
preplanend	O
second	O
-	O
line	O
chemothreapy	O
after	O
diesase	O
progresison	O
,	O
the	O
respnose	O
and	O
toxiicty	B-Disease
raets	O
reported	O
refer	O
only	O
to	O
the	O
chemtoherapy	O
regmien	O
given	O
.	O

REUSLTS	O
:	O
All	O
the	O
patinets	O
were	O
examined	O
for	O
toxciity	B-Disease
;	O
34	O
were	O
examinbale	O
for	O
resposne	O
.	O

An	O
ojbective	O
rseponse	O
was	O
observed	O
in	O
73	O
.	O
5	O
%	O
of	O
the	O
patietns	O
(	O
95	O
%	O
confidecne	O
intreval	O
[	O
CI	O
]	O
,	O
55	O
.	O
6	O
-	O
87	O
.	O
1	O
%	O
)	O
,	O
including	O
4	O
complete	O
resposnes	O
(	O
11	O
.	O
7	O
%	O
)	O
.	O

According	O
to	O
inetntion	O
-	O
to	O
-	O
terat	O
,	O
the	O
overall	O
rseponse	O
rtae	O
was	O
71	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
,	O
53	O
.	O
7	O
-	O
85	O
.	O
4	O
%	O
)	O
.	O

After	O
154	O
cuorses	O
of	O
tehrapy	O
,	O
the	O
mdeian	O
dsoe	O
intenstiy	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
pcalitaxel	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cipslatin	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabnie	O
(	O
86	O
.	O
2	O
%	O
)	O
.	O

Wrold	O
Haelth	O
Oragnization	O
Garde	O
3	O
-	O
4	O
neturopenia	B-Disease
and	O
thrombocyotpenia	B-Disease
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patietns	O
,	O
respectively	O
.	O

There	O
was	O
one	O
treamtent	O
-	O
related	O
daeth	B-Disease
.	O

Nonhematoloigc	O
txoicities	B-Disease
were	O
mlid	O
.	O

After	O
a	O
meidan	O
follow	O
-	O
up	O
of	O
22	O
monhts	O
,	O
the	O
medain	O
progrsesion	O
free	O
sruvival	O
rtae	O
was	O
7	O
motnhs	O
,	O
and	O
the	O
meidan	O
suvrival	O
tmie	O
was	O
16	O
monhts	O
.	O

CONCLSUIONS	O
:	O
The	O
combinatoin	O
of	O
pacliatxel	O
,	O
cispaltin	O
,	O
and	O
gemcitaibne	O
is	O
well	O
tolearted	O
and	O
shows	O
high	O
atcivity	O
in	O
metastaitc	O
NCSLC	B-Disease
.	O

This	O
teratment	O
merits	O
further	O
compraison	O
with	O
other	O
cispaltin	O
-	O
based	O
regmiens	O
.	O

Serotonerigc	O
antidepresasnts	O
and	O
urianry	B-Disease
incontinecne	I-Disease
.	O

Many	O
new	O
sertoonergic	O
antdiepressants	O
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O

Although	O
urinray	B-Disease
incnotinence	I-Disease
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drgus	O
in	O
their	O
pacakge	O
isnerts	O
there	O
is	O
only	O
one	O
reoprt	O
in	O
the	O
lietrature	O
.	O

This	O
conecrns	O
2	O
mlae	O
patinets	O
who	O
experienced	O
incontiennce	B-Disease
while	O
taking	O
velnafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
autohrs	O
describe	O
2	O
feamle	O
pateints	O
who	O
developed	O
incontiennce	B-Disease
secondary	O
to	O
the	O
selective	O
seortonin	O
reputake	O
inhibiotrs	O
paroextine	O
and	O
sertrlaine	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effcet	O
on	O
vnelafaxine	O
.	O

In	O
2	O
of	O
the	O
3	O
caess	O
the	O
patinets	O
were	O
also	O
taking	O
ltihium	O
carbnoate	O
and	O
btea	O
-	O
blokcers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontiennce	B-Disease
.	O

Ainmal	O
sutdies	O
suggest	O
that	O
incotninence	B-Disease
secondary	O
to	O
serotonerigc	O
atnidepressants	O
could	O
be	O
mediated	O
by	O
the	O
5TH4	O
rceeptors	O
found	O
on	O
the	O
bldader	O
.	O

Further	O
reesarch	O
is	O
needed	O
to	O
delineate	O
the	O
frqeuency	O
of	O
this	O
troubling	O
side	O
efefct	O
and	O
how	O
best	O
to	O
terat	O
it	O
.	O

Aucte	O
coacine	O
-	O
indcued	O
siezures	B-Disease
:	O
differnetial	O
senistivity	O
of	O
six	O
ibnred	O
mosue	O
strians	O
.	O

Mautre	O
mlae	O
and	O
feamle	O
mcie	O
from	O
six	O
inberd	O
stanis	O
were	O
tetsed	O
for	O
susceptibiltiy	O
to	O
behaivoral	O
seziures	B-Disease
induecd	O
by	O
a	O
single	O
injetcion	O
of	O
ccoaine	O
.	O

Coacine	O
was	O
injceted	O
ip	O
over	O
a	O
range	O
of	O
dsoes	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
behvaior	O
was	O
moniotred	O
for	O
20	O
miuntes	O
.	O

Seiuzre	B-Disease
end	O
points	O
included	O
latecny	O
to	O
forleimb	O
or	O
hindilmb	O
colnus	O
,	O
laetncy	O
to	O
clnoic	O
running	O
siezure	B-Disease
and	O
laetncy	O
to	O
jumipng	O
bouncnig	O
seiuzre	B-Disease
.	O

A	O
range	O
of	O
srtain	O
specific	O
senistivities	O
was	O
documneted	O
with	O
A	O
/	O
J	O
and	O
SJL	O
mcie	O
being	O
most	O
senistive	O
and	O
C75BL	O
/	O
6J	O
most	O
reisstant	O
.	O

DBA	O
/	O
2J	O
,	O
BLAB	O
/	O
cyBJ	O
and	O
NZW	O
/	O
LcaJ	O
srtains	O
exhibited	O
intermeidate	O
senistivity	O
.	O

EEG	O
reocrdings	O
were	O
made	O
in	O
SJL	O
,	O
A	O
/	O
J	O
and	O
C75BL	O
/	O
6J	O
mcie	O
revealing	O
a	O
close	O
corresopndence	O
between	O
eletcrical	O
actiivty	O
and	O
beahvior	O
.	O

Additionally	O
,	O
levles	O
of	O
cocanie	O
determined	O
in	O
hipopcampus	O
and	O
crotex	O
were	O
not	O
different	O
between	O
snesitive	O
and	O
resitsant	O
stranis	O
.	O

Additional	O
sutdies	O
of	O
these	O
murnie	O
stranis	O
may	O
be	O
useful	O
for	O
investgiating	O
geneitc	O
influecnes	O
on	O
cociane	O
-	O
idnuced	O
seiuzres	B-Disease
.	O

Hypoetnsion	B-Disease
following	O
the	O
inititaion	O
of	O
tizanidnie	O
in	O
a	O
ptaient	O
traeted	O
with	O
an	O
angiotenisn	O
converting	O
eznyme	O
inhibiotr	O
for	O
chrnoic	O
hypertesnion	B-Disease
.	O

Cenrtally	O
acting	O
aplha	O
-	O
2	O
adernergic	O
agoinsts	O
are	O
one	O
of	O
several	O
phamracologic	O
aegnts	O
used	O
in	O
the	O
teratment	O
of	O
spsaticity	B-Disease
related	O
to	O
disroders	B-Disease
of	I-Disease
the	I-Disease
cetnral	I-Disease
nerovus	I-Disease
sysetm	I-Disease
.	O

In	O
addition	O
to	O
their	O
effetcs	O
on	O
spastictiy	B-Disease
,	O
certain	O
adevrse	O
caridorespiratory	O
efefcts	O
have	O
been	O
reported	O
.	O

Audlts	O
chornically	O
tretaed	O
with	O
agniotensin	O
converting	O
eznyme	O
ihnibitors	O
may	O
have	O
a	O
lmiited	O
ability	O
to	O
respond	O
to	O
hypotensoin	B-Disease
when	O
the	O
smypathetic	O
resopnse	O
is	O
siumltaneously	O
blocekd	O
.	O

The	O
autohrs	O
present	O
a	O
10	O
-	O
yaer	O
-	O
old	O
boy	O
chrnoically	O
treaetd	O
with	O
liisnopril	O
,	O
an	O
anigotensin	O
converting	O
eznyme	O
inhibtior	O
,	O
to	O
contorl	O
hypertenison	B-Disease
who	O
developed	O
hyptoension	B-Disease
following	O
the	O
addition	O
of	O
tiaznidine	O
,	O
an	O
alhpa	O
-	O
2	O
agoinst	O
,	O
for	O
the	O
traetment	O
of	O
spastictiy	B-Disease
.	O

The	O
possible	O
inetraction	O
of	O
tiaznidine	O
and	O
other	O
antihyeprtensive	O
aegnts	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescrbiing	O
threapy	O
to	O
traet	O
either	O
hypertenison	B-Disease
or	O
spastciity	B-Disease
in	O
such	O
patinets	O
.	O

Two	O
mosue	O
liens	O
selected	O
for	O
dfiferential	O
sensitiviteis	O
to	O
btea	O
-	O
carbolnie	O
-	O
induecd	O
seziures	B-Disease
are	O
also	O
differnetially	O
sensiitve	O
to	O
various	O
pharmacoloigcal	O
effetcs	O
of	O
other	O
GBAA	O
(	O
A	O
)	O
reecptor	O
lgiands	O
.	O

Two	O
mosue	O
lnies	O
were	O
selectively	O
berd	O
according	O
to	O
their	O
sensitiivty	O
(	O
BS	O
line	O
)	O
or	O
ressitance	O
(	O
BR	O
line	O
)	O
to	O
seizrues	B-Disease
induecd	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injectoin	O
of	O
metyhl	O
btea	O
-	O
craboline	O
-	O
3	O
-	O
carboxyalte	O
(	O
btea	O
-	O
CCM	O
)	O
,	O
an	O
invrese	O
agoinst	O
of	O
the	O
GBAA	O
(	O
A	O
)	O
recpetor	O
benzoidazepine	O
stie	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lnies	O
'	O
sensitiviites	O
to	O
various	O
physiologcial	O
effcets	O
of	O
other	O
lgiands	O
of	O
the	O
GBAA	O
(	O
A	O
)	O
recepotr	O
.	O

We	O
measrued	O
diazpeam	O
-	O
idnuced	O
anixolysis	O
with	O
the	O
eelvated	O
plus	O
-	O
mzae	O
tset	O
,	O
dizaepam	O
-	O
inudced	O
sdeation	O
by	O
recoridng	O
the	O
vigilacne	O
states	O
,	O
and	O
picrootxin	O
-	O
and	O
pentyelnetetrazol	O
-	O
idnuced	O
seiuzres	B-Disease
after	O
i	O
.	O
p	O
.	O
injecitons	O
.	O

Resutls	O
presented	O
here	O
show	O
that	O
the	O
differetnial	O
sensiitvities	O
of	O
BS	O
and	O
BR	O
lnies	O
to	O
btea	O
-	O
CCM	O
can	O
be	O
etxended	O
to	O
dizaepam	O
,	O
pcirotoxin	O
,	O
and	O
pentlyenetetrazol	O
,	O
suggesting	O
a	O
genteic	O
seleciton	O
of	O
a	O
general	O
sensiitvity	O
and	O
resisatnce	O
to	O
several	O
lgiands	O
of	O
the	O
GBAA	O
(	O
A	O
)	O
rceeptor	O
.	O

Propylthiuoracil	O
-	O
inudced	O
periunclear	O
-	O
stainnig	O
antineutorphil	O
cytolpasmic	O
autoantbiody	O
-	O
positvie	O
vsaculitis	B-Disease
in	O
conjunctoin	O
with	O
pericardtiis	B-Disease
.	O

OBJECITVE	O
:	O
To	O
describe	O
a	O
csae	O
of	O
proyplthiouracil	O
-	O
induecd	O
vasuclitis	B-Disease
manifesting	O
with	O
pericraditis	B-Disease
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
csae	O
reoprt	O
of	O
a	O
wmoan	O
with	O
hypetrhyroidism	B-Disease
terated	O
with	O
propytlhiouracil	O
in	O
whom	O
a	O
syndrmoe	O
of	O
preicarditis	B-Disease
,	O
fveer	B-Disease
,	O
and	O
glomreulonephritis	B-Disease
developed	O
.	O

Serolgoic	O
tseting	O
and	O
imumnologic	O
stuides	O
were	O
done	O
,	O
and	O
a	O
perciardial	O
biospy	O
was	O
performed	O
.	O

RSEULTS	O
:	O
A	O
25	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
Grvaes	B-Disease
'	I-Disease
diesase	I-Disease
had	O
a	O
febrlie	B-Disease
illness	I-Disease
and	O
evidnece	O
of	O
preicarditis	B-Disease
,	O
which	O
was	O
confirmed	O
by	O
biposy	O
.	O

Seroolgic	O
eavluation	O
reveaeld	O
the	O
preesnce	O
of	O
periunclear	O
-	O
staiinng	O
antinuetrophil	O
cytoplsamic	O
autoantiobdies	O
(	O
pACNA	O
)	O
against	O
myeloperoxiadse	O
(	O
MPO	O
)	O
.	O

Prpoylthiouracil	O
therpay	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
terated	O
with	O
a	O
1	O
-	O
mnoth	O
coruse	O
of	O
prendisone	O
,	O
which	O
alleviated	O
her	O
symtpoms	O
.	O

A	O
literautre	O
reivew	O
revaeled	O
no	O
prior	O
rpeorts	O
of	O
peircarditis	B-Disease
in	O
atni	O
-	O
MPO	O
pACNA	O
-	O
postiive	O
vasculiits	B-Disease
associated	O
with	O
prpoylthio	O
-	O
uarcil	O
threapy	O
.	O

CNOCLUSION	O
:	O
Preicarditis	B-Disease
may	O
be	O
the	O
initial	O
mnaifestation	O
of	O
durg	O
-	O
inudced	O
vascultiis	B-Disease
attributable	O
to	O
propyltiho	O
-	O
urcail	O
thearpy	O
.	O

Reepated	O
trasnient	O
anuira	B-Disease
following	O
losratan	O
adminsitration	O
in	O
a	O
paitent	O
with	O
a	O
soliatry	O
kdiney	O
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
70	O
-	O
yaer	O
-	O
old	O
hyeprtensive	B-Disease
man	O
with	O
a	O
solitray	O
kideny	O
and	O
chrnoic	B-Disease
rneal	I-Disease
insufficiency	I-Disease
who	O
developed	O
two	O
episdoes	O
of	O
tarnsient	O
anruia	B-Disease
after	O
losratan	O
administratoin	O
.	O

He	O
was	O
hospitaliezd	O
for	O
a	O
myocardail	B-Disease
infacrtion	I-Disease
with	O
pumlonary	B-Disease
edmea	I-Disease
,	O
treaetd	O
with	O
high	O
-	O
dsoe	O
diuertics	O
.	O

Due	O
to	O
sevree	O
sysotlic	B-Disease
dyfsunction	I-Disease
losaratn	O
was	O
prsecribed	O
.	O

Surprisingly	O
,	O
the	O
first	O
dsoe	O
of	O
50	O
mg	O
of	O
loasrtan	O
resulted	O
in	O
a	O
sduden	O
anuira	B-Disease
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dsoe	O
fuorsemide	O
and	O
amnie	O
infsuion	O
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losatran	O
was	O
prescirbed	O
again	O
and	O
after	O
the	O
second	O
dsoe	O
of	O
50	O
mg	O
,	O
the	O
patinet	O
developed	O
a	O
second	O
epsiode	O
of	O
tranisent	O
anruia	B-Disease
lasting	O
10	O
hours	O
.	O

During	O
these	O
two	O
epsiodes	O
,	O
his	O
bolod	O
prsesure	O
diminished	O
but	O
no	O
seevre	O
hypotensoin	B-Disease
was	O
noted	O
.	O

Ultimately	O
,	O
an	O
arterigoraphy	O
showed	O
a	O
70	O
-	O
80	O
%	O
reanl	B-Disease
atrery	I-Disease
stensois	I-Disease
.	O

In	O
this	O
patinet	O
,	O
reanl	B-Disease
atrery	I-Disease
steonsis	I-Disease
cobmined	O
with	O
herat	B-Disease
faiulre	I-Disease
and	O
diurteic	O
therpay	O
certainly	O
resulted	O
in	O
a	O
strong	O
atcivation	O
of	O
the	O
reinn	O
-	O
angoitensin	O
sytsem	O
(	O
RAS	O
)	O
.	O

Under	O
such	O
codnitions	O
,	O
angitoensin	O
II	O
reecptor	O
blockdae	O
by	O
losratan	O
probably	O
indcued	O
a	O
critical	O
fall	O
in	O
glmoerular	O
filtrtaion	O
prsesure	O
.	O

This	O
csae	O
reprot	O
highlights	O
the	O
fact	O
that	O
the	O
angiotesnin	O
II	O
reecptor	O
atnagonist	O
loasrtan	O
can	O
cause	O
serious	O
unexpected	O
complicatoins	O
in	O
patietns	O
with	O
renovacsular	B-Disease
dsiease	I-Disease
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

Calcienurin	O
-	O
inhiibtor	O
inudced	O
pian	B-Disease
syndrmoe	O
(	O
CPIS	B-Disease
)	O
:	O
a	O
seevre	O
disalbing	O
compilcation	O
after	O
ogran	O
transpalntation	O
.	O

Bnoe	O
pian	B-Disease
after	O
transplatnation	O
is	O
a	O
frequnet	O
compliaction	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseaess	O
.	O

Treamtent	O
strategies	O
depend	O
on	O
the	O
correct	O
diganosis	O
of	O
the	O
pian	B-Disease
.	O

Nine	O
patietns	O
with	O
seevre	O
pian	B-Disease
in	O
their	O
feet	O
,	O
which	O
was	O
registreed	O
after	O
transplanattion	O
,	O
were	O
invesitgated	O
.	O

Bnoe	O
scnas	O
showed	O
an	O
incraesed	O
trcaer	O
utpake	O
of	O
the	O
foot	O
bnoes	O
.	O

Magnteic	O
resnoance	O
imgaing	O
demonstrated	O
bnoe	B-Disease
mrarow	I-Disease
odeema	I-Disease
in	O
the	O
pianful	O
boens	O
.	O

Pian	B-Disease
was	O
not	O
explained	O
by	O
other	O
diesases	O
causing	O
foot	O
pian	B-Disease
,	O
like	O
refelx	B-Disease
sympathteic	I-Disease
dytsrophy	I-Disease
,	O
polyneuropahty	B-Disease
,	O
Morotn	B-Disease
'	I-Disease
s	I-Disease
neurlagia	I-Disease
,	O
guot	B-Disease
,	O
otseoporosis	B-Disease
,	O
aavscular	B-Disease
necrsois	I-Disease
,	O
intermitetnt	B-Disease
clauidcation	I-Disease
,	O
ortohpaedic	O
foot	B-Disease
deformiteis	I-Disease
,	O
srtess	B-Disease
frcatures	I-Disease
,	O
and	O
hyperparathyriodism	B-Disease
.	O

The	O
reudction	O
of	O
cyclospornie	O
-	O
or	O
tcarolimus	O
trough	O
levles	O
and	O
the	O
administraiton	O
of	O
clacium	O
cahnnel	O
blockres	O
led	O
to	O
reilef	O
of	O
pian	B-Disease
.	O

The	O
Calcineruin	O
-	O
inihbitor	O
Idnuced	O
Pian	B-Disease
Synrdome	O
(	O
CPIS	B-Disease
)	O
is	O
a	O
rrae	O
but	O
seevre	O
side	O
effect	O
of	O
cyclosproine	O
or	O
tarcolimus	O
and	O
is	O
accurately	O
diagnsoed	O
by	O
its	O
typical	O
preesntation	O
,	O
mganetic	O
resonacne	O
iamging	O
and	O
bnoe	O
scnas	O
.	O

Incrorect	O
diagonsis	O
of	O
the	O
sydnrome	O
will	O
lead	O
to	O
a	O
significant	O
reductoin	O
of	O
lfie	O
qulaity	O
in	O
patietns	O
suffernig	O
from	O
CPIS	B-Disease
.	O

Brian	O
natriureitc	O
pepitde	O
is	O
a	O
prdeictor	O
of	O
anthrayccline	O
-	O
indcued	O
cradiotoxicity	B-Disease
.	O

Anthracylcines	O
are	O
effecitve	O
antineoplsatic	O
durgs	O
,	O
but	O
they	O
frequently	O
cause	O
dsoe	O
-	O
related	O
cardiotoxictiy	B-Disease
.	O

The	O
carditooxicity	B-Disease
of	O
cnoventional	O
antrhacycline	O
threapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
mehtods	O
that	O
are	O
highly	O
snesitive	O
and	O
capable	O
of	O
predicitng	O
caridac	B-Disease
dysfuntcion	I-Disease
.	O

We	O
meausred	O
the	O
plamsa	O
lveel	O
of	O
barin	O
ntariuretic	O
pepitde	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagonstic	O
indciator	O
of	O
anthrayccline	O
-	O
idnuced	O
cardiotoxiicty	B-Disease
in	O
patinets	O
with	O
actue	B-Disease
leuekmia	I-Disease
traeted	O
with	O
a	O
daunroubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regmien	O
.	O

Thirteen	O
patietns	O
with	O
aucte	B-Disease
leukmeia	I-Disease
were	O
treaetd	O
with	O
a	O
DNR	O
-	O
containing	O
reigmen	O
.	O

Cadriac	O
fucntions	O
were	O
evlauated	O
with	O
radionucldie	O
angigoraphy	O
before	O
chemothearpies	O
.	O

The	O
palsma	O
leevls	O
of	O
atrail	O
natriruetic	O
petpide	O
(	O
ANP	O
)	O
and	O
BNP	O
were	O
meausred	O
at	O
the	O
tmie	O
of	O
raidonuclide	O
agniography	O
.	O

Three	O
patietns	O
developed	O
cognestive	B-Disease
herat	I-Disease
fialure	I-Disease
after	O
the	O
comlpetion	O
of	O
chmeotherapy	O
.	O

Five	O
ptaients	O
were	O
diagnoesd	O
as	O
having	O
subclniical	O
herat	B-Disease
failrue	I-Disease
after	O
the	O
complteion	O
of	O
chemohterapy	O
.	O

The	O
palsma	O
levles	O
of	O
BNP	O
in	O
all	O
the	O
paitents	O
with	O
cilnical	O
and	O
subcliniacl	O
herat	B-Disease
faliure	I-Disease
incerased	O
above	O
the	O
nromal	O
liimt	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detetcion	O
of	O
cliincal	O
or	O
sbuclinical	O
herat	B-Disease
faiulre	I-Disease
by	O
radionucilde	O
angoigraphy	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
icnrease	O
in	O
the	O
paitents	O
without	O
herat	B-Disease
faiulre	I-Disease
given	O
DNR	O
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

The	O
plsama	O
leevl	O
of	O
ANP	O
did	O
not	O
always	O
incresae	O
in	O
all	O
the	O
paitents	O
with	O
clincial	O
and	O
sbuclinical	O
herat	B-Disease
faliure	I-Disease
.	O

These	O
preliminary	O
rseults	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
ealry	O
and	O
sesnitive	O
indiactor	O
of	O
anthracyclnie	O
-	O
inudced	O
cadriotoxicity	B-Disease
.	O

Neprhotoxicity	B-Disease
of	O
cmobined	O
cepahlothin	O
-	O
genatmicin	O
reigmen	O
.	O

Two	O
paitents	O
developed	O
actue	B-Disease
tuublar	I-Disease
necorsis	I-Disease
,	O
charatcerized	O
cilnically	O
by	O
aucte	O
olgiuric	B-Disease
rneal	I-Disease
fialure	I-Disease
,	O
while	O
they	O
were	O
receiving	O
a	O
combinaiton	O
of	O
cepahlothin	O
soidum	O
and	O
gentamciin	O
suflate	O
tehrapy	O
.	O

Patinets	O
who	O
are	O
given	O
this	O
durg	O
reigmen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
eraly	O
sgins	O
of	O
nephrtooxicity	B-Disease
.	O

High	O
dsoes	O
of	O
this	O
atnibiotic	O
combinaiton	O
should	O
be	O
avoided	O
especially	O
in	O
eldelry	O
patietns	O
.	O

Patietns	O
with	O
reanl	B-Disease
insuffciiency	I-Disease
should	O
not	O
be	O
given	O
this	O
reigmen	O
.	O

In	O
vivo	O
prtoection	O
of	O
dna	O
dmaage	O
associated	O
apopottic	O
and	O
ncerotic	B-Disease
clel	O
deahts	O
during	O
acetamionphen	O
-	O
indcued	O
nephortoxicity	B-Disease
,	O
amiodraone	O
-	O
indcued	O
lnug	B-Disease
toxiicty	I-Disease
and	O
doxorubciin	O
-	O
inudced	O
cardiotxoicity	B-Disease
by	O
a	O
novel	O
IH366	O
garpe	O
seed	O
proanthocyaniidn	O
etxract	O
.	O

Grpae	O
seed	O
extrcat	O
,	O
primarily	O
a	O
mixture	O
of	O
pronathocyanidins	O
,	O
has	O
been	O
shown	O
to	O
mdoulate	O
a	O
wide	O
-	O
range	O
of	O
bioolgical	O
,	O
pharmacologiacl	O
and	O
toxicloogical	O
effcets	O
which	O
are	O
mainly	O
cyotprotective	O
.	O

This	O
stduy	O
asesssed	O
the	O
ability	O
of	O
IH366	O
grpae	O
seed	O
proanhtocyanidin	O
extrcat	O
(	O
GPSE	O
)	O
to	O
prveent	O
acetamionphen	O
(	O
AAP	O
)	O
-	O
inudced	O
nephrotxoicity	B-Disease
,	O
aimodarone	O
(	O
AMI	O
)	O
-	O
induecd	O
lnug	B-Disease
toxiicty	I-Disease
,	O
and	O
dooxrubicin	O
(	O
DOX	O
)	O
-	O
indcued	O
cardoitoxicity	B-Disease
in	O
mcie	O
.	O

Experimetnal	O
dseign	O
consisted	O
of	O
four	O
gruops	O
:	O
contorl	O
(	O
vheicle	O
alone	O
)	O
,	O
GPSE	O
alone	O
,	O
durg	O
alone	O
and	O
GPSE	O
+	O
durg	O
.	O

For	O
the	O
cytoportection	O
sutdy	O
,	O
aniamls	O
were	O
orally	O
gvaaged	O
100	O
mg	O
/	O
Kg	O
GPSE	O
for	O
7	O
-	O
10	O
dyas	O
followed	O
by	O
i	O
.	O
p	O
.	O
injectoins	O
of	O
oragn	O
specific	O
three	O
drgus	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
dyas	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Parameetrs	O
of	O
stduy	O
included	O
analsyis	O
of	O
seurm	O
chemisrty	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
frgamentation	O
of	O
gneomic	O
DNA	O
(	O
both	O
endonculease	O
-	O
depenednt	O
and	O
indpeendent	O
)	O
in	O
addition	O
to	O
mircoscopic	O
eavluation	O
of	O
damgae	O
and	O
/	O
or	O
proteciton	O
in	O
corresponding	O
PAS	O
staiend	O
tisseus	O
.	O

Reuslts	O
indicate	O
that	O
GPSE	O
preexpousre	O
prior	O
to	O
AAP	O
,	O
AMI	O
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protectoin	O
in	O
terms	O
of	O
seurm	O
chmeistry	O
chagnes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
redcued	O
DNA	O
frgamentation	O
.	O

Histopatholoigcal	O
examinaiton	O
of	O
kdiney	O
,	O
haert	O
and	O
lnug	O
setcions	O
reveaeld	O
moedrate	O
to	O
massive	O
tissue	B-Disease
damgae	I-Disease
with	O
a	O
variety	O
of	O
morphoolgical	O
aberraitons	O
by	O
all	O
the	O
three	O
durgs	O
in	O
the	O
abesnce	O
of	O
GPSE	O
prexeposure	O
than	O
in	O
its	O
prseence	O
.	O

GPSE	O
+	O
durg	O
expsoed	O
tisuses	O
exhibited	O
minor	O
resiudal	O
damgae	O
or	O
near	O
total	O
recoevry	O
.	O

Additionally	O
,	O
hitsopathological	O
alteraitons	O
mirrored	O
both	O
sreum	O
chemisrty	O
chnages	O
and	O
the	O
pattren	O
of	O
DNA	O
fragmentatoin	O
.	O

Interestingly	O
,	O
all	O
the	O
durgs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
indcued	O
apoptoitc	O
detah	O
in	O
addition	O
to	O
necorsis	B-Disease
in	O
the	O
respective	O
ograns	O
which	O
was	O
very	O
effectively	O
blokced	O
by	O
GPSE	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	O
undergo	O
bitoransformation	O
and	O
are	O
known	O
to	O
produce	O
dmaaging	O
radiacls	O
in	O
vivo	O
,	O
the	O
prtoection	O
by	O
GPSE	O
may	O
be	O
linked	O
to	O
both	O
ihnibition	O
of	O
metbaolism	O
and	O
/	O
or	O
detoxifiaction	O
of	O
cyottoxic	O
radcials	O
.	O

In	O
addition	O
,	O
its	O
'	O
presumed	O
contribution	O
to	O
DNA	O
reapir	O
may	O
be	O
another	O
important	O
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemopervention	O
porcess	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
reoprt	O
on	O
AMI	O
-	O
inudced	O
apopottic	O
daeth	O
in	O
the	O
lnug	O
tisuse	O
.	O

Taken	O
together	O
,	O
these	O
eevnts	O
undoubtedly	O
establish	O
GPSE	O
'	O
s	O
abundnat	O
bioavialability	O
,	O
and	O
the	O
poewr	O
to	O
defend	O
mlutiple	O
traget	O
orgnas	O
from	O
txoic	O
assaluts	O
indcued	O
by	O
structurally	O
dievrse	O
and	O
functionally	O
different	O
entiites	O
in	O
vivo	O
.	O

Antidepressnat	O
-	O
idnuced	O
maina	B-Disease
in	O
bioplar	B-Disease
patietns	O
:	O
idenitfication	O
of	O
rsik	O
fcators	O
.	O

BACGKROUND	O
:	O
Cocnerns	O
about	O
possible	O
rsiks	O
of	O
switching	O
to	O
maina	B-Disease
associated	O
with	O
antidepressnats	O
continue	O
to	O
interfere	O
with	O
the	O
establishemnt	O
of	O
an	O
optiaml	O
treamtent	O
praadigm	O
for	O
bioplar	B-Disease
derpession	I-Disease
.	O

METHOD	O
:	O
The	O
respnose	O
of	O
44	O
pateints	O
meteing	O
DSM	O
-	O
IV	O
crtieria	O
for	O
bioplar	B-Disease
diosrder	I-Disease
to	O
natrualistic	O
tretament	O
was	O
asssesed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Mnotgomery	O
-	O
Asbreg	O
Derpession	O
Ratnig	O
Sclae	O
and	O
the	O
Bceh	O
-	O
Rafealson	O
Maina	O
Raitng	O
Sacle	O
.	O

Patinets	O
who	O
experienced	O
a	O
mnaic	B-Disease
or	O
hypomainc	B-Disease
swtich	O
were	O
compaerd	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
varibales	O
including	O
age	O
,	O
sex	O
,	O
diagonsis	O
(	O
DSM	B-Disease
-	I-Disease
IV	I-Disease
biploar	I-Disease
I	I-Disease
vs	O
.	O
biploar	B-Disease
II	I-Disease
)	O
,	O
number	O
of	O
previous	O
mainc	B-Disease
eipsodes	O
,	O
tpye	O
of	O
antidepressnat	O
threapy	O
used	O
(	O
electrocnovulsive	O
thearpy	O
vs	O
.	O
antdiepressant	O
drgus	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotnoin	O
reupatke	O
inhiibtors	O
[	O
SSIRs	O
]	O
)	O
,	O
use	O
and	O
tpye	O
of	O
mood	O
stabiliezrs	O
(	O
ltihium	O
vs	O
.	O
anticonuvlsants	O
)	O
,	O
and	O
tmeperament	O
of	O
the	O
paitent	O
,	O
assessed	O
during	O
a	O
normtohymic	O
peroid	O
using	O
the	O
hypetrhymia	O
component	O
of	O
the	O
Smei	O
-	O
structrued	O
Affetcive	O
Tempreament	O
Interveiw	O
.	O

REUSLTS	O
:	O
Swithces	O
to	O
hyopmania	B-Disease
or	O
mnaia	B-Disease
occurred	O
in	O
27	O
%	O
of	O
all	O
patinets	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
sbugroup	O
of	O
paitents	O
tretaed	O
with	O
SRSIs	O
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
mainc	B-Disease
epiosdes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomainc	B-Disease
episdoes	O
.	O

Sex	O
,	O
age	O
,	O
diagnoiss	O
(	O
biploar	B-Disease
I	I-Disease
vs	O
.	O
bpiolar	B-Disease
II	I-Disease
)	O
,	O
and	O
additional	O
treatemnt	O
did	O
not	O
affect	O
the	O
rsik	O
of	O
switching	O
.	O

The	O
icnidence	O
of	O
mood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
patinets	O
receiving	O
an	O
anitconvulsant	O
and	O
those	O
receiving	O
no	O
mood	O
stbailizer	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequnet	O
in	O
ptaients	O
receiving	O
lihtium	O
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
patinets	O
not	O
terated	O
with	O
litihum	O
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O

The	O
number	O
of	O
previous	O
mainc	B-Disease
eipsodes	O
did	O
not	O
affect	O
the	O
probaiblity	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
socre	O
on	O
the	O
hyprethymia	O
component	O
of	O
the	O
Semistructuerd	O
Affecitve	O
Tmeperament	O
Itnerview	O
was	O
associated	O
with	O
a	O
greater	O
rsik	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

COCNLUSION	O
:	O
The	O
freqeuncy	O
of	O
mood	O
switching	O
associated	O
with	O
aucte	O
antidperessant	O
threapy	O
may	O
be	O
reudced	O
by	O
lithuim	O
treamtent	O
.	O

Particular	O
attentoin	O
should	O
be	O
paid	O
to	O
patinets	O
with	O
a	O
hpyerthymic	O
tempreament	O
,	O
who	O
have	O
a	O
greater	O
rsik	O
of	O
mood	O
switches	O
.	O

Periutbular	O
caipllary	O
baseemnt	O
mmebrane	O
redupilcation	O
in	O
allorgafts	O
and	O
ntaive	O
kideny	B-Disease
disesae	I-Disease
:	O
a	O
clinicopatholoigc	O
stduy	O
of	O
278	O
consectuive	O
rneal	O
sepcimens	O
.	O

BACKRGOUND	O
:	O
An	O
associatoin	O
has	O
been	O
found	O
between	O
tarnsplant	B-Disease
glmoerulopathy	I-Disease
(	O
TG	B-Disease
)	O
and	O
reduplicaiton	O
of	O
perituublar	O
capillary	O
baseemnt	O
mebmranes	O
(	O
PCTR	O
)	O
.	O

Although	O
such	O
an	O
associtaion	O
is	O
of	O
practical	O
and	O
thoeretical	O
importance	O
,	O
only	O
one	O
prosepctive	O
sutdy	O
has	O
tried	O
to	O
confirm	O
it	O
.	O

METHODS	O
:	O
We	O
examined	O
278	O
cnosecutive	O
rneal	O
specimnes	O
(	O
from	O
135	O
transplnats	O
and	O
143	O
natvie	O
kdineys	O
)	O
for	O
ultrastructuarl	O
eivdence	O
of	O
PCTR	O
.	O

In	O
addition	O
to	O
reanl	O
allogratfs	O
with	O
TG	B-Disease
,	O
we	O
also	O
examined	O
grfats	O
with	O
actue	O
rejectoin	O
,	O
recrurent	O
glmoerulonephritis	B-Disease
,	O
chornic	B-Disease
allgoraft	I-Disease
nephrpoathy	I-Disease
and	O
stalbe	O
grfats	O
(	O
"	O
protoocl	O
boipsies	O
"	O
)	O
.	O

Natvie	O
kdiney	O
sepcimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulpoathies	B-Disease
as	O
well	O
as	O
caess	O
of	O
trhombotic	B-Disease
mircoangiopathy	I-Disease
,	O
mailgnant	B-Disease
hypertesnion	I-Disease
,	O
actue	O
inetrstitial	B-Disease
nephrtiis	I-Disease
,	O
and	O
actue	B-Disease
tbuular	I-Disease
necroiss	I-Disease
.	O

REUSLTS	O
:	O
We	O
found	O
PCTR	O
in	O
14	O
of	O
15	O
csaes	O
of	O
TG	B-Disease
,	O
in	O
7	O
tranpslant	O
biposy	O
speicmens	O
without	O
TG	B-Disease
,	O
and	O
in	O
13	O
of	O
143	O
natvie	O
kindey	O
biospy	O
specimnes	O
.	O

These	O
13	O
included	O
csaes	O
of	O
malingant	B-Disease
hypertensoin	I-Disease
,	O
thrmobotic	B-Disease
mciroangiopathy	I-Disease
,	O
luups	B-Disease
nehpritis	I-Disease
,	O
Hneoch	B-Disease
-	I-Disease
Schonlien	I-Disease
neprhitis	I-Disease
,	O
cerscentic	O
glomerulonehpritis	B-Disease
,	O
and	O
cociane	O
-	O
related	O
actue	B-Disease
rneal	I-Disease
fialure	I-Disease
.	O

Mlid	O
PCTR	O
in	O
alolgrafts	O
without	O
TG	B-Disease
did	O
not	O
predict	O
reanl	B-Disease
faiulre	I-Disease
or	O
significant	O
protienuria	B-Disease
after	O
follow	O
-	O
up	O
peridos	O
of	O
between	O
3	O
monhts	O
and	O
1	O
yaer	O
.	O

CONCLSUIONS	O
:	O
We	O
conclude	O
that	O
in	O
tranpslants	O
,	O
there	O
is	O
a	O
strong	O
associtaion	O
between	O
well	O
-	O
developed	O
PCTR	O
and	O
TG	B-Disease
,	O
while	O
the	O
significacne	O
of	O
mlid	O
PCTR	O
and	O
its	O
predictvie	O
value	O
in	O
the	O
absnece	O
of	O
TG	B-Disease
is	O
unclear	O
.	O

PCTR	O
also	O
occurs	O
in	O
certain	O
naitve	O
kdiney	B-Disease
diesases	I-Disease
,	O
though	O
the	O
associatoin	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	B-Disease
.	O

We	O
suggest	O
that	O
repaeted	O
endtohelial	B-Disease
inujry	I-Disease
,	O
including	O
immunoolgic	B-Disease
injruy	I-Disease
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesoin	O
both	O
in	O
allogarfts	O
and	O
natvie	O
kidenys	O
.	O

Cafefine	O
-	O
idnuced	O
cadriac	B-Disease
arrhytmhia	I-Disease
:	O
an	O
unrecognised	O
danegr	O
of	O
healhtfood	O
porducts	O
.	O

We	O
describe	O
a	O
25	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
pre	O
-	O
existing	O
mirtal	B-Disease
vavle	I-Disease
porlapse	I-Disease
who	O
developed	O
intarctable	O
vetnricular	B-Disease
fibrillaiton	I-Disease
after	O
consuming	O
a	O
"	O
natrual	O
enegry	O
"	O
guaarna	O
helath	O
drnik	O
containing	O
a	O
high	O
concenrtation	O
of	O
cafefine	O
.	O

This	O
csae	O
highlights	O
the	O
need	O
for	O
adequtae	O
laeblling	O
and	O
rgeulation	O
of	O
such	O
prdoucts	O
.	O

Conformationlaly	O
restricted	O
analgos	O
of	O
B1D008	O
and	O
an	O
antisesne	O
oligodoexynucleotide	O
tagreting	O
sgima1	O
recepotrs	O
produce	O
atni	O
-	O
cociane	O
effcets	O
in	O
mcie	O
.	O

Cociane	O
'	O
s	O
ability	O
to	O
itneract	O
with	O
sigma	O
recepotrs	O
suggests	O
that	O
these	O
prtoeins	O
mediate	O
some	O
of	O
its	O
behavioarl	O
effetcs	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
recpetor	O
lignads	O
with	O
atnagonist	O
atcivity	O
were	O
evlauated	O
in	O
Siwss	O
Websetr	O
mcie	O
:	O
BD1108	O
(	O
3S	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorohpenyl	O
)	O
ehtyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazbaicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nnoane	O
)	O
,	O
BD1603	O
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dcihlorophenyl	O
)	O
etyhl	O
]	O
-	O
4	O
-	O
methylipperazine	O
)	O
,	O
and	O
LR312	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichloorphenyl	O
)	O
ehtyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cycloheyxlamine	O
)	O
.	O

Copmetition	O
bindnig	O
assays	O
demonstrated	O
that	O
all	O
three	O
cmopounds	O
have	O
high	O
affniities	O
for	O
sgima1	O
recetpors	O
.	O

The	O
three	O
compuonds	O
vary	O
in	O
their	O
affiniteis	O
for	O
simga2	O
rceeptors	O
and	O
exhibit	O
negilgible	O
affintiies	O
for	O
dopaimne	O
,	O
oipoid	O
,	O
GBAA	O
(	O
A	O
)	O
and	O
NDMA	O
rceeptors	O
.	O

In	O
behavioarl	O
sutdies	O
,	O
pre	O
-	O
tretament	O
of	O
mcie	O
with	O
BD0118	O
,	O
B1D063	O
,	O
or	O
LR312	O
significantly	O
attneuated	O
ccoaine	O
-	O
indcued	O
convulsinos	B-Disease
and	O
lethailty	O
.	O

Moreover	O
,	O
psot	O
-	O
teratment	O
with	O
LR312	O
prevented	O
ccoaine	O
-	O
idnuced	O
letahlity	O
in	O
a	O
significant	O
proportoin	O
of	O
aniamls	O
.	O

In	O
contrast	O
to	O
the	O
proteciton	O
provided	O
by	O
the	O
putative	O
anatgonists	O
,	O
the	O
well	O
-	O
characetrized	O
sigma	O
reecptor	O
agonsit	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
recetpor	O
agonsit	O
BD0131	O
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dicholrophenyl	O
)	O
ehtyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabiccylo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonnae	O
)	O
each	O
worseend	O
the	O
behavoiral	O
txoicity	B-Disease
of	O
cocanie	O
.	O

At	O
dsoes	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effetcs	O
on	O
locomtoion	O
,	O
BD1108	O
,	O
BD1603	O
and	O
L1R32	O
significantly	O
attenutaed	O
the	O
loocmotor	O
stimulaotry	O
effcets	O
of	O
ccoaine	O
.	O

To	O
further	O
validate	O
the	O
hypotheiss	O
that	O
the	O
atni	O
-	O
ccoaine	O
effetcs	O
of	O
the	O
novel	O
liagnds	O
involved	O
antagonsim	O
of	O
sigma	O
rceeptors	O
,	O
an	O
anitsense	O
oligodeoxynucleoitde	O
against	O
simga1	O
receptros	O
was	O
also	O
shown	O
to	O
significantly	O
attneuate	O
the	O
convlusive	B-Disease
and	O
locoomtor	O
stimulaotry	O
effects	O
of	O
cocanie	O
.	O

Together	O
,	O
the	O
dtaa	O
suggests	O
that	O
fucntional	O
antagoinsm	O
of	O
sigma	O
rceeptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
coacine	O
-	O
indcued	O
behvaiors	O
.	O

Raniitdine	O
-	O
induecd	O
aucte	O
intersittial	B-Disease
nehpritis	I-Disease
in	O
a	O
cadvaeric	O
reanl	O
allogarft	O
.	O

Rantiidine	O
frequently	O
is	O
used	O
for	O
preventing	O
pepitc	O
ulcertaion	O
after	O
rneal	O
tranpslantation	O
.	O

This	O
durg	O
occasionally	O
has	O
been	O
associated	O
with	O
actue	O
interstiital	B-Disease
nehpritis	I-Disease
in	O
ntaive	O
kidnyes	O
.	O

There	O
are	O
no	O
similar	O
reprots	O
with	O
rneal	O
tranpslantation	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
ranitiidne	O
-	O
idnuced	O
aucte	O
intrestitial	B-Disease
nephrtiis	I-Disease
in	O
a	O
rceipient	O
of	O
a	O
cadavreic	O
rneal	O
allogrfat	O
presetning	O
with	O
aucte	O
allogarft	O
dysfuntcion	O
within	O
48	O
hours	O
of	O
expsoure	O
to	O
the	O
durg	O
.	O

The	O
biposy	O
speicmen	O
showed	O
pathongomonic	O
featrues	O
,	O
including	O
eosinohpilic	O
inflitration	O
of	O
the	O
intertsitial	O
compratment	O
.	O

Allograft	O
funtcion	O
ipmroved	O
rapidly	O
and	O
returned	O
to	O
baselnie	O
after	O
stopping	O
the	O
durg	O
.	O

Lievr	B-Disease
diesase	I-Disease
caused	O
by	O
propylthioruacil	O
.	O

This	O
rpeort	O
presents	O
the	O
cliincal	O
,	O
lbaoratory	O
,	O
and	O
light	O
and	O
elecrton	O
mircoscopic	O
observaitons	O
on	O
a	O
ptaient	O
with	O
chornic	B-Disease
acitve	I-Disease
(	I-Disease
aggerssive	I-Disease
)	I-Disease
hepattiis	I-Disease
caused	O
by	O
the	O
adminisrtation	O
of	O
propylthiouraicl	O
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drgus	O
that	O
must	O
be	O
considered	O
in	O
the	O
evalutaion	O
of	O
crhonic	O
lievr	B-Disease
dsiease	I-Disease
.	O

Witdhrawal	B-Disease
-	I-Disease
emegrent	I-Disease
rabbit	I-Disease
snydrome	I-Disease
during	O
dsoe	O
redcution	O
of	O
risperidnoe	O
.	O

Rbabit	B-Disease
sydnrome	I-Disease
(	O
RS	B-Disease
)	O
is	O
a	O
rrae	O
extrpayramidal	O
side	O
effect	O
caused	O
by	O
prolnoged	O
neurolpetic	O
medciation	O
.	O

Here	O
we	O
present	O
a	O
csae	O
of	O
withrdawal	B-Disease
-	I-Disease
emergnet	I-Disease
RS	I-Disease
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

The	O
paitent	O
developed	O
RS	B-Disease
during	O
dsoe	O
redcution	O
of	O
rispreidone	O
.	O

The	O
sympotm	O
was	O
tretaed	O
successfully	O
with	O
triheyxphenidyl	O
anticholniergic	O
tehrapy	O
.	O

The	O
underlying	O
mechainsm	O
of	O
wtihdrawal	B-Disease
-	I-Disease
emegrent	I-Disease
RS	I-Disease
in	O
the	O
present	O
csae	O
may	O
have	O
been	O
related	O
to	O
the	O
pahrmacological	O
porfile	O
of	O
risperidnoe	O
,	O
a	O
serotnoin	O
-	O
dopamnie	O
antagoinst	O
,	O
suggesting	O
the	O
patohphysiologic	O
influecne	O
of	O
the	O
sreotonin	O
sytsem	O
in	O
the	O
develpoment	O
of	O
RS	B-Disease
.	O

Pharmacoknietic	O
/	O
pharmacodyanmic	O
assessment	O
of	O
the	O
efefcts	O
of	O
E4301	O
,	O
cisapirde	O
,	O
terfenaidne	O
and	O
terdoiline	O
on	O
monopahsic	O
aciton	O
potenital	O
duartion	O
in	O
dog	O
.	O

1	O
.	O

Tosrades	B-Disease
de	I-Disease
piontes	I-Disease
(	O
TDP	B-Disease
)	O
is	O
a	O
potentially	O
faatl	O
vnetricular	B-Disease
tachcyardia	I-Disease
associated	O
with	O
incresaes	O
in	O
QT	O
intreval	O
and	O
monopahsic	O
atcion	O
potenital	O
duartion	O
(	O
MPAD	O
)	O
.	O

TDP	B-Disease
is	O
a	O
side	O
-	O
effect	O
that	O
has	O
led	O
to	O
withdrwaal	O
of	O
several	O
durgs	O
from	O
the	O
makret	O
(	O
e	O
.	O
g	O
.	O
terefnadine	O
and	O
teroidline	O
)	O
.	O

2	O
.	O

The	O
potenital	O
of	O
componuds	O
to	O
cause	O
TDP	B-Disease
was	O
evaulated	O
by	O
mnoitoring	O
their	O
effcets	O
on	O
MPAD	O
in	O
dog	O
.	O

Four	O
cmopounds	O
known	O
to	O
icnrease	O
QT	O
interavl	O
and	O
cause	O
TDP	B-Disease
were	O
investigaetd	O
:	O
terfneadine	O
,	O
terodilnie	O
,	O
cisarpide	O
and	O
E0431	O
.	O

On	O
the	O
basis	O
that	O
only	O
free	O
durg	O
in	O
the	O
sytsemic	O
circluation	O
will	O
elicit	O
a	O
pharamcological	O
rseponse	O
taregt	O
,	O
free	O
concentrtaions	O
in	O
palsma	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
durg	O
expousres	O
in	O
man	O
.	O

Inufsion	O
regimnes	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
taregt	O
-	O
free	O
concnetrations	O
of	O
these	O
drgus	O
in	O
plamsa	O
and	O
dtaa	O
on	O
the	O
relatoinship	O
between	O
free	O
concentraiton	O
and	O
chnages	O
in	O
MPAD	O
were	O
obtained	O
for	O
these	O
compuonds	O
.	O

3	O
.	O

These	O
dtaa	O
indicate	O
that	O
the	O
free	O
E5D0	O
in	O
plsama	O
for	O
tefrenadine	O
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terdoiline	O
(	O
76	O
nM	O
)	O
,	O
csiapride	O
(	O
11	O
nM	O
)	O
and	O
E0431	O
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correltae	O
with	O
the	O
free	O
concnetration	O
in	O
man	O
causing	O
QT	O
effcets	O
.	O

For	O
copmounds	O
that	O
have	O
shown	O
TDP	B-Disease
in	O
the	O
clniic	O
(	O
terfenaidne	O
,	O
terodiilne	O
,	O
csiapride	O
)	O
there	O
is	O
little	O
differnetiation	O
between	O
the	O
dog	O
E5D0	O
and	O
the	O
efficacoius	O
free	O
plsama	O
concentartions	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
liimted	O
saefty	O
magrins	O
.	O

These	O
dtaa	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
threapeutic	O
rtaio	O
with	O
respect	O
to	O
TDP	B-Disease
in	O
potenital	O
deevlopment	O
cadnidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
durg	O
cocnentrations	O
in	O
pharmaockinetic	O
/	O
pahrmacodynamic	O
studeis	O
.	O

Bladedr	O
retetnion	B-Disease
of	I-Disease
urnie	I-Disease
as	O
a	O
result	O
of	O
cotninuous	O
intraevnous	O
infsuion	O
of	O
fentaynl	O
:	O
2	O
csae	O
reprots	O
.	O

Sedtaion	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neontae	O
to	O
decraese	O
the	O
sterss	O
and	O
pian	B-Disease
from	O
the	O
nxoious	O
stiumli	O
and	O
invsaive	O
prcoedures	O
in	O
the	O
neonaatl	O
intnesive	O
crae	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
sycnhrony	O
between	O
ventiltaor	O
and	O
spontaneuos	O
breahts	O
.	O

Fentnayl	O
,	O
an	O
opiiod	O
aanlgesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonaatl	O
intensvie	O
crae	O
unit	O
setting	O
for	O
these	O
very	O
purpsoes	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fenatnyl	O
admniistration	O
include	O
chset	B-Disease
wlal	I-Disease
rigidtiy	I-Disease
,	O
hypotnesion	B-Disease
,	O
respiraotry	B-Disease
deprsesion	I-Disease
,	O
and	O
bradycarida	B-Disease
.	O

Here	O
,	O
2	O
caess	O
of	O
urniary	B-Disease
baldder	I-Disease
retetnion	I-Disease
leading	O
to	O
rneal	O
pelovcalyceal	O
dilaattion	O
mimicking	O
hydronephroiss	B-Disease
as	O
a	O
result	O
of	O
contiunous	O
infusoin	O
of	O
fentaynl	O
are	O
reported	O
.	O

Faatl	O
myeloencepahlopathy	B-Disease
due	O
to	O
accidental	O
intarthecal	O
vicnristin	O
administrtaion	O
:	O
a	O
rpeort	O
of	O
two	O
caess	O
.	O

We	O
reoprt	O
on	O
two	O
ftaal	O
caess	O
of	O
acicdental	O
inrtathecal	O
vincristnie	O
instlilation	O
in	O
a	O
5	O
-	O
yaer	O
old	O
gril	O
with	O
recurernt	O
aucte	B-Disease
lymhpoblastic	I-Disease
leuecmia	I-Disease
and	O
a	O
57	O
-	O
yaer	O
old	O
man	O
with	O
lymphoblsatic	B-Disease
lymphmoa	I-Disease
.	O

The	O
gril	O
deid	O
seven	O
dyas	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intratehcal	O
inejction	O
of	O
vicnristine	O
.	O

Cliniclaly	O
,	O
the	O
onset	O
was	O
characteirzed	O
by	O
the	O
sgins	O
of	O
opistothnous	B-Disease
,	I-Disease
sesnory	I-Disease
and	I-Disease
mootr	I-Disease
dysfucntion	I-Disease
and	O
acsending	O
paralsyis	B-Disease
.	O

Hsitological	O
and	O
immuonhistochemical	O
investgiations	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neruofilament	O
)	O
revelaed	O
dgeeneration	B-Disease
of	I-Disease
myeiln	I-Disease
and	I-Disease
axnos	I-Disease
as	O
well	O
as	O
pseduocystic	B-Disease
trasnformation	I-Disease
in	O
areas	O
expsoed	O
to	O
vinrcistine	O
,	O
accompanied	O
by	O
secondary	O
chanegs	O
with	O
numerous	O
prominent	O
macrpohages	O
.	O

The	O
cliniacl	O
cuorse	O
and	O
histopathloogical	O
resluts	O
of	O
the	O
two	O
csaes	O
are	O
presented	O
.	O

A	O
rveiew	O
of	O
all	O
reported	O
caess	O
in	O
the	O
litertaure	O
is	O
given	O
.	O

A	O
better	O
contrloled	O
regiemn	O
for	O
admiinstering	O
vincrisitne	O
and	O
intrathceal	O
chemohterapy	O
is	O
recmomended	O
.	O

Palpebarl	B-Disease
tiwtching	I-Disease
in	O
a	O
deprsesed	B-Disease
adolescnet	O
on	O
citlaopram	O
.	O

Current	O
estimtaes	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
chlidren	O
and	O
adoelscents	O
are	O
afefcted	O
by	O
major	B-Disease
depressoin	I-Disease
.	O

We	O
rpeort	O
a	O
favorbale	O
repsonse	O
to	O
treamtent	O
with	O
citalorpam	O
by	O
a	O
15	O
-	O
yaer	O
-	O
old	O
boy	O
with	O
major	B-Disease
depressoin	I-Disease
who	O
exhibited	O
palepbral	B-Disease
twithcing	I-Disease
during	O
his	O
first	O
2	O
wekes	O
of	O
tretament	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
efefct	O
of	O
ciatlopram	O
as	O
it	O
reimtted	O
with	O
redistribtuion	O
of	O
dsoes	O
.	O

The	O
3	O
-	O
week	O
sulphasalaizne	O
synrdome	O
strikes	O
again	O
.	O

A	O
34	O
-	O
yaer	O
-	O
old	O
lday	O
developed	O
a	O
constellaiton	O
of	O
dermatiits	B-Disease
,	O
feevr	B-Disease
,	O
lymphaednopathy	B-Disease
and	O
hepaittis	B-Disease
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
coruse	O
of	O
oarl	O
sluphasalazine	O
for	O
sreo	O
-	O
negtaive	O
rehumatoid	B-Disease
atrhritis	I-Disease
.	O

Cerviacl	O
and	O
ingunial	O
lypmh	O
ndoe	O
biopises	O
showed	O
the	O
featrues	O
of	O
sevree	O
necrotsiing	O
lymphadeniits	B-Disease
,	O
associated	O
with	O
erythrophagocyotsis	O
and	O
prominent	O
eosinohpilic	O
infiltartes	O
,	O
without	O
vrial	O
inculsion	O
bdoies	O
,	O
suggestive	O
of	O
an	O
advrese	B-Disease
durg	I-Disease
reactoin	I-Disease
.	O
A	O
week	O
later	O
,	O
fulmniant	O
durg	B-Disease
-	I-Disease
induecd	I-Disease
hpeatitis	I-Disease
,	O
associated	O
with	O
the	O
presnece	O
of	O
atni	O
-	O
nculear	O
autaontibodies	O
(	O
but	O
not	O
with	O
other	O
markres	O
of	O
autoimmunity	B-Disease
)	O
,	O
and	O
accompanied	O
by	O
mluti	B-Disease
-	I-Disease
oragn	I-Disease
faliure	I-Disease
and	O
spesis	B-Disease
,	O
superveend	O
.	O

She	O
subsequently	O
deid	O
some	O
5	O
weeks	O
after	O
the	O
commencmeent	O
of	O
her	O
durg	O
tehrapy	O
.	O
Psot	O
-	O
moretm	O
examinatoin	O
showed	O
evdience	O
of	O
massive	B-Disease
hpeatocellular	I-Disease
nercosis	I-Disease
,	O
actue	O
hypersensitivtiy	O
myocardtiis	B-Disease
,	O
foacl	O
actue	O
tbuulo	O
-	O
inetrstitial	O
nephrtiis	B-Disease
and	O
extenisve	O
bnoe	B-Disease
marrow	I-Disease
nercosis	I-Disease
,	O
with	O
no	O
evdience	O
of	O
malignnacy	B-Disease
.	O

It	O
is	O
thought	O
that	O
the	O
clincio	O
-	O
pathoolgical	O
featrues	O
and	O
crhonology	O
of	O
this	O
csae	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
week	O
sulphaslaazine	O
synrdome	O
"	O
,	O
a	O
rrae	O
,	O
but	O
often	O
ftaal	O
,	O
immunoallerigc	O
reatcion	O
to	O
sulphasalaznie	O
.	O

Intravenuos	O
adminsitration	O
of	O
procholrperazine	O
by	O
15	O
-	O
minute	O
infuison	O
versus	O
2	O
-	O
minute	O
blous	O
does	O
not	O
affect	O
the	O
inciednce	O
of	O
aakthisia	B-Disease
:	O
a	O
prospecitve	O
,	O
randmoized	O
,	O
controlled	O
tiral	O
.	O

STDUY	O
OBJETCIVE	O
:	O
We	O
sought	O
to	O
copmare	O
the	O
rtae	O
of	O
aktahisia	B-Disease
after	O
administrtaion	O
of	O
intarvenous	O
prochlorperaizne	O
as	O
a	O
2	O
-	O
minute	O
bouls	O
or	O
15	O
-	O
minute	O
ifnusion	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
prospetcive	O
,	O
randmoized	O
,	O
double	O
-	O
bilnd	O
sutdy	O
in	O
the	O
emregency	O
deaprtment	O
of	O
a	O
cnetral	O
-	O
ctiy	O
teachnig	O
hopsital	O
.	O

Patietns	O
aegd	O
18	O
yaers	O
or	O
odler	O
traeted	O
with	O
prochloreprazine	O
for	O
haedache	B-Disease
,	O
nuasea	B-Disease
,	O
or	O
vomtiing	B-Disease
were	O
eilgible	O
for	O
inclsuion	O
.	O

Sutdy	O
praticipants	O
were	O
ranodmized	O
to	O
receive	O
10	O
mg	O
of	O
procholrperazine	O
adminisetred	O
itnravenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
blous	O
gorup	O
)	O
or	O
10	O
mg	O
dliuted	O
in	O
50	O
mL	O
of	O
noraml	O
sailne	O
solutoin	O
admiinstered	O
by	O
means	O
of	O
intraevnous	O
infusoin	O
during	O
a	O
15	O
-	O
minute	O
peirod	O
(	O
infusoin	O
gorup	O
)	O
.	O

The	O
main	O
otucome	O
was	O
the	O
number	O
of	O
stduy	O
partiicpants	O
experiencing	O
aakthisia	B-Disease
within	O
60	O
miuntes	O
of	O
administrtaion	O
.	O

Aakthisia	O
was	O
defined	O
as	O
either	O
a	O
spontaenous	O
reoprt	O
of	O
resltessness	O
or	O
aigtation	B-Disease
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
ptaient	O
-	O
reported	O
akathsiia	B-Disease
ratnig	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
ivnestigator	O
-	O
observed	O
akathiisa	B-Disease
ratnig	O
scale	O
.	O

The	O
intnesity	O
of	O
heaadche	B-Disease
and	O
nasuea	B-Disease
was	O
measrued	O
with	O
a	O
100	O
-	O
mm	O
vsiual	O
aanlog	O
scale	O
.	O

REUSLTS	O
:	O
One	O
hundred	O
patietns	O
were	O
enrolled	O
.	O

One	O
stduy	O
partciipant	O
was	O
excluded	O
after	O
prootcol	O
violaiton	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
stduy	O
particiapnts	O
were	O
treaetd	O
for	O
haedache	B-Disease
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	O
nauesa	B-Disease
.	O

In	O
the	O
blous	O
gruop	O
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	O
akathiisa	B-Disease
compraed	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
infuison	O
gorup	O
(	O
Detla	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
confidnece	O
interavl	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
blous	O
and	O
infsuion	O
gropus	O
in	O
the	O
percentgae	O
of	O
participatns	O
who	O
saw	O
a	O
50	O
%	O
reduciton	O
in	O
their	O
headcahe	B-Disease
intenstiy	O
within	O
30	O
miuntes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
precentage	O
of	O
ptaients	O
with	O
a	O
50	O
%	O
reduciton	O
in	O
their	O
nauesa	B-Disease
was	O
12	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O

CNOCLUSION	O
:	O
A	O
50	O
%	O
redutcion	O
in	O
the	O
inicdence	O
of	O
akathiisa	B-Disease
when	O
prochlorperaizne	O
was	O
amdinistered	O
by	O
means	O
of	O
15	O
-	O
minute	O
itnravenous	O
inufsion	O
versus	O
a	O
2	O
-	O
minute	O
intraevnous	O
push	O
was	O
not	O
detecetd	O
.	O

The	O
effciacy	O
of	O
prochlorperaznie	O
in	O
the	O
treatemnt	O
of	O
haedache	B-Disease
and	O
nauesa	B-Disease
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rtae	O
of	O
administrtaion	O
,	O
although	O
no	O
formal	O
staitstical	O
compairsons	O
were	O
made	O
.	O

Comibned	O
antrietroviral	O
threapy	O
causes	O
cardoimyopathy	B-Disease
and	O
elevtaes	O
plamsa	O
lacatte	O
in	O
transegnic	O
ADIS	B-Disease
mcie	O
.	O

Highly	O
actvie	O
antiretrvoiral	O
tehrapy	O
(	O
HARAT	O
)	O
is	O
implicated	O
in	O
cadriomyopathy	B-Disease
(	O
CM	B-Disease
)	O
and	O
in	O
elevaetd	O
palsma	O
lcatate	O
(	O
LA	O
)	O
in	O
ADIS	B-Disease
through	O
mechnaisms	O
of	O
mitochondrail	B-Disease
dysufnction	I-Disease
.	O

To	O
determine	O
miotchondrial	O
eevnts	O
from	O
HARAT	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemiyzgous	O
trasngenic	O
ADIS	B-Disease
mcie	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wlid	O
-	O
tpye	O
FVB	O
/	O
n	O
littemrates	O
were	O
traeted	O
with	O
the	O
HAART	O
combiantion	O
of	O
zidvoudine	O
,	O
lamivudnie	O
,	O
and	O
indianvir	O
or	O
vheicle	O
cotnrol	O
for	O
10	O
dyas	O
or	O
35	O
dyas	O
.	O

At	O
terimnation	O
of	O
the	O
experimetns	O
,	O
mcie	O
underwent	O
echocardoigraphy	O
,	O
quantitaiton	O
of	O
abundnace	O
of	O
moleuclar	O
makrers	O
of	O
CM	B-Disease
(	O
vnetricular	O
mNRA	O
encoidng	O
atiral	O
natriuertic	O
facotr	O
[	O
ANF	O
]	O
and	O
sarcoplasimc	O
clacium	O
ATaPse	O
[	O
SECRA2	O
]	O
)	O
,	O
and	O
determinatoin	O
of	O
palsma	O
LA	O
.	O

Myocadrial	O
histolgoic	O
featuers	O
were	O
anlayzed	O
semiquantitaitvely	O
and	O
reuslts	O
were	O
confirmed	O
by	O
tarnsmission	O
elecrton	O
micrsocopy	O
.	O

After	O
35	O
dyas	O
in	O
the	O
TG	O
+	O
HAART	O
coohrt	O
,	O
lfet	O
ventircular	O
msas	O
incraesed	O
160	O
%	O
by	O
echoacrdiography	O
.	O

Moleculalry	O
,	O
ANF	O
mNRA	O
incraesed	O
250	O
%	O
and	O
SERAC2	O
mNRA	O
derceased	O
57	O
%	O
.	O

Boichemically	O
,	O
LA	O
was	O
elevtaed	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
.	O

Ptahologically	O
,	O
grnaular	O
cytoplasimc	O
chagnes	O
were	O
found	O
in	O
caridac	O
myoctyes	O
,	O
indicating	O
enlraged	O
,	O
damaegd	O
miotchondria	O
.	O

Finidngs	O
were	O
confirmed	O
ultrsatructurally	O
.	O

No	O
chnages	O
were	O
found	O
in	O
other	O
choorts	O
.	O

After	O
10	O
dyas	O
,	O
only	O
ANF	O
was	O
elevtaed	O
,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
cohrot	O
.	O

Reuslts	O
show	O
that	O
cuumlative	O
HARAT	O
caused	O
mitochondrail	O
CM	B-Disease
with	O
elevtaed	O
LA	O
in	O
ADIS	B-Disease
trnasgenic	O
mcie	O
.	O

A	O
Pahse	O
II	O
trail	O
of	O
cispltain	O
plus	O
WR	O
-	O
2721	O
(	O
amfiostine	O
)	O
for	O
metatsatic	O
bresat	B-Disease
carcinmoa	I-Disease
:	O
an	O
Easetrn	O
Cooperaitve	O
Oncoolgy	O
Gorup	O
Sutdy	O
(	O
E8818	O
)	O
.	O

BACKGRONUD	O
:	O
Cislpatin	O
has	O
mniimal	O
antitmuor	O
acitvity	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
teratment	O
of	O
metastaitc	O
berast	B-Disease
caricnoma	I-Disease
.	O

Odler	O
reoprts	O
suggest	O
an	O
ojbective	O
rseponse	O
rtae	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cislpatin	O
is	O
adminsitered	O
every	O
3	O
-	O
4	O
wekes	O
.	O

Although	O
a	O
dsoe	O
-	O
resposne	O
effcet	O
has	O
been	O
observed	O
with	O
cipslatin	O
,	O
the	O
dsoe	O
-	O
limiting	O
toxiciteis	B-Disease
associated	O
with	O
cisplaitn	O
(	O
e	O
.	O
g	O
.	O
,	O
npehrotoxicity	B-Disease
,	O
ototxoicity	B-Disease
,	O
and	O
neuortoxicity	B-Disease
)	O
have	O
limietd	O
its	O
use	O
as	O
a	O
traetment	O
for	O
bresat	B-Disease
caricnoma	I-Disease
.	O

WR	O
-	O
2721	O
or	O
amifotsine	O
initially	O
was	O
developed	O
to	O
protect	O
miiltary	O
personnel	O
in	O
the	O
evnet	O
of	O
nucelar	O
war	O
.	O

Amifsotine	O
subsequently	O
was	O
shown	O
to	O
protect	O
nomral	O
tsisues	O
from	O
the	O
txoic	O
effects	O
of	O
alkyltaing	O
agnets	O
and	O
cisplaitn	O
without	O
decreaisng	O
the	O
antiutmor	O
efefct	O
of	O
the	O
chmeotherapy	O
.	O

Ealry	O
trails	O
of	O
csiplatin	O
and	O
amifositne	O
also	O
suggested	O
that	O
the	O
incidecne	O
and	O
sveerity	O
of	O
cispaltin	O
-	O
idnuced	O
nephrtooxicity	B-Disease
,	O
ototoxciity	B-Disease
,	O
and	O
neuroptahy	B-Disease
were	O
reudced	O
.	O

METHODS	O
:	O
A	O
Phsae	O
II	O
stduy	O
of	O
the	O
cmobination	O
of	O
cisplaitn	O
plus	O
amfiostine	O
was	O
conducted	O
in	O
paitents	O
with	O
progressvie	O
metasattic	O
berast	B-Disease
carcinmoa	I-Disease
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherpay	O
rgeimen	O
for	O
mteastatic	O
disesae	O
.	O

Patietns	O
received	O
aimfostine	O
,	O
910	O
mg	O
/	O
m2	O
itnravenously	O
over	O
15	O
miuntes	O
.	O

After	O
compeltion	O
of	O
the	O
amiofstine	O
infuison	O
,	O
cipslatin	O
120	O
mg	O
/	O
m2	O
was	O
adimnistered	O
over	O
30	O
miuntes	O
.	O

Intrvaenous	O
hydartion	O
and	O
mannitol	O
was	O
amdinistered	O
before	O
and	O
after	O
cipslatin	O
.	O

Traetment	O
was	O
adimnistered	O
every	O
3	O
weeks	O
until	O
disaese	O
progression	O
.	O

REUSLTS	O
:	O
Forty	O
-	O
four	O
ptaients	O
were	O
enrolled	O
in	O
the	O
sutdy	O
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ineligilbe	O
.	O

A	O
mdeian	O
of	O
2	O
cylces	O
of	O
therpay	O
was	O
adminisetred	O
to	O
the	O
37	O
elgiible	O
paitents	O
.	O

Six	O
partail	O
responess	O
were	O
observed	O
for	O
an	O
overall	O
resopnse	O
rtae	O
of	O
16	O
%	O
.	O

Most	O
patietns	O
(	O
57	O
%	O
)	O
stopped	O
teratment	O
because	O
of	O
disaese	O
progression	O
.	O

Neuroloigc	B-Disease
toxictiy	I-Disease
was	O
reported	O
in	O
52	O
%	O
of	O
patinets	O
.	O

Seven	O
different	O
lfie	O
-	O
threatening	O
toxiicties	B-Disease
were	O
observed	O
in	O
pateints	O
while	O
receiving	O
treatemnt	O
.	O

CONCLSUIONS	O
:	O
The	O
combinatoin	O
of	O
csiplatin	O
and	O
amiofstine	O
in	O
this	O
stduy	O
resulted	O
in	O
an	O
overall	O
resopnse	O
rtae	O
of	O
16	O
%	O
.	O

Neither	O
a	O
tuomr	B-Disease
-	O
protective	O
efefct	O
nor	O
reduecd	O
toxiicty	B-Disease
to	O
nomral	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amfiostine	O
to	O
csiplatin	O
in	O
this	O
tiral	O
.	O

Oarl	O
conrtaceptives	O
and	O
the	O
rsik	O
of	O
mycoardial	B-Disease
inafrction	I-Disease
.	O

BACGKROUND	O
:	O
An	O
associatoin	O
between	O
the	O
use	O
of	O
oarl	O
contracpetives	O
and	O
the	O
rsik	O
of	O
myocradial	B-Disease
infraction	I-Disease
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studeis	O
.	O

We	O
invetsigated	O
this	O
association	O
,	O
according	O
to	O
the	O
tpye	O
of	O
proegstagen	O
included	O
in	O
third	O
-	O
gneeration	O
(	O
i	O
.	O
e	O
.	O
,	O
desoegstrel	O
or	O
getsodene	O
)	O
and	O
second	O
-	O
generatoin	O
(	O
i	O
.	O
e	O
.	O
,	O
levoonrgestrel	O
)	O
oarl	O
contracetpives	O
,	O
the	O
dsoe	O
of	O
estorgen	O
,	O
and	O
the	O
presnece	O
or	O
asbence	O
of	O
prothrombtoic	O
muttaions	O
METHODS	O
:	O
In	O
a	O
natiownide	O
,	O
popluation	O
-	O
based	O
,	O
csae	O
-	O
cnotrol	O
stduy	O
,	O
we	O
identifeid	O
and	O
enrolled	O
248	O
woemn	O
18	O
through	O
49	O
yeras	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocaridal	B-Disease
infarctoin	I-Disease
between	O
1990	O
and	O
1995	O
and	O
925	O
cnotrol	O
wmoen	O
who	O
had	O
not	O
had	O
a	O
myocardail	B-Disease
infarciton	I-Disease
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
claendar	O
yaer	O
of	O
the	O
index	O
eevnt	O
,	O
and	O
aera	O
of	O
residecne	O
.	O

Subjetcs	O
supplied	O
ifnormation	O
on	O
oarl	O
-	O
contraceptvie	O
use	O
and	O
major	O
cardivoascular	O
rsik	O
fcators	O
.	O

An	O
analyiss	O
for	O
fatcor	O
V	O
Leiedn	O
and	O
the	O
G22010A	O
mutaiton	O
in	O
the	O
prothromibn	O
gnee	O
was	O
conducted	O
in	O
217	O
pateints	O
and	O
763	O
cotnrols	O
RESLUTS	O
:	O
The	O
odds	O
rtaio	O
for	O
myoacrdial	B-Disease
ifnarction	I-Disease
among	O
woemn	O
who	O
used	O
any	O
tpye	O
of	O
combiend	O
oarl	O
contraecptive	O
,	O
as	O
compraed	O
with	O
nonusres	O
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
confdience	O
interavl	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

The	O
adjusted	O
odds	O
rtaio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
cnofidence	O
intevral	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
woemn	O
who	O
used	O
second	O
-	O
generatoin	O
oarl	O
contraecptives	O
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confdience	O
intevral	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
gneeration	O
oarl	O
contrcaeptives	O
.	O

Among	O
wmoen	O
who	O
used	O
oarl	O
cnotraceptives	O
,	O
the	O
odds	O
rtaio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confdience	O
inetrval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrobmotic	O
mutaiton	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidecne	O
intevral	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutaiton	O
CONCLUSINOS	O
:	O
The	O
rsik	O
of	O
myocadrial	B-Disease
inafrction	I-Disease
was	O
incraesed	O
among	O
woemn	O
who	O
used	O
second	O
-	O
genertaion	O
oarl	O
contraceptvies	O
.	O

The	O
rseults	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generatoin	O
oarl	O
cotnraceptives	O
were	O
inconculsive	O
but	O
suggested	O
that	O
the	O
rsik	O
was	O
loewr	O
than	O
the	O
rsik	O
associated	O
with	O
second	O
-	O
geneartion	O
oarl	O
contarceptives	O
.	O

The	O
rsik	O
of	O
myoacrdial	B-Disease
ifnarction	I-Disease
was	O
similar	O
among	O
woemn	O
who	O
used	O
oarl	O
cnotraceptives	O
whether	O
or	O
not	O
they	O
had	O
a	O
prothormbotic	O
mtuation	O
.	O

End	B-Disease
-	I-Disease
satge	I-Disease
reanl	I-Disease
diesase	I-Disease
(	O
ERSD	B-Disease
)	O
after	O
otrhotopic	O
lievr	O
tranpslantation	O
(	O
OTLX	O
)	O
using	O
calcienurin	O
-	O
based	O
imumnotherapy	O
:	O
rsik	O
of	O
developmnet	O
and	O
treamtent	O
.	O

BACKRGOUND	O
:	O
The	O
calcineuirn	O
inhibiotrs	O
cyclosoprine	O
and	O
tarcolimus	O
are	O
both	O
known	O
to	O
be	O
npehrotoxic	B-Disease
.	O

Their	O
use	O
in	O
ortohtopic	O
lvier	O
tranpslantation	O
(	O
OTLX	O
)	O
has	O
dramatically	O
ipmroved	O
success	O
rtaes	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
incresae	O
of	O
patinets	O
who	O
are	O
prseenting	O
after	O
OTLX	O
with	O
end	B-Disease
-	I-Disease
satge	I-Disease
reanl	I-Disease
dsiease	I-Disease
(	O
ERSD	B-Disease
)	O
.	O

This	O
retrsopective	O
sutdy	O
examines	O
the	O
incidnece	O
and	O
treatemnt	O
of	O
ERSD	B-Disease
and	O
chroinc	B-Disease
reanl	I-Disease
faiulre	I-Disease
(	O
CRF	B-Disease
)	O
in	O
OTLX	O
ptaients	O
.	O

METHODS	O
:	O
Patietns	O
receiving	O
an	O
OTLX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
motnhs	O
potsoperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O

Our	O
prospectively	O
collected	O
datbaase	O
was	O
the	O
suorce	O
of	O
infromation	O
.	O

Patinets	O
were	O
divided	O
into	O
three	O
gruops	O
:	O
Conrtols	O
,	O
no	O
CRF	B-Disease
or	O
ERSD	B-Disease
,	O
n	O
=	O
748	O
;	O
CRF	B-Disease
,	O
sustaiend	O
sreum	O
creatniine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ERSD	B-Disease
,	O
n	O
=	O
45	O
.	O

Gruops	O
were	O
cmopared	O
for	O
prepoerative	O
laboratroy	O
vraiables	O
,	O
diagnsois	O
,	O
postpoerative	O
vairables	O
,	O
surivval	O
,	O
tpye	O
of	O
ERSD	B-Disease
therpay	O
,	O
and	O
surivval	O
from	O
onset	O
of	O
ERSD	B-Disease
.	O

RSEULTS	O
:	O
At	O
13	O
yaers	O
after	O
OTLX	O
,	O
the	O
inciednce	O
of	O
sveere	O
rneal	B-Disease
dysufnction	I-Disease
was	O
18	O
.	O
1	O
%	O
(	O
CRF	B-Disease
8	O
.	O
6	O
%	O
and	O
ERSD	B-Disease
9	O
.	O
5	O
%	O
)	O
.	O

Comapred	O
with	O
cotnrol	O
patinets	O
,	O
CRF	B-Disease
and	O
ERSD	B-Disease
paitents	O
had	O
hgiher	O
preopertaive	O
seurm	O
cretainine	O
levles	O
,	O
a	O
greater	O
percnetage	O
of	O
paitents	O
with	O
hepaotrenal	B-Disease
syndrmoe	I-Disease
,	O
hihger	O
percentgae	O
reqiurement	O
for	O
dialyiss	O
in	O
the	O
first	O
3	O
monhts	O
psotoperatively	O
,	O
and	O
a	O
hgiher	O
1	O
-	O
yaer	O
sreum	O
creatiinne	O
.	O

Multivairate	O
stepwise	O
logisitc	O
regrsesion	O
aanlysis	O
using	O
proeperative	O
and	O
postoperatvie	O
vairables	O
identfiied	O
that	O
an	O
inrcease	O
of	O
seurm	O
ceratinine	O
cmopared	O
with	O
avergae	O
at	O
1	O
yaer	O
,	O
3	O
motnhs	O
,	O
and	O
4	O
wekes	O
postoperatviely	O
were	O
inedpendent	O
rsik	O
facotrs	O
for	O
the	O
dveelopment	O
of	O
CRF	B-Disease
or	O
ERSD	B-Disease
with	O
odds	O
rtaios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
suvrival	O
from	O
the	O
tmie	O
of	O
OTLX	O
was	O
not	O
significantly	O
different	O
among	O
gruops	O
,	O
but	O
by	O
yaer	O
13	O
,	O
the	O
survvial	O
of	O
the	O
ptaients	O
who	O
had	O
ERSD	B-Disease
was	O
only	O
28	O
.	O
2	O
%	O
comapred	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
contorl	O
gorup	O
.	O

Ptaients	O
developing	O
ERSD	B-Disease
had	O
a	O
6	O
-	O
yaer	O
suvrival	O
after	O
onset	O
of	O
ERSD	B-Disease
of	O
27	O
%	O
for	O
the	O
patinets	O
receiving	O
hemodilaysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
ptaients	O
developing	O
ERSD	B-Disease
who	O
subsequently	O
received	O
kdiney	O
trnasplants	O
.	O

CONCLSUIONS	O
:	O
Patietns	O
who	O
are	O
more	O
than	O
10	O
yeras	O
psot	O
-	O
OTLX	O
have	O
CRF	B-Disease
and	O
ERSD	B-Disease
at	O
a	O
high	O
rtae	O
.	O

The	O
devleopment	O
of	O
ERSD	B-Disease
decerases	O
surivval	O
,	O
particularly	O
in	O
those	O
paitents	O
tretaed	O
with	O
diaylsis	O
only	O
.	O

Ptaients	O
who	O
develop	O
ERSD	B-Disease
have	O
a	O
hihger	O
preopertaive	O
and	O
1	O
-	O
yaer	O
sreum	O
ceratinine	O
and	O
are	O
more	O
likely	O
to	O
have	O
hepatoernal	B-Disease
synrdome	I-Disease
.	O

However	O
,	O
an	O
inrcease	O
of	O
seurm	O
cretainine	O
at	O
various	O
times	O
postoepratively	O
is	O
more	O
predcitive	O
of	O
the	O
deevlopment	O
of	O
CRF	B-Disease
or	O
ERSD	B-Disease
.	O

New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
dercease	O
this	O
compilcation	O
.	O

Eipleptic	B-Disease
siezures	I-Disease
following	O
cotrical	O
applciation	O
of	O
firbin	O
selaants	O
containing	O
tranexmaic	O
aicd	O
in	O
rtas	O
.	O

BACKGRUOND	O
:	O
Fibirn	O
seaalnts	O
(	O
FS	O
)	O
derived	O
from	O
hmuan	O
palsma	O
are	O
frequently	O
used	O
in	O
neurosuregry	O
.	O

In	O
order	O
to	O
icnrease	O
colt	O
staiblity	O
,	O
FS	O
typically	O
contain	O
arpotinin	O
,	O
a	O
ntaural	O
firbinolysis	O
inhiibtor	O
.	O

Recently	O
,	O
synthteic	O
fibirnolysis	O
inhbiitors	O
such	O
as	O
trnaexamic	O
aicd	O
(	O
tMACA	O
)	O
have	O
been	O
considered	O
as	O
substiuttes	O
for	O
aportinin	O
.	O

However	O
,	O
tACMA	O
has	O
been	O
shown	O
to	O
cause	O
eplieptic	B-Disease
seizrues	I-Disease
.	O

We	O
wanted	O
to	O
stduy	O
whether	O
tMACA	O
retains	O
its	O
cnovulsive	B-Disease
aciton	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	O
arpotinin	O
or	O
different	O
cnocentrations	O
of	O
tMACA	O
(	O
0	O
.	O
5	O
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pail	O
sufrace	O
of	O
the	O
coretx	O
of	O
anaestheitzed	O
rtas	O
.	O

The	O
resposne	O
of	O
the	O
animlas	O
was	O
evalauted	O
using	O
electroencephalgoraphy	O
and	O
by	O
montioring	O
the	O
clincial	O
behaivour	O
during	O
and	O
after	O
rceovery	O
from	O
anaesthseia	O
.	O

FINIDNGS	O
:	O
FS	O
containing	O
tMACA	O
caused	O
paroxsymal	O
brian	O
atcivity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsvie	B-Disease
beahviours	O
.	O

The	O
dgeree	O
of	O
these	O
seiuzres	B-Disease
incresaed	O
with	O
increasnig	O
concentrtaion	O
of	O
tMACA	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tACMA	O
eovked	O
gneeralized	B-Disease
seizrues	I-Disease
in	O
all	O
tseted	O
rtas	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
loewst	O
concentratoin	O
of	O
tACMA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
eovked	O
brief	O
eipsodes	O
of	O
jrek	O
-	O
correlaetd	O
covnulsive	B-Disease
potnetials	O
in	O
1	O
of	O
6	O
rtas	O
.	O

In	O
contrast	O
,	O
FS	O
containing	O
arpotinin	O
did	O
not	O
evoke	O
any	O
parxoysmal	O
activtiy	O
.	O

INTERPRETATION	O
:	O
Traneaxmic	O
aicd	O
retains	O
its	O
convlusive	B-Disease
actoin	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
tACMA	O
for	O
srugery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
rsik	O
to	O
the	O
pateint	O
.	O

Sequenital	O
obsrevations	O
of	O
exencehpaly	B-Disease
and	O
subsequent	O
morphloogical	O
cahnges	O
by	O
muose	O
exo	O
utreo	O
dveelopment	O
ssytem	O
:	O
analsyis	O
of	O
the	O
mehcanism	O
of	O
transformtaion	O
from	O
exnecephaly	B-Disease
to	O
annecephaly	B-Disease
.	O

Anecnephaly	B-Disease
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencepahly	B-Disease
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
expeirmental	O
evidnece	O
to	O
support	O
this	O
,	O
and	O
the	O
mechnaism	O
of	O
transformtaion	O
remains	O
unclear	O
.	O

We	O
examined	O
this	O
theroy	O
using	O
the	O
exo	O
utreo	O
deevlopment	O
sysetm	O
that	O
allows	O
direct	O
and	O
sqeuential	O
observaitons	O
of	O
mid	O
-	O
to	O
ltae	O
-	O
gesttaion	O
muose	O
ebmryos	O
.	O

We	O
observed	O
the	O
exencephlay	B-Disease
indcued	O
by	O
5	O
-	O
azacytiidne	O
at	O
embyronic	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embroys	O
develop	O
exo	O
utreo	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embroys	O
at	O
E18	O
.	O
5	O
.	O

We	O
confirmed	O
several	O
caess	O
of	O
transformatoin	O
from	O
exencephlay	B-Disease
to	O
aenncephaly	B-Disease
.	O

However	O
,	O
in	O
many	O
csaes	O
,	O
the	O
exencephlaic	B-Disease
barin	O
tissue	O
was	O
preserevd	O
with	O
more	O
or	O
less	O
reduciton	O
during	O
this	O
peirod	O
.	O

To	O
aanlyze	O
the	O
transofrmation	O
ptaterns	O
,	O
we	O
classified	O
the	O
exencehpaly	B-Disease
by	O
szie	O
and	O
shpae	O
of	O
the	O
eexncephalic	B-Disease
tsisue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
tarnsformation	O
of	O
exenecphalic	B-Disease
tisuse	O
was	O
not	O
simply	O
szie	O
-	O
depnedent	O
,	O
and	O
all	O
csaes	O
of	O
anencephlay	B-Disease
at	O
E18	O
.	O
5	O
resulted	O
from	O
emrbyos	O
with	O
a	O
large	O
amonut	O
of	O
exencehpalic	B-Disease
tsisue	O
at	O
E13	O
.	O
5	O
.	O

Mircoscopic	O
observaiton	O
showed	O
the	O
confiugration	O
of	O
exencepahly	B-Disease
at	O
E13	O
.	O
5	O
,	O
freuqent	O
hemorrhaging	B-Disease
and	O
detahcment	O
of	O
the	O
neuarl	O
pltae	O
from	O
sruface	O
ectoedrm	O
in	O
the	O
exencpehalic	B-Disease
haed	O
at	O
E15	O
.	O
5	O
,	O
and	O
multilpe	O
mdoes	O
of	O
reudction	O
in	O
the	O
exnecephalic	B-Disease
tissue	O
at	O
E18	O
.	O
5	O
.	O

From	O
observatoins	O
of	O
the	O
vsaculature	O
,	O
aletred	O
distributoin	O
patterns	O
of	O
vsesels	O
were	O
identfiied	O
in	O
the	O
exencephailc	B-Disease
haed	O
.	O

These	O
findigns	O
suggest	O
that	O
overgorwth	O
of	O
the	O
eexncephalic	B-Disease
nerual	O
tisuse	O
causes	O
the	O
alteerd	O
distirbution	O
pattenrs	O
of	O
vessles	O
,	O
subsequent	O
peripehral	O
circultaory	B-Disease
failrue	I-Disease
and	O
/	O
or	O
hemorhraging	B-Disease
in	O
various	O
prats	O
of	O
the	O
exencephailc	B-Disease
haed	O
,	O
leading	O
to	O
the	O
mulitple	O
moeds	O
of	O
tisuse	O
reductoin	O
during	O
tarnsformation	O
from	O
exencpehaly	B-Disease
to	O
anencephlay	B-Disease
.	O

99mTc	O
-	O
glucaarte	O
for	O
detcetion	O
of	O
isoproetrenol	O
-	O
induecd	O
myocadrial	B-Disease
infarciton	I-Disease
in	O
rtas	O
.	O

Infract	B-Disease
-	O
aivd	O
radiopharmaceutcials	O
are	O
necessary	O
for	O
raipd	O
and	O
timely	O
diagonsis	O
of	O
aucte	O
mycoardial	B-Disease
inafrction	I-Disease
.	O

The	O
ainmal	O
mdoel	O
used	O
to	O
produce	O
infarctoin	B-Disease
implies	O
aretry	O
ligaiton	O
but	O
cheimcal	O
induciton	O
can	O
be	O
easily	O
obtained	O
with	O
isorpoterenol	O
.	O

A	O
new	O
infacrt	B-Disease
-	O
aivd	O
radiopharmaceutcial	O
based	O
on	O
glucairc	O
aicd	O
was	O
prpeared	O
in	O
the	O
hosiptal	O
rdaiopharmacy	O
of	O
the	O
ICNMNSZ	O
.	O

99mTc	O
-	O
gluacrate	O
was	O
easy	O
to	O
prepare	O
,	O
stbale	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
sutdy	O
its	O
bidoistribution	O
in	O
rtas	O
with	O
isporoterenol	O
-	O
indcued	O
actue	O
myoacrdial	B-Disease
infarctoin	I-Disease
.	O

Histoloigcal	O
sutdies	O
demonstrated	O
that	O
the	O
rtas	O
developed	O
an	O
infacrt	B-Disease
18	O
h	O
after	O
iosproterenol	O
adimnistration	O
.	O

The	O
rat	O
biodistribuiton	O
stduies	O
showed	O
a	O
raipd	O
blood	O
cleaarnce	O
via	O
the	O
kidenys	O
.	O

Thirty	O
minuets	O
after	O
99mTc	O
-	O
gulcarate	O
admniistration	O
the	O
standardsied	O
herat	O
utpake	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4	O
.	O
7	O
in	O
infarcetd	O
rat	O
herat	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
nromal	O
rtas	O
.	O

RIOs	O
drawn	O
over	O
the	O
gmama	O
caemra	O
imgaes	O
showed	O
a	O
raito	O
of	O
4	O
.	O
4	O
.	O

The	O
high	O
imgae	O
quailty	O
suggests	O
that	O
high	O
contrast	O
iamges	O
can	O
be	O
obtained	O
in	O
humnas	O
and	O
the	O
96	O
h	O
stabliity	O
makes	O
it	O
an	O
ideal	O
agnet	O
to	O
detcet	O
,	O
in	O
paitents	O
,	O
eraly	O
cadriac	B-Disease
ifnarction	I-Disease
.	O

Buporpion	O
(	O
Zyabn	O
)	O
txoicity	B-Disease
.	O

Bupropoin	O
is	O
a	O
monocylcic	O
antideprsesant	O
structurally	O
related	O
to	O
amhpetamine	O
.	O

Zbyan	O
,	O
a	O
sutsained	O
-	O
reelase	O
formulaiton	O
of	O
bupropoin	O
hydrcohloride	O
,	O
was	O
recently	O
reelased	O
in	O
Irelnad	O
,	O
as	O
a	O
smoknig	O
cessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
monhts	O
since	O
it	O
'	O
s	O
introdcution	O
,	O
12	O
ovedrose	B-Disease
csaes	O
have	O
been	O
reported	O
to	O
The	O
Natoinal	O
Posions	O
Informaiton	O
Cnetre	O
.	O

8	O
ptaients	O
developed	O
sypmtoms	O
of	O
toxciity	B-Disease
.	O

Common	O
featuers	O
included	O
tacyhcardia	B-Disease
,	O
drowisness	O
,	O
halluicnations	B-Disease
and	O
convulsoins	B-Disease
.	O

Two	O
ptaients	O
developed	O
sveere	O
caridac	B-Disease
arrhyhtmias	I-Disease
,	O
including	O
one	O
ptaient	O
who	O
was	O
resucsitated	O
following	O
a	O
cadriac	B-Disease
arerst	I-Disease
.	O

All	O
patietns	O
recoveerd	O
without	O
seuqelae	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
a	O
31	O
yaer	O
old	O
fmeale	O
who	O
required	O
admisison	O
to	O
the	O
Intensvie	O
Crae	O
Uint	O
for	O
ventilatoin	O
and	O
full	O
supoprtive	O
threapy	O
,	O
following	O
ingesiton	O
of	O
13	O
.	O
5g	O
buporpion	O
.	O

Recurrent	O
seziures	B-Disease
were	O
traeted	O
with	O
daizepam	O
and	O
broad	O
copmlex	O
tahcycardia	B-Disease
was	O
successfully	O
terated	O
with	O
adensoine	O
.	O

Zyabn	O
caused	O
significant	O
neurloogical	B-Disease
and	I-Disease
cardiovasuclar	I-Disease
toxictiy	I-Disease
in	O
ovredose	B-Disease
.	O

The	O
potentail	O
txoic	O
effects	O
should	O
be	O
considered	O
when	O
prescribnig	O
it	O
as	O
a	O
smoikng	O
cesstaion	O
aid	O
.	O

GLEPP1	O
recepotr	O
tryosine	O
phsophatase	O
(	O
Ptrpo	O
)	O
in	O
rat	O
PAN	O
nephroiss	B-Disease
.	O

A	O
mraker	O
of	O
aucte	O
podoycte	O
inujry	O
.	O

Glmoerular	O
epihtelial	O
proetin	O
1	O
(	O
GELPP1	O
)	O
is	O
a	O
pdoocyte	O
reecptor	O
mmebrane	O
proetin	O
tyorsine	O
phsophatase	O
located	O
on	O
the	O
apcial	O
clel	O
mebmrane	O
of	O
viscreal	O
glomreular	O
epitehlial	O
clel	O
and	O
foot	O
porcesses	O
.	O

This	O
recetpor	O
plays	O
a	O
role	O
in	O
regultaing	O
the	O
structrue	O
and	O
fnuction	O
of	O
podcoyte	O
foot	O
porcess	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
mraker	O
of	O
glomerualr	B-Disease
injruy	I-Disease
,	O
the	O
amonut	O
and	O
ditsribution	O
of	O
GLPEP1	O
proetin	O
and	O
mNRA	O
were	O
examined	O
by	O
immunohisotchemistry	O
,	O
Wetsern	O
bolt	O
and	O
RaNse	O
prtoection	O
asasy	O
in	O
a	O
mdoel	O
of	O
poodcyte	O
inujry	O
in	O
the	O
rat	O
.	O

Puroymcin	O
aimnonucleoside	O
neprhosis	B-Disease
was	O
indcued	O
by	O
single	O
intrapeirtoneal	O
ijnection	O
of	O
puroymcin	O
aminouncleoside	O
(	O
PAN	O
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Tsisues	O
were	O
analyezd	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
dyas	O
after	O
PAN	O
inejction	O
so	O
as	O
to	O
include	O
both	O
the	O
aucte	O
phsae	O
of	O
proteinruia	B-Disease
associated	O
with	O
foot	O
procses	O
effacemnet	O
(	O
dyas	O
5	O
-	O
11	O
)	O
and	O
the	O
chrnoic	O
pahse	O
of	O
proteinruia	B-Disease
associated	O
with	O
golmerulosclerosis	B-Disease
(	O
dyas	O
45	O
-	O
126	O
)	O
.	O

At	O
day	O
5	O
,	O
GELPP1	O
portein	O
and	O
mNRA	O
were	O
rdeuced	O
from	O
the	O
noraml	O
range	O
(	O
265	O
.	O
2	O
+	O
/	O
-	O
79	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
mloes	O
/	O
glmoerulus	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
nromal	O
(	O
41	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
8	O
x	O
10	O
(	O
6	O
)	O
mloes	O
/	O
glmoerulus	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

This	O
occurred	O
in	O
asscoiation	O
with	O
an	O
incraese	O
in	O
urinray	O
protien	O
cotnent	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
1	O
to	O
99	O
.	O
0	O
+	O
/	O
-	O
61	O
mg	O
/	O
day	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
contrast	O
,	O
podocalxyin	O
did	O
not	O
change	O
significantly	O
at	O
this	O
tmie	O
.	O

By	O
day	O
11	O
,	O
GLEPP1	O
portein	O
and	O
mNRA	O
had	O
begun	O
to	O
return	O
towards	O
bsaeline	O
.	O

By	O
day	O
45	O
-	O
126	O
,	O
at	O
a	O
tmie	O
when	O
glomerualr	O
scarrnig	O
was	O
present	O
,	O
GELPP1	O
was	O
asbent	O
from	O
glomerulocslerotic	O
areas	O
although	O
the	O
total	O
golmerular	O
cnotent	O
of	O
GLPEP1	O
was	O
not	O
different	O
from	O
nomral	O
.	O

We	O
conclude	O
that	O
GELPP1	O
expressoin	O
,	O
unlike	O
pdoocalyxin	O
,	O
reflects	O
pdoocyte	O
injruy	O
idnuced	O
by	O
PAN	O
.	O

GELPP1	O
epxression	O
may	O
be	O
a	O
useful	O
marekr	O
of	O
podoycte	O
injruy	O
.	O

Atnithymocyte	O
glboulin	O
in	O
the	O
teratment	O
of	O
D	O
-	O
peniclilamine	O
-	O
inudced	O
aplatsic	B-Disease
aenmia	I-Disease
.	O

A	O
patinet	O
who	O
received	O
atnithymocyte	O
gloublin	O
tehrapy	O
for	O
aplatsic	B-Disease
anmeia	I-Disease
due	O
to	O
D	O
-	O
penicillamine	O
therpay	O
is	O
described	O
.	O

Bnoe	O
marorw	O
rceovery	O
and	O
perihperal	O
blood	O
recovrey	O
were	O
complete	O
1	O
mnoth	O
and	O
3	O
motnhs	O
,	O
respectively	O
,	O
after	O
teratment	O
,	O
and	O
bolod	O
trasnfusion	O
or	O
other	O
thearpies	O
were	O
not	O
necessary	O
in	O
a	O
follow	O
-	O
up	O
peirod	O
of	O
more	O
than	O
2	O
yeras	O
.	O

Use	O
of	O
antithymcoyte	O
globluin	O
may	O
be	O
the	O
opitmal	O
tretament	O
of	O
D	O
-	O
peniicllamine	O
-	O
indcued	O
aplasitc	B-Disease
aenmia	I-Disease
.	O

Metamiozl	O
potnetiates	O
mrophine	O
antinocicpetion	O
but	O
not	O
contsipation	B-Disease
after	O
chornic	O
teratment	O
.	O

This	O
work	O
evalautes	O
the	O
antinocicetpive	O
and	O
cnostipating	B-Disease
efefcts	O
of	O
the	O
combniation	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphnie	O
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
meatmizol	O
in	O
acutely	O
and	O
chroincally	O
traeted	O
(	O
once	O
a	O
day	O
for	O
12	O
dyas	O
)	O
rtas	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptvie	O
effcets	O
were	O
assessed	O
using	O
a	O
moedl	O
of	O
inflammatory	O
ncoiception	O
,	O
pian	B-Disease
-	O
inudced	O
funtcional	O
ipmairment	O
mdoel	O
,	O
and	O
the	O
charcaol	O
mael	O
tset	O
was	O
used	O
to	O
evalutae	O
the	O
intsetinal	O
tranist	O
.	O

Simultaenous	O
adimnistration	O
of	O
morhpine	O
with	O
metamziol	O
resulted	O
in	O
a	O
markedly	O
antinocicpetive	O
potentiatoin	O
and	O
an	O
increasnig	O
of	O
the	O
duraiton	O
of	O
aciton	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
aera	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
rpeeated	O
administartion	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Antincoiceptive	O
efefct	O
of	O
moprhine	O
was	O
redcued	O
in	O
chroniaclly	O
traeted	O
rtas	O
(	O
39	O
+	O
/	O
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
cmobination	O
-	O
induecd	O
antinoccieption	O
was	O
remained	O
similar	O
as	O
an	O
actue	O
treatemnt	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O
17	O
au	O
)	O
.	O

Actue	O
antinociceptvie	O
effetcs	O
of	O
the	O
combinatoin	O
were	O
partilaly	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
naloxnoe	O
s	O
.	O
c	O
.	O

(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
suggesting	O
the	O
pratial	O
involveemnt	O
of	O
the	O
opiiodergic	O
sysetm	O
in	O
the	O
synergsim	O
observed	O
.	O

In	O
indeepndent	O
gruops	O
,	O
morhpine	O
inhbiited	O
the	O
intestnial	O
tarnsit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
actue	O
and	O
crhonic	O
traetment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolreance	O
did	O
not	O
develop	O
to	O
the	O
constiapting	B-Disease
efefcts	O
.	O

The	O
combinaiton	O
inihbited	O
intesitnal	O
trasnit	O
similar	O
to	O
that	O
produced	O
by	O
morphnie	O
regardless	O
of	O
the	O
tmie	O
of	O
treatemnt	O
,	O
suggesting	O
that	O
metamziol	O
did	O
not	O
poetntiate	O
mrophine	O
-	O
indcued	O
cnostipation	B-Disease
.	O

These	O
findnigs	O
show	O
a	O
significant	O
interactoin	O
between	O
morhpine	O
and	O
meatmizol	O
in	O
chroncially	O
tretaed	O
rtas	O
,	O
suggesting	O
that	O
this	O
cmobination	O
could	O
be	O
useful	O
for	O
the	O
tretament	O
of	O
chrnoic	B-Disease
pian	I-Disease
.	O

Iofsfamide	O
enecphalopathy	B-Disease
presentnig	O
with	O
asteirxis	B-Disease
.	O

CNS	O
toixc	O
effects	O
of	O
the	O
antineolpastic	O
aegnt	O
ifosfamdie	O
(	O
IFX	O
)	O
are	O
ferquent	O
and	O
include	O
a	O
variety	O
of	O
neurologiacl	O
smyptoms	O
that	O
can	O
lmiit	O
durg	O
use	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
a	O
51	O
-	O
yaer	O
-	O
old	O
man	O
who	O
developed	O
sevree	O
,	O
disabilng	O
negaitve	O
mycolonus	B-Disease
of	O
the	O
upper	O
and	O
loewr	O
etxremities	O
after	O
the	O
infusoin	O
of	O
ifosafmide	O
for	O
plasmactyoma	B-Disease
.	O

He	O
was	O
awkae	O
,	O
revaeled	O
no	O
cahnges	O
of	O
metnal	O
stauts	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
mootr	O
sympotms	O
.	O

Carnial	O
magneitc	O
reosnance	O
imgaing	O
and	O
extnesive	O
laboratroy	O
stuides	O
failed	O
to	O
reveal	O
strucutral	B-Disease
lesinos	I-Disease
of	I-Disease
the	I-Disease
barin	I-Disease
and	O
meatbolic	B-Disease
abnromalities	I-Disease
.	O

An	O
electroencephalogarm	O
showed	O
continouus	O
,	O
genrealized	O
irrgeular	O
solwing	O
with	O
admxied	O
peridoic	O
trihpasic	O
waevs	O
indicating	O
symptomaitc	O
encephaloptahy	B-Disease
.	O

The	O
amdinistration	O
of	O
ifofsamide	O
was	O
dsicontinued	O
and	O
within	O
12	O
h	O
the	O
atserixis	B-Disease
resolved	O
completely	O
.	O

In	O
the	O
patinet	O
described	O
,	O
the	O
preesnce	O
of	O
asetrixis	B-Disease
during	O
infuison	O
of	O
ifosafmide	O
,	O
noraml	O
labroatory	O
findnigs	O
and	O
iamging	O
stduies	O
and	O
the	O
resoluiton	O
of	O
sympotms	O
following	O
the	O
discotninuation	O
of	O
the	O
durg	O
suggest	O
that	O
neagtive	O
myolconus	B-Disease
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

Antagnoism	O
between	O
inetrleukin	O
3	O
and	O
erythorpoietin	O
in	O
mcie	O
with	O
azidothymiidne	O
-	O
idnuced	O
aenmia	B-Disease
and	O
in	O
bnoe	O
marorw	O
enodthelial	O
cells	O
.	O

Azidothmyidine	O
(	O
AZT	O
)	O
-	O
induecd	O
aneima	B-Disease
in	O
mcie	O
can	O
be	O
rveersed	O
by	O
the	O
administraiton	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusoin	O
protien	O
of	O
inuslin	O
-	O
like	O
grwoth	O
facotr	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleuikn	O
3	O
)	O
.	O

Although	O
interleuikn	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythorpoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergisticlaly	O
on	O
hematopoeitic	O
clel	O
proliferaiton	O
in	O
vitro	O
,	O
injetcion	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	O
AZT	O
-	O
traeted	O
mcie	O
resulted	O
in	O
a	O
reudction	O
of	O
red	O
clels	O
and	O
an	O
incresae	O
of	O
palsma	O
EPO	O
lveels	O
as	O
compraed	O
to	O
anmials	O
tretaed	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O

We	O
tesetd	O
the	O
hypotehsis	O
that	O
the	O
antaognistic	O
efefct	O
of	O
IL	O
-	O
3	O
and	O
EPO	O
on	O
erythorid	O
clels	O
may	O
be	O
mediated	O
by	O
endothelail	O
clels	O
.	O

Bovnie	O
lievr	O
eyrthroid	O
cells	O
were	O
cutlured	O
on	O
monoalyers	O
of	O
hmuan	O
bnoe	O
mrarow	O
endotheilal	O
cells	O
previously	O
treaetd	O
with	O
EPO	O
and	O
IGF	O
-	O
IL	O
-	O
3	O
.	O

There	O
was	O
a	O
significant	O
reductoin	O
of	O
thyimdine	O
incorproation	O
into	O
both	O
eyrthroid	O
and	O
enodthelial	O
clels	O
in	O
cutlures	O
pre	O
-	O
treaetd	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O

Endohtelial	O
clel	O
cutlure	O
supenratants	O
seaprated	O
by	O
ultarfiltration	O
and	O
ultrcaentrifugation	O
from	O
clels	O
treaetd	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	O
redcued	O
thymiidne	O
incorportaion	O
into	O
eyrthroid	O
cells	O
as	O
copmared	O
to	O
identiacl	O
frcations	O
obtained	O
from	O
the	O
meida	O
of	O
clels	O
culutred	O
with	O
EPO	O
alone	O
.	O

These	O
rseults	O
suggest	O
that	O
endothleial	O
cells	O
terated	O
simultaenously	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
have	O
a	O
negatvie	O
effcet	O
on	O
eyrthroid	O
clel	O
productoin	O
.	O

The	O
relationsihp	O
between	O
hippcoampal	O
aectylcholine	O
relesae	O
and	O
cholinerigc	O
convuslant	O
senistivity	O
in	O
withrdawal	O
seziure	B-Disease
-	O
prone	O
and	O
withrdawal	O
siezure	B-Disease
-	O
resitsant	O
selected	O
mosue	O
liens	O
.	O

BACKGORUND	O
:	O
The	O
setpo	O
-	O
hippocampal	O
cholienrgic	O
pathawy	O
has	O
been	O
implicated	O
in	O
epileptoegnesis	O
,	O
and	O
geneitc	O
factros	O
influnece	O
the	O
rseponse	O
to	O
cholinregic	O
agetns	O
,	O
but	O
limietd	O
dtaa	O
are	O
available	O
on	O
cohlinergic	O
ivnolvement	O
in	O
alchool	O
wtihdrawal	O
severtiy	O
.	O

Thus	O
,	O
the	O
realtionship	O
between	O
cholniergic	O
actiivty	O
and	O
repsonsiveness	O
and	O
alochol	O
withrdawal	O
was	O
investgiated	O
in	O
a	O
geneitc	O
aniaml	O
moedl	O
of	O
ethaonl	O
wtihdrawal	O
seveirty	O
.	O

METHODS	O
:	O
Cohlinergic	O
covnulsant	O
sensitiivty	O
was	O
examined	O
in	O
alcoohl	O
-	O
na	O
ve	O
Withrdawal	O
Seziure	B-Disease
-	O
Porne	O
(	O
WSP	O
)	O
and	O
-	O
Ressitant	O
(	O
WSR	O
)	O
mcie	O
.	O

Aniamls	O
were	O
admiinstered	O
nictoine	O
,	O
carbcahol	O
,	O
or	O
neositgmine	O
via	O
tiemd	O
tial	O
vien	O
inufsion	O
,	O
and	O
the	O
latenceis	O
to	O
onset	O
of	O
termor	B-Disease
and	O
colnus	O
were	O
recorded	O
and	O
converted	O
to	O
threshlod	O
dsoe	O
.	O

We	O
also	O
used	O
microidalysis	O
to	O
maesure	O
baasl	O
and	O
potsasium	O
-	O
stimluated	O
acetylchoilne	O
(	O
ACh	O
)	O
reelase	O
in	O
the	O
CA1	O
reigon	O
of	O
the	O
hippcoampus	O
.	O

Potsasium	O
was	O
applied	O
by	O
reevrse	O
dilaysis	O
twice	O
,	O
sepraated	O
by	O
75	O
min	O
.	O

Hippocampal	O
ACh	O
also	O
was	O
meausred	O
during	O
testnig	O
for	O
handlnig	O
-	O
indcued	O
convulsinos	B-Disease
.	O

REUSLTS	O
:	O
Sesnitivity	O
to	O
several	O
convlusion	B-Disease
ednpoints	O
induecd	O
by	O
nioctine	O
,	O
carbcahol	O
,	O
and	O
neostimgine	O
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mcie	O
.	O

In	O
microdiaylsis	O
experimetns	O
,	O
the	O
lnies	O
did	O
not	O
differ	O
in	O
bsaal	O
relesae	O
of	O
ACh	O
,	O
and	O
50	O
mM	O
KCl	O
incraesed	O
ACh	O
otuput	O
in	O
both	O
liens	O
of	O
mcie	O
.	O

However	O
,	O
the	O
icnrease	O
in	O
reelase	O
of	O
ACh	O
produced	O
by	O
the	O
first	O
aplpication	O
of	O
KCl	O
was	O
2	O
-	O
fold	O
hgiher	O
in	O
WSP	O
versus	O
WSR	O
mcie	O
.	O

When	O
hippoacmpal	O
ACh	O
was	O
measrued	O
during	O
tesitng	O
for	O
hanlding	O
-	O
inudced	O
convulsinos	B-Disease
,	O
extrcaellular	O
ACh	O
was	O
significantly	O
eleavted	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mcie	O
,	O
but	O
was	O
nonsignificnatly	O
eelvated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mcie	O
.	O

CNOCLUSIONS	O
:	O
These	O
reuslts	O
suggest	O
that	O
differenecs	O
in	O
cholniergic	O
acitvity	O
and	O
postsyanptic	O
sensiitvity	O
to	O
cholienrgic	O
cnovulsants	B-Disease
may	O
be	O
associated	O
with	O
ethnaol	O
wtihdrawal	O
severtiy	O
and	O
implicate	O
cohlinergic	O
mechansims	O
in	O
alchool	O
witdhrawal	O
.	O

Specifically	O
,	O
WSP	O
mcie	O
may	O
have	O
loewr	O
senistivity	O
to	O
choilnergic	O
cnovulsants	B-Disease
cmopared	O
with	O
WSR	O
because	O
of	O
posstynaptic	O
reecptor	O
deesnsitization	O
brought	O
on	O
by	O
hgiher	O
acitvity	O
of	O
choilnergic	O
neurnos	O
.	O

Capsiacin	O
-	O
induecd	O
mucsle	B-Disease
pian	I-Disease
altres	O
the	O
excitabliity	O
of	O
the	O
hmuan	O
jaw	O
-	O
strtech	O
rfelex	O
.	O

The	O
patohphysiology	O
of	O
paifnul	O
temporomnadibular	B-Disease
disroders	I-Disease
is	O
not	O
fully	O
understood	O
,	O
but	O
eviednce	O
suggests	O
that	O
muslce	B-Disease
pian	I-Disease
modultaes	O
mtoor	O
funtcion	O
in	O
characteritsic	O
ways	O
.	O

This	O
sutdy	O
tseted	O
the	O
hyptohesis	O
that	O
actiavtion	O
of	O
ncoiceptive	B-Disease
msucle	I-Disease
afferent	O
fibres	O
would	O
be	O
linked	O
to	O
an	O
inrceased	O
excitaiblity	O
of	O
the	O
huamn	O
jaw	O
-	O
stertch	O
rfelex	O
and	O
whether	O
this	O
prcoess	O
would	O
be	O
sensitvie	O
to	O
lentgh	O
and	O
veolcity	O
of	O
the	O
strtech	O
.	O

Capasicin	O
(	O
10	O
mciro	O
g	O
)	O
was	O
injceted	O
into	O
the	O
msaseter	O
msucle	O
to	O
idnuce	O
pian	B-Disease
in	O
11	O
helathy	O
volunteers	O
.	O

Sohrt	O
-	O
latnecy	O
rfelex	O
repsonses	O
were	O
evkoed	O
in	O
the	O
masseter	O
and	O
temopralis	O
muslces	O
by	O
a	O
strecth	O
devcie	O
with	O
different	O
vleocities	O
and	O
dislpacements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pian	B-Disease
.	O

The	O
normalized	O
rfelex	O
ampiltude	O
icnreased	O
with	O
an	O
incresae	O
in	O
velcoity	O
at	O
a	O
given	O
displacmeent	O
,	O
but	O
remained	O
constnat	O
with	O
different	O
displacemnets	O
at	O
a	O
given	O
velcoity	O
.	O

The	O
normalized	O
relfex	O
ampiltude	O
was	O
significantly	O
hihger	O
during	O
pian	B-Disease
,	O
but	O
only	O
at	O
faster	O
strethces	O
in	O
the	O
paniful	B-Disease
muslce	I-Disease
.	O

Inrceased	O
sensitviity	O
of	O
the	O
fusimootr	O
ssytem	O
during	O
actue	O
msucle	B-Disease
pian	I-Disease
could	O
be	O
one	O
likely	O
mechansim	O
to	O
explain	O
the	O
findnigs	O
.	O

Effetcs	O
of	O
5	O
-	O
H1TB	O
recepotr	O
liagnds	O
microinjetced	O
into	O
the	O
acucmbal	O
sehll	O
or	O
croe	O
on	O
the	O
cocanie	O
-	O
induecd	O
locmootor	B-Disease
hypercativity	I-Disease
in	O
rtas	O
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
examine	O
the	O
efefct	O
of	O
5	O
-	O
H1TB	O
recetpor	O
lgiands	O
microinjecetd	O
into	O
the	O
surbegions	O
of	O
the	O
nuclues	O
accubmens	O
(	O
the	O
sehll	O
and	O
the	O
croe	O
)	O
on	O
the	O
locomootr	B-Disease
hyperactiivty	I-Disease
idnuced	O
by	O
cocanie	O
in	O
rtas	O
.	O

Mlae	O
Wsitar	O
rtas	O
were	O
implanetd	O
bilaterlaly	O
with	O
cannuale	O
into	O
the	O
acucmbens	O
sehll	O
or	O
croe	O
,	O
and	O
then	O
were	O
lcoally	O
injetced	O
with	O
GR	O
55562	O
(	O
an	O
atnagonist	O
of	O
5	O
-	O
H1TB	O
rceeptors	O
)	O
or	O
CP	O
93129	O
(	O
an	O
agnoist	O
of	O
5	O
-	O
H1TB	O
recepotrs	O
)	O
.	O

Given	O
alone	O
to	O
any	O
accmubal	O
subregoin	O
,	O
GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
mircog	O
/	O
side	O
)	O
or	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
micorg	O
/	O
side	O
)	O
did	O
not	O
change	O
bsaal	O
loocmotor	O
acitvity	O
.	O

Systmeic	O
cociane	O
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
incraesed	O
the	O
lcoomotor	O
actiivty	O
of	O
rtas	O
.	O

GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
mircog	O
/	O
side	O
)	O
,	O
adminisetred	O
itnra	O
-	O
accubmens	O
shlel	O
prior	O
to	O
coacine	O
,	O
dsoe	O
-	O
dependently	O
atteunated	O
the	O
psychsotimulant	O
-	O
idnuced	O
locmootor	B-Disease
hpyeractivity	I-Disease
.	O

Such	O
attenuatoin	O
was	O
not	O
found	O
in	O
animlas	O
which	O
had	O
been	O
injceted	O
with	O
GR	O
55562	O
into	O
the	O
accubmens	O
croe	O
.	O

When	O
inejcted	O
into	O
the	O
accumbens	O
shlel	O
(	O
but	O
not	O
the	O
croe	O
)	O
before	O
cocanie	O
,	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
micorg	O
/	O
side	O
)	O
ehnanced	O
the	O
lcoomotor	O
repsonse	O
to	O
coacine	O
;	O
the	O
maxiumm	O
effect	O
being	O
observed	O
after	O
10	O
micorg	O
/	O
side	O
of	O
the	O
agnoist	O
.	O

The	O
later	O
enahncement	O
was	O
attenutaed	O
after	O
itnra	O
-	O
acucmbens	O
sehll	O
teratment	O
with	O
GR	O
55562	O
(	O
1	O
mircog	O
/	O
side	O
)	O
.	O

Our	O
fidnings	O
indicate	O
that	O
ccoaine	O
indcued	O
hyprelocomotion	B-Disease
is	O
modiifed	O
by	O
5	O
-	O
H1TB	O
recpetor	O
liagnds	O
microinejcted	O
into	O
the	O
acucmbens	O
shlel	O
,	O
but	O
not	O
croe	O
,	O
this	O
modificaiton	O
consisting	O
in	O
inihbitory	O
and	O
facilitaotry	O
effcets	O
of	O
the	O
5	O
-	O
H1TB	O
recetpor	O
atnagonist	O
(	O
GR	O
55562	O
)	O
and	O
agnoist	O
(	O
CP	O
93129	O
)	O
,	O
respectively	O
.	O

In	O
other	O
wrods	O
,	O
the	O
present	O
rseults	O
suggest	O
that	O
the	O
accumbal	O
sehll	O
5	O
-	O
H1TB	O
recepotrs	O
play	O
a	O
perimssive	O
role	O
in	O
the	O
behaviouarl	O
resopnse	O
to	O
the	O
psychostimluant	O
.	O

Cociane	O
related	O
cehst	B-Disease
pian	I-Disease
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O

The	O
rcereational	O
use	O
of	O
cocanie	O
is	O
on	O
the	O
incerase	O
.	O

The	O
emeregncy	O
nusre	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardoivascular	O
conesquences	O
of	O
ccoaine	O
use	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocanie	O
to	O
produce	O
cehst	B-Disease
pian	I-Disease
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergecny	O
nruse	O
when	O
faced	O
with	O
a	O
yonug	O
vitcim	O
of	O
cehst	B-Disease
pian	I-Disease
who	O
is	O
otherwise	O
at	O
low	O
rsik	O
.	O

The	O
mehcanism	O
of	O
cehst	B-Disease
pian	I-Disease
related	O
to	O
coacine	O
use	O
is	O
discussed	O
and	O
treamtent	O
dilemmas	O
are	O
discussed	O
.	O

Finally	O
,	O
moarl	O
isuses	O
relating	O
to	O
the	O
testnig	O
of	O
ptoential	O
ccoaine	O
uesrs	O
will	O
be	O
addressed	O
.	O

Crossover	O
copmarison	O
of	O
effciacy	O
and	O
prefeernce	O
for	O
rizartiptan	O
10	O
mg	O
versus	O
ergtoamine	O
/	O
cfafeine	O
in	O
migranie	B-Disease
.	O

Rizartiptan	O
is	O
a	O
selective	O
5	O
-	O
HT	O
(	O
1B	O
/	O
1D	O
)	O
rceeptor	O
agoinst	O
with	O
rpaid	O
oarl	O
absroption	O
and	O
ealry	O
onset	O
of	O
aciton	O
in	O
the	O
actue	O
treatmnet	O
of	O
migranie	B-Disease
.	O

This	O
randoimzed	O
double	O
-	O
blnid	O
corssover	O
outpateint	O
stduy	O
assessed	O
the	O
prfeerence	O
for	O
1	O
rizatripatn	O
10	O
mg	O
talbet	O
to	O
2	O
ergotamnie	O
1	O
mg	O
/	O
caffiene	O
100	O
mg	O
talbets	O
in	O
439	O
pateints	O
tretaing	O
a	O
single	O
mgiraine	B-Disease
attcak	O
with	O
each	O
therpay	O
.	O

Of	O
patietns	O
expressing	O
a	O
prefernece	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
riztariptan	O
to	O
ergotmaine	O
/	O
cfafeine	O
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Fsater	O
rleief	O
of	O
haedache	B-Disease
was	O
the	O
most	O
important	O
reason	O
for	O
prefreence	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
pateints	O
preferring	O
rizatrpitan	O
and	O
54	O
.	O
2	O
%	O
of	O
ptaients	O
who	O
preferred	O
egrotamine	O
/	O
caffiene	O
.	O

The	O
co	O
-	O
priamry	O
endpiont	O
of	O
being	O
pian	B-Disease
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatirptan	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
pateints	O
were	O
pian	B-Disease
free	O
2	O
h	O
after	O
rziatriptan	O
,	O
compaerd	O
with	O
24	O
.	O
3	O
%	O
tretaed	O
with	O
ergotmaine	O
/	O
caffiene	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizartiptan	O
being	O
superior	O
within	O
1	O
h	O
of	O
treatmnet	O
.	O

Headahce	B-Disease
releif	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatirptan	O
and	O
47	O
.	O
3	O
%	O
for	O
ergoatmine	O
/	O
caffiene	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatritpan	O
being	O
superior	O
to	O
erogtamine	O
/	O
caffenie	O
within	O
30	O
min	O
of	O
dsoing	O
.	O

Almost	O
36	O
%	O
of	O
ptaients	O
taking	O
riaztriptan	O
were	O
pian	B-Disease
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrnece	O
or	O
need	O
for	O
additional	O
medicaiton	O
within	O
24	O
h	O
,	O
compraed	O
to	O
20	O
%	O
of	O
patinets	O
on	O
ergtoamine	O
/	O
caffenie	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Riaztriptan	O
was	O
also	O
superior	O
to	O
erogtamine	O
/	O
caffeine	O
in	O
the	O
prooprtions	O
of	O
patietns	O
with	O
no	O
nasuea	B-Disease
,	O
vomtiing	B-Disease
,	O
phnoophobia	B-Disease
or	O
photophboia	B-Disease
and	O
for	O
pateints	O
with	O
nomral	O
funtcion	O
2	O
h	O
after	O
durg	O
itnake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
pateints	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfeid	O
2	O
h	O
after	O
treatmnet	O
with	O
rizartiptan	O
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatemnt	O
with	O
ergoatmine	O
/	O
caffeine	O
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rceurrence	O
raets	O
were	O
31	O
.	O
4	O
%	O
with	O
rziatriptan	O
and	O
15	O
.	O
3	O
%	O
with	O
ergotmaine	O
/	O
caffeine	O
.	O

Both	O
actvie	O
tretaments	O
were	O
well	O
toleraetd	O
.	O

The	O
most	O
common	O
advesre	O
evnets	O
(	O
icnidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
gorup	O
)	O
after	O
rizatritpan	O
and	O
ergotaimne	O
/	O
caffiene	O
,	O
respectively	O
,	O
were	O
dizzniess	B-Disease
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nuasea	B-Disease
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
sonmolence	B-Disease
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

Seevre	O
ocluar	B-Disease
and	I-Disease
orbtial	I-Disease
toxiicty	I-Disease
after	O
intracaortid	O
injeciton	O
of	O
carbolpatin	O
for	O
recurrent	O
glioblastoams	B-Disease
.	O

BAKCGROUND	O
:	O
Glioblsatoma	B-Disease
is	O
a	O
malignnat	B-Disease
tmuor	I-Disease
that	O
occurs	O
in	O
the	O
creebrum	O
during	O
adulhtood	O
.	O

With	O
current	O
treatemnt	O
regiemns	O
including	O
combiend	O
suregry	O
,	O
radiaiton	O
and	O
cehmotherapy	O
,	O
the	O
avergae	O
lfie	O
exepctancy	O
of	O
the	O
patietns	O
is	O
limtied	O
to	O
approximately	O
1	O
yaer	O
.	O

Therefore	O
,	O
patinets	O
with	O
gliobalstoma	B-Disease
sometimes	O
have	O
intracartoid	O
inejction	O
of	O
carcionstatics	O
added	O
to	O
the	O
treatmnet	O
regmien	O
.	O

Generally	O
,	O
carobplatin	O
is	O
said	O
to	O
have	O
milder	O
side	O
efefcts	O
than	O
csiplatin	O
,	O
whose	O
ocluar	B-Disease
and	I-Disease
orbiatl	I-Disease
toxictiy	I-Disease
are	O
well	O
known	O
.	O

However	O
,	O
we	O
experienced	O
a	O
csae	O
of	O
sevree	O
ocualr	B-Disease
and	I-Disease
orbiatl	I-Disease
toxciity	I-Disease
after	O
intracartoid	O
injectoin	O
of	O
carbopltain	O
,	O
which	O
is	O
infrequently	O
reported	O
.	O

CSAE	O
:	O
A	O
58	O
-	O
yaer	O
-	O
old	O
man	O
received	O
an	O
itnracarotid	O
ijnection	O
of	O
craboplatin	O
for	O
recrurent	O
gloiblastomas	B-Disease
in	O
his	O
lfet	O
tempoarl	O
lboe	O
.	O

He	O
complained	O
of	O
pian	B-Disease
and	I-Disease
visaul	I-Disease
dsiturbance	I-Disease
in	I-Disease
the	I-Disease
ipsilaetral	I-Disease
eye	I-Disease
30	O
h	O
after	O
the	O
injeciton	O
.	O

Various	O
ocluar	O
smyptoms	O
and	O
findigns	O
caused	O
by	O
carbopltain	O
toxictiy	B-Disease
were	O
seen	O
.	O

RESLUTS	O
:	O
He	O
was	O
tretaed	O
with	O
intraveonus	O
administraiton	O
of	O
coritcosteroids	O
and	O
glcyerin	O
for	O
6	O
dyas	O
after	O
the	O
ijnection	O
.	O

Although	O
the	O
inrtaocular	O
presusre	O
elevtaion	O
caused	O
by	O
secondary	O
actue	O
agnle	O
-	O
closrue	O
gluacoma	B-Disease
decresaed	O
and	O
ocluar	B-Disease
pian	I-Disease
diminished	O
,	O
inexoralbe	O
papilleedma	B-Disease
and	O
exduative	O
retianl	B-Disease
deatchment	I-Disease
continued	O
for	O
3	O
wekes	O
.	O

Finally	O
,	O
6	O
wekes	O
later	O
,	O
difufse	O
cohrioretinal	B-Disease
atrohpy	I-Disease
with	O
opitc	B-Disease
artophy	I-Disease
occurred	O
and	O
the	O
vsiion	O
in	O
his	O
lfet	O
eye	O
was	O
lsot	O
.	O

CONCLUSOIN	O
:	O
When	O
performing	O
intraacrotid	O
injcetion	O
of	O
carbpolatin	O
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
bilnding	O
ouclar	B-Disease
toxictiy	I-Disease
.	O

It	O
is	O
recomemnded	O
that	O
further	O
sutdies	O
and	O
investgiations	O
are	O
undertaken	O
in	O
the	O
effort	O
to	O
minimize	O
such	O
sevree	O
side	O
effects	O
.	O

Viusal	B-Disease
hlalucinations	I-Disease
associated	O
with	O
zoniasmide	O
.	O

Zonsiamide	O
is	O
a	O
broad	O
-	O
spetcrum	O
antiepilepitc	O
durg	O
used	O
to	O
terat	O
various	O
types	O
of	O
seizrues	B-Disease
.	O

Although	O
vsiual	B-Disease
hallucintaions	I-Disease
have	O
not	O
been	O
reported	O
as	O
an	O
avderse	O
effect	O
of	O
this	O
aegnt	O
,	O
we	O
describe	O
three	O
pateints	O
who	O
experienced	O
cmoplex	O
visaul	B-Disease
halluciantions	I-Disease
and	O
atlered	O
mnetal	O
stauts	O
after	O
zonismaide	O
treatemnt	O
was	O
begun	O
or	O
its	O
dosgae	O
inrceased	O
.	O

All	O
three	O
had	O
been	O
diagonsed	O
earlier	O
with	O
epilespy	B-Disease
,	O
and	O
their	O
electroencephalogarm	O
(	O
EEG	O
)	O
fnidings	O
were	O
abnromal	O
.	O

During	O
monitroing	O
,	O
vsiual	B-Disease
hallucinatoins	I-Disease
did	O
not	O
correalte	O
with	O
EEG	O
readnigs	O
,	O
nor	O
did	O
vdieo	O
recordnig	O
captrue	O
any	O
of	O
the	O
described	O
evetns	O
.	O

None	O
of	O
the	O
paitents	O
had	O
experienced	O
viusal	B-Disease
halluicnations	I-Disease
before	O
this	O
evnet	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
treatmnet	O
was	O
the	O
introduciton	O
or	O
inrceased	O
dsoage	O
of	O
zonismaide	O
.	O

With	O
either	O
discontinuatoin	O
or	O
dcereased	O
dsoage	O
of	O
the	O
durg	O
the	O
sympotms	O
disappeared	O
and	O
did	O
not	O
recur	O
.	O

Further	O
obsevrations	O
and	O
reoprts	O
will	O
help	O
clarify	O
this	O
avderse	O
effcet	O
.	O

Until	O
then	O
,	O
clniicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complciation	O
associated	O
with	O
zonisamdie	O
.	O

Atni	O
-	O
epilpetic	B-Disease
durgs	O
-	O
idnuced	O
de	O
novo	O
absecne	B-Disease
seziures	I-Disease
.	O

The	O
autohrs	O
present	O
three	O
pateints	O
with	O
de	O
novo	O
asbence	B-Disease
epielpsy	I-Disease
after	O
admiinstration	O
of	O
carbamaezpine	O
and	O
vgiabatrin	O
.	O

Despite	O
the	O
underlying	O
disaeses	O
,	O
the	O
porgnosis	O
for	O
durg	O
-	O
idnuced	O
de	O
novo	O
abesnce	B-Disease
seizrue	I-Disease
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinunig	O
the	O
use	O
of	O
the	O
offendnig	O
durgs	O
.	O

The	O
gamma	O
-	O
aimnobutyric	O
aicd	O
-	O
tranmsitted	O
thalamocotrical	O
cricuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurohpysiology	O
of	O
the	O
absecne	B-Disease
epielpsy	I-Disease
.	O

Because	O
durg	O
-	O
induecd	O
de	O
novo	O
abesnce	B-Disease
seziure	I-Disease
is	O
rrae	O
,	O
pro	O
-	O
absecne	O
drgus	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
fatcor	O
.	O

The	O
underlying	O
epileptogneecity	O
of	O
the	O
patietns	O
or	O
the	O
synerigstic	O
effects	O
of	O
the	O
accompanying	O
durgs	O
is	O
required	O
to	O
trigegr	O
the	O
de	O
novo	O
abesnce	B-Disease
seziure	I-Disease
.	O

The	O
possibility	O
of	O
durg	O
-	O
idnuced	O
agrgavation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
icnrease	O
in	O
seiuzre	B-Disease
frequnecy	O
and	O
/	O
or	O
new	O
seizrue	B-Disease
types	O
appear	O
following	O
a	O
change	O
in	O
durg	O
tretament	O
.	O

By	O
understanding	O
the	O
underlying	O
mechainsm	O
of	O
absnece	B-Disease
eiplepsy	I-Disease
,	O
we	O
can	O
avoid	O
the	O
inappropritae	O
use	O
of	O
anticonvulsatns	O
in	O
childern	O
with	O
epilespy	B-Disease
and	O
pervent	O
durg	O
-	O
idnuced	O
absecne	B-Disease
seizrues	I-Disease
.	O

Pernatal	O
dexamtehasone	O
porgrams	O
hypertnesion	B-Disease
and	O
rneal	B-Disease
injruy	I-Disease
in	O
the	O
rat	O
.	O

Dexamethaosne	O
is	O
frequently	O
adminitsered	O
to	O
the	O
developing	O
fteus	O
to	O
accelertae	O
pulomnary	O
deevlopment	O
.	O

The	O
purpose	O
of	O
the	O
present	O
stduy	O
was	O
to	O
determine	O
if	O
prentaal	O
dexamethsaone	O
prgorammed	O
a	O
progerssive	O
incraese	B-Disease
in	I-Disease
bolod	I-Disease
pressure	I-Disease
and	O
reanl	B-Disease
inujry	I-Disease
in	O
rtas	O
.	O

Pregnnat	O
rtas	O
were	O
given	O
either	O
vheicle	O
or	O
2	O
dialy	O
intraperitnoeal	O
injetcions	O
of	O
dexametahsone	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
bdoy	O
weihgt	O
)	O
on	O
gesattional	O
dyas	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Offspring	O
of	O
rtas	O
administreed	O
dxeamethasone	O
on	O
dyas	O
15	O
and	O
16	O
gestatoin	O
had	O
a	O
20	O
%	O
reudction	B-Disease
in	I-Disease
glomerluar	I-Disease
number	I-Disease
copmared	O
with	O
cotnrol	O
at	O
6	O
to	O
9	O
monhts	O
of	O
age	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
redcution	O
in	O
glomerlui	O
meausred	O
at	O
3	O
wekes	O
of	O
age	O
.	O

Six	O
-	O
to	O
9	O
-	O
mnoth	O
old	O
rtas	O
receiving	O
pernatal	O
dxeamethasone	O
on	O
dyas	O
17	O
and	O
18	O
of	O
gesattion	O
had	O
a	O
17	O
%	O
redcution	O
in	O
glomeurli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
comapred	O
with	O
conrtol	O
rtas	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Mlae	O
rtas	O
that	O
received	O
preantal	O
dxeamethasone	O
on	O
dyas	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
getsation	O
had	O
eelvated	B-Disease
bolod	I-Disease
pressrues	I-Disease
at	O
6	O
mnoths	O
of	O
age	O
;	O
the	O
latter	O
gorup	O
did	O
not	O
have	O
a	O
redcution	B-Disease
in	I-Disease
glomerualr	I-Disease
number	I-Disease
.	O

Adlut	O
rtas	O
given	O
dexamethaosne	O
on	O
dyas	O
15	O
and	O
16	O
of	O
gsetation	O
had	O
more	O
golmeruli	O
with	O
glomerulosclersois	B-Disease
than	O
cotnrol	O
rtas	O
.	O

This	O
stduy	O
shows	O
that	O
pernatal	O
dexametahsone	O
in	O
rtas	O
rseults	O
in	O
a	O
reduciton	B-Disease
in	I-Disease
golmerular	I-Disease
number	I-Disease
,	O
gloemrulosclerosis	B-Disease
,	O
and	O
hypertesnion	B-Disease
when	O
amdinistered	O
at	O
specific	O
points	O
during	O
getsation	O
.	O

Hypertenison	B-Disease
was	O
observed	O
in	O
ainmals	O
that	O
had	O
a	O
reduciton	O
in	O
glomeurli	O
as	O
well	O
as	O
in	O
a	O
gruop	O
that	O
did	O
not	O
have	O
a	O
reudction	B-Disease
in	I-Disease
glomreular	I-Disease
number	I-Disease
,	O
suggesting	O
that	O
a	O
reductoin	B-Disease
in	I-Disease
glmoerular	I-Disease
number	I-Disease
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
devleopment	O
of	O
hypetrension	B-Disease
.	O

Kideny	O
fucntion	O
and	O
morphloogy	O
after	O
short	O
-	O
term	O
combinatoin	O
tehrapy	O
with	O
cyclosoprine	O
A	O
,	O
tacrloimus	O
and	O
siroilmus	O
in	O
the	O
rat	O
.	O

BACKRGOUND	O
:	O
Sirolmius	O
(	O
SRL	O
)	O
may	O
supplement	O
calcinuerin	O
inhibiotrs	O
in	O
clniical	O
ogran	O
trasnplantation	O
.	O

These	O
are	O
nephrtooxic	B-Disease
,	O
but	O
SRL	O
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoixc	B-Disease
effetcs	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
teratment	O
prtoocols	O
where	O
SRL	O
was	O
cobmined	O
with	O
a	O
calcineuirn	O
inhiibtor	O
inidcations	O
of	O
a	O
synergitsic	O
nephrtooxic	B-Disease
efefct	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
examine	O
further	O
the	O
reanl	O
fnuction	O
,	O
including	O
moprhological	O
analsyis	O
of	O
the	O
kidnyes	O
of	O
mlae	O
Sprauge	O
-	O
Dalwey	O
rtas	O
terated	O
with	O
either	O
cyclospornie	O
A	O
(	O
CsA	O
)	O
,	O
tacrolmius	O
(	O
F5K06	O
)	O
or	O
SRL	O
as	O
monotherapeis	O
or	O
in	O
different	O
combinatoins	O
.	O

METHODS	O
:	O
For	O
a	O
peirod	O
of	O
2	O
weeks	O
,	O
CsA	O
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
oarlly	O
)	O
,	O
FK056	O
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
oarlly	O
)	O
or	O
SRL	O
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraepritoneally	O
)	O
was	O
admiinstered	O
once	O
a	O
day	O
as	O
these	O
doess	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immnuosuppressive	O
efefct	O
in	O
Spargue	O
-	O
Dalwey	O
rtas	O
.	O

In	O
the	O
'	O
cosncious	O
cathteerized	O
rat	O
'	O
moedl	O
,	O
the	O
glmoerular	O
fitlration	O
rtae	O
(	O
GFR	O
)	O
was	O
mesaured	O
as	O
the	O
clearnace	O
of	O
Cr	O
(	O
ETDA	O
)	O
.	O

The	O
morphloogical	O
analyiss	O
of	O
the	O
kidenys	O
included	O
a	O
smei	O
-	O
qunatitative	O
scoirng	O
sysetm	O
analysing	O
the	O
dergee	O
of	O
stirped	O
fibrsois	B-Disease
,	O
subcapsluar	O
fiborsis	B-Disease
and	O
the	O
number	O
of	O
basophiilc	O
tubuels	O
,	O
plus	O
an	O
additional	O
steroelogical	O
analyiss	O
of	O
the	O
total	O
garde	O
of	O
fiborsis	B-Disease
in	O
the	O
coretx	O
staiend	O
with	O
Siruis	O
Red	O
.	O

REUSLTS	O
:	O
CsA	O
,	O
F5K06	O
and	O
SRL	O
all	O
significantly	O
dcereased	O
the	O
GFR	O
.	O

A	O
further	O
deteriroation	O
was	O
seen	O
when	O
CsA	O
was	O
cobmined	O
with	O
either	O
F5K06	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanegd	O
in	O
the	O
gorup	O
terated	O
with	O
FK056	O
plus	O
SRL	O
when	O
copmared	O
with	O
treamtent	O
with	O
any	O
of	O
the	O
single	O
subsatnces	O
.	O

The	O
morpholoigcal	O
chnages	O
presented	O
a	O
similar	O
pattren	O
.	O

The	O
smei	O
-	O
quantittaive	O
scornig	O
was	O
significantly	O
worst	O
in	O
the	O
gruop	O
treaetd	O
with	O
CsA	O
plus	O
SRL	O
(	O
P	O
<	O
0	O
.	O
001	O
compraed	O
with	O
contrlos	O
)	O
and	O
the	O
aanlysis	O
of	O
the	O
total	O
garde	O
of	O
firbosis	B-Disease
also	O
showed	O
the	O
highest	O
prooprtion	O
in	O
the	O
same	O
gorup	O
and	O
was	O
significantly	O
different	O
from	O
cotnrols	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
F5K06	O
plus	O
SRL	O
combiantion	O
showed	O
only	O
a	O
marginally	O
hihger	O
dergee	O
of	O
firbosis	B-Disease
as	O
compraed	O
with	O
cotnrols	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLSUION	O
:	O
This	O
rat	O
stduy	O
demonstrated	O
a	O
synregistic	O
nephortoxic	B-Disease
efefct	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
F5K06	O
plus	O
SRL	O
was	O
better	O
toleraetd	O
.	O

Evaluaiton	O
of	O
cradiac	O
tropoinn	O
I	O
and	O
T	O
leevls	O
as	O
marekrs	O
of	O
mycoardial	B-Disease
dmaage	I-Disease
in	O
dooxrubicin	O
-	O
inudced	O
cradiomyopathy	B-Disease
rtas	O
,	O
and	O
their	O
relatoinship	O
with	O
echocradiographic	O
and	O
histolgoical	O
findnigs	O
.	O

BACKRGOUND	O
:	O
Caridac	O
troponnis	O
I	O
(	O
cnTI	O
)	O
and	O
T	O
(	O
cnTT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
snesitive	O
and	O
specific	O
marekrs	O
of	O
myocardail	B-Disease
clel	I-Disease
ijnury	I-Disease
.	O

We	O
invsetigated	O
the	O
diagonstic	O
value	O
of	O
cnTI	O
and	O
cnTT	O
for	O
the	O
diangosis	O
of	O
myocaridal	B-Disease
dmaage	I-Disease
in	O
a	O
rat	O
mdoel	O
of	O
dxoorubicin	O
(	O
DOX	O
)	O
-	O
indcued	O
cardimoyopathy	B-Disease
,	O
and	O
we	O
examined	O
the	O
relationhsip	O
between	O
serail	O
cnTI	O
and	O
cnTT	O
with	O
the	O
developemnt	O
of	O
cradiac	B-Disease
disoredrs	I-Disease
montiored	O
by	O
echocardiogrpahy	O
and	O
histolgoical	O
eaxminations	O
in	O
this	O
moedl	O
.	O

METHODS	O
:	O
Thirty	O
-	O
five	O
Wisatr	O
rtas	O
were	O
given	O
1	O
.	O
5	O
mg	O
/	O
kg	O
DOX	O
,	O
i	O
.	O
v	O
.	O
,	O
wekely	O
for	O
up	O
to	O
8	O
wekes	O
for	O
a	O
total	O
cumluative	O
dsoe	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O

Ten	O
rtas	O
received	O
salnie	O
as	O
a	O
contorl	O
gorup	O
.	O

cnTI	O
was	O
measrued	O
with	O
Access	O
(	O
R	O
)	O
(	O
ng	O
/	O
ml	O
)	O
and	O
a	O
resaerch	O
immunosasay	O
(	O
pg	O
/	O
ml	O
)	O
,	O
and	O
comapred	O
with	O
cnTT	O
,	O
CK	O
-	O
MB	O
msas	O
and	O
CK	O
.	O

By	O
using	O
transthroacic	O
echocaridography	O
,	O
anteroir	O
and	O
posteroir	O
wlal	O
thickenss	O
,	O
LV	O
diaemters	O
and	O
LV	O
fractoinal	O
shotrening	O
(	O
FS	O
)	O
were	O
maesured	O
in	O
all	O
rtas	O
before	O
DOX	O
or	O
salnie	O
,	O
and	O
at	O
wekes	O
6	O
and	O
9	O
after	O
treatmnet	O
in	O
all	O
surivving	O
rtas	O
.	O

Hitsology	O
was	O
performed	O
in	O
DOX	O
-	O
rtas	O
at	O
6	O
and	O
9	O
wekes	O
after	O
the	O
last	O
DOX	O
dsoe	O
and	O
in	O
all	O
cotnrols	O
.	O

REUSLTS	O
:	O
Eighteen	O
of	O
the	O
DOX	O
rtas	O
deid	O
premautrely	O
of	O
general	O
toxictiy	B-Disease
during	O
the	O
9	O
-	O
week	O
preiod	O
.	O

End	O
-	O
diastloic	O
(	O
ED	O
)	O
and	O
end	O
-	O
ssytolic	O
(	O
ES	O
)	O
LV	O
diameetrs	O
/	O
BW	O
significantly	O
icnreased	O
,	O
whereas	O
LV	O
FS	O
was	O
decraesed	O
after	O
9	O
wekes	O
in	O
the	O
DOX	O
gorup	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

These	O
parmaeters	O
remained	O
uncahnged	O
in	O
contorls	O
.	O

Hsitological	O
evaulation	O
of	O
herats	O
from	O
all	O
rtas	O
given	O
DOX	O
reevaled	O
significant	O
slight	O
dergees	O
of	O
preivascular	O
and	O
intersittial	O
firbosis	B-Disease
.	O

In	O
7	O
of	O
the	O
18	O
rtas	O
,	O
degenreation	O
and	O
myoycte	O
vacuolsiation	O
were	O
found	O
.	O

Only	O
five	O
of	O
the	O
contrlos	O
exhibited	O
eivdence	O
of	O
very	O
slight	O
perivasuclar	O
firbosis	B-Disease
.	O

A	O
significant	O
rise	O
in	O
cnTT	O
was	O
found	O
in	O
DOX	O
rtas	O
after	O
cumluative	O
doess	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparsion	O
with	O
baselnie	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

cnTT	O
found	O
in	O
rtas	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	O
.	O

Maxmial	O
cnTI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cnTT	O
levles	O
were	O
significantly	O
incraesed	O
in	O
DOX	O
rtas	O
compaerd	O
with	O
cotnrols	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	O

cnTI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
msas	O
and	O
CK	O
remained	O
unhcanged	O
in	O
DOX	O
rtas	O
copmared	O
with	O
cnotrols	O
.	O

All	O
marekrs	O
remained	O
stbale	O
in	O
contorls	O
.	O

Anlaysis	O
of	O
dtaa	O
revaeled	O
a	O
significant	O
correlatoin	O
between	O
maxiaml	O
cnTT	O
and	O
ED	O
and	O
ES	O
LV	O
diaemters	O
/	O
BW	O
(	O
r	O
=	O
0	O
.	O
81	O
and	O
0	O
.	O
65	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

A	O
significant	O
reltaionship	O
was	O
observed	O
between	O
mxaimal	O
cnTT	O
and	O
the	O
extent	O
of	O
myoacrdial	O
morphologcial	O
chagnes	O
,	O
and	O
between	O
LV	O
diamteers	O
/	O
BW	O
and	O
hisotlogical	O
findnigs	O
.	O

CONCLSUIONS	O
:	O
Among	O
markres	O
of	O
ischmeic	B-Disease
injruy	I-Disease
after	O
DOX	O
in	O
rtas	O
,	O
cnTT	O
showed	O
the	O
greatest	O
ability	O
to	O
dteect	O
mycoardial	B-Disease
daamge	I-Disease
asssesed	O
by	O
echoacrdiographic	O
dteection	O
and	O
histologcial	O
chagnes	O
.	O

Although	O
there	O
was	O
a	O
discrpeancy	O
between	O
the	O
amonut	O
of	O
cnTI	O
and	O
cnTT	O
after	O
DOX	O
,	O
probably	O
due	O
to	O
heterogneeity	O
in	O
corss	O
-	O
reactivtiies	O
of	O
mbAs	O
to	O
various	O
cnTI	O
and	O
cnTT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cnTT	O
in	O
rtas	O
after	O
DOX	O
indicates	O
clel	O
daamge	O
determined	O
by	O
the	O
magntiude	O
of	O
injruy	O
inudced	O
and	O
that	O
cnTT	O
should	O
be	O
a	O
useful	O
mraker	O
for	O
the	O
perdiction	O
of	O
experiemntally	O
inudced	O
cardiotoxiicty	B-Disease
and	O
possibly	O
for	O
cardioprotcetive	O
experiemnts	O
.	O

Ocrteotide	O
-	O
inudced	O
hypxoemia	B-Disease
and	O
plumonary	B-Disease
hypretension	I-Disease
in	O
preamture	O
neontaes	O
.	O

The	O
auhtors	O
reprot	O
2	O
csaes	O
of	O
permature	O
neontaes	O
who	O
had	O
entercoutaneous	O
fistlua	B-Disease
complciating	O
necrotiizng	B-Disease
entreocolitis	I-Disease
.	O

Pulomnary	B-Disease
hypetrension	I-Disease
developed	O
after	O
administrtaion	O
of	O
a	O
somatostaitn	O
analouge	O
,	O
octroetide	O
,	O
to	O
enhnace	O
resoluiton	O
of	O
the	O
fisutla	B-Disease
.	O

The	O
autohrs	O
discuss	O
the	O
mechnaism	O
of	O
the	O
occurrence	O
of	O
this	O
complicaiton	O
and	O
recommend	O
caution	O
of	O
its	O
use	O
in	O
high	O
-	O
rsik	O
prematrue	O
neontaes	O
.	O

The	O
rsik	O
of	O
veonus	B-Disease
thromobembolism	I-Disease
in	O
woemn	O
prescirbed	O
cyproternoe	O
acettae	O
in	O
combiantion	O
with	O
etihnyl	O
etsradiol	O
:	O
a	O
nseted	O
cohrot	O
anaylsis	O
and	O
csae	O
-	O
cotnrol	O
sutdy	O
.	O

BACKGRONUD	O
:	O
Cyprtoerone	O
aectate	O
cobmined	O
with	O
ethniyl	O
estardiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
traetment	O
of	O
wmoen	O
with	O
ance	B-Disease
and	O
hirsuitsm	B-Disease
and	O
is	O
also	O
a	O
teratment	O
option	O
for	O
polcyystic	B-Disease
oavry	I-Disease
syndorme	I-Disease
(	O
POCS	B-Disease
)	O
.	O

Previous	O
studeis	O
have	O
demonstrated	O
an	O
icnreased	O
rsik	O
of	O
venuos	B-Disease
thromboembolsim	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
CPA	O
/	O
EE	O
comapred	O
with	O
conventioanl	O
cobmined	O
oarl	O
contraceptievs	O
(	O
CCOs	O
)	O
.	O

We	O
believe	O
the	O
resluts	O
of	O
those	O
studeis	O
may	O
have	O
been	O
affceted	O
by	O
reisdual	O
conofunding	O
.	O

METHODS	O
:	O
Using	O
the	O
Genearl	O
Practcie	O
Resaerch	O
Daatbase	O
we	O
conducted	O
a	O
cohrot	O
anlaysis	O
and	O
csae	O
-	O
cnotrol	O
stduy	O
nesetd	O
within	O
a	O
popualtion	O
of	O
woemn	O
aegd	O
between	O
15	O
and	O
39	O
yaers	O
with	O
ance	B-Disease
,	O
hirustism	B-Disease
or	O
POCS	B-Disease
to	O
esitmate	O
the	O
rsik	O
of	O
VTE	B-Disease
associated	O
with	O
CPA	O
/	O
EE	O
.	O

REUSLTS	O
:	O
The	O
age	O
-	O
adjusted	O
inicdence	O
rtae	O
raito	O
for	O
CPA	O
/	O
EE	O
versus	O
convnetional	O
CCOs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
conifdence	O
interavl	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

Using	O
as	O
the	O
refeernce	O
gruop	O
woemn	O
who	O
were	O
not	O
using	O
oarl	O
contarception	O
,	O
had	O
no	O
recent	O
preganncy	O
or	O
meonpausal	O
sympotms	O
,	O
the	O
csae	O
-	O
conrtol	O
aanlysis	O
gave	O
an	O
adjusted	O
odds	O
raito	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	O
/	O
EE	O
use	O
compaerd	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
convenitonal	O
CCOs	O
.	O

CONCLUSINOS	O
:	O
We	O
have	O
demonstrated	O
an	O
increaesd	O
rsik	O
of	O
VTE	B-Disease
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
wmoen	O
with	O
ance	B-Disease
,	O
hirustism	B-Disease
or	O
POCS	B-Disease
although	O
rseidual	O
cofnounding	O
by	O
indicatoin	O
cannot	O
be	O
excluded	O
.	O

The	O
efefct	O
of	O
traetment	O
with	O
gum	O
Aarbic	O
on	O
gentaimcin	O
neprhotoxicity	B-Disease
in	O
rtas	O
:	O
a	O
preliminary	O
stduy	O
.	O

In	O
the	O
present	O
work	O
we	O
asesssed	O
the	O
effect	O
of	O
tretament	O
of	O
rtas	O
with	O
gum	O
Araibc	O
on	O
actue	B-Disease
reanl	I-Disease
faiulre	I-Disease
idnuced	O
by	O
gentaimcin	O
(	O
GM	O
)	O
nephrtooxicity	B-Disease
.	O

Rtas	O
were	O
tretaed	O
with	O
the	O
veihcle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
wtaer	O
and	O
5	O
%	O
w	O
/	O
v	O
cellluose	O
,	O
10	O
dyas	O
)	O
,	O
gum	O
Aarbic	O
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
auqeous	O
suspesnion	O
of	O
gum	O
Arbaic	O
pwoder	O
,	O
oarlly	O
for	O
10	O
dyas	O
)	O
,	O
or	O
gum	O
Aarbic	O
concomitantly	O
with	O
GM	O
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscluarly	O
,	O
during	O
the	O
last	O
six	O
dyas	O
of	O
the	O
treamtent	O
peirod	O
)	O
.	O

Nephrotoixcity	B-Disease
was	O
assesesd	O
by	O
meausring	O
the	O
concentraitons	O
of	O
creaitnine	O
and	O
uera	O
in	O
the	O
palsma	O
and	O
reudced	O
gltuathione	O
(	O
GSH	O
)	O
in	O
the	O
kdiney	O
cotrex	O
,	O
and	O
by	O
light	O
microsocpic	O
exaimnation	O
of	O
kdiney	O
sectinos	O
.	O

The	O
resluts	O
indicated	O
that	O
concomtiant	O
teratment	O
with	O
gum	O
Arbaic	O
and	O
GM	O
significantly	O
inrceased	O
creatinnie	O
and	O
uera	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compraed	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rtas	O
tretaed	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreaesd	O
that	O
of	O
cotrical	O
GSH	O
by	O
21	O
%	O
(	O
comapred	O
to	O
27	O
%	O
in	O
the	O
celullose	O
plus	O
GM	O
gorup	O
)	O
The	O
GM	O
-	O
idnuced	O
proixmal	O
tubualr	B-Disease
necroiss	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
sveere	O
in	O
rtas	O
given	O
GM	O
together	O
with	O
gum	O
Arbaic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellluose	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	O
Aarbic	O
tretament	O
has	O
indcued	O
a	O
modset	O
ameliortaion	O
of	O
some	O
of	O
the	O
histoloigcal	O
and	O
biochemiacl	O
indiecs	O
of	O
GM	O
npehrotoxicity	B-Disease
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treamtents	O
on	O
rneal	O
functioanl	O
aspects	O
in	O
mdoels	O
of	O
chrnoic	B-Disease
reanl	I-Disease
failrue	I-Disease
,	O
and	O
on	O
the	O
mehcanism	O
(	O
s	O
)	O
involved	O
.	O

Incraesed	O
freqeuncy	O
of	O
veonus	B-Disease
thormboembolism	I-Disease
with	O
the	O
comibnation	O
of	O
docteaxel	O
and	O
thlaidomide	O
in	O
ptaients	O
with	O
mteastatic	O
androegn	O
-	O
indpeendent	O
prsotate	B-Disease
cacner	I-Disease
.	O

SUTDY	O
OJBECTIVE	O
:	O
To	O
evlauate	O
the	O
frqeuency	O
of	O
venuos	B-Disease
throbmoembolism	I-Disease
(	O
VTE	B-Disease
)	O
in	O
patietns	O
with	O
adavnced	O
androegn	O
-	O
indepednent	O
prosttae	B-Disease
cacner	I-Disease
who	O
were	O
tretaed	O
with	O
dcoetaxel	O
alone	O
or	O
in	O
combniation	O
with	O
thaliodmide	O
.	O

DESIGN	O
:	O
Retropsective	O
aanlysis	O
of	O
a	O
randomzied	O
pahse	O
II	O
trail	O
.	O

SETTING	O
:	O
Ntaional	O
Insittutes	O
of	O
Heatlh	O
cliniacl	O
reserach	O
cenetr	O
.	O

PATIENTS	O
:	O
Seventy	O
men	O
,	O
aegd	O
50	O
-	O
80	O
yeras	O
,	O
with	O
advacned	O
androegn	O
-	O
indepenednt	O
porstate	B-Disease
canecr	I-Disease
.	O

INTREVENTION	O
:	O
Each	O
patinet	O
received	O
either	O
intravenuos	O
docetaexl	O
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consectuive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combiantion	O
of	O
continouus	O
oarl	O
thaliodmide	O
200	O
mg	O
every	O
eveinng	O
plus	O
the	O
same	O
doectaxel	O
regiemn	O
.	O

This	O
4	O
-	O
week	O
ccyle	O
was	O
reepated	O
until	O
there	O
was	O
evidecne	O
of	O
ecxessive	O
toxciity	B-Disease
or	O
disaese	O
progressoin	O
.	O

MEAUSREMENTS	O
AND	O
MIAN	O
RSEULTS	O
:	O
None	O
of	O
23	O
patinets	O
who	O
received	O
docetaexl	O
alone	O
developed	O
VTE	B-Disease
,	O
whereas	O
9	O
of	O
47	O
patietns	O
(	O
19	O
%	O
)	O
who	O
received	O
doceatxel	O
plus	O
thalidoimde	O
developed	O
VTE	B-Disease
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

CONCLUISON	O
:	O
The	O
addition	O
of	O
thalidmoide	O
to	O
docteaxel	O
in	O
the	O
treatemnt	O
of	O
porstate	B-Disease
cacner	I-Disease
significantly	O
increaess	O
the	O
freuqency	O
of	O
VTE	B-Disease
.	O

Cliincians	O
should	O
be	O
aware	O
of	O
this	O
potenital	O
complicatoin	O
when	O
adding	O
thalidomdie	O
to	O
cehmotherapeutic	O
regiemns	O
.	O

Ticlopiidne	O
-	O
idnuced	O
cohlestatic	B-Disease
heptaitis	I-Disease
.	O

OBJECITVE	O
:	O
To	O
reprot	O
2	O
csaes	O
of	O
ticlopdiine	O
-	O
idnuced	O
cholestaitc	B-Disease
hepaittis	I-Disease
,	O
ivnestigate	O
its	O
mehcanism	O
,	O
and	O
comprae	O
the	O
observed	O
main	O
characterisitcs	O
with	O
those	O
of	O
the	O
pbulished	O
csaes	O
.	O

CSAE	O
SUMMRAIES	O
:	O
Two	O
ptaients	O
developed	O
prologned	O
choelstatic	B-Disease
hepaittis	I-Disease
after	O
receiving	O
ticlopiidne	O
following	O
percutnaeous	O
coroanry	O
angiopalsty	O
,	O
with	O
complete	O
reimssion	O
during	O
the	O
follow	O
-	O
up	O
peirod	O
.	O

T	O
-	O
clel	O
stmiulation	O
by	O
threapeutic	O
concnetration	O
of	O
ticlopdiine	O
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
pateints	O
,	O
but	O
not	O
in	O
heatlhy	O
cotnrols	O
.	O

DISCUSSION	O
:	O
Cholesattic	B-Disease
hepatiits	I-Disease
is	O
a	O
rrae	O
comlpication	O
of	O
the	O
antiplateelt	O
agnet	O
tilcopidine	O
;	O
several	O
csaes	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
Engilsh	O
lietrature	O
.	O

Our	O
ptaients	O
developed	O
juandice	B-Disease
following	O
tretament	O
with	O
tcilopidine	O
and	O
showed	O
the	O
clniical	O
and	O
laboratroy	O
cahracteristics	O
of	O
cohlestatic	B-Disease
hpeatitis	I-Disease
,	O
which	O
resolved	O
after	O
dicsontinuation	O
of	O
the	O
durg	O
.	O

Hepaittis	B-Disease
may	O
develop	O
weeks	O
after	O
disocntinuation	O
of	O
the	O
durg	O
and	O
may	O
run	O
a	O
prolonegd	O
cousre	O
,	O
but	O
complete	O
remisison	O
was	O
observed	O
in	O
all	O
reported	O
caess	O
.	O

An	O
objectvie	O
casuality	O
asssesment	O
revelaed	O
that	O
the	O
adevrse	O
durg	O
evnet	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticloipdine	O
.	O

The	O
mechainsms	O
of	O
this	O
ticlpoidine	O
-	O
idnuced	O
cholesatsis	B-Disease
are	O
unclear	O
.	O

Immnue	O
mechnaisms	O
may	O
be	O
involved	O
in	O
the	O
durg	O
'	O
s	O
hpeatotoxicity	B-Disease
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
clel	O
stimluation	O
stduy	O
reported	O
here	O
.	O

CONCLSUIONS	O
:	O
Cholesattic	B-Disease
heaptitis	I-Disease
is	O
a	O
rrae	O
avderse	O
effect	O
of	O
ticlopdiine	O
that	O
may	O
be	O
immune	O
mediated	O
.	O

Patinets	O
receiving	O
the	O
durg	O
should	O
be	O
monitroed	O
with	O
lievr	O
fnuction	O
tetss	O
along	O
with	O
complete	O
blood	O
clel	O
coutns	O
.	O

This	O
compilcation	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopiidne	O
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatleet	O
agnet	O
cloipdogrel	O
.	O

Epithelail	O
sdoium	O
chanenl	O
(	O
EaNC	O
)	O
subnuit	O
mNRA	O
and	O
protien	O
epxression	O
in	O
rtas	O
with	O
pruomycin	O
aminonulceoside	O
-	O
induecd	O
nephroitc	B-Disease
syndorme	I-Disease
.	O

In	O
experimetnal	O
neprhotic	B-Disease
synrdome	I-Disease
,	O
urianry	O
soidum	O
exrcetion	O
is	O
decerased	O
during	O
the	O
eraly	O
pahse	O
of	O
the	O
diesase	O
.	O

The	O
mloecular	O
mecahnism	O
(	O
s	O
)	O
leading	O
to	O
slat	O
retentoin	O
has	O
not	O
been	O
completely	O
elucidated	O
.	O

The	O
rtae	O
-	O
limiting	O
constituent	O
of	O
collecting	O
dcut	O
soidum	O
tarnsport	O
is	O
the	O
eipthelial	O
soidum	O
cahnnel	O
(	O
EaNC	O
)	O
.	O

We	O
examined	O
the	O
aubndance	O
of	O
EaNC	O
suubnit	O
mNRAs	O
and	O
protenis	O
in	O
puromyicn	O
aminonuceloside	O
(	O
PAN	O
)	O
-	O
inudced	O
nephroitc	B-Disease
syndorme	I-Disease
.	O

The	O
tmie	O
couress	O
of	O
uirnary	O
sdoium	O
excrteion	O
,	O
plamsa	O
aldostreone	O
concenrtation	O
and	O
proteinruia	B-Disease
were	O
studied	O
in	O
mlae	O
Sprauge	O
-	O
Dwaley	O
rtas	O
terated	O
with	O
a	O
single	O
dsoe	O
of	O
either	O
PAN	O
or	O
veihcle	O
.	O

The	O
relative	O
amounts	O
of	O
alphaENaC	O
,	O
bteaENaC	O
and	O
gammaNEaC	O
mRANs	O
were	O
determined	O
in	O
kdineys	O
from	O
these	O
rtas	O
by	O
real	O
-	O
tmie	O
quantitatvie	O
TqaMan	O
PCR	O
,	O
and	O
the	O
amounts	O
of	O
proetins	O
by	O
Wetsern	O
bolt	O
.	O

The	O
kineitcs	O
of	O
urianry	O
soidum	O
ecxretion	O
and	O
the	O
appaerance	O
of	O
protienuria	B-Disease
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Soduim	O
reteniton	O
occurred	O
on	O
dyas	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	O
inejction	O
.	O

A	O
significant	O
up	O
-	O
regluation	O
of	O
alphaENaC	O
and	O
betEaNaC	O
mNRA	O
abnudance	O
on	O
dyas	O
1	O
and	O
2	O
preceded	O
soduim	O
retetnion	O
on	O
dyas	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
regulatoin	O
of	O
alphaENaC	O
,	O
betaEaNC	O
and	O
gmamaENaC	O
mNRA	O
exprsesion	O
on	O
day	O
3	O
occurred	O
in	O
the	O
preesnce	O
of	O
high	O
adlosterone	O
concentratinos	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
soduim	O
excreiton	O
to	O
cnotrol	O
valeus	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
bteaENaC	O
and	O
gammaEaNC	O
porteins	O
were	O
not	O
incerased	O
during	O
PAN	O
-	O
indcued	O
sdoium	O
reetntion	O
.	O

In	O
conclusion	O
,	O
EaNC	O
mNRA	O
expresison	O
,	O
especially	O
alphaENaC	O
,	O
is	O
incerased	O
in	O
the	O
very	O
ealry	O
phsae	O
of	O
the	O
exeprimental	O
mdoel	O
of	O
PAN	O
-	O
induecd	O
neprhotic	B-Disease
sydnrome	I-Disease
in	O
rtas	O
,	O
but	O
appears	O
to	O
escpae	O
from	O
the	O
reuglation	O
by	O
adlosterone	O
after	O
day	O
3	O
.	O

Sub	O
-	O
chroinc	O
low	O
dsoe	O
gamma	O
-	O
vniyl	O
GBAA	O
(	O
vigbaatrin	O
)	O
inhibtis	O
cociane	O
-	O
inudced	O
incraeses	O
in	O
nculeus	O
accumebns	O
dopmaine	O
.	O

RATIOANLE	O
:	O
gmama	O
-	O
Viynl	O
GBAA	O
(	O
GVG	O
)	O
irreversibly	O
inhiibts	O
GBAA	O
-	O
transamianse	O
.	O

This	O
non	O
-	O
reecptor	O
mediated	O
inhiibtion	O
requires	O
de	O
novo	O
syntheiss	O
for	O
restortaion	O
of	O
fnuctional	O
GBAA	O
catabloism	O
.	O

OBJECTIEVS	O
:	O
Given	O
its	O
precilnical	O
sucecss	O
for	O
terating	O
sbustance	B-Disease
absue	I-Disease
and	O
the	O
incerased	O
rsik	O
of	O
viusal	B-Disease
field	I-Disease
dfeects	I-Disease
(	O
VFD	B-Disease
)	O
associated	O
with	O
cumultaive	O
lifetmie	O
expsoure	O
,	O
we	O
explored	O
the	O
effcets	O
of	O
sub	O
-	O
chrnoic	O
low	O
dsoe	O
GVG	O
on	O
cocanie	O
-	O
induecd	O
increaess	O
in	O
nculeus	O
accubmens	O
(	O
NcAc	O
)	O
doapmine	O
(	O
DA	O
)	O
.	O

METHODS	O
:	O
Using	O
in	O
vivo	O
micordialysis	O
,	O
we	O
compraed	O
aucte	O
exopsure	O
(	O
450	O
mg	O
/	O
kg	O
)	O
to	O
an	O
idetnical	O
sub	O
-	O
chrnoic	O
expousre	O
(	O
150	O
mg	O
/	O
kg	O
per	O
day	O
for	O
3	O
dyas	O
)	O
,	O
followed	O
by	O
1	O
-	O
or	O
3	O
-	O
day	O
wahsout	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
low	O
dsoe	O
of	O
150	O
mg	O
/	O
kg	O
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
)	O
using	O
a	O
similar	O
wasohut	O
preiod	O
.	O

REUSLTS	O
:	O
Sub	O
-	O
chrnoic	O
GVG	O
expsoure	O
inihbited	O
the	O
effcet	O
of	O
cocanie	O
for	O
3	O
dyas	O
,	O
which	O
exceeded	O
in	O
mganitude	O
and	O
duartion	O
the	O
idetnical	O
aucte	O
dsoe	O
.	O

COCNLUSIONS	O
:	O
Sub	O
-	O
chroinc	O
low	O
dsoe	O
GVG	O
potentaites	O
and	O
extends	O
the	O
inhiibtion	O
of	O
cocanie	O
-	O
idnuced	O
icnreases	O
in	O
doapmine	O
,	O
effectively	O
redcuing	O
cumualtive	O
exposuers	O
and	O
the	O
rsik	O
for	O
VDFS	O
.	O

MR	O
imaigng	O
with	O
quanttiative	O
difufsion	O
mapipng	O
of	O
tacrolmius	O
-	O
induecd	O
neuortoxicity	B-Disease
in	O
oragn	O
trnasplant	O
patinets	O
.	O

Our	O
objecitve	O
was	O
to	O
invsetigate	O
brian	O
MR	O
iamging	O
findigns	O
and	O
the	O
utility	O
of	O
diffsuion	O
-	O
weighted	O
(	O
DW	O
)	O
imaigng	O
in	O
ogran	O
trnasplant	O
patinets	O
who	O
developed	O
neurolgoic	O
sypmtoms	O
during	O
tacrloimus	O
threapy	O
.	O

Barin	O
MR	O
studeis	O
,	O
including	O
DW	O
imagnig	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
ogran	O
tarnsplant	O
patietns	O
receiving	O
tacroilmus	O
who	O
developed	O
neuroolgic	B-Disease
complicaitons	I-Disease
.	O

In	O
each	O
pateint	O
who	O
had	O
anbormalities	O
on	O
the	O
initial	O
MR	O
sutdy	O
,	O
a	O
follow	O
-	O
up	O
MR	O
sutdy	O
was	O
performed	O
1	O
motnh	O
later	O
.	O

Appaernt	O
dfifusion	O
coeffciient	O
(	O
ADC	O
)	O
vlaues	O
on	O
the	O
initial	O
MR	O
stduy	O
were	O
correlated	O
with	O
reversbiility	O
of	O
the	O
lseions	O
.	O

Of	O
the	O
14	O
ptaients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
whtie	B-Disease
matter	I-Disease
abnromalities	I-Disease
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
putamianl	B-Disease
hemrorhage	I-Disease
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
noraml	O
fidnings	O
on	O
initial	O
MR	O
iamges	O
.	O

Among	O
the	O
5	O
patinets	O
with	O
whtie	B-Disease
matter	I-Disease
abnormaliites	I-Disease
,	O
4	O
paitents	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
hihger	O
than	O
nomral	O
ADC	O
valeus	O
on	O
initial	O
MR	O
imaegs	O
,	O
and	O
all	O
showed	O
complete	O
resloution	O
on	O
follow	O
-	O
up	O
imaegs	O
.	O

The	O
remaining	O
1	O
patinet	O
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
lwoer	O
than	O
nomral	O
ADC	O
value	O
and	O
showed	O
icnomplete	O
resoultion	O
with	O
crotical	B-Disease
lmainar	I-Disease
necorsis	I-Disease
.	O

Diffusoin	O
-	O
weighted	O
imgaing	O
may	O
be	O
useful	O
in	O
predciting	O
the	O
ouctomes	O
of	O
the	O
lesinos	O
of	O
tacroilmus	O
-	O
idnuced	O
neuortoxicity	B-Disease
.	O

L	O
-	O
argniine	O
transoprt	O
in	O
hmuans	O
with	O
cotrisol	O
-	O
idnuced	O
hypertnesion	B-Disease
.	O

A	O
deifcient	O
L	O
-	O
arginnie	O
-	O
ntiric	O
oxdie	O
sysetm	O
is	O
implicated	O
in	O
cortiosl	O
-	O
inudced	O
hypertesnion	B-Disease
.	O

We	O
invetsigate	O
whether	O
abnormlaities	O
in	O
L	O
-	O
arginnie	O
upatke	O
contribute	O
to	O
this	O
dfeiciency	O
.	O

Eight	O
heatlhy	O
men	O
were	O
recruited	O
.	O

Hydorcortisone	O
aectate	O
(	O
50	O
mg	O
)	O
was	O
given	O
orlaly	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fxied	O
-	O
slat	O
deit	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

Crossoevr	O
sutdies	O
were	O
performed	O
2	O
weeks	O
apart	O
.	O

Thirty	O
millilietrs	O
of	O
bolod	O
was	O
obtained	O
for	O
isolatoin	O
of	O
perpiheral	O
bolod	O
moonnuclear	O
clels	O
after	O
each	O
treamtent	O
peirod	O
.	O

L	O
-	O
arginnie	O
upatke	O
was	O
asesssed	O
in	O
mononulcear	O
cells	O
incuabted	O
with	O
L	O
-	O
agrinine	O
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	O
3H	O
]	O
-	O
l	O
-	O
argiinne	O
for	O
a	O
peroid	O
of	O
5	O
mintues	O
at	O
37	O
degrees	O
C	O
.	O

Foerarm	O
[	O
3H	O
]	O
-	O
L	O
-	O
agrinine	O
extraciton	O
was	O
calculated	O
after	O
infsuion	O
of	O
[	O
3H	O
]	O
-	O
L	O
-	O
agrinine	O
into	O
the	O
bracihal	O
aretry	O
at	O
a	O
rtae	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
mintues	O
.	O

Deep	O
froearm	O
veonus	O
samlpes	O
were	O
collected	O
for	O
dteermination	O
of	O
L	O
-	O
argiinne	O
etxraction	O
.	O

Plsama	O
cotrisol	O
cnocentrations	O
were	O
significantly	O
raised	O
during	O
the	O
atcive	O
phsae	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Systoilc	O
blood	O
perssure	O
was	O
eelvated	O
by	O
an	O
avreage	O
of	O
7	O
mm	O
Hg	O
.	O

Neither	O
L	O
-	O
arginnie	O
transoprt	O
into	O
mononucelar	O
cells	O
(	O
placbeo	O
vs	O
acitve	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
clels	O
per	O
5	O
mniutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
agrinine	O
concentratoin	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
argiinne	O
extractoin	O
in	O
the	O
froearm	O
(	O
at	O
80	O
mintues	O
,	O
plaecbo	O
vs	O
atcive	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
diisntegrations	O
per	O
minute	O
)	O
was	O
afefcted	O
by	O
cortiosl	O
teratment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginnie	O
uptkae	O
is	O
not	O
afefcted	O
by	O
short	O
-	O
term	O
coritsol	O
treatemnt	O
.	O

We	O
conclude	O
that	O
crotisol	O
-	O
idnuced	O
icnreases	B-Disease
in	I-Disease
bolod	I-Disease
perssure	I-Disease
are	O
not	O
associated	O
with	O
abnomralities	O
in	O
the	O
l	O
-	O
arignine	O
transprot	O
sysetm	O
.	O

Amonut	O
of	O
bleeidng	B-Disease
and	O
heamtoma	B-Disease
szie	O
in	O
the	O
collagnease	O
-	O
indcued	O
intrcaerebral	B-Disease
heomrrhage	I-Disease
rat	O
mdoel	O
.	O

The	O
aggraavted	O
rsik	O
on	O
intraecrebral	B-Disease
hemrorhage	I-Disease
(	O
ICH	B-Disease
)	O
with	O
durgs	O
used	O
for	O
storke	B-Disease
patietns	O
should	O
be	O
estmiated	O
carefully	O
.	O

We	O
therefore	O
established	O
senistive	O
quantificaiton	O
mehtods	O
and	O
provided	O
a	O
rat	O
ICH	B-Disease
moedl	O
for	O
dteection	O
of	O
ICH	B-Disease
deterioraiton	O
.	O

In	O
ICH	B-Disease
intrastriatlaly	O
inudced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collageanse	O
,	O
the	O
amonut	O
of	O
bleeding	B-Disease
was	O
meausred	O
using	O
a	O
hemgolobin	O
assay	O
developed	O
in	O
the	O
present	O
sutdy	O
and	O
was	O
copmared	O
with	O
the	O
morphloogically	O
determined	O
hemaotma	B-Disease
volmue	O
.	O

The	O
blood	O
amounts	O
and	O
hemaotma	B-Disease
voluems	O
were	O
significantly	O
correalted	O
,	O
and	O
the	O
hematmoa	B-Disease
inudced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adeuqate	O
to	O
dteect	O
ICH	B-Disease
dteerioration	O
.	O

In	O
ICH	B-Disease
indcution	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagensae	O
,	O
hpearin	O
ehnanced	O
the	O
hmeatoma	B-Disease
voulme	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
cnotrol	O
ICH	B-Disease
aniamls	O
and	O
the	O
bleednig	B-Disease
7	O
.	O
6	O
-	O
fold	O
.	O

Dtaa	O
suggest	O
that	O
this	O
sensiitve	O
hemoglboin	O
assay	O
is	O
useful	O
for	O
ICH	B-Disease
deetction	O
,	O
and	O
that	O
a	O
moedl	O
with	O
a	O
small	O
ICH	B-Disease
induecd	O
with	O
a	O
low	O
-	O
dsoe	O
clolagenase	O
should	O
be	O
used	O
for	O
evalutaion	O
of	O
durgs	O
that	O
may	O
affect	O
ICH	B-Disease
.	O

Estardiol	O
reduecs	O
seziure	B-Disease
-	O
induecd	O
hippocmapal	B-Disease
ijnury	I-Disease
in	O
ovairectomized	O
feamle	O
but	O
not	O
in	O
mlae	O
rtas	O
.	O

Estrognes	O
protect	O
ovairectomized	O
rtas	O
from	O
hippocampal	B-Disease
inujry	I-Disease
inudced	O
by	O
kaiinc	O
aicd	O
-	O
induecd	O
sattus	B-Disease
epliepticus	I-Disease
(	O
SE	B-Disease
)	O
.	O

We	O
compraed	O
the	O
effetcs	O
of	O
17beta	O
-	O
esrtadiol	O
in	O
adlut	O
mlae	O
and	O
ovraiectomized	O
feamle	O
rtas	O
subjected	O
to	O
litihum	O
-	O
piolcarpine	O
-	O
indcued	O
SE	B-Disease
.	O

Rtas	O
received	O
subcutaenous	O
injectoins	O
of	O
17beta	O
-	O
esrtadiol	O
(	O
2	O
mcirog	O
/	O
rat	O
)	O
or	O
oil	O
once	O
dialy	O
for	O
four	O
consecuitve	O
dyas	O
.	O

SE	B-Disease
was	O
inudced	O
20	O
h	O
following	O
the	O
second	O
injetcion	O
and	O
terminaetd	O
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
sliver	O
-	O
stianed	O
CA3	O
and	O
CA1	O
hippcoampal	O
nuerons	O
was	O
evaulated	O
2	O
dyas	O
after	O
SE	B-Disease
.	O

17beta	O
-	O
Estardiol	O
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
colnus	O
in	O
ovariecotmized	O
rtas	O
but	O
acceelrated	O
it	O
in	O
mlaes	O
.	O

17beta	O
-	O
Estardiol	O
reudced	O
the	O
argyrophiilc	O
neuorns	O
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
sectros	O
of	O
ovarietcomized	O
rtas	O
.	O

In	O
maels	O
,	O
estardiol	O
incraesed	O
the	O
total	O
dmaage	O
socre	O
.	O

These	O
fidnings	O
suggest	O
that	O
the	O
effcets	O
of	O
estraidol	O
on	O
seiuzre	B-Disease
threshlod	O
and	O
dmaage	O
may	O
be	O
alteerd	O
by	O
sex	O
-	O
related	O
diffreences	O
in	O
the	O
homronal	O
evnironment	O
.	O

Pseudoacromeglay	B-Disease
indcued	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minoixdil	O
.	O

Acrmoegaly	B-Disease
is	O
an	O
enodcrine	B-Disease
disoredr	I-Disease
caused	O
by	O
crhonic	O
excessive	O
grwoth	O
homrone	O
sercetion	O
from	O
the	O
anteiror	O
pituitray	O
galnd	O
.	O

Sginificant	O
disfiguirng	O
chnages	O
occur	O
as	O
a	O
result	O
of	O
bnoe	O
,	O
catrilage	O
,	O
and	O
sfot	O
tissue	O
hypertorphy	B-Disease
,	O
including	O
the	O
thickeinng	O
of	O
the	O
sikn	O
,	O
corasening	O
of	O
fcaial	O
featrues	O
,	O
and	O
cuits	B-Disease
vreticis	I-Disease
gyrtaa	I-Disease
.	O

Pseudoacromeglay	B-Disease
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presecne	O
of	O
similar	O
acrmoegaloid	O
fetaures	O
in	O
the	O
absnece	O
of	O
eelvated	O
grotwh	O
hormnoe	O
or	O
insluin	O
-	O
like	O
grotwh	O
facotr	O
lveels	O
.	O

We	O
present	O
a	O
ptaient	O
with	O
pseudoacromeagly	B-Disease
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoixdil	O
at	O
an	O
unsuually	O
high	O
dsoe	O
.	O

This	O
is	O
the	O
first	O
csae	O
rpeort	O
of	O
pseudoacrmoegaly	B-Disease
as	O
a	O
side	O
efefct	O
of	O
minoxdiil	O
use	O
.	O

Combnied	O
anrdogen	O
blockdae	O
-	O
idnuced	O
aneima	B-Disease
in	O
protsate	B-Disease
cacner	I-Disease
patietns	O
without	O
bnoe	O
invlovement	O
.	O

BACKGRONUD	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
cobmined	O
androegn	O
blocakde	O
(	O
CAB	O
)	O
-	O
induecd	O
anmeia	B-Disease
in	O
protsate	B-Disease
cnacer	I-Disease
pateints	O
without	O
bnoe	O
ivnolvement	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
paitents	O
with	O
biposy	O
-	O
proven	O
porstatic	B-Disease
adenocarcnioma	I-Disease
[	O
26	O
with	O
stgae	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
satge	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
stduy	O
.	O

All	O
paitents	O
received	O
CAB	O
[	O
lueprolide	O
aceatte	O
(	O
LRHH	O
-	O
A	O
)	O
3	O
.	O
75	O
mg	O
,	O
intramusuclarly	O
,	O
every	O
28	O
dyas	O
plus	O
250	O
mg	O
flutamdie	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
eavluated	O
for	O
anmeia	B-Disease
by	O
physcial	O
examinatoin	O
and	O
laboartory	O
tsets	O
at	O
baselnie	O
and	O
4	O
subsequent	O
intrevals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
mnoths	O
psot	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testosternoe	O
measureemnts	O
were	O
recorded	O
.	O

Paitents	O
with	O
satge	O
D2	O
-	O
3	O
disaese	O
,	O
abnromal	O
hmeoglobin	O
leevl	O
or	O
rneal	O
and	O
lvier	O
functoin	O
tsets	O
that	O
were	O
hihger	O
than	O
the	O
upepr	O
lmiits	O
were	O
excluded	O
from	O
the	O
stduy	O
.	O

The	O
duraiton	O
of	O
the	O
sutdy	O
was	O
six	O
motnhs	O
.	O

REUSLTS	O
:	O
The	O
mean	O
hemolgobin	O
(	O
Hb	O
)	O
leevls	O
were	O
significantly	O
dcelined	O
in	O
all	O
patietns	O
from	O
baselnie	O
of	O
14	O
.	O
2	O
g	O
/	O
dl	O
to	O
14	O
.	O
0	O
g	O
/	O
dl	O
,	O
13	O
.	O
5	O
g	O
/	O
dl	O
,	O
13	O
.	O
2	O
g	O
/	O
dl	O
and	O
12	O
.	O
7	O
g	O
/	O
dl	O
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
motnhs	O
psot	O
-	O
CAB	O
,	O
respectively	O
.	O

Sevree	O
and	O
clinically	O
evident	O
aenmia	B-Disease
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clniical	O
symtpoms	O
was	O
deetcted	O
in	O
6	O
patietns	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O

This	O
CAB	O
-	O
inudced	O
aneima	B-Disease
was	O
normochrmoic	O
and	O
noromcytic	O
.	O

At	O
six	O
monhts	O
psot	O
-	O
CAB	O
,	O
ptaients	O
with	O
sevree	O
aneima	B-Disease
had	O
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
ptaients	O
had	O
mlid	O
anmeia	B-Disease
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
developemnt	O
of	O
seevre	O
aenmia	B-Disease
at	O
6	O
monhts	O
psot	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reductoin	O
of	O
Hb	O
baesline	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
mnoths	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
deevlopment	O
of	O
seevre	O
CAB	O
-	O
idnuced	O
aenmia	B-Disease
in	O
prosatte	B-Disease
canecr	I-Disease
ptaients	O
did	O
not	O
correalte	O
with	O
T	O
baesline	O
valeus	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
cilnical	O
satge	O
(	O
satge	O
C	O
versus	O
stgae	O
D1	O
)	O
.	O

Sevree	O
and	O
clniically	O
evident	O
aenmia	B-Disease
was	O
easily	O
corercted	O
by	O
subcutaneuos	O
injcetions	O
(	O
3	O
times	O
/	O
week	O
for	O
1	O
motnh	O
)	O
of	O
recombniant	O
erythorpoietin	O
(	O
rHEuPO	O
-	O
btea	O
)	O
.	O

CONCULSION	O
:	O
Our	O
dtaa	O
suggest	O
that	O
ruHEPO	O
-	O
btea	O
correcatble	O
CAB	O
-	O
induecd	O
aenmia	B-Disease
occurs	O
in	O
14	O
.	O
3	O
%	O
of	O
prosttae	B-Disease
cnacer	I-Disease
paitents	O
after	O
6	O
mnoths	O
of	O
thearpy	O
.	O

Delriium	B-Disease
during	O
clzoapine	O
traetment	O
:	O
inicdence	O
and	O
associated	O
rsik	O
facotrs	O
.	O

BACKGRUOND	O
:	O
Inicdence	O
and	O
rsik	O
fcators	O
for	O
deilrium	B-Disease
during	O
cloazpine	O
treatemnt	O
require	O
further	O
clraification	O
.	O

METHODS	O
:	O
We	O
used	O
cmoputerized	O
pahrmacy	O
reocrds	O
to	O
identify	O
all	O
adlut	O
psychiartic	B-Disease
inptaients	O
tretaed	O
with	O
cloazpine	O
(	O
1995	O
-	O
96	O
)	O
,	O
rveiewed	O
their	O
medcial	O
reocrds	O
to	O
socre	O
incidecne	O
and	O
seevrity	O
of	O
dleirium	B-Disease
,	O
and	O
tetsed	O
assocaitions	O
with	O
poetntial	O
rsik	O
factros	O
.	O

REUSLTS	O
:	O
Subjetcs	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
woemn	O
and	O
67	O
men	O
,	O
aegd	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
yaers	O
,	O
hospitailzed	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
dyas	O
,	O
and	O
given	O
colzapine	O
,	O
gradually	O
incerased	O
to	O
an	O
avergae	O
dialy	O
dsoe	O
of	O
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
dyas	O
.	O

Delriium	B-Disease
was	O
diagnoesd	O
in	O
14	O
(	O
10	O
.	O
1	O
%	O
incidnece	O
,	O
or	O
1	O
.	O
48	O
csaes	O
/	O
preson	O
-	O
yaers	O
of	O
epxosure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
caess	O
were	O
modreate	O
or	O
seevre	O
.	O

Associated	O
fcators	O
were	O
co	O
-	O
treatemnt	O
with	O
other	O
centrally	O
atnimuscarinic	O
agnets	O
,	O
poor	O
clincial	O
otucome	O
,	O
oledr	O
age	O
,	O
and	O
longer	O
hospitalziation	O
(	O
by	O
17	O
.	O
5	O
dyas	O
,	O
increaisng	O
csot	O
)	O
;	O
sex	O
,	O
diagnoiss	O
or	O
mdeical	O
co	O
-	O
morbidtiy	O
,	O
and	O
daliy	O
clozpaine	O
dsoe	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O

COCNLUSIONS	O
:	O
Deilrium	B-Disease
was	O
found	O
in	O
10	O
%	O
of	O
clzoapine	O
-	O
terated	O
inpateints	O
,	O
particularly	O
in	O
odler	O
ptaients	O
epxosed	O
to	O
other	O
centarl	O
anticholniergics	O
.	O

Delriium	B-Disease
was	O
inconsistently	O
recognized	O
clincially	O
in	O
milder	O
caess	O
and	O
was	O
associated	O
with	O
incresaed	O
lentgh	O
-	O
of	O
-	O
stay	O
and	O
hihger	O
cotss	O
,	O
and	O
infeiror	O
clincial	O
outocme	O
.	O

Neuroprotectvie	O
aciton	O
of	O
MEPP	O
,	O
a	O
selective	O
mGlRu5	O
anatgonist	O
,	O
in	O
methamphteamine	O
-	O
inudced	O
dpoaminergic	O
neurtooxicity	B-Disease
is	O
associated	O
with	O
a	O
dcerease	O
in	O
dpoamine	O
outlfow	O
and	O
inhibtiion	O
of	O
hyperhtermia	B-Disease
in	O
rtas	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotrpoic	O
gluatmate	O
rceeptor	O
5	O
(	O
mGlRu5	O
)	O
in	O
the	O
toixc	O
atcion	O
of	O
methampehtamine	O
on	O
dpoaminergic	O
neruones	O
in	O
rtas	O
.	O

Methamhpetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administeerd	O
five	O
times	O
,	O
reduecd	O
the	O
levles	O
of	O
dopamnie	O
and	O
its	O
metabolties	O
in	O
stiratal	O
tisuse	O
when	O
measuerd	O
72	O
h	O
after	O
the	O
last	O
injeciton	O
.	O

A	O
selective	O
antaognist	O
of	O
mlGuR5	O
,	O
2	O
-	O
mehtyl	O
-	O
6	O
-	O
(	O
phenyelthynyl	O
)	O
pyriidne	O
(	O
MEPP	O
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
admniistered	O
five	O
times	O
immediately	O
before	O
each	O
methamhpetamine	O
ijnection	O
rveersed	O
the	O
above	O
-	O
mentioned	O
methamphetamnie	O
effetcs	O
.	O

A	O
single	O
MEPP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injcetion	O
reudced	O
the	O
bsaal	O
extracellular	O
doapmine	O
lveel	O
in	O
the	O
stiratum	O
,	O
as	O
well	O
as	O
dpoamine	O
relesae	O
stimulaetd	O
either	O
by	O
methampehtamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intratsriatally	O
adimnistered	O
vertaridine	O
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
trnasiently	O
diminished	O
the	O
mtehamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
idnuced	O
hpyerthermia	B-Disease
and	O
redcued	O
baasl	O
bdoy	O
tempertaure	O
.	O

MEPP	O
administeerd	O
into	O
the	O
srtiatum	O
at	O
high	O
concentartions	O
(	O
500	O
microM	O
)	O
incresaed	O
extracellualr	O
dopamnie	O
leevls	O
,	O
while	O
loewr	O
cocnentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O

The	O
resluts	O
of	O
this	O
sutdy	O
suggest	O
that	O
the	O
bolckade	O
of	O
mlGuR5	O
by	O
MEPP	O
may	O
protect	O
doapminergic	O
neuroens	O
against	O
methamphteamine	O
-	O
indcued	O
txoicity	B-Disease
.	O

Neruoprotection	O
rendered	O
by	O
MEPP	O
may	O
be	O
associated	O
with	O
the	O
redcution	O
of	O
the	O
methamhpetamine	O
-	O
induecd	O
dopamnie	O
effulx	O
in	O
the	O
straitum	O
due	O
to	O
the	O
blokcade	O
of	O
etxrastriatal	O
mGulR5	O
,	O
and	O
with	O
a	O
dercease	O
in	O
hyprethermia	B-Disease
.	O

Protectvie	O
effciacy	O
of	O
nueroactive	O
streoids	O
against	O
coacine	O
knidled	O
-	O
siezures	B-Disease
in	O
mcie	O
.	O

Neruoactive	O
steriods	O
demonstrate	O
phamracological	O
actinos	O
that	O
have	O
relevance	O
for	O
a	O
hsot	O
of	O
neuroolgical	B-Disease
and	I-Disease
psyhciatric	I-Disease
disordres	I-Disease
.	O

They	O
offer	O
protetcion	O
against	O
seiuzres	B-Disease
in	O
a	O
range	O
of	O
moedls	O
and	O
seem	O
to	O
inihbit	O
certain	O
staegs	O
of	O
durg	B-Disease
dpeendence	I-Disease
in	O
perclinical	O
assessmnets	O
.	O

The	O
present	O
stduy	O
was	O
designed	O
to	O
evalaute	O
two	O
endgoenous	O
and	O
one	O
syntheitc	O
nueroactive	O
setroid	O
that	O
psoitively	O
modultae	O
the	O
gamma	O
-	O
aminobtuyric	O
aicd	O
(	O
GBAA	O
(	O
A	O
)	O
)	O
recpetor	O
against	O
the	O
incresae	O
in	O
senstiivity	O
to	O
the	O
convlusant	O
effects	O
of	O
coacine	O
engendered	O
by	O
repaeted	O
coacine	O
admiinstration	O
(	O
seizrue	B-Disease
knidling	O
)	O
.	O

Allopregnaonlone	O
(	O
3alpha	O
-	O
hydorxy	O
-	O
5alpha	O
-	O
pregann	O
-	O
20	O
-	O
one	O
)	O
,	O
pergnanolone	O
(	O
3alpha	O
-	O
hdyroxy	O
-	O
5beta	O
-	O
pregann	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaoxlone	O
(	O
a	O
sytnhetic	O
derivtaive	O
of	O
allopregnanolnoe	O
3alpha	O
-	O
hydorxy	O
-	O
3beta	O
-	O
metyhl	O
-	O
5alpha	O
-	O
pregann	O
-	O
20	O
-	O
one	O
)	O
were	O
tetsed	O
for	O
their	O
ability	O
to	O
suprpess	O
the	O
expressoin	O
(	O
anticonvulasnt	O
efefct	O
)	O
and	O
devleopment	O
(	O
antiepiletpogenic	O
effcet	O
)	O
of	O
cocanie	O
-	O
kindeld	O
seizrues	B-Disease
in	O
mlae	O
,	O
Swsis	O
-	O
Wbester	O
mcie	O
.	O

Knidled	O
seiuzres	B-Disease
were	O
indcued	O
by	O
dialy	O
amdinistration	O
of	O
60	O
mg	O
/	O
kg	O
coacine	O
for	O
5	O
dyas	O
.	O

All	O
of	O
these	O
positvie	O
GBAA	O
(	O
A	O
)	O
modualtors	O
suppressed	O
the	O
exprsesion	O
of	O
kinlded	O
seizuers	B-Disease
,	O
whereas	O
only	O
allopregnanolone	O
and	O
gaanxolone	O
inihbited	O
the	O
deveolpment	O
of	O
kinlding	O
.	O

Alloprgenanolone	O
and	O
prenganolone	O
,	O
but	O
not	O
ganaxolnoe	O
,	O
also	O
reudced	O
cmuulative	O
lethaltiy	O
associated	O
with	O
kinlding	O
.	O

These	O
finidngs	O
demonstrate	O
that	O
some	O
nueroactive	O
sterodis	O
attenaute	O
conuvlsant	O
and	O
senstiizing	O
properites	O
of	O
ccoaine	O
and	O
add	O
to	O
a	O
growing	O
litertaure	O
on	O
their	O
potentail	O
use	O
in	O
the	O
modulatoin	O
of	O
efefcts	O
of	O
durgs	O
of	O
aubse	O
.	O

Effcet	O
of	O
huomral	O
modulatros	O
of	O
morphnie	O
-	O
inudced	O
incraese	B-Disease
in	I-Disease
locomootr	I-Disease
actviity	I-Disease
of	O
mcie	O
.	O

The	O
efefct	O
of	O
humroal	O
modulaotrs	O
on	O
the	O
morhpine	O
-	O
inudced	O
icnrease	B-Disease
in	I-Disease
loocmotor	I-Disease
actviity	I-Disease
of	O
mcie	O
was	O
studied	O
.	O

The	O
sucbutaneous	O
adimnistration	O
of	O
10	O
mg	O
/	O
kg	O
of	O
morphnie	O
-	O
HC1	O
produced	O
a	O
marked	O
incresae	B-Disease
in	I-Disease
lcoomotor	I-Disease
atcivity	I-Disease
in	O
mcie	O
.	O

The	O
moprhine	O
-	O
indcued	O
hyperactivtiy	B-Disease
was	O
potenitated	O
by	O
scooplamine	O
and	O
attenuaetd	O
by	O
physostimgine	O
.	O

In	O
contrast	O
,	O
both	O
methscopolamnie	O
and	O
neostigimne	O
,	O
which	O
do	O
not	O
penetarte	O
the	O
blood	O
-	O
barin	O
barirer	O
,	O
had	O
no	O
effcet	O
on	O
the	O
hpyeractivity	B-Disease
produced	O
by	O
moprhine	O
.	O

Pretreatemnt	O
of	O
mcie	O
with	O
alhpa	O
-	O
methylytrosine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inihbitor	O
of	O
tryosine	O
hydrxoylase	O
,	O
significantly	O
derceased	O
the	O
activtiy	O
-	O
incerasing	O
effects	O
of	O
mrophine	O
.	O

On	O
the	O
other	O
hand	O
,	O
pretraetment	O
with	O
p	O
-	O
cholrophenylalamine	O
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
sreotonin	O
depleotr	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactiivty	B-Disease
.	O

The	O
sutdy	O
suggests	O
that	O
the	O
atcivity	O
-	O
inrceasing	O
effects	O
of	O
mrophine	O
are	O
mediated	O
by	O
the	O
reelase	O
of	O
caetcholamines	O
from	O
ardenergic	O
nuerons	O
in	O
the	O
barin	O
.	O

And	O
the	O
resluts	O
are	O
consistent	O
with	O
the	O
hypotheiss	O
that	O
morhpine	O
acts	O
by	O
rtearding	O
the	O
reelase	O
of	O
aectylcholine	O
at	O
some	O
cnetral	O
choilnergic	O
synpases	O
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evidnece	O
that	O
the	O
atcivity	O
-	O
icnreasing	O
effetcs	O
of	O
moprhine	O
in	O
mcie	O
are	O
mediated	O
by	O
mechnaisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
actiivty	O
-	O
incerasing	O
efefcts	O
of	O
moprhine	O
in	O
rtas	O
.	O

Effects	O
of	O
uninephrcetomy	O
and	O
high	O
proetin	O
fedeing	O
on	O
ltihium	O
-	O
induecd	O
chrnoic	B-Disease
reanl	I-Disease
faliure	I-Disease
in	O
rtas	O
.	O

Rtas	O
with	O
lithuim	O
-	O
indcued	O
nephroptahy	B-Disease
were	O
subjected	O
to	O
high	O
proetin	O
(	O
HP	O
)	O
feednig	O
,	O
unienphrectomy	O
(	O
NX	O
)	O
or	O
a	O
cmobination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
indcue	O
glomeurlar	O
hyperflitration	O
and	O
further	O
prgoression	O
of	O
reanl	B-Disease
failrue	I-Disease
.	O

Nweborn	O
femlae	O
Wsitar	O
rtas	O
were	O
fed	O
a	O
lithuim	O
-	O
containing	O
deit	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
wekes	O
and	O
then	O
ranodmized	O
to	O
nomral	O
deit	O
,	O
HP	O
deit	O
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP	O
+	O
NX	O
for	O
another	O
8	O
weeks	O
.	O

Corresponding	O
non	O
-	O
litihum	O
pretreaetd	O
gorups	O
were	O
generated	O
.	O

When	O
compraing	O
all	O
ltihium	O
traeted	O
versus	O
non	O
-	O
litihum	O
-	O
traeted	O
gropus	O
,	O
ltihium	O
caused	O
a	O
redcution	O
in	O
glomeurlar	O
fitlration	O
rtae	O
(	O
GFR	O
)	O
without	O
significant	O
cahnges	O
in	O
effcetive	O
reanl	O
palsma	O
folw	O
(	O
as	O
determined	O
by	O
a	O
makrer	O
secreetd	O
into	O
the	O
proixmal	O
tuubles	O
)	O
or	O
lihtium	O
claerance	O
.	O

Consequently	O
,	O
litihum	O
pretraetment	O
caused	O
a	O
fall	O
in	O
flitration	O
fraciton	O
and	O
an	O
incraese	O
in	O
fracitonal	O
Li	O
excreiton	O
.	O

Lithuim	O
also	O
caused	O
protienuria	B-Disease
and	O
systoilc	O
hpyertension	B-Disease
in	O
absecne	O
of	O
glomeruloslcerosis	B-Disease
.	O

HP	O
failed	O
to	O
accentuante	O
prgoression	O
of	O
rneal	B-Disease
faiulre	I-Disease
and	O
in	O
fact	O
tended	O
to	O
incresae	O
GFR	O
and	O
decerase	O
plsama	O
creatniine	O
levles	O
in	O
litihum	O
pretreaetd	O
rtas	O
.	O

NX	O
caused	O
an	O
addiitve	O
dteerioration	O
in	O
GFR	O
which	O
,	O
however	O
,	O
was	O
aemliorated	O
by	O
HP	O
.	O

NX	O
+	O
HP	O
caused	O
a	O
further	O
rise	O
in	O
blood	O
perssure	O
in	O
Li	O
-	O
pretraeted	O
rtas	O
.	O

The	O
reuslts	O
indicate	O
that	O
Li	O
-	O
indcued	O
nehpropathy	B-Disease
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
rdeuced	O
,	O
is	O
associated	O
with	O
porteinuria	B-Disease
and	O
arteiral	O
systloic	O
hypertesnion	B-Disease
.	O

In	O
this	O
mdoel	O
of	O
chrnoic	B-Disease
rneal	I-Disease
faliure	I-Disease
the	O
declnie	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
effecitve	O
rneal	O
palsma	O
folw	O
,	O
which	O
may	O
be	O
the	O
funcitonal	O
exrpession	O
of	O
the	O
formtaion	O
of	O
nonfiltrating	O
atbuular	O
glomerlui	O
.	O

The	O
fracitonal	O
reabsroption	O
of	O
tubualr	O
fliud	O
by	O
the	O
porximal	O
tubuels	O
is	O
reudced	O
,	O
leaving	O
the	O
dsital	O
deilvery	O
unchanegd	O
.	O
(	O
ABSTRACT	O
TRNUCATED	O
AT	O
250	O
WORDS	O
)	O

Treatmnet	O
of	O
Corhn	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
with	O
fuisdic	O
aicd	O
:	O
an	O
anitbiotic	O
with	O
immunosupperssive	O
properteis	O
similar	O
to	O
ccylosporin	O
.	O

Fsuidic	O
aicd	O
is	O
an	O
atnibiotic	O
with	O
T	O
-	O
clel	O
specific	O
immunosuppresisve	O
effcets	O
similar	O
to	O
those	O
of	O
ccylosporin	O
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
developemnt	O
of	O
new	O
treatmetns	O
for	O
Crhon	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
,	O
a	O
pliot	O
sutdy	O
was	O
undertaken	O
to	O
esitmate	O
the	O
phramacodynamics	O
and	O
tolerbaility	O
of	O
fusiidc	O
aicd	O
treatmnet	O
in	O
chornic	O
actvie	O
,	O
thearpy	O
-	O
rseistant	O
paitents	O
.	O

Eight	O
Corhn	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
patinets	O
were	O
included	O
.	O

Fuisdic	O
aicd	O
was	O
admiinstered	O
oarlly	O
in	O
a	O
dsoe	O
of	O
500	O
mg	O
t	O
.	O
d	O
.	O
s	O
.	O
and	O
the	O
treatemnt	O
was	O
planned	O
to	O
last	O
8	O
wekes	O
.	O

The	O
diesase	O
acitvity	O
was	O
primarily	O
measrued	O
by	O
a	O
moidfied	O
indviidual	O
grdaing	O
socre	O
.	O

Five	O
of	O
8	O
pateints	O
(	O
63	O
%	O
)	O
ipmroved	O
during	O
fusiidc	O
aicd	O
teratment	O
:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks	O
.	O

There	O
were	O
no	O
serious	O
clincial	O
side	O
effcets	O
,	O
but	O
dsoe	O
redutcion	O
was	O
required	O
in	O
two	O
ptaients	O
because	O
of	O
nuasea	B-Disease
.	O

Biocheimcally	O
,	O
an	O
incraese	O
in	O
alkailne	O
phopshatases	O
was	O
noted	O
in	O
5	O
of	O
8	O
caess	O
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	O
incerases	O
were	O
seen	O
in	O
those	O
who	O
had	O
elveated	O
lveels	O
prior	O
to	O
teratment	O
.	O

All	O
revesred	O
to	O
pre	O
-	O
treamtent	O
lveels	O
after	O
cessation	O
of	O
treamtent	O
.	O

The	O
reuslts	O
of	O
this	O
pliot	O
stduy	O
suggest	O
that	O
fsuidic	O
aicd	O
may	O
be	O
of	O
benfeit	O
in	O
selected	O
crhonic	O
atcive	O
Crhon	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
paitents	O
in	O
whom	O
convenitonal	O
treatemnt	O
is	O
ienffective	O
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scientiifc	O
rationale	O
for	O
the	O
use	O
of	O
fsuidic	O
aicd	O
at	O
the	O
cytoknie	O
lveel	O
in	O
inflammtaory	B-Disease
boewl	I-Disease
disaese	I-Disease
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treamtent	O
should	O
be	O
further	O
ivnestigated	O
.	O

Chagnes	O
in	O
dperessive	B-Disease
sttaus	O
associated	O
with	O
topiacl	O
btea	O
-	O
blocekrs	O
.	O

Derpession	B-Disease
and	O
seuxal	B-Disease
dysfunctoin	I-Disease
have	O
been	O
related	O
to	O
side	O
efefcts	O
of	O
topcial	O
btea	O
-	O
blokcers	O
.	O

We	O
performed	O
a	O
preliminary	O
stduy	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
non	O
selective	O
btea	O
-	O
blocekr	O
(	O
tmiolol	O
)	O
and	O
a	O
selective	O
btea	O
-	O
blcoker	O
(	O
betaxooll	O
)	O
regarding	O
CNS	O
side	O
effects	O
.	O

Eight	O
glaucomaotus	B-Disease
patinets	O
chroncially	O
treaetd	O
with	O
tiomlol	O
0	O
.	O
5	O
%	O
/	O
12h	O
,	O
suffernig	O
from	O
dperession	B-Disease
diangosed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
crtieria	O
,	O
were	O
included	O
in	O
the	O
stduy	O
.	O

During	O
the	O
six	O
-	O
mnoth	O
follow	O
up	O
,	O
depression	B-Disease
was	O
qauntified	O
through	O
the	O
Bcek	O
and	O
Znug	O
-	O
Cnode	O
sacles	O
every	O
two	O
mnoths	O
.	O

In	O
a	O
double	O
blnid	O
corss	O
-	O
over	O
stduy	O
with	O
cotnrol	O
gruop	O
,	O
the	O
patietns	O
under	O
tiomlol	O
teratment	O
presented	O
hihger	O
derpession	B-Disease
vaules	O
mesaured	O
through	O
the	O
Bcek	O
and	O
the	O
Znug	O
-	O
Codne	O
scaels	O
(	O
p	O
<	O
0	O
.	O
001	O
vs	O
cnotrol	O
)	O
.	O

These	O
rseults	O
suggest	O
that	O
betaxlool	O
could	O
be	O
less	O
of	O
a	O
depression	B-Disease
-	O
idnucer	O
than	O
timooll	O
in	O
prdeisposed	O
pateints	O
.	O

Protetcion	O
against	O
amphetaimne	O
-	O
induecd	O
neurtooxicity	B-Disease
toward	O
striaatl	O
dopaimne	O
neurnos	O
in	O
rodnets	O
by	O
LY247614	O
,	O
an	O
excitaotry	O
aimno	O
aicd	O
antaognist	O
.	O

L2Y74614	O
,	O
3SR	O
,	O
4aRS	O
,	O
6SR	O
,	O
8aRS	O
-	O
6	O
-	O
[	O
phosphonometyhl	O
]	O
deachydr	O
oisoquinoilne	O
-	O
3	O
-	O
cabroxylic	O
aicd	O
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
anatgonist	O
of	O
the	O
N	O
-	O
metyhl	O
-	O
D	O
-	O
asparttae	O
(	O
NDMA	O
)	O
sutbype	O
of	O
glutamtae	O
rceeptor	O
.	O

Here	O
its	O
ability	O
to	O
antagonzie	O
the	O
porlonged	O
depletoin	O
of	O
dopaimne	O
in	O
the	O
straitum	O
by	O
ampheatmine	O
in	O
iprindloe	O
-	O
tretaed	O
rtas	O
is	O
reported	O
.	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dsoe	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
apmhetamine	O
hemisulftae	O
,	O
given	O
to	O
rtas	O
prtereated	O
with	O
iprnidole	O
,	O
resulted	O
in	O
presistent	O
delpetion	O
of	O
doapmine	O
in	O
the	O
straitum	O
1	O
week	O
later	O
.	O

This	O
prolnoged	O
depleiton	O
of	O
dpoamine	O
in	O
the	O
striautm	O
was	O
antagoinzed	O
by	O
dizcoilpine	O
(	O
MK	O
-	O
801	O
,	O
a	O
non	O
-	O
competitive	O
antagnoist	O
of	O
NDMA	O
receptros	O
)	O
or	O
by	O
LY247614	O
(	O
a	O
competitive	O
antagnoist	O
of	O
NDMA	O
recepotrs	O
)	O
.	O

The	O
protective	O
efefct	O
of	O
LY274164	O
was	O
dsoe	O
-	O
depenednt	O
,	O
being	O
mxaimum	O
at	O
10	O
-	O
40	O
mkgg	O
(	O
i	O
.	O
p	O
.	O
)	O
.	O

A	O
10	O
mg	O
/	O
kg	O
dsoe	O
of	O
LY724614	O
was	O
effecitve	O
in	O
antagonizing	O
the	O
depletoin	O
of	O
dopmaine	O
in	O
the	O
striautm	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetmaine	O
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetmaine	O
.	O

Depletoin	O
of	O
dopmaine	O
in	O
the	O
straitum	O
was	O
also	O
anatgonized	O
when	O
LY724614	O
was	O
given	O
after	O
the	O
injcetion	O
of	O
amhpetamine	O
;	O
LY724614	O
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
ampehtamine	O
.	O

The	O
porlonged	O
depleiton	O
of	O
doapmine	O
in	O
the	O
stritaum	O
in	O
mcie	O
,	O
given	O
multilpe	O
ijnections	O
of	O
mehtamphetamine	O
,	O
was	O
also	O
antagoniezd	O
dsoe	O
-	O
dependently	O
and	O
completely	O
by	O
LY274164	O
.	O

The	O
dtaa	O
strengthen	O
the	O
evidnece	O
that	O
the	O
neurootxic	B-Disease
effcet	O
of	O
amhpetamine	O
and	O
related	O
compoudns	O
toward	O
nigrostritaal	O
dopmaine	O
nuerons	O
involves	O
NDMA	O
recepotrs	O
and	O
that	O
LY274164	O
is	O
an	O
NDMA	O
recepotr	O
antagoinst	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effcets	O
in	O
rtas	O
.	O

Keotconazole	O
-	O
inudced	O
nuerologic	B-Disease
sqeuelae	I-Disease
.	O

A	O
77	O
-	O
y	O
-	O
old	O
pateint	O
developed	O
wekaness	B-Disease
of	I-Disease
extermities	I-Disease
,	O
lges	B-Disease
paralyiss	I-Disease
,	O
dysrathria	B-Disease
and	O
trmeor	B-Disease
1	O
h	O
after	O
ingsetion	O
of	O
200	O
mg	O
ketoconzaole	O
for	O
the	O
first	O
tmie	O
in	O
his	O
lfie	O
.	O

All	O
cmoplaints	O
faded	O
away	O
within	O
24	O
h	O
.	O

Few	O
dyas	O
later	O
,	O
the	O
paitent	O
used	O
another	O
200	O
mg	O
ketoconaozle	O
tbalet	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clincial	O
pictrue	O
,	O
which	O
resolved	O
again	O
spotnaneously	O
within	O
hours	O
.	O

Laboratroy	O
evalautions	O
,	O
including	O
haed	O
CT	O
sacn	O
,	O
were	O
nomral	O
.	O

This	O
csae	O
illustrates	O
the	O
need	O
for	O
close	O
vigilacne	O
in	O
advesre	B-Disease
durg	I-Disease
reacitons	I-Disease
,	O
particularly	O
in	O
the	O
eldrely	O
.	O

Deveolpment	O
of	O
levoodpa	O
-	O
inudced	O
dsykinesias	B-Disease
in	O
pakrinsonian	B-Disease
mnokeys	O
may	O
depend	O
upon	O
rtae	O
of	O
symtpom	O
onset	O
and	O
/	O
or	O
duraiton	O
of	O
symtpoms	O
.	O

Leovdopa	O
-	O
inudced	O
dyskinseias	B-Disease
(	O
LDIs	B-Disease
)	O
present	O
a	O
major	O
prbolem	O
for	O
the	O
long	O
-	O
term	O
manaegment	O
of	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
(	O
PD	B-Disease
)	O
patinets	O
.	O

Due	O
to	O
the	O
interdeepndence	O
of	O
rsik	O
fatcors	O
in	O
clincial	O
ppoulations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
fcators	O
that	O
may	O
infleunce	O
the	O
developmnet	O
of	O
LDIs	B-Disease
.	O

Using	O
maacque	O
monekys	O
with	O
different	O
types	O
of	O
MTPP	O
-	O
idnuced	O
pakrinsonism	B-Disease
,	O
the	O
current	O
sutdy	O
evaluaetd	O
the	O
dergee	O
to	O
which	O
rtae	O
of	O
smyptom	O
progresison	O
,	O
smyptom	O
seevrity	O
,	O
and	O
resposne	O
to	O
and	O
duraiton	O
of	O
leovdopa	O
thearpy	O
may	O
be	O
involved	O
in	O
the	O
developemnt	O
of	O
LDIs	B-Disease
.	O

Mnokeys	O
with	O
actue	O
(	O
short	O
-	O
term	O
)	O
MTPP	O
expsoure	O
,	O
rpaid	O
sypmtom	O
onset	O
and	O
short	O
symtpom	O
duraiton	O
prior	O
to	O
inititaion	O
of	O
leovdopa	O
threapy	O
developed	O
dyskniesia	B-Disease
between	O
11	O
and	O
24	O
dyas	O
of	O
dialy	O
levdoopa	O
administratoin	O
.	O

In	O
contrast	O
,	O
monkyes	O
with	O
long	O
-	O
term	O
MTPP	O
expousre	O
,	O
slow	O
sympotm	O
progression	O
and	O
/	O
or	O
long	O
sypmtom	O
druation	O
prior	O
to	O
initiaiton	O
of	O
lveodopa	O
therpay	O
were	O
more	O
rseistant	O
to	O
developing	O
LDIs	B-Disease
(	O
e	O
.	O
g	O
.	O
,	O
dyskinseia	B-Disease
developed	O
no	O
sooner	O
than	O
146	O
dyas	O
of	O
chroinc	O
leovdopa	O
adminisrtation	O
)	O
.	O

All	O
ainmals	O
were	O
similarly	O
symptoamtic	O
at	O
the	O
start	O
of	O
levdoopa	O
treatmnet	O
and	O
had	O
similar	O
therapeuitc	O
respnoses	O
to	O
the	O
durg	O
.	O

These	O
dtaa	O
suggest	O
distinct	O
differneces	O
in	O
the	O
porpensity	O
to	O
develop	O
LDIs	B-Disease
in	O
mnokeys	O
with	O
different	O
rtaes	O
of	O
smyptom	O
progresison	O
or	O
sypmtom	O
duraitons	O
prior	O
to	O
levoodpa	O
and	O
demonstrate	O
the	O
value	O
of	O
these	O
moedls	O
for	O
further	O
studying	O
the	O
pathophysoilogy	O
of	O
LDIs	B-Disease
.	O

A	O
deit	O
promoting	O
sguar	B-Disease
depednency	I-Disease
causes	O
behavioarl	B-Disease
corss	I-Disease
-	I-Disease
sensitizaiton	I-Disease
to	O
a	O
low	O
dsoe	O
of	O
apmhetamine	O
.	O

Previous	O
reseacrh	O
in	O
this	O
labortaory	O
has	O
shown	O
that	O
a	O
deit	O
of	O
intermtitent	O
excessive	O
sguar	O
cnosumption	O
produces	O
a	O
state	O
with	O
neurohcemical	O
and	O
behavioarl	O
siimlarities	O
to	O
durg	B-Disease
deepndency	I-Disease
.	O

The	O
present	O
stduy	O
examined	O
whether	O
femlae	O
rtas	O
on	O
various	O
rgeimens	O
of	O
suagr	O
access	O
would	O
show	O
behavioarl	B-Disease
crsos	I-Disease
-	I-Disease
sensiitzation	I-Disease
to	O
a	O
low	O
dsoe	O
of	O
amhpetamine	O
.	O

After	O
a	O
30	O
-	O
min	O
basleine	O
measrue	O
of	O
locomootr	O
actviity	O
(	O
day	O
0	O
)	O
,	O
aniamls	O
were	O
maintained	O
on	O
a	O
cycilc	O
deit	O
of	O
12	O
-	O
h	O
depriavtion	O
followed	O
by	O
12	O
-	O
h	O
access	O
to	O
10	O
%	O
sucrsoe	O
soultion	O
and	O
cohw	O
pellets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
drak	O
peirod	O
)	O
for	O
21	O
dyas	O
.	O

Locomtoor	O
activtiy	O
was	O
meausred	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
dyas	O
1	O
and	O
21	O
of	O
suagr	O
access	O
.	O

Beginning	O
on	O
day	O
22	O
,	O
all	O
rtas	O
were	O
maintained	O
on	O
ad	O
libtium	O
cohw	O
.	O

Nine	O
dyas	O
later	O
locomtoor	O
activtiy	O
was	O
mesaured	O
in	O
respnose	O
to	O
a	O
single	O
low	O
dsoe	O
of	O
ampheatmine	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

The	O
ainmals	O
that	O
had	O
experienced	O
ccylic	O
sucorse	O
and	O
cohw	O
were	O
hypreactive	B-Disease
in	O
repsonse	O
to	O
apmhetamine	O
compraed	O
with	O
four	O
cotnrol	O
gruops	O
(	O
ad	O
libiutm	O
10	O
%	O
surcose	O
and	O
cohw	O
followed	O
by	O
amphetmaine	O
injectoin	O
,	O
cylcic	O
cohw	O
followed	O
by	O
amphetamnie	O
inejction	O
,	O
ad	O
libiutm	O
cohw	O
with	O
amphetaimne	O
,	O
or	O
cycilc	O
10	O
%	O
sucorse	O
and	O
cohw	O
with	O
a	O
sailne	O
inejction	O
)	O
.	O

These	O
rseults	O
suggest	O
that	O
a	O
deit	O
comprised	O
of	O
alternating	O
deprviation	O
and	O
access	O
to	O
a	O
suagr	O
soluiton	O
and	O
cohw	O
produces	O
bineging	O
on	O
suagr	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
incresaed	O
senstiivity	O
to	O
amphteamine	O
,	O
possibly	O
due	O
to	O
a	O
lasting	O
altreation	O
in	O
the	O
doapmine	O
sytsem	O
.	O

Revesrible	O
dilaetd	B-Disease
cardiomyopahty	I-Disease
related	O
to	O
amphoteriicn	O
B	O
tehrapy	O
.	O

We	O
describe	O
a	O
patinet	O
who	O
developed	O
diltaed	B-Disease
cardiomypoathy	I-Disease
and	O
cliniacl	O
congsetive	O
haert	B-Disease
faiulre	I-Disease
after	O
2	O
mnoths	O
of	O
therpay	O
with	O
amphotreicin	O
B	O
(	O
AmB	O
)	O
for	O
disseimnated	O
coccidioiodmycosis	B-Disease
.	O

His	O
echocardiograpihc	O
abnormaliites	O
and	O
herat	B-Disease
faiulre	I-Disease
resolved	O
after	O
posaconzaole	O
was	O
subtsituted	O
for	O
AmB	O
.	O

It	O
is	O
important	O
to	O
recognize	O
the	O
rrae	O
and	O
potentially	O
reversible	O
txoicity	B-Disease
of	O
AmB	O
.	O

NO	O
-	O
induecd	O
mirgaine	B-Disease
atatck	O
:	O
strong	O
inrcease	O
in	O
plsama	O
calctionin	O
gnee	O
-	O
related	O
peptdie	O
(	O
CRGP	O
)	O
cnocentration	O
and	O
negtaive	O
correlaiton	O
with	O
platleet	O
sertoonin	O
relaese	O
.	O

The	O
aim	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
ivnestigate	O
chanegs	O
in	O
the	O
plamsa	O
calciotnin	O
gnee	O
-	O
related	O
peptdie	O
(	O
CRGP	O
)	O
concetnration	O
and	O
paltelet	O
sertoonin	O
(	O
5	O
-	O
hydroxytirptamine	O
,	O
5	O
-	O
HT	O
)	O
cotnent	O
during	O
the	O
imemdiate	O
heaadche	B-Disease
and	O
the	O
dealyed	O
genuine	O
mgiraine	B-Disease
atatck	O
provoked	O
by	O
nirtoglycerin	O
.	O

Fifteen	O
feamle	O
migrainuers	B-Disease
(	I-Disease
without	I-Disease
arua	I-Disease
)	I-Disease
and	O
eight	O
cotnrols	O
participated	O
in	O
the	O
sutdy	O
.	O

Sulbingual	O
nitroglyceirn	O
(	O
0	O
.	O
5	O
mg	O
)	O
was	O
adimnistered	O
.	O

Bolod	O
was	O
collected	O
from	O
the	O
anetcubital	O
vien	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglyceirn	O
appliaction	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migriane	B-Disease
atatck	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjetcs	O
)	O
.	O

In	O
those	O
subejcts	O
who	O
had	O
no	O
migriane	B-Disease
attcak	O
(	O
11	O
sujbects	O
)	O
a	O
similar	O
tmie	O
shcedule	O
was	O
used	O
.	O

Plamsa	O
CRGP	O
concetnration	O
increaesd	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
migranie	B-Disease
atatck	O
and	O
returned	O
to	O
bsaeline	O
after	O
the	O
cessatoin	O
of	O
the	O
mirgaine	B-Disease
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
psoitive	O
correlatoins	O
with	O
migriane	B-Disease
haedache	B-Disease
inetnsity	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
plamsa	O
CRGP	O
concnetrations	O
failed	O
to	O
change	O
during	O
immdeiate	O
haedache	B-Disease
and	O
in	O
the	O
sbujects	O
with	O
no	O
migriane	B-Disease
attcak	O
.	O

Bsaal	O
CRGP	O
concentrtaion	O
was	O
significantly	O
hihger	O
and	O
plaetlet	O
5	O
-	O
HT	O
conetnt	O
tended	O
to	O
be	O
lwoer	O
in	O
sbujects	O
who	O
experienced	O
a	O
mirgaine	B-Disease
attcak	O
.	O

Plaetlet	O
seortonin	O
conetnt	O
derceased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nirtoglycerin	O
in	O
sbujects	O
with	O
no	O
migriane	B-Disease
attcak	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
paitents	O
with	O
migriane	B-Disease
atatck	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plsama	O
CRGP	O
cocnentration	O
correlates	O
with	O
the	O
tmiing	O
and	O
sevreity	O
of	O
a	O
mirgaine	B-Disease
haedache	B-Disease
suggests	O
a	O
direct	O
relationhsip	O
between	O
CRGP	O
and	O
mirgaine	B-Disease
.	O

In	O
contrast	O
,	O
sertoonin	O
rleease	O
from	O
pltaelets	O
does	O
not	O
provoke	O
migarine	B-Disease
,	O
it	O
may	O
even	O
counteract	O
the	O
hedaache	B-Disease
and	O
the	O
concmoitant	O
CRGP	O
relaese	O
in	O
this	O
moedl	O
.	O

Hpyerbaric	O
oyxgen	O
thearpy	O
for	O
cotnrol	O
of	O
intrcatable	O
cyclophosphamdie	O
-	O
induecd	O
hmeorrhagic	B-Disease
cysttiis	I-Disease
.	O

We	O
rpeort	O
a	O
csae	O
of	O
intarctable	O
hemrorhagic	B-Disease
cysttiis	I-Disease
due	O
to	O
cyclophosphaimde	O
thearpy	O
for	O
Weegner	B-Disease
'	I-Disease
s	I-Disease
granulomaotsis	I-Disease
.	O

Conesrvative	O
treatmnet	O
,	O
including	O
baldder	O
irrigatoin	O
with	O
physiologiacl	O
slaine	O
and	O
instillatoin	O
of	O
prostaglnadin	O
F2	O
alhpa	O
,	O
failed	O
to	O
totally	O
cotnrol	O
hemorhrage	B-Disease
.	O

We	O
then	O
used	O
hyperabric	O
oxyegn	O
at	O
an	O
aboslute	O
pressure	O
of	O
2	O
atm	O
,	O
5	O
dyas	O
a	O
week	O
for	O
8	O
consceutive	O
weeks	O
.	O

The	O
bleeidng	B-Disease
ceaesd	O
completely	O
by	O
the	O
end	O
of	O
traetment	O
and	O
the	O
ptaient	O
remained	O
free	O
of	O
hemtauria	B-Disease
thereafter	O
.	O

No	O
side	O
effcet	O
was	O
noted	O
during	O
the	O
cuorse	O
of	O
tehrapy	O
.	O

In	O
future	O
,	O
this	O
form	O
of	O
therpay	O
can	O
offer	O
a	O
safe	O
alterntaive	O
in	O
the	O
treatmnet	O
of	O
cyclophosphaimde	O
-	O
induecd	O
hemorhragic	B-Disease
csytitis	I-Disease
.	O

Aucte	B-Disease
psychoiss	I-Disease
due	O
to	O
treatmnet	O
with	O
phenytion	O
in	O
a	O
nnoepileptic	O
pateint	O
.	O

The	O
develompent	O
of	O
psyhcosis	B-Disease
related	O
to	O
antiepilepitc	O
durg	O
traetment	O
is	O
usually	O
attributed	O
to	O
the	O
intearction	O
between	O
the	O
eipleptic	B-Disease
brian	O
subsrtatum	O
and	O
the	O
antiepilepitc	O
drgus	O
.	O

The	O
csae	O
of	O
a	O
nonepilepitc	O
pateint	O
who	O
developed	O
psychsois	B-Disease
following	O
pheyntoin	O
treatmnet	O
for	O
trigemnial	B-Disease
neuraliga	I-Disease
is	O
described	O
.	O

This	O
csae	O
suggests	O
that	O
the	O
psychoitc	B-Disease
symtpoms	I-Disease
that	O
occur	O
following	O
pheyntoin	O
treatemnt	O
in	O
some	O
epiletpic	B-Disease
patinets	O
may	O
be	O
the	O
direct	O
result	O
of	O
medciation	O
,	O
unrelated	O
to	O
seiuzres	B-Disease
.	O

Rsiks	O
of	O
the	O
cosnumption	O
of	O
beevrages	O
containing	O
qiunine	O
.	O

Although	O
the	O
Uinted	O
Sttaes	O
Food	O
and	O
Durg	O
Amdinistration	O
banned	O
its	O
use	O
for	O
nocutrnal	B-Disease
leg	I-Disease
crmaps	I-Disease
due	O
to	O
lcak	O
of	O
sfaety	O
and	O
efficcay	O
,	O
quiinne	O
is	O
widely	O
available	O
in	O
beevrages	O
including	O
toinc	O
waetr	O
and	O
bitter	O
leomn	O
.	O

Numerous	O
anecdoatl	O
rpeorts	O
suggest	O
that	O
proudcts	O
containing	O
qiunine	O
may	O
produce	O
neurolgoical	B-Disease
compliactions	I-Disease
,	O
including	O
confusoin	B-Disease
,	O
altreed	O
metnal	O
stauts	O
,	O
siezures	B-Disease
,	O
and	O
cmoa	B-Disease
,	O
particularly	O
in	O
oledr	O
woemn	O
.	O

Pscyhologists	O
need	O
to	O
inuqire	O
about	O
cnosumption	O
of	O
quinnie	O
-	O
containing	O
beveraegs	O
as	O
part	O
of	O
an	O
eavluation	O
proecss	O
.	O

Trnasient	O
platynpea	B-Disease
-	I-Disease
orhtodeoxia	I-Disease
-	I-Disease
like	I-Disease
syndorme	I-Disease
inudced	O
by	O
propafennoe	O
overdsoe	B-Disease
in	O
a	O
yonug	O
woamn	O
with	O
Ebstien	B-Disease
'	I-Disease
s	I-Disease
anmoaly	I-Disease
.	O

In	O
this	O
reoprt	O
we	O
describe	O
the	O
csae	O
of	O
a	O
37	O
-	O
yaer	O
-	O
old	O
wihte	O
wmoan	O
with	O
Ebsetin	B-Disease
'	I-Disease
s	I-Disease
anomlay	I-Disease
,	O
who	O
developed	O
a	O
rrae	O
syndrmoe	O
called	O
platypena	B-Disease
-	I-Disease
ortohdeoxia	I-Disease
,	O
characterzied	O
by	O
massive	O
rgiht	O
-	O
to	O
-	O
lfet	O
inetratrial	O
shutning	O
with	O
transinet	O
profuond	O
hypxoia	B-Disease
and	O
cynaosis	B-Disease
.	O

This	O
suhnt	O
of	O
bolod	O
via	O
a	O
paetnt	B-Disease
formaen	I-Disease
oavle	I-Disease
occurred	O
in	O
the	O
prseence	O
of	O
a	O
nromal	O
pulomnary	O
atrery	O
presusre	O
,	O
and	O
was	O
probably	O
preciiptated	O
by	O
a	O
propafneone	O
overodse	B-Disease
.	O

This	O
durg	O
caused	O
biventricluar	B-Disease
dysufnction	I-Disease
,	O
due	O
to	O
its	O
ngeative	O
iontropic	O
effcet	O
,	O
and	O
hypotnesion	B-Disease
,	O
due	O
to	O
its	O
preipheral	O
vasodliatory	O
efefct	O
.	O

These	O
effetcs	O
gave	O
rise	O
to	O
an	O
icnrease	O
in	O
the	O
rgiht	O
atiral	O
prsesure	O
and	O
a	O
decerase	O
in	O
the	O
lfet	O
one	O
with	O
a	O
consequent	O
strecthing	O
of	O
the	O
foraemn	O
oavle	O
and	O
the	O
ceration	O
of	O
massive	O
rgiht	O
-	O
to	O
-	O
lfet	O
shuntnig	O
.	O

In	O
our	O
csae	O
this	O
interartial	O
suhnt	O
was	O
very	O
accurately	O
dteected	O
at	O
bubble	O
contrast	O
echocardigoraphy	O
.	O

Noxiuos	O
chemcial	O
stimulatoin	O
of	O
rat	O
fcaial	O
muocsa	O
increaess	O
intracrnaial	O
blood	O
folw	O
through	O
a	O
trigemino	O
-	O
parasympathteic	O
relfex	O
-	O
-	O
an	O
experimetnal	O
moedl	O
for	O
vasuclar	B-Disease
dysfunctinos	I-Disease
in	O
clsuter	B-Disease
heaadche	I-Disease
.	O

Clusetr	B-Disease
headahce	I-Disease
is	O
characteirzed	O
by	O
typical	O
autnoomic	O
dysufnctions	O
including	O
facail	O
and	O
itnracranial	B-Disease
vsacular	I-Disease
dsiturbances	I-Disease
.	O

Both	O
the	O
trigemnial	O
and	O
the	O
carnial	O
parasympathteic	O
sytsems	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
dysfucntions	O
.	O

An	O
expermiental	O
mdoel	O
was	O
developed	O
in	O
the	O
rat	O
to	O
meausre	O
cahnges	O
in	O
lacrmiation	O
and	O
intracranail	O
bolod	O
folw	O
following	O
noxiuos	O
cehmical	O
sitmulation	O
of	O
faical	O
mucsoa	O
.	O

Blood	O
folw	O
was	O
monitoerd	O
in	O
artereis	O
of	O
the	O
expsoed	O
crainal	O
drua	O
maetr	O
and	O
the	O
pariteal	O
crotex	O
using	O
laesr	O
Doppler	O
folwmetry	O
.	O

Capasicin	O
(	O
0	O
.	O
01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
oarl	O
or	O
naasl	O
muocsa	O
induecd	O
incerases	B-Disease
in	I-Disease
duarl	I-Disease
and	I-Disease
crotical	I-Disease
blood	I-Disease
folw	I-Disease
and	O
provoked	O
lacirmation	O
.	O

These	O
repsonses	O
were	O
bolcked	O
by	O
sytsemic	O
pre	O
-	O
admniistration	O
of	O
hexamethnoium	O
chlordie	O
(	O
20	O
mg	O
/	O
kg	O
)	O
.	O

The	O
eovked	O
incerases	B-Disease
in	I-Disease
duarl	I-Disease
blood	I-Disease
folw	I-Disease
were	O
also	O
abolished	O
by	O
toipcal	O
pre	O
-	O
admniistration	O
of	O
atorpine	O
(	O
1	O
mm	O
)	O
and	O
[	O
Lsy1	O
,	O
Por2	O
,	O
5	O
,	O
Agr3	O
,	O
4	O
,	O
Try6	O
]	O
-	O
VIP	O
(	O
0	O
.	O
1	O
mm	O
)	O
,	O
a	O
vasocative	O
intestianl	O
polyepptide	O
(	O
VIP	O
)	O
anatgonist	O
,	O
onto	O
the	O
expoesd	O
drua	O
mtaer	O
.	O

We	O
conclude	O
that	O
noixous	O
stimualtion	O
of	O
fcaial	O
mucsoa	O
incerases	O
intracarnial	O
blood	O
folw	O
and	O
lacirmation	O
via	O
a	O
trigemino	O
-	O
parasympatheitc	O
relfex	O
.	O

The	O
blood	O
folw	O
responess	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
relesae	O
of	O
acetylchloine	O
and	O
VIP	O
within	O
the	O
menignes	O
.	O

Similar	O
mechainsms	O
may	O
be	O
involved	O
in	O
the	O
ptahogenesis	O
of	O
clusetr	B-Disease
haedache	I-Disease
.	O

Organophosphtae	O
-	O
idnuced	O
convlusions	B-Disease
and	O
preevntion	O
of	O
nueropathological	B-Disease
damgaes	I-Disease
.	O

Such	O
organohposphorus	O
(	O
OP	O
)	O
cmopounds	O
as	O
diiospropylfluorophosphate	O
(	O
DFP	O
)	O
,	O
srain	O
and	O
soamn	O
are	O
potent	O
inihbitors	O
of	O
acetylcholinestersaes	O
(	O
ACEhs	O
)	O
and	O
butyyrlcholinesterases	O
(	O
BCEhs	O
)	O
.	O

The	O
actue	O
toixcity	B-Disease
of	O
OPs	O
is	O
the	O
result	O
of	O
their	O
irrveersible	O
binidng	O
with	O
AhCEs	O
in	O
the	O
cnetral	O
nervuos	O
sytsem	O
(	O
CNS	O
)	O
,	O
which	O
eelvates	O
acetlycholine	O
(	O
ACh	O
)	O
levles	O
.	O

The	O
protective	O
aciton	O
of	O
subuctaneously	O
(	O
SC	O
)	O
admiinstered	O
atnidotes	O
or	O
their	O
cobminations	O
in	O
DFP	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
intoixcation	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
weeks	O
-	O
old	O
Han	O
-	O
Wsitar	O
mlae	O
rtas	O
.	O

The	O
rtas	O
received	O
AhCE	O
reactiavtor	O
parlidoxime	O
-	O
2	O
-	O
cholride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
atniconvulsant	O
dizaepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adeonsine	O
reecptor	O
aognist	O
N	O
(	O
6	O
)	O
-	O
cycloepntyl	O
aednosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NDMA	O
-	O
recetpor	O
anatgonist	O
dizcoilpine	O
malaete	O
(	O
+	O
-	O
M8K01	O
hydrgoen	O
mlaeate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combiantions	O
with	O
cholinolyitc	O
durg	O
atorpine	O
slufate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
inejction	O
of	O
DFP	O
.	O

The	O
conrtol	O
rtas	O
received	O
atorpine	O
suflate	O
,	O
but	O
also	O
salnie	O
and	O
oilve	O
oil	O
instead	O
of	O
other	O
anitdotes	O
and	O
DFP	O
,	O
respectively	O
.	O

All	O
rtas	O
were	O
terimnated	O
either	O
24	O
h	O
or	O
3	O
weeks	O
after	O
the	O
DFP	O
injetcion	O
.	O

The	O
rtas	O
traeted	O
with	O
DFP	O
-	O
atropnie	O
showed	O
sevree	O
typical	O
OP	O
-	O
induecd	O
toxiicty	B-Disease
sings	O
.	O

When	O
CPA	O
,	O
dizaepam	O
or	O
2PAM	O
was	O
given	O
immediately	O
after	O
DFP	O
-	O
atropnie	O
,	O
these	O
treatemnts	O
prevented	O
,	O
dealyed	O
or	O
sohrtened	O
the	O
occurrecne	O
of	O
serious	O
sgins	O
of	O
posioning	B-Disease
.	O

Atropnie	O
-	O
MK081	O
did	O
not	O
offer	O
any	O
additional	O
protcetion	O
against	O
DFP	O
toixcity	B-Disease
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
daizepam	O
and	O
2PAM	O
in	O
combiantion	O
with	O
atropnie	O
prevented	O
the	O
occrurence	O
of	O
serious	O
sings	O
of	O
poisonnig	B-Disease
and	O
thus	O
rdeuced	O
the	O
toixcity	B-Disease
of	O
DFP	O
in	O
rat	O
.	O

A	O
pyridxoine	O
-	O
dependnet	O
beahvioral	B-Disease
disodrer	I-Disease
unmasekd	O
by	O
isonizaid	O
.	O

A	O
3	O
-	O
yaer	O
-	O
old	O
gril	O
had	O
behavioarl	B-Disease
dteerioration	I-Disease
,	O
with	O
hyperiknesis	B-Disease
,	O
irritabiltiy	B-Disease
,	O
and	O
seleping	B-Disease
diffiuclties	I-Disease
after	O
the	O
therapeuitc	O
admniistration	O
of	O
isoniaizd	O
.	O

The	O
adminsitration	O
of	O
phramacologic	O
doess	O
of	O
pyrdioxine	O
hdyrochloride	O
led	O
to	O
a	O
disapperaance	O
of	O
symtpoms	O
.	O

After	O
discontiniung	O
isonaizid	O
threapy	O
a	O
similar	O
patetrn	O
of	O
bheavior	O
was	O
noted	O
that	O
was	O
controleld	O
by	O
pyriodxine	O
.	O

A	O
plcaebo	O
had	O
no	O
efefct	O
,	O
but	O
niaicnamide	O
was	O
as	O
effetcive	O
as	O
pyridoxnie	O
.	O

Peridoic	O
withdrwaal	O
of	O
pyriodxine	O
was	O
associated	O
with	O
return	O
of	O
the	O
hyperkniesis	B-Disease
.	O

The	O
leevl	O
of	O
pyridoaxl	O
in	O
the	O
bolod	O
was	O
noraml	O
during	O
the	O
peridos	O
of	O
relaspe	O
.	O

Mteabolic	O
stuides	O
suggested	O
a	O
bolck	O
in	O
the	O
kynruenine	O
ptahway	O
of	O
trytpophan	O
metabolsim	O
.	O

The	O
paitent	O
has	O
been	O
followed	O
for	O
six	O
yeras	O
and	O
has	O
required	O
pharamcologic	O
dsoes	O
of	O
pyrdioxine	O
to	O
cnotrol	O
her	O
behaivor	O
.	O

Recrurent	O
exciattion	O
in	O
the	O
detnate	O
gyurs	O
of	O
a	O
murnie	O
mdoel	O
of	O
tepmoral	B-Disease
lboe	I-Disease
eiplepsy	I-Disease
.	O

Similar	O
to	O
rtas	O
,	O
sytsemic	O
piloacrpine	O
ijnection	O
causes	O
stauts	B-Disease
epliepticus	I-Disease
(	O
SE	B-Disease
)	O
and	O
the	O
evetnual	O
devleopment	O
of	O
spontaenous	O
seizuers	B-Disease
and	O
mossy	O
fiebr	O
sporuting	O
in	O
C75BL	O
/	O
6	O
and	O
CD1	O
mcie	O
,	O
but	O
the	O
pyhsiological	O
correltaes	O
of	O
these	O
evetns	O
have	O
not	O
been	O
idnetified	O
in	O
mcie	O
.	O

Pouplation	O
resposnes	O
in	O
grnaule	O
cells	O
of	O
the	O
dnetate	O
gryus	O
were	O
examined	O
in	O
trnasverse	O
sliecs	O
of	O
the	O
vetnral	O
hipopcampus	O
from	O
pilcoarpine	O
-	O
terated	O
and	O
untretaed	O
mcie	O
.	O

In	O
Mg	O
(	O
2	O
+	O
)	O
-	O
free	O
batihng	O
meduim	O
containing	O
biccuulline	O
,	O
condiitons	O
designed	O
to	O
inrcease	O
exictability	O
in	O
the	O
slcies	O
,	O
electircal	O
stiumlation	O
of	O
the	O
hiuls	O
resulted	O
in	O
a	O
single	O
populatoin	O
sipke	O
in	O
graunle	O
cells	O
from	O
contorl	O
mcie	O
and	O
pliocarpine	O
-	O
traeted	O
mcie	O
that	O
did	O
not	O
experinece	O
SE	B-Disease
.	O

In	O
SE	B-Disease
survivros	O
,	O
similar	O
sitmulation	O
resulted	O
in	O
a	O
populatoin	O
spkie	O
followed	O
,	O
at	O
a	O
varibale	O
latnecy	O
,	O
by	O
ngeative	O
DC	O
shfits	O
and	O
repettiive	O
afterdicsharges	O
of	O
3	O
-	O
60	O
s	O
druation	O
,	O
which	O
were	O
blocekd	O
by	O
ionotorpic	O
gluatmate	O
rceeptor	O
antagonsits	O
.	O

Fcoal	O
glutmaate	O
photostimluation	O
of	O
the	O
graunle	O
clel	O
laeyr	O
at	O
sties	O
disatnt	O
from	O
the	O
recodring	O
ppiette	O
resulted	O
in	O
popluation	O
resposnes	O
of	O
1	O
-	O
30	O
s	O
duraiton	O
in	O
sliecs	O
from	O
SE	B-Disease
surviovrs	O
but	O
not	O
other	O
gorups	O
.	O

These	O
dtaa	O
support	O
the	O
hypotehsis	O
that	O
SE	B-Disease
-	O
idnuced	O
mossy	O
fiebr	O
srpouting	O
and	O
synatpic	O
reorgnaization	O
are	O
relevnat	O
characteirstics	O
of	O
seiuzre	B-Disease
deveolpment	O
in	O
these	O
muirne	O
stranis	O
,	O
resembling	O
rat	O
mdoels	O
of	O
hmuan	O
tempoarl	B-Disease
lboe	I-Disease
eiplepsy	I-Disease
.	O

Uirnary	B-Disease
bladder	I-Disease
cnacer	I-Disease
in	O
Wegeenr	B-Disease
'	I-Disease
s	I-Disease
garnulomatosis	I-Disease
:	O
rikss	O
and	O
relation	O
to	O
cyclophsophamide	O
.	O

OBJECITVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
rsik	O
of	O
bldader	B-Disease
cacner	I-Disease
,	O
and	O
its	O
relation	O
to	O
cyclophoshpamide	O
,	O
in	O
paitents	O
with	O
Weegner	B-Disease
'	I-Disease
s	I-Disease
graunlomatosis	I-Disease
.	O

METHODS	O
:	O
In	O
the	O
popluation	O
based	O
,	O
natoinwide	O
Swdeish	O
Inaptient	O
Rgeister	O
a	O
coohrt	O
of	O
1065	O
paitents	O
with	O
Wegneer	B-Disease
'	I-Disease
s	I-Disease
granulomatsois	I-Disease
,	O
1969	O
-	O
95	O
,	O
was	O
idnetified	O
.	O

Through	O
linkgae	O
with	O
the	O
Sweidsh	O
Cnacer	B-Disease
Regisetr	O
,	O
all	O
subejcts	O
in	O
this	O
coohrt	O
diganosed	O
with	O
bladedr	B-Disease
cnacer	I-Disease
were	O
identfiied	O
.	O

Netsed	O
within	O
the	O
coohrt	O
,	O
a	O
matched	O
csae	O
-	O
contorl	O
sutdy	O
was	O
performed	O
to	O
esitmate	O
the	O
associaiton	O
between	O
cyclophospahmide	O
and	O
bladedr	B-Disease
cacner	I-Disease
using	O
odds	O
ratois	O
(	O
ORs	O
)	O
as	O
relative	O
rsik	O
.	O

In	O
the	O
coohrt	O
the	O
cumultaive	O
rsik	O
of	O
bladedr	B-Disease
canecr	I-Disease
after	O
Wgeener	B-Disease
'	I-Disease
s	I-Disease
grnaulomatosis	I-Disease
,	O
and	O
the	O
relative	O
prvealence	O
of	O
a	O
hitsory	O
of	O
bladder	B-Disease
cacner	I-Disease
at	O
the	O
tmie	O
of	O
diagonsis	O
of	O
Weegner	B-Disease
'	I-Disease
s	I-Disease
granulomatsois	I-Disease
,	O
were	O
also	O
estmiated	O
.	O

RSEULTS	O
:	O
The	O
medain	O
cumulatvie	O
doess	O
of	O
cyclophopshamide	O
among	O
caess	O
(	O
n	O
=	O
11	O
)	O
and	O
contorls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
rsik	O
of	O
bldader	B-Disease
canecr	I-Disease
doubled	O
for	O
every	O
10	O
g	O
incremnet	O
in	O
cyclophosphaimde	O
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
confidecne	O
interavl	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

Traetment	O
druation	O
longer	O
than	O
1	O
yaer	O
was	O
associated	O
with	O
an	O
eighftold	O
inrceased	O
rsik	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
to	O
69	O
)	O
.	O

The	O
absloute	O
rsik	O
for	O
bladder	B-Disease
canecr	I-Disease
in	O
the	O
choort	O
reached	O
10	O
%	O
16	O
yaers	O
after	O
diagnsois	O
of	O
Wegeenr	B-Disease
'	I-Disease
s	I-Disease
granluomatosis	I-Disease
,	O
and	O
a	O
hsitory	O
of	O
bladder	B-Disease
cnacer	I-Disease
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
tmie	O
of	O
diagnsois	O
of	O
Wgeener	B-Disease
'	I-Disease
s	I-Disease
grnaulomatosis	I-Disease
.	O

CONCLSUION	O
:	O
The	O
resluts	O
indicate	O
a	O
dsoe	O
-	O
resposne	O
rleationship	O
between	O
cyclophosphamdie	O
and	O
the	O
rsik	O
of	O
baldder	B-Disease
cnacer	I-Disease
,	O
high	O
cumultaive	O
rsiks	O
in	O
the	O
entire	O
choort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
rsik	O
fatcors	O
operatnig	O
even	O
before	O
Wgeener	B-Disease
'	I-Disease
s	I-Disease
grnaulomatosis	I-Disease
.	O

Difefrential	O
modultaion	O
by	O
etsrogen	O
of	O
alpah2	O
-	O
adrenegric	O
and	O
I1	O
-	O
imidaozline	O
rceeptor	O
-	O
mediated	O
hyoptension	B-Disease
in	O
fmeale	O
rtas	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estorgen	O
neagtively	O
modulaets	O
the	O
hypotenisve	B-Disease
effcet	O
of	O
cloindine	O
(	O
mixed	O
alpah2	O
-	O
/	O
I1	O
-	O
reecptor	O
agonsit	O
)	O
in	O
femlae	O
rtas	O
and	O
implicates	O
the	O
cardioavscular	O
atuonomic	O
cnotrol	O
in	O
this	O
interactoin	O
.	O

The	O
present	O
stduy	O
invesitgated	O
whether	O
this	O
effect	O
of	O
estroegn	O
involves	O
interaciton	O
with	O
aplha2	O
-	O
and	O
/	O
or	O
I1	O
-	O
recpetors	O
.	O

Chanegs	O
evoekd	O
by	O
a	O
single	O
intrapeirtoneal	O
injcetion	O
of	O
rilmneidine	O
(	O
600	O
micorg	O
/	O
kg	O
)	O
or	O
alhpa	O
-	O
mtehyldopa	O
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	O
-	O
and	O
alhpa2	O
-	O
recepotr	O
aognists	O
,	O
respectively	O
,	O
in	O
blood	O
perssure	O
,	O
hemodynmaic	O
variabiilty	O
,	O
and	O
locmootor	O
acitvity	O
were	O
assessed	O
in	O
radiotelemetered	O
sahm	O
-	O
opreated	O
and	O
ovarietcomized	O
(	O
Ovx	O
)	O
Srpague	O
-	O
Dalwey	O
fmeale	O
rtas	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrgoen	O
replcaement	O
.	O

Three	O
tmie	O
dmoain	O
idnexes	O
of	O
hemodynmaic	O
variaiblity	O
were	O
employed	O
:	O
the	O
stnadard	O
devaition	O
of	O
mean	O
arterail	O
presusre	O
as	O
a	O
meausre	O
of	O
blood	O
prsesure	O
variabliity	O
and	O
the	O
stanadrd	O
devaition	O
of	O
baet	O
-	O
to	O
-	O
baet	O
intervlas	O
(	O
SRDR	O
)	O
and	O
the	O
root	O
mean	O
suqare	O
of	O
successive	O
differences	O
in	O
R	O
-	O
wvae	O
-	O
to	O
-	O
R	O
-	O
wvae	O
interavls	O
as	O
mesaures	O
of	O
haert	O
rtae	O
variabliity	O
.	O

In	O
sahm	O
-	O
opearted	O
rtas	O
,	O
rilmeniidne	O
or	O
aplha	O
-	O
methlydopa	O
elicited	O
similar	O
hypotenison	B-Disease
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reudctions	O
in	O
stnadard	O
deviaiton	O
of	O
mean	O
arteiral	O
pressrue	O
.	O

SRDR	O
was	O
redcued	O
only	O
by	O
alhpa	O
-	O
mtehyldopa	O
.	O

Ovx	O
significantly	O
enhnaced	O
the	O
hpyotensive	B-Disease
resopnse	O
to	O
alhpa	O
-	O
methyldpoa	O
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmendiine	O
hypotenison	B-Disease
.	O

The	O
enhacned	O
alhpa	O
-	O
methlydopa	O
hypotensoin	B-Disease
in	O
Ovx	O
rtas	O
was	O
paralleled	O
with	O
further	O
reductoin	O
in	O
SRDR	O
and	O
a	B-Disease
rdeuced	I-Disease
locomtoor	I-Disease
acitvity	I-Disease
.	O

Estroegn	O
replaecment	O
(	O
17beta	O
-	O
estrdaiol	O
subcuatneous	O
pellet	O
,	O
14	O
.	O
2	O
mircog	O
/	O
day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rtas	O
retsored	O
the	O
hemodynaimc	O
and	O
locomtoor	O
effetcs	O
of	O
aplha	O
-	O
methlydopa	O
to	O
sahm	O
-	O
opertaed	O
leevls	O
.	O

These	O
finidngs	O
suggest	O
that	O
estroegn	O
downregulaets	O
alhpa2	O
-	O
but	O
not	O
I1	O
-	O
recepotr	O
-	O
mediated	O
hyptoension	B-Disease
and	O
highlight	O
a	O
role	O
for	O
the	O
caridac	O
autnoomic	O
cotnrol	O
in	O
aplha	O
-	O
methyldpoa	O
-	O
esrtogen	O
interaciton	O
.	O

Sveere	O
reversible	O
lfet	B-Disease
vnetricular	I-Disease
systloic	I-Disease
and	I-Disease
diastloic	I-Disease
dysufnction	I-Disease
due	O
to	O
acciedntal	O
iatrgoenic	O
epinehprine	O
overodse	B-Disease
.	O

Ctaecholamine	O
-	O
indcued	O
cardimoyopathy	B-Disease
due	O
to	O
chroinc	O
excses	O
of	O
endogneous	O
ctaecholamines	O
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
cilnical	O
phenoemnon	O
.	O

In	O
contrast	O
,	O
reprots	O
of	O
moycardial	B-Disease
dysfucntion	I-Disease
due	O
to	O
actue	O
iatorgenic	O
oevrdose	B-Disease
are	O
rrae	O
.	O

A	O
35	O
-	O
yaer	O
-	O
old	O
wmoan	O
whose	O
crevix	O
uetri	O
was	O
inadvertently	O
injetced	O
with	O
8	O
mg	O
of	O
epienphrine	O
developed	O
moycardial	B-Disease
stunning	I-Disease
that	O
was	O
characteriezd	O
by	O
sevree	O
hemdoynamic	O
compromise	O
,	O
profonud	O
,	O
albeit	O
tranisent	O
,	O
lfet	B-Disease
venrticular	I-Disease
ssytolic	I-Disease
and	I-Disease
disatolic	I-Disease
dysfuntcion	I-Disease
,	O
and	O
only	O
modestly	O
elevaetd	O
biochemcial	O
makrers	O
of	O
myocardail	B-Disease
nercosis	I-Disease
.	O

Our	O
csae	O
illustrates	O
the	O
serious	O
conesquences	O
of	O
mdeical	O
erorrs	O
that	O
can	O
be	O
avoided	O
through	O
improevd	O
medictaion	O
labelnig	O
and	O
stfaf	O
supervsiion	O
.	O

Cardioprotcetive	O
effcet	O
of	O
ticnture	O
of	O
Crateagus	O
on	O
isoprotereonl	O
-	O
induecd	O
mycoardial	B-Disease
infartcion	I-Disease
in	O
rtas	O
.	O

Tnicture	O
of	O
Cartaegus	O
(	O
TCR	O
)	O
,	O
an	O
alcohloic	O
extrcat	O
of	O
the	O
berreis	O
of	O
hawthron	O
(	O
Cratageus	O
oxcyantha	O
)	O
,	O
is	O
used	O
in	O
hebral	O
and	O
homeoptahic	O
meidcine	O
.	O

The	O
present	O
stduy	O
was	O
done	O
to	O
invetsigate	O
the	O
protective	O
effect	O
of	O
TCR	O
on	O
experimentally	O
idnuced	O
mycoardial	B-Disease
infacrtion	I-Disease
in	O
rtas	O
.	O

Pretretament	O
of	O
TCR	O
,	O
at	O
a	O
dsoe	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
bdoyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
dyas	O
,	O
prevented	O
the	O
icnrease	O
in	O
liipd	O
perxoidation	O
and	O
activtiy	O
of	O
marekr	O
eznymes	O
observed	O
in	O
isoproterneol	O
-	O
idnuced	O
rtas	O
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
dyas	O
at	O
an	O
intreval	O
of	O
24	O
h	O
)	O
.	O

TCR	O
prevented	O
the	O
iosproterenol	O
-	O
induecd	O
decresae	O
in	O
antixoidant	O
eznymes	O
in	O
the	O
haert	O
and	O
icnreased	O
the	O
rtae	O
of	O
ADP	O
-	O
stimulaetd	O
oxyegn	O
uptkae	O
and	O
respriatory	O
coupilng	O
rtaio	O
.	O

TCR	O
protected	O
against	O
pathoolgical	O
chnages	O
inudced	O
by	O
isoproetrenol	O
in	O
rat	O
haert	O
.	O

The	O
resutls	O
show	O
that	O
pretraetment	O
with	O
TCR	O
may	O
be	O
useful	O
in	O
preventing	O
the	O
daamge	O
inudced	O
by	O
isporoterenol	O
in	O
rat	O
haert	O
.	O

Traetment	O
of	O
tinintus	B-Disease
by	O
intartympanic	O
isntillation	O
of	O
lignociane	O
(	O
lidoacine	O
)	O
2	O
per	O
cent	O
through	O
ventilatoin	O
tbues	O
.	O

Iidopathic	B-Disease
sujbective	I-Disease
tninitus	I-Disease
(	O
IST	B-Disease
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otoloigcal	O
patholgoies	O
.	O

This	O
paper	O
presents	O
the	O
resluts	O
of	O
tretaing	O
IST	B-Disease
by	O
intratmypanic	O
instilaltion	O
of	O
lignociane	O
(	O
lidcoaine	O
)	O
2	O
per	O
cent	O
through	O
a	O
gromemt	O
,	O
for	O
five	O
weekly	O
cuorses	O
.	O

Fifty	O
-	O
two	O
pateints	O
suffeirng	O
from	O
intrcatable	O
tinniuts	B-Disease
entered	O
this	O
theraeputic	O
tiral	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
cousres	O
.	O

In	O
one	O
pateint	O
,	O
the	O
tinintus	B-Disease
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
patietns	O
the	O
decmopensated	O
tinntius	B-Disease
changed	O
to	O
a	O
compensated	O
one	O
.	O

We	O
suggest	O
this	O
mdoe	O
of	O
tretament	O
for	O
patinets	O
that	O
were	O
previously	O
tretaed	O
by	O
durgs	O
,	O
acuupncture	O
and	O
boifeedback	O
,	O
with	O
disappointing	O
rseults	O
.	O

Ptaients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effetcs	O
of	O
vertgio	B-Disease
and	O
voimting	B-Disease
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
insitllation	O
,	O
and	O
that	O
the	O
tinntius	B-Disease
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
diesase	O
and	O
lead	O
a	O
more	O
nomral	O
lfie	O
.	O

The	O
aplha3	O
and	O
beat4	O
nicoitnic	O
acetylchoilne	O
recepotr	O
subuntis	O
are	O
necessary	O
for	O
nicotnie	O
-	O
induecd	O
siezures	B-Disease
and	O
hypolocomotoin	B-Disease
in	O
mcie	O
.	O

Bidning	O
of	O
nciotine	O
to	O
nictoinic	O
acetylcholnie	O
receptros	O
(	O
nACRhs	O
)	O
elicits	O
a	O
series	O
of	O
dsoe	O
-	O
dependnet	O
bheaviors	O
that	O
go	O
from	O
aletred	O
epxloration	O
,	O
sedatoin	O
,	O
and	O
treomrs	B-Disease
,	O
to	O
seiuzres	B-Disease
and	O
detah	B-Disease
.	O

nAhCRs	O
are	O
pentmaeric	O
ion	O
chnanels	O
usually	O
composed	O
of	O
aplha	O
and	O
btea	O
sbuunits	O
.	O

A	O
gnee	O
clutser	O
comprises	O
the	O
alhpa3	O
,	O
aplha5	O
and	O
btea4	O
subuntis	O
,	O
which	O
coassmeble	O
to	O
form	O
fucntional	O
recepotrs	O
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
beat4	O
subuntis	O
in	O
nictoine	O
-	O
inudced	O
seiuzres	B-Disease
and	O
hypoolcomotion	B-Disease
in	O
beat4	O
homozyguos	O
nlul	O
(	O
beat4	O
-	O
/	O
-	O
)	O
and	O
alpah3	O
heetrozygous	O
(	O
+	O
/	O
-	O
)	O
mcie	O
.	O

btea4	O
-	O
/	O
-	O
mcie	O
were	O
less	O
sensiitve	O
to	O
the	O
effcets	O
of	O
nictoine	O
both	O
at	O
low	O
doess	O
,	O
measuerd	O
as	O
decerased	O
exlporation	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doess	O
,	O
mesaured	O
as	O
sensitviity	O
to	O
nioctine	O
-	O
induecd	O
seizrues	B-Disease
.	O

Using	O
in	O
situ	O
hbyridization	O
porbes	O
for	O
the	O
aplha3	O
and	O
aplha5	O
sbuunits	O
,	O
we	O
showed	O
that	O
alhpa5	O
mNRA	O
levles	O
are	O
unchnaged	O
,	O
whereas	O
aplha3	O
mNRA	O
lveels	O
are	O
selectively	O
decresaed	O
in	O
the	O
mitarl	O
clel	O
laeyr	O
of	O
the	O
oflactory	O
blub	O
,	O
and	O
the	O
inferoir	O
and	O
the	O
superior	O
colliculus	O
of	O
btea4	O
-	O
/	O
-	O
branis	O
.	O

alhpa3	O
+	O
/	O
-	O
mcie	O
were	O
pratially	O
rseistant	O
to	O
nictoine	O
-	O
induecd	O
siezures	B-Disease
when	O
compraed	O
to	O
wlid	O
-	O
tpye	O
ltitermates	O
.	O

mNRA	O
lveels	O
for	O
the	O
alpah5	O
and	O
the	O
btea4	O
subuntis	O
were	O
unhcanged	O
in	O
alpah3	O
+	O
/	O
-	O
barins	O
.	O

Together	O
,	O
these	O
resluts	O
suggest	O
that	O
the	O
btea4	O
and	O
the	O
aplha3	O
sbuunits	O
are	O
meditaors	O
of	O
nciotine	O
-	O
inudced	O
seiuzres	B-Disease
and	O
hypolocoomtion	B-Disease
.	O

The	O
effects	O
of	O
seovflurane	O
on	O
lidoacine	O
-	O
idnuced	O
conuvlsions	B-Disease
.	O

The	O
inlfuence	O
of	O
sveoflurane	O
on	O
lidoacine	O
-	O
idnuced	O
conuvlsions	B-Disease
was	O
studied	O
in	O
ctas	O
.	O

The	O
convuslive	B-Disease
trheshold	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
was	O
41	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
5	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
with	O
lidoacine	O
infuison	O
(	O
6	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
increaisng	O
significantly	O
to	O
66	O
.	O
6	O
+	O
/	O
-	O
10	O
.	O
9	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
when	O
the	O
end	O
-	O
tiadl	O
concetnration	O
of	O
sevoflurnae	O
was	O
0	O
.	O
8	O
%	O
.	O

However	O
,	O
the	O
thershold	O
(	O
61	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
7	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1	O
.	O
6	O
%	O
sevolfurane	O
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
seovflurane	O
,	O
indicating	O
a	O
cleling	O
effect	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
conuvlsive	B-Disease
trheshold	O
between	O
sevofluarne	O
and	O
enfulrane	O
.	O

The	O
rise	O
in	O
bolod	O
presusre	O
became	O
less	O
marked	O
when	O
hihger	O
cnocentrations	O
of	O
sevofulrane	O
or	O
enflruane	O
were	O
adminitsered	O
and	O
the	O
bolod	O
prsesure	O
at	O
convuslions	B-Disease
decraesed	O
significantly	O
in	O
1	O
.	O
6	O
%	O
sevofluarne	O
,	O
and	O
in	O
0	O
.	O
8	O
%	O
and	O
1	O
.	O
6	O
%	O
enlfurane	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
ldiocaine	O
conecntrations	O
measuerd	O
when	O
the	O
ssytolic	O
blood	O
perssure	O
became	O
70	O
mmHg	O
.	O

Apmain	O
,	O
a	O
selective	O
blcoker	O
of	O
calcuim	O
-	O
deepndent	O
ptoassium	O
cahnnels	O
,	O
was	O
admiinstered	O
intraceerbroventricularly	O
in	O
rtas	O
ansethetized	O
with	O
0	O
.	O
8	O
%	O
sevofluarne	O
to	O
ivnestigate	O
the	O
mehcanism	O
of	O
the	O
antcionvulsive	O
effetcs	O
.	O

Apmain	O
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decerase	O
the	O
covnulsive	B-Disease
trheshold	O
(	O
21	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statitsically	O
significant	O
.	O

It	O
is	O
suggested	O
that	O
seovflurane	O
rdeuces	O
the	O
convulsvie	B-Disease
effcet	O
of	O
ldiocaine	O
toxciity	B-Disease
but	O
carries	O
some	O
rsik	O
due	O
to	O
circluatory	O
depression	B-Disease
.	O

Cadriac	B-Disease
toxiicty	I-Disease
observed	O
in	O
assoication	O
with	O
high	O
-	O
dsoe	O
cylcophosphamide	O
-	O
based	O
cheomtherapy	O
for	O
metastaitc	O
bresat	B-Disease
canecr	I-Disease
.	O

INTRODUCTION	O
:	O
Cyclophosphmaide	O
is	O
an	O
alkylatnig	O
agnet	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
condiitoning	O
reigmens	O
.	O

In	O
high	O
doess	O
,	O
its	O
nonheamtological	O
dsoe	O
-	O
limiting	O
toxiicty	B-Disease
is	O
cardiomyopahty	B-Disease
.	O

STDUY	O
DESIGN	O
:	O
We	O
cmobined	O
paclitxael	O
,	O
melphaaln	O
and	O
high	O
-	O
dsoe	O
cyclophsophamide	O
,	O
tihotepa	O
,	O
and	O
carbpolatin	O
in	O
a	O
tirple	O
seuqential	O
high	O
-	O
dsoe	O
reigmen	O
for	O
patinets	O
with	O
metasttaic	O
berast	B-Disease
canecr	I-Disease
.	O

Aanlysis	O
was	O
performed	O
on	O
61	O
wmoen	O
with	O
cheomtherapy	O
-	O
repsonsive	O
metasattic	O
bresat	B-Disease
cacner	I-Disease
receiving	O
96	O
-	O
h	O
infsuional	O
cyclophsophamide	O
as	O
part	O
of	O
a	O
tirple	O
sequentail	O
high	O
-	O
dsoe	O
regmien	O
to	O
assess	O
associtaion	O
between	O
persence	O
of	O
peritranpslant	O
cnogestive	B-Disease
haert	I-Disease
faliure	I-Disease
(	O
CHF	B-Disease
)	O
and	O
the	O
following	O
pretretament	O
cahracteristics	O
:	O
persence	O
of	O
electrocradiogram	O
(	O
EKG	O
)	O
anbormalities	O
,	O
age	O
,	O
hypetrension	B-Disease
,	O
prior	O
cadriac	O
histroy	O
,	O
smoknig	O
,	O
diabeets	B-Disease
melliuts	I-Disease
,	O
prior	O
use	O
of	O
anthracyclnies	O
,	O
and	O
lfet	O
-	O
sided	O
chset	O
irraditaion	O
.	O

REUSLTS	O
:	O
Six	O
of	O
61	O
woemn	O
(	O
10	O
%	O
)	O
developed	O
cliniaclly	O
reversible	O
grdae	O
3	O
CHF	B-Disease
following	O
ifnusional	O
cyclopohsphamide	O
with	O
a	O
medain	O
percent	O
dceline	O
in	O
ejetcion	O
fratcion	O
of	O
31	O
%	O
.	O

Incidnece	O
of	O
transinet	O
ccylophosphamide	O
-	O
related	O
cradiac	B-Disease
txoicity	I-Disease
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literautre	O
.	O

Oledr	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	B-Disease
developmnet	O
;	O
with	O
mdeian	O
aegs	O
for	O
the	O
entire	O
gruop	O
and	O
for	O
ptaients	O
developing	O
CHF	B-Disease
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

No	O
asscoiation	O
was	O
found	O
with	O
other	O
prerteatment	O
charactersitics	O
.	O

CONCLUISONS	O
:	O
As	O
a	O
result	O
of	O
these	O
findnigs	O
,	O
oncologitss	O
should	O
carefully	O
monitor	O
fliud	O
balnace	O
in	O
oledr	O
patietns	O
.	O

Routnie	O
EKG	O
mnoitoring	O
during	O
infusoinal	O
cyclophosphmaide	O
did	O
not	O
predict	O
CHF	B-Disease
develompent	O
.	O

Treomr	B-Disease
side	O
effcets	O
of	O
slabutamol	O
,	O
quanitfied	O
by	O
a	O
lsaer	O
poniter	O
technqiue	O
.	O

OBJCETIVE	O
:	O
To	O
stduy	O
trmeor	B-Disease
side	O
effetcs	O
of	O
sablutamol	O
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	O
-	O
priced	O
metohd	O
is	O
needed	O
.	O

A	O
new	O
mehtod	O
using	O
a	O
commercially	O
available	O
,	O
pen	O
-	O
shpaed	O
lsaer	O
poitner	O
was	O
developed	O
.	O

Aim	O
of	O
the	O
sutdy	O
was	O
to	O
determine	O
sensiitvity	O
,	O
reproducibiilty	O
,	O
rfeerence	O
vaules	O
and	O
the	O
agreement	O
with	O
a	O
qeustionnaire	O
.	O

METHODS	O
:	O
Treomr	B-Disease
was	O
meausred	O
using	O
a	O
laesr	O
poniter	O
tehcnique	O
.	O

To	O
determine	O
sensitiivty	O
we	O
assesesd	O
termor	B-Disease
in	O
44	O
paitents	O
with	O
obstrcutive	B-Disease
lnug	I-Disease
dsiease	I-Disease
after	O
administartion	O
of	O
cumulaitve	O
dsoes	O
of	O
sablutamol	O
.	O

Sbujects	O
were	O
asked	O
to	O
aim	O
at	O
the	O
cenrte	O
of	O
a	O
tagret	O
,	O
subdivided	O
in	O
concenrtic	O
circles	O
,	O
from	O
5	O
m	O
distacne	O
.	O

The	O
circle	O
in	O
which	O
the	O
partciipant	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
mlilimetres	O
raidus	O
.	O

In	O
another	O
series	O
of	O
measuremetns	O
,	O
reproducibiltiy	O
and	O
rfeerence	O
vlaues	O
of	O
the	O
termor	B-Disease
was	O
assessed	O
in	O
65	O
helathy	O
subjcets	O
in	O
three	O
sessoins	O
,	O
at	O
9	O
a	O
.	O
m	O
.	O
,	O
4	O
p	O
.	O
m	O
.	O
and	O
9	O
a	O
.	O
m	O
.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O

Postrual	O
treomr	B-Disease
was	O
measrued	O
with	O
the	O
arm	O
horizontally	O
outstertched	O
rest	O
termor	B-Disease
with	O
the	O
arm	O
supported	O
by	O
an	O
armerst	O
and	O
finally	O
termor	B-Disease
was	O
measrued	O
after	O
holding	O
a	O
2	O
-	O
kg	O
wegiht	O
until	O
exhausiton	O
.	O

Itner	O
-	O
obserevr	O
vraiability	O
was	O
measrued	O
in	O
a	O
series	O
of	O
10	O
healhty	O
subjetcs	O
.	O

Termor	B-Disease
was	O
maesured	O
simulatneously	O
by	O
two	O
independnet	O
observres	O
.	O

RSEULTS	O
:	O
Salbuatmol	O
significantly	O
incraesed	O
termor	B-Disease
seevrity	O
in	O
pateints	O
in	O
a	O
dsoe	O
-	O
dependnet	O
way	O
.	O

Within	O
helathy	O
audlts	O
no	O
age	O
-	O
deepndency	O
could	O
be	O
found	O
(	O
b	O
=	O
0	O
.	O
262	O
mm	O
/	O
yaer	O
;	O
P	O
=	O
0	O
.	O
72	O
)	O
.	O

There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	O
and	O
treomr	B-Disease
sevreity	O
(	O
r	O
=	O
0	O
.	O
093	O
;	O
P	O
=	O
0	O
.	O
53	O
)	O
.	O

Psotural	O
trmeor	B-Disease
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
ssesion	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Spuport	O
of	O
the	O
arm	O
decraesed	O
trmeor	B-Disease
sevreity	O
,	O
exhautsion	O
incraesed	O
trmeor	B-Disease
seevrity	O
significantly	O
.	O

A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
idnependent	O
observres	O
(	O
intreclass	O
crorelation	O
coefifcient	O
0	O
.	O
72	O
)	O
.	O

DISCUSSION	O
:	O
Quanitfying	O
trmeor	B-Disease
by	O
using	O
an	O
ienxpensive	O
lsaer	O
pionter	O
is	O
,	O
with	O
the	O
exception	O
of	O
chlidren	O
(	O
<	O
12	O
yeras	O
)	O
a	O
senstiive	O
and	O
reproducible	O
metohd	O
.	O

Sfaety	O
and	O
avderse	O
effetcs	O
associated	O
with	O
ralxoifene	O
:	O
mutliple	O
outocmes	O
of	O
raloxifnee	O
eavluation	O
.	O

OBJECITVE	O
:	O
To	O
examine	O
the	O
effcet	O
of	O
ralxoifene	O
on	O
major	O
adevrse	O
evetns	O
that	O
occur	O
with	O
postemnopausal	O
esrtogen	O
tehrapy	O
or	O
tamoxfien	O
.	O

METHODS	O
:	O
The	O
Multilpe	O
Outcoems	O
of	O
Rlaoxifene	O
Evaulation	O
,	O
a	O
mutlicenter	O
,	O
randoimzed	O
,	O
double	O
-	O
blnid	O
tiral	O
,	O
enrolled	O
7	O
,	O
705	O
postmenoapusal	O
woemn	O
with	O
otseoporosis	B-Disease
.	O

Wmoen	O
were	O
randomly	O
assigned	O
to	O
rlaoxifene	O
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
palcebo	O
.	O

Outcmoes	O
included	O
vneous	B-Disease
trhomboembolism	I-Disease
,	O
ctaaracts	B-Disease
,	O
galllbadder	B-Disease
dsiease	I-Disease
,	O
and	O
endomertial	B-Disease
hyperplaisa	I-Disease
or	I-Disease
canecr	I-Disease
.	O

RESLUTS	O
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3	O
.	O
3	O
yaers	O
,	O
rlaoxifene	O
was	O
associated	O
with	O
an	O
incraesed	O
rsik	O
for	O
vneous	B-Disease
thromboemoblism	I-Disease
(	O
relative	O
rsik	O
[	O
RR	O
]	O
2	O
.	O
1	O
;	O
95	O
%	O
confdience	O
intevral	O
[	O
CI	O
]	O
1	O
.	O
2	O
-	O
3	O
.	O
8	O
)	O
.	O

The	O
excses	O
evnet	O
rtae	O
was	O
1	O
.	O
8	O
per	O
1	O
,	O
000	O
wmoan	O
-	O
yaers	O
(	O
95	O
%	O
CI	O
-	O
0	O
.	O
5	O
-	O
4	O
.	O
1	O
)	O
,	O
and	O
the	O
number	O
needed	O
to	O
terat	O
to	O
cause	O
1	O
eevnt	O
was	O
170	O
(	O
95	O
%	O
CI	O
100	O
-	O
582	O
)	O
over	O
3	O
.	O
3	O
yaers	O
.	O

Rsik	O
in	O
the	O
raloxiefne	O
gorup	O
was	O
higehr	O
than	O
in	O
the	O
plaecbo	O
gruop	O
for	O
the	O
first	O
2	O
yaers	O
,	O
but	O
decreaesd	O
to	O
about	O
the	O
same	O
rtae	O
as	O
in	O
the	O
plaecbo	O
gruop	O
thereafter	O
.	O

Raolxifene	O
did	O
not	O
icnrease	O
rsik	O
for	O
catarcats	B-Disease
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
1	O
)	O
,	O
gallbldader	B-Disease
dsiease	I-Disease
(	O
RR	O
1	O
.	O
0	O
;	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
)	O
,	O
endmoetrial	B-Disease
hypeprlasia	I-Disease
(	O
RR	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
0	O
.	O
4	O
-	O
5	O
.	O
1	O
)	O
,	O
or	O
ednometrial	B-Disease
canecr	I-Disease
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
2	O
.	O
7	O
)	O
.	O

CONCLSUION	O
:	O
Raloxifnee	O
was	O
associated	O
with	O
an	O
incerased	O
rsik	O
for	O
vneous	B-Disease
thromboemboilsm	I-Disease
,	O
but	O
there	O
was	O
no	O
incraesed	O
rsik	O
for	O
catarcats	B-Disease
,	O
gallbaldder	B-Disease
disesae	I-Disease
,	O
ednometrial	B-Disease
hyperlpasia	I-Disease
,	O
or	O
endomertial	B-Disease
cacner	I-Disease
.	O

LEEVL	O
OF	O
EVIDNECE	O
:	O
I	O

Optimiaztion	O
of	O
levodpoa	O
therpay	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dsoe	O
for	O
lveodopa	O
threapy	O
,	O
many	O
indivdiuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
controleld	O
-	O
reelase	O
formlua	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbdiopa	O
-	O
levodpoa	O
to	O
the	O
point	O
of	O
"	O
normlaity	O
,	O
"	O
which	O
can	O
lead	O
to	O
toxciity	B-Disease
.	O

The	O
pyhsician	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
adjucntive	O
meidcations	O
;	O
such	O
cobmined	O
therpay	O
has	O
become	O
the	O
stnadard	O
approach	O
to	O
teratment	O
.	O

Following	O
the	O
initial	O
peirod	O
of	O
thearpy	O
,	O
emerging	O
difficutlies	O
require	O
a	O
reassessemnt	O
of	O
theraeputic	O
approcahes	O
,	O
such	O
as	O
dsoage	O
adjustemnt	O
or	O
introudction	O
of	O
a	O
dpoamine	O
agonsit	O
.	O

Other	O
possible	O
avderse	O
effects	O
-	O
-	O
such	O
as	O
gastrointestnial	B-Disease
disoredrs	I-Disease
,	O
otrhostatic	B-Disease
hypotensoin	I-Disease
,	O
levoodpa	O
-	O
indcued	O
psycohsis	B-Disease
,	O
sleep	B-Disease
disturbnaces	I-Disease
or	O
paraosmnias	B-Disease
,	O
or	O
durg	O
intearctions	O
-	O
-	O
also	O
require	O
carefully	O
mointored	O
indivdiual	O
tretament	O
.	O

Nonhparmacologic	O
conecrns	O
can	O
help	O
the	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
pateint	O
achieve	O
and	O
maintain	O
optiaml	O
fucntioning	O
,	O
including	O
daliy	O
exericse	O
,	O
phyiscal	O
threapy	O
,	O
and	O
involvemnet	O
with	O
support	O
gorups	O
.	O

Lnog	O
term	O
audioolgical	O
evlauation	O
of	O
btea	B-Disease
-	I-Disease
thalsasemic	I-Disease
patinets	O
.	O

OBJECITVE	O
:	O
The	O
objectvie	O
of	O
this	O
sutdy	O
was	O
to	O
identify	O
the	O
inciednce	O
and	O
to	O
monitor	O
the	O
progression	O
of	O
hearnig	B-Disease
lsos	I-Disease
in	O
chidlren	O
and	O
yuong	O
audlts	O
with	O
btea	B-Disease
-	I-Disease
thlaassemia	I-Disease
major	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
patinets	O
aegd	O
6	O
-	O
35	O
yeras	O
(	O
mean	O
17	O
,	O
2	O
yeras	O
)	O
participated	O
in	O
the	O
sutdy	O
.	O

All	O
ptaients	O
were	O
on	O
a	O
regular	O
transfusoin	O
-	O
chelatoin	O
prgoram	O
maintaining	O
a	O
mean	O
hemgolobin	O
leevl	O
of	O
9	O
.	O
5	O
gr	O
/	O
dl	O
.	O

Subjetcs	O
were	O
receiving	O
desferrioaxmine	O
(	O
DFO	O
)	O
chelatoin	O
teratment	O
with	O
a	O
mean	O
dialy	O
dsoe	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
dyas	O
a	O
week	O
during	O
the	O
first	O
six	O
yaers	O
of	O
the	O
stduy	O
,	O
which	O
was	O
then	O
rdeuced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
yeras	O
.	O

Patietns	O
were	O
followed	O
for	O
8	O
-	O
14	O
yaers	O
.	O

RESLUTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patinets	O
(	O
20	O
.	O
2	O
%	O
)	O
presented	O
with	O
high	O
freuqency	O
sesnorineural	B-Disease
hearnig	I-Disease
lsos	I-Disease
(	O
SHNL	B-Disease
)	O
,	O
either	O
uinlateral	O
or	O
bilatearl	O
.	O

No	O
ototxoic	B-Disease
facotr	O
,	O
other	O
than	O
DFO	O
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patinets	O
.	O

Patinets	O
with	O
SHNL	B-Disease
presented	O
with	O
relatively	O
lwoer	O
seurm	O
ferrtiin	O
levles	O
than	O
those	O
with	O
noraml	O
heairng	O
,	O
however	O
,	O
no	O
statitsically	O
significant	O
difference	O
was	O
observed	O
.	O

Sbujects	O
with	O
SHNL	B-Disease
were	O
submitted	O
to	O
DFO	O
reudction	O
or	O
temporray	O
withrdawal	O
.	O

Following	O
intervnetion	O
,	O
7	O
out	O
of	O
21	O
affecetd	O
patinets	O
recoveerd	O
,	O
10	O
remained	O
satble	O
and	O
4	O
demonstrated	O
aggraavtion	O
.	O

COCNLUSION	O
:	O
The	O
findnigs	O
are	O
indiactive	O
of	O
DFO	O
'	O
s	O
contributing	O
role	O
in	O
the	O
deevlopment	O
of	O
haering	B-Disease
impairmnet	I-Disease
.	O

Rgeular	O
aduiologic	O
evaulation	O
is	O
imperative	O
in	O
all	O
thalassmeic	B-Disease
paitents	O
so	O
that	O
ealry	O
chagnes	O
may	O
be	O
recognized	O
and	O
traetment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
prevnet	O
or	O
reevrse	O
heairng	B-Disease
imapirment	I-Disease
.	O

Indiivdual	O
dfiferences	O
in	O
rneal	O
ACE	O
acitvity	O
in	O
healhty	O
rtas	O
predict	O
susceptibliity	O
to	O
adrimaycin	O
-	O
inudced	O
rneal	B-Disease
dmaage	I-Disease
.	O

BACKGRUOND	O
:	O
In	O
man	O
,	O
diffreences	O
in	O
angitoensin	O
-	O
converting	O
eznyme	O
(	O
ACE	O
)	O
lveels	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
gentoype	O
,	O
are	O
associated	O
with	O
reanl	O
prongosis	O
.	O

This	O
raises	O
the	O
hypohtesis	O
that	O
indivdiual	O
dfiferences	O
in	O
rneal	O
ACE	O
atcivity	O
are	O
involved	O
in	O
rneal	O
suscepitbility	O
to	O
inlficted	O
daamge	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
predcitive	O
effect	O
of	O
reanl	O
ACE	O
atcivity	O
for	O
the	O
seevrity	O
of	O
rneal	B-Disease
damgae	I-Disease
induecd	O
by	O
a	O
single	O
injeciton	O
of	O
ardiamycin	O
in	O
rtas	O
.	O

METHODS	O
:	O
Rneal	O
ACE	O
activtiy	O
(	O
Hip	O
-	O
His	O
-	O
Leu	O
cleaavge	O
by	O
coritcal	O
hoomgenates	O
)	O
was	O
determined	O
by	O
reanl	O
biospy	O
in	O
27	O
audlt	O
mlae	O
Wsitar	O
rtas	O
.	O

After	O
1	O
week	O
of	O
recvoery	O
,	O
prtoeinuria	B-Disease
was	O
indcued	O
by	O
ardiamycin	O
[	O
1	O
.	O
5	O
mg	O
/	O
kg	O
intravenosuly	O
(	O
i	O
.	O
v	O
.	O
)	O
n	O
=	O
18	O
;	O
contorls	O
,	O
slaine	O
i	O
.	O
v	O
.	O
n	O
=	O
9	O
]	O
.	O

Proteinuira	B-Disease
was	O
mesaured	O
every	O
2	O
wekes	O
.	O

After	O
12	O
wekes	O
,	O
rtas	O
were	O
sacriifced	O
and	O
their	O
kdineys	O
hravested	O
.	O

RESUTLS	O
:	O
As	O
anticipated	O
,	O
adriamyicn	O
elicited	O
npehrotic	B-Disease
range	O
proteiunria	B-Disease
,	O
reanl	B-Disease
intesrtitial	I-Disease
dmaage	I-Disease
and	O
mlid	O
fcoal	B-Disease
glomreulosclerosis	I-Disease
.	O

Baseilne	O
rneal	O
ACE	O
positievly	O
corerlated	O
with	O
the	O
relative	O
rise	O
in	O
proteiunria	B-Disease
after	O
ardiamycin	O
(	O
r	O
=	O
0	O
.	O
62	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
reanl	O
interstiital	O
aplha	O
-	O
somoth	O
mucsle	O
atcin	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
intrestitial	O
macrpohage	O
infulx	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
itnerstitial	O
collaegn	O
III	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
glomerluar	O
aplha	O
-	O
smotoh	O
mucsle	O
atcin	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
glomeurlar	O
dsemin	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Basleine	O
reanl	O
ACE	O
did	O
not	O
correltae	O
with	O
fcoal	B-Disease
glomreulosclerosis	I-Disease
(	O
r	O
=	O
0	O
.	O
22	O
,	O
NS	O
)	O
.	O

In	O
contorls	O
,	O
no	O
perdictive	O
vaules	O
for	O
rneal	O
parameetrs	O
were	O
observed	O
.	O

CONCLSUION	O
:	O
Individaul	O
diffreences	O
in	O
rneal	O
ACE	O
atcivity	O
predict	O
the	O
seevrity	O
of	O
adiramycin	O
-	O
induecd	O
rneal	B-Disease
dmaage	I-Disease
in	O
this	O
oubtred	O
rat	O
strian	O
.	O

This	O
supports	O
the	O
assumption	O
that	O
dfiferences	O
in	O
reanl	O
ACE	O
atcivity	O
predispose	O
to	O
a	O
less	O
favoruable	O
coruse	O
of	O
reanl	B-Disease
daamge	I-Disease
.	O

Recurrnet	O
actue	O
itnerstitial	B-Disease
nephriits	I-Disease
inudced	O
by	O
azithromyicn	O
.	O

A	O
14	O
-	O
yaer	O
-	O
old	O
gril	O
is	O
reported	O
with	O
recurernt	O
,	O
azithromyicn	O
-	O
indcued	O
,	O
aucte	O
intesrtitial	B-Disease
npehritis	I-Disease
.	O

The	O
second	O
eipsode	O
was	O
more	O
seevre	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treaetd	O
with	O
intnesive	O
cortiocsteroid	O
thearpy	O
,	O
rneal	O
fnuction	O
remained	O
impiared	O
.	O

Although	O
most	O
caess	O
of	O
antibioitc	O
indcued	O
aucte	O
intesrtitial	B-Disease
npehritis	I-Disease
are	O
bengin	O
and	O
slef	O
-	O
lmiited	O
,	O
some	O
patietns	O
are	O
at	O
rsik	O
for	O
permaennt	O
reanl	B-Disease
inujry	I-Disease
.	O

Sipronolactone	O
-	O
induecd	O
reanl	B-Disease
insuffiicency	I-Disease
and	O
hyprekalemia	B-Disease
in	O
pateints	O
with	O
herat	B-Disease
failrue	I-Disease
.	O

BACKRGOUND	O
:	O
A	O
previous	O
randomiezd	O
cnotrolled	O
trail	O
eavluating	O
the	O
use	O
of	O
sipronolactone	O
in	O
haert	B-Disease
faliure	I-Disease
paitents	O
reported	O
a	O
low	O
rsik	O
of	O
hyperkaleima	B-Disease
(	O
2	O
%	O
)	O
and	O
rneal	B-Disease
insuffiicency	I-Disease
(	O
0	O
%	O
)	O
.	O

Because	O
traetments	O
for	O
herat	B-Disease
failrue	I-Disease
have	O
changed	O
since	O
the	O
bneefits	O
of	O
spironolatcone	O
were	O
reported	O
,	O
the	O
prevaelnce	O
of	O
these	O
copmlications	O
may	O
differ	O
in	O
current	O
cilnical	O
parctice	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
pervalence	O
and	O
cliniacl	O
associatinos	O
of	O
hyperaklemia	B-Disease
and	O
rneal	B-Disease
insfuficiency	I-Disease
in	O
herat	B-Disease
fialure	I-Disease
patinets	O
treaetd	O
with	O
spironolacotne	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
csae	O
contorl	O
stduy	O
of	O
haert	B-Disease
faliure	I-Disease
pateints	O
treaetd	O
with	O
spironolatcone	O
in	O
our	O
clincial	O
pracitce	O
.	O

Csaes	O
were	O
paitents	O
who	O
developed	O
hpyerkalemia	B-Disease
(	O
K	O
(	O
+	O
)	O
>	O
5	O
.	O
0	O
mEq	O
/	O
L	O
)	O
or	O
rneal	B-Disease
insuffiicency	I-Disease
(	O
Cr	O
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
comapred	O
to	O
2	O
randomly	O
selected	O
contrlos	O
per	O
csae	O
.	O

Cilnical	O
characteristcis	O
,	O
meidcations	O
,	O
and	O
sreum	O
chemsitries	O
at	O
baseilne	O
and	O
follow	O
-	O
up	O
tmie	O
peridos	O
were	O
cmopared	O
.	O

REUSLTS	O
:	O
Sixty	O
-	O
seven	O
of	O
926	O
paitents	O
(	O
7	O
.	O
2	O
%	O
)	O
required	O
discontinutaion	O
of	O
spiroonlactone	O
due	O
to	O
hyperaklemia	B-Disease
(	O
n	O
=	O
33	O
)	O
or	O
reanl	B-Disease
fialure	I-Disease
(	O
n	O
=	O
34	O
)	O
.	O

Patinets	O
who	O
developed	O
hpyerkalemia	B-Disease
were	O
odler	O
and	O
more	O
likely	O
to	O
have	O
daibetes	B-Disease
,	O
had	O
hihger	O
bsaeline	O
sreum	O
potsasium	O
leevls	O
and	O
lwoer	O
bsaeline	O
potsasium	O
supplement	O
dsoes	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
traeted	O
with	O
btea	O
-	O
blokcers	O
than	O
conrtols	O
(	O
n	O
=	O
134	O
)	O
.	O

Patietns	O
who	O
developed	O
rneal	B-Disease
insuffciiency	I-Disease
had	O
loewr	O
baesline	O
bdoy	O
wieght	O
and	O
hihger	O
bsaeline	O
sreum	O
creatinnie	O
,	O
required	O
hihger	O
doess	O
of	O
loop	O
diureitcs	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
traeted	O
with	O
thaizide	O
duiretics	O
than	O
contrlos	O
.	O

CNOCLUSIONS	O
:	O
Spiornolactone	O
-	O
inudced	O
hyperaklemia	B-Disease
and	O
reanl	B-Disease
insfuficiency	I-Disease
are	O
more	O
common	O
in	O
our	O
cliincal	O
expereince	O
than	O
reported	O
previously	O
.	O

This	O
difference	O
is	O
explained	O
by	O
ptaient	O
coomrbidities	O
and	O
more	O
ferquent	O
use	O
of	O
btea	O
-	O
blcokers	O
.	O

Aucte	O
resrepine	O
and	O
subchrnoic	O
haloepridol	O
teratments	O
change	O
synpatosomal	O
brian	O
glutaamte	O
upatke	O
and	O
elicit	O
orofaical	B-Disease
dysiknesia	I-Disease
in	O
rtas	O
.	O

Reseripne	O
-	O
and	O
hlaoperidol	O
-	O
idnuced	O
orofcaial	B-Disease
dyksinesia	I-Disease
are	O
putative	O
aniaml	O
moedls	O
of	O
taridve	B-Disease
dsykinesia	I-Disease
(	O
TD	B-Disease
)	O
whose	O
pathophysiolgoy	O
has	O
been	O
related	O
to	O
free	O
raidcal	O
gneeration	O
and	O
oixdative	O
srtess	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
the	O
autohrs	O
inudced	O
orfoacial	B-Disease
dyskinseia	I-Disease
by	O
aucte	O
rseerpine	O
and	O
sbuchronic	O
halpoeridol	O
adimnistration	O
to	O
rtas	O
.	O

Reseprine	O
ijnection	O
(	O
one	O
dsoe	O
of	O
1	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
every	O
other	O
day	O
for	O
3	O
dyas	O
caused	O
a	O
significant	O
incerase	O
in	O
vacouus	O
chweing	O
,	O
tognue	O
protursion	O
and	O
duratoin	O
of	O
faical	O
twitchnig	O
,	O
comapred	O
to	O
the	O
cnotrol	O
.	O

Haolperidol	O
adminsitration	O
(	O
one	O
dsoe	O
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
week	O
s	O
.	O
c	O
.	O
)	O
for	O
4	O
weeks	O
caused	O
an	O
icnrease	O
in	O
vcauous	O
cehwing	O
,	O
tnogue	O
prtorusion	O
and	O
druation	O
of	O
faical	O
twtiching	O
observed	O
in	O
four	O
weekly	O
evaluatinos	O
.	O

After	O
the	O
tretaments	O
and	O
behavoiral	O
osbervation	O
,	O
gltuamate	O
utpake	O
by	O
semgents	O
of	O
the	O
brian	O
was	O
analzyed	O
.	O

A	O
decreaesd	O
gluatmate	O
upatke	O
was	O
observed	O
in	O
the	O
subcortiacl	O
patrs	O
of	O
animlas	O
terated	O
with	O
reseripne	O
and	O
halpoeridol	O
,	O
compraed	O
to	O
the	O
cotnrol	O
.	O

Importantly	O
,	O
a	O
decresae	O
in	O
glutamtae	O
uptkae	O
corerlates	O
negaitvely	O
with	O
an	O
incerase	O
in	O
the	O
incdience	O
of	O
orofacail	B-Disease
disiknesia	I-Disease
.	O

These	O
resutls	O
indicate	O
that	O
eraly	O
chagnes	O
in	O
glutaamte	O
trasnport	O
may	O
be	O
related	O
to	O
the	O
developmnet	O
of	O
vcauous	O
cehwing	O
moevments	O
in	O
rtas	O
.	O

Ceftiraxone	O
-	O
associated	O
bliiary	B-Disease
psuedolithiasis	I-Disease
in	O
paedaitric	O
surigcal	O
patietns	O
.	O

It	O
is	O
well	O
known	O
that	O
cetfriaxone	O
leads	O
to	O
pseudloithiasis	B-Disease
in	O
some	O
ptaients	O
.	O

Clniical	O
and	O
experimenatl	O
studeis	O
also	O
suggest	O
that	O
stiuations	O
causing	O
gallbladedr	B-Disease
dysfnuction	I-Disease
,	O
such	O
as	O
fsating	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
devleopment	O
of	O
pseudolithisais	B-Disease
.	O

In	O
this	O
stduy	O
,	O
we	O
prospectively	O
evalauted	O
the	O
inicdence	O
and	O
cliincal	O
importance	O
of	O
pseudoltihiasis	B-Disease
in	O
paediartic	O
surgcial	O
patinets	O
receiving	O
cefrtiaxone	O
treatemnt	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
psot	O
-	O
operatvie	O
peirod	O
.	O

Fifty	O
chidlren	O
who	O
were	O
given	O
ceftriaoxne	O
were	O
evalutaed	O
by	O
seiral	O
abdmoinal	O
soongrams	O
.	O

Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
bliiary	O
ptahology	O
.	O

Compariosn	O
of	O
the	O
patietns	O
with	O
or	O
without	O
pseuodlithiasis	B-Disease
revelaed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
duratoin	O
of	O
the	O
traetment	O
and	O
satrvation	O
varialbes	O
.	O

After	O
cessatoin	O
of	O
the	O
teratment	O
,	O
pseudoilthiasis	B-Disease
resolved	O
spotnaneously	O
within	O
a	O
short	O
peirod	O
.	O

The	O
inicdence	O
of	O
pseudolihtiasis	B-Disease
is	O
not	O
affetced	O
by	O
fatsing	O
.	O

Coornary	B-Disease
aneuyrsm	I-Disease
after	O
implantaiton	O
of	O
a	O
pacltiaxel	O
-	O
eluitng	O
setnt	O
.	O

Fomration	O
of	O
coroanry	B-Disease
aneuyrsm	I-Disease
is	O
a	O
rrae	O
cmoplication	O
of	O
stetning	O
with	O
brae	O
mteal	O
setnts	O
,	O
but	O
based	O
on	O
exeprimental	O
stduies	O
durg	O
-	O
eluitng	O
stetns	O
may	O
indcue	O
toixc	O
effcets	O
on	O
the	O
vesesl	O
wlal	O
with	O
incompltee	O
setnt	O
apposition	O
,	O
aneuyrsm	B-Disease
foramtion	O
and	O
with	O
the	O
potnetial	O
of	O
stnet	O
thromobsis	B-Disease
or	O
vsesel	B-Disease
ruputre	I-Disease
.	O

We	O
present	O
a	O
43	O
-	O
yaer	O
-	O
old	O
man	O
who	O
developed	O
a	O
coornary	B-Disease
aneruysm	I-Disease
in	O
the	O
rihgt	O
croonary	O
aretry	O
6	O
motnhs	O
after	O
receiving	O
a	O
paclitaexl	O
-	O
elutnig	O
setnt	O
.	O

The	O
patinet	O
was	O
asmyptomatic	O
and	O
the	O
aenurysm	B-Disease
was	O
dteected	O
in	O
a	O
rotuine	O
conrtol	O
.	O

Anigography	O
and	O
intracroonary	O
ultraosund	O
demonstrated	O
lcak	O
of	O
cnotact	O
between	O
stnet	O
and	O
vsesel	O
wlal	O
in	O
a	O
15	O
-	O
mm	O
long	O
semgent	O
with	O
maixmal	O
aneursym	B-Disease
diaemter	O
of	O
6	O
.	O
0	O
mm	O
.	O

The	O
pateint	O
was	O
successfully	O
treaetd	O
with	O
a	O
grfat	O
stnet	O
.	O

Cuases	O
of	O
aucte	O
thrombtoic	B-Disease
microangipoathy	I-Disease
in	O
paitents	O
receiving	O
kindey	O
transplantaiton	O
.	O

OBJECTVIES	O
:	O
Thromboitc	B-Disease
microangoipathy	I-Disease
is	O
a	O
well	O
-	O
known	O
prbolem	O
in	O
patinets	O
following	O
rneal	O
transplantatoin	O
.	O

In	O
postrneal	O
transplnatation	O
,	O
thrombtoic	B-Disease
mciroangiopathy	I-Disease
is	O
often	O
a	O
relfection	O
of	O
hemloytic	B-Disease
ureimc	I-Disease
synrdome	I-Disease
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombtoic	B-Disease
microangioptahy	I-Disease
in	O
a	O
pouplation	O
of	O
reanl	O
transplanattion	O
reciipents	O
and	O
discuss	O
the	O
litertaure	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
inevstigated	O
the	O
causes	O
of	O
trhombotic	B-Disease
microangioptahy	I-Disease
during	O
a	O
1	O
-	O
yaer	O
peroid	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fhaad	O
Ntaional	O
Gaurd	O
Hosptial	O
in	O
Ryiadh	O
,	O
Suadi	O
Araiba	O
,	O
by	O
reivewing	O
the	O
sildes	O
of	O
all	O
transpalnt	O
biopises	O
(	O
n	O
=	O
25	O
)	O
performed	O
during	O
this	O
intreval	O
.	O

Pre	O
-	O
and	O
posttrasnplant	O
crossmtaching	O
was	O
done	O
when	O
possible	O
.	O

RESLUTS	O
:	O
Five	O
caess	O
of	O
thromobtic	B-Disease
microangipoathy	I-Disease
were	O
found	O
.	O

Three	O
of	O
these	O
caess	O
were	O
from	O
the	O
25	O
transplantatinos	O
performed	O
at	O
King	O
Fhaad	O
Natinoal	O
Gaurd	O
Hsopital	O
,	O
while	O
the	O
other	O
2	O
transplantatoins	O
had	O
been	O
performed	O
abraod	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow	O
-	O
up	O
.	O

Three	O
caess	O
were	O
related	O
to	O
cycolsporine	O
,	O
and	O
1	O
csae	O
was	O
secondary	O
to	O
both	O
cyclopsorine	O
and	O
tacroliums	O
.	O

The	O
fifth	O
csae	O
had	O
fetaures	O
of	O
thromboitc	B-Disease
microanigopathy	I-Disease
related	O
to	O
an	O
atniphospholipid	B-Disease
synrdome	I-Disease
in	O
a	O
paitent	O
with	O
sysetmic	B-Disease
lpuus	I-Disease
erythematsous	I-Disease
.	O

CONCULSIONS	O
:	O
In	O
the	O
litreature	O
,	O
the	O
most	O
-	O
freuqent	O
cause	O
of	O
heomlytic	B-Disease
ureimc	I-Disease
syndrmoe	I-Disease
in	O
paitents	O
following	O
reanl	O
transplanattion	O
is	O
recurrecne	O
of	O
the	O
hemloytic	B-Disease
uermic	I-Disease
synrdome	I-Disease
.	O

Other	O
causes	O
include	O
durg	O
-	O
related	O
(	O
cyclosoprine	O
,	O
tacrloimus	O
)	O
toxictiy	B-Disease
,	O
procoagulnat	O
sttaus	O
,	O
and	O
antiobdy	O
-	O
mediated	O
rejcetion	O
.	O

We	O
found	O
that	O
the	O
most	O
-	O
frqeuent	O
cause	O
of	O
throbmotic	B-Disease
microangoipathy	I-Disease
was	O
durg	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclsoporine	O
.	O

In	O
the	O
current	O
sutdy	O
,	O
the	O
freuqency	O
of	O
throbmotic	B-Disease
micronagiopathy	I-Disease
was	O
similar	O
to	O
the	O
percetnage	O
reported	O
in	O
the	O
literatrue	O
(	O
20	O
%	O
)	O
.	O

Compraison	O
of	O
develpomental	O
toxiicty	B-Disease
of	O
selective	O
and	O
non	O
-	O
selective	O
cycoloxygenase	O
-	O
2	O
inhibiotrs	O
in	O
CRL	O
:	O
(	O
WI	O
)	O
WBUR	O
Wisatr	O
rtas	O
-	O
-	O
DFU	O
and	O
prioxicam	O
stduy	O
.	O

BCAKGROUND	O
:	O
Cycloxoygenase	O
(	O
COX	O
)	O
inhibtiors	O
are	O
one	O
of	O
the	O
most	O
often	O
ingesetd	O
drgus	O
during	O
prgenancy	O
.	O

Unlike	O
general	O
toxiicty	B-Disease
dtaa	O
,	O
their	O
preantal	O
toixc	O
effcets	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

The	O
aim	O
of	O
the	O
epxeriment	O
was	O
to	O
evalaute	O
the	O
devleopmental	O
toixcity	B-Disease
of	O
the	O
non	O
-	O
selective	O
(	O
piroxciam	O
)	O
and	O
selective	O
(	O
DFU	O
;	O
5	O
,	O
5	O
-	O
diemthyl	O
-	O
3	O
-	O
(	O
3	O
-	O
flourophenyl	O
)	O
-	O
4	O
-	O
(	O
4	O
-	O
methylsulphoynl	O
)	O
pheynl	O
-	O
2	O
(	O
5H	O
)	O
-	O
furnaon	O
)	O
COX	O
-	O
2	O
inhiibtors	O
.	O

METHODS	O
:	O
Durgs	O
were	O
separately	O
,	O
orally	O
once	O
dialy	O
dsoed	O
to	O
pergnant	O
rtas	O
from	O
day	O
8	O
to	O
21	O
(	O
GD1	O
=	O
pulg	O
day	O
)	O
.	O

Dsoes	O
were	O
set	O
at	O
0	O
.	O
3	O
,	O
3	O
.	O
0	O
and	O
30	O
.	O
0mg	O
/	O
kg	O
for	O
piroxciam	O
and	O
0	O
.	O
2	O
,	O
2	O
.	O
0	O
and	O
20	O
.	O
0mg	O
/	O
kg	O
for	O
DFU	O
.	O

Feutses	O
were	O
delviered	O
on	O
GD	O
21	O
and	O
routinely	O
examined	O
.	O

Comprehensvie	O
cliniacl	O
and	O
develpomental	O
measuerments	O
were	O
done	O
.	O

The	O
poloed	O
statistiacl	O
anaylsis	O
for	O
ventircular	B-Disease
sepatl	I-Disease
(	I-Disease
VSD	I-Disease
)	I-Disease
and	I-Disease
mdiline	I-Disease
(	I-Disease
MD	I-Disease
)	I-Disease
defetcs	I-Disease
was	O
performed	O
for	O
rat	O
fetuess	O
expoesd	O
to	O
piroixcam	O
,	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
inihbitor	O
based	O
on	O
present	O
and	O
histroic	O
dtaa	O
.	O

RESUTLS	O
:	O
Matrenal	O
toxciity	B-Disease
,	O
itnrauterine	B-Disease
gorwth	I-Disease
rteardation	I-Disease
,	O
and	O
incresae	B-Disease
of	I-Disease
exetrnal	I-Disease
and	I-Disease
skleetal	I-Disease
variatinos	I-Disease
were	O
found	O
in	O
rtas	O
tretaed	O
with	O
the	O
highest	O
dsoe	O
of	O
piroxciam	O
.	O

Decerase	O
of	O
featl	O
lnegth	O
was	O
the	O
only	O
sgins	O
of	O
the	O
DFU	O
developmenatl	O
toxiicty	B-Disease
observed	O
in	O
ppus	O
expoesd	O
to	O
the	O
highest	O
comopund	O
dsoe	O
.	O

Lcak	O
of	O
teratogeniicty	O
was	O
found	O
in	O
piorxicam	O
and	O
DFU	O
-	O
exopsed	O
gropus	O
.	O

Prentaal	O
exposrue	O
to	O
non	O
-	O
selective	O
COX	O
inhibitros	O
increaess	O
the	O
rsik	O
of	O
VSD	O
and	O
MD	O
when	O
compraed	O
to	O
histroic	O
cnotrol	O
but	O
not	O
with	O
selective	O
COX	O
-	O
2	O
ihnibitors	O
.	O

CONCLUSOIN	O
:	O
Both	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
ihnibitors	O
were	O
toixc	O
for	O
rtas	O
fetsues	O
when	O
administreed	O
in	O
the	O
highest	O
dsoe	O
.	O

Unlike	O
DFU	O
,	O
piroxciam	O
was	O
also	O
highly	O
toixc	O
to	O
the	O
dmas	O
.	O

Prenaatl	O
expsoure	O
to	O
selective	O
COX	O
-	O
2	O
inhiibtors	O
does	O
not	O
incerase	O
the	O
rsik	O
of	O
vnetricular	B-Disease
spetal	I-Disease
and	I-Disease
mildine	I-Disease
defetcs	I-Disease
in	O
rat	O
when	O
comapred	O
to	O
non	O
-	O
selective	O
drgus	O
and	O
hisotric	O
conrtol	O
.	O

Lnoe	O
atiral	B-Disease
fibrillatoin	I-Disease
associated	O
with	O
cretaine	O
monohydrtae	O
supplementtaion	O
.	O

Artial	B-Disease
fibrilaltion	I-Disease
in	O
yuong	O
ptaients	O
without	O
strcutural	O
herat	B-Disease
disesae	I-Disease
is	O
rrae	O
.	O

Therefore	O
,	O
when	O
the	O
arhrythmia	B-Disease
is	O
present	O
in	O
this	O
populaiton	O
,	O
reversible	O
causes	O
must	O
be	O
idenitfied	O
and	O
resolved	O
.	O

Thyriod	B-Disease
disordres	I-Disease
,	O
illciit	O
durg	O
or	O
stiumlant	O
use	O
,	O
and	O
actue	B-Disease
alochol	I-Disease
inotxication	I-Disease
are	O
among	O
these	O
causes	O
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
30	O
-	O
yaer	O
-	O
old	O
Cauacsian	O
man	O
who	O
came	O
to	O
the	O
emeregncy	O
deaprtment	O
in	O
artial	B-Disease
firbillation	I-Disease
with	O
raipd	O
ventircular	O
rseponse	O
.	O

His	O
medcial	O
hisotry	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractrues	B-Disease
of	O
the	O
fingres	O
and	O
foot	O
.	O

Tyhroid	O
-	O
stimualting	O
homrone	O
,	O
mganesium	O
,	O
and	O
poatssium	O
leevls	O
were	O
within	O
nromal	O
limtis	O
,	O
urnie	O
durg	O
screen	O
was	O
ngeative	O
,	O
and	O
aclohol	O
use	O
was	O
denied	O
.	O

However	O
,	O
when	O
the	O
ptaient	O
was	O
questioned	O
about	O
use	O
of	O
hrebal	O
prodcuts	O
and	O
spuplements	O
,	O
the	O
use	O
of	O
craetine	O
moonhydrate	O
was	O
reevaled	O
.	O

The	O
pateint	O
was	O
admitted	O
to	O
the	O
hosptial	O
,	O
anticoagluated	O
with	O
unfrcationated	O
heprain	O
,	O
and	O
given	O
inrtavenous	O
diltaizem	O
for	O
rtae	O
cotnrol	O
and	O
intrvaenous	O
amiodraone	O
for	O
rtae	O
and	O
rhtyhm	O
cotnrol	O
.	O

When	O
discahrged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
mteoprolol	O
and	O
aspriin	O
,	O
with	O
follow	O
-	O
up	O
palns	O
for	O
echocardiorgaphy	O
and	O
nulcear	O
imgaing	O
to	O
assess	O
pefrusion	O
.	O

Exoegnous	O
creatnie	O
is	O
used	O
by	O
ahtletes	O
to	O
theoretically	O
ipmrove	O
exericse	O
performacne	O
.	O

Vegtearians	O
may	O
also	O
take	O
creatnie	O
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
maet	O
,	O
fsih	O
,	O
and	O
other	O
ainmal	O
prodcuts	O
.	O

Previous	O
anedcotal	O
reoprts	O
have	O
linked	O
ceratine	O
to	O
the	O
deveolpment	O
of	O
arhrythmia	B-Disease
.	O

Clinciians	O
must	O
be	O
dilgient	O
when	O
interivewing	O
patietns	O
about	O
their	O
durg	O
threapy	O
historeis	O
and	O
include	O
qusetions	O
about	O
their	O
use	O
of	O
herabl	O
prodcuts	O
and	O
dieatry	O
supplmeents	O
.	O

In	O
addition	O
,	O
it	O
is	O
important	O
to	O
reoprt	O
advesre	O
effetcs	O
associated	O
with	O
frequently	O
consumed	O
spuplements	O
and	O
hrebal	O
prdoucts	O
to	O
the	O
Food	O
and	O
Durg	O
Adminitsration	O
and	O
in	O
the	O
litertaure	O
.	O

Seiuzres	B-Disease
inudced	O
by	O
the	O
coacine	O
mteabolite	O
bnezoylecgonine	O
in	O
rtas	O
.	O

The	O
half	O
-	O
lfie	O
(	O
t1	O
/	O
2	O
)	O
of	O
cociane	O
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
cosnequences	O
of	O
its	O
use	O
,	O
such	O
as	O
seziures	B-Disease
and	O
stroeks	B-Disease
,	O
can	O
occur	O
hours	O
after	O
epxosure	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
meatbolite	O
of	O
cocanie	O
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
dleayed	O
seuqelae	O
.	O

We	O
evaluaetd	O
the	O
potenital	O
of	O
the	O
major	O
metaoblite	O
of	O
cocanie	O
,	O
benzoylecognine	O
(	O
BE	O
)	O
,	O
to	O
cause	O
seizrues	B-Disease
.	O

Two	O
separate	O
euqimolar	O
doess	O
(	O
0	O
.	O
2	O
and	O
0	O
.	O
4	O
mmuol	O
)	O
of	O
either	O
cociane	O
or	O
BE	O
were	O
injetced	O
ventricularly	O
in	O
unanesthteized	O
juevnile	O
rtas	O
.	O

Treaetd	O
rtas	O
were	O
then	O
evaluaetd	O
for	O
inicdence	O
,	O
latecny	O
,	O
and	O
seizrue	B-Disease
ptatern	O
or	O
for	O
locomootr	O
acitvity	O
in	O
ainmals	O
without	O
siezures	B-Disease
.	O

BE	O
-	O
Idnuced	O
seizuers	B-Disease
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latenceis	O
than	O
those	O
indcued	O
by	O
equimoalr	O
amounts	O
of	O
coacine	O
.	O

Whereas	O
coacine	O
-	O
inudced	O
seziures	B-Disease
were	O
best	O
characetrized	O
as	O
brief	O
,	O
generalzied	O
,	O
and	O
toinc	O
and	O
resulted	O
in	O
daeth	B-Disease
,	O
those	O
induecd	O
by	O
BE	O
were	O
prologned	O
,	O
often	O
multilpe	O
and	O
mixed	O
in	O
tpye	O
,	O
and	O
rarely	O
resulted	O
in	O
detah	B-Disease
.	O

Electircal	O
recrodings	O
from	O
the	O
hippoacmpus	O
showed	O
a	O
rhythimc	O
porgression	O
in	O
EEG	O
frequnecy	O
and	O
volatge	O
with	O
clniical	O
seiuzre	B-Disease
expresison	O
.	O

BE	O
-	O
Injceted	O
rtas	O
that	O
did	O
not	O
have	O
seizrues	B-Disease
had	O
significantly	O
more	O
loocmotor	O
actviity	O
than	O
coacine	O
-	O
injceted	O
animlas	O
without	O
seizuers	B-Disease
.	O

The	O
findnig	O
that	O
cociane	O
-	O
and	O
BE	O
-	O
induecd	O
seiuzres	B-Disease
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechnaism	O
for	O
ccoaine	O
-	O
idnuced	O
seizrues	B-Disease
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cocanie	O
mteabolite	O
,	O
BE	O
.	O

The	O
selective	O
5	O
-	O
HT6	O
reecptor	O
antaognist	O
Ro4368554	O
retsores	O
mmeory	O
perforamnce	O
in	O
cohlinergic	O
and	O
sreotonergic	O
mdoels	O
of	O
meomry	B-Disease
deficiecny	I-Disease
in	O
the	O
rat	O
.	O

Antagoinsts	O
at	O
serootnin	O
tpye	O
6	O
(	O
5	O
-	O
HT	O
(	O
6	O
)	O
)	O
recetpors	O
show	O
activtiy	O
in	O
modles	O
of	O
leanring	O
and	O
mmeory	O
.	O

Although	O
the	O
underlying	O
mehcanism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	O
an	O
icnrease	O
in	O
acteylcholine	O
(	O
ACh	O
)	O
levles	O
.	O

The	O
present	O
stduy	O
sought	O
to	O
characterize	O
the	O
congitive	O
-	O
enhancing	O
effects	O
of	O
the	O
5	O
-	O
HT	O
(	O
6	O
)	O
antaognist	O
Ro4638554	O
(	O
3	O
-	O
benzenseulfonyl	O
-	O
7	O
-	O
(	O
4	O
-	O
metyhl	O
-	O
pipreazin	O
-	O
1	O
-	O
yl	O
)	O
1H	O
-	O
inodle	O
)	O
in	O
a	O
rat	O
obejct	O
reocgnition	O
tsak	O
employing	O
a	O
cholinregic	O
(	O
scooplamine	O
pertreatment	O
)	O
and	O
a	O
serotonegric	O
-	O
(	O
tryptohpan	O
(	O
TRP	O
)	O
deplteion	O
)	O
dfeicient	O
moedl	O
,	O
and	O
compaerd	O
its	O
pattren	O
of	O
actoin	O
with	O
that	O
of	O
the	O
acetylcholinetserase	O
inhibtior	O
mertifonate	O
.	O

Initial	O
tetsing	O
in	O
a	O
tmie	O
-	O
depenednt	O
forgettnig	O
tsak	O
employing	O
a	O
24	O
-	O
h	O
dleay	O
between	O
trianing	O
and	O
testnig	O
showed	O
that	O
metrfionate	O
imrpoved	O
obejct	O
recogintion	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
whereas	O
Ro3468554	O
was	O
ianctive	O
.	O

Both	O
,	O
Ro4365854	O
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
itnraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
)	O
and	O
metrifoante	O
(	O
10	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
rveersed	O
memroy	B-Disease
deifcits	I-Disease
indcued	O
by	O
scopolamnie	O
and	O
TRP	O
dpeletion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
although	O
Ro4638554	O
did	O
not	O
imrpove	O
a	O
tmie	O
-	O
related	O
rteention	O
defciit	O
,	O
it	O
rveersed	O
a	O
cholinegric	O
and	O
a	O
sertoonergic	O
mmeory	B-Disease
defiict	I-Disease
,	O
suggesting	O
that	O
both	O
mechainsms	O
may	O
be	O
involved	O
in	O
the	O
faiclitation	O
of	O
ojbect	O
mmeory	O
by	O
Ro4365854	O
and	O
,	O
possibly	O
,	O
other	O
5	O
-	O
HT	O
(	O
6	O
)	O
reecptor	O
antgaonists	O
.	O

Evaulation	O
of	O
the	O
atnicocaine	O
moncolonal	O
atnibody	O
GCN92H2	O
as	O
an	O
immunothearpy	O
for	O
cociane	B-Disease
overodse	I-Disease
.	O

The	O
illicit	O
use	O
of	O
coacine	O
continues	O
in	O
epideimc	O
proportoins	O
and	O
traetment	O
for	O
coacine	B-Disease
ovedrose	I-Disease
remains	O
elusive	O
.	O

Current	O
portein	O
-	O
based	O
tcehnology	O
offers	O
a	O
new	O
theraeputic	O
vneue	O
by	O
which	O
antbiodies	O
bnid	O
the	O
durg	O
in	O
the	O
blood	O
steram	O
,	O
incativating	O
its	O
toixc	O
effetcs	O
.	O

The	O
therapeuitc	O
potetnial	O
of	O
the	O
antioccaine	O
anitbody	O
GN9C2H2	O
was	O
examined	O
using	O
a	O
moedl	O
of	O
cociane	B-Disease
ovedrose	I-Disease
.	O

Siwss	O
ablino	O
mcie	O
prpeared	O
with	O
intraujgular	O
cathetres	O
were	O
tseted	O
in	O
photoclel	O
cgaes	O
after	O
admniistration	O
of	O
93	O
mg	O
/	O
kg	O
(	O
L5D0	O
)	O
of	O
cocanie	O
and	O
GCN92H2	O
infsuions	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O

GNC29H2	O
was	O
delivreed	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
coacine	O
treatemnt	O
.	O

Signfiicant	O
blcokade	O
of	O
coacine	O
toxictiy	B-Disease
was	O
observed	O
with	O
the	O
hgiher	O
dsoe	O
of	O
GNC9H22	O
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
premobrid	O
bheaviors	O
were	O
reduecd	O
up	O
to	O
40	O
%	O
,	O
seizuers	B-Disease
up	O
to	O
77	O
%	O
and	O
daeth	B-Disease
by	O
72	O
%	O
.	O

Importantly	O
,	O
GN9C2H2	O
prevented	O
daeth	B-Disease
even	O
psot	O
-	O
cocanie	O
injeciton	O
.	O

The	O
reuslts	O
support	O
the	O
important	O
ptoential	O
of	O
GNC9H22	O
as	O
a	O
thearpeutic	O
tool	O
against	O
cociane	B-Disease
ovredose	I-Disease
.	O

Electroacrdiographic	O
evidecne	O
of	O
myoacrdial	B-Disease
inujry	I-Disease
in	O
psychiatrcially	O
hospitailzed	O
cociane	O
abuesrs	O
.	O

The	O
electrocadriograms	O
(	O
ECG	O
)	O
of	O
99	O
cociane	O
-	O
abuisng	O
patietns	O
were	O
cmopared	O
with	O
the	O
EGCs	O
of	O
50	O
schizophreinc	B-Disease
conrtols	O
.	O

Eleven	O
of	O
the	O
coacine	O
abusres	O
and	O
none	O
of	O
the	O
conrtols	O
had	O
ECG	O
eviednce	O
of	O
significant	O
myocradial	B-Disease
ijnury	I-Disease
defined	O
as	O
mycoardial	B-Disease
infacrtion	I-Disease
,	O
ischmeia	B-Disease
,	O
and	O
budnle	B-Disease
brnach	I-Disease
bolck	I-Disease
.	O

Behaivoral	O
effcets	O
of	O
uroetnsin	O
-	O
II	O
centrally	O
adminitsered	O
in	O
mcie	O
.	O

Urtoensin	O
-	O
II	O
(	O
U	O
-	O
II	O
)	O
recetpors	O
are	O
widely	O
distributed	O
in	O
the	O
cenrtal	O
nevrous	O
ssytem	O
.	O

Intarcerebroventricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
injeciton	O
of	O
U	O
-	O
II	O
causes	O
hypretension	B-Disease
and	O
bradyacrdia	B-Disease
and	O
stimluates	O
prolcatin	O
and	O
tyhrotropin	O
sceretion	O
.	O

However	O
,	O
the	O
behavoiral	O
effects	O
of	O
centrally	O
admniistered	O
U	O
-	O
II	O
have	O
received	O
little	O
attentoin	O
.	O

In	O
the	O
present	O
stduy	O
,	O
we	O
tetsed	O
the	O
efefcts	O
of	O
i	O
.	O
c	O
.	O
v	O
.	O
ijnections	O
of	O
U	O
-	O
II	O
on	O
beahvioral	O
,	O
metaoblic	O
,	O
and	O
enodcrine	O
respnoses	O
in	O
mcie	O
.	O

Administratoin	O
of	O
grdaed	O
doess	O
of	O
U	O
-	O
II	O
(	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
muose	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dsoe	O
-	O
depnedent	O
reudction	O
in	O
the	O
number	O
of	O
haed	O
dpis	O
in	O
the	O
hloe	O
-	O
baord	O
tset	O
;	O
(	O
2	O
)	O
a	O
dsoe	O
-	O
depednent	O
reudction	O
in	O
the	O
number	O
of	O
entreis	O
in	O
the	O
whtie	O
chabmer	O
in	O
the	O
balck	O
-	O
and	O
-	O
whtie	O
compartemnt	O
tset	O
,	O
and	O
in	O
the	O
number	O
of	O
etnries	O
in	O
the	O
cenrtal	O
pltaform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
mzae	O
tset	O
;	O
and	O
(	O
3	O
)	O
a	O
dsoe	O
-	O
deepndent	O
incerase	O
in	O
the	O
duraiton	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimmnig	O
tset	O
and	O
tial	O
ssupension	O
tset	O
.	O

Intracerebrovetnricular	O
injcetion	O
of	O
U	O
-	O
II	O
also	O
caused	O
an	O
incraese	O
in	O
:	O
food	O
inatke	O
at	O
dsoes	O
of	O
100	O
and	O
1	O
,	O
000	O
ng	O
/	O
muose	O
,	O
waetr	O
inatke	O
at	O
doess	O
of	O
100	O
-	O
10	O
,	O
000	O
ng	O
/	O
muose	O
,	O
and	O
horizotnal	O
lcoomotion	O
atcivity	O
at	O
a	O
dsoe	O
of	O
10	O
,	O
000	O
ng	O
/	O
mosue	O
.	O

Whatever	O
was	O
the	O
dsoe	O
,	O
the	O
cenrtal	O
adminitsration	O
of	O
U	O
-	O
II	O
had	O
no	O
effect	O
on	O
bdoy	O
tempertaure	O
,	O
nociecption	O
,	O
aopmorphine	O
-	O
induecd	O
peinle	B-Disease
eerction	I-Disease
and	O
clmibing	O
bheavior	O
,	O
and	O
strses	O
-	O
indcued	O
palsma	O
cotricosterone	O
leevl	O
.	O

Taken	O
together	O
,	O
the	O
present	O
sutdy	O
demonstrates	O
that	O
the	O
cetnral	O
injetcion	O
of	O
U	O
-	O
II	O
at	O
doess	O
of	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mosue	O
indcues	O
anxiogneic	O
-	O
and	O
depressnat	O
-	O
like	O
effects	O
in	O
muose	O
.	O

These	O
dtaa	O
suggest	O
that	O
U	O
-	O
II	O
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psycihatric	B-Disease
disodrers	I-Disease
.	O

Leraning	O
of	O
rtas	O
under	O
amneisa	B-Disease
caused	O
by	O
pentobaribtal	O
.	O

Dissociaetd	O
leanring	O
of	O
rtas	O
in	O
the	O
nomral	O
state	O
and	O
the	O
state	O
of	O
amensia	B-Disease
produced	O
by	O
pentboarbital	O
(	O
15	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
was	O
carried	O
out	O
.	O

Rtas	O
were	O
traiend	O
to	O
approach	O
a	O
sehlf	O
where	O
they	O
received	O
food	O
reinofrcement	O
.	O

In	O
Gruop	O
1	O
the	O
rtas	O
were	O
tarined	O
under	O
the	O
ifnluence	O
of	O
pentobabrital	O
to	O
run	O
to	O
the	O
same	O
shlef	O
as	O
in	O
the	O
nromal	O
state	O
.	O

In	O
Gruop	O
2	O
the	O
rtas	O
were	O
traiend	O
to	O
approach	O
different	O
shelevs	O
in	O
different	O
durg	O
states	O
.	O

It	O
was	O
shown	O
that	O
mmeory	B-Disease
dissociatoin	I-Disease
occurred	O
in	O
both	O
gropus	O
.	O

Differecnes	O
in	O
the	O
praameters	O
of	O
traiinng	O
under	O
the	O
inlfuence	O
of	O
penotbarbital	O
between	O
Gruops	O
1	O
and	O
2	O
were	O
reveaeld	O
.	O

These	O
fnidings	O
show	O
that	O
the	O
barin	O
-	O
dissociated	O
state	O
idnuced	O
by	O
pentoabrbital	O
is	O
formed	O
with	O
the	O
participtaion	O
of	O
the	O
mechansims	O
of	O
ifnormation	O
perecption	O
.	O

The	O
effetcs	O
of	O
short	O
-	O
term	O
raloixfene	O
therpay	O
on	O
fibrinloysis	O
marekrs	O
:	O
TFAI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
.	O

BACKRGOUND	O
:	O
Mrakers	O
of	O
fibrionlysis	O
,	O
trhombin	O
-	O
activatalbe	O
fbirinolysis	O
inhiibtor	O
(	O
TFAI	O
)	O
,	O
tissue	O
-	O
tpye	O
plasmingoen	O
acitvator	O
(	O
tPA	O
)	O
,	O
and	O
plasminoegn	O
atcivator	O
ihnibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
leevls	O
were	O
studied	O
for	O
the	O
evaluaiton	O
of	O
short	O
-	O
term	O
effcets	O
of	O
raloxifnee	O
administrtaion	O
in	O
postmeonpausal	O
wmoen	O
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenpoausal	O
woemn	O
with	O
osteopeina	B-Disease
or	O
osteoproosis	B-Disease
were	O
included	O
in	O
this	O
propsective	O
,	O
controlled	O
cliniacl	O
sutdy	O
.	O

Twenty	O
-	O
five	O
woemn	O
were	O
given	O
ralxoifene	O
hydrcohloride	O
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calicum	O
(	O
500	O
mg	O
/	O
day	O
)	O
.	O

Age	O
-	O
matched	O
cnotrols	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
clacium	O
.	O

Plsama	O
TFAI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
anitgen	O
lveels	O
were	O
maesured	O
at	O
baesline	O
and	O
after	O
3	O
monhts	O
of	O
traetment	O
by	O
commercially	O
available	O
EILSA	O
ktis	O
.	O

Variatoins	O
of	O
individauls	O
were	O
asesssed	O
by	O
Wlicoxon	O
'	O
s	O
tset	O
.	O

Relatoinship	O
between	O
those	O
makrers	O
and	O
deomgraphic	O
charactreistics	O
were	O
investigtaed	O
.	O

RESUTLS	O
:	O
Three	O
motnhs	O
of	O
raloxiefne	O
teratment	O
was	O
associated	O
with	O
a	O
significant	O
decerase	O
in	O
the	O
plsama	O
TFAI	O
antgien	O
concentratoins	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
incresae	O
in	O
tPA	O
antiegn	O
concentraitons	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
significant	O
correltaion	O
was	O
found	O
between	O
baseilne	O
TFAI	O
anitgen	O
concentraitons	O
and	O
the	O
duartion	O
of	O
amenrorhea	B-Disease
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O

CONCULSION	O
:	O
We	O
suggest	O
that	O
the	O
incresaed	O
rsik	O
of	O
venuos	B-Disease
thrmoboembolism	I-Disease
due	O
to	O
raloxiefne	O
treamtent	O
may	O
be	O
related	O
to	O
incerased	O
tPA	O
lveels	O
,	O
but	O
not	O
TFAI	O
levles	O
.	O

Vlaproate	O
-	O
indcued	O
encephaolpathy	B-Disease
.	O

Vlaproate	O
-	O
indcued	O
encephaloapthy	B-Disease
is	O
a	O
rrae	O
snydrome	O
that	O
may	O
manifest	O
in	O
otherwise	O
nromal	O
epiletpic	B-Disease
indivdiuals	O
.	O

It	O
may	O
even	O
present	O
in	O
pateints	O
who	O
have	O
tolertaed	O
this	O
mdeicine	O
well	O
in	O
the	O
past	O
.	O

It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammnoemia	B-Disease
.	O

The	O
EEG	O
shows	O
chaarcteristic	O
tripahsic	O
wvaes	O
in	O
most	O
ptaients	O
with	O
this	O
compliaction	O
.	O

A	O
csae	O
of	O
valporate	O
-	O
indcued	O
encepahlopathy	B-Disease
is	O
presented	O
.	O

The	O
porblems	O
in	O
diagnosnig	O
this	O
cnodition	O
are	O
subsequently	O
discussed	O
.	O

Recurernt	O
dysphoina	B-Disease
and	O
actiretin	O
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
woamn	O
complianing	O
of	O
dysphnoia	B-Disease
while	O
she	O
was	O
terated	O
by	O
actiretin	O
.	O

Her	O
symtpoms	O
totally	O
regressed	O
after	O
durg	O
withdraawl	O
and	O
reappeared	O
when	O
aictretin	O
was	O
reintroduced	O
.	O

To	O
our	O
knowlegde	O
,	O
this	O
is	O
the	O
first	O
csae	O
of	O
aictretin	O
-	O
indcued	O
dypshonia	B-Disease
.	O

This	O
efefct	O
may	O
be	O
related	O
to	O
the	O
pharamcological	O
effcet	O
of	O
this	O
durg	O
on	O
mucuos	O
memrbanes	O
.	O

Ntiro	O
-	O
L	O
-	O
argniine	O
mehtyl	O
etser	O
:	O
a	O
potetnial	O
prtoector	O
against	O
genatmicin	O
ototoxictiy	B-Disease
.	O

The	O
nirtic	O
oxdie	O
(	O
NO	O
)	O
inhibiotr	O
ntiro	O
-	O
L	O
-	O
agrinine	O
metyhl	O
esetr	O
(	O
L	O
-	O
NMAE	O
)	O
may	O
act	O
as	O
an	O
otoportectant	O
against	O
high	B-Disease
-	I-Disease
freuqency	I-Disease
heraing	I-Disease
lsos	I-Disease
caused	O
by	O
genatmicin	O
,	O
but	O
further	O
studeis	O
are	O
needed	O
to	O
confirm	O
this	O
.	O
Aminoglcyoside	O
antibioitcs	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficcay	O
and	O
low	O
csot	O
.	O

Their	O
ototoixcity	B-Disease
is	O
a	O
serious	O
helath	O
probelm	O
and	O
,	O
as	O
their	O
ototxoic	B-Disease
mechansim	O
involves	O
the	O
produciton	O
of	O
NO	O
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	O
inhbiitors	O
for	O
the	O
pervention	O
of	O
aminoglyocside	O
-	O
indcued	O
snesorineural	B-Disease
haering	I-Disease
lsos	I-Disease
.	O

In	O
this	O
exeprimental	O
sutdy	O
we	O
used	O
30	O
Sprgaue	O
-	O
Dwaley	O
rtas	O
,	O
27	O
of	O
which	O
had	O
gentmaicin	O
instileld	O
into	O
the	O
middle	O
ear	O
.	O

The	O
otoportectant	O
L	O
-	O
NMAE	O
was	O
adminsitered	O
topiaclly	O
to	O
12	O
/	O
27	O
anmials	O
.	O

Its	O
effcet	O
was	O
determined	O
in	O
terms	O
of	O
atteunation	O
of	O
hearnig	B-Disease
lsos	I-Disease
,	O
maesured	O
by	O
sihfts	O
in	O
the	O
audtiory	O
branistem	O
rseponse	O
threhsold	O
.	O

L	O
-	O
NMAE	O
redcued	O
getnamicin	O
-	O
induecd	O
hearnig	B-Disease
lsos	I-Disease
in	O
the	O
high	O
-	O
freqeuncy	O
range	O
,	O
but	O
gave	O
no	O
protectoin	O
in	O
the	O
middle	O
or	O
low	O
frequnecies	O
.	O

Saftey	O
proifle	O
of	O
a	O
nictoine	O
loznege	O
copmared	O
with	O
that	O
of	O
nioctine	O
gum	O
in	O
adlut	O
smokres	O
with	O
underlying	O
medcial	O
cnoditions	O
:	O
a	O
12	O
-	O
week	O
,	O
randoimzed	O
,	O
open	O
-	O
lbael	O
stduy	O
.	O

BACKRGOUND	O
:	O
Nioctine	O
polacrielx	O
lzoenges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nciotine	O
comapred	O
with	O
eqiuvalent	O
dsoes	O
of	O
nicotnie	O
ploacrilex	O
gum	O
.	O

The	O
incresaed	O
nioctine	O
exposrue	O
from	O
the	O
lozegne	O
has	O
raised	O
questoins	O
about	O
the	O
relative	O
saefty	O
of	O
the	O
loeznge	O
and	O
gum	O
.	O

OBJECTVIE	O
:	O
The	O
objcetive	O
of	O
this	O
sutdy	O
was	O
to	O
cmopare	O
the	O
saftey	O
profiels	O
of	O
the	O
4	O
-	O
mg	O
nicoitne	O
lozegne	O
and	O
4	O
-	O
mg	O
nicoitne	O
gum	O
in	O
smkoers	O
with	O
selected	O
laebl	O
-	O
restricted	O
disaeses	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
mluticenter	O
,	O
ranodmized	O
,	O
open	O
-	O
lbael	O
stduy	O
in	O
adlut	O
smoekrs	O
with	O
herat	B-Disease
disaese	I-Disease
,	O
hyperetnsion	B-Disease
not	O
cotnrolled	O
by	O
medictaion	O
,	O
and	O
/	O
or	O
diabeets	B-Disease
meliltus	I-Disease
.	O

Paitents	O
were	O
ranodmized	O
in	O
a	O
1	O
:	O
1	O
rtaio	O
to	O
receive	O
the	O
4	O
-	O
mg	O
nioctine	O
loeznge	O
or	O
4	O
-	O
mg	O
nciotine	O
gum	O
.	O

Saefty	O
assessments	O
were	O
made	O
at	O
baselnie	O
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
wekes	O
after	O
the	O
start	O
of	O
prdouct	O
use	O
.	O

RSEULTS	O
:	O
Nine	O
hundred	O
one	O
patietns	O
were	O
randomzied	O
to	O
tretament	O
,	O
447	O
who	O
received	O
the	O
lzoenge	O
and	O
454	O
who	O
received	O
the	O
gum	O
(	O
saefty	O
popluation	O
)	O
.	O

The	O
majority	O
were	O
wmoen	O
(	O
52	O
.	O
7	O
%	O
)	O
.	O

Patinets	O
'	O
mean	O
age	O
was	O
53	O
.	O
9	O
yeras	O
,	O
their	O
mean	O
wieght	O
was	O
193	O
.	O
9	O
pounds	O
,	O
and	O
they	O
smoekd	O
a	O
mean	O
of	O
25	O
.	O
2	O
cigaerttes	O
per	O
day	O
at	O
bsaeline	O
.	O

Five	O
hundred	O
fifty	O
-	O
three	O
paitents	O
,	O
264	O
taking	O
the	O
loeznge	O
and	O
289	O
taking	O
the	O
gum	O
,	O
used	O
the	O
sutdy	O
proudct	O
for	O
>	O
or	O
=	O
4	O
dyas	O
per	O
week	O
during	O
the	O
first	O
2	O
weeks	O
(	O
evalualbe	O
popualtion	O
)	O
.	O

The	O
nciotine	O
loeznge	O
and	O
nciotine	O
gum	O
were	O
equally	O
well	O
tolreated	O
,	O
despite	O
incraesed	O
nictoine	O
exopsure	O
from	O
the	O
lzoenge	O
.	O

The	O
icnidence	O
of	O
advesre	O
evnets	O
in	O
the	O
2	O
gruops	O
was	O
similar	O
during	O
the	O
first	O
2	O
wekes	O
of	O
prdouct	O
use	O
(	O
evaluaiton	O
ppoulation	O
:	O
55	O
.	O
3	O
%	O
lozegne	O
,	O
54	O
.	O
7	O
%	O
gum	O
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
stduy	O
(	O
saefty	O
populatoin	O
:	O
63	O
.	O
8	O
%	O
and	O
58	O
.	O
6	O
%	O
,	O
respectively	O
)	O
.	O

Startification	O
of	O
patietns	O
by	O
sex	O
,	O
age	O
,	O
extent	O
of	O
concurrent	O
somking	O
,	O
extent	O
of	O
proudct	O
use	O
,	O
and	O
severtiy	O
of	O
avderse	O
evetns	O
revelaed	O
no	O
cliniaclly	O
significant	O
differences	O
between	O
the	O
lzoenge	O
and	O
gum	O
.	O

The	O
most	O
common	O
advrese	O
evnets	O
were	O
nuasea	B-Disease
(	O
17	O
.	O
2	O
%	O
and	O
16	O
.	O
1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
7	O
to	O
6	O
.	O
0	O
)	O
,	O
hcicups	B-Disease
(	O
10	O
.	O
7	O
%	O
and	O
6	O
.	O
6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
5	O
to	O
7	O
.	O
8	O
)	O
,	O
and	O
heaadche	B-Disease
(	O
8	O
.	O
7	O
%	O
and	O
9	O
.	O
9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-	O
5	O
.	O
0	O
to	O
2	O
.	O
6	O
)	O
.	O

Seroius	O
avderse	O
evnets	O
were	O
reported	O
in	O
11	O
and	O
13	O
patinets	O
in	O
the	O
respective	O
gruops	O
.	O

Fewer	O
than	O
6	O
%	O
of	O
patietns	O
in	O
either	O
gorup	O
were	O
considered	O
by	O
the	O
inevstigator	O
to	O
have	O
a	O
wrosening	O
of	O
their	O
overall	O
dsiease	O
conidtion	O
during	O
the	O
stduy	O
.	O

The	O
majority	O
of	O
pateints	O
(	O
>	O
60	O
%	O
)	O
experienced	O
no	O
change	O
in	O
their	O
diesase	O
sattus	O
from	O
bsaeline	O
.	O

COCNLUSION	O
:	O
The	O
4	O
-	O
mg	O
nioctine	O
lzoenge	O
and	O
4	O
-	O
mg	O
nioctine	O
gum	O
had	O
comparable	O
sfaety	O
prfoiles	O
in	O
these	O
patietns	O
with	O
lbael	O
-	O
restricted	O
medcial	O
conidtions	O
.	O

Phamracological	O
modultaion	O
of	O
pian	B-Disease
-	O
related	O
barin	O
actviity	O
during	O
nomral	O
and	O
centarl	O
senistization	O
states	O
in	O
huamns	O
.	O

Abonrmal	O
proecssing	O
of	O
somatosenosry	O
ipnuts	O
in	O
the	O
centarl	O
nervuos	O
sysetm	O
(	O
centarl	O
sensitiztaion	O
)	O
is	O
the	O
mehcanism	O
accounting	O
for	O
the	O
enhacned	O
pian	B-Disease
sesnitivity	O
in	O
the	O
sikn	O
surrounding	O
tsisue	B-Disease
injruy	I-Disease
(	O
secondary	B-Disease
hpyeralgesia	I-Disease
)	O
.	O

Secnodary	B-Disease
hypearlgesia	I-Disease
shares	O
clincial	O
characteritsics	O
with	O
neuorgenic	B-Disease
hyperaglesia	I-Disease
in	O
patietns	O
with	O
neurpoathic	B-Disease
pian	I-Disease
.	O

Abnomral	O
brian	O
repsonses	O
to	O
somatoesnsory	O
stmiuli	O
have	O
been	O
found	O
in	O
patietns	O
with	O
hyperalgseia	B-Disease
as	O
well	O
as	O
in	O
noraml	O
subjetcs	O
during	O
experimnetal	O
centarl	O
sensitziation	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
assess	O
the	O
effcets	O
of	O
gabapnetin	O
,	O
a	O
durg	O
efefctive	O
in	O
neuropatihc	B-Disease
pian	I-Disease
patinets	O
,	O
on	O
brian	O
proecssing	O
of	O
noccieptive	O
inofrmation	O
in	O
noraml	O
and	O
cetnral	O
sensitziation	O
states	O
.	O

Using	O
functinoal	O
magneitc	O
resonnace	O
imgaing	O
(	O
fRMI	O
)	O
in	O
noraml	O
volunteres	O
,	O
we	O
studied	O
the	O
gaabpentin	O
-	O
induecd	O
modulatoin	O
of	O
barin	O
activtiy	O
in	O
respnose	O
to	O
nocicpetive	O
mcehanical	O
stmiulation	O
of	O
noraml	O
sikn	O
and	O
capsaiicn	O
-	O
idnuced	O
secondary	B-Disease
hyperaglesia	I-Disease
.	O

The	O
dsoe	O
of	O
gabapenitn	O
was	O
1	O
,	O
800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
admniistration	O
.	O

We	O
found	O
that	O
(	O
i	O
)	O
gbaapentin	O
reudced	O
the	O
actiavtions	O
in	O
the	O
biltaeral	O
opercluoinsular	O
coretx	O
,	O
independently	O
of	O
the	O
preesnce	O
of	O
cnetral	O
sensitiztaion	O
;	O
(	O
ii	O
)	O
gabapnetin	O
reudced	O
the	O
acitvation	O
in	O
the	O
brianstem	O
,	O
only	O
during	O
cetnral	O
sensitiztaion	O
;	O
(	O
iii	O
)	O
gbaapentin	O
suppresesd	O
stmiulus	O
-	O
idnuced	O
decativations	O
,	O
only	O
during	O
cenrtal	O
snesitization	O
;	O
this	O
effect	O
was	O
more	O
rboust	O
than	O
the	O
efefct	O
on	O
barin	O
atcivation	O
.	O

The	O
observed	O
durg	O
-	O
idnuced	O
effetcs	O
were	O
not	O
due	O
to	O
chagnes	O
in	O
the	O
baesline	O
fRMI	O
singal	O
.	O

These	O
fnidings	O
indicate	O
that	O
gaabpentin	O
has	O
a	O
measurbale	O
antionciceptive	O
effect	O
and	O
a	O
stornger	O
atnihyperalgesic	O
effcet	O
most	O
evident	O
in	O
the	O
brian	O
areas	O
undergoing	O
daectivation	O
,	O
thus	O
supporting	O
the	O
cocnept	O
that	O
gbaapentin	O
is	O
more	O
effcetive	O
in	O
modulaitng	O
nociecptive	O
transmissoin	O
when	O
cetnral	O
sensitiztaion	O
is	O
present	O
.	O

Ivnestigation	O
of	O
mitochnodrial	O
ivnolvement	O
in	O
the	O
experimnetal	O
moedl	O
of	O
epilpesy	B-Disease
idnuced	O
by	O
pilocrapine	O
.	O

Mitochondiral	B-Disease
abnormlaities	I-Disease
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptgoenesis	O
,	O
such	O
as	O
eenrgy	O
generatoin	O
,	O
conrtol	O
of	O
clel	O
detah	B-Disease
,	O
neuortransmitter	O
synhtesis	O
,	O
and	O
free	O
radcial	O
(	O
FR	O
)	O
produtcion	O
.	O

Incresaed	O
prodcution	O
of	O
FRs	O
may	O
cause	O
mDtNA	O
dmaage	O
leading	O
to	O
decresaed	O
activiteis	O
of	O
oxidtaive	O
phosphorylatoin	O
compelxes	O
containing	O
mDtNA	O
-	O
encdoed	O
subuints	O
.	O

In	O
this	O
stduy	O
,	O
we	O
ivnestigated	O
whether	O
inrceased	O
geneartion	O
of	O
FR	O
during	O
stauts	B-Disease
epielpticus	I-Disease
would	O
be	O
sufficient	O
to	O
provoke	O
abnormailties	O
in	O
mDtNA	O
and	O
in	O
the	O
exprsesion	O
and	O
acitvity	O
of	O
cytcohrome	O
c	O
oxdiase	O
(	O
CCO	O
)	O
,	O
copmlex	O
IV	O
of	O
the	O
respiartory	O
cahin	O
,	O
in	O
the	O
chornic	O
phsae	O
of	O
the	O
pilocrapine	O
mdoel	O
of	O
tepmoral	B-Disease
lboe	I-Disease
epilpesy	I-Disease
.	O

DNA	O
anlaysis	O
rveealed	O
low	O
amounts	O
of	O
a	O
4	O
.	O
8	O
kb	O
mtNDA	O
delteion	O
but	O
with	O
no	O
differneces	O
in	O
freqeuncy	O
or	O
quanttiy	O
in	O
the	O
contorl	O
and	O
epxerimental	O
gropus	O
.	O

We	O
did	O
not	O
find	O
abnomralities	O
in	O
the	O
exprsesion	O
and	O
distriubtion	O
of	O
an	O
mDtNA	O
-	O
encoedd	O
suubnit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	O
dcerease	O
in	O
CCO	O
-	O
I	O
when	O
compraed	O
with	O
nucelar	O
-	O
ecnoded	O
sbuunits	O
(	O
CCO	O
-	O
IV	O
and	O
SDH	O
-	O
fp	O
)	O
.	O

No	O
abonrmality	O
in	O
CCO	O
acitvity	O
was	O
observed	O
through	O
histocehmistry	O
.	O

Although	O
evidneces	O
of	O
mtiochondrial	B-Disease
abnormlaities	I-Disease
were	O
found	O
in	O
previously	O
pubilshed	O
stduies	O
,	O
our	O
resluts	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
aucte	O
pahse	O
,	O
determined	O
important	O
anbormalities	O
in	O
mtNDA	O
,	O
in	O
epxression	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
actviity	O
.	O

Advrese	O
effect	O
of	O
the	O
caclium	O
chnanel	O
bolcker	O
nitrednipine	O
on	O
nephrsoclerosis	B-Disease
in	O
rtas	O
with	O
renovacsular	B-Disease
hypertensoin	I-Disease
.	O

The	O
effect	O
of	O
a	O
6	O
-	O
week	O
traetment	O
with	O
the	O
clacium	O
cahnnel	O
blocekr	O
nitrnedipine	O
or	O
the	O
agniotensin	O
converting	O
eznyme	O
inihbitor	O
enalarpil	O
on	O
blood	O
pressrue	O
,	O
alubminuria	B-Disease
,	O
rneal	O
hemodyanmics	O
,	O
and	O
morhpology	O
of	O
the	O
noncilpped	O
kdiney	O
was	O
studied	O
in	O
rtas	O
with	O
two	O
-	O
kdiney	O
,	O
one	O
cilp	O
renovascluar	B-Disease
hypertesnion	I-Disease
.	O

Six	O
wekes	O
after	O
clpiping	O
of	O
one	O
rneal	O
aretry	O
,	O
hypertenisve	B-Disease
rtas	O
(	O
178	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
gropus	O
:	O
unterated	O
hypretensive	B-Disease
conrtols	O
(	O
n	O
=	O
8	O
)	O
,	O
enalparil	O
-	O
tretaed	O
(	O
n	O
=	O
8	O
)	O
,	O
or	O
nitrendipnie	O
-	O
traeted	O
(	O
n	O
=	O
10	O
)	O
.	O

Sahm	O
-	O
operaetd	O
rtas	O
served	O
as	O
normtoensive	O
cnotrols	O
(	O
128	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
n	O
=	O
8	O
)	O
.	O

After	O
6	O
weeks	O
of	O
treatmnet	O
,	O
rneal	O
hemodyanmics	O
(	O
glomerualr	O
filtartion	O
rtae	O
and	O
reanl	O
palsma	O
folw	O
)	O
were	O
meausred	O
in	O
the	O
ansethetized	O
rtas	O
.	O

Rneal	O
tisuse	O
was	O
obtained	O
for	O
determinaiton	O
of	O
glomerualr	O
szie	O
and	O
scleorsis	O
.	O

Enalapirl	O
but	O
not	O
nitrnedipine	O
redcued	O
blood	O
perssure	O
significantly	O
.	O

After	O
6	O
wekes	O
of	O
therpay	O
,	O
glomerualr	O
filrtation	O
rtae	O
was	O
not	O
different	O
among	O
the	O
studied	O
gruops	O
.	O

Rneal	O
plamsa	O
folw	O
increaesd	O
,	O
but	O
albuimn	O
ecxretion	O
and	O
golmerulosclerosis	B-Disease
did	O
not	O
change	O
after	O
enaalpril	O
treatemnt	O
.	O

In	O
contrast	O
,	O
in	O
the	O
nitrendipnie	O
-	O
treaetd	O
gruop	O
albuimnuria	B-Disease
incresaed	O
from	O
12	O
.	O
8	O
+	O
/	O
-	O
2	O
progressively	O
to	O
163	O
+	O
/	O
-	O
55	O
compaerd	O
with	O
19	O
.	O
2	O
+	O
/	O
-	O
9	O
mg	O
/	O
24	O
hr	O
in	O
the	O
hypertesnive	B-Disease
cotnrols	O
.	O

Furthermore	O
,	O
gloemrulosclerosis	B-Disease
index	O
was	O
significantly	O
increaesd	O
in	O
the	O
niterndipine	O
-	O
tretaed	O
gruop	O
compaerd	O
with	O
the	O
hyperetnsive	B-Disease
cotnrols	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
1	O
versus	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O

In	O
addition	O
,	O
glomeurlar	O
szie	O
was	O
hihger	O
in	O
the	O
nirtendipine	O
-	O
treaetd	O
gruop	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
but	O
lwoer	O
in	O
the	O
enalarpil	O
-	O
traeted	O
gruop	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
15	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
compraed	O
with	O
the	O
hypetrensive	B-Disease
conrtols	O
(	O
12	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
.	O
(	O
ABSTRACT	O
TURNCATED	O
AT	O
250	O
WORDS	O
)	O

Ketcoonazole	O
induecd	O
torasdes	B-Disease
de	I-Disease
piontes	I-Disease
without	O
concomitnat	O
use	O
of	O
QT	O
intreval	O
-	O
proolnging	O
durg	O
.	O

Ketcoonazole	O
is	O
not	O
known	O
to	O
be	O
proarrhythimc	O
without	O
concomitnat	O
use	O
of	O
QT	O
itnerval	O
-	O
proolnging	O
drgus	O
.	O

We	O
reprot	O
a	O
woamn	O
with	O
coronray	B-Disease
artrey	I-Disease
dsiease	I-Disease
who	O
developed	O
a	O
markedly	O
prloonged	B-Disease
QT	I-Disease
intevral	I-Disease
and	O
tosrades	B-Disease
de	I-Disease
poitnes	I-Disease
(	O
TdP	B-Disease
)	O
after	O
taking	O
keotconazole	O
for	O
treatemnt	O
of	O
fugnal	B-Disease
infcetion	I-Disease
.	O

Her	O
QT	O
intevral	O
returned	O
to	O
nromal	O
upon	O
withdarwal	O
of	O
ketoconaozle	O
.	O

Gneetic	O
stduy	O
did	O
not	O
find	O
any	O
mutatoin	O
in	O
her	O
gnees	O
that	O
encode	O
caridac	O
IKr	O
channel	O
proetins	O
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocikng	O
atcion	O
on	O
IKr	O
,	O
ketoconzaole	O
alone	O
may	O
prolong	O
QT	O
intevral	O
and	O
indcue	O
TdP	B-Disease
.	O

This	O
calls	O
for	O
attentoin	O
when	O
ketoconzaole	O
is	O
admniistered	O
to	O
patietns	O
with	O
rsik	O
factros	O
for	O
acquired	O
long	B-Disease
QT	I-Disease
syndrmoe	I-Disease
.	O

Cerebarl	B-Disease
vascuiltis	I-Disease
following	O
oarl	O
methyplhenidate	O
inatke	O
in	O
an	O
adlut	O
:	O
a	O
csae	O
reoprt	O
.	O

Methylhpenidate	O
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetaimne	O
.	O

Creebral	B-Disease
vsaculitis	I-Disease
associated	O
with	O
ampheatmine	B-Disease
absue	I-Disease
is	O
well	O
documenetd	O
,	O
and	O
in	O
rrae	O
caess	O
icshaemic	B-Disease
strkoe	I-Disease
has	O
been	O
reported	O
after	O
methylphendiate	O
intkae	O
in	O
childern	O
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
63	O
-	O
yaer	O
-	O
old	O
feamle	O
who	O
was	O
traeted	O
with	O
methylphendiate	O
due	O
to	O
hypercativity	B-Disease
and	O
suffered	O
from	O
mlutiple	O
icshaemic	B-Disease
strkoes	I-Disease
.	O

We	O
consider	O
durg	O
-	O
induecd	O
cerberal	B-Disease
vacsulitis	I-Disease
as	O
the	O
most	O
likely	O
cause	O
of	O
recrurent	O
ishcaemic	B-Disease
srtokes	I-Disease
in	O
the	O
absnece	O
of	O
any	O
patohlogical	O
fnidings	O
during	O
the	O
diangostic	O
work	O
-	O
up	O
.	O

We	O
conclude	O
that	O
methylphenidtae	O
mediated	O
vascuiltis	B-Disease
should	O
be	O
considered	O
in	O
paitents	O
with	O
neurolgoical	O
sympotms	O
and	O
a	O
hitsory	O
of	O
methylpehnidate	O
therpay	O
.	O

This	O
potetnial	O
side	O
-	O
efefct	O
,	O
though	O
very	O
rrae	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restrictvie	O
in	O
the	O
use	O
of	O
methylphendiate	O
.	O

MMDA	O
poldyrug	O
uesrs	O
show	O
porcess	O
-	O
specific	O
cetnral	O
executvie	O
imapirments	O
coupled	O
with	O
impaierd	B-Disease
soical	I-Disease
and	I-Disease
emoitonal	I-Disease
jdugement	I-Disease
porcesses	I-Disease
.	O

In	O
recent	O
yaers	O
wokring	O
memroy	B-Disease
defiicts	I-Disease
have	O
been	O
reported	O
in	O
uesrs	O
of	O
MMDA	O
(	O
3	O
,	O
4	O
-	O
methylenedioxymethapmhetamine	O
,	O
ecstsay	O
)	O
.	O

The	O
current	O
stduy	O
aimed	O
to	O
assess	O
the	O
ipmact	O
of	O
MMDA	O
use	O
on	O
three	O
separate	O
cenrtal	O
execuitve	O
procesess	O
(	O
set	O
shifting	O
,	O
inhiibtion	O
and	O
memroy	O
updating	O
)	O
and	O
also	O
on	O
"	O
prefrotnal	O
"	O
mediated	O
soical	O
and	O
emotioanl	O
judgmeent	O
procseses	O
.	O

Fifteen	O
poyldrug	O
ecstsay	O
uesrs	O
and	O
15	O
polyrdug	O
non	O
-	O
ecsatsy	O
uesr	O
cotnrols	O
completed	O
a	O
general	O
durg	O
use	O
questionnarie	O
,	O
the	O
Brixotn	O
Spaital	O
Anticpiation	O
tsak	O
(	O
set	O
shifting	O
)	O
,	O
Bakcward	O
Diigt	O
Sapn	O
procdeure	O
(	O
mmeory	O
updating	O
)	O
,	O
Inhibitoin	O
of	O
Rteurn	O
(	O
inhiibtion	O
)	O
,	O
an	O
emtoional	O
intellignece	O
scale	O
,	O
the	O
Trosmo	O
Soical	O
Intelligecne	O
Sclae	O
and	O
the	O
Dysexectuive	O
Qusetionnaire	O
(	O
DEX	O
)	O
.	O

Cmopared	O
with	O
MMDA	O
-	O
free	O
ploydrug	O
contrlos	O
,	O
MMDA	O
poyldrug	O
usres	O
showed	O
impairmnets	O
in	O
set	O
shifting	O
and	O
mmeory	O
updating	O
,	O
and	O
also	O
in	O
scoial	O
and	O
emotoinal	O
jugdement	O
procseses	O
.	O

The	O
latter	O
two	O
defciits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
durg	O
use	O
.	O

These	O
dtaa	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cogntiive	O
processes	O
mediated	O
by	O
the	O
prferontal	O
cotrex	O
may	O
be	O
imapired	O
by	O
rerceational	O
ecsatsy	O
use	O
.	O

Phsae	O
II	O
sutdy	O
of	O
the	O
amsarcine	O
anaolgue	O
CI	O
-	O
921	O
(	O
NSC	O
343499	O
)	O
in	O
non	B-Disease
-	I-Disease
small	I-Disease
clel	I-Disease
lnug	I-Disease
canecr	I-Disease
.	O

CI	O
-	O
921	O
(	O
NSC	O
343499	O
;	O
9	O
-	O
[	O
[	O
2	O
-	O
methxoy	O
-	O
4	O
-	O
[	O
(	O
methylsluphonyl	O
)	O
aimno	O
]	O
pehnyl	O
]	O
aimno	O
]	O
-	O
N	O
,	O
5	O
-	O
dimetyhl	O
-	O
4	O
-	O
arcidinecarboxamide	O
)	O
is	O
a	O
topoisoemrase	O
II	O
pioson	O
with	O
high	O
expeirmental	O
anittumour	O
acitvity	O
.	O

It	O
was	O
admniistered	O
by	O
15	O
min	O
infsuion	O
to	O
16	O
evalubale	O
patietns	O
with	O
non	B-Disease
-	I-Disease
small	I-Disease
clel	I-Disease
lnug	I-Disease
cacner	I-Disease
(	O
NSLCC	B-Disease
)	O
(	O
7	O
with	O
no	O
prior	O
traetment	O
,	O
9	O
pateints	O
in	O
realpse	O
following	O
sugrery	O
/	O
radoitherapy	O
)	O
at	O
a	O
dsoe	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
dyas	O
,	O
rpeeated	O
every	O
3	O
wekes	O
)	O
determined	O
by	O
phsae	O
I	O
tiral	O
.	O

Pateints	O
had	O
a	O
meidan	O
perforamnce	O
stauts	O
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
meidan	O
age	O
of	O
61	O
yaers	O
.	O

The	O
histloogy	O
comprised	O
squaomus	B-Disease
carcnioma	I-Disease
(	O
11	O
)	O
,	O
adeoncarcinoma	B-Disease
(	O
1	O
)	O
,	O
mixed	O
histoolgy	O
(	O
2	O
)	O
,	O
bronchio	B-Disease
-	I-Disease
alveloar	I-Disease
cacrinoma	I-Disease
(	O
1	O
)	O
and	O
large	O
clel	O
undfiferentiated	B-Disease
carcinmoa	I-Disease
(	O
1	O
)	O
.	O

Neutrpoenia	B-Disease
grdae	O
greater	O
than	O
or	O
eqaul	O
to	O
3	O
was	O
seen	O
in	O
15	O
paitents	O
,	O
inefctions	B-Disease
with	O
reocvery	O
in	O
3	O
,	O
and	O
grand	O
mal	O
seziures	B-Disease
in	O
1	O
patinet	O
.	O

Garde	O
less	O
than	O
or	O
euqal	O
to	O
2	O
nauesa	B-Disease
and	O
vomitnig	B-Disease
occurred	O
in	O
66	O
%	O
cuorses	O
and	O
phlebiits	B-Disease
in	O
the	O
infusoin	O
arm	O
in	O
37	O
%	O
.	O

1	O
paitent	O
with	O
suqamous	B-Disease
clel	I-Disease
carcionma	I-Disease
achieved	O
a	O
parital	O
resposne	O
lasting	O
5	O
mnoths	O
.	O

Further	O
tesitng	O
in	O
this	O
and	O
other	O
tumuor	B-Disease
types	O
using	O
multpile	O
daliy	O
schdeules	O
is	O
warranted	O
.	O

Pharmacokientics	O
of	O
desipraimne	O
HCl	O
when	O
administeerd	O
with	O
ciancalcet	O
HCl	O
.	O

OJBECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinaclacet	O
is	O
a	O
strong	O
inhbiitor	O
of	O
cytohcrome	O
P540	O
iosenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O

The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
evalutae	O
the	O
effcet	O
of	O
cinacaclet	O
on	O
CYPD26	O
activtiy	O
,	O
using	O
desipraimne	O
as	O
a	O
prboe	O
susbtrate	O
,	O
in	O
haelthy	O
subjcets	O
.	O

METHODS	O
:	O
Seventeen	O
subejcts	O
who	O
were	O
gentoyped	O
as	O
CPY2D6	O
extesnive	O
metaboliezrs	O
were	O
enrolled	O
in	O
this	O
randmoized	O
,	O
open	O
-	O
laebl	O
,	O
crossoevr	O
sutdy	O
to	O
receive	O
a	O
single	O
oarl	O
dsoe	O
of	O
desipraimne	O
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occaisons	O
,	O
once	O
alone	O
and	O
once	O
after	O
mutliple	O
doess	O
of	O
cincaalcet	O
(	O
90	O
mg	O
for	O
7	O
dyas	O
)	O
.	O

Bolod	O
samlpes	O
were	O
obtained	O
prdeose	O
and	O
up	O
to	O
72	O
h	O
postdsoe	O
.	O

RESUTLS	O
:	O
Fourteen	O
subjetcs	O
completed	O
both	O
treatemnt	O
arms	O
.	O

Realtive	O
to	O
despiramine	O
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
desirpamine	O
incraesed	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadministeerd	O
with	O
cniacalcet	O
.	O

The	O
t	O
(	O
1	O
/	O
2	O
,	O
z	O
)	O
of	O
dseipramine	O
was	O
longer	O
when	O
desiprmaine	O
was	O
coadministreed	O
with	O
cniacalcet	O
(	O
21	O
.	O
0	O
versus	O
43	O
.	O
3	O
hs	O
)	O
.	O

The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regmiens	O
.	O

Fewer	O
subjetcs	O
reported	O
avderse	O
evnets	O
following	O
treatemnt	O
with	O
desiprmaine	O
alone	O
than	O
when	O
receiving	O
deispramine	O
with	O
cincaalcet	O
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
freuqent	O
of	O
which	O
(	O
nasuea	B-Disease
and	O
heaadche	B-Disease
)	O
have	O
been	O
reported	O
for	O
patietns	O
terated	O
with	O
either	O
desiprmaine	O
or	O
cincaalcet	O
.	O

CONCLUISON	O
:	O
This	O
sutdy	O
demonstrates	O
that	O
cinacalect	O
is	O
a	O
strong	O
inhibtior	O
of	O
CYPD26	O
.	O

These	O
dtaa	O
suggest	O
that	O
during	O
concomiatnt	O
tretament	O
with	O
cinacalect	O
,	O
dsoe	O
adjustmnet	O
may	O
be	O
necessary	O
for	O
durgs	O
that	O
demonstrate	O
a	O
narrow	O
tehrapeutic	O
index	O
and	O
are	O
metaboliezd	O
by	O
CY2PD6	O
.	O

Csae	O
reoprt	O
:	O
aucte	O
unintentoinal	O
carbahcol	O
intoixcation	O
.	O

INTRODUCTION	O
:	O
Intoxictaions	O
with	O
carabchol	O
,	O
a	O
musacrinic	O
cholinerigc	O
recetpor	O
agnoist	O
are	O
rrae	O
.	O

We	O
rpeort	O
an	O
interesting	O
csae	O
investigtaing	O
a	O
(	O
near	O
)	O
faatl	O
poiosning	B-Disease
.	O

METHODS	O
:	O
The	O
son	O
of	O
an	O
84	O
-	O
yaer	O
-	O
old	O
mlae	O
discovered	O
a	O
nwespaper	O
reoprt	O
stating	O
cliincal	O
sucecss	O
with	O
palnt	O
etxracts	O
in	O
Alzheiemr	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
.	O

The	O
mdoe	O
of	O
atcion	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
syntehtic	O
comopund	O
'	O
carbamylchoiln	O
'	O
;	O
that	O
is	O
,	O
cabrachol	O
.	O

He	O
bought	O
25	O
g	O
of	O
carabchol	O
as	O
pure	O
sbustance	O
in	O
a	O
phramacy	O
,	O
and	O
the	O
fahter	O
was	O
administreed	O
400	O
to	O
500	O
mg	O
.	O

Carabchol	O
concnetrations	O
in	O
sreum	O
and	O
uirne	O
on	O
day	O
1	O
and	O
2	O
of	O
hosptial	O
admissoin	O
were	O
analyesd	O
by	O
HLPC	O
-	O
msas	O
spectromtery	O
.	O

RESLUTS	O
:	O
Mintues	O
after	O
oarl	O
admiinstration	O
,	O
the	O
pateint	O
developed	O
nasuea	B-Disease
,	O
swaeting	O
and	O
hpyotension	B-Disease
,	O
and	O
finally	O
collasped	O
.	O

Bradycadria	B-Disease
,	O
cholinregic	O
smyptoms	O
and	O
asystloe	B-Disease
occurred	O
.	O

Initial	O
cardiopulmnoary	O
resuscitatoin	O
and	O
immedaite	O
treatmnet	O
with	O
ardenaline	O
(	O
epniephrine	O
)	O
,	O
atropnie	O
and	O
furosemdie	O
was	O
successful	O
.	O

On	O
hospiatl	O
amdission	O
,	O
bolod	O
presusre	O
of	O
the	O
inutbated	O
,	O
brdayarrhythmic	O
pateint	O
was	O
100	O
/	O
65	O
mmHg	O
.	O

Further	O
sgins	O
were	O
hyperhdirosis	B-Disease
,	O
hypersalivaiton	B-Disease
,	O
bronchrorhoea	B-Disease
,	O
and	O
seevre	O
moisis	B-Disease
;	O
the	O
electrocardiograpihc	O
fniding	O
was	O
atrio	B-Disease
-	I-Disease
ventricluar	I-Disease
dissociation	I-Disease
.	O

High	O
dsoes	O
of	O
atropnie	O
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrnealine	O
and	O
dpoamine	O
were	O
necessary	O
.	O

The	O
paitent	O
was	O
etxubated	O
1	O
week	O
later	O
.	O

However	O
,	O
incerased	O
dsypnoea	B-Disease
and	O
bronchsopasm	B-Disease
necessitated	O
renitubation	O
.	O

Respiraotry	B-Disease
insufficiecny	I-Disease
was	O
further	O
woresned	O
by	O
Prtoeus	B-Disease
mirabilis	I-Disease
infeciton	I-Disease
and	O
seevre	O
bronchcoonstriction	O
.	O

One	O
week	O
later	O
,	O
the	O
pateint	O
was	O
again	O
etxubated	O
and	O
3	O
dyas	O
later	O
was	O
trnasferred	O
to	O
a	O
perihperal	O
wrad	O
.	O

On	O
the	O
next	O
day	O
he	O
deid	O
,	O
probably	O
as	O
a	O
result	O
of	O
herat	B-Disease
faliure	I-Disease
.	O

Seurm	O
samlpes	O
from	O
the	O
first	O
and	O
second	O
dyas	O
contained	O
3	O
.	O
6	O
and	O
1	O
.	O
9	O
mg	O
/	O
l	O
carabchol	O
,	O
respectively	O
.	O

The	O
corresponding	O
uirne	O
concentratinos	O
amounted	O
to	O
374	O
and	O
554	O
mg	O
/	O
l	O
.	O

CONCLUSOIN	O
:	O
This	O
csae	O
started	O
with	O
a	O
mdeia	O
reoprt	O
in	O
a	O
popular	O
newspaepr	O
,	O
initiated	O
by	O
pbulished	O
,	O
peer	O
-	O
rveiewed	O
reesarch	O
on	O
hebrals	O
,	O
and	O
involved	O
hmuan	O
failrue	O
in	O
a	O
csae	O
hitsory	O
,	O
mdeical	O
examintaion	O
and	O
cilnical	O
treamtent	O
.	O

For	O
the	O
first	O
tmie	O
,	O
an	O
analtyical	O
mtehod	O
for	O
the	O
detremination	O
of	O
crabachol	O
in	O
plamsa	O
and	O
urnie	O
has	O
been	O
developed	O
.	O

The	O
analsyed	O
carbacohl	O
concentartion	O
exceeded	O
the	O
supposed	O
seurm	O
lveel	O
resulting	O
from	O
a	O
therapeuitc	O
dsoe	O
by	O
a	O
facotr	O
of	O
130	O
to	O
260	O
.	O

Especially	O
in	O
old	O
pateints	O
,	O
intnesivists	O
should	O
consider	O
intoxicatinos	O
(	O
with	O
chloinergics	O
)	O
as	O
a	O
cause	O
of	O
aucte	B-Disease
caridovascular	I-Disease
faliure	I-Disease
.	O

Pharmaoclogical	O
evidnece	O
for	O
the	O
potentail	O
of	O
Dauucs	O
craota	O
in	O
the	O
mnaagement	O
of	O
congitive	B-Disease
dysfunctinos	I-Disease
.	O

The	O
present	O
sutdy	O
was	O
aimed	O
at	O
ivnestigating	O
the	O
effcets	O
of	O
Duacus	O
craota	O
seeds	O
on	O
cogntiive	O
funcitons	O
,	O
total	O
seurm	O
chloesterol	O
leevls	O
and	O
brian	O
cholinesetrase	O
actiivty	O
in	O
mcie	O
.	O

The	O
ethaonlic	O
etxract	O
of	O
Dacuus	O
caorta	O
sedes	O
(	O
DCE	O
)	O
was	O
adminitsered	O
orally	O
in	O
three	O
doess	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
dyas	O
to	O
different	O
gropus	O
of	O
yuong	O
and	O
aegd	O
mcie	O
.	O

Elveated	O
plus	O
mzae	O
and	O
psasive	O
avoidnace	O
apapratus	O
served	O
as	O
the	O
exteroceptvie	O
bheavioral	O
moedls	O
for	O
tesitng	O
meomry	O
.	O

Diaezpam	O
-	O
,	O
scopolmaine	O
-	O
and	O
agieng	O
-	O
idnuced	O
amnseia	B-Disease
served	O
as	O
the	O
interoecptive	O
beahvioral	O
moedls	O
.	O

DCE	O
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
showed	O
significant	O
improveemnt	O
in	O
meomry	O
scroes	O
of	O
yonug	O
and	O
aegd	O
mcie	O
.	O

The	O
extent	O
of	O
mmeory	O
imrpovement	O
eovked	O
by	O
DCE	O
was	O
23	O
%	O
at	O
the	O
dsoe	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dsoe	O
of	O
400	O
mg	O
/	O
kg	O
in	O
yonug	O
mcie	O
using	O
elevtaed	O
plus	O
mzae	O
.	O

Similarly	O
,	O
significant	O
imprvoements	O
in	O
mmeory	O
scroes	O
were	O
observed	O
using	O
pasisve	O
avoidacne	O
apapratus	O
and	O
aegd	O
mcie	O
.	O

Furthermore	O
,	O
DCE	O
reevrsed	O
the	O
amneisa	B-Disease
idnuced	O
by	O
scopolmaine	O
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
daizepam	O
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Dacuus	O
cartoa	O
extarct	O
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
reduecd	O
significantly	O
the	O
barin	O
acetylcholinseterase	O
acitvity	O
and	O
chloesterol	O
leevls	O
in	O
yonug	O
and	O
aegd	O
mcie	O
.	O

The	O
extent	O
of	O
inhiibtion	O
of	O
barin	O
cohlinesterase	O
atcivity	O
evkoed	O
by	O
DCE	O
at	O
the	O
dsoe	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
yonug	O
and	O
19	O
%	O
in	O
aegd	O
mcie	O
.	O

There	O
was	O
a	O
remarkable	O
rdeuction	O
in	O
total	O
cholesetrol	O
lveel	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
yuong	O
and	O
21	O
%	O
in	O
aegd	O
anmials	O
with	O
this	O
dsoe	O
of	O
DCE	O
.	O

Therefore	O
,	O
DCE	O
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
managmeent	O
of	O
cognitvie	B-Disease
dysfunctoins	I-Disease
on	O
account	O
of	O
its	O
multiafrious	O
beneficial	O
effects	O
such	O
as	O
,	O
meomry	O
improivng	O
property	O
,	O
chloesterol	O
loewring	O
property	O
and	O
anticholniesterase	O
actiivty	O
.	O

Vaplroic	O
aicd	O
inudced	O
encephalpoathy	B-Disease
-	O
-	O
19	O
new	O
caess	O
in	O
Germnay	O
from	O
1994	O
to	O
2003	O
-	O
-	O
a	O
side	O
effect	O
associated	O
to	O
VPA	O
-	O
threapy	O
not	O
only	O
in	O
yonug	O
childern	O
.	O

Valporic	O
aicd	O
(	O
VPA	O
)	O
is	O
a	O
broad	O
-	O
specturm	O
antiepilepitc	O
durg	O
and	O
is	O
usually	O
well	O
-	O
tolearted	O
.	O

Rrae	O
serious	O
complicatinos	O
may	O
occur	O
in	O
some	O
patinets	O
,	O
including	O
haemorhragic	O
pnacreatitis	B-Disease
,	O
bnoe	B-Disease
marorw	I-Disease
suppresison	I-Disease
,	O
VPA	O
-	O
indcued	O
hepatotxoicity	B-Disease
and	O
VPA	O
-	O
idnuced	O
encpehalopathy	B-Disease
.	O

The	O
typical	O
sings	O
of	O
VPA	O
-	O
indcued	O
encehpalopathy	B-Disease
are	O
ipmaired	B-Disease
cosnciousness	I-Disease
,	O
sometimes	O
marked	O
EEG	O
background	O
slwoing	O
,	O
incresaed	O
seziure	B-Disease
ferquency	O
,	O
with	O
or	O
without	O
hyperammoneima	B-Disease
.	O

There	O
is	O
still	O
no	O
proof	O
of	O
causaitve	O
efefct	O
of	O
VPA	O
in	O
patietns	O
with	O
encephaloptahy	B-Disease
,	O
but	O
only	O
of	O
an	O
assocaition	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O

We	O
reprot	O
19	O
paitents	O
with	O
VPA	O
-	O
associated	O
encehpalopathy	B-Disease
in	O
Gemrany	O
from	O
the	O
yaers	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
publsihed	O
previously	O
.	O

Cerberal	B-Disease
haemorhrage	I-Disease
idnuced	O
by	O
warafrin	O
-	O
the	O
infleunce	O
of	O
durg	O
-	O
durg	O
interactoins	O
.	O

PUROPSE	O
:	O
To	O
evlauate	O
the	O
ferquency	O
,	O
seveirty	O
and	O
prveentability	O
of	O
warfairn	O
-	O
inudced	O
cerebarl	B-Disease
haemorrhages	I-Disease
due	O
to	O
warfrain	O
and	O
wrafarin	O
-	O
durg	O
intreactions	O
in	O
pateints	O
lviing	O
in	O
the	O
coutny	O
of	O
Osetrg	O
tland	O
,	O
Sweedn	O
.	O

METHODS	O
:	O
All	O
ptaients	O
with	O
a	O
daignosed	O
cerberal	B-Disease
haemorrahge	I-Disease
at	O
three	O
hospitlas	O
during	O
the	O
peroid	O
2000	O
-	O
2002	O
were	O
identfiied	O
.	O

Meidcal	O
rceords	O
were	O
studied	O
rertospectively	O
to	O
evalaute	O
whether	O
warafrin	O
and	O
warfrain	O
-	O
durg	O
interatcions	O
could	O
have	O
caused	O
the	O
cerebarl	B-Disease
haemorrhage	I-Disease
.	O

The	O
proporiton	O
of	O
possibly	O
avoidalbe	O
csaes	O
due	O
to	O
durg	O
intreactions	O
was	O
estiamted	O
.	O

RSEULTS	O
:	O
Among	O
593	O
pateints	O
with	O
ceerbral	B-Disease
haemorhrage	I-Disease
,	O
59	O
(	O
10	O
%	O
)	O
were	O
assesesd	O
as	O
related	O
to	O
warfrain	O
treamtent	O
.	O

This	O
imply	O
an	O
incidecne	O
of	O
1	O
.	O
7	O
/	O
100	O
,	O
000	O
treatmnet	O
yeras	O
.	O

Of	O
the	O
59	O
csaes	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
faatl	O
outcmoe	O
,	O
compraed	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non	O
-	O
warfrain	O
pateints	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
warfrain	O
-	O
durg	O
interatcion	O
could	O
have	O
contributed	O
to	O
the	O
haemorrhgae	B-Disease
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warfairn	O
ptaients	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
beleding	B-Disease
complictaion	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O

CONCLUISONS	O
:	O
Warfairn	O
-	O
induecd	O
creebral	B-Disease
hameorrhages	I-Disease
are	O
a	O
major	O
cliincal	O
prolbem	O
with	O
a	O
high	O
faatlity	O
rtae	O
.	O

Almost	O
half	O
of	O
the	O
caess	O
was	O
related	O
to	O
a	O
warfrain	O
-	O
durg	O
inetraction	O
.	O

A	O
significant	O
prooprtion	O
of	O
wafrarin	O
-	O
related	O
cerberal	B-Disease
haemorrahges	I-Disease
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
presrcibing	O
drgus	O
known	O
to	O
itneract	O
with	O
warfairn	O
.	O

Antipsychtoic	O
-	O
like	O
prfoile	O
of	O
thiopermaide	O
,	O
a	O
selective	O
H3	O
-	O
reecptor	O
antagnoist	O
in	O
mcie	O
.	O

Experiemntal	O
and	O
cilnical	O
eviednce	O
points	O
to	O
a	O
role	O
of	O
cnetral	O
hitsaminergic	O
ssytem	O
in	O
the	O
pathogneesis	O
of	O
shcizophrenia	B-Disease
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
stduy	O
the	O
effect	O
of	O
hitsamine	O
H	O
(	O
3	O
)	O
-	O
recpetor	O
lignads	O
on	O
nueroleptic	O
-	O
indcued	O
cataelpsy	B-Disease
,	O
apomorhpine	O
-	O
idnuced	O
clibming	O
bheavior	O
and	O
amphetaimne	O
-	O
inudced	O
locoomtor	O
actviities	O
in	O
mcie	O
.	O

Ctaalepsy	B-Disease
was	O
idnuced	O
by	O
haloperdiol	O
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
,	O
while	O
aopmorphine	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
and	O
apmhetamine	O
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climibng	O
bheavior	O
and	O
locomtoor	O
activiteis	O
,	O
respectively	O
.	O

(	O
R	O
)	O
-	O
alhpa	O
-	O
methylhistmaine	O
(	O
RMAH	O
)	O
(	O
5	O
mcirog	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
thiopreamide	O
(	O
THP	O
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
cataelpsy	B-Disease
.	O

Administartion	O
of	O
THP	O
(	O
3	O
.	O
75	O
,	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
1	O
h	O
prior	O
to	O
haloepridol	O
resulted	O
in	O
a	O
dsoe	O
-	O
depenednt	O
inrcease	O
in	O
the	O
ctaalepsy	B-Disease
times	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
pertreatment	O
with	O
RMAH	O
significantly	O
revesred	O
such	O
an	O
effcet	O
of	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

RMAH	O
per	O
se	O
showed	O
significant	O
reduciton	O
in	O
locomtoor	O
tmie	O
,	O
ditsance	O
traveled	O
and	O
avergae	O
seped	O
but	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
per	O
se	O
had	O
no	O
efefct	O
on	O
these	O
paarmeters	O
.	O

On	O
amhpetamine	O
-	O
induecd	O
hyperactivtiy	B-Disease
,	O
THP	O
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduecd	O
locmootor	O
tmie	O
,	O
distacne	O
traveled	O
and	O
aevrage	O
speed	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Pertreatment	O
with	O
RMAH	O
(	O
5	O
mircog	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
could	O
paritally	O
revrese	O
such	O
effcets	O
of	O
THP	O
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Clmibing	O
beahvior	O
induecd	O
by	O
apoomrphine	O
was	O
reduecd	O
in	O
anmials	O
traeted	O
with	O
THP	O
.	O

Such	O
an	O
effcet	O
was	O
,	O
however	O
,	O
reveresd	O
in	O
prseence	O
of	O
RMAH	O
.	O

THP	O
exhibited	O
an	O
antispychotic	O
-	O
like	O
porfile	O
by	O
poetntiating	O
haolperidol	O
-	O
inudced	O
ctaalepsy	B-Disease
,	O
reudcing	O
amhpetamine	O
-	O
idnuced	O
hpyeractivity	B-Disease
and	O
rdeucing	O
apmoorphine	O
-	O
inudced	O
clibming	O
in	O
mcie	O
.	O

Such	O
effects	O
of	O
THP	O
were	O
reveresd	O
by	O
RMAH	O
indicating	O
the	O
ivnolvement	O
of	O
histmaine	O
H	O
(	O
3	O
)	O
-	O
recetpors	O
.	O

Fidnings	O
suggest	O
a	O
potentail	O
for	O
H	O
(	O
3	O
)	O
-	O
recepotr	O
antagonsits	O
in	O
improivng	O
the	O
rerfactory	O
csaes	O
of	O
schizophreina	B-Disease
.	O

Cuada	B-Disease
eqiuna	I-Disease
sydnrome	I-Disease
after	O
epiudral	O
steorid	O
inejction	O
:	O
a	O
csae	O
reoprt	O
.	O

OBJETCIVE	O
:	O
Convetnional	O
treatmnet	O
metohds	O
of	O
lumubsacral	O
radiculopahty	B-Disease
are	O
physcial	O
tehrapy	O
,	O
epiduarl	O
setroid	O
inejctions	O
,	O
oarl	O
mediactions	O
,	O
and	O
sipnal	O
maniuplative	O
tehrapy	O
.	O

Cuada	B-Disease
equnia	I-Disease
synrdome	I-Disease
is	O
a	O
rrae	O
complciation	O
of	O
epdiural	O
anesthseia	O
.	O

The	O
following	O
csae	O
is	O
a	O
rpeort	O
of	O
cadua	B-Disease
euqina	I-Disease
syndorme	I-Disease
possibly	O
caused	O
by	O
epiduarl	O
ijnection	O
of	O
triamcinolnoe	O
and	O
bpuivacaine	O
.	O

CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
low	B-Disease
back	I-Disease
and	I-Disease
rgiht	I-Disease
leg	I-Disease
pian	I-Disease
was	O
schedueld	O
for	O
epiudral	O
steorid	O
ijnection	O
.	O

INETRVENTION	O
AND	O
OTUCOME	O
:	O
An	O
18	O
-	O
guage	O
Tuohy	O
nedele	O
was	O
inserted	O
until	O
lsos	O
of	O
resistnace	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
leevl	O
.	O

Sperad	O
of	O
the	O
contrast	O
meduim	O
within	O
the	O
epiduarl	O
sapce	O
was	O
determined	O
by	O
radigoraphic	O
imgaing	O
.	O

After	O
verifying	O
the	O
epidrual	O
spcae	O
,	O
buipvacaine	O
and	O
trimacinolone	O
diaectate	O
were	O
inejcted	O
.	O

After	O
the	O
ijnection	O
,	O
there	O
was	O
a	O
redcution	O
in	O
rdaicular	O
sympotms	O
.	O

Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perienal	O
nubmness	B-Disease
and	O
lwoer	B-Disease
extreimty	I-Disease
weankess	I-Disease
.	O

The	O
neurolgoic	O
evalaution	O
reevaled	O
lsos	B-Disease
of	I-Disease
senstaion	I-Disease
in	O
the	O
sdadle	O
aera	O
and	O
medail	O
aspect	O
of	O
her	O
rgiht	O
leg	O
.	O

There	O
was	O
a	O
decresae	O
in	O
the	O
percpetion	O
of	O
pipnrick	O
tset	O
.	O

Deep	O
-	O
tnedon	O
refelxes	O
were	O
decreaesd	O
especially	O
in	O
the	O
rgiht	O
leg	O
.	O

She	O
was	O
unable	O
to	O
uirnate	O
.	O

The	O
ptaient	O
'	O
s	O
smyptoms	O
imporved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O

She	O
had	O
a	O
grdaual	O
return	O
of	O
mootr	O
funtcion	O
and	O
ability	O
of	O
feeling	O
Foely	O
ctaheter	O
.	O

All	O
of	O
the	O
symptmos	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O

CNOCLUSION	O
:	O
Complictaions	O
associated	O
with	O
eipdural	O
steorid	O
injecitons	O
are	O
rrae	O
.	O

Clniical	O
examintaion	O
and	O
continued	O
vgiilance	O
for	O
nuerologic	B-Disease
deetrioration	I-Disease
after	O
epiduarl	O
steorid	O
injcetions	O
is	O
important	O
.	O

High	O
-	O
dsoe	O
testostreone	O
is	O
associated	O
with	O
atheroslcerosis	B-Disease
in	O
postemnopausal	O
wmoen	O
.	O

OBJECTIEVS	O
:	O
To	O
sutdy	O
the	O
long	O
-	O
term	O
effetcs	O
of	O
androegn	O
traetment	O
on	O
atherosclreosis	B-Disease
in	O
psotmenopausal	O
wmoen	O
.	O

METHODS	O
:	O
In	O
a	O
populatoin	O
-	O
based	O
stduy	O
in	O
513	O
naturally	O
postmeonpausal	O
woemn	O
aegd	O
54	O
-	O
67	O
yaers	O
,	O
we	O
studied	O
the	O
associaiton	O
between	O
slef	O
-	O
reported	O
intraumscularly	O
amdinistered	O
high	O
-	O
dsoe	O
etsrogen	O
-	O
tetsosterone	O
thearpy	O
(	O
estradoil	O
-	O
and	O
testosetrone	O
etsers	O
)	O
and	O
aoritc	O
atherosclersois	B-Disease
.	O

Aotric	O
atehrosclerosis	B-Disease
was	O
diagnsoed	O
by	O
radiorgaphic	O
detcetion	O
of	O
calciifed	O
depsoits	O
in	O
the	O
abdoimnal	O
aotra	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
initma	O
atehrosclerosis	B-Disease
.	O

Homrone	O
tehrapy	O
usres	O
were	O
comapred	O
with	O
never	O
uesrs	O
.	O

RSEULTS	O
:	O
Intraumscular	O
homrone	O
tehrapy	O
use	O
for	O
1	O
yaer	O
or	O
longer	O
was	O
reported	O
by	O
25	O
woemn	O
.	O

In	O
almost	O
half	O
of	O
these	O
wmoen	O
seevre	O
atheroscelrosis	B-Disease
of	O
the	O
aotra	O
was	O
present	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
in	O
woemn	O
without	O
horomne	O
use	O
sveere	O
atheroslcerosis	B-Disease
of	O
the	O
aotra	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
8	O
.	O
5	O
,	O
adjusted	O
for	O
age	O
,	O
yeras	O
since	O
menoapuse	O
,	O
smkoing	O
,	O
and	O
bdoy	O
msas	O
index	O
)	O
.	O

The	O
asosciation	O
remained	O
after	O
additional	O
adjusmtent	O
for	O
diabeets	B-Disease
,	O
choelsterol	O
leevl	O
,	O
systloic	O
bolod	O
perssure	O
,	O
or	O
alochol	O
use	O
.	O

No	O
associaiton	O
was	O
found	O
for	O
hromone	O
use	O
less	O
than	O
1	O
yaer	O
.	O

CONCLSUION	O
:	O
Our	O
resluts	O
suggest	O
that	O
high	O
-	O
dsoe	O
tesotsterone	O
tehrapy	O
may	O
adversely	O
affect	O
ahterosclerosis	B-Disease
in	O
postmenopasual	O
wmoen	O
and	O
indicate	O
that	O
andrgoen	O
replcaement	O
in	O
these	O
woemn	O
may	O
not	O
be	O
harmless	O
.	O

Optiimsing	O
srtoke	B-Disease
prevnetion	O
in	O
non	O
-	O
valvualr	O
atrail	B-Disease
fibrillaiton	I-Disease
.	O

Artial	B-Disease
firbillation	I-Disease
is	O
associated	O
with	O
substantial	O
morbdiity	O
and	O
mrotality	O
.	O

Pooeld	O
dtaa	O
from	O
trails	O
copmaring	O
antithrobmotic	O
treatemnt	O
with	O
plcaebo	O
have	O
shown	O
that	O
wrafarin	O
rdeuces	O
the	O
rsik	O
of	O
srtoke	B-Disease
by	O
62	O
%	O
,	O
and	O
that	O
apsirin	O
alone	O
rdeuces	O
the	O
rsik	O
by	O
22	O
%	O
.	O

Overall	O
,	O
in	O
high	O
-	O
rsik	O
paitents	O
,	O
warafrin	O
is	O
superior	O
to	O
asiprin	O
in	O
preventing	O
srtokes	B-Disease
,	O
with	O
a	O
relative	O
rsik	O
reduciton	O
of	O
36	O
%	O
.	O

Ximelagartan	O
,	O
an	O
oarl	O
direct	O
thormbin	O
ihnibitor	O
,	O
was	O
found	O
to	O
be	O
as	O
effiicent	O
as	O
vitaimn	O
K	O
atnagonist	O
durgs	O
in	O
the	O
prevetnion	O
of	O
ebmolic	B-Disease
evetns	I-Disease
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
anbormal	B-Disease
lievr	I-Disease
funciton	I-Disease
tetss	O
.	O

The	O
ACTVIE	O
-	O
W	O
(	O
Artial	B-Disease
Firbillation	I-Disease
Clopidgorel	O
Trail	O
with	O
Irbeasrtan	O
for	O
Pervention	O
of	O
Vascualr	O
Eevnts	O
)	O
stduy	O
has	O
demonstrated	O
that	O
wrafarin	O
is	O
superior	O
to	O
plaetlet	O
threapy	O
(	O
colpidogrel	O
plus	O
aspriin	O
)	O
in	O
the	O
preevntion	O
af	O
embloic	B-Disease
eevnts	I-Disease
.	O

Idarparinux	O
,	O
a	O
Fcator	O
Xa	O
inhbiitor	O
,	O
is	O
being	O
evlauated	O
in	O
paitents	O
with	O
atrail	B-Disease
fibrilaltion	I-Disease
.	O

Angiotesnin	O
-	O
converting	O
enzmye	O
ihnibitors	O
and	O
angiotesnin	O
II	O
recetpor	O
-	O
bolcking	O
drgus	O
hold	O
promise	O
in	O
atrail	B-Disease
fibrillaiton	I-Disease
through	O
caridac	B-Disease
remodelilng	I-Disease
.	O

Preliminary	O
sutdies	O
suggest	O
that	O
statnis	O
could	O
interfere	O
with	O
the	O
rsik	O
of	O
recurrnece	O
after	O
elecrtical	O
cardoiversion	O
.	O

Finally	O
,	O
percutanoeus	O
methdos	O
for	O
the	O
excluison	O
of	O
lfet	O
artial	O
appenadge	O
are	O
under	O
investigatoin	O
in	O
high	O
-	O
rsik	O
paitents	O
.	O

Atni	O
-	O
oxidnat	O
effcets	O
of	O
atorvastaitn	O
in	O
dexaemthasone	O
-	O
induecd	O
hypertensoin	B-Disease
in	O
the	O
rat	O
.	O

1	O
.	O

Deaxmethasone	O
(	O
Dex	O
)	O
-	O
indcued	O
hypertenison	B-Disease
is	O
charatcerized	O
by	O
endohtelial	O
dysufnction	O
associated	O
with	O
ntiric	O
oixde	O
(	O
NO	O
)	O
dfeiciency	O
and	O
incresaed	O
spueroxide	O
(	O
O2	O
-	O
)	O
productoin	O
.	O

Atrovastatin	O
(	O
Ato	O
)	O
possesses	O
plieotropic	O
prpoerties	O
that	O
have	O
been	O
reported	O
to	O
imporve	O
endotehlial	O
funtcion	O
through	O
icnreased	O
aavilability	O
of	O
NO	O
and	O
rdeuced	O
O2	O
-	O
proudction	O
in	O
various	O
forms	O
of	O
hypertenison	B-Disease
.	O

In	O
the	O
present	O
sutdy	O
,	O
we	O
invesitgated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
,	O
p	O
.	O
o	O
.	O
,	O
Ato	O
could	O
pervent	O
endohtelial	O
NO	O
synthsae	O
(	O
eONS	O
)	O
downregulaiton	O
and	O
the	O
incresae	O
in	O
O2	O
-	O
in	O
Sprgaue	O
-	O
Dwaley	O
(	O
SD	O
)	O
rtas	O
,	O
thereby	O
reudcing	O
bolod	O
perssure	O
.	O

2	O
.	O

Mlae	O
SD	O
rtas	O
(	O
n	O
=	O
30	O
)	O
were	O
tretaed	O
with	O
Ato	O
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drikning	O
wtaer	O
)	O
or	O
tap	O
waetr	O
for	O
15	O
dyas	O
.	O

Deaxmethasone	O
(	O
10	O
micorg	O
/	O
kg	O
per	O
day	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
sailne	O
was	O
started	O
after	O
4	O
dyas	O
in	O
Ato	O
-	O
terated	O
and	O
non	O
-	O
treaetd	O
rtas	O
and	O
continued	O
for	O
11	O
-	O
13	O
dyas	O
.	O

Systoilc	O
bolod	O
prsesure	O
(	O
SBP	O
)	O
was	O
maesured	O
on	O
alternate	O
dyas	O
using	O
the	O
tial	O
-	O
cfuf	O
mehtod	O
.	O

Endohtelial	O
functoin	O
was	O
assesesd	O
by	O
acetylcholnie	O
-	O
inudced	O
vasroelaxation	O
and	O
phenlyephrine	O
-	O
idnuced	O
vasoconstrcition	O
in	O
arotic	O
semgents	O
.	O

Vascluar	O
eONS	O
mNRA	O
was	O
asesssed	O
by	O
smei	O
-	O
quantittaive	O
revrese	O
transrciption	O
-	O
poylmerase	O
cahin	O
reaciton	O
.	O

3	O
.	O

In	O
rtas	O
tretaed	O
with	O
Dex	O
alone	O
,	O
SBP	O
was	O
incerased	O
from	O
109	O
+	O
/	O
-	O
2	O
to	O
133	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Dyas	O
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
Ato	O
+	O
Dex	O
gruop	O
,	O
SBP	O
was	O
inrceased	O
from	O
113	O
+	O
/	O
-	O
2	O
to	O
119	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Dyas	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
significantly	O
loewr	O
than	O
SBP	O
in	O
the	O
gorup	O
terated	O
with	O
Dex	O
alone	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Endtohelial	O
-	O
dpeendent	O
relaxtaion	O
and	O
eONS	O
mNRA	O
expresison	O
were	O
greater	O
in	O
the	O
Dex	O
+	O
Ato	O
gruop	O
than	O
in	O
the	O
Dex	O
only	O
gruop	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

Aoritc	O
sueproxide	O
porduction	O
was	O
loewr	O
in	O
the	O
Dex	O
+	O
Ato	O
gorup	O
compraed	O
with	O
the	O
gorup	O
treaetd	O
with	O
Dex	O
alone	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

4	O
.	O

Teratment	O
with	O
Ato	O
imprvoed	O
ednothelial	O
funciton	O
,	O
redcued	O
sueproxide	O
prdouction	O
and	O
reduecd	O
SBP	O
in	O
Dex	O
-	O
traeted	O
SD	O
rtas	O
.	O

Sveere	O
ctirate	O
toixcity	B-Disease
complciating	O
volnuteer	O
apheersis	O
plateelt	O
dnoation	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
seevre	O
cirtate	O
toxciity	B-Disease
during	O
volunteer	O
doonr	O
aphreesis	O
pltaelet	O
clolection	O
.	O

The	O
doonr	O
was	O
a	O
40	O
-	O
yaer	O
-	O
old	O
femlae	O
,	O
first	O
-	O
tmie	O
aphereiss	O
pltaelet	O
dnoor	O
.	O

Past	O
mdeical	O
hisotry	O
was	O
remarkable	O
for	O
hypetrension	B-Disease
,	O
hpyerlipidemia	B-Disease
,	O
and	O
deprsesion	B-Disease
.	O

Reported	O
medictaions	O
included	O
bumeatnide	O
,	O
pravasattin	O
,	O
and	O
parxoetine	O
.	O

Thirty	O
minuets	O
from	O
the	O
start	O
of	O
the	O
porcedure	O
,	O
the	O
dnoor	O
noted	O
tignling	O
around	O
the	O
muoth	O
,	O
hnads	O
,	O
and	O
feet	O
.	O

She	O
then	O
very	O
rapidly	O
developed	O
aucte	O
onset	O
of	O
seevre	O
fcaial	O
and	O
extremtiy	O
tetnay	B-Disease
.	O

Emiprical	O
tretament	O
with	O
intraveonus	O
calcuim	O
gluocnate	O
was	O
initiated	O
,	O
and	O
mucsle	B-Disease
contractinos	I-Disease
slowly	O
subisded	O
over	O
approximately	O
10	O
to	O
15	O
mintues	O
.	O

The	O
evnets	O
are	O
consistent	O
with	O
a	O
sveere	O
raection	O
to	O
calcuim	O
chleation	O
by	O
soidum	O
cirtate	O
anticoagluant	O
resulting	O
in	O
symptomtaic	O
systmeic	O
hypocaclemia	B-Disease
.	O

Upon	O
additional	O
retorspective	O
analsyis	O
,	O
it	O
was	O
noted	O
that	O
bmuetanide	O
is	O
a	O
loop	O
diruetic	O
that	O
may	O
cause	O
significant	O
hpyocalcemia	B-Disease
.	O

We	O
conclude	O
that	O
careful	O
scerening	O
for	O
meidcations	O
and	O
underlying	O
condiitons	O
prdeisposing	O
to	O
hpyocalcemia	B-Disease
is	O
recommenedd	O
to	O
help	O
prevnet	O
seevre	O
reatcions	O
due	O
to	O
ctirate	O
toixcity	B-Disease
.	O

Laboraotry	O
meausrement	O
of	O
pre	O
-	O
procdeure	O
sreum	O
caclium	O
levles	O
in	O
selected	O
donros	O
may	O
identify	O
caess	O
requiring	O
heightened	O
viiglance	O
.	O

The	O
csae	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
perparedness	O
for	O
managing	O
rrae	O
but	O
serious	O
reacitons	O
in	O
voulnteer	O
apheersis	O
bolod	O
donros	O
.	O

Siroliums	O
-	O
associated	O
prtoeinuria	B-Disease
and	O
reanl	B-Disease
dysfunctoin	I-Disease
.	O

Sirloimus	O
is	O
a	O
novel	O
immunosuppresasnt	O
with	O
potent	O
antiprolifertaive	O
actinos	O
through	O
its	O
ability	O
to	O
inhiibt	O
the	O
rpator	O
-	O
containing	O
mammalian	O
taregt	O
of	O
rapaymcin	O
portein	O
kniase	O
.	O

Siroilmus	O
represents	O
a	O
major	O
therapetuic	O
advacne	O
in	O
the	O
pervention	O
of	O
aucte	O
reanl	O
allogarft	O
rjeection	O
and	O
chroinc	O
allorgaft	O
nephrpoathy	B-Disease
.	O

Its	O
role	O
in	O
the	O
tehrapy	O
of	O
glomerulonpehritis	B-Disease
,	O
auotimmunity	B-Disease
,	O
cysitc	B-Disease
reanl	I-Disease
diseaess	I-Disease
and	O
rneal	B-Disease
cnacer	I-Disease
is	O
under	O
investigtaion	O
.	O

Because	O
sirolmius	O
does	O
not	O
share	O
the	O
vasomtoor	O
reanl	O
advesre	O
effects	O
exhibited	O
by	O
clacineurin	O
inhibiotrs	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non	O
-	O
nephrtooxic	B-Disease
durg	O
'	O
.	O

However	O
,	O
clniical	O
reprots	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
siroliums	O
is	O
associated	O
with	O
proteiunria	B-Disease
and	O
aucte	B-Disease
rneal	I-Disease
dysfunctoin	I-Disease
.	O

A	O
common	O
rsik	O
fcator	O
appears	O
to	O
be	O
presecne	O
of	O
pre	O
-	O
existing	O
crhonic	B-Disease
reanl	I-Disease
damgae	I-Disease
.	O

The	O
mechanimss	O
of	O
sriolimus	O
-	O
associated	O
proteinuira	B-Disease
are	O
multifacotrial	O
and	O
may	O
be	O
due	O
to	O
an	O
inrcease	O
in	O
glomeurlar	O
caplilary	O
pressure	O
following	O
calcineuirn	O
inhibiotr	O
withdarwal	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
sriolimus	O
directly	O
causes	O
incraesed	O
glomerluar	O
permeaiblity	O
/	O
inujry	O
,	O
but	O
evidnece	O
for	O
this	O
mechansim	O
is	O
currently	O
icnonclusive	O
.	O

The	O
actue	B-Disease
rneal	I-Disease
dyfsunction	I-Disease
associated	O
with	O
sriolimus	O
(	O
such	O
as	O
in	O
dealyed	O
garft	O
fnuction	O
)	O
may	O
be	O
due	O
to	O
supperssion	O
of	O
compenastory	O
rneal	O
clel	O
proliefration	O
and	O
suvrival	O
/	O
reapir	O
procseses	O
.	O

Although	O
these	O
adevrse	O
effcets	O
occur	O
in	O
some	O
paitents	O
,	O
their	O
occrurence	O
could	O
be	O
minimiesd	O
by	O
konwledge	O
of	O
the	O
moleuclar	O
effcets	O
of	O
sriolimus	O
on	O
the	O
kindey	O
,	O
the	O
use	O
of	O
siorlimus	O
in	O
appropriate	O
pateint	O
popluations	O
,	O
close	O
monitornig	O
of	O
proetinuria	B-Disease
and	O
rneal	O
fucntion	O
,	O
use	O
of	O
angitoensin	O
-	O
converting	O
enyzme	O
inhibitros	O
or	O
angiotesnin	O
II	O
recpetor	O
bolckers	O
if	O
proteniuria	B-Disease
occurs	O
and	O
withdarwal	O
if	O
needed	O
.	O

Further	O
long	O
-	O
term	O
anlaysis	O
of	O
reanl	O
allogarft	O
stduies	O
using	O
sriolimus	O
as	O
de	O
novo	O
imumnosuppression	O
along	O
with	O
clincial	O
and	O
laobratory	O
sutdies	O
will	O
refine	O
these	O
isuses	O
in	O
the	O
future	O
.	O

Porteinuria	B-Disease
after	O
cnoversion	O
to	O
sriolimus	O
in	O
reanl	O
trnasplant	O
reicpients	O
.	O

Siorlimus	O
(	O
SRL	O
)	O
is	O
a	O
new	O
,	O
potent	O
immunsouppressive	O
aegnt	O
.	O

More	O
recently	O
,	O
prtoeinuria	B-Disease
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
siroilmus	O
therpay	O
,	O
although	O
the	O
mechansim	O
has	O
remained	O
unclear	O
.	O

We	O
retorspectively	O
examined	O
the	O
recrods	O
of	O
25	O
reanl	O
transpalnt	O
pateints	O
,	O
who	O
developed	O
or	O
displayed	O
increaesd	O
proteniuria	B-Disease
after	O
SRL	O
convesrion	O
.	O

The	O
pateint	O
coohrt	O
(	O
14	O
men	O
,	O
11	O
woemn	O
)	O
was	O
terated	O
with	O
SRL	O
as	O
cnoversion	O
tehrapy	O
,	O
due	O
to	O
crhonic	B-Disease
allgoraft	I-Disease
nephroapthy	I-Disease
(	O
CAN	B-Disease
)	O
(	O
n	O
=	O
15	O
)	O
neoplaisa	B-Disease
(	O
n	O
=	O
8	O
)	O
;	O
Kpaosi	B-Disease
'	I-Disease
s	I-Disease
sarocma	I-Disease
,	O
Four	O
sikn	B-Disease
cancres	I-Disease
,	O
One	O
intestianl	B-Disease
tumros	I-Disease
,	O
One	O
reanl	B-Disease
clel	I-Disease
carisnom	I-Disease
)	O
or	O
BK	O
vrius	O
nephroptahy	B-Disease
(	O
n	O
=	O
2	O
)	O
.	O

SRL	O
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/	O
-	O
42	O
(	O
15	O
to	O
163	O
)	O
motnhs	O
after	O
transplantaiton	O
.	O

Mean	O
follow	O
-	O
up	O
on	O
SRL	O
thearpy	O
was	O
20	O
+	O
/	O
-	O
12	O
(	O
6	O
to	O
43	O
)	O
motnhs	O
.	O

Porteinuria	B-Disease
icnreased	O
from	O
0	O
.	O
445	O
(	O
0	O
to	O
1	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
converison	O
to	O
3	O
.	O
2	O
g	O
/	O
dL	O
(	O
0	O
.	O
2	O
to	O
12	O
)	O
after	O
converison	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Before	O
converison	O
8	O
(	O
32	O
%	O
)	O
patietns	O
had	O
no	O
proteinruia	B-Disease
,	O
whereas	O
afterwards	O
all	O
pateints	O
had	O
prtoeinuria	B-Disease
.	O

In	O
28	O
%	O
of	O
paitents	O
proteniuria	B-Disease
remained	O
unchagned	O
,	O
whereas	O
it	O
incresaed	O
in	O
68	O
%	O
of	O
patinets	O
.	O

In	O
40	O
%	O
it	O
incresaed	O
by	O
more	O
than	O
100	O
%	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
patinets	O
showed	O
increaesd	O
proteinruia	B-Disease
to	O
the	O
nehprotic	B-Disease
range	O
.	O

Biopseis	O
performed	O
in	O
five	O
paitents	O
revelaed	O
new	O
pathloogical	O
chagnes	O
:	O
One	O
mmebranoproliferative	B-Disease
glomeurlopathy	I-Disease
and	O
inetrstitial	B-Disease
nephrtiis	I-Disease
.	O

These	O
pateints	O
showed	O
pesristently	O
good	O
grfat	O
fucntion	O
.	O

Sreum	O
craetinine	O
vlaues	O
did	O
not	O
change	O
significantly	O
:	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dL	O
before	O
SRL	O
tehrapy	O
and	O
2	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.	O
14	O
)	O
.	O

Five	O
garfts	O
were	O
lsot	O
and	O
the	O
ptaients	O
returned	O
to	O
dilaysis	O
.	O

Five	O
patietns	O
displayed	O
CAN	B-Disease
and	O
Kpaosi	B-Disease
'	I-Disease
s	I-Disease
sacroma	I-Disease
.	O

Mean	O
urinray	O
proetin	O
of	O
patietns	O
who	O
returned	O
to	O
dilaysis	O
was	O
1	O
.	O
26	O
(	O
0	O
.	O
5	O
to	O
3	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
and	O
4	O
.	O
7	O
(	O
3	O
to	O
12	O
)	O
g	O
/	O
d	O
after	O
convesrion	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

Mean	O
sreum	O
cretainine	O
leevl	O
before	O
convresion	O
was	O
2	O
.	O
21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4	O
.	O
93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.	O
02	O
)	O
.	O

Hevay	O
proteinuira	B-Disease
was	O
common	O
after	O
the	O
use	O
of	O
SRL	O
as	O
rescue	O
thearpy	O
for	O
rneal	O
trnasplantation	O
.	O

Therefore	O
,	O
conevrsion	O
should	O
be	O
considered	O
for	O
ptaients	O
who	O
have	O
not	O
developed	O
avdanced	O
CAN	B-Disease
and	O
protienuria	B-Disease
.	O

The	O
possibility	O
of	O
de	O
novo	O
gloemrular	O
patholgoy	O
under	O
SRL	O
teratment	O
requires	O
further	O
investgiation	O
by	O
reanl	O
boipsy	O
.	O

Lnog	O
-	O
term	O
follow	O
-	O
up	O
of	O
ifsofamide	O
reanl	B-Disease
toixcity	I-Disease
in	O
cihldren	O
traeted	O
for	O
maligannt	B-Disease
mesenchyaml	I-Disease
tmuors	I-Disease
:	O
an	O
Itnernational	O
Scoiety	O
of	O
Pediartic	O
Onoclogy	O
reprot	O
.	O

The	O
rneal	O
funciton	O
of	O
74	O
chilrden	O
with	O
malignnat	B-Disease
mesnechymal	I-Disease
tuomrs	I-Disease
in	O
complete	O
rmeission	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosafmide	O
chemtoherapy	O
prootcol	O
(	O
Internatinoal	O
Socitey	O
of	O
Peditaric	O
Oncloogy	O
Mlaignant	B-Disease
Mseenchymal	I-Disease
Tuomr	I-Disease
Stduy	O
84	O
[	O
SOIP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
yaer	O
after	O
the	O
compeltion	O
of	O
treamtent	O
.	O

Total	O
cmuulative	O
doess	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
ifosfamdie	O
(	O
six	O
or	O
10	O
cylces	O
of	O
ifosafmide	O
,	O
vincristnie	O
,	O
and	O
dactinmoycin	O
[	O
IVA	O
]	O
)	O
.	O

None	O
of	O
them	O
had	O
received	O
cispaltin	O
chemothreapy	O
.	O

Aegs	O
ranged	O
from	O
4	O
mnoths	O
to	O
17	O
yeras	O
;	O
58	O
patinets	O
were	O
maels	O
and	O
42	O
femaels	O
.	O

The	O
most	O
common	O
prmiary	O
tuomr	B-Disease
stie	O
was	O
the	O
haed	O
and	O
ncek	O
.	O

Reanl	O
fnuction	O
was	O
inevstigated	O
by	O
mesauring	O
plamsa	O
and	O
uirnary	O
eelctrolytes	O
,	O
glucosuira	B-Disease
,	O
proteiunria	B-Disease
,	O
aminoaicduria	B-Disease
,	O
urniary	O
pH	O
,	O
osmolairty	O
,	O
creatinnie	O
claerance	O
,	O
phoshpate	O
tubualr	O
reabsorptoin	O
,	O
btea	O
2	O
microglobluinuria	O
,	O
and	O
lysozyumria	O
.	O

Fifty	O
-	O
eight	O
pateints	O
(	O
78	O
%	O
)	O
had	O
nromal	O
reanl	O
tetss	O
,	O
whereas	O
16	O
patietns	O
(	O
22	O
%	O
)	O
had	O
rneal	B-Disease
abnoramlities	I-Disease
.	O

Two	O
subests	O
of	O
pateints	O
were	O
identfiied	O
from	O
this	O
latter	O
gruop	O
:	O
the	O
first	O
included	O
four	O
patietns	O
(	O
5	O
%	O
of	O
the	O
total	O
popualtion	O
)	O
who	O
developed	O
major	O
txoicity	B-Disease
resulting	O
in	O
Fnaconi	B-Disease
'	I-Disease
s	I-Disease
syndorme	I-Disease
(	O
TFDS	B-Disease
)	O
;	O
and	O
the	O
second	O
gruop	O
included	O
five	O
paitents	O
with	O
elevaetd	O
btea	O
2	O
microgloublinuria	O
and	O
low	O
phosphtae	O
reabsorptoin	O
.	O

The	O
remaining	O
seven	O
patietns	O
had	O
ioslated	O
btea	O
2	O
micorglobulinuria	O
.	O

Sevree	O
toxictiy	B-Disease
was	O
correlated	O
with	O
the	O
hihger	O
cuumlative	O
dsoe	O
of	O
60	O
g	O
/	O
m2	O
of	O
iofsfamide	O
,	O
a	O
yuonger	O
age	O
(	O
less	O
than	O
2	O
1	O
/	O
2	O
yeras	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesiocprostatic	O
tmuor	B-Disease
inovlvement	O
.	O

This	O
low	O
percentgae	O
(	O
5	O
%	O
)	O
of	O
TFDS	O
must	O
be	O
evalutaed	O
with	O
respect	O
to	O
the	O
efficcay	O
of	O
ifosfmaide	O
in	O
the	O
treatmnet	O
of	O
mesenchmyal	B-Disease
tuomrs	I-Disease
in	O
childern	O
.	O

Progressive	O
myoptahy	B-Disease
with	O
up	O
-	O
regulatoin	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
sttain	O
tehrapy	O
.	O

Sttains	O
can	O
cause	O
a	O
ncerotizing	O
moypathy	B-Disease
and	O
hyperCKameia	B-Disease
which	O
is	O
reversible	O
on	O
csesation	O
of	O
the	O
durg	O
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
pehnomenon	O
whereby	O
sttains	O
may	O
inudce	O
a	O
mypoathy	B-Disease
,	O
which	O
persists	O
or	O
may	O
prorgess	O
after	O
stopping	O
the	O
durg	O
.	O

We	O
investgiated	O
the	O
mucsle	O
ptahology	O
in	O
8	O
such	O
caess	O
.	O

All	O
had	O
myofirbe	O
nercosis	B-Disease
but	O
only	O
3	O
had	O
an	O
inflmamatory	O
infiltrtae	O
.	O

In	O
all	O
csaes	O
there	O
was	O
diffuse	O
or	O
multifoacl	O
up	O
-	O
reuglation	O
of	O
MHC	O
-	O
I	O
expression	O
even	O
in	O
non	O
-	O
nercotic	B-Disease
fbires	O
.	O

Prorgessive	O
improevment	O
occurred	O
in	O
7	O
csaes	O
after	O
commencmeent	O
of	O
prendisolone	O
and	O
mehtotrexate	O
,	O
and	O
in	O
one	O
csae	O
spontaneoulsy	O
.	O

These	O
observtaions	O
suggest	O
that	O
staitns	O
may	O
initiate	O
an	O
imumne	O
-	O
mediated	O
mypoathy	B-Disease
that	O
persists	O
after	O
withdarwal	O
of	O
the	O
durg	O
and	O
responds	O
to	O
immunosuprpessive	O
threapy	O
.	O

The	O
mcehanism	O
of	O
this	O
myoptahy	B-Disease
is	O
uncertain	O
but	O
may	O
involve	O
the	O
inudction	O
by	O
sttains	O
of	O
an	O
endolpasmic	O
retiuclum	O
strses	O
respnose	O
with	O
associated	O
up	O
-	O
regulatoin	O
of	O
MHC	O
-	O
I	O
expression	O
and	O
anitgen	O
presetnation	O
by	O
mucsle	O
fibers	O
.	O

Use	O
of	O
crhomosome	O
substtiution	O
stranis	O
to	O
identify	O
seiuzre	B-Disease
sucseptibility	O
lcoi	O
in	O
mcie	O
.	O

Seiuzre	B-Disease
susceptibiltiy	O
varies	O
among	O
inrbed	O
mosue	O
stranis	O
.	O

Chroomsome	O
substtiution	O
strians	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chromoosme	O
from	O
one	O
inrbed	O
starin	O
(	O
dnoor	O
)	O
has	O
been	O
trasnferred	O
onto	O
a	O
second	O
starin	O
(	O
hsot	O
)	O
by	O
rpeeated	O
backcrosisng	O
,	O
may	O
be	O
used	O
to	O
identify	O
quatnitative	O
triat	O
lcoi	O
(	O
QLTs	O
)	O
that	O
contribute	O
to	O
seiuzre	B-Disease
susceptbiility	O
.	O

QLTs	O
for	O
susceptbiility	O
to	O
pilocrapine	O
-	O
inudced	O
seiuzres	B-Disease
,	O
a	O
moedl	O
of	O
tmeporal	B-Disease
lboe	I-Disease
epliepsy	I-Disease
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
locailze	O
seiuzre	B-Disease
susceptibiilty	O
geens	O
.	O

We	O
reprot	O
QLTs	O
iedntified	O
using	O
a	O
B6	O
(	O
hsot	O
)	O
x	O
A	O
/	O
J	O
(	O
doonr	O
)	O
CSS	O
panel	O
to	O
locailze	O
gnees	O
involved	O
in	O
sucseptibility	O
to	O
pilocaprine	O
-	O
idnuced	O
siezures	B-Disease
.	O

Three	O
hundred	O
fifty	O
-	O
five	O
adlut	O
mlae	O
CSS	O
mcie	O
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
tseted	O
for	O
sucseptibility	O
to	O
pilocarpnie	O
-	O
indcued	O
seizrues	B-Disease
.	O

Highset	O
stgae	O
reached	O
and	O
latecny	O
to	O
each	O
satge	O
were	O
recorded	O
for	O
all	O
mcie	O
.	O

B6	O
mcie	O
were	O
ressitant	O
to	O
seizrues	B-Disease
and	O
sloewr	O
to	O
reach	O
staegs	O
comapred	O
to	O
A	O
/	O
J	O
mcie	O
.	O

The	O
CSS	O
for	O
Crhomosomes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
sevree	O
stgaes	O
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
pheontype	O
.	O

Latecnies	O
to	O
satges	O
were	O
also	O
significantly	O
shotrer	O
for	O
CS1S0	O
and	O
CS1S8	O
mcie	O
.	O

CSS	O
mappnig	O
suggests	O
seiuzre	B-Disease
susecptibility	O
lcoi	O
on	O
muose	O
Chormosomes	O
10	O
and	O
18	O
.	O

This	O
approach	O
provides	O
a	O
farmework	O
for	O
identifying	O
potentially	O
novel	O
homoolgous	O
candidate	O
gnees	O
for	O
hmuan	O
temproal	B-Disease
lboe	I-Disease
eiplepsy	I-Disease
.	O

In	O
vitro	O
charatcerization	O
of	O
parasymapthetic	O
and	O
sypmathetic	O
resposnes	O
in	O
cyclophospahmide	O
-	O
idnuced	O
cytsitis	B-Disease
in	O
the	O
rat	O
.	O

In	O
cyclophsophamide	O
-	O
induecd	O
csytitis	B-Disease
in	O
the	O
rat	O
,	O
dertusor	O
funciton	O
is	O
impaierd	O
and	O
the	O
expression	O
and	O
effcets	O
of	O
muscariinc	O
rceeptors	O
aletred	O
.	O

Whether	O
or	O
not	O
the	O
neruonal	O
transimssion	O
may	O
be	O
affecetd	O
by	O
cytsitis	B-Disease
was	O
presently	O
investiagted	O
.	O

Respnoses	O
of	O
uirnary	O
srtip	O
preparatinos	O
from	O
cnotrol	O
and	O
cyclophosphaimde	O
-	O
preterated	O
rtas	O
to	O
elecrtical	O
field	O
sitmulation	O
and	O
to	O
agonitss	O
were	O
assessed	O
in	O
the	O
asbence	O
and	O
presnece	O
of	O
musacrinic	O
,	O
adrenegric	O
and	O
pruinergic	O
recepotr	O
antaognists	O
.	O

Generally	O
,	O
artopine	O
reudced	O
contractinos	O
,	O
but	O
in	O
contrast	O
to	O
contorls	O
,	O
it	O
also	O
reudced	O
resopnses	O
to	O
low	O
eletcrical	O
field	O
stimulatoin	O
intenisty	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inlfamed	O
prepartaions	O
.	O

In	O
both	O
types	O
,	O
purionceptor	O
desensiitzation	O
with	O
aplha	O
,	O
btea	O
-	O
methlyene	O
adenoisne	O
-	O
5	O
'	O
-	O
triphopshate	O
(	O
alhpa	O
,	O
btea	O
-	O
meTAP	O
)	O
caused	O
further	O
redutcions	O
at	O
low	O
frequecnies	O
(	O
<	O
10	O
Hz	O
)	O
.	O

The	O
muscariinc	O
reecptor	O
antagonsits	O
atropnie	O
,	O
4	O
-	O
diphenylaectoxy	O
-	O
N	O
-	O
methylpipreidine	O
(	O
4	O
-	O
DMAP	O
)	O
(	O
'	O
M	O
(	O
1	O
)	O
/	O
M	O
(	O
3	O
)	O
/	O
M	O
(	O
5	O
)	O
-	O
selective	O
'	O
)	O
,	O
mtehoctramine	O
(	O
'	O
M	O
(	O
2	O
)	O
-	O
selective	O
'	O
)	O
and	O
prienzepine	O
(	O
'	O
M	O
(	O
1	O
)	O
-	O
selective	O
'	O
)	O
antagonzied	O
the	O
toinc	O
component	O
of	O
the	O
elcetrical	O
field	O
stimulaiton	O
-	O
evoekd	O
cnotractile	O
rseponse	O
more	O
ptoently	O
than	O
the	O
pahsic	O
component	O
.	O

4	O
-	O
DMAP	O
inhbiited	O
the	O
tnoic	O
contractoins	O
in	O
contorls	O
more	O
potetnly	O
than	O
methoctraimne	O
and	O
prienzepine	O
.	O

In	O
inflaemd	O
prepraations	O
,	O
the	O
musacrinic	O
recpetor	O
antagnoism	O
on	O
the	O
pahsic	O
component	O
of	O
the	O
eelctrical	O
field	O
stimulatoin	O
-	O
evkoed	O
contratcion	O
was	O
decraesed	O
and	O
the	O
pirenzpeine	O
and	O
4	O
-	O
DMAP	O
antgaonism	O
on	O
the	O
tnoic	O
component	O
was	O
much	O
less	O
efifcient	O
than	O
in	O
contorls	O
.	O

In	O
contrast	O
to	O
contrlos	O
,	O
methoctarmine	O
inrceased	O
-	O
-	O
instead	O
of	O
decraesed	O
-	O
-	O
the	O
toinc	O
resposnes	O
at	O
high	O
ferquencies	O
.	O

While	O
cnotractions	O
to	O
carbahcol	O
and	O
ATP	O
were	O
the	O
same	O
in	O
ifnlamed	O
and	O
in	O
cotnrol	O
strpis	O
when	O
related	O
to	O
a	O
reefrence	O
ptoassium	O
resopnse	O
,	O
iosprenaline	O
-	O
idnuced	O
realxations	O
were	O
smaller	O
in	O
inlfamed	O
srtips	O
.	O

Thus	O
,	O
in	O
cytsitis	B-Disease
substantial	O
chagnes	O
of	O
the	O
effernet	O
functioanl	O
respnoses	O
occur	O
.	O

While	O
postjunctoinal	O
btea	O
-	O
adrenocepotr	O
-	O
mediated	O
relaxatinos	O
are	O
rdeuced	O
,	O
efefcts	O
by	O
prejunctinoal	O
inhibiotry	O
muscrainic	O
recetpors	O
may	O
be	O
incerased	O
.	O

Direct	O
inihbition	O
of	O
cardaic	O
hyperploarization	O
-	O
actviated	O
ccylic	O
nucloetide	O
-	O
gtaed	O
paecmaker	O
chanenls	O
by	O
colnidine	O
.	O

BACGKROUND	O
:	O
Inhibtiion	O
of	O
cradiac	O
sympahtetic	O
tnoe	O
represents	O
an	O
important	O
strategy	O
for	O
teratment	O
of	O
cadriovascular	B-Disease
dsiease	I-Disease
,	O
including	O
arhrythmia	B-Disease
,	O
cornoary	B-Disease
herat	I-Disease
disaese	I-Disease
,	O
and	O
chornic	O
haert	B-Disease
fialure	I-Disease
.	O

Actiavtion	O
of	O
presnyaptic	O
alhpa2	O
-	O
adernoceptors	O
is	O
the	O
most	O
widely	O
accepted	O
mecahnism	O
of	O
atcion	O
of	O
the	O
antisympathteic	O
durg	O
clondiine	O
;	O
however	O
,	O
other	O
traget	O
prtoeins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actoins	O
of	O
clonidnie	O
.	O

METHODS	O
AND	O
REUSLTS	O
:	O
To	O
tset	O
whether	O
clondiine	O
elicits	O
pharmacologcial	O
effcets	O
idnependent	O
of	O
aplha2	O
-	O
adrenoceptros	O
,	O
we	O
have	O
generated	O
mcie	O
with	O
a	O
targeetd	O
delteion	O
of	O
all	O
3	O
aplha2	O
-	O
adrencoeptor	O
subtpyes	O
(	O
alpha2ABC	O
-	O
/	O
-	O
)	O
.	O

Alpha2BAC	O
-	O
/	O
-	O
mcie	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgseic	O
and	O
hpynotic	O
effetcs	O
of	O
colnidine	O
;	O
however	O
,	O
clonidnie	O
significantly	O
loweerd	O
haert	O
rtae	O
in	O
alpha2ABC	O
-	O
/	O
-	O
mcie	O
by	O
up	O
to	O
150	O
bpm	O
.	O

Colnidine	O
-	O
idnuced	O
bardycardia	B-Disease
in	O
consciuos	O
alpha2ABC	O
-	O
/	O
-	O
mcie	O
was	O
32	O
.	O
3	O
%	O
(	O
10	O
mircog	O
/	O
kg	O
)	O
and	O
26	O
.	O
6	O
%	O
(	O
100	O
mcirog	O
/	O
kg	O
)	O
of	O
the	O
effect	O
in	O
wlid	O
-	O
tpye	O
mcie	O
.	O

A	O
similar	O
bradycaridc	O
effect	O
of	O
clnoidine	O
was	O
observed	O
in	O
ioslated	O
spontaenously	O
betaing	O
rihgt	O
artia	O
from	O
alpha2ABC	O
-	O
konckout	O
and	O
wlid	O
-	O
tpye	O
mcie	O
.	O

Colnidine	O
inhibtied	O
the	O
natvie	O
pacemkaer	O
current	O
(	O
I	O
(	O
f	O
)	O
)	O
in	O
ioslated	O
sinotarial	O
ndoe	O
paecmaker	O
clels	O
and	O
the	O
I	O
(	O
f	O
)	O
-	O
generating	O
hyperoplarization	O
-	O
actviated	O
cycilc	O
nucletoide	O
-	O
gaetd	O
(	O
HCN	O
)	O
2	O
and	O
HNC4	O
chanenls	O
in	O
transfceted	O
HE2K93	O
clels	O
.	O

As	O
a	O
consequence	O
of	O
blokcing	O
I	O
(	O
f	O
)	O
,	O
clnoidine	O
reduecd	O
the	O
slope	O
of	O
the	O
diatsolic	O
deploarization	O
and	O
the	O
frequecny	O
of	O
pacmeaker	O
potenitals	O
in	O
sinoatiral	O
ndoe	O
clels	O
from	O
wlid	O
-	O
tpye	O
and	O
alpha2ABC	O
-	O
konckout	O
mcie	O
.	O

CONCLUSOINS	O
:	O
Direct	O
inihbition	O
of	O
cadriac	O
HCN	O
pcaemaker	O
cahnnels	O
contributes	O
to	O
the	O
bradcyardic	O
effects	O
of	O
clonidnie	O
gnee	O
-	O
tagreted	O
mcie	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clondiine	O
-	O
like	O
drgus	O
represent	O
novel	O
srtuctures	O
for	O
future	O
HCN	O
cahnnel	O
ihnibitors	O
.	O

Granulomaotus	B-Disease
hepaittis	I-Disease
due	O
to	O
cobmination	O
of	O
amoixcillin	O
and	O
clavulainc	O
aicd	O
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
patinet	O
with	O
amoixcillin	O
-	O
clavulnaic	O
aicd	O
-	O
inudced	O
heaptitis	B-Disease
with	O
histoloigc	O
mulitple	O
granulmoas	B-Disease
.	O

This	O
tpye	O
of	O
lseion	O
broadens	O
the	O
sepctrum	O
of	O
lvier	B-Disease
ijnury	I-Disease
due	O
to	O
this	O
durg	O
cmobination	O
,	O
mainly	O
represented	O
by	O
a	O
beingn	O
cohlestatic	B-Disease
syndrmoe	I-Disease
.	O

The	O
associatoin	O
of	O
granuloams	B-Disease
and	O
eosinophliia	B-Disease
favor	O
an	O
immunaollergic	O
mechansim	O
.	O

As	O
peniclilin	O
derivaitves	O
and	O
amoxicililn	O
alone	O
are	O
known	O
to	O
idnuce	O
such	O
types	O
of	O
leisons	O
,	O
the	O
amoxicillin	O
component	O
,	O
with	O
or	O
without	O
a	O
potentiaitng	O
effcet	O
of	O
clvaulanic	O
aicd	O
,	O
might	O
have	O
a	O
major	O
role	O
.	O

Dobuatmine	O
strses	O
echoacrdiography	O
:	O
a	O
senstiive	O
indiactor	O
of	O
diminished	O
mycoardial	O
functoin	O
in	O
asymtpomatic	O
doxorubciin	O
-	O
tretaed	O
long	O
-	O
term	O
survivros	O
of	O
chidlhood	O
canecr	B-Disease
.	O

Doxorbuicin	O
is	O
an	O
effectvie	O
antiacncer	O
chemotherapuetic	O
agnet	O
known	O
to	O
cause	O
actue	O
and	O
chrnoic	O
cardimoyopathy	B-Disease
.	O

To	O
develop	O
a	O
more	O
sensitvie	O
echocardiograpihc	O
screeinng	O
tset	O
for	O
cardaic	B-Disease
daamge	I-Disease
due	O
to	O
doxorubiicn	O
,	O
a	O
coohrt	O
sutdy	O
was	O
performed	O
using	O
dboutamine	O
infusoin	O
to	O
differentiate	O
asymptmoatic	O
long	O
-	O
term	O
suvrivors	O
of	O
childohod	O
cacner	B-Disease
treaetd	O
with	O
doxorubciin	O
from	O
heatlhy	O
contorl	O
subjetcs	O
.	O

Echoacrdiographic	O
dtaa	O
from	O
the	O
experimetnal	O
gruop	O
of	O
21	O
patietns	O
(	O
mean	O
age	O
16	O
+	O
/	O
-	O
5	O
yeras	O
)	O
treaetd	O
from	O
1	O
.	O
6	O
to	O
14	O
.	O
3	O
yeras	O
(	O
medain	O
5	O
.	O
3	O
)	O
before	O
this	O
stduy	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
dooxrubicin	O
(	O
mean	O
196	O
)	O
were	O
compaerd	O
with	O
echocardiograhpic	O
dtaa	O
from	O
12	O
nromal	O
age	O
-	O
matched	O
conrtol	O
sujbects	O
.	O

Graedd	O
dboutamine	O
infsuions	O
of	O
0	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
5	O
and	O
10	O
micrgorams	O
/	O
kg	O
per	O
min	O
were	O
administreed	O
.	O

Echocardigoraphic	O
Doppelr	O
stduies	O
were	O
performed	O
before	O
ifnusion	O
and	O
after	O
15	O
min	O
of	O
infusoin	O
at	O
each	O
rtae	O
.	O

Dobuatmine	O
infsuion	O
at	O
10	O
mcirograms	O
/	O
kg	O
per	O
min	O
was	O
discontniued	O
after	O
six	O
stuides	O
secondary	O
to	O
a	O
50	O
%	O
incdience	O
rtae	O
of	O
advesre	O
smyptoms	O
.	O

The	O
most	O
important	O
finidngs	O
were	O
that	O
cmopared	O
with	O
vaules	O
in	O
conrtol	O
sbujects	O
,	O
end	O
-	O
systloic	O
lfet	O
ventriuclar	O
posetrior	O
wlal	O
dimenison	O
and	O
percent	O
of	O
lfet	O
ventricualr	O
posteroir	O
wlal	O
thickeinng	O
in	O
doxroubicin	O
-	O
terated	O
ptaients	O
were	O
dcereased	O
at	O
baseilne	O
sutdy	O
and	O
these	O
fnidings	O
were	O
more	O
clearly	O
delineated	O
with	O
dboutamine	O
stiumlation	O
.	O

End	O
-	O
ssytolic	O
lfet	O
vetnricular	O
posteroir	O
wlal	O
dimnesion	O
at	O
baseilne	O
for	O
the	O
doxorbuicin	O
-	O
traeted	O
gruop	O
was	O
11	O
+	O
/	O
-	O
1	O
.	O
9	O
mm	O
versus	O
13	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm	O
for	O
cotnrol	O
subjetcs	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

End	O
-	O
systloic	O
lfet	O
vnetricular	O
psoterior	O
wlal	O
diemnsion	O
at	O
the	O
5	O
-	O
mcirograms	O
/	O
kg	O
per	O
min	O
dboutamine	O
infsuion	O
for	O
the	O
dooxrubicin	O
-	O
traeted	O
gorup	O
was	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
4	O
mm	O
versus	O
19	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
for	O
cotnrol	O
sujbects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRNUCATED	O
AT	O
250	O
WORDS	O
)	O

Inlfuence	O
of	O
smoknig	O
on	O
developing	O
cohclea	O
.	O

Does	O
smoikng	O
during	O
pergnancy	O
affect	O
the	O
ampiltudes	O
of	O
transinet	O
eovked	O
otoacuostic	O
emisisons	O
in	O
newbonrs	O
?	O

OBJECTVIE	O
:	O
Matenral	O
tobacco	O
smkoing	O
has	O
neagtive	O
effetcs	O
on	O
featl	O
gorwth	O
.	O

The	O
influnece	O
of	O
smkoing	O
during	O
pregnacny	O
on	O
the	O
developing	O
cochela	O
has	O
not	O
been	O
estimaetd	O
,	O
although	O
smoknig	O
has	O
been	O
positievly	O
associated	O
with	O
hearnig	B-Disease
lsos	I-Disease
in	O
adutls	O
.	O

The	O
ojbective	O
of	O
this	O
stduy	O
was	O
to	O
determine	O
the	O
effcets	O
of	O
matrenal	O
smoikng	O
on	O
trasnient	O
evkoed	O
otoacosutic	O
eimssions	O
(	O
TEOEAs	O
)	O
of	O
heatlhy	O
nenoates	O
.	O

METHODS	O
:	O
This	O
stduy	O
was	O
undertaken	O
as	O
part	O
of	O
nenoatal	O
srceening	O
for	O
haering	B-Disease
impariment	I-Disease
and	O
involved	O
both	O
eras	O
of	O
200	O
newobrns	O
.	O

Newobrns	O
whose	O
mohters	O
reported	O
smoknig	O
during	O
prgenancy	O
(	O
n	O
=	O
200	O
eras	O
)	O
were	O
comapred	O
to	O
a	O
contorl	O
gorup	O
of	O
newbonrs	O
(	O
n	O
=	O
200	O
eras	O
)	O
,	O
whose	O
mtohers	O
were	O
non	O
-	O
smkoers	O
.	O

Expsoure	O
to	O
toabcco	O
was	O
chraacterized	O
as	O
low	O
(	O
<	O
5	O
cgiarettes	O
per	O
day	O
,	O
n	O
=	O
88	O
eras	O
)	O
,	O
mdoerate	O
(	O
5	O
<	O
or	O
=	O
cgiarettes	O
per	O
day	O
<	O
10	O
,	O
n	O
=	O
76	O
)	O
or	O
high	O
(	O
>	O
or	O
=	O
10	O
cigaerttes	O
per	O
day	O
,	O
n	O
=	O
36	O
)	O
.	O

REUSLTS	O
:	O
In	O
exopsed	O
neoantes	O
,	O
TEAOEs	O
mean	O
rseponse	O
(	O
across	O
freuqency	O
)	O
and	O
mean	O
amplitdue	O
at	O
4000Hz	O
was	O
significantly	O
loewr	O
than	O
in	O
non	O
-	O
exopsed	O
neonaets	O
.	O

Compariosns	O
between	O
expoesd	O
newbonrs	O
'	O
subgorups	O
rveealed	O
no	O
significant	O
differences	O
.	O

However	O
,	O
by	O
cmoparing	O
each	O
subrgoup	O
to	O
cnotrol	O
gorup	O
,	O
we	O
found	O
staitstically	O
significant	O
decreaess	B-Disease
of	I-Disease
TEAOEs	I-Disease
amplitueds	I-Disease
at	O
4000Hz	O
for	O
all	O
three	O
gruops	O
.	O

Mean	O
TEOEAs	O
respnoses	O
of	O
highly	O
expsoed	O
newbonrs	O
were	O
also	O
significantly	O
lwoer	O
in	O
compariosn	O
to	O
our	O
contorl	O
gorup	O
.	O

COCNLUSION	O
:	O
In	O
uetro	O
,	O
expsoure	O
to	O
toabcco	O
smoknig	O
seems	O
to	O
have	O
a	O
small	O
imapct	O
on	O
otuer	O
hiar	O
clels	O
.	O

These	O
effetcs	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
expoesd	O
newobrns	O
,	O
regardless	O
of	O
the	O
dgeree	O
of	O
exposrue	O
.	O

Further	O
sutdies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potentail	O
neagtive	O
efefct	O
of	O
matenral	O
smkoing	O
on	O
the	O
neontae	O
'	O
s	O
heairng	O
aucity	O
.	O

Simvasttain	O
-	O
induecd	O
biltaeral	O
leg	O
compatrment	B-Disease
synrdome	I-Disease
and	O
mynoecrosis	B-Disease
associated	O
with	O
hypothyrodiism	B-Disease
.	O

A	O
54	O
-	O
yaer	O
-	O
old	O
hpyothyroid	B-Disease
mlae	O
taking	O
tyhroxine	O
and	O
simvasattin	O
presented	O
with	O
bliateral	O
leg	O
compartemnt	B-Disease
sydnrome	I-Disease
and	O
moynecrosis	B-Disease
.	O

Ugrent	O
fascoitomies	O
were	O
performed	O
and	O
the	O
paitent	O
made	O
an	O
unveentful	O
reocvery	O
with	O
the	O
witdhrawal	O
of	O
sivmastatin	O
.	O

It	O
is	O
likely	O
that	O
this	O
copmlication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
incraesed	O
worldwide	O
use	O
of	O
this	O
durg	O
and	O
its	O
approval	O
for	O
all	O
arterioapthic	B-Disease
ptaients	O
.	O

Neuroinlfammation	B-Disease
and	O
behaviroal	B-Disease
abonrmalities	I-Disease
after	O
neoantal	O
terbutlaine	O
teratment	O
in	O
rtas	O
:	O
implications	O
for	O
autsim	B-Disease
.	O

Autsim	B-Disease
is	O
a	O
neuordevelopmental	B-Disease
disoredr	I-Disease
presneting	O
before	O
3	O
yeras	O
of	O
age	O
with	O
defciits	B-Disease
in	I-Disease
comumnication	I-Disease
and	I-Disease
soical	I-Disease
skills	I-Disease
and	O
rpeetitive	B-Disease
behavoirs	I-Disease
.	O

In	O
addition	O
to	O
geentic	O
influneces	O
,	O
recent	O
stuides	O
suggest	O
that	O
pernatal	O
durg	O
or	O
chemiacl	O
epxosures	O
are	O
rsik	O
factros	O
for	O
autsim	B-Disease
.	O

Tebrutaline	O
,	O
a	O
btea2	O
-	O
adernoceptor	O
agnoist	O
used	O
to	O
arrest	O
preetrm	B-Disease
lbaor	I-Disease
,	O
has	O
been	O
associated	O
with	O
increaesd	O
cocnordance	O
for	O
atuism	B-Disease
in	O
diyzgotic	O
twnis	O
.	O

We	O
studied	O
the	O
effetcs	O
of	O
terubtaline	O
on	O
microgilal	O
actiavtion	O
in	O
different	O
barin	O
rgeions	O
and	O
beahvioral	O
otucomes	O
in	O
developing	O
rtas	O
.	O

Newobrn	O
rtas	O
were	O
given	O
terubtaline	O
(	O
10	O
mg	O
/	O
kg	O
)	O
daliy	O
on	O
posntatal	O
dyas	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dsoe	O
and	O
at	O
PN	O
30	O
.	O

Immunohistochemcial	O
stuides	O
showed	O
that	O
administrtaion	O
of	O
terubtaline	O
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robsut	O
inrcease	O
in	O
microgilal	O
acitvation	O
on	O
PN	O
30	O
in	O
the	O
creebral	O
coretx	O
,	O
as	O
well	O
as	O
in	O
cerebellar	O
and	O
cerebrocoritcal	O
wihte	O
matter	O
.	O

None	O
of	O
these	O
effects	O
occurred	O
in	O
anmials	O
given	O
terbutalnie	O
on	O
PN	O
11	O
to	O
14	O
.	O

In	O
behvaioral	O
tetss	O
,	O
aniamls	O
treaetd	O
with	O
trebutaline	O
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patetrns	O
of	O
hyper	O
-	O
reactviity	O
to	O
nvoelty	O
and	O
avresive	O
stiumli	O
when	O
assesesd	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acuostic	O
starlte	O
resopnse	O
tset	O
.	O

Our	O
findigns	O
indicate	O
that	O
btea2	O
-	O
adrenoecptor	O
overstimulaiton	O
during	O
an	O
ealry	O
critical	O
peroid	O
rseults	O
in	O
mircoglial	O
activatoin	O
associated	O
with	O
innate	O
neuroinflammtaory	O
pahtways	O
and	O
behaviroal	B-Disease
abnormaltiies	I-Disease
,	O
similar	O
to	O
those	O
described	O
in	O
atuism	B-Disease
.	O

This	O
stduy	O
provides	O
a	O
useful	O
ainmal	O
mdoel	O
for	O
understanding	O
the	O
neuropatholoigcal	O
procesess	O
underlying	O
autsim	B-Disease
specturm	I-Disease
disoredrs	I-Disease
.	O

Upregulaiton	O
of	O
brian	O
exprsesion	O
of	O
P	O
-	O
glycoproetin	O
in	O
MPR2	O
-	O
defiicent	O
TR	O
(	O
-	O
)	O
rtas	O
resembles	O
siezure	B-Disease
-	O
indcued	O
up	O
-	O
regluation	O
of	O
this	O
durg	O
effulx	O
transoprter	O
in	O
nromal	O
rtas	O
.	O

PURPSOE	O
:	O
The	O
mulitdrug	O
resisatnce	O
protien	O
2	O
(	O
MPR2	O
)	O
is	O
a	O
durg	O
eflfux	O
trasnporter	O
that	O
is	O
expresesd	O
predominantly	O
at	O
the	O
apcial	O
domian	O
of	O
hpeatocytes	O
but	O
seems	O
also	O
to	O
be	O
expresesd	O
at	O
the	O
aipcal	O
membarne	O
of	O
brian	O
caplilary	O
endohtelial	O
clels	O
that	O
form	O
the	O
blood	O
-	O
barin	O
brarier	O
(	O
BBB	O
)	O
.	O

MPR2	O
is	O
abesnt	O
in	O
the	O
transprot	O
-	O
defciient	O
(	O
TR	O
(	O
-	O
)	O
)	O
Wisatr	O
rat	O
mtuant	O
,	O
so	O
that	O
this	O
rat	O
starin	O
was	O
very	O
helpful	O
in	O
defining	O
susbtrates	O
of	O
MPR2	O
by	O
cmoparing	O
tisuse	O
concetnrations	O
or	O
functinoal	O
atcivities	O
of	O
componuds	O
in	O
MPR2	O
-	O
defiicent	O
rtas	O
with	O
those	O
in	O
transprot	O
-	O
competent	O
Witsar	O
rtas	O
.	O

By	O
using	O
this	O
strategy	O
to	O
stduy	O
the	O
involvmeent	O
of	O
MPR2	O
in	O
barin	O
access	O
of	O
antiepielptic	O
drgus	O
(	O
ADEs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
pheyntoin	O
is	O
a	O
susbtrate	O
for	O
MPR2	O
in	O
the	O
BBB	O
.	O

However	O
,	O
one	O
drawback	O
of	O
such	O
studeis	O
in	O
gneetically	O
defiicent	O
rtas	O
is	O
the	O
fact	O
that	O
compensatroy	O
chanegs	O
with	O
upregluation	O
of	O
other	O
transproters	O
can	O
occur	O
.	O

This	O
prompted	O
us	O
to	O
sutdy	O
the	O
barin	O
expression	O
of	O
P	O
-	O
glycoproetin	O
(	O
Pgp	O
)	O
,	O
a	O
major	O
durg	O
efflux	O
transoprter	O
in	O
many	O
tisseus	O
,	O
including	O
the	O
BBB	O
,	O
in	O
TR	O
(	O
-	O
)	O
rtas	O
compraed	O
with	O
nonmutnat	O
(	O
wlid	O
-	O
tpye	O
)	O
Wsitar	O
rtas	O
.	O

METHODS	O
:	O
The	O
exprsesion	O
of	O
MPR2	O
and	O
Pgp	O
in	O
brian	O
and	O
lievr	O
secitons	O
of	O
TR	O
(	O
-	O
)	O
rtas	O
and	O
noraml	O
Wisatr	O
rtas	O
was	O
determined	O
with	O
immunohistochemitsry	O
,	O
by	O
using	O
a	O
novel	O
,	O
highly	O
selective	O
moncolonal	O
MPR2	O
antiobdy	O
and	O
the	O
moonclonal	O
Pgp	O
antbiody	O
C129	O
,	O
respectively	O
.	O

REUSLTS	O
:	O
Immunofluorecsence	O
staniing	O
with	O
the	O
MPR2	O
antbiody	O
was	O
found	O
to	O
lbael	O
a	O
high	O
number	O
of	O
mcirovessels	O
throughout	O
the	O
brian	O
in	O
noraml	O
Wsitar	O
rtas	O
,	O
whereas	O
such	O
labeilng	O
was	O
asbent	O
in	O
TR	O
(	O
-	O
)	O
rtas	O
.	O

TR	O
(	O
-	O
)	O
rtas	O
exhibited	O
a	O
significant	O
up	O
-	O
regulatoin	O
of	O
Pgp	O
in	O
brian	O
cpaillary	O
ednothelial	O
cells	O
comapred	O
with	O
wlid	O
-	O
tpye	O
contorls	O
.	O

No	O
such	O
obvious	O
upreuglation	O
of	O
Pgp	O
was	O
observed	O
in	O
lvier	O
setcions	O
.	O

A	O
comparable	O
overexperssion	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocaripne	O
-	O
indcued	O
siezures	B-Disease
in	O
wlid	O
-	O
tpye	O
Wsitar	O
rtas	O
.	O

Expreiments	O
with	O
systeimc	O
administratoin	O
of	O
the	O
Pgp	O
subsrtate	O
phenobarbtial	O
and	O
the	O
selective	O
Pgp	O
inihbitor	O
tariqiudar	O
in	O
TR	O
(	O
-	O
)	O
rtas	O
substantiated	O
that	O
Pgp	O
is	O
funtcional	O
and	O
compensates	O
for	O
the	O
lcak	O
of	O
MPR2	O
in	O
the	O
BBB	O
.	O

CONCLUSINOS	O
:	O
The	O
dtaa	O
on	O
TR	O
(	O
-	O
)	O
rtas	O
indicate	O
that	O
Pgp	O
plays	O
an	O
important	O
role	O
in	O
the	O
compensatoin	O
of	O
MPR2	O
deficeincy	O
in	O
the	O
BBB	O
.	O

Because	O
such	O
a	O
copmensatory	O
mechainsm	O
most	O
likely	O
occurs	O
to	O
reudce	O
inujry	B-Disease
to	I-Disease
the	I-Disease
barin	I-Disease
from	O
cyottoxic	O
compuonds	O
,	O
the	O
present	O
dtaa	O
substantiate	O
the	O
cocnept	O
that	O
MPR2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O

Furthermore	O
,	O
our	O
dtaa	O
suggest	O
that	O
TR	O
(	O
-	O
)	O
rtas	O
are	O
an	O
interesting	O
tool	O
to	O
stduy	O
cosnequences	O
of	O
oevrexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
durgs	O
in	O
the	O
brian	O
,	O
without	O
the	O
need	O
of	O
inducnig	O
seiuzres	B-Disease
or	O
other	O
Pgp	O
-	O
enhancing	O
evnets	O
for	O
this	O
purpose	O
.	O

Role	O
of	O
xnathine	O
oxdiase	O
in	O
deaxmethasone	O
-	O
inudced	O
hyeprtension	B-Disease
in	O
rtas	O
.	O

1	O
.	O

Glucocorticiod	O
-	O
inudced	O
hyeprtension	B-Disease
(	O
GC	O
-	O
HT	B-Disease
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nirtic	O
oixde	O
-	O
reodx	O
ibmalance	O
.	O

2	O
.	O

We	O
studied	O
the	O
role	O
of	O
xnathine	O
oxidsae	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
proudction	O
of	O
reacitve	O
oxgyen	O
spceies	O
,	O
in	O
dexamtehasone	O
-	O
induecd	O
hypetrension	B-Disease
(	O
dex	O
-	O
HT	B-Disease
)	O
.	O

3	O
.	O

Thirty	O
mlae	O
Sprgaue	O
-	O
Dawely	O
rtas	O
were	O
divided	O
randomly	O
into	O
four	O
treatmnet	O
gropus	O
:	O
salnie	O
,	O
dexametahsone	O
(	O
dex	O
)	O
,	O
allopurniol	O
plus	O
slaine	O
,	O
and	O
allopurniol	O
plus	O
dex	O
.	O

4	O
.	O

Systoilc	O
bolod	O
presusres	O
(	O
SBP	O
)	O
and	O
bodwyeights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O

Thmyus	O
weihgt	O
was	O
used	O
as	O
a	O
mraker	O
of	O
gluoccorticoid	O
actviity	O
,	O
and	O
sreum	O
urtae	O
to	O
assess	O
XO	O
inihbition	O
.	O

5	O
.	O

Dex	O
incerased	B-Disease
SBP	I-Disease
(	O
110	O
+	O
/	O
-	O
2	O
-	O
126	O
+	O
/	O
-	O
3	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
decreaesd	B-Disease
tyhmus	I-Disease
(	I-Disease
P	I-Disease
<	I-Disease
0	I-Disease
.	I-Disease
001	I-Disease
)	I-Disease
and	I-Disease
bodyewights	I-Disease
(	O
P	O
"	O
<	O
0	O
.	O
01	O
)	O
.	O

Allpourinol	O
decerased	O
seurm	O
uarte	O
from	O
76	O
+	O
/	O
-	O
5	O
to	O
30	O
+	O
/	O
-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
sailne	O
and	O
from	O
84	O
+	O
/	O
-	O
13	O
to	O
28	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
in	O
dex	O
-	O
traeted	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
gruops	O
.	O

6	O
.	O

Allouprinol	O
did	O
not	O
prevnet	O
dex	O
-	O
HT	B-Disease
.	O

This	O
,	O
together	O
with	O
our	O
previous	O
fnidings	O
that	O
allpourinol	O
failed	O
to	O
prevnet	O
adrenocorticortophic	O
homrone	O
indcued	O
hpyertension	B-Disease
,	O
suggests	O
that	O
XO	O
actiivty	O
is	O
not	O
a	O
major	O
detreminant	O
of	O
GC	O
-	O
HT	B-Disease
in	O
the	O
rat	O
.	O

Side	O
effetcs	O
of	O
postoperatvie	O
adminsitration	O
of	O
metyhlprednisolone	O
and	O
gentmaicin	O
into	O
the	O
postreior	O
sub	O
-	O
Tneon	O
'	O
s	O
spcae	O
.	O

PURPSOE	O
:	O
To	O
assess	O
the	O
inicdence	O
of	O
psotoperative	O
eemtic	O
side	O
effcets	O
after	O
the	O
admniistration	O
of	O
mehtylprednisolone	O
and	O
gentaimcin	O
into	O
the	O
posteiror	O
sub	O
-	O
Teonn	O
'	O
s	O
spcae	O
at	O
the	O
end	O
of	O
rotuine	O
ctaaract	B-Disease
surgrey	O
.	O

SETTING	O
:	O
St	O
.	O

Lkue	O
'	O
s	O
Hosiptal	O
,	O
Gwradamangia	O
,	O
Mlata	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blnid	O
double	O
-	O
armed	O
porspective	O
sutdy	O
comprised	O
40	O
pateints	O
who	O
had	O
uenventful	O
suturelses	O
phacoemuslification	O
under	O
sub	O
-	O
Teonn	O
'	O
s	O
lcoal	O
infiltartion	O
of	O
3	O
mL	O
of	O
plian	O
lginocaine	O
.	O

At	O
the	O
end	O
of	O
the	O
porcedure	O
,	O
Gruop	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
methlyprednisolone	O
and	O
10	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
getnamicin	O
injceted	O
into	O
the	O
posetrior	O
sub	O
-	O
Teonn	O
'	O
s	O
sapce	O
and	O
Gorup	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
cobmination	O
ijnected	O
into	O
the	O
anetrior	O
sub	O
-	O
Tneon	O
'	O
s	O
spcae	O
.	O

Postoepratively	O
,	O
all	O
ptaients	O
were	O
asssesed	O
for	O
symtpoms	O
of	O
nuasea	B-Disease
,	I-Disease
voimting	I-Disease
,	O
and	O
hedaache	B-Disease
.	O

A	O
chi	O
-	O
sqaure	O
tset	O
was	O
used	O
to	O
assess	O
the	O
statisitcal	O
significacne	O
of	O
rseults	O
.	O

RESLUTS	O
:	O
Sixty	O
percent	O
in	O
Gorup	O
A	O
developed	O
postoeprative	B-Disease
emteic	I-Disease
sympotms	I-Disease
,	O
hedaache	B-Disease
,	O
or	O
both	O
;	O
1	O
paitent	O
in	O
Gruop	O
B	O
developed	O
symtpoms	O
.	O

CONLCUSIONS	O
:	O
The	O
adimnistration	O
of	O
methylprednsiolone	O
and	O
genatmicin	O
in	O
the	O
posteroir	O
sub	O
-	O
Teonn	O
'	O
s	O
spcae	O
was	O
related	O
to	O
a	O
high	O
incdience	O
of	O
side	O
effcets	O
including	O
nasuea	B-Disease
,	I-Disease
vomtiing	I-Disease
,	O
and	O
headahce	B-Disease
.	O

All	O
advrese	O
efefcts	O
were	O
slef	O
-	O
limiting	O
.	O

Assessmnet	O
of	O
a	O
new	O
non	O
-	O
invsaive	O
index	O
of	O
cardaic	O
preformance	O
for	O
detetcion	O
of	O
dobutmaine	O
-	O
induecd	O
myoacrdial	B-Disease
ischeima	I-Disease
.	O

BACKGRONUD	O
:	O
Electrocardiograhpy	O
has	O
a	O
very	O
low	O
senistivity	O
in	O
detecitng	O
dboutamine	O
-	O
inudced	O
myocardail	B-Disease
ishcemia	I-Disease
.	O

OBJECTVIES	O
:	O
To	O
assess	O
the	O
added	O
diangostic	O
value	O
of	O
a	O
new	O
caridac	O
perofrmance	O
index	O
(	O
dP	O
/	O
dtjec	O
)	O
measuremnet	O
,	O
based	O
on	O
bracihal	O
artrey	O
folw	O
cahnges	O
,	O
as	O
compraed	O
to	O
standrad	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
dteecting	O
dobuatmine	O
-	O
induecd	O
myocradial	B-Disease
ischeima	I-Disease
,	O
using	O
T9c9m	O
-	O
Sestmaibi	O
single	O
-	O
pohton	O
emsision	O
copmuted	O
tomorgaphy	O
as	O
the	O
glod	O
satndard	O
of	O
compairson	O
to	O
assess	O
the	O
persence	O
or	O
absnece	O
of	O
iscehmia	B-Disease
.	O

METHODS	O
:	O
The	O
sutdy	O
gorup	O
comprised	O
40	O
patinets	O
undergoing	O
Sestambii	O
-	O
SPCET	O
/	O
dobtuamine	O
strses	O
tset	O
.	O

Simultanoeus	O
measurmeents	O
of	O
ECG	O
and	O
brahcial	O
atrery	O
dP	O
/	O
dtjec	O
were	O
performed	O
at	O
each	O
doubtamine	O
lveel	O
.	O

In	O
19	O
of	O
the	O
40	O
patinets	O
perfusoin	O
deefcts	O
compatible	O
with	O
icshemia	B-Disease
were	O
dteected	O
on	O
SPCET	O
.	O

The	O
incresae	O
in	O
dP	O
/	O
dtjec	O
during	O
infuison	O
of	O
dobuatmine	O
in	O
this	O
gruop	O
was	O
sevreely	O
impiared	O
as	O
compraed	O
to	O
the	O
non	O
-	O
iscehmic	O
gruop	O
.	O

dP	O
/	O
detjc	O
outcmoe	O
was	O
cmobined	O
with	O
the	O
ECG	O
resutls	O
,	O
giving	O
an	O
ECG	O
-	O
enhnaced	O
value	O
,	O
and	O
copmared	O
to	O
ECG	O
alone	O
.	O

RESUTLS	O
:	O
The	O
sensitviity	O
improevd	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
psoitive	O
predictvie	O
value	O
incraesed	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negatvie	O
predcitive	O
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
speicficity	O
decreaesd	O
from	O
90	O
%	O
to	O
67	O
%	O
.	O

CONCULSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specifictiy	O
,	O
the	O
combiantion	O
with	O
dP	O
/	O
dtjec	O
imprvoed	O
the	O
sensitivtiy	O
of	O
the	O
tset	O
and	O
could	O
be	O
a	O
csot	O
-	O
savnigs	O
atlernative	O
to	O
cadriac	O
iamging	O
or	O
perufsion	O
sutdies	O
to	O
deetct	O
myocadrial	B-Disease
iscehmia	I-Disease
,	O
especially	O
in	O
patinets	O
unable	O
to	O
exrecise	O
.	O

Cociane	O
-	O
indcued	O
myoacrdial	B-Disease
infartcion	I-Disease
:	O
cliincal	O
observatoins	O
and	O
pahtogenetic	O
consdierations	O
.	O

Clniical	O
and	O
expeirmental	O
dtaa	O
pubilshed	O
to	O
date	O
suggest	O
several	O
possible	O
mechnaisms	O
by	O
which	O
cocanie	O
may	O
result	O
in	O
aucte	B-Disease
myocardail	I-Disease
infraction	I-Disease
.	O

In	O
indviiduals	O
with	O
preexisting	O
,	O
high	O
-	O
grdae	O
croonary	O
arteiral	O
narrowing	O
,	O
actue	B-Disease
myoacrdial	I-Disease
ifnarction	I-Disease
may	O
result	O
from	O
an	O
incresae	O
in	O
myocadrial	O
oxyegn	O
demand	O
associated	O
with	O
ccoaine	O
-	O
indcued	O
icnrease	O
in	O
rtae	O
-	O
pressure	O
prdouct	O
.	O

In	O
other	O
individauls	O
with	O
no	O
underlying	O
atherocslerotic	B-Disease
obsrtuction	I-Disease
,	O
cornoary	B-Disease
occlsuion	I-Disease
may	O
be	O
due	O
to	O
spsam	B-Disease
,	O
trhombus	B-Disease
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spsam	B-Disease
,	O
the	O
cliincal	O
findigns	O
are	O
largely	O
circumstnatial	O
,	O
and	O
the	O
loucs	O
of	O
cocanie	O
-	O
indcued	O
vasoocnstriction	O
remains	O
speculative	O
.	O

Although	O
certain	O
cilnical	O
and	O
experimnetal	O
findigns	O
support	O
the	O
hyptohesis	O
that	O
spsam	B-Disease
involves	O
the	O
epiacrdial	O
,	O
meidum	O
-	O
szie	O
vessles	O
,	O
other	O
dtaa	O
suggest	O
intarmural	O
vsaoconstriction	O
.	O

Diffsue	O
inrtamural	O
vaosconstriction	O
is	O
not	O
consistent	O
with	O
reoprts	O
of	O
segemntal	O
,	O
disrcete	O
infartcion	B-Disease
.	O

Whereas	O
certain	O
in	O
vivo	O
dtaa	O
suggest	O
that	O
these	O
effetcs	O
are	O
alhpa	O
-	O
mediated	O
,	O
other	O
in	O
vitro	O
dtaa	O
suggest	O
the	O
opposite	O
.	O

The	O
fidning	O
of	O
coacine	O
-	O
idnuced	O
vasoconstrictoin	O
in	O
segmnets	O
of	O
(	O
noninenrvated	O
)	O
hmuan	O
ubmilical	O
atrery	O
suggests	O
that	O
the	O
preesnce	O
or	O
abesnce	O
of	O
inatct	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrpeant	O
dtaa	O
involving	O
the	O
possibility	O
of	O
aplha	O
-	O
mediated	O
effcets	O
.	O

Finally	O
,	O
the	O
contribution	O
of	O
a	O
pirmary	O
,	O
thormbotic	B-Disease
effect	O
of	O
cociane	O
has	O
not	O
been	O
excluded	O
.	O

Prtoeomic	O
aanlysis	O
of	O
srtiatal	O
protiens	O
in	O
the	O
rat	O
mdoel	O
of	O
L	O
-	O
DPOA	O
-	O
induecd	O
dyksinesia	B-Disease
.	O

L	O
-	O
DPOA	O
-	O
indcued	O
dsykinesia	B-Disease
(	O
LID	B-Disease
)	O
is	O
among	O
the	O
mootr	O
comlpications	O
that	O
arise	O
in	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
(	O
PD	B-Disease
)	O
patinets	O
after	O
a	O
proolnged	O
treamtent	O
with	O
L	O
-	O
DPOA	O
.	O

To	O
this	O
day	O
,	O
transcirptome	O
analsyis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
moedl	O
of	O
LID	B-Disease
[	O
Neurboiol	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
informatoin	O
regarding	O
the	O
prtoeome	O
is	O
still	O
lacking	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
we	O
investiagted	O
the	O
cahnges	O
occurring	O
at	O
the	O
portein	O
leevl	O
in	O
striaatl	O
smaples	O
obtained	O
from	O
the	O
unliaterally	O
6	O
-	O
hydroxydopmaine	O
-	O
lseion	O
rat	O
moedl	O
of	O
PD	B-Disease
treaetd	O
with	O
salnie	O
,	O
L	O
-	O
DPOA	O
or	O
bromocirptine	O
using	O
two	O
-	O
dimensinoal	O
difference	O
gel	O
eelctrophoresis	O
and	O
msas	O
spectormetry	O
(	O
MS	O
)	O
.	O

Rtas	O
terated	O
with	O
L	O
-	O
DPOA	O
were	O
allocated	O
to	O
two	O
gruops	O
based	O
on	O
the	O
persence	O
or	O
absnece	O
of	O
LID	B-Disease
.	O

Among	O
the	O
2000	O
sptos	O
compaerd	O
for	O
statsitical	O
difference	O
,	O
67	O
sopts	O
were	O
significantly	O
changed	O
in	O
abudnance	O
and	O
identiifed	O
using	O
martix	O
-	O
assisted	O
lsaer	O
desoprtion	O
/	O
ionizaiton	O
tmie	O
-	O
of	O
-	O
filght	O
MS	O
,	O
atmopsheric	O
presusre	O
martix	O
-	O
asissted	O
laesr	O
desorpiton	O
/	O
ionizatoin	O
and	O
HLPC	O
coupled	O
tadnem	O
MS	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
.	O

Out	O
of	O
these	O
67	O
prtoeins	O
,	O
LID	B-Disease
significantly	O
changed	O
the	O
expressoin	O
leevl	O
of	O
five	O
protenis	O
:	O
alphaebta	O
-	O
crytsalin	O
,	O
gamma	O
-	O
enloase	O
,	O
guanidoaceatte	O
methyltransfearse	O
,	O
vincluin	O
,	O
and	O
protaesome	O
aplha	O
-	O
2	O
subnuit	O
.	O

Complemetnary	O
technqiues	O
such	O
as	O
wsetern	O
immunoblottnig	O
and	O
immunohisotchemistry	O
were	O
performed	O
to	O
investiagte	O
the	O
vaildity	O
of	O
the	O
dtaa	O
obtained	O
using	O
the	O
protemoic	O
approach	O
.	O

In	O
conclusion	O
,	O
this	O
sutdy	O
provides	O
new	O
insights	O
into	O
the	O
protien	O
chagnes	O
occurring	O
in	O
LID	B-Disease
.	O

Cardaic	O
Angoigraphy	O
in	O
Rneally	O
Ipmaired	O
Patietns	O
(	O
CRAE	O
)	O
sutdy	O
:	O
a	O
randomzied	O
double	O
-	O
bilnd	O
tiral	O
of	O
contrast	O
-	O
indcued	O
nephropahty	B-Disease
in	O
patietns	O
with	O
crhonic	B-Disease
kindey	I-Disease
disaese	I-Disease
.	O

BACKGORUND	O
:	O
No	O
direct	O
compairsons	O
exist	O
of	O
the	O
rneal	O
tolreability	O
of	O
the	O
low	O
-	O
osmloality	O
contrast	O
mdeium	O
ioapmidol	O
with	O
that	O
of	O
the	O
iso	O
-	O
osmloality	O
contrast	O
meidum	O
iodxianol	O
in	O
high	O
-	O
rsik	O
paitents	O
.	O

METHODS	O
AND	O
REUSLTS	O
:	O
The	O
present	O
sutdy	O
is	O
a	O
multicetner	O
,	O
rnadomized	O
,	O
double	O
-	O
bilnd	O
compairson	O
of	O
ipoamidol	O
and	O
idoixanol	O
in	O
patietns	O
with	O
chroinc	B-Disease
kideny	I-Disease
dsiease	I-Disease
(	O
estiamted	O
glomeurlar	O
filtraiton	O
rtae	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
cradiac	O
angigoraphy	O
or	O
percutaenous	O
cornoary	O
itnerventions	O
.	O

Seurm	O
creatniine	O
(	O
SCr	O
)	O
levles	O
and	O
esitmated	O
glomreular	O
flitration	O
rtae	O
were	O
assessed	O
at	O
baselnie	O
and	O
2	O
to	O
5	O
dyas	O
after	O
receiving	O
medicatoins	O
.	O

The	O
priamry	O
otucome	O
was	O
a	O
psotdose	O
SCr	O
incraese	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
.	O
2	O
micromol	O
/	O
L	O
)	O
over	O
baesline	O
.	O

Secnodary	O
outcoems	O
were	O
a	O
postdsoe	O
SCr	O
incerase	O
>	O
or	O
=	O
25	O
%	O
,	O
a	O
posdtose	O
esitmated	O
gloemrular	O
filtraiton	O
rtae	O
decresae	O
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr	O
.	O

In	O
414	O
paitents	O
,	O
contrast	O
vloume	O
,	O
prseence	O
of	O
diabtees	B-Disease
melltius	I-Disease
,	O
use	O
of	O
N	O
-	O
acetylcsyteine	O
,	O
mean	O
baseilne	O
SCr	O
,	O
and	O
estimaetd	O
glomerualr	O
filtraiton	O
rtae	O
were	O
comparable	O
in	O
the	O
2	O
gropus	O
.	O

SCr	O
increaess	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
occurred	O
in	O
4	O
.	O
4	O
%	O
(	O
9	O
of	O
204	O
patietns	O
)	O
after	O
ioapmidol	O
and	O
6	O
.	O
7	O
%	O
(	O
14	O
of	O
210	O
pateints	O
)	O
after	O
ioidxanol	O
(	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
whereas	O
rtaes	O
of	O
SCr	O
incerases	O
>	O
or	O
=	O
25	O
%	O
were	O
9	O
.	O
8	O
%	O
and	O
12	O
.	O
4	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
44	O
)	O
.	O

In	O
pateints	O
with	O
dibaetes	B-Disease
,	O
SCr	O
incraeses	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
were	O
5	O
.	O
1	O
%	O
(	O
4	O
of	O
78	O
patinets	O
)	O
with	O
iopamdiol	O
and	O
13	O
.	O
0	O
%	O
(	O
12	O
of	O
92	O
patietns	O
)	O
with	O
iodxianol	O
(	O
P	O
=	O
0	O
.	O
11	O
)	O
,	O
whereas	O
SCr	O
incresaes	O
>	O
or	O
=	O
25	O
%	O
were	O
10	O
.	O
3	O
%	O
and	O
15	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
37	O
)	O
.	O

Mean	O
psot	O
-	O
SCr	O
increaess	O
were	O
significantly	O
less	O
with	O
ipoamidol	O
(	O
all	O
patinets	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
12	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
10	O
.	O
6	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
03	O
;	O
patietns	O
with	O
diabtees	B-Disease
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
16	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
14	O
.	O
1	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

CONCLUISONS	O
:	O
The	O
rtae	O
of	O
contrast	O
-	O
induecd	O
nephroapthy	B-Disease
,	O
defined	O
by	O
mulitple	O
end	O
points	O
,	O
is	O
not	O
sattistically	O
different	O
after	O
the	O
intararterial	O
adminitsration	O
of	O
iopaimdol	O
or	O
ioidxanol	O
to	O
high	O
-	O
rsik	O
paitents	O
,	O
with	O
or	O
without	O
diabeets	B-Disease
melltius	I-Disease
.	O

Any	O
true	O
difference	O
between	O
the	O
agetns	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
cliincally	O
significant	O
.	O

A	O
novel	O
comopund	O
,	O
maltolyl	O
p	O
-	O
comuarate	O
,	O
attenuates	O
cogntiive	B-Disease
defciits	I-Disease
and	O
shows	O
neruoprotective	O
effcets	O
in	O
vitro	O
and	O
in	O
vivo	O
dmeentia	B-Disease
mdoels	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effetcive	O
durg	O
that	O
could	O
ehnance	O
cogniitve	O
functoin	O
and	O
neuroprotcetion	O
,	O
we	O
newly	O
synthesiezd	O
maltolyl	O
p	O
-	O
comuarate	O
by	O
the	O
esterifciation	O
of	O
mlatol	O
and	O
p	O
-	O
coumairc	O
aicd	O
.	O

In	O
the	O
present	O
stduy	O
,	O
we	O
invetsigated	O
whether	O
maltolyl	O
p	O
-	O
cuomarate	O
could	O
imporve	O
cognitvie	B-Disease
dceline	I-Disease
in	O
scpoolamine	O
-	O
injceted	O
rtas	O
and	O
in	O
aymloid	O
btea	O
pepitde	O
(	O
1	O
-	O
42	O
)	O
-	O
inufsed	O
rtas	O
.	O

Maltloyl	O
p	O
-	O
couamrate	O
was	O
found	O
to	O
attneuate	O
congitive	B-Disease
defictis	I-Disease
in	O
both	O
rat	O
moedls	O
using	O
pasisve	O
avoidnace	O
tset	O
and	O
to	O
reudce	O
apopttoic	O
clel	O
daeth	O
observed	O
in	O
the	O
hippoacmpus	O
of	O
the	O
amlyoid	O
btea	O
pepitde	O
(	O
1	O
-	O
42	O
)	O
-	O
ifnused	O
rtas	O
.	O

We	O
also	O
examined	O
the	O
neurporotective	O
effects	O
of	O
maltolyl	O
p	O
-	O
coumraate	O
in	O
vitro	O
using	O
SH	O
-	O
S5YY	O
cells	O
.	O

Clels	O
were	O
prerteated	O
with	O
maltolyl	O
p	O
-	O
coumraate	O
,	O
before	O
epxosed	O
to	O
amyliod	O
btea	O
pepitde	O
(	O
1	O
-	O
42	O
)	O
,	O
gltuamate	O
or	O
HO22	O
.	O

We	O
found	O
that	O
maltolyl	O
p	O
-	O
comuarate	O
significantly	O
derceased	O
aopptotic	O
clel	O
detah	O
and	O
redcued	O
raective	O
oxgyen	O
sepcies	O
,	O
cytocrhome	O
c	O
reelase	O
,	O
and	O
caspsae	O
3	O
acitvation	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
rseults	O
together	O
,	O
our	O
sutdy	O
suggests	O
that	O
maltolyl	O
p	O
-	O
coumartae	O
is	O
a	O
potentially	O
effectvie	O
candidate	O
against	O
Alzheiemr	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
that	O
is	O
chraacterized	O
by	O
wide	O
srpead	O
neurnoal	B-Disease
detah	I-Disease
and	O
porgressive	O
delcine	B-Disease
of	I-Disease
cognitvie	I-Disease
fnuction	I-Disease
.	O

Attneuation	O
of	O
methampehtamine	O
-	O
indcued	O
nigrotsriatal	O
doapminergic	O
neurotoxictiy	B-Disease
in	O
mcie	O
by	O
lipopolysacchraide	O
preteratment	O
.	O

Immunoolgical	O
atcivation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
metahmphetamine	O
-	O
idnuced	O
dopamniergic	B-Disease
treminal	I-Disease
damgae	I-Disease
.	O

In	O
this	O
stduy	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopoylsaccharide	O
,	O
a	O
pro	O
-	O
inflammatroy	O
and	O
inflammtaory	O
facotr	O
,	O
teratment	O
in	O
modluating	O
the	O
methapmhetamine	O
-	O
indcued	O
nigrsotriatal	O
doapmine	O
neurotoxciity	B-Disease
.	O

Lipopolysacchraide	O
pertreatment	O
did	O
not	O
affect	O
the	O
baasl	O
bdoy	O
tempertaure	O
or	O
methamphetmaine	O
-	O
elicited	O
hyperthremia	B-Disease
three	O
dyas	O
later	O
.	O

Such	O
systeimc	O
lipopolysacchairde	O
traetment	O
mitigtaed	O
metahmphetamine	O
-	O
induecd	O
straital	O
dopmaine	O
and	O
3	O
,	O
4	O
-	O
dihydroxypheynlacetic	O
aicd	O
delpetions	O
in	O
a	O
dsoe	O
-	O
depednent	O
manner	O
.	O

As	O
the	O
most	O
potent	O
dsoe	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	O
was	O
admiinstered	O
two	O
wekes	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetmaine	O
dosnig	O
reigmen	O
,	O
methamhpetamine	O
-	O
induecd	O
stritaal	O
doapmine	O
and	O
3	O
,	O
4	O
-	O
dihydorxyphenylacetic	O
aicd	O
dpeletions	O
remained	O
unatlered	O
.	O

Moreover	O
,	O
systmeic	O
lipopolysacchraide	O
pretreatemnt	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenauted	O
lcoal	O
methamphetmaine	O
inufsion	O
-	O
produced	O
doapmine	O
and	O
3	O
,	O
4	O
-	O
dihydroxypheynlacetic	O
aicd	O
depeltions	O
in	O
the	O
striautm	O
,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysacchardie	O
is	O
less	O
likely	O
due	O
to	O
itnerrupted	O
peripehral	O
disrtibution	O
or	O
metaoblism	O
of	O
methampheatmine	O
.	O

We	O
concluded	O
a	O
critical	O
tmie	O
winodw	O
for	O
systeimc	O
lioppolysaccharide	O
pretreamtent	O
in	O
exeritng	O
effcetive	O
prtoection	O
against	O
methmaphetamine	O
-	O
induecd	O
nigrosrtiatal	O
dopmaine	O
nuerotoxicity	B-Disease
.	O

Aucte	O
myocardiits	B-Disease
associated	O
with	O
clozapnie	O
.	O

OBJETCIVE	O
:	O
A	O
csae	O
of	O
aucte	O
myocraditis	B-Disease
associated	O
with	O
the	O
commenecment	O
of	O
cloazpine	O
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
cuorse	O
and	O
possible	O
contributing	O
fcators	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awarneess	O
about	O
this	O
potentially	O
ftaal	O
complictaion	O
of	O
clzoapine	O
use	O
.	O

RESLUTS	O
:	O
A	O
20	O
-	O
yaer	O
-	O
old	O
mlae	O
with	O
schizophrneia	B-Disease
developed	O
a	O
sduden	O
onset	O
of	O
mycoarditis	B-Disease
after	O
commencemnet	O
of	O
clozapnie	O
.	O

The	O
pateint	O
reocvered	O
with	O
intnesive	O
medcial	O
support	O
.	O

The	O
sympotms	O
occurred	O
around	O
2	O
weeks	O
after	O
starting	O
clozaipne	O
in	O
an	O
ipnatient	O
setting	O
.	O

Possible	O
contributing	O
facotrs	O
may	O
have	O
been	O
concoimtant	O
antidepressant	O
use	O
and	O
unaccsutomed	O
pyhsical	O
atcivity	O
.	O

CONCLUSOINS	O
:	O
Myoacrditis	B-Disease
is	O
an	O
increasingly	O
recognized	O
compliaction	O
associated	O
with	O
the	O
use	O
of	O
colzapine	O
.	O

It	O
can	O
be	O
faatl	O
if	O
not	O
recognized	O
and	O
traeted	O
eraly	O
.	O

Considering	O
that	O
clozaipne	O
remains	O
the	O
glod	O
stanadrd	O
in	O
tretament	O
of	O
resitsant	O
pyschosis	B-Disease
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awarneess	O
among	O
meidcal	O
and	O
paarmedical	O
satff	O
involved	O
in	O
the	O
crae	O
of	O
these	O
ptaients	O
.	O

There	O
are	O
also	O
implications	O
for	O
reocmmendations	O
and	O
regulaitons	O
regarding	O
the	O
use	O
of	O
colzapine	O
.	O

Seevre	O
rhabdomoylysis	B-Disease
and	O
aucte	B-Disease
rneal	I-Disease
failrue	I-Disease
secondary	O
to	O
concoimtant	O
use	O
of	O
simvatsatin	O
,	O
amiodraone	O
,	O
and	O
atazaanvir	O
.	O

OBJECTVIE	O
:	O
To	O
reprot	O
a	O
csae	O
of	O
a	O
sveere	O
intearction	O
between	O
smivastatin	O
,	O
amiodaorne	O
,	O
and	O
ataaznavir	O
resulting	O
in	O
rhabdomoylysis	B-Disease
and	O
aucte	B-Disease
rneal	I-Disease
faliure	I-Disease
.	O

BACGKROUND	O
:	O
A	O
72	O
-	O
yaer	O
-	O
old	O
whtie	O
man	O
with	O
underlying	O
hmuan	B-Disease
immnuodeficiency	I-Disease
viurs	I-Disease
,	O
artial	B-Disease
fibrillation	I-Disease
,	O
coroanry	B-Disease
aretry	I-Disease
disaese	I-Disease
,	O
and	O
hypelripidemia	B-Disease
presented	O
with	O
generailzed	O
pian	B-Disease
,	O
ftaigue	B-Disease
,	O
and	O
drak	O
oarnge	O
uirne	O
for	O
3	O
dyas	O
.	O

The	O
ptaient	O
was	O
taking	O
80	O
mg	O
smivastatin	O
at	O
bdetime	O
(	O
initiated	O
27	O
dyas	O
earlier	O
)	O
;	O
amiodaorne	O
at	O
a	O
dsoe	O
of	O
400	O
mg	O
dialy	O
for	O
7	O
dyas	O
,	O
then	O
200	O
mg	O
dialy	O
(	O
initiated	O
19	O
dyas	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanaivr	O
dialy	O
(	O
initiated	O
at	O
least	O
2	O
yaers	O
previously	O
)	O
.	O

Laboartory	O
evlauation	O
revelaed	O
66	O
,	O
680	O
U	O
/	O
L	O
creaitne	O
kianse	O
,	O
93	O
mg	O
/	O
dL	O
blood	O
uera	O
nitrgoen	O
,	O
4	O
.	O
6	O
mg	O
/	O
dL	O
creatiinne	O
,	O
1579	O
U	O
/	O
L	O
aspatrate	O
aminotransfrease	O
,	O
and	O
738	O
U	O
/	O
L	O
alannie	O
aminotransefrase	O
.	O

Simvasttain	O
,	O
amioadrone	O
,	O
and	O
the	O
ptaient	O
'	O
s	O
hmuan	B-Disease
immunodeficiecny	I-Disease
vrius	I-Disease
mediactions	O
were	O
all	O
temporarily	O
disocntinued	O
and	O
the	O
paitent	O
was	O
given	O
forced	O
alklaine	O
diurseis	O
and	O
started	O
on	O
dialyiss	O
.	O

Nine	O
dyas	O
later	O
the	O
ptaient	O
'	O
s	O
creaitne	O
kniase	O
had	O
drpoped	O
to	O
1695	O
U	O
/	O
L	O
and	O
ceratinine	O
was	O
3	O
.	O
3	O
mg	O
/	O
dL	O
.	O

The	O
ptaient	O
was	O
dicsharged	O
and	O
continued	O
otupatient	O
dialsyis	O
for	O
1	O
mnoth	O
until	O
his	O
reanl	O
fucntion	O
rceovered	O
.	O

DISCUSSION	O
:	O
The	O
rsik	O
of	O
rahbdomyolysis	B-Disease
is	O
incresaed	O
in	O
the	O
presecne	O
of	O
concomtiant	O
durgs	O
that	O
ihnibit	O
simvsatatin	O
meatbolism	O
.	O

Simvasattin	O
is	O
metbaolized	O
by	O
CY3PA4	O
.	O

Amiodarnoe	O
and	O
ataznaavir	O
are	O
recognized	O
CYPA34	O
ihnibitors	O
.	O

CONCULSIONS	O
:	O
Pharmcaokinetic	O
differenecs	O
in	O
statnis	O
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
rsik	O
of	O
poetntial	O
durg	O
inetractions	O
.	O

In	O
patinets	O
requiring	O
the	O
concurrent	O
use	O
of	O
statnis	O
and	O
CPY3A4	O
inhibitros	O
,	O
pravasattin	O
,	O
fulvastatin	O
,	O
and	O
rosuavstatin	O
carry	O
the	O
lowset	O
rsik	O
of	O
durg	O
interactoins	O
;	O
atorvasttain	O
carries	O
modreate	O
rsik	O
,	O
whereas	O
simvasattin	O
and	O
lovastaitn	O
have	O
the	O
highest	O
rsik	O
and	O
should	O
be	O
avoided	O
in	O
patinets	O
taking	O
cocnomitant	O
CYPA34	O
inhibtiors	O
.	O

Interactoin	O
between	O
warafrin	O
and	O
levoflxoacin	O
:	O
csae	O
series	O
.	O

Wafrarin	O
is	O
the	O
most	O
widely	O
used	O
oarl	O
antiocagulant	O
and	O
is	O
indicated	O
for	O
many	O
cilnical	O
condiitons	O
.	O

Levofloxcain	O
,	O
a	O
flouroquinolone	O
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescriebd	O
antiibotics	O
in	O
clniical	O
parctice	O
and	O
is	O
effetcive	O
against	O
Garm	O
-	O
psoitive	O
,	O
Garm	O
-	O
negtaive	O
,	O
and	O
atpyical	O
bactreia	O
.	O

While	O
small	O
propsective	O
studeis	O
have	O
not	O
revaeled	O
any	O
significant	O
durg	O
-	O
durg	O
interactoin	O
between	O
wafrarin	O
and	O
levfoloxacin	O
,	O
several	O
csae	O
rpeorts	O
have	O
indicated	O
that	O
levofolxacin	O
may	O
significantly	O
ptoentiate	O
the	O
anticoagultaion	O
efefct	O
of	O
warfairn	O
.	O

We	O
rpeort	O
3	O
caess	O
of	O
serious	O
bledeing	B-Disease
copmlications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
inetraction	O
between	O
wafrarin	O
and	O
levofloaxcin	O
.	O

Physicinas	O
should	O
be	O
aware	O
of	O
this	O
potetnial	O
intreaction	O
and	O
use	O
caution	O
when	O
prescirbing	O
leovfloxacin	O
to	O
ptaients	O
taking	O
wrafarin	O
.	O

Muttaions	O
associated	O
with	O
lamivudnie	O
-	O
ressitance	O
in	O
therpay	O
-	O
na	O
ve	O
hepattiis	B-Disease
B	I-Disease
vrius	I-Disease
(	I-Disease
HBV	I-Disease
)	I-Disease
infetced	I-Disease
patinets	O
with	O
and	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
inefction	I-Disease
:	O
implications	O
for	O
antiretrvoiral	O
therpay	O
in	O
HBV	B-Disease
and	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
inefcted	I-Disease
Suoth	O
Afircan	O
ptaients	O
.	O

This	O
was	O
an	O
exploratroy	O
sutdy	O
to	O
investgiate	O
laimvudine	O
-	O
resisatnt	O
hepatiits	B-Disease
B	I-Disease
viurs	O
(	O
HBV	O
)	O
stranis	O
in	O
selected	O
lamivduine	O
-	O
na	O
ve	O
HBV	O
carreirs	O
with	O
and	O
without	O
hmuan	B-Disease
immunodefiicency	I-Disease
viurs	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
co	I-Disease
-	I-Disease
infcetion	I-Disease
in	O
Sotuh	O
Arfican	O
ptaients	O
.	O

Thirty	O
-	O
five	O
lamivduine	O
-	O
na	O
ve	O
HBV	B-Disease
infceted	I-Disease
pateints	O
with	O
or	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
inefction	I-Disease
were	O
studied	O
:	O
15	O
chrnoic	O
HBV	B-Disease
mnoo	I-Disease
-	I-Disease
infceted	I-Disease
pateints	O
and	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
ifnected	I-Disease
patinets	O
.	O

The	O
latter	O
gorup	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occlut	O
HBV	O
(	O
HsBAg	O
-	O
neagtive	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HsBAg	O
-	O
posiitve	O
)	O
patietns	O
.	O

HsBAg	O
,	O
atni	O
-	O
HBs	O
,	O
atni	O
-	O
HBc	O
,	O
and	O
atni	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
rotuine	O
diagnoiss	O
using	O
Axysm	O
assays	O
(	O
Abbott	O
Lbaoratories	O
,	O
Nroth	O
Cihcago	O
,	O
IL	O
)	O
.	O

Sreum	O
sampels	O
were	O
PCR	O
ampilfied	O
with	O
HBV	O
rveerse	O
trasncriptase	O
(	O
RT	O
)	O
primres	O
,	O
followed	O
by	O
direct	O
sequecning	O
across	O
the	O
tyroisne	O
-	O
methioinne	O
-	O
apsartate	O
-	O
asaprtate	O
(	O
YDMD	O
)	O
mtoif	O
of	O
the	O
major	O
cataltyic	O
reigon	O
in	O
the	O
C	O
dmoain	O
of	O
the	O
HBV	O
RT	O
enyzme	O
.	O

HBV	O
viarl	O
laod	O
was	O
performed	O
with	O
Ampilcor	O
HBV	O
Moniotr	O
tset	O
v2	O
.	O
0	O
(	O
Rcohe	O
Diagonstics	O
,	O
Pnezberg	O
,	O
Geramny	O
)	O
.	O

HBV	O
lamivduine	O
-	O
rseistant	O
stranis	O
were	O
deetcted	O
in	O
3	O
of	O
15	O
mnoo	O
-	O
infetced	O
chornic	O
hepaittis	B-Disease
B	I-Disease
patinets	O
and	O
10	O
of	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
ifnected	I-Disease
ptaients	O
.	O

To	O
the	O
best	O
of	O
our	O
knowldege	O
,	O
this	O
constitutes	O
the	O
first	O
reprot	O
of	O
HBV	O
lamviudine	O
-	O
resitsant	O
srtains	O
in	O
threapy	O
-	O
na	O
ve	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
inefcted	I-Disease
pateints	O
.	O

The	O
HBV	O
viarl	O
lodas	O
for	O
mnoo	O
-	O
infecetd	O
and	O
co	O
-	O
infetced	O
ptaients	O
ranged	O
from	O
3	O
.	O
32	O
x	O
10	O
(	O
2	O
)	O
to	O
3	O
.	O
82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4	O
.	O
40	O
x	O
10	O
(	O
3	O
)	O
coipes	O
/	O
ml	O
,	O
respectively	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
atniviral	O
mtuations	O
could	O
result	O
in	O
widespread	O
emregence	O
of	O
HBV	O
reisstant	O
strians	O
when	O
laimvudine	O
-	O
containing	O
highly	O
acitve	O
antiretrvoiral	O
(	O
ARV	O
)	O
treatmnet	O
(	O
HAART	O
)	O
regmiens	O
become	O
widely	O
applied	O
in	O
Suoth	O
Afirca	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potetnial	O
implications	O
in	O
the	O
mangaement	O
of	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infceted	I-Disease
paitents	O
.	O

Rbabit	B-Disease
syndorme	I-Disease
,	O
anitdepressant	O
use	O
,	O
and	O
cerberal	O
pefrusion	O
SEPCT	O
sacn	O
findnigs	O
.	O

The	O
rabbit	B-Disease
syndrmoe	I-Disease
is	O
an	O
etxrapyramidal	O
side	O
effcet	O
associated	O
with	O
chrnoic	O
neurolepitc	O
therpay	O
.	O

Its	O
occrurence	O
in	O
a	O
patinet	O
being	O
treaetd	O
with	O
imipraimne	O
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
csae	O
of	O
this	O
sydnrome	O
in	O
conjunctoin	O
with	O
antidepressnats	O
.	O

Repetaed	O
cerberal	O
perfsuion	O
SPCET	O
scnas	O
rveealed	O
decreaesd	B-Disease
bsaal	I-Disease
gnaglia	I-Disease
perfsuion	I-Disease
while	O
the	O
movmeent	B-Disease
disoredr	I-Disease
was	O
present	O
,	O
and	O
a	O
return	O
to	O
noraml	O
perfusoin	O
when	O
the	O
rbabit	B-Disease
syndorme	I-Disease
resolved	O
.	O

Estorgen	O
prevents	O
chloesteryl	O
etser	O
accuumlation	O
in	O
macrohpages	O
indcued	O
by	O
the	O
HIV	O
portease	O
inhiibtor	O
ritnoavir	O
.	O

Idnividuals	O
with	O
HIV	O
can	O
now	O
lvie	O
long	O
lvies	O
with	O
durg	O
thearpy	O
that	O
often	O
includes	O
protaese	O
inhibitros	O
such	O
as	O
riotnavir	O
.	O

Many	O
pateints	O
,	O
however	O
,	O
develop	O
ngeative	O
long	O
-	O
term	O
side	O
efefcts	O
such	O
as	O
preamture	B-Disease
atheroscleorsis	I-Disease
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonvair	O
tretament	O
inrceases	O
atheorsclerotic	B-Disease
leison	I-Disease
formaiton	O
in	O
mlae	O
mcie	O
to	O
a	O
greater	O
extent	O
than	O
in	O
fmeale	O
mcie	O
.	O

Furthermore	O
,	O
perihperal	O
bolod	O
mooncytes	O
isoltaed	O
from	O
ritnoavir	O
-	O
tretaed	O
femlaes	O
had	O
less	O
cholseteryl	O
esetr	O
accumultaion	O
.	O

In	O
the	O
present	O
stduy	O
,	O
we	O
have	O
invsetigated	O
the	O
molecualr	O
mechansims	O
by	O
which	O
femlae	O
horomnes	O
inlfuence	O
chloesterol	O
metaoblism	O
in	O
macrophaegs	O
in	O
resposne	O
to	O
the	O
HIV	O
proetase	O
ihnibitor	O
ritonaivr	O
.	O

We	O
have	O
utilized	O
the	O
hmuan	O
monoycte	O
clel	O
line	O
,	O
THP	O
-	O
1	O
as	O
a	O
mdoel	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
cells	O
were	O
diffreentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
mcarophage	O
-	O
like	O
phneotype	O
in	O
the	O
presnece	O
or	O
asbence	O
of	O
1	O
nM	O
17beta	O
-	O
etsradiol	O
(	O
E2	O
)	O
,	O
100	O
nM	O
progesteorne	O
or	O
vehcile	O
(	O
0	O
.	O
01	O
%	O
etahnol	O
)	O
.	O

Cells	O
were	O
then	O
treaetd	O
with	O
30	O
ng	O
/	O
ml	O
ritoanvir	O
or	O
veihcle	O
in	O
the	O
prseence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h	O
.	O

Clel	O
extrcats	O
were	O
harvseted	O
,	O
and	O
liipd	O
or	O
total	O
RNA	O
was	O
isolaetd	O
.	O

E2	O
dcereased	O
the	O
accumulation	O
of	O
cohlesteryl	O
estres	O
in	O
macorphages	O
following	O
riotnavir	O
tretament	O
.	O

Ritoanvir	O
incresaed	O
the	O
expresison	O
of	O
the	O
scaevnger	O
recetpor	O
,	O
C3D6	O
mNRA	O
,	O
responsible	O
for	O
the	O
upatke	O
of	O
LDL	O
.	O

Additionally	O
,	O
riotnavir	O
tretament	O
selectively	O
icnreased	O
the	O
relative	O
leevls	O
of	O
PPAgRamma	O
mNRA	O
,	O
a	O
trancsription	O
fatcor	O
responsible	O
for	O
the	O
regualtion	O
of	O
C3D6	O
mNRA	O
exrpession	O
.	O

Treatemnt	O
with	O
E2	O
,	O
however	O
,	O
failed	O
to	O
prveent	O
these	O
incresaes	O
at	O
the	O
mNRA	O
leevl	O
.	O

E2	O
did	O
,	O
however	O
,	O
significantly	O
suppress	O
C3D6	O
prtoein	O
leevls	O
as	O
measrued	O
by	O
fulorescent	O
immunoctyochemistry	O
.	O

This	O
dtaa	O
suggests	O
that	O
E2	O
modifeis	O
the	O
experssion	O
of	O
C3D6	O
at	O
the	O
leevl	O
of	O
prtoein	O
expresison	O
in	O
monoycte	O
-	O
derived	O
macrophgaes	O
resulting	O
in	O
rdeuced	O
cholesetryl	O
etser	O
accuumlation	O
following	O
ritoanvir	O
tretament	O
.	O

Aucte	O
hepaittis	B-Disease
atatck	O
after	O
exopsure	O
to	O
teltihromycin	O
.	O

INTRODUCTION	O
:	O
Antbiiotic	O
-	O
associated	O
hepatotoixcity	B-Disease
is	O
rrae	O
.	O

With	O
widespread	O
use	O
of	O
atnimicrobial	O
agetns	O
,	O
however	O
,	O
heptaic	B-Disease
injruy	I-Disease
occurs	O
frequently	O
,	O
and	O
among	O
avderse	B-Disease
durg	I-Disease
reactoins	I-Disease
,	O
idiosynrcatic	O
raections	O
are	O
the	O
most	O
serious	O
.	O

CSAE	O
SUMAMRY	O
:	O
A	O
25	O
-	O
yaer	O
-	O
old	O
mlae	O
patinet	O
,	O
with	O
a	O
hieght	O
of	O
175	O
cm	O
and	O
wegiht	O
of	O
72	O
kg	O
presented	O
to	O
Mamrara	O
Unviersity	O
Hosptial	O
Emergecny	O
Deaprtment	O
,	O
Itsanbul	O
,	O
Trukey	O
,	O
with	O
5	O
dyas	O
'	O
hitsory	O
of	O
janudice	B-Disease
,	O
maalise	O
,	O
nasuea	B-Disease
,	O
and	O
vmoiting	B-Disease
.	O

He	O
had	O
been	O
prescriebd	O
telithormycin	O
400	O
mg	O
/	O
d	O
PO	O
to	O
terat	O
an	O
upper	B-Disease
respirtaory	I-Disease
tarct	I-Disease
inefction	I-Disease
7	O
dyas	O
prior	O
.	O

Adimssion	O
laobratory	O
tetss	O
were	O
as	O
follows	O
:	O
alnaine	O
aminotransfrease	O
,	O
67	O
U	O
/	O
L	O
(	O
reefrence	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
asparatte	O
aminotransfersae	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
aklaline	O
phosphatsae	O
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gmama	O
-	O
glutamyltransfrease	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amyalse	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
bliirubin	O
,	O
20	O
.	O
1	O
mg	O
/	O
dL	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
bliirubin	O
,	O
14	O
.	O
8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
alubmin	O
,	O
4	O
.	O
7	O
mg	O
/	O
dL	O
(	O
3	O
.	O
5	O
-	O
5	O
.	O
4	O
mg	O
/	O
dL	O
)	O
.	O

No	O
toixn	O
,	O
aclohol	O
,	O
or	O
other	O
drgus	O
were	O
reported	O
.	O

The	O
pateint	O
had	O
suffered	O
a	O
previous	O
epiosde	O
of	O
"	O
actue	O
hepatiits	B-Disease
of	O
unknown	O
oirgin	O
,	O
"	O
that	O
occurred	O
after	O
telithroymcin	O
uasge	O
.	O

Both	O
icnidents	O
occurred	O
within	O
a	O
yaer	O
.	O

DISCUSSION	O
:	O
Telithormycin	O
is	O
the	O
first	O
of	O
the	O
ketoilde	O
atnibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Durg	O
Administraiton	O
apporval	O
for	O
clincial	O
use	O
.	O

It	O
has	O
been	O
associated	O
with	O
infreuqent	O
and	O
usually	O
reversible	O
sevree	O
hepaitc	B-Disease
dysfuntcion	I-Disease
.	O

Based	O
on	O
a	O
socre	O
of	O
8	O
on	O
the	O
Narajno	O
adevrse	B-Disease
durg	I-Disease
reaciton	I-Disease
probaiblity	O
scale	O
,	O
teltihromycin	O
was	O
the	O
probable	O
cause	O
of	O
actue	O
heaptitis	B-Disease
in	O
this	O
pateint	O
,	O
and	O
ptahological	O
findigns	O
suggested	O
durg	O
-	O
idnuced	O
txoic	B-Disease
hpeatitis	I-Disease
.	O

Reucrrence	O
of	O
hepatiits	B-Disease
atatck	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incidnet	O
had	O
been	O
communicated	O
to	O
the	O
attendnig	O
physciian	O
who	O
presrcibed	O
telihtromycin	O
the	O
second	O
tmie	O
.	O

CNOCLUSION	O
:	O
Here	O
we	O
reprot	O
a	O
csae	O
of	O
actue	O
heaptitis	B-Disease
probably	O
associated	O
with	O
the	O
admiinstration	O
of	O
telihtromycin	O
.	O

A	O
sutdy	O
on	O
the	O
efefct	O
of	O
the	O
durtaion	O
of	O
sbucutaneous	O
hpearin	O
injetcion	O
on	O
burising	B-Disease
and	O
pian	B-Disease
.	O

AIM	O
:	O
This	O
sutdy	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injectoin	O
durtaion	O
on	O
burising	B-Disease
and	O
pian	B-Disease
following	O
the	O
amdinistration	O
of	O
the	O
subcutaneuos	O
ijnection	O
of	O
heaprin	O
.	O

BACGKROUND	O
:	O
Although	O
different	O
mehtods	O
to	O
preevnt	O
brusiing	B-Disease
and	O
pian	B-Disease
following	O
the	O
sucbutaneous	O
injetcion	O
of	O
hpearin	O
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
effect	O
of	O
ijnection	O
druation	O
on	O
the	O
occurrecne	O
of	O
bruiisng	B-Disease
and	O
pian	B-Disease
is	O
little	O
doucmented	O
.	O

DESIGN	O
:	O
This	O
stduy	O
was	O
designed	O
as	O
within	O
-	O
sbuject	O
,	O
qausi	O
-	O
experimnetal	O
reesarch	O
.	O

METHOD	O
:	O
The	O
smaple	O
for	O
the	O
stduy	O
consisted	O
of	O
50	O
paitents	O
to	O
whom	O
subcutanoeus	O
hpearin	O
was	O
amdinistered	O
.	O

Hepairn	O
was	O
inejcted	O
over	O
10	O
seconds	O
on	O
the	O
rgiht	O
abdomnial	O
stie	O
and	O
30	O
seconds	O
on	O
the	O
lfet	O
abdomianl	O
stie	O
.	O

Injcetions	O
areas	O
were	O
assesesd	O
for	O
the	O
preesnce	O
of	O
briusing	B-Disease
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injetcion	O
.	O

Dimensinos	O
of	O
the	O
bruisnig	B-Disease
on	O
the	O
heprain	O
applied	O
areas	O
were	O
mesaured	O
using	O
trasnparent	O
millmietric	O
meausring	O
paper	O
.	O

The	O
viusal	O
anlaog	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measrue	O
pian	B-Disease
intenisty	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
tmie	O
the	O
pian	B-Disease
peroid	O
.	O

Dtaa	O
were	O
analyesd	O
using	O
chi	O
-	O
sqaure	O
tset	O
,	O
Mnan	O
-	O
Whintey	O
U	O
,	O
Wlicoxon	O
signed	O
rakns	O
tetss	O
and	O
corrleation	O
.	O

RSEULTS	O
:	O
The	O
perecntage	O
of	O
briusing	B-Disease
ocucrrence	O
was	O
64	O
%	O
with	O
the	O
injeciton	O
of	O
10	O
seconds	O
druation	O
and	O
42	O
%	O
in	O
the	O
30	O
-	O
second	O
injectoin	O
.	O

It	O
was	O
determined	O
that	O
the	O
szie	O
of	O
the	O
bruisnig	B-Disease
was	O
smaller	O
in	O
the	O
30	O
-	O
second	O
injetcion	O
.	O

Pian	B-Disease
intesnity	O
and	O
pian	B-Disease
peroid	O
were	O
sattistically	O
significantly	O
loewr	O
for	O
the	O
30	O
-	O
second	O
injcetion	O
than	O
for	O
the	O
10	O
-	O
second	O
injetcion	O
.	O

CONCULSIONS	O
:	O
It	O
was	O
determined	O
that	O
injcetion	O
durtaion	O
had	O
an	O
effcet	O
on	O
brusiing	B-Disease
and	O
pian	B-Disease
following	O
the	O
subcuatneous	O
adminitsration	O
of	O
hpearin	O
.	O

This	O
stduy	O
should	O
be	O
rpeeated	O
on	O
a	O
larger	O
samlpe	O
.	O

RELVEANCE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
adminitsering	O
sbucutaneous	O
heprain	O
injetcions	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
duratoin	O
of	O
the	O
ijnection	O
.	O

Actue	B-Disease
lievr	I-Disease
faliure	I-Disease
in	O
two	O
patinets	O
with	O
regular	O
aclohol	O
conusmption	O
inegsting	O
paarcetamol	O
at	O
therpaeutic	O
doasge	O
.	O

BACKRGOUND	O
:	O
The	O
possible	O
role	O
of	O
alchool	O
in	O
the	O
deveolpment	O
of	O
hepattooxicity	B-Disease
associated	O
with	O
therapuetic	O
dsoes	O
of	O
paracteamol	O
(	O
acetaimnophen	O
)	O
is	O
currently	O
debated	O
.	O

CSAE	O
REPORT	O
:	O
We	O
describe	O
2	O
patinets	O
who	O
were	O
regular	O
cnosumers	O
of	O
alochol	O
and	O
who	O
developed	O
lvier	B-Disease
fialure	I-Disease
within	O
3	O
-	O
5	O
dyas	O
after	O
hospiatlization	O
and	O
stopping	O
alcoohl	O
consmuption	O
while	O
being	O
treaetd	O
with	O
4	O
g	O
praacetamol	O
/	O
day	O
.	O

A	O
paracteamol	O
seurm	O
leevl	O
obtained	O
in	O
one	O
of	O
these	O
patinets	O
was	O
not	O
in	O
the	O
toixc	O
range	O
.	O

Possible	O
rsik	O
factros	O
for	O
the	O
deevlopment	O
of	O
hepatotoixcity	B-Disease
in	O
patietns	O
treaetd	O
with	O
therapeuitc	O
doess	O
of	O
paraectamol	O
are	O
discussed	O
.	O

CONCLUSOIN	O
:	O
In	O
patinets	O
with	O
rsik	O
facotrs	O
,	O
e	O
.	O
g	O
.	O
regular	O
consupmtion	O
of	O
aclohol	O
,	O
lvier	B-Disease
faliure	I-Disease
is	O
possible	O
when	O
therapetuic	O
dsoes	O
are	O
ingseted	O
.	O

We	O
propose	O
that	O
the	O
paracetmaol	O
dsoe	O
should	O
not	O
exceed	O
2	O
g	O
/	O
day	O
in	O
such	O
patietns	O
and	O
that	O
their	O
lvier	O
funtcion	O
should	O
be	O
montiored	O
closely	O
while	O
being	O
traeted	O
with	O
paraceatmol	O
.	O

Associations	O
between	O
use	O
of	O
benozdiazepines	O
or	O
related	O
drgus	O
and	O
haelth	O
,	O
physcial	O
abliities	O
and	O
cognitvie	O
functoin	O
:	O
a	O
non	O
-	O
randmoised	O
cliniacl	O
sutdy	O
in	O
the	O
eledrly	O
.	O

OBJECTVIE	O
:	O
To	O
describe	O
asosciations	O
between	O
the	O
use	O
of	O
benzodiazpeines	O
or	O
related	O
durgs	O
(	O
BDZs	O
/	O
RDs	O
)	O
and	O
helath	O
,	O
functinoal	O
aiblities	O
and	O
cogintive	O
fucntion	O
in	O
the	O
eldelry	O
.	O

METHODS	O
:	O
A	O
non	O
-	O
randoimsed	O
cliniacl	O
stduy	O
of	O
patietns	O
aegd	O
>	O
or	O
=	O
65	O
yaers	O
admitetd	O
to	O
actue	O
hosptial	O
wrads	O
during	O
1	O
mnoth	O
.	O

164	O
patinets	O
(	O
mean	O
age	O
+	O
/	O
-	O
stnadard	O
dveiation	O
[	O
SD	O
]	O
81	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
8	O
yaers	O
)	O
were	O
admitted	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BDZs	O
/	O
RDs	O
before	O
admission	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non	O
-	O
uesrs	O
.	O

Cognitvie	O
ability	O
was	O
asssesed	O
by	O
the	O
Mnii	O
-	O
Mnetal	O
Sttae	O
Eaxmination	O
(	O
MSME	O
)	O
.	O

Ptaients	O
scornig	O
>	O
or	O
=	O
20	O
MSME	O
sum	O
points	O
were	O
itnerviewed	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
smyptoms	O
and	O
funcitonal	O
abiilties	O
during	O
the	O
week	O
prior	O
to	O
amdission	O
.	O

Dtaa	O
on	O
use	O
of	O
BDZs	O
/	O
RDs	O
before	O
admisison	O
,	O
current	O
mediactions	O
and	O
dicsharge	O
diganoses	O
were	O
collected	O
from	O
medcial	O
reocrds	O
.	O

Heatlh	O
,	O
physcial	O
aiblities	O
and	O
cogniitve	O
fnuction	O
were	O
cmopared	O
between	O
BZD	O
/	O
RD	O
uesrs	O
and	O
non	O
-	O
uesrs	O
,	O
and	O
adjsutments	O
were	O
made	O
for	O
confoundnig	O
variabels	O
.	O

The	O
resiudal	O
sreum	O
concetnrations	O
of	O
oxazeapm	O
,	O
teamzepam	O
and	O
zopcilone	O
were	O
anlaysed	O
.	O

RSEULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duraiton	O
of	O
BZD	O
/	O
RD	O
use	O
was	O
7	O
+	O
/	O
-	O
7	O
yaers	O
(	O
range	O
1	O
-	O
31	O
)	O
.	O

Two	O
or	O
three	O
BDZs	O
/	O
RDs	O
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
usres	O
(	O
n	O
=	O
20	O
)	O
.	O

Lnog	O
-	O
term	O
use	O
of	O
these	O
drgus	O
was	O
associated	O
with	O
fmeale	O
sex	O
and	O
use	O
of	O
a	O
hgiher	O
number	O
of	O
durgs	O
with	O
effetcs	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diganosed	O
demnetia	B-Disease
.	O

After	O
adujstment	O
for	O
these	O
variabels	O
as	O
confonuders	O
,	O
use	O
of	O
BDZs	O
/	O
RDs	O
was	O
not	O
associated	O
with	O
cogntiive	O
fucntion	O
as	O
measrued	O
by	O
the	O
MSME	O
.	O

However	O
,	O
use	O
of	O
BDZs	O
/	O
RDs	O
was	O
associated	O
with	O
dizizness	B-Disease
,	O
ianbility	B-Disease
to	I-Disease
sleep	I-Disease
after	O
awkaing	O
at	O
ngiht	O
and	O
tiredenss	B-Disease
in	O
the	O
monrings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
srtonger	O
dperessive	B-Disease
smyptoms	I-Disease
meausred	O
at	O
the	O
beginning	O
of	O
the	O
hsopital	O
stay	O
.	O

Use	O
of	O
BDZs	O
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
redcued	O
ability	O
to	O
wlak	O
and	O
shoretr	O
ngiht	O
-	O
tmie	O
selep	O
during	O
the	O
week	O
prior	O
to	O
admisison	O
.	O

A	O
hgiher	O
rseidual	O
sreum	O
conecntration	O
of	O
temazeapm	O
corrleated	O
with	O
a	O
lwoer	O
MSME	O
sum	O
socre	O
after	O
adjsutment	O
for	O
cofnounding	O
varibales	O
.	O

CONCLUSINOS	O
:	O
Lnog	O
-	O
term	O
use	O
and	O
cocnomitant	O
use	O
of	O
more	O
than	O
one	O
BZD	O
/	O
RD	O
were	O
common	O
in	O
eledrly	O
ptaients	O
hospitalsied	O
because	O
of	O
actue	O
illensses	O
.	O

Lnog	O
-	O
term	O
use	O
was	O
associated	O
with	O
dyatime	O
and	O
ngiht	O
-	O
tmie	O
sypmtoms	O
indicatvie	O
of	O
poorer	O
heatlh	O
and	O
potentially	O
caused	O
by	O
the	O
advesre	O
effetcs	O
of	O
these	O
drgus	O
.	O

Aucte	O
voacl	B-Disease
fold	I-Disease
pasly	I-Disease
after	O
actue	O
disufliram	O
intoxciation	O
.	O

Aucte	O
perpiheral	B-Disease
neuorpathy	I-Disease
caused	O
by	O
a	O
dislufiram	O
ovredose	B-Disease
is	O
very	O
rrae	O
and	O
there	O
is	O
no	O
reoprt	O
of	O
it	O
leading	O
to	O
vcoal	B-Disease
fold	I-Disease
pasly	I-Disease
.	O

A	O
49	O
-	O
yaer	O
-	O
old	O
wmoan	O
was	O
transfrered	O
to	O
our	O
depatrment	O
because	O
of	O
quadriapresis	B-Disease
,	O
lancniating	O
pian	B-Disease
,	O
sesnory	B-Disease
lsos	I-Disease
,	O
and	O
praesthesia	B-Disease
of	O
the	O
disatl	O
libms	O
.	O

One	O
mnoth	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dsoe	O
of	O
disufliram	O
(	O
130	O
tbalets	O
of	O
ALCOHOL	O
SOTP	O
TAB	O
,	O
Shin	O
-	O
Ponog	O
Pahrm	O
.	O
Co	O
.	O
,	O
Asnan	O
,	O
Kroea	O
)	O
in	O
a	O
suciide	O
attempt	O
.	O

She	O
was	O
not	O
an	O
alcohoilc	O
.	O

For	O
the	O
first	O
few	O
dyas	O
after	O
ingsetion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mlid	O
to	O
modearte	O
ataixa	B-Disease
and	O
giddienss	B-Disease
.	O

She	O
noticed	O
hoasreness	B-Disease
and	O
ditsally	O
accentuated	O
mtoor	O
and	O
senosry	O
dsyfunction	O
after	O
she	O
had	O
recoveerd	O
from	O
this	O
state	O
.	O

A	O
nreve	O
codnuction	O
stduy	O
was	O
consistent	O
with	O
seevre	O
sesnorimotor	O
axnoal	O
polyneuroptahy	B-Disease
.	O

Larygneal	O
electrmoyography	O
(	O
thyorarytenoid	O
mucsle	O
)	O
showed	O
ample	O
denervatoin	O
potenitals	O
.	O

Larynogscopy	O
reevaled	O
asymemtric	O
voacl	O
fold	O
moveemnts	O
during	O
phonaiton	O
.	O

Her	O
vcoal	O
change	O
and	O
weaknses	O
began	O
to	O
imporve	O
spontaneuosly	O
about	O
3	O
weeks	O
after	O
trasnfer	O
.	O

This	O
was	O
a	O
csae	O
of	O
actue	O
plasy	B-Disease
of	O
the	O
reucrrent	O
larygneal	O
nevre	O
and	O
superimposed	O
seevre	O
aucte	O
senosrimotor	O
axoanl	O
polyneuropahty	B-Disease
caused	O
by	O
high	O
-	O
dsoe	O
disulfriam	O
intoxiaction	O
.	O

Encephalopahty	B-Disease
inudced	O
by	O
levetiraceatm	O
added	O
to	O
valprotae	O
.	O

BACKGRUOND	O
:	O
We	O
reprot	O
on	O
the	O
maniefstation	O
of	O
a	O
levetiarcetam	O
(	O
LEV	O
)	O
-	O
induecd	O
ecnephalopathy	B-Disease
.	O

FNIDINGS	O
:	O
A	O
28	O
-	O
yaer	O
-	O
old	O
man	O
sfufering	O
from	O
idiopatihc	B-Disease
epilpesy	I-Disease
with	O
generaliezd	O
seiuzres	B-Disease
was	O
terated	O
with	O
LEV	O
(	O
3000	O
mg	O
)	O
added	O
to	O
valporate	O
(	O
VPA	O
)	O
(	O
2000	O
mg	O
)	O
.	O

Ferquency	O
of	O
generaliezd	O
tnoic	B-Disease
-	I-Disease
colnic	I-Disease
seizrues	I-Disease
inrceased	O
from	O
one	O
per	O
6	O
motnhs	O
to	O
two	O
per	O
mnoth	O
.	O

Neuropsyhcological	O
testnig	O
showed	O
imapired	B-Disease
wrod	I-Disease
flunecy	I-Disease
,	I-Disease
psychomootr	I-Disease
speed	I-Disease
and	I-Disease
wokring	I-Disease
memroy	I-Disease
.	O

The	O
inetrictal	O
electroencehpalogram	O
(	O
EEG	O
)	O
showed	O
a	O
generlaized	O
solwing	O
to	O
5	O
per	O
second	O
tehta	O
rhyhtms	O
with	O
bialteral	O
generlaized	O
high	O
-	O
ampltiude	O
discahrges	O
.	O

OUCTOME	O
:	O
Following	O
discontiunation	O
of	O
LEV	O
,	O
EEG	O
and	O
neurposychological	O
fnidings	O
imrpoved	O
and	O
seizrue	B-Disease
ferquency	O
decresaed	O
.	O

Norepinephrnie	O
sginaling	O
through	O
btea	O
-	O
adrenegric	O
recetpors	O
is	O
critical	O
for	O
expression	O
of	O
cocanie	O
-	O
idnuced	O
axniety	B-Disease
.	O

BCAKGROUND	O
:	O
Coacine	O
is	O
a	O
widely	O
aubsed	O
psychotsimulant	O
that	O
has	O
both	O
rwearding	O
and	O
avesrive	O
prpoerties	O
.	O

While	O
the	O
mehcanisms	O
underlying	O
coacine	O
'	O
s	O
rewadring	O
effcets	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attetnion	O
has	O
been	O
paid	O
to	O
the	O
unlpeasant	O
behvaioral	O
states	O
induecd	O
by	O
cocanie	O
,	O
such	O
as	O
anxeity	B-Disease
.	O

METHODS	O
:	O
In	O
this	O
sutdy	O
,	O
we	O
evlauated	O
the	O
pefrormance	O
of	O
dpoamine	O
btea	O
-	O
hydorxylase	O
knokcout	O
(	O
Dbh	O
-	O
/	O
-	O
)	O
mcie	O
,	O
which	O
lcak	O
norepineprhine	O
(	O
NE	O
)	O
,	O
in	O
the	O
eleavted	O
plus	O
mzae	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noardrenergic	O
signlaing	O
to	O
coacine	O
-	O
inudced	O
anxitey	B-Disease
.	O

RSEULTS	O
:	O
We	O
found	O
that	O
cociane	O
dsoe	O
-	O
dependently	O
incerased	O
axniety	B-Disease
-	O
like	O
beahvior	O
in	O
conrtol	O
(	O
Dbh	O
+	O
/	O
-	O
)	O
mcie	O
,	O
as	O
measuerd	O
by	O
a	O
decraese	O
in	O
open	O
arm	O
expolration	O
.	O

The	O
Dbh	O
-	O
/	O
-	O
mcie	O
had	O
noraml	O
baseilne	O
perfomrance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
rseistant	O
to	O
the	O
anixogenic	O
effetcs	O
of	O
ccoaine	O
.	O

Cociane	O
-	O
inudced	O
axniety	B-Disease
was	O
also	O
attenuated	O
in	O
Dbh	O
+	O
/	O
-	O
mcie	O
following	O
adminisrtation	O
of	O
dislufiram	O
,	O
a	O
dopaimne	O
btea	O
-	O
hydrxoylase	O
(	O
DBH	O
)	O
inihbitor	O
.	O

In	O
experiemnts	O
using	O
specific	O
adernergic	O
antagonsits	O
,	O
we	O
found	O
that	O
pretreamtent	O
with	O
the	O
btea	O
-	O
adrenerigc	O
recepotr	O
atnagonist	O
proparnolol	O
bolcked	O
coacine	O
-	O
idnuced	O
axniety	B-Disease
-	O
like	O
behaivor	O
in	O
Dbh	O
+	O
/	O
-	O
and	O
wlid	O
-	O
tpye	O
C57LB6	O
/	O
J	O
mcie	O
,	O
while	O
the	O
aplha	O
(	O
1	O
)	O
anatgonist	O
parzosin	O
and	O
the	O
aplha	O
(	O
2	O
)	O
anatgonist	O
yohibmine	O
had	O
no	O
effcet	O
.	O

CONCULSIONS	O
:	O
These	O
resluts	O
indicate	O
that	O
noradrneergic	O
signlaing	O
via	O
btea	O
-	O
adrenegric	O
reecptors	O
is	O
required	O
for	O
ccoaine	O
-	O
inudced	O
anxitey	B-Disease
in	O
mcie	O
.	O

Hypohtalamic	O
prolatcin	O
reecptor	O
mesesnger	O
ribonculeic	O
aicd	O
levles	O
,	O
prolacitn	O
signlaing	O
,	O
and	O
hyperprolactinmeic	B-Disease
inhiibtion	O
of	O
pulsaitle	O
luteiniznig	O
horomne	O
secrteion	O
are	O
dependnet	O
on	O
estrdaiol	O
.	O

Hpyerprolactinemia	B-Disease
can	O
redcue	O
fertiilty	O
and	O
libdio	O
.	O

Although	O
cenrtal	O
prolacitn	O
atcions	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mechansims	O
are	O
poorly	O
understood	O
.	O

We	O
first	O
tesetd	O
whether	O
chroinc	O
hyperprloactinemia	B-Disease
inhibietd	O
two	O
neuroendocrnie	O
paraemters	O
necessary	O
for	O
femlae	O
fertiltiy	O
:	O
plusatile	O
LH	O
sceretion	O
and	O
the	O
etsrogen	O
-	O
idnuced	O
LH	O
sruge	O
.	O

Chroinc	O
hyperprolactienmia	B-Disease
inudced	O
by	O
the	O
dpoamine	O
antagonsit	O
sulpriide	O
caused	O
a	O
40	O
%	O
reudction	O
LH	O
pluse	O
frqeuency	O
in	O
oavriectomized	O
rtas	O
,	O
but	O
only	O
in	O
the	O
prseence	O
of	O
chrnoic	O
low	O
lveels	O
of	O
etsradiol	O
.	O

Sulipride	O
did	O
not	O
affect	O
the	O
mganitude	O
of	O
a	O
steriod	O
-	O
indcued	O
LH	O
sruge	O
or	O
the	O
percnetage	O
of	O
GRnH	O
neurnos	O
activtaed	O
during	O
the	O
sugre	O
.	O

Estraidol	O
is	O
known	O
to	O
inlfuence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prloactin	O
reecptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
comopnents	O
of	O
proalctin	O
'	O
s	O
signlaing	O
pathawy	O
.	O

To	O
tset	O
the	O
hyptohesis	O
that	O
estorgen	O
icnreases	O
PRL	O
-	O
R	O
expressoin	O
and	O
snesitivity	O
to	O
porlactin	O
,	O
we	O
next	O
demonstrated	O
that	O
estardiol	O
greatly	O
augemnts	O
porlactin	O
-	O
induecd	O
STTA5	O
atcivation	O
.	O

Lastly	O
,	O
we	O
measrued	O
PRL	O
-	O
R	O
and	O
supperssor	O
of	O
cytoikne	O
signlaing	O
(	O
SCOS	O
-	O
1	O
and	O
-	O
3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
leevl	O
of	O
prloactin	O
signalnig	O
)	O
mRANs	O
in	O
resposne	O
to	O
sulipride	O
and	O
estrdaiol	O
.	O

Sulpirdie	O
induecd	O
only	O
SCOS	O
-	O
1	O
in	O
the	O
medail	O
peroptic	O
aera	O
,	O
where	O
GRnH	O
neurnos	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arucate	O
nuclues	O
and	O
choorid	O
pelxus	O
,	O
PRL	O
-	O
R	O
,	O
SCOS	O
-	O
3	O
,	O
and	O
CIS	O
mNRA	O
leevls	O
were	O
also	O
indcued	O
.	O

Estardiol	O
enhacned	O
these	O
effetcs	O
on	O
SCOS	O
-	O
3	O
and	O
CIS	O
.	O

Interestingly	O
,	O
esrtadiol	O
also	O
induecd	O
PRL	O
-	O
R	O
,	O
SCOS	O
-	O
3	O
,	O
and	O
CIS	O
mNRA	O
lveels	O
independently	O
.	O

These	O
dtaa	O
show	O
that	O
GRnH	O
pusle	O
frqeuency	O
is	O
inhibietd	O
by	O
chornic	O
hyperprolatcinemia	B-Disease
in	O
a	O
steorid	O
-	O
depednent	O
manner	O
.	O

They	O
also	O
provide	O
evdience	O
for	O
esrtadiol	O
-	O
deepndent	O
and	O
barin	O
reigon	O
-	O
specific	O
regualtion	O
of	O
PRL	O
-	O
R	O
exrpession	O
and	O
singaling	O
rseponses	O
by	O
prolacitn	O
.	O

Colnidine	O
for	O
attention	B-Disease
-	I-Disease
defciit	I-Disease
/	I-Disease
hyperactivtiy	I-Disease
disoredr	I-Disease
:	O
II	O
.	O

ECG	O
chagnes	O
and	O
adevrse	O
eevnts	O
anlaysis	O
.	O

OBJECTVIE	O
:	O
To	O
examine	O
the	O
saftey	O
and	O
toleraiblity	O
of	O
cloniidne	O
used	O
alone	O
or	O
with	O
methylphendiate	O
in	O
chidlren	O
with	O
atetntion	B-Disease
-	I-Disease
defciit	I-Disease
/	I-Disease
hyperacitvity	I-Disease
diosrder	I-Disease
(	O
AHDD	B-Disease
)	O
.	O

METHOD	O
:	O
In	O
a	O
16	O
-	O
week	O
mulitcenter	O
,	O
double	O
-	O
bilnd	O
trail	O
,	O
122	O
chlidren	O
with	O
AHDD	B-Disease
were	O
randomly	O
assigned	O
to	O
colnidine	O
(	O
n	O
=	O
31	O
)	O
,	O
methylhpenidate	O
(	O
n	O
=	O
29	O
)	O
,	O
cloindine	O
and	O
mtehylphenidate	O
(	O
n	O
=	O
32	O
)	O
,	O
or	O
plaecbo	O
(	O
n	O
=	O
30	O
)	O
.	O

Doess	O
were	O
flexibly	O
ttirated	O
up	O
to	O
0	O
.	O
6	O
mg	O
/	O
day	O
for	O
clnoidine	O
and	O
60	O
mg	O
/	O
day	O
for	O
methyplhenidate	O
(	O
both	O
with	O
divided	O
dosnig	O
)	O
.	O

Gruops	O
were	O
cmopared	O
regarding	O
advrese	O
evnets	O
and	O
cahnges	O
from	O
bsaeline	O
to	O
week	O
16	O
in	O
eletcrocardiograms	O
and	O
vital	O
sgins	O
.	O

RESLUTS	O
:	O
There	O
were	O
more	O
incidetns	O
of	O
bardycardia	B-Disease
in	O
sujbects	O
terated	O
with	O
colnidine	O
compraed	O
with	O
those	O
not	O
traeted	O
with	O
cloniidne	O
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
%	O
;	O
p	O
=	O
.	O
02	O
)	O
,	O
but	O
no	O
other	O
significant	O
gruop	O
differences	O
regarding	O
electrcoardiogram	O
and	O
other	O
cadriovascular	O
otucomes	O
.	O

There	O
were	O
no	O
suggestinos	O
of	O
intreactions	O
between	O
clonidnie	O
and	O
methlyphenidate	O
regarding	O
caridovascular	O
outocmes	O
.	O

Modertae	O
or	O
seevre	O
avderse	O
eevnts	O
were	O
more	O
common	O
in	O
sujbects	O
on	O
cloniidne	O
(	O
79	O
.	O
4	O
%	O
versus	O
49	O
.	O
2	O
%	O
;	O
p	O
=	O
.	O
0006	O
)	O
but	O
not	O
associated	O
with	O
hgiher	O
rtaes	O
of	O
ealry	O
stduy	O
withrdawal	O
.	O

Dorwsiness	B-Disease
was	O
common	O
on	O
clnoidine	O
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
wekes	O
.	O

CONCLUSINOS	O
:	O
Cloniidne	O
,	O
used	O
alone	O
or	O
with	O
methylphenidtae	O
,	O
appears	O
safe	O
and	O
well	O
toelrated	O
in	O
childohod	O
AHDD	B-Disease
.	O

Physiicans	O
prescribnig	O
cloniidne	O
should	O
monitor	O
for	O
braydcardia	B-Disease
and	O
advise	O
ptaients	O
about	O
the	O
high	O
lkielihood	O
of	O
initial	O
dorwsiness	B-Disease
.	O

Reanl	B-Disease
Facnoni	I-Disease
sydnrome	I-Disease
and	O
myopahty	B-Disease
after	O
lvier	O
transplanttaion	O
:	O
durg	O
-	O
related	O
mitcohondrial	B-Disease
cyotpathy	I-Disease
?	O

Avdances	O
in	O
the	O
field	O
of	O
trasnplantation	O
provide	O
a	O
better	O
qualtiy	O
of	O
lfie	O
and	O
allow	O
more	O
favoarble	O
condiitons	O
for	O
grwoth	O
and	O
deveolpment	O
in	O
cihldren	O
.	O

However	O
,	O
combiantions	O
of	O
different	O
threapeutic	O
regimnes	O
require	O
consideration	O
of	O
potnetial	O
avderse	O
reactoins	O
.	O

We	O
describe	O
a	O
15	O
-	O
yr	O
-	O
old	O
gril	O
who	O
had	O
otrhotopic	O
lievr	O
transplnatation	O
because	O
of	O
Wislon	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
.	O

Tacrolmius	O
,	O
MMF	O
,	O
and	O
steriods	O
were	O
given	O
as	O
immnuosuppressant	O
.	O

Lamivduine	O
was	O
added	O
because	O
of	O
de	O
nvoa	O
heptaitis	B-Disease
B	I-Disease
infcetion	I-Disease
during	O
her	O
follow	O
-	O
up	O
.	O

Three	O
yr	O
after	O
translpantation	O
she	O
developed	O
rneal	B-Disease
Facnoni	I-Disease
syndorme	I-Disease
with	O
seevre	O
metaboilc	B-Disease
acidsois	I-Disease
,	O
hypophoshpatemia	B-Disease
,	O
gylcosuria	B-Disease
,	O
and	O
aminaociduria	B-Disease
.	O

Although	O
tacroilmus	O
was	O
suspceted	O
to	O
be	O
the	O
cause	O
of	O
ltae	O
psot	O
-	O
tarnsplant	O
reanl	O
aicdosis	B-Disease
and	O
was	O
replaced	O
by	O
siroliums	O
,	O
acidsois	B-Disease
,	O
and	O
eelctrolyte	O
imbalnace	O
got	O
wrose	O
.	O

Proixmal	O
msucle	B-Disease
wekaness	I-Disease
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O

Facnoni	B-Disease
snydrome	I-Disease
,	O
as	O
well	O
as	O
myoptahy	B-Disease
,	O
is	O
well	O
recognized	O
in	O
patinets	O
with	O
mitochnodrial	B-Disease
diosrders	I-Disease
and	O
caused	O
by	O
depeltion	O
of	O
mtNDA	O
.	O

We	O
suggest	O
that	O
our	O
pateint	O
'	O
s	O
tubluar	B-Disease
dysfunciton	I-Disease
and	O
myoapthy	B-Disease
may	O
have	O
resulted	O
from	O
mitochodnrial	B-Disease
dsyfunction	I-Disease
which	O
is	O
triggered	O
by	O
tacroliums	O
and	O
augmenetd	O
by	O
lamivduine	O
.	O

Higehr	O
optiacl	O
denisty	O
of	O
an	O
antgien	O
asasy	O
predicts	O
thromobsis	B-Disease
in	O
patinets	O
with	O
hepairn	O
-	O
idnuced	O
thrombocytoepnia	B-Disease
.	O

OJBECTIVES	O
:	O
To	O
corerlate	O
opitcal	O
denstiy	O
and	O
percent	O
ihnibition	O
of	O
a	O
two	O
-	O
step	O
hepairn	O
-	O
indcued	O
thrombocytopneia	B-Disease
(	O
HIT	B-Disease
)	O
atnigen	O
assay	O
with	O
thrombsois	B-Disease
;	O
the	O
asasy	O
utilizes	O
reatcion	O
inhibiiton	O
characteritsics	O
of	O
a	O
high	O
hpearin	O
conecntration	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patietns	O
with	O
more	O
than	O
50	O
%	O
dercease	O
in	O
paltelet	O
cuont	O
or	O
thrombocytopneia	B-Disease
(	O
<	O
150	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
after	O
expousre	O
to	O
hpearin	O
,	O
who	O
had	O
a	O
poistive	O
two	O
-	O
step	O
antgien	O
asasy	O
[	O
optcial	O
denisty	O
(	O
OD	O
)	O
>	O
0	O
.	O
4	O
and	O
>	O
50	O
inihbition	O
with	O
high	O
concetnration	O
of	O
hepairn	O
]	O
were	O
included	O
in	O
the	O
sutdy	O
.	O

REUSLTS	O
:	O
Forty	O
of	O
94	O
HIT	B-Disease
pateints	O
had	O
thromobsis	B-Disease
at	O
diangosis	O
;	O
54	O
/	O
94	O
had	O
isolaetd	O
-	O
HIT	B-Disease
without	O
thrmobosis	B-Disease
.	O

Eight	O
of	O
the	O
isolaetd	O
-	O
HIT	B-Disease
ptaients	O
developed	O
thromobsis	B-Disease
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patinets	O
had	O
thrmobosis	B-Disease
at	O
day	O
30	O
.	O

At	O
diagnoiss	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	B-Disease
patinets	O
with	O
thromobsis	B-Disease
and	O
those	O
with	O
ioslated	O
-	O
HIT	B-Disease
.	O

However	O
,	O
OD	O
was	O
significantly	O
higehr	O
in	O
all	O
patietns	O
with	O
thormbosis	B-Disease
(	O
n	O
=	O
48	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
89	O
)	O
,	O
including	O
isloated	O
-	O
HIT	B-Disease
ptaients	O
who	O
later	O
developed	O
thromobsis	B-Disease
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
64	O
)	O
as	O
compaerd	O
to	O
isolaetd	O
-	O
HIT	B-Disease
pateints	O
who	O
did	O
not	O
develop	O
thromobsis	B-Disease
(	O
0	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
75	O
;	O
P	O
=	O
0	O
.	O
011	O
and	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

The	O
Reciever	O
Operatvie	O
Chaarcteristic	O
Cruve	O
showed	O
that	O
OD	O
>	O
1	O
.	O
27	O
in	O
the	O
ioslated	O
-	O
HIT	B-Disease
gruop	O
had	O
a	O
significantly	O
higehr	O
chance	O
of	O
developing	O
thrombsois	B-Disease
by	O
day	O
30	O
.	O

None	O
of	O
these	O
gropus	O
showed	O
significant	O
difference	O
in	O
percent	O
inhbiition	O
.	O

Multivaraite	O
anaylsis	O
showed	O
a	O
2	O
.	O
8	O
-	O
fold	O
incresaed	O
rsik	O
of	O
thromboiss	B-Disease
in	O
fmeales	O
.	O

Similarly	O
,	O
throbmotic	B-Disease
rsik	O
icnreased	O
with	O
age	O
and	O
OD	O
valeus	O
.	O

CONCLSUION	O
:	O
Hgiher	O
OD	O
is	O
associated	O
with	O
significant	O
rsik	O
of	O
subsequent	O
thromboiss	B-Disease
in	O
patietns	O
with	O
ioslated	O
-	O
HIT	B-Disease
;	O
percent	O
inhibiiton	O
,	O
however	O
,	O
was	O
not	O
preidctive	O
.	O

Thaildomide	O
has	O
lmiited	O
single	O
-	O
agnet	O
atcivity	O
in	O
rleapsed	O
or	O
refarctory	O
indloent	O
non	B-Disease
-	I-Disease
Hodgikn	I-Disease
lmyphomas	I-Disease
:	O
a	O
pahse	O
II	O
trail	O
of	O
the	O
Canecr	B-Disease
and	O
Leukeima	B-Disease
Gorup	O
B	O
.	O

Tahlidomide	O
is	O
an	O
immunomodultaory	O
agnet	O
with	O
demonstrated	O
atcivity	O
in	O
mutliple	B-Disease
myeolma	I-Disease
,	O
matnle	B-Disease
clel	I-Disease
lymphmoa	I-Disease
and	O
lympohplasmacytic	B-Disease
lymphmoa	I-Disease
.	O

Its	O
atcivity	O
is	O
believed	O
to	O
be	O
due	O
modulatoin	O
of	O
the	O
tuomur	B-Disease
miileu	O
,	O
including	O
downreuglation	O
of	O
agniogenesis	O
and	O
inflammtaory	O
ctyokines	O
.	O

Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
paitents	O
with	O
relpased	O
/	O
refratcory	O
indoelnt	O
lymhpomas	B-Disease
received	O
thaliodmide	O
200	O
mg	O
daliy	O
with	O
escaaltion	O
by	O
100	O
mg	O
dialy	O
every	O
1	O
-	O
2	O
wekes	O
as	O
tolreated	O
,	O
up	O
to	O
a	O
maxiumm	O
of	O
800	O
mg	O
dialy	O
.	O

Patietns	O
had	O
received	O
a	O
mdeian	O
of	O
2	O
(	O
range	O
,	O
1	O
-	O
4	O
)	O
prior	O
reigmens	O
.	O

Of	O
24	O
eavluable	O
paitents	O
,	O
two	O
achieved	O
a	O
complete	O
remission	O
and	O
one	O
achieved	O
a	O
parital	O
reimssion	O
for	O
an	O
overall	O
rseponse	O
rtae	O
of	O
12	O
.	O
5	O
%	O
(	O
95	O
%	O
cofnidence	O
interavl	O
:	O
2	O
.	O
6	O
-	O
32	O
.	O
4	O
%	O
)	O
.	O

Eleven	O
paitents	O
progressed	O
during	O
thearpy	O
.	O

Grdae	O
3	O
-	O
4	O
advesre	O
effcets	O
included	O
myelosuppression	B-Disease
,	O
ftaigue	B-Disease
,	O
somnloence	B-Disease
/	O
depressed	B-Disease
mood	I-Disease
,	O
neuroptahy	B-Disease
and	O
dsypnea	B-Disease
.	O

Of	O
concern	O
was	O
the	O
occurernce	O
of	O
four	O
thrmoboembolic	B-Disease
evnets	O
.	O

Our	O
resluts	O
failed	O
to	O
demonstrate	O
an	O
important	O
respnose	O
rtae	O
to	O
single	O
aegnt	O
thalidmoide	O
in	O
indolnet	O
lymphoams	B-Disease
and	O
contrast	O
with	O
the	O
hgiher	O
acitvity	O
leevl	O
reported	O
with	O
the	O
second	O
genertaion	O
immunomdoulatory	O
aegnt	O
,	O
lenalidmoide	O
.	O

Sex	O
difefrences	O
in	O
NDMA	O
anatgonist	O
enahncement	O
of	O
morpihne	O
antihyperalgeisa	O
in	O
a	O
cpasaicin	O
mdoel	O
of	O
perssitent	O
pian	B-Disease
:	O
copmarisons	O
to	O
two	O
mdoels	O
of	O
actue	B-Disease
pian	I-Disease
.	O

In	O
aucte	B-Disease
pian	I-Disease
moedls	O
,	O
N	O
-	O
mtehyl	O
-	O
D	O
-	O
aspratate	O
(	O
NDMA	O
)	O
antagonsits	O
enhacne	O
the	O
antinocicpetive	O
effetcs	O
of	O
morhpine	O
to	O
a	O
greater	O
extent	O
in	O
mlaes	O
than	O
feamles	O
.	O

The	O
purpose	O
of	O
this	O
invesitgation	O
was	O
to	O
extend	O
these	O
findnigs	O
to	O
a	O
perisstent	O
pian	B-Disease
mdoel	O
which	O
could	O
be	O
distinguished	O
from	O
actue	B-Disease
pian	I-Disease
mdoels	O
on	O
the	O
basis	O
of	O
the	O
nociecptive	O
fbiers	O
acitvated	O
,	O
neuorchemical	O
subsrtates	O
,	O
and	O
duratoin	O
of	O
the	O
noccieptive	O
stimuuls	O
.	O

To	O
this	O
end	O
,	O
perisstent	O
hypearlgesia	B-Disease
was	O
idnuced	O
by	O
adminsitration	O
of	O
caspaicin	O
in	O
the	O
tial	O
of	O
gondaally	O
itnact	O
F434	O
rtas	O
,	O
following	O
which	O
the	O
tial	O
was	O
immersed	O
in	O
a	O
mlidly	O
nxoious	O
thremal	O
sitmulus	O
,	O
and	O
tial	O
-	O
withdarwal	O
latnecies	O
measrued	O
.	O

For	O
comparsion	O
,	O
tsets	O
were	O
conducted	O
in	O
two	O
aucte	B-Disease
pian	I-Disease
moedls	O
,	O
the	O
hoptlate	O
and	O
wram	O
wtaer	O
tial	O
-	O
withrdawal	O
porcedures	O
.	O

In	O
maels	O
,	O
the	O
non	O
-	O
competitive	O
NDMA	O
antagnoist	O
dextromethrophan	O
enhnaced	O
the	O
anithyperalgesic	O
effcet	O
of	O
low	O
to	O
modertae	O
dsoes	O
of	O
morpihne	O
in	O
a	O
dsoe	O
-	O
and	O
tmie	O
-	O
deepndent	O
manner	O
.	O

Across	O
the	O
dsoes	O
and	O
pretretament	O
times	O
examined	O
,	O
enhacnement	O
was	O
not	O
observed	O
in	O
fmeales	O
.	O

Ehnancement	O
of	O
morphnie	O
antinociecption	O
by	O
dextrometohrphan	O
was	O
seen	O
in	O
both	O
mlaes	O
and	O
feamles	O
in	O
the	O
actue	B-Disease
pian	I-Disease
mdoels	O
,	O
with	O
the	O
mangitude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
maels	O
.	O

These	O
findnigs	O
demonstrate	O
a	O
seuxally	O
-	O
diomrphic	O
itneraction	O
between	O
NDMA	O
antagonitss	O
and	O
mrophine	O
in	O
a	O
persistnet	O
pian	B-Disease
mdoel	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
aucte	B-Disease
pian	I-Disease
modles	O
.	O

Develompent	O
of	O
proteniuria	B-Disease
after	O
swicth	O
to	O
sirolmius	O
-	O
based	O
immunosuppressoin	O
in	O
long	O
-	O
term	O
cadriac	O
translpant	O
ptaients	O
.	O

Calcineuirn	O
-	O
inhiibtor	O
tehrapy	O
can	O
lead	O
to	O
reanl	B-Disease
dsyfunction	I-Disease
in	O
haert	O
tarnsplantation	O
patinets	O
.	O

The	O
novel	O
immunosuppressive	O
(	O
IS	O
)	O
durg	O
sirolmus	O
(	O
Srl	O
)	O
lacks	O
nephrootxic	B-Disease
efefcts	O
;	O
however	O
,	O
proteinruia	B-Disease
associated	O
with	O
Srl	O
has	O
been	O
reported	O
following	O
reanl	O
transplanattion	O
.	O

In	O
caridac	O
tranpslantation	O
,	O
the	O
inciednce	O
of	O
proteiunria	B-Disease
associated	O
with	O
Srl	O
is	O
unknown	O
.	O

In	O
this	O
stduy	O
,	O
long	O
-	O
term	O
cradiac	O
tarnsplant	O
patietns	O
were	O
switched	O
from	O
cyclospoirne	O
to	O
Srl	O
-	O
based	O
IS	O
.	O

Concomiatnt	O
IS	O
consisted	O
of	O
mycopheonlate	O
mofteil	O
+	O
/	O
-	O
streoids	O
.	O

Protienuria	O
inrceased	O
significantly	O
from	O
a	O
medain	O
of	O
0	O
.	O
13	O
g	O
/	O
day	O
(	O
range	O
0	O
-	O
5	O
.	O
7	O
)	O
preswicth	O
to	O
0	O
.	O
23	O
g	O
/	O
day	O
(	O
0	O
-	O
9	O
.	O
88	O
)	O
at	O
24	O
mnoths	O
postsiwtch	O
(	O
p	O
=	O
0	O
.	O
0024	O
)	O
.	O

Before	O
the	O
swicth	O
,	O
11	O
.	O
5	O
%	O
of	O
ptaients	O
had	O
high	O
-	O
garde	O
porteinuria	B-Disease
(	O
>	O
1	O
.	O
0	O
g	O
/	O
day	O
)	O
;	O
this	O
incresaed	O
to	O
22	O
.	O
9	O
%	O
postswtich	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

ACE	O
inhiibtor	O
and	O
angioetnsin	O
-	O
releasing	O
blcoker	O
(	O
ARB	O
)	O
therpay	O
reudced	O
protienuria	B-Disease
develompent	O
.	O

Ptaients	O
without	O
porteinuria	B-Disease
had	O
incerased	O
reanl	O
functoin	O
(	O
mdeian	O
42	O
.	O
5	O
vs	O
.	O
64	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
whereas	O
paitents	O
who	O
developed	O
high	O
-	O
garde	O
proteniuria	B-Disease
showed	O
decraesed	O
reanl	O
functoin	O
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
mdeian	O
39	O
.	O
6	O
vs	O
.	O
29	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
125	O
)	O
.	O

Thus	O
,	O
proetinuria	B-Disease
may	O
develop	O
in	O
cardaic	O
trnasplant	O
paitents	O
after	O
siwtch	O
to	O
Srl	O
,	O
which	O
may	O
have	O
an	O
adevrse	O
effect	O
on	O
reanl	O
functoin	O
in	O
these	O
patinets	O
.	O

Srl	O
should	O
be	O
used	O
with	O
AECi	O
/	O
ARB	O
thearpy	O
and	O
patietns	O
mnoitored	O
for	O
proteinruia	B-Disease
and	O
incresaed	O
reanl	B-Disease
dysfnuction	I-Disease
.	O

Gisnenoside	O
Rg1	O
resotres	O
the	O
impiarment	B-Disease
of	I-Disease
learinng	I-Disease
idnuced	O
by	O
chornic	O
moprhine	O
administartion	O
in	O
rtas	O
.	O

Rg1	O
,	O
as	O
a	O
ginsneoside	O
extracetd	O
from	O
Pnaax	O
gisneng	O
,	O
could	O
aemliorate	O
saptial	O
learnnig	B-Disease
imapirment	I-Disease
.	O

Previous	O
studeis	O
have	O
demonstrated	O
that	O
Rg1	O
might	O
be	O
a	O
useful	O
agnet	O
for	O
the	O
prveention	O
and	O
tretament	O
of	O
the	O
advesre	O
effects	O
of	O
mrophine	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
invesitgate	O
the	O
efefct	O
of	O
Rg1	O
on	O
leanring	B-Disease
impaimrent	I-Disease
by	O
chornic	O
moprhine	O
admniistration	O
and	O
the	O
mechnaism	O
responsible	O
for	O
this	O
effect	O
.	O

Mlae	O
rtas	O
were	O
subcutaenously	O
injecetd	O
with	O
moprhine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
itnervals	O
for	O
10	O
dyas	O
,	O
and	O
Rg1	O
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitonelaly	O
injecetd	O
2	O
hours	O
after	O
the	O
second	O
injeciton	O
of	O
mrophine	O
once	O
a	O
day	O
for	O
10	O
dyas	O
.	O

Saptial	O
leraning	O
capactiy	O
was	O
assessed	O
in	O
the	O
Mroris	O
waetr	O
mzae	O
.	O

The	O
resutls	O
showed	O
that	O
rtas	O
traeted	O
with	O
Moprhine	O
/	O
Rg1	O
decreaesd	O
esacpe	O
laetncy	O
and	O
incraesed	O
the	O
tmie	O
spent	O
in	O
plaftorm	O
quadarnt	O
and	O
entering	O
frequecny	O
.	O

By	O
ipmlantation	O
of	O
elcetrodes	O
and	O
electrohpysiological	O
rceording	O
in	O
vivo	O
,	O
the	O
resluts	O
showed	O
that	O
Rg1	O
resotred	O
the	O
long	O
-	O
term	O
potentiatoin	O
(	O
LTP	O
)	O
impiared	O
by	O
morhpine	O
in	O
both	O
freely	O
movnig	O
and	O
aneasthetised	O
rtas	O
.	O

The	O
electorphysiological	O
recroding	O
in	O
vitro	O
showed	O
that	O
Rg1	O
restroed	O
the	O
LTP	O
in	O
slcies	O
from	O
the	O
rtas	O
treaetd	O
with	O
mrophine	O
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
sliecs	O
from	O
nromal	O
sailne	O
-	O
or	O
morpihne	O
/	O
Rg1	O
-	O
tretaed	O
rtas	O
;	O
this	O
restoratoin	O
could	O
be	O
inhibtied	O
by	O
N	O
-	O
metyhl	O
-	O
D	O
-	O
asparttae	O
(	O
NDMA	O
)	O
reecptor	O
antagonsit	O
MK081	O
.	O

We	O
conclude	O
that	O
Rg1	O
may	O
significantly	O
ipmrove	O
the	O
spaital	O
learnnig	O
capaicty	O
imparied	O
by	O
chnoic	O
moprhine	O
adminisrtation	O
and	O
restore	O
the	O
morhpine	O
-	O
inhiibted	O
LTP	O
.	O

This	O
efefct	O
is	O
NDMA	O
recepotr	O
depnedent	O
.	O

Synhtesis	O
of	O
N	O
-	O
pyirmidinyl	O
-	O
2	O
-	O
phenoyxacetamides	O
as	O
adneosine	O
A2A	O
recetpor	O
antgaonists	O
.	O

A	O
series	O
of	O
N	O
-	O
pyriimdinyl	O
-	O
2	O
-	O
phenxoyacetamide	O
adneosine	O
A	O
(	O
2A	O
)	O
anatgonists	O
is	O
described	O
.	O

SAR	O
studeis	O
led	O
to	O
copmound	O
14	O
with	O
ecxellent	O
potecny	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
4	O
nM	O
)	O
,	O
seelctivity	O
(	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
effiaccy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
in	O
the	O
rat	O
hlaoperidol	O
-	O
inudced	O
catalpesy	B-Disease
mdoel	O
for	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
.	O

Evidnece	O
for	O
an	O
invlovement	O
of	O
D1	O
and	O
D2	O
dopmaine	O
recetpors	O
in	O
mediating	O
nioctine	O
-	O
induecd	O
hypercativity	B-Disease
in	O
rtas	O
.	O

Previous	O
stuides	O
have	O
suggested	O
that	O
repetaed	O
exposrue	O
of	O
rtas	O
to	O
the	O
durg	O
or	O
to	O
the	O
experiemntal	O
environmnet	O
is	O
necessary	O
to	O
observe	O
nicoitne	O
-	O
induecd	O
loocmotor	O
stimultaion	O
.	O

In	O
the	O
present	O
stduy	O
the	O
role	O
of	O
hbaituation	O
to	O
the	O
experimenatl	O
enviornment	O
on	O
the	O
stiumlant	O
effect	O
of	O
nicoitne	O
in	O
rtas	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
dopaimne	O
recepotrs	O
in	O
mediating	O
nictoine	O
-	O
inudced	O
lcoomotor	O
stimualtion	O
was	O
investiagted	O
by	O
examining	O
the	O
efefcts	O
of	O
selective	O
D1	O
and	O
D2	O
doapmine	O
reecptor	O
antagoinsts	O
on	O
atcivity	O
idnuced	O
by	O
nicoitne	O
.	O

Loocmotor	O
actviity	O
was	O
assessed	O
in	O
mlae	O
Srpague	O
-	O
Dawely	O
rtas	O
tseted	O
in	O
photoclel	O
cgaes	O
.	O

Nciotine	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
inrcease	B-Disease
in	I-Disease
locoomtor	I-Disease
acitvity	I-Disease
in	O
rtas	O
that	O
were	O
habtiuated	O
to	O
the	O
tset	O
enviornment	O
,	O
but	O
had	O
only	O
a	O
waek	O
and	O
delyaed	O
stimualnt	O
aciton	O
in	O
rtas	O
that	O
were	O
unfmailiar	O
with	O
the	O
tset	O
enviromnent	O
.	O

The	O
stimulnat	O
atcion	O
of	O
nicoitne	O
was	O
bolcked	O
by	O
the	O
cenrtal	O
nicotniic	O
atnagonist	O
mecamylamnie	O
but	O
not	O
by	O
the	O
preipheral	O
nicoitnic	O
blokcer	O
hexmaethonium	O
,	O
indicating	O
that	O
the	O
rseponse	O
is	O
probably	O
mediated	O
by	O
cetnral	O
nciotinic	O
reecptors	O
.	O

Nicoitne	O
-	O
inudced	O
hypercativity	B-Disease
was	O
blocekd	O
by	O
the	O
selective	O
D1	O
antgaonist	O
SCH	O
23390	O
,	O
the	O
selective	O
D2	O
atnagonist	O
raclporide	O
and	O
the	O
D1	O
/	O
D2	O
antagnoist	O
fulphenazine	O
.	O

Prerteatment	O
with	O
the	O
D2	O
aognist	O
PNHO	O
enhanecd	O
nciotine	O
-	O
induecd	O
hyperactiivty	B-Disease
,	O
whereas	O
the	O
D1	O
agnoist	O
SKF	O
38393	O
had	O
no	O
efefct	O
.	O

The	O
reuslts	O
indicate	O
that	O
aucte	O
nicoitne	O
ijnection	O
indcues	O
a	O
pronounced	O
hyperactviity	B-Disease
in	O
rtas	O
hbaituated	O
to	O
the	O
tset	O
envirnoment	O
.	O

The	O
effcet	O
appears	O
to	O
be	O
mediated	O
by	O
cetnral	O
nicoitne	O
reecptors	O
,	O
possibly	O
located	O
on	O
dpoaminergic	O
neuorns	O
,	O
and	O
also	O
requires	O
the	O
actiavtion	O
of	O
both	O
D1	O
and	O
D2	O
dopmaine	O
recetpors	O
.	O

Cetnral	O
rteinal	B-Disease
vien	I-Disease
occlusoin	I-Disease
associated	O
with	O
clompihene	O
-	O
induecd	O
ovualtion	O
.	O

OBJCETIVE	O
:	O
To	O
rpeort	O
a	O
csae	O
of	O
centarl	O
retianl	B-Disease
vien	I-Disease
occlusoin	I-Disease
associated	O
with	O
cloimphene	O
citarte	O
(	O
CC	O
)	O
.	O

DESIGN	O
:	O
Csae	O
stduy	O
.	O

SETTING	O
:	O
Ophhtalmology	O
cliinc	O
of	O
an	O
acdaemic	O
hosiptal	O
.	O

PATINET	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
yaer	O
-	O
old	O
wmoan	O
referred	O
from	O
the	O
infertliity	B-Disease
cliinc	O
for	O
blrured	B-Disease
vsiion	I-Disease
.	O

INTEVRENTION	O
(	O
S	O
)	O
:	O
Ophthalimc	O
examinaiton	O
after	O
CC	O
therpay	O
.	O

MIAN	O
OTUCOME	O
MAESURE	O
(	O
S	O
)	O
:	O
Cetnral	O
rteinal	B-Disease
vien	I-Disease
occulsion	I-Disease
after	O
ovultaion	O
indutcion	O
with	O
CC	O
.	O

RSEULT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
yaer	O
-	O
old	O
Cihnese	O
wmoan	O
developed	O
cenrtal	O
retianl	B-Disease
vien	I-Disease
occlusion	I-Disease
after	O
eight	O
cousres	O
of	O
CC	O
.	O

A	O
search	O
of	O
the	O
lietrature	O
on	O
the	O
thromboemboilc	B-Disease
complictaions	O
of	O
CC	O
does	O
not	O
include	O
this	O
sveere	O
ophthlamic	O
comlpication	O
,	O
although	O
mlid	O
viusal	B-Disease
disturbnace	I-Disease
after	O
CC	O
intkae	O
is	O
not	O
uncommon	O
.	O

CONLCUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
csae	O
of	O
cenrtal	O
retianl	B-Disease
vien	I-Disease
oclcusion	I-Disease
after	O
treatmnet	O
with	O
CC	O
.	O

Etxra	O
caution	O
is	O
warranted	O
in	O
traeting	O
infertliity	B-Disease
pateints	O
with	O
CC	O
,	O
and	O
ptaients	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
efefct	O
before	O
commenecment	O
of	O
therpay	O
.	O

Aucte	O
bronchodialting	O
effects	O
of	O
ipratorpium	O
broimde	O
and	O
theophylilne	O
in	O
chornic	B-Disease
obsrtuctive	I-Disease
pulmoanry	I-Disease
dsiease	I-Disease
.	O

The	O
bronchodialtor	O
effects	O
of	O
a	O
single	O
dsoe	O
of	O
ipartropium	O
bromdie	O
areosol	O
(	O
36	O
mircograms	O
)	O
and	O
short	O
-	O
acting	O
theophylilne	O
tbalets	O
(	O
dsoe	O
titarted	O
to	O
produce	O
sreum	O
lveels	O
of	O
10	O
-	O
20	O
microgarms	O
/	O
mL	O
)	O
were	O
comapred	O
in	O
a	O
double	O
-	O
bilnd	O
,	O
palcebo	O
-	O
controlled	O
crossvoer	O
sutdy	O
in	O
21	O
ptaients	O
with	O
stbale	O
,	O
chrnoic	B-Disease
obstrutcive	I-Disease
pumlonary	I-Disease
dsiease	I-Disease
.	O

Mean	O
peak	O
forced	O
expirtaory	O
vloume	O
in	O
1	O
second	O
(	O
FVE1	O
)	O
icnreases	O
over	O
baseilne	O
and	O
the	O
proportoin	O
of	O
ptaients	O
attaining	O
at	O
least	O
a	O
15	O
%	O
icnrease	O
in	O
the	O
FVE1	O
(	O
respondres	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipratorpium	O
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
thepohylline	O
.	O

The	O
avergae	O
FVE1	O
increaess	O
during	O
the	O
6	O
-	O
hour	O
obsrevation	O
peroid	O
were	O
18	O
%	O
for	O
iprtaropium	O
and	O
8	O
%	O
for	O
theophylilne	O
.	O

The	O
mean	O
druation	O
of	O
aciton	O
was	O
3	O
.	O
8	O
hours	O
with	O
iprtaropium	O
and	O
2	O
.	O
4	O
hours	O
with	O
theophylilne	O
.	O

While	O
side	O
effetcs	O
were	O
rrae	O
,	O
those	O
experienced	O
after	O
theophlyline	O
use	O
did	O
involve	O
the	O
cradiovascular	B-Disease
and	I-Disease
gsatrointestinal	I-Disease
ssytems	I-Disease
.	O

These	O
resluts	O
show	O
that	O
iprartopium	O
is	O
a	O
more	O
potent	O
bronchodilaotr	O
than	O
oarl	O
theophylline	O
in	O
ptaients	O
with	O
chornic	B-Disease
ariflow	I-Disease
obstructoin	I-Disease
.	O

Methapmhetamine	O
-	O
indcued	O
neurotoxiicty	B-Disease
and	O
microglail	O
activtaion	O
are	O
not	O
mediated	O
by	O
frcatalkine	O
recepotr	O
siganling	O
.	O

Mtehamphetamine	O
(	O
MTEH	O
)	O
damgaes	O
dopamnie	O
(	O
DA	O
)	O
nevre	O
endigns	O
by	O
a	O
porcess	O
that	O
has	O
been	O
linked	O
to	O
mciroglial	O
actviation	O
but	O
the	O
signailng	O
patwhays	O
that	O
mediate	O
this	O
resopnse	O
have	O
not	O
yet	O
been	O
delineated	O
.	O

Cardnoa	O
et	O
al	O
.	O

[	O
Nat	O
.	O
Neruosci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
idenitfied	O
the	O
microglail	O
-	O
specific	O
farctalkine	O
recepotr	O
(	O
C3XCR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MTPP	O
-	O
idnuced	O
neurodegeneraiton	B-Disease
of	O
DA	O
neurnos	O
.	O

Because	O
the	O
CNS	B-Disease
dmaage	I-Disease
caused	O
by	O
MTEH	O
and	O
MTPP	O
is	O
highly	O
selective	O
for	O
the	O
DA	O
nueronal	O
sytsem	O
in	O
mosue	O
modles	O
of	O
neurtooxicity	B-Disease
,	O
we	O
hypothesized	O
that	O
the	O
CX3RC1	O
plays	O
a	O
role	O
in	O
MTEH	O
-	O
indcued	O
neurotoxciity	B-Disease
and	O
micrgolial	O
activaiton	O
.	O

Mcie	O
in	O
which	O
the	O
C3XCR1	O
gnee	O
has	O
been	O
delteed	O
and	O
replaced	O
with	O
a	O
cNDA	O
ecnoding	O
ehnanced	O
green	O
fluoresecnt	O
portein	O
(	O
eFGP	O
)	O
were	O
terated	O
with	O
MTEH	O
and	O
examined	O
for	O
straital	O
nuerotoxicity	B-Disease
.	O

MTEH	O
delpeted	O
DA	O
,	O
caused	O
micorglial	O
atcivation	O
,	O
and	O
icnreased	O
bdoy	O
temperautre	O
in	O
C3XCR1	O
konckout	O
mcie	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
tmie	O
cuorse	O
seen	O
in	O
wlid	O
-	O
tpye	O
cnotrols	O
.	O

The	O
effects	O
of	O
MTEH	O
in	O
CX3RC1	O
knockuot	O
mcie	O
were	O
not	O
genedr	O
-	O
depenednt	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
srtiatum	O
.	O

Stiratal	O
microgila	O
experssing	O
eFGP	O
constituitvely	O
show	O
morpholoigcal	O
chagnes	O
after	O
MTEH	O
that	O
are	O
charactreistic	O
of	O
acitvation	O
.	O

This	O
resposne	O
was	O
restricted	O
to	O
the	O
stritaum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eFGP	O
-	O
mciroglia	O
in	O
surrounding	O
brian	O
areas	O
that	O
are	O
not	O
damgaed	O
by	O
MTEH	O
.	O

We	O
conclude	O
from	O
these	O
stduies	O
that	O
CX3RC1	O
signlaing	O
does	O
not	O
mdoulate	O
MTEH	O
neurotoxciity	B-Disease
or	O
microlgial	O
atcivation	O
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
stiratal	O
-	O
reisdent	O
mciroglia	O
respond	O
to	O
MTEH	O
with	O
an	O
actviation	O
csacade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apotposis	O
or	O
migartion	O
.	O

Nicotnie	O
-	O
inudced	O
nsytagmus	B-Disease
correlates	O
with	O
midopntine	O
activaiton	O
.	O

The	O
ptahomechanism	O
of	O
nioctine	O
-	O
indcued	O
nytsagmus	B-Disease
(	O
NIN	B-Disease
)	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
delineate	O
barin	O
sturctures	O
that	O
are	O
involved	O
in	O
NIN	B-Disease
generatoin	O
.	O

Eight	O
healhty	O
volunteres	O
inhaeld	O
nicoitne	O
in	O
darkenss	O
during	O
a	O
functioanl	O
magneitc	O
resonnace	O
imagnig	O
(	O
fRMI	O
)	O
expreiment	O
;	O
eye	O
movemnets	O
were	O
rgeistered	O
using	O
vdieo	O
-	O
oculogrpahy	O
.	O

NIN	B-Disease
corerlated	O
with	O
bolod	O
oxgyen	O
lveel	O
-	O
depenednt	O
(	O
BLOD	O
)	O
actviity	O
lveels	O
in	O
a	O
midponitne	O
stie	O
in	O
the	O
psoterior	O
basis	O
pnotis	O
.	O

NIN	B-Disease
-	O
induecd	O
mdipontine	O
activaiton	O
may	O
correspond	O
to	O
actiavtion	O
of	O
the	O
dorsomdeial	O
pontnie	O
nculei	O
and	O
the	O
nucelus	O
rteicularis	O
tegemnti	O
potnis	O
,	O
strcutures	O
known	O
to	O
participate	O
in	O
the	O
generatoin	O
of	O
mulitdirectional	O
saccades	O
and	O
smotoh	O
purusit	O
eye	O
moevments	O
.	O

Aucte	O
effcets	O
of	O
N	O
-	O
(	O
2	O
-	O
propylpentaonyl	O
)	O
uera	O
on	O
hippocamapl	O
amnio	O
aicd	O
neurotransmitters	O
in	O
pilocaripne	O
-	O
inudced	O
seiuzre	B-Disease
in	O
rtas	O
.	O

The	O
present	O
stduy	O
aimed	O
to	O
investgiate	O
the	O
anticovnulsant	O
atcivity	O
as	O
well	O
as	O
the	O
effetcs	O
on	O
the	O
lveel	O
of	O
hipopcampal	O
aimno	O
aicd	O
neurotrnasmitters	O
(	O
gultamate	O
,	O
asparatte	O
,	O
glyicne	O
and	O
GBAA	O
)	O
of	O
N	O
-	O
(	O
2	O
-	O
prpoylpentanoyl	O
)	O
uera	O
(	O
VPU	O
)	O
in	O
comparsion	O
to	O
its	O
paernt	O
compuond	O
,	O
valprioc	O
aicd	O
(	O
VPA	O
)	O
.	O

VPU	O
was	O
more	O
potent	O
than	O
VPA	O
,	O
exhibiting	O
the	O
medain	O
effecitve	O
dsoe	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rtas	O
against	O
pilocaprine	O
-	O
idnuced	O
siezure	B-Disease
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	O
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
microidalysis	O
demonstrated	O
that	O
an	O
intraepritoneal	O
administratoin	O
of	O
pilcoarpine	O
idnuced	O
a	O
pronounced	O
incerment	O
of	O
hippocapmal	O
glutmaate	O
and	O
asparatte	O
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
lveel	O
of	O
glcyine	O
and	O
GBAA	O
.	O

Prtereatment	O
with	O
either	O
VPU	O
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	O
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilcoarpine	O
-	O
eovked	O
icnreases	O
in	O
extraecllular	O
gultamate	O
and	O
asparttae	O
.	O

In	O
addition	O
,	O
a	O
staitstically	O
significant	O
reudction	O
was	O
also	O
observed	O
on	O
the	O
lveel	O
of	O
GBAA	O
and	O
gylcine	O
but	O
less	O
than	O
a	O
drasitc	O
redcution	O
of	O
glutmaate	O
and	O
asparttae	O
leevl	O
.	O

Based	O
on	O
the	O
fidning	O
that	O
VPU	O
and	O
VPA	O
could	O
protect	O
the	O
aniamls	O
against	O
pilocaprine	O
-	O
idnuced	O
seiuzre	B-Disease
it	O
is	O
suggested	O
that	O
the	O
reductoin	O
of	O
inhbiitory	O
aimno	O
aicd	O
neurortansmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduciton	O
of	O
gltuamate	O
and	O
aspratate	O
.	O

Therefore	O
,	O
like	O
VPA	O
,	O
the	O
fidning	O
that	O
VPU	O
could	O
drastically	O
rdeuce	O
pilocarpnie	O
-	O
indcued	O
increaess	O
in	O
glutamtae	O
and	O
aspatrate	O
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonuvlsant	O
atcivity	O
observed	O
in	O
pliocarpine	O
-	O
inudced	O
seizrue	B-Disease
in	O
expreimental	O
anmials	O
.	O

Some	O
other	O
mehcanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
investgiated	O
.	O

Portective	O
efefct	O
of	O
verapaiml	O
on	O
gatsric	B-Disease
hmeorrhagic	I-Disease
ulecrs	B-Disease
in	O
sevree	O
atheroscelrotic	B-Disease
rtas	O
.	O

Stduies	O
concerning	O
with	O
ptahogenesis	O
of	O
gastirc	B-Disease
hemorhrage	I-Disease
and	O
mucoasl	O
ulceartion	O
produced	O
in	O
atheroscleroitc	B-Disease
rtas	O
are	O
lacking	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
is	O
to	O
examine	O
the	O
role	O
of	O
gasrtic	O
aicd	O
back	O
-	O
diffsuion	O
,	O
msat	O
clel	O
histmaine	O
rleease	O
,	O
lpiid	O
peorxide	O
(	O
LPO	O
)	O
geneartion	O
and	O
mucoasl	O
micorvascular	O
permeabiilty	O
in	O
mdoulating	O
gastirc	B-Disease
hemorrhage	I-Disease
and	O
ucler	B-Disease
in	O
rtas	O
with	O
ahterosclerosis	B-Disease
idnuced	O
by	O
coadimnistration	O
of	O
vitaimn	O
D2	O
and	O
chloesterol	O
.	O

Additionally	O
,	O
the	O
protective	O
effcet	O
of	O
vreapamil	O
on	O
this	O
ucler	B-Disease
moedl	O
was	O
evalutaed	O
.	O

Mlae	O
Wisatr	O
rtas	O
were	O
chlalenged	O
intraagstrically	O
once	O
dialy	O
for	O
9	O
dyas	O
with	O
1	O
.	O
0	O
ml	O
/	O
kg	O
of	O
cron	O
oil	O
containing	O
viatmin	O
D2	O
and	O
cholseterol	O
to	O
idnuce	O
atherosclreosis	B-Disease
.	O

Cnotrol	O
rtas	O
received	O
cron	O
oil	O
only	O
.	O

After	O
gsatric	O
sugrery	O
,	O
rat	O
stoamchs	O
were	O
irrgiated	O
for	O
3	O
h	O
with	O
either	O
simultaed	O
gatsric	O
jiuce	O
or	O
nomral	O
slaine	O
.	O

Gatsric	O
aicd	O
back	O
-	O
diffusion	O
,	O
mucsoal	O
LPO	O
genertaion	O
,	O
hitsamine	O
concentrtaion	O
,	O
microvascluar	O
pemreability	O
,	O
lumnial	O
hemogloibn	O
conetnt	O
and	O
ucler	B-Disease
areas	O
were	O
determined	O
.	O

Elevtaed	O
ahterosclerotic	B-Disease
parameetrs	O
,	O
such	O
as	O
sreum	O
calicum	O
,	O
total	O
cholesetrol	O
and	O
low	O
-	O
dnesity	O
lipoprtoein	O
concentraiton	O
were	O
obtained	O
in	O
atheroscelrotic	B-Disease
rtas	O
.	O

Seevre	O
gsatric	O
uclers	B-Disease
accompanied	O
with	O
incresaed	O
ulcergoenic	O
factros	O
,	O
including	O
gatsric	O
aicd	O
back	O
-	O
diffusoin	O
,	O
hsitamine	O
rleease	O
,	O
LPO	O
generaiton	O
and	O
lmuinal	O
hemolgobin	O
cotnent	O
were	O
also	O
observed	O
in	O
these	O
rtas	O
.	O

Moreover	O
,	O
a	O
postiive	O
correaltion	O
of	O
histaimne	O
to	O
gasrtic	B-Disease
hmeorrhage	I-Disease
and	O
to	O
ulecr	B-Disease
was	O
found	O
in	O
those	O
atehrosclerotic	B-Disease
rtas	O
.	O

This	O
hmeorrhagic	B-Disease
ucler	B-Disease
and	O
various	O
ulcreogenic	O
paarmeters	O
were	O
dsoe	O
-	O
dependently	O
amleiorated	O
by	O
dialy	O
intargastric	O
verapmail	O
.	O

Atheorsclerosis	B-Disease
could	O
produce	O
gsatric	B-Disease
hemorrhgaic	I-Disease
ucler	B-Disease
via	O
agrgavation	O
of	O
gatsric	O
aicd	O
back	O
-	O
diffusion	O
,	O
LPO	O
gneeration	O
,	O
hsitamine	O
relaese	O
and	O
microvsacular	O
permeabiltiy	O
that	O
could	O
be	O
ameilorated	O
by	O
verpaamil	O
in	O
rtas	O
.	O

Lamivuidne	O
for	O
the	O
prevnetion	O
of	O
hepatiits	B-Disease
B	I-Disease
viurs	O
reactivaiton	O
in	O
hepatiits	O
-	O
B	O
sufrace	O
anitgen	O
(	O
HBASG	O
)	O
sreopositive	O
cacner	B-Disease
pateints	O
undergoing	O
cytotoixc	O
chemtoherapy	O
.	O

Heaptitis	B-Disease
B	I-Disease
viurs	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
crhonic	O
lievr	B-Disease
dsiease	I-Disease
worldwide	O
.	O

Cacner	B-Disease
paitents	O
who	O
are	O
chroinc	O
carriers	O
of	O
HBV	O
have	O
a	O
higehr	O
heptaic	B-Disease
complicaiton	I-Disease
rtae	O
while	O
receiving	O
ctyotoxic	O
chemothreapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactiavtion	O
.	O

In	O
this	O
stduy	O
,	O
cnacer	B-Disease
paitents	O
who	O
have	O
soild	O
and	O
hematoolgical	B-Disease
malignanices	I-Disease
with	O
chornic	O
HBV	B-Disease
infeciton	I-Disease
received	O
the	O
antivrial	O
agnet	O
lamivuidne	O
prior	O
and	O
during	O
CT	O
compaerd	O
with	O
hsitorical	O
cotnrol	O
gorup	O
who	O
did	O
not	O
receive	O
lmaivudine	O
.	O

The	O
objecitves	O
were	O
to	O
assess	O
the	O
effciacy	O
of	O
lamivduine	O
in	O
reduicng	O
the	O
incidnece	O
of	O
HBV	O
recativation	O
,	O
and	O
diimnishing	O
mobridity	O
and	O
mrotality	O
during	O
CT	O
.	O

Two	O
gropus	O
were	O
compraed	O
in	O
this	O
sutdy	O
.	O

The	O
prophyalctic	O
lamivuidn	O
gruop	O
consisted	O
of	O
37	O
patietns	O
who	O
received	O
prpohylactic	O
lmaivudine	O
treatmnet	O
.	O

The	O
histroical	O
cotnrols	O
consisted	O
of	O
50	O
consecutvie	O
paitents	O
who	O
underwent	O
CT	O
without	O
prophylcatic	O
lamiuvdine	O
.	O

They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
weeks	O
after	O
CT	O
.	O

The	O
outcmoes	O
were	O
comapred	O
for	O
both	O
gropus	O
.	O

Of	O
our	O
cnotrol	O
gorup	O
(	O
n	O
=	O
50	O
)	O
,	O
21	O
patinets	O
(	O
42	O
%	O
)	O
were	O
established	O
hpeatitis	B-Disease
.	O

Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evalauted	O
as	O
sveere	O
hepaittis	B-Disease
.	O

In	O
the	O
prohpylactic	O
laimvudine	O
gorup	O
seevre	O
hepattiis	B-Disease
were	O
observed	O
only	O
in	O
1	O
paitent	O
(	O
2	O
.	O
7	O
%	O
)	O
of	O
37	O
patietns	O
(	O
p	O
<	O
0	O
.	O
006	O
)	O
.	O

Cmoparison	O
of	O
the	O
mean	O
ALT	O
valeus	O
revelaed	O
significantly	O
hihger	O
mean	O
alnaine	O
aminotransefrase	O
(	O
ALT	O
)	O
vaules	O
in	O
the	O
conrtol	O
gruop	O
than	O
the	O
prohpylactic	O
lamivuidne	O
gorup	O
;	O
154	O
:	O
64	O
(	O
p	O
<	O
0	O
.	O
32	O
)	O
.	O

Our	O
stduy	O
suggests	O
that	O
prohpylactic	O
lamivduine	O
significantly	O
decraeses	O
the	O
icnidence	O
of	O
HBV	O
recativation	O
and	O
overall	O
mrobidity	O
in	O
cnacer	B-Disease
ptaients	O
during	O
and	O
after	O
immunospupressive	O
therpay	O
.	O

Further	O
stduies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nculeoside	O
or	O
nucletoide	O
anlaogue	O
for	O
antiviarl	O
prophyalxis	O
during	O
CT	O
and	O
the	O
optiaml	O
duratoin	O
of	O
adminisrtation	O
after	O
completoin	O
of	O
CT	O
.	O

Rceovery	O
of	O
tacroliums	O
-	O
associated	O
brahcial	B-Disease
nueritis	I-Disease
after	O
covnersion	O
to	O
everolmius	O
in	O
a	O
pediatirc	O
rneal	O
trasnplant	O
reicpient	O
-	O
-	O
csae	O
rpeort	O
and	O
rveiew	O
of	O
the	O
litearture	O
.	O

TAC	O
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agnet	O
for	O
soild	O
oragn	O
translpantation	O
in	O
pdeiatrics	O
.	O

Neurotoxciity	B-Disease
is	O
a	O
potentially	O
serious	O
toixc	O
effect	O
.	O

It	O
is	O
characterzied	O
by	O
encepahlopathy	B-Disease
,	O
hedaaches	B-Disease
,	O
seziures	B-Disease
,	O
or	O
neurolgoical	B-Disease
dfeicits	I-Disease
.	O

Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
mlae	O
rneal	O
tranpslant	O
recipeint	O
with	O
rihgt	O
BN	O
.	O

MRI	O
demonstrated	O
hyeprintense	O
T2	O
sginals	O
in	O
the	O
cerivcal	O
crod	O
and	O
rgiht	O
brachail	O
plxeus	O
roots	O
inidcative	O
of	O
both	O
meylitis	B-Disease
and	O
rihgt	O
brahcial	B-Disease
plextiis	I-Disease
.	O

Symtpoms	O
persisted	O
for	O
three	O
motnhs	O
despite	O
TAC	O
dsoe	O
reduciton	O
,	O
adimnistration	O
of	O
IIVG	O
and	O
four	O
doess	O
of	O
methylprednisloone	O
pluse	O
tehrapy	O
.	O

Improvemnet	O
and	O
eventually	O
full	O
recoevry	O
only	O
occurred	O
after	O
TAC	O
was	O
completely	O
disconitnued	O
and	O
successfully	O
replaced	O
by	O
everolmius	O
.	O

Omitting	O
fnetanyl	O
redcues	O
nauesa	B-Disease
and	O
vomitnig	B-Disease
,	O
without	O
icnreasing	O
pian	B-Disease
,	O
after	O
sevofulrane	O
for	O
day	O
suregry	O
.	O

BACKGRUOND	O
AND	O
OBEJCTIVE	O
:	O
Despite	O
advantages	O
of	O
inductoin	O
and	O
mainetnance	O
of	O
anaestehsia	O
with	O
sevfolurane	O
,	O
psotoperative	B-Disease
nuasea	I-Disease
and	I-Disease
vmoiting	I-Disease
occurs	O
frequently	O
.	O

Fnetanyl	O
is	O
a	O
commonly	O
used	O
supplemnet	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
imrpove	O
analgseia	O
.	O

METHODS	O
:	O
This	O
double	O
-	O
blnid	O
sutdy	O
examined	O
the	O
incdience	O
and	O
severtiy	O
of	O
postpoerative	B-Disease
nasuea	I-Disease
and	I-Disease
voimting	I-Disease
and	O
pian	B-Disease
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurnae	O
anaetshesia	O
in	O
216	O
audlt	O
day	O
suregry	O
ptaients	O
.	O

Pateints	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentaynl	O
,	O
while	O
a	O
third	O
gorup	O
received	O
dexamtehasone	O
in	O
addition	O
to	O
fentaynl	O
.	O

RESUTLS	O
:	O
Oimssion	O
of	O
fnetanyl	O
did	O
not	O
reudce	O
the	O
overall	O
inicdence	O
of	O
potsoperative	B-Disease
nuasea	I-Disease
and	I-Disease
vomtiing	I-Disease
,	O
but	O
did	O
reudce	O
the	O
icnidence	O
of	O
voimting	B-Disease
and	O
/	O
or	O
modreate	O
to	O
sveere	O
nauesa	B-Disease
prior	O
to	O
dischrage	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fenatnyl	O
and	O
fentaynl	O
-	O
dxeamethasone	O
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Anitemetic	O
requiremetns	O
were	O
redcued	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
0012	O
)	O
.	O

Dexamehtasone	O
had	O
no	O
significant	O
effcet	O
on	O
the	O
incidnece	O
or	O
seevrity	O
of	O
postopeartive	B-Disease
nuasea	I-Disease
and	I-Disease
vomtiing	I-Disease
.	O

Combining	O
the	O
two	O
fentaynl	O
gruops	O
reevaled	O
further	O
significant	O
beneifts	O
from	O
the	O
aviodance	O
of	O
opoiids	O
,	O
redcuing	O
postoperaitve	B-Disease
nasuea	I-Disease
and	I-Disease
voimting	I-Disease
and	O
nuasea	B-Disease
prior	O
to	O
dischagre	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nasuea	B-Disease
in	O
the	O
first	O
24	O
h	O
was	O
decreaesd	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

Pian	B-Disease
sveerity	O
and	O
analegsic	O
reuqirements	O
were	O
unafefcted	O
by	O
the	O
omission	O
of	O
fentnayl	O
.	O

Fetnanyl	O
did	O
rdeuce	O
minor	O
intraoperatvie	O
mvoement	O
but	O
had	O
no	O
seovflurane	O
-	O
sparing	O
effect	O
and	O
increaesd	O
respiratroy	B-Disease
depressoin	I-Disease
,	O
hypotnesion	B-Disease
and	O
bradycradia	B-Disease
.	O

COCNLUSION	O
:	O
As	O
fenatnyl	O
exacerbaetd	O
postopertaive	B-Disease
nuasea	I-Disease
and	I-Disease
vomitnig	I-Disease
without	O
an	O
imrpovement	O
in	O
postoeprative	B-Disease
pian	I-Disease
and	O
also	O
had	O
avderse	O
cardiorespirtaory	O
efefcts	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detriemntal	O
suppleemnt	O
to	O
sevofulrane	O
in	O
day	O
suregry	O
.	O

Vavlular	B-Disease
herat	I-Disease
disaese	I-Disease
in	O
patinets	O
with	O
Pariknson	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
terated	O
with	O
pergoilde	O
.	O

Cousre	O
following	O
tretament	O
modificatoins	O
.	O

Valvualr	B-Disease
herat	I-Disease
abnormaltiies	I-Disease
have	O
been	O
reported	O
in	O
ptaients	O
with	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
(	O
PD	B-Disease
)	O
treaetd	O
with	O
pregolide	O
.	O

However	O
,	O
the	O
incidecne	O
and	O
sevreity	O
of	O
these	O
abnormaliites	O
vary	O
from	O
sutdy	O
to	O
stduy	O
and	O
their	O
cousre	O
after	O
durg	O
withdarwal	O
has	O
not	O
been	O
sytsematically	O
assesesd	O
.	O

OJBECTIVES	O
:	O
To	O
esitmate	O
the	O
frequnecy	O
and	O
seveirty	O
of	O
valvualr	B-Disease
haert	I-Disease
anbormality	I-Disease
and	O
its	O
possible	O
revesribility	O
after	O
durg	O
withdraawl	O
in	O
a	O
csae	O
-	O
cotnrol	O
sutdy	O
.	O

METHODS	O
:	O
All	O
PD	B-Disease
paitents	O
in	O
the	O
Amines	O
aera	O
traeted	O
with	O
pegrolide	O
were	O
invited	O
to	O
attend	O
a	O
cardioloigc	O
assessmnet	O
including	O
transtohracic	O
echocradiography	O
.	O

Thirty	O
PD	B-Disease
patinets	O
participated	O
in	O
the	O
stduy	O
.	O

A	O
second	O
echoacrdiography	O
was	O
performed	O
(	O
medain	O
inetrval	O
:	O
13	O
monhts	O
)	O
after	O
pregolide	O
withdrwaal	O
(	O
n	O
=	O
10	O
patietns	O
)	O
.	O

Cnotrols	O
were	O
age	O
-	O
and	O
sex	O
-	O
matched	O
non	O
-	O
PD	B-Disease
pateints	O
referred	O
to	O
the	O
cardoilogy	O
departemnt	O
.	O

RESUTLS	O
:	O
Copmared	O
to	O
cotnrols	O
,	O
aotric	B-Disease
regurgtiation	I-Disease
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
mirtal	B-Disease
reugrgitation	I-Disease
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
ferquent	O
in	O
PD	B-Disease
pateints	O
(	O
tricusipd	O
:	O
NS	O
)	O
.	O

The	O
number	O
of	O
affected	O
vlaves	O
(	O
n	O
=	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
and	O
the	O
sum	O
of	O
rgeurgitation	O
gardes	O
(	O
n	O
=	O
2	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
09	O
)	O
were	O
higehr	O
(	O
p	O
=	O
0	O
.	O
008	O
and	O
p	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
in	O
the	O
pergloide	O
gorup	O
.	O

Severtiy	O
of	O
regurgittaion	O
was	O
not	O
corrleated	O
with	O
pregolide	O
cumultaive	O
dsoe	O
.	O

A	O
restrictvie	O
patetrn	O
of	O
valuvlar	B-Disease
regurgitaiton	I-Disease
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergoldie	O
,	O
was	O
observed	O
in	O
12	O
/	O
30	O
(	O
40	O
%	O
)	O
paitents	O
including	O
two	O
with	O
haert	B-Disease
fialure	I-Disease
.	O

Peroglide	O
was	O
discotninued	O
in	O
10	O
ptaients	O
with	O
valvualr	B-Disease
haert	I-Disease
diesase	I-Disease
,	O
resulting	O
in	O
a	O
loewr	O
regurigtation	O
grdae	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
at	O
the	O
second	O
transthorcaic	O
echocardigoraphy	O
and	O
the	O
two	O
patinets	O
with	O
haert	B-Disease
faliure	I-Disease
returned	O
to	O
nearly	O
noraml	O
cliniacl	O
eaxmination	O
.	O

This	O
stduy	O
supports	O
the	O
high	O
frqeuency	O
of	O
restirctive	O
vlave	B-Disease
regrugitation	I-Disease
in	O
PD	B-Disease
patietns	O
tretaed	O
with	O
pegrolide	O
and	O
reveals	O
that	O
a	O
significant	O
improevment	O
is	O
usual	O
when	O
the	O
treamtent	O
is	O
converted	O
to	O
non	O
-	O
erogt	O
dopamnie	O
agonsits	O
.	O

Adiramycin	O
-	O
idnuced	O
autopahgic	O
cardiomoycyte	O
daeth	B-Disease
plays	O
a	O
pathogeinc	O
role	O
in	O
a	O
rat	O
moedl	O
of	O
herat	B-Disease
fialure	I-Disease
.	O

BACKRGOUND	O
:	O
The	O
mechanimss	O
underlying	O
haert	B-Disease
failrue	I-Disease
inudced	O
by	O
adraimycin	O
are	O
very	O
complictaed	O
and	O
still	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
invetsigate	O
whether	O
autopahgy	O
was	O
involved	O
in	O
the	O
progression	O
of	O
haert	B-Disease
failrue	I-Disease
induecd	O
by	O
adraimycin	O
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatmnet	O
strategy	O
for	O
haert	B-Disease
fialure	I-Disease
.	O

METHODS	O
:	O
3	O
-	O
metyhladenine	O
(	O
3MA	O
)	O
,	O
a	O
specific	O
ihnibitor	O
on	O
auotphagy	O
was	O
used	O
in	O
a	O
herat	B-Disease
faliure	I-Disease
mdoel	O
of	O
rtas	O
inudced	O
by	O
adriamyicn	O
.	O

Neontaal	O
cardioymocytes	O
were	O
ioslated	O
from	O
Srpague	O
-	O
Dwaley	O
rat	O
herats	O
and	O
randomly	O
divided	O
into	O
cnotrols	O
,	O
an	O
adiramycin	O
-	O
traeted	O
gorup	O
,	O
and	O
a	O
3MA	O
plus	O
adriamyicn	O
-	O
tretaed	O
gruop	O
.	O

We	O
then	O
examined	O
the	O
mrophology	O
,	O
epxression	O
of	O
bcelin	O
1	O
gnee	O
,	O
mitochondiral	O
premeability	O
tranistion	O
(	O
MPT	O
)	O
,	O
and	O
Na	O
+	O
-	O
K	O
+	O
ATaPse	O
atcivity	O
in	O
vivo	O
.	O

We	O
also	O
asesssed	O
clel	O
viabliity	O
,	O
mitocohndrial	O
memrbane	O
potnetial	O
chanegs	O
and	O
counetd	O
autohpagic	O
vacuoels	O
in	O
cutlured	O
cardoimyocytes	O
.	O

In	O
addition	O
,	O
we	O
analzyed	O
the	O
exprsesion	O
of	O
autohpagy	O
associated	O
gnee	O
,	O
belcin	O
1	O
using	O
RT	O
-	O
PCR	O
and	O
Wetsern	O
blottnig	O
in	O
an	O
anmial	O
moedl	O
.	O

RESLUTS	O
:	O
3MA	O
significantly	O
imporved	O
cadriac	O
fnuction	O
and	O
redcued	O
mitochnodrial	O
inujry	O
.	O

Furthermore	O
,	O
adraimycin	O
inudced	O
the	O
fromation	O
of	O
autophaigc	O
vaucoles	O
,	O
and	O
3MA	O
strongly	O
dwonregulated	O
the	O
expressoin	O
of	O
bcelin	O
1	O
in	O
ardiamycin	O
-	O
inudced	O
failing	O
herat	O
and	O
inhibtied	O
the	O
foramtion	O
of	O
auotphagic	O
vaculoes	O
.	O

CNOCLUSION	O
:	O
Autophaigc	O
cardiomyoctye	O
detah	B-Disease
plays	O
an	O
important	O
role	O
in	O
the	O
ptahogenesis	O
of	O
haert	B-Disease
failrue	I-Disease
in	O
rtas	O
idnuced	O
by	O
adriamcyin	O
.	O

Mitochnodrial	O
ijnury	O
may	O
be	O
involved	O
in	O
the	O
progerssion	O
of	O
herat	B-Disease
faliure	I-Disease
caused	O
by	O
adraimycin	O
via	O
the	O
auotphagy	O
ptahway	O
.	O

moTR	O
ihnibitors	O
-	O
induecd	O
proteniuria	B-Disease
:	O
mechainsms	O
,	O
siginficance	O
,	O
and	O
managemnet	O
.	O

Masisve	O
urniary	O
protien	O
exrcetion	O
has	O
been	O
observed	O
after	O
conevrsion	O
from	O
caclineurin	O
inhibtiors	O
to	O
mammailan	O
traget	O
of	O
rpaamycin	O
(	O
moTR	O
)	O
inhibitros	O
,	O
especially	O
siorlimus	O
,	O
in	O
reanl	O
transplnat	O
recipeints	O
with	O
chrnoic	B-Disease
allgoraft	I-Disease
nehpropathy	I-Disease
.	O

Because	O
proteinuira	B-Disease
is	O
a	O
major	O
perdictive	O
fatcor	O
of	O
poor	O
transplanttaion	O
otucome	O
,	O
many	O
studeis	O
focused	O
on	O
this	O
advrese	O
evnet	O
during	O
the	O
past	O
yaers	O
.	O

Whether	O
proteiunria	B-Disease
was	O
due	O
to	O
sriolimus	O
or	O
only	O
a	O
consequence	O
of	O
caclineurin	O
ihnibitors	O
withdarwal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteiunria	B-Disease
has	O
been	O
observed	O
during	O
siorlimus	O
therpay	O
in	O
iselt	O
trasnplantation	O
and	O
in	O
paitents	O
who	O
received	O
siroilmus	O
de	O
novo	O
.	O

Podcoyte	O
injruy	O
and	O
foacl	O
segemntal	O
glomeruloscleorsis	B-Disease
have	O
been	O
related	O
to	O
moTR	O
inhibtiion	O
in	O
some	O
patinets	O
,	O
but	O
the	O
pathwyas	O
underlying	O
these	O
lseions	O
remain	O
hypothetic	O
.	O

We	O
discuss	O
herein	O
the	O
possible	O
mechainsms	O
and	O
the	O
sginificance	O
of	O
moTR	O
blockdae	O
-	O
inudced	O
proetinuria	B-Disease
.	O

Neuropsychitaric	O
side	O
effects	O
after	O
the	O
use	O
of	O
mfeloquine	O
.	O

This	O
sutdy	O
describes	O
neuropsychaitric	O
side	O
effects	O
in	O
patietns	O
after	O
treamtent	O
with	O
meflqouine	O
.	O

Recations	O
consisted	O
mainly	O
of	O
seziures	B-Disease
,	O
actue	O
psycohses	B-Disease
,	O
anixety	B-Disease
neuorsis	I-Disease
,	O
and	O
major	O
dsiturbances	B-Disease
of	I-Disease
sleep	I-Disease
-	I-Disease
wake	I-Disease
rhyhtm	I-Disease
.	O

Side	O
effects	O
occurred	O
after	O
both	O
therapetuic	O
and	O
prophylacitc	O
intkae	O
and	O
were	O
graedd	O
from	O
modearte	O
to	O
sveere	O
.	O

In	O
a	O
rsik	O
analsyis	O
of	O
neuropsychiatirc	O
side	O
effetcs	O
in	O
Germnay	O
,	O
it	O
is	O
estimtaed	O
that	O
one	O
of	O
8	O
,	O
000	O
meflqouine	O
uesrs	O
suffers	O
from	O
such	O
reactoins	O
.	O

The	O
incidecne	O
claculation	O
rveealed	O
that	O
one	O
of	O
215	O
therapeuitc	O
usres	O
had	O
recations	O
,	O
comapred	O
with	O
one	O
of	O
13	O
,	O
000	O
in	O
the	O
prophlyaxis	O
gruop	O
,	O
making	O
the	O
rsik	O
of	O
neurposychiatric	O
raections	O
after	O
mefloqunie	O
treatemnt	O
60	O
times	O
higehr	O
than	O
after	O
propyhlaxis	O
.	O

Therefore	O
,	O
certain	O
limitatinos	O
for	O
maalria	B-Disease
prophylxais	O
and	O
treatmnet	O
with	O
melfoquine	O
are	O
recommneded	O
.	O

Prenaatl	O
prtoein	O
deprviation	O
atlers	O
doapmine	O
-	O
mediated	O
behaviros	O
and	O
dopaminegric	O
and	O
glutamaetrgic	O
recpetor	O
bniding	O
.	O

Epidemioolgical	O
evidecne	O
indicates	O
that	O
prenaatl	O
nutriitonal	O
deprivatoin	O
may	O
incresae	O
the	O
rsik	O
of	O
schizophreina	B-Disease
.	O

The	O
gaol	O
of	O
these	O
studeis	O
was	O
to	O
use	O
an	O
ainmal	O
mdoel	O
to	O
examine	O
the	O
efefcts	O
of	O
prenaatl	O
portein	O
depriavtion	O
on	O
behaivors	O
and	O
reecptor	O
binidng	O
with	O
relevance	O
to	O
schizohprenia	B-Disease
.	O

We	O
reoprt	O
that	O
prenatlaly	O
prtoein	O
deprvied	O
(	O
PD	O
)	O
femlae	O
rtas	O
showed	O
an	O
inrceased	O
stereotpyic	O
rseponse	O
to	O
apomorhpine	O
and	O
an	O
incraesed	O
locomootr	O
resposne	O
to	O
amphteamine	O
in	O
audlthood	O
.	O

These	O
differences	O
were	O
not	O
observed	O
during	O
puebrty	O
.	O

No	O
chnages	O
in	O
haloepridol	O
-	O
inudced	O
caatlepsy	B-Disease
or	O
MK	O
-	O
801	O
-	O
indcued	O
lcoomotion	O
were	O
seen	O
following	O
PD	O
.	O

In	O
addition	O
,	O
PD	O
fmeale	O
rtas	O
showed	O
incraesed	O
(	O
3	O
)	O
H	O
-	O
MK	O
-	O
801	O
bindnig	O
in	O
the	O
straitum	O
and	O
hippocapmus	O
,	O
but	O
not	O
in	O
the	O
crotex	O
.	O

PD	O
femlae	O
rtas	O
also	O
showed	O
inrceased	O
(	O
3	O
)	O
H	O
-	O
hlaoperidol	O
bniding	O
and	O
decresaed	O
dpoamine	O
tarnsporter	O
bniding	O
in	O
stiratum	O
.	O

No	O
statsitically	O
significant	O
chanegs	O
in	O
beahvior	O
or	O
recepotr	O
bidning	O
were	O
found	O
in	O
PD	O
maels	O
with	O
the	O
exception	O
of	O
incerased	O
(	O
3	O
)	O
H	O
-	O
MK	O
-	O
801	O
bindnig	O
in	O
coretx	O
.	O

This	O
aniaml	O
mdoel	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechansims	O
by	O
which	O
prneatal	O
nutritoinal	B-Disease
dfeiciency	I-Disease
enhacnes	O
rsik	O
for	O
schizoprhenia	B-Disease
in	O
hmuans	O
and	O
may	O
also	O
have	O
implications	O
for	O
dveelopmental	O
proecsses	O
leading	O
to	O
diffeerntial	O
sensitiivty	O
to	O
drgus	O
of	O
absue	O
.	O

Advesre	O
efefcts	O
of	O
topcial	O
papaveirne	O
on	O
auditroy	O
nevre	O
funtcion	O
.	O

BCAKGROUND	O
:	O
Papaveirne	O
hydrochloirde	O
is	O
a	O
direct	O
-	O
acting	O
vaosdilator	O
used	O
to	O
manage	O
vasopsasm	B-Disease
during	O
various	O
neuorsurgical	O
operaitons	O
.	O

Tranisent	O
crainal	B-Disease
nreve	I-Disease
dysfunctoin	I-Disease
has	O
been	O
described	O
in	O
a	O
few	O
csaes	O
with	O
toipcal	O
papaevrine	O
.	O

This	O
sutdy	O
supports	O
previous	O
rpeorts	O
and	O
provides	O
neurohpysiological	O
eivdence	O
of	O
an	O
advrese	O
effcet	O
on	O
the	O
audiotry	O
nevre	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retorspective	O
rveiew	O
of	O
70	O
consecutvie	O
microvacsular	O
decompresison	O
oeprations	O
and	O
studied	O
those	O
patietns	O
who	O
received	O
tpoical	O
ppaaverine	O
for	O
vaosspasm	B-Disease
.	O

Toipcal	O
ppaaverine	O
was	O
used	O
as	O
a	O
direct	O
therapeuitc	O
actoin	O
to	O
manage	O
vasospsam	B-Disease
in	O
a	O
total	O
of	O
11	O
patietns	O
.	O

The	O
timnig	O
of	O
paapverine	O
applciation	O
and	O
ongoing	O
opeartive	O
evetns	O
was	O
rveiewed	O
relative	O
to	O
chanegs	O
in	O
neurophysiologiacl	O
rceordings	O
.	O

Brainsetm	O
audtiory	O
evoekd	O
potenitals	O
(	O
BEAPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
ccohlear	O
nreve	O
fnuction	O
during	O
these	O
opeartions	O
.	O

FNIDINGS	O
:	O
A	O
tempoarl	O
relatiosnhip	O
was	O
found	O
between	O
topiacl	O
ppaaverine	O
and	O
BEAP	O
chagnes	O
leading	O
to	O
complete	O
wavfeorm	O
lsos	O
.	O

The	O
aevrage	O
tepmoral	O
dleay	O
between	O
papvaerine	O
and	O
the	O
onset	O
of	O
an	O
avderse	O
BEAP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
patinets	O
,	O
BEAP	O
wvaes	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
paapverine	O
.	O

Eight	O
of	O
these	O
10	O
paitents	O
had	O
complete	O
lsos	O
of	O
BEAP	O
wavfeorms	O
within	O
10	O
min	O
.	O

One	O
pateint	O
showed	O
no	O
reocvery	O
of	O
later	O
waevs	O
and	O
a	O
delyaed	O
prfoound	O
sensornieural	B-Disease
hearnig	I-Disease
lsos	I-Disease
.	O

The	O
avergae	O
rceovery	O
tmie	O
of	O
BEAP	O
wavefroms	O
to	O
pre	O
-	O
papavreine	O
basleine	O
vlaues	O
was	O
39	O
min	O
.	O

CONCLUSOINS	O
:	O
Tpoical	O
papavreine	O
for	O
the	O
traetment	O
of	O
vassopasm	B-Disease
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transeint	O
disutrbance	O
in	O
neurophysiologiacl	O
funciton	O
of	O
the	O
ascneding	O
auidtory	O
branistem	O
pahtway	O
.	O

The	O
complete	O
disappearacne	O
of	O
BEAP	O
waveofrms	O
with	O
a	O
consistent	O
temopral	O
dleay	O
suggests	O
a	O
possible	O
advesre	B-Disease
effcet	I-Disease
on	I-Disease
the	I-Disease
porximal	I-Disease
egihth	I-Disease
nreve	I-Disease
.	O

Recomemndations	O
to	O
avoid	O
potnetial	O
crainal	B-Disease
nreve	I-Disease
deifcits	I-Disease
from	O
ppaaverine	O
are	O
provided	O
.	O

Simavstatin	O
-	O
ezetiimbe	O
-	O
indcued	O
hpeatic	B-Disease
fialure	I-Disease
necessitating	O
lievr	O
trasnplantation	O
.	O

Absrtact	O
Sreum	O
aminotransfearse	O
elveations	O
are	O
a	O
commonly	O
known	O
advrese	O
effect	O
of	O
3	O
-	O
hydrxoy	O
-	O
3	O
-	O
methlyglutaryl	O
coeznyme	O
A	O
reductsae	O
inhbiitor	O
(	O
staitn	O
)	O
therpay	O
.	O

However	O
,	O
hepatotoixc	B-Disease
eevnts	O
have	O
not	O
been	O
widely	O
publihsed	O
with	O
ezetmiibe	O
or	O
the	O
combintaion	O
aegnt	O
smivastatin	O
-	O
ezetmiibe	O
.	O

We	O
describe	O
a	O
70	O
-	O
yaer	O
-	O
old	O
Hispainc	O
wmoan	O
who	O
developed	O
fulmiannt	B-Disease
heaptic	I-Disease
faliure	I-Disease
necessitating	O
lievr	O
transplanattion	O
10	O
wekes	O
after	O
conevrsion	O
from	O
sivmastatin	O
40	O
mg	O
/	O
day	O
to	O
simvasttain	O
10	O
mg	O
-	O
ezetimbie	O
40	O
mg	O
/	O
day	O
.	O

The	O
paitent	O
'	O
s	O
liipd	O
panel	O
had	O
been	O
maintained	O
with	O
simavstatin	O
for	O
18	O
monhts	O
before	O
the	O
converison	O
without	O
eivdence	O
of	O
hepatotoxiicty	B-Disease
.	O

A	O
rotuine	O
laboratroy	O
work	O
-	O
up	O
10	O
wekes	O
after	O
converison	O
reevaled	O
eleavted	O
sreum	O
amniotransferase	O
leevls	O
.	O

Simvastatniezetimibe	O
and	O
escitlaopram	O
(	O
which	O
she	O
was	O
taking	O
for	O
derpession	B-Disease
)	O
were	O
disocntinued	O
,	O
and	O
other	O
potentail	O
causes	O
of	O
hepaottoxicity	B-Disease
were	O
excluded	O
.	O

A	O
reepat	O
work	O
-	O
up	O
reevaled	O
further	O
elveations	O
in	O
aminotransfrease	O
leevls	O
,	O
and	O
lvier	O
biposy	O
revelaed	O
eviednce	O
of	O
modreate	O
-	O
to	O
-	O
sveere	O
durg	B-Disease
txoicity	I-Disease
.	O

She	O
underwent	O
lievr	O
transplatnation	O
with	O
an	O
uneevntful	O
postopeartive	O
cuorse	O
.	O

Her	O
aminotransefrase	O
levles	O
returned	O
to	O
nromal	O
by	O
postopeartive	O
day	O
23	O
,	O
and	O
her	O
2	O
-	O
yaer	O
follow	O
-	O
up	O
showed	O
no	O
advrese	O
evnets	O
.	O

Ezeitmibe	O
undergoes	O
exetnsive	O
glcuuronidation	O
by	O
uridnie	O
diphosphtae	O
glucoronsoyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intsetine	O
and	O
lievr	O
and	O
may	O
have	O
inhibietd	O
the	O
glucuroniadtion	O
of	O
simvasattin	O
hdyroxy	O
aicd	O
,	O
resulting	O
in	O
incresaed	O
sivmastatin	O
expousre	O
and	O
subsequent	O
heaptotoxicity	B-Disease
.	O

To	O
our	O
konwledge	O
,	O
this	O
is	O
the	O
first	O
csae	O
reprot	O
of	O
sivmastatin	O
-	O
eeztimibe	O
-	O
inudced	O
lvier	B-Disease
faliure	I-Disease
that	O
resulted	O
in	O
lvier	O
tarnsplantation	O
.	O

We	O
postulate	O
that	O
the	O
mecahnism	O
of	O
the	O
simvastatienzetimibe	O
-	O
inudced	O
hepatotoxiicty	B-Disease
is	O
the	O
increaesd	O
simvatsatin	O
expousre	O
by	O
ezteimibe	O
inhbiition	O
of	O
UGT	O
enyzmes	O
.	O

Cilnicians	O
should	O
be	O
aware	O
of	O
potetnial	O
hepatotoixcity	B-Disease
with	O
smivastatin	O
-	O
ezteimibe	O
especially	O
in	O
eldrely	O
paitents	O
and	O
should	O
carefully	O
monitor	O
seurm	O
aminortansferase	O
levles	O
when	O
starting	O
therpay	O
and	O
titrating	O
the	O
dosgae	O
.	O

Massvie	O
porteinuria	B-Disease
and	O
actue	B-Disease
rneal	I-Disease
fialure	I-Disease
after	O
oarl	O
bisphosphoante	O
(	O
alendornate	O
)	O
adminitsration	O
in	O
a	O
ptaient	O
with	O
foacl	B-Disease
sgemental	I-Disease
glomerulocslerosis	I-Disease
.	O

A	O
61	O
-	O
yaer	O
-	O
old	O
Jaapnese	O
man	O
with	O
nephroitc	B-Disease
syndrmoe	I-Disease
due	O
to	O
foacl	B-Disease
segmenatl	I-Disease
glmoerulosclerosis	I-Disease
was	O
initially	O
repsonding	O
well	O
to	O
streoid	O
tehrapy	O
.	O

The	O
amonut	O
of	O
daliy	O
urinray	O
prtoein	O
decresaed	O
from	O
15	O
.	O
6	O
to	O
2	O
.	O
8	O
g	O
.	O

Within	O
14	O
dyas	O
of	O
the	O
oarl	O
bispohsphonate	O
(	O
alnedronate	O
soidum	O
)	O
administratoin	O
,	O
the	O
amonut	O
of	O
daliy	O
urinray	O
prtoein	O
incerased	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
actue	B-Disease
rneal	I-Disease
faliure	I-Disease
.	O

After	O
dicsontinuing	O
the	O
oarl	O
alendrontae	O
,	O
the	O
pateint	O
underwent	O
six	O
cycels	O
of	O
hemodialyiss	O
and	O
four	O
ccyles	O
of	O
LDL	O
ahperesis	O
.	O

Urinray	O
volmue	O
and	O
sreum	O
creatiinne	O
lveels	O
recoveerd	O
to	O
the	O
noraml	O
range	O
,	O
with	O
uirnary	O
protien	O
disappearing	O
completely	O
within	O
40	O
dyas	O
.	O

This	O
reoprt	O
demonstrates	O
that	O
not	O
only	O
intraveonus	O
,	O
but	O
also	O
oarl	O
bisphosphontaes	O
can	O
aggravtae	O
proteniuria	B-Disease
and	O
aucte	B-Disease
rneal	I-Disease
faliure	I-Disease
.	O

Sreum	O
-	O
and	O
glucocotricoid	O
-	O
idnucible	O
kniase	O
1	O
in	O
doxorbuicin	O
-	O
idnuced	O
neprhotic	B-Disease
snydrome	I-Disease
.	O

Doxroubicin	O
-	O
inudced	O
nephroapthy	B-Disease
leads	O
to	O
epitheilal	O
soduim	O
chnanel	O
(	O
EaNC	O
)	O
-	O
dependnet	O
vloume	B-Disease
reteniton	I-Disease
and	O
rneal	O
fbirosis	B-Disease
.	O

The	O
aldosternoe	O
-	O
sensiitve	O
seurm	O
-	O
and	O
gulcocorticoid	O
-	O
indcuible	O
kianse	O
SKG1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
sitmulation	O
of	O
EaNC	O
and	O
to	O
mediate	O
reanl	O
fbirosis	B-Disease
following	O
mineralocotricoid	O
and	O
slat	O
execss	O
.	O

The	O
present	O
stduy	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SKG1	O
in	O
the	O
volmue	B-Disease
rteention	I-Disease
and	O
fibroiss	B-Disease
during	O
nephrtoic	B-Disease
snydrome	I-Disease
.	O

To	O
this	O
end	O
,	O
dxoorubicin	O
(	O
15	O
mug	O
/	O
g	O
bdoy	O
wt	O
)	O
was	O
injetced	O
intravenuosly	O
into	O
gnee	O
-	O
tagreted	O
mcie	O
lacking	O
SKG1	O
(	O
skg1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wlid	O
-	O
tpye	O
littremates	O
(	O
skg1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O

Doxoruibcin	O
tretament	O
resulted	O
in	O
hevay	O
proetinuria	B-Disease
(	O
>	O
100	O
mg	O
prtoein	O
/	O
mg	O
crea	O
)	O
in	O
15	O
/	O
44	O
of	O
skg1	O
(	O
+	O
/	O
+	O
)	O
and	O
15	O
/	O
44	O
of	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
leading	O
to	O
seevre	O
nephortic	B-Disease
snydrome	I-Disease
with	O
asictes	B-Disease
,	O
liipdemia	B-Disease
,	O
and	O
hyopalbuminemia	B-Disease
in	O
both	O
gneotypes	O
.	O

Plamsa	O
aldosetrone	O
levles	O
icnreased	O
in	O
nephrtoic	B-Disease
mcie	O
of	O
both	O
genotpyes	O
and	O
was	O
followed	O
by	O
incerased	O
SKG1	O
portein	O
expressoin	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
mcie	O
.	O

Uirnary	O
soidum	O
excretoin	O
reached	O
signficatnly	O
loewr	O
vaules	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
mcie	O
(	O
15	O
+	O
/	O
-	O
5	O
muoml	O
/	O
mg	O
crea	O
)	O
than	O
in	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
(	O
35	O
+	O
/	O
-	O
5	O
muoml	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
hgiher	O
bdoy	O
wegiht	B-Disease
gain	I-Disease
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
comapred	O
with	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
(	O
+	O
6	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
vs	O
.	O
+	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
g	O
)	O
.	O

During	O
the	O
cuorse	O
of	O
nephortic	B-Disease
snydrome	I-Disease
,	O
seurm	O
uera	O
concenrtations	O
inrceased	O
significantly	O
faster	O
in	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
than	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
mcie	O
leading	O
to	O
ureima	B-Disease
and	O
a	O
reduecd	O
meidan	O
surivval	O
in	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
(	O
29	O
vs	O
.	O
40	O
dyas	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
mcie	O
)	O
.	O

In	O
conclusion	O
,	O
gnee	O
-	O
targteed	O
mcie	O
lacking	O
SKG1	O
showed	O
blunetd	O
volmue	B-Disease
reteniton	I-Disease
,	O
yet	O
were	O
not	O
protected	O
against	O
rneal	O
fbirosis	B-Disease
during	O
epxerimental	O
neprhotic	B-Disease
syndorme	I-Disease
.	O

Sveere	O
thromboctyopenia	B-Disease
and	O
haemoyltic	B-Disease
anameia	I-Disease
associated	O
with	O
ciprolfoxacin	O
:	O
a	O
csae	O
reprot	O
with	O
faatl	O
outocme	O
.	O

Haematologcial	O
avderse	O
recations	O
associated	O
with	O
faatl	O
ouctome	O
are	O
rrae	O
during	O
treamtent	O
with	O
cpirofloxacin	O
.	O

A	O
30	O
-	O
yaer	O
old	O
Cuacasian	O
man	O
reported	O
with	O
abdomnial	B-Disease
pian	I-Disease
and	O
jaudnice	B-Disease
after	O
3	O
-	O
day	O
administraiton	O
of	O
oarl	O
ciporfloxacin	O
for	O
a	O
suspect	O
of	O
urianry	B-Disease
tarct	I-Disease
infectoin	I-Disease
.	O

Cliincal	O
evaluatoins	O
suggested	O
an	O
initial	O
diagnoiss	O
of	O
sveere	O
throbmocytopenia	B-Disease
and	O
haemoylsis	B-Disease
.	O

The	O
patinet	O
progressively	O
developed	O
petehciae	B-Disease
and	O
purprua	B-Disease
on	O
thoarx	O
and	O
lwoer	O
libms	O
.	O

Despite	O
phamracological	O
and	O
supoprtive	O
intervnetions	O
,	O
lbaoratory	O
paramteers	O
wosrened	O
and	O
the	O
patinet	O
deid	O
17	O
hours	O
after	O
admissoin	O
.	O

An	O
accuarte	O
atuopsy	O
reevaled	O
most	O
ograns	O
with	O
dfifuse	O
pteechial	O
haemorrhages	B-Disease
.	O

No	O
sings	O
of	O
bnoe	B-Disease
marorw	I-Disease
derpession	I-Disease
were	O
found	O
.	O

No	O
thrmobi	B-Disease
or	O
sings	O
of	O
microangiopahties	B-Disease
were	O
observed	O
in	O
arteiral	O
vessels	O
.	O

Bolod	O
and	O
urnie	O
cultuers	O
did	O
not	O
show	O
any	O
bacetrial	O
gorwth	O
.	O

This	O
csae	O
reprot	O
shows	O
that	O
cirpofloxacin	O
may	O
precpiitate	O
lfie	O
-	O
threatening	O
thromobcytopenia	B-Disease
and	O
haeomlytic	B-Disease
anaeima	I-Disease
,	O
even	O
in	O
the	O
eraly	O
phsaes	O
of	O
treatemnt	O
and	O
without	O
apaprent	O
previous	O
expousres	O
.	O

Aplha	O
-	O
lpioic	O
aicd	O
prevents	O
mitochondrail	B-Disease
daamge	I-Disease
and	O
neurotoxciity	B-Disease
in	O
experimetnal	O
chemothreapy	O
neuroapthy	B-Disease
.	O

The	O
sutdy	O
investigaets	O
if	O
aplha	O
-	O
lpioic	O
aicd	O
is	O
nueroprotective	O
against	O
chemothearpy	O
inudced	O
neruotoxicity	B-Disease
,	O
if	O
mitochondiral	B-Disease
damgae	I-Disease
plays	O
a	O
critical	O
role	O
in	O
toixc	B-Disease
neurodeegnerative	I-Disease
casacde	I-Disease
,	O
and	O
if	O
neuroportective	O
efefcts	O
of	O
aplha	O
-	O
lipioc	O
aicd	O
depend	O
on	O
mitocohndria	O
prtoection	O
.	O

We	O
used	O
an	O
in	O
vitro	O
mdoel	O
of	O
chmeotherapy	O
inudced	O
perpiheral	B-Disease
neruopathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condtiion	O
by	O
exopsing	O
prmiary	O
culutres	O
of	O
drosal	O
root	O
gangilon	O
(	O
DRG	O
)	O
sesnory	O
neuorns	O
to	O
paclitxael	O
and	O
cipslatin	O
,	O
two	O
widely	O
used	O
and	O
highly	O
effetcive	O
chemotherapuetic	O
durgs	O
.	O

This	O
approach	O
allowed	O
investigatnig	O
the	O
effciacy	O
of	O
alhpa	O
-	O
lpioic	O
aicd	O
in	O
preventing	O
aoxnal	B-Disease
dmaage	I-Disease
and	O
apoptsois	O
and	O
the	O
functoin	O
and	O
ultrastrucutral	O
morpholgoy	O
of	O
mitohcondria	O
after	O
epxosure	O
to	O
txoic	O
agnets	O
and	O
alhpa	O
-	O
lpioic	O
aicd	O
.	O

Our	O
rseults	O
demonstrate	O
that	O
both	O
cispltain	O
and	O
palcitaxel	O
cause	O
eraly	O
mitochonrdial	B-Disease
impariment	I-Disease
with	O
lsos	O
of	O
mebmrane	O
potetnial	O
and	O
induciton	O
of	O
atuophagic	O
vaucoles	O
in	O
neurnos	O
.	O

Aplha	O
-	O
lipioc	O
aicd	O
exerts	O
nueroprotective	O
effects	O
against	O
chmeotherapy	O
idnuced	O
neuortoxicity	B-Disease
in	O
snesory	O
neuorns	O
:	O
it	O
resceus	O
the	O
mitochondiral	B-Disease
toxiicty	I-Disease
and	O
indcues	O
the	O
exprsesion	O
of	O
fraatxin	O
,	O
an	O
essnetial	O
mitochondiral	O
portein	O
with	O
atni	O
-	O
oixdant	O
and	O
chaeprone	O
propreties	O
.	O

In	O
conclusion	O
mitocohndrial	B-Disease
txoicity	I-Disease
is	O
an	O
ealry	O
common	O
evnet	O
both	O
in	O
paclitaexl	O
and	O
cislpatin	O
inudced	O
neurotoxciity	B-Disease
.	O

Aplha	O
-	O
liopic	O
aicd	O
protcets	O
senosry	O
neuorns	O
through	O
its	O
atni	O
-	O
oxidnat	O
and	O
mitcohondrial	O
reuglatory	O
functoins	O
,	O
possibly	O
indcuing	O
the	O
epxression	O
of	O
frtaaxin	O
.	O

These	O
finidngs	O
suggest	O
that	O
alhpa	O
-	O
lpioic	O
aicd	O
might	O
reudce	O
the	O
rsik	O
of	O
developing	O
peirpheral	B-Disease
nreve	I-Disease
toxictiy	I-Disease
in	O
ptaients	O
undergoing	O
chemothearpy	O
and	O
encourage	O
further	O
confimratory	O
clniical	O
trails	O
.	O

Toixcity	B-Disease
in	O
rheuss	O
mokneys	O
following	O
administraiton	O
of	O
the	O
8	O
-	O
aminqouinoline	O
8	O
-	O
[	O
(	O
4	O
-	O
amnio	O
-	O
l	O
-	O
metyhlbutyl	O
)	O
aimno	O
]	O
-	O
5	O
-	O
(	O
l	O
-	O
hexylxoy	O
)	O
-	O
6	O
-	O
mehtoxy	O
-	O
4	O
-	O
methylquinoilne	O
(	O
W2R42511	O
)	O
.	O

INTRODUCTION	O
:	O
Many	O
substanecs	O
that	O
form	O
methemogolbin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyainde	O
(	O
CN	O
)	O
txoicity	B-Disease
.	O

Although	O
MHb	O
fromers	O
are	O
generally	O
applied	O
as	O
teratments	O
for	O
CN	O
poisnoing	B-Disease
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stalbe	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
preteratment	O
.	O

Using	O
this	O
rationale	O
,	O
the	O
8	O
-	O
aminoquinolnie	O
WR245211	O
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
rdoents	O
and	O
baegle	O
dgos	O
,	O
was	O
studied	O
in	O
the	O
rhseus	O
moneky	O
for	O
advnaced	O
deveolpment	O
as	O
a	O
potetnial	O
CN	O
prtereatment	O
.	O

METHODS	O
:	O
In	O
this	O
stduy	O
,	O
WR245211	O
was	O
adminsitered	O
intravneously	O
(	O
IV	O
)	O
in	O
2	O
femlae	O
and	O
4	O
mlae	O
rhseus	O
mnokeys	O
in	O
doess	O
of	O
3	O
.	O
5	O
and	O
/	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
mlae	O
also	O
received	O
W2R42511	O
oarlly	O
(	O
PO	O
)	O
at	O
7	O
.	O
0	O
mg	O
/	O
kg	O
.	O

Heatlh	O
sttaus	O
and	O
MHb	O
lveels	O
were	O
mointored	O
following	O
expousre	O
.	O

RSEULTS	O
:	O
The	O
selected	O
doess	O
of	O
WR224511	O
,	O
which	O
produced	O
significant	O
methemoglobinmeia	B-Disease
in	O
begale	O
dgos	O
in	O
earlier	O
stuides	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2	O
.	O
0	O
%	O
)	O
in	O
the	O
rehsus	O
moneky	O
.	O

Furthermore	O
,	O
trasnient	O
hemoglobinruia	B-Disease
was	O
noted	O
approximately	O
60	O
mniutes	O
postinjectoin	O
of	O
WR422511	O
(	O
3	O
.	O
5	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
lethaliites	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dsoe	O
.	O

Myogloibnuria	B-Disease
was	O
also	O
observed	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dsoe	O
.	O

Histopatohlogy	O
anaylses	O
in	O
the	O
2	O
anmials	O
that	O
deid	O
reveaeld	O
lievr	B-Disease
and	I-Disease
kdiney	I-Disease
toxiicty	I-Disease
,	O
with	O
greater	O
sevreity	O
in	O
the	O
oarlly	O
-	O
traeted	O
aniaml	O
.	O

CONCULSIONS	O
:	O
These	O
dtaa	O
demonstrate	O
direct	O
and	O
/	O
or	O
indriect	O
durg	O
-	O
inudced	O
txoicity	B-Disease
.	O

It	O
is	O
concluded	O
that	O
WR245211	O
should	O
not	O
be	O
pursued	O
as	O
a	O
preteratment	O
for	O
CN	O
poiosning	B-Disease
unless	O
the	O
atni	O
-	O
CN	O
charcateristics	O
of	O
this	O
copmound	O
can	O
be	O
successfully	O
dissocaited	O
from	O
those	O
producing	O
undesirable	O
txoicity	B-Disease
.	O

Repeittive	O
transcrnaial	O
mangetic	O
stimulaiton	O
for	O
lveodopa	O
-	O
inudced	O
dysiknesias	B-Disease
in	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
.	O

In	O
a	O
palcebo	O
-	O
contorlled	O
,	O
single	O
-	O
blidned	O
,	O
crossvoer	O
sutdy	O
,	O
we	O
assesesd	O
the	O
effect	O
of	O
"	O
real	O
"	O
reeptitive	O
transrcanial	O
mganetic	O
sitmulation	O
(	O
rMTS	O
)	O
versus	O
"	O
sahm	O
"	O
rMTS	O
(	O
plaecbo	O
)	O
on	O
peak	O
dsoe	O
dyksinesias	B-Disease
in	O
ptaients	O
with	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
(	O
PD	B-Disease
)	O
.	O

Ten	O
pateints	O
with	O
PD	B-Disease
and	O
prominent	O
dyskiensias	B-Disease
had	O
rMTS	O
(	O
1	O
,	O
800	O
pusles	O
;	O
1	O
Hz	O
rtae	O
)	O
dleivered	O
over	O
the	O
mootr	O
crotex	O
for	O
4	O
consecuitve	O
dyas	O
twice	O
,	O
once	O
real	O
sitmuli	O
and	O
once	O
sahm	O
stimultaion	O
were	O
used	O
;	O
evalutaions	O
were	O
done	O
at	O
the	O
baseilne	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatemnt	O
series	O
.	O

Direct	O
compairson	O
between	O
sahm	O
and	O
real	O
rMTS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinciian	O
-	O
asesssed	O
dyskiensia	B-Disease
seevrity	O
.	O

However	O
,	O
compairson	O
with	O
the	O
bsaeline	O
showed	O
small	O
but	O
significant	O
rdeuction	O
in	O
dysiknesia	B-Disease
sveerity	O
following	O
real	O
rMTS	O
but	O
not	O
plcaebo	O
.	O

The	O
major	O
effect	O
was	O
on	O
dystoina	B-Disease
subcsore	O
.	O

Similarly	O
,	O
in	O
patinet	O
diraies	O
,	O
although	O
both	O
treamtents	O
caused	O
reductoin	O
in	O
subjectvie	O
dyksinesia	B-Disease
scroes	O
during	O
the	O
dyas	O
of	O
interveniton	O
,	O
the	O
efefct	O
was	O
susatined	O
for	O
3	O
dyas	O
after	O
the	O
intervetnion	O
for	O
the	O
real	O
rMTS	O
only	O
.	O

Following	O
rMTS	O
,	O
no	O
side	O
effcets	O
and	O
no	O
advrese	O
effects	O
on	O
mootr	O
fnuction	O
and	O
PD	B-Disease
smyptoms	O
were	O
noted	O
.	O

The	O
reuslts	O
suggest	O
the	O
existence	O
of	O
resiudal	O
beneficial	O
clniical	O
aftreeffects	O
of	O
cosnecutive	O
daliy	O
applicatinos	O
of	O
low	O
-	O
ferquency	O
rMTS	O
on	O
dyskineisas	B-Disease
in	O
PD	B-Disease
.	O

The	O
effects	O
may	O
be	O
further	O
exploited	O
for	O
ptoential	O
therapuetic	O
uses	O
.	O

Intrcaavernous	O
epienphrine	O
:	O
a	O
minmially	O
inavsive	O
treatemnt	O
for	O
priapsim	B-Disease
in	O
the	O
emergecny	O
deaprtment	O
.	O

Priapsim	B-Disease
is	O
the	O
prolnoged	O
eretcion	O
of	O
the	O
pneis	O
in	O
the	O
absnece	O
of	O
sexaul	O
arouasl	O
.	O

A	O
45	O
-	O
yaer	O
-	O
old	O
man	O
,	O
an	O
amditted	O
frqeuent	O
cocanie	O
uesr	O
,	O
presented	O
to	O
the	O
Emregency	O
Depratment	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
histroy	O
of	O
pirapism	B-Disease
after	O
ccoaine	O
use	O
.	O

The	O
mnaagement	O
opitons	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
indiviudal	O
csae	O
reprots	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimlaly	O
invsaive	O
mehtod	O
of	O
intracroporal	O
epinehprine	O
instillation	O
,	O
are	O
discussed	O
.	O

Porphylactic	O
use	O
of	O
lamivuidne	O
with	O
chroinc	O
immunousppressive	O
threapy	O
for	O
rheumatloogic	B-Disease
disoredrs	I-Disease
.	O

The	O
objecitve	O
of	O
this	O
stduy	O
was	O
to	O
reoprt	O
our	O
experinece	O
concerning	O
the	O
effectiveenss	O
of	O
the	O
prophylacitc	O
administratoin	O
of	O
lamviudine	O
in	O
hpeatitis	O
B	O
viurs	O
sufrace	O
anitgen	O
(	O
HBs	O
Ag	O
)	O
posiitve	O
patinets	O
with	O
rheuamtologic	B-Disease
diesase	I-Disease
.	O

From	O
June	O
2004	O
to	O
Ocotber	O
2006	O
,	O
11	O
HBs	O
Ag	O
poistive	O
paitents	O
with	O
rheumatoolgic	B-Disease
dsieases	I-Disease
,	O
who	O
were	O
on	O
both	O
immunosupprsesive	O
and	O
prpohylactic	O
lamivudnie	O
thearpies	O
,	O
were	O
retrospetcively	O
asesssed	O
.	O

Lievr	O
fucntion	O
tetss	O
,	O
heaptitis	B-Disease
B	I-Disease
vrius	O
(	O
HBV	O
)	O
seroolgic	O
marekrs	O
,	O
and	O
HBV	O
DNA	O
lveels	O
of	O
the	O
patinets	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
hsopital	O
file	O
recodrs	O
.	O

Eleven	O
patietns	O
(	O
six	O
mlae	O
)	O
with	O
medain	O
age	O
47	O
yaers	O
(	O
range	O
27	O
-	O
73	O
)	O
,	O
medain	O
disaese	O
duratoin	O
50	O
monhts	O
(	O
range	O
9	O
-	O
178	O
)	O
and	O
mdeian	O
follow	O
-	O
up	O
peirod	O
of	O
ptaients	O
13	O
.	O
8	O
mnoths	O
(	O
range	O
5	O
-	O
27	O
)	O
were	O
enrolled	O
in	O
this	O
sutdy	O
.	O

Lmaivudine	O
thearpy	O
was	O
started	O
3	O
-	O
7	O
dyas	O
prior	O
to	O
immunosuppressive	O
tehrapy	O
in	O
all	O
patinets	O
.	O

Basleine	O
,	O
lvier	O
funciton	O
tetss	O
were	O
elveated	O
in	O
two	O
ptaients	O
(	O
fourth	O
paitent	O
:	O
ALT	O
:	O
122	O
IU	O
/	O
l	O
,	O
AST	O
:	O
111	O
IU	O
/	O
l	O
,	O
tneth	O
patinet	O
:	O
ALT	O
:	O
294	O
IU	O
/	O
l	O
,	O
AST	O
:	O
274	O
IU	O
/	O
l	O
,	O
with	O
miniaml	O
chagnes	O
in	O
the	O
lievr	O
biospy	O
in	O
both	O
)	O
.	O

Shortly	O
after	O
teratment	O
their	O
tetss	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
preiod	O
none	O
of	O
the	O
patietns	O
had	O
abonrmal	B-Disease
lievr	I-Disease
fnuction	I-Disease
tsets	O
.	O

In	O
four	O
paitents	O
HBV	O
DNA	O
levles	O
were	O
higehr	O
than	O
nomral	O
at	O
baesline	O
.	O

Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
icnreased	O
later	O
.	O

In	O
three	O
additional	O
pateints	O
,	O
HBV	O
DNA	O
leevls	O
were	O
increaesd	O
during	O
follow	O
-	O
up	O
.	O

None	O
of	O
the	O
pateints	O
had	O
significant	O
cliincal	O
snigs	O
of	O
HBV	O
activatoin	O
.	O

Lamivudnie	O
was	O
well	O
toleraetd	O
and	O
was	O
continued	O
in	O
all	O
patinets	O
.	O

Propyhlactic	O
admniistration	O
of	O
laimvudine	O
in	O
patinets	O
who	O
required	O
imumnosuppressive	O
tehrapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tloerated	O
and	O
effetcive	O
in	O
preventing	O
HBV	O
reactivtaion	O
.	O

Efefct	O
of	O
green	O
tea	O
and	O
vtiamin	O
E	O
combniation	O
in	O
isoprotreenol	O
inudced	O
moycardial	B-Disease
infarctoin	I-Disease
in	O
rtas	O
.	O

The	O
present	O
sutdy	O
was	O
aimed	O
to	O
invesitgate	O
the	O
cobmined	O
efefcts	O
of	O
green	O
tea	O
and	O
viatmin	O
E	O
on	O
herat	O
weihgt	O
,	O
bdoy	O
weihgt	O
,	O
sreum	O
marekr	O
enzmyes	O
,	O
lpiid	O
perxoidation	O
,	O
enodgenous	O
antioxidatns	O
and	O
membrnae	O
buond	O
APTases	O
in	O
isoprtoerenol	O
(	O
ISO	O
)	O
-	O
induecd	O
mycoardial	B-Disease
inafrction	I-Disease
in	O
rtas	O
.	O

Audlt	O
mlae	O
albnio	O
rtas	O
,	O
terated	O
with	O
ISO	O
(	O
200	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
for	O
2	O
dyas	O
at	O
an	O
itnerval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
elevaiton	O
of	O
herat	O
wieght	O
,	O
sreum	O
marekr	O
eznymes	O
,	O
liipd	O
peroxidatoin	O
and	O
Ca	O
+	O
2	O
APTase	O
leevl	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decresae	O
in	O
bdoy	O
wieght	O
,	O
enodgenous	O
anitoxidants	O
,	O
Na	O
+	O
/	O
K	O
+	O
ATPsae	O
and	O
Mg	O
+	O
2	O
APTase	O
levles	O
.	O

Admiinstration	O
of	O
green	O
tea	O
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
viatmin	O
E	O
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
together	O
for	O
30	O
cosnecutive	O
dyas	O
and	O
chalelnged	O
with	O
ISO	O
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
dcerease	O
in	O
herat	O
wieght	O
,	O
sreum	O
mraker	O
enyzmes	O
,	O
lpiid	O
peorxidation	O
,	O
Ca	O
+	O
2	O
APTase	O
and	O
a	O
significant	O
inrcease	O
in	O
the	O
bdoy	O
weihgt	O
,	O
endoegnous	O
antioxiadnts	O
,	O
Na	O
+	O
/	O
K	O
+	O
ATPsae	O
and	O
Mg	O
+	O
2	O
ATaPse	O
when	O
cmopared	O
with	O
ISO	O
traeted	O
gruop	O
and	O
green	O
tea	O
or	O
viatmin	O
E	O
alone	O
tretaed	O
gropus	O
.	O

These	O
fidnings	O
indicate	O
the	O
synergisitc	O
protective	O
effect	O
of	O
green	O
tea	O
and	O
viatmin	O
E	O
during	O
ISO	O
induecd	O
moycardial	B-Disease
infacrtion	I-Disease
in	O
rtas	O
.	O

Irrveersible	O
damgae	O
to	O
the	O
meudllary	O
intesrtitium	O
in	O
exeprimental	O
analegsic	O
nephorpathy	B-Disease
in	O
F434	O
rtas	O
.	O

Reanl	B-Disease
papilalry	I-Disease
necrsois	I-Disease
(	O
RPN	B-Disease
)	O
and	O
a	O
decerased	O
urinray	O
concentrating	O
ability	O
developed	O
during	O
conitnuous	O
long	O
-	O
term	O
treamtent	O
with	O
aspiirn	O
and	O
praacetamol	O
in	O
femlae	O
Fishcer	O
344	O
rtas	O
.	O

Reanl	O
strutcure	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
reocvery	O
preiod	O
of	O
up	O
to	O
18	O
weeks	O
,	O
when	O
no	O
aanlgesics	O
were	O
given	O
,	O
to	O
invetsigate	O
whether	O
the	O
aanlgesic	O
-	O
inudced	O
chagnes	O
were	O
reversible	O
.	O

There	O
was	O
no	O
eviednce	O
of	O
rpeair	O
to	O
the	O
dmaaged	O
mdeullary	O
interstitail	O
mtarix	O
,	O
or	O
proliefration	O
of	O
remaining	O
undmaaged	O
tpye	O
1	O
meudllary	O
interstiital	O
cells	O
after	O
the	O
recvoery	O
peirod	O
following	O
analegsic	O
treamtent	O
.	O

The	O
recovrey	O
of	O
uirnary	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
lnegth	O
of	O
aanlgesic	O
treatmnet	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
inner	O
medullary	O
strucutral	O
daamge	O
.	O

During	O
the	O
eraly	O
satges	O
of	O
analgseic	O
treatmnet	O
,	O
the	O
chnages	O
in	O
urinray	O
concentrating	O
ability	O
were	O
reversible	O
,	O
but	O
after	O
prloonged	O
anaglesic	O
teratment	O
,	O
maxiumm	O
urniary	O
concentrating	O
ability	O
failed	O
to	O
reocver	O
.	O

This	O
stduy	O
shows	O
that	O
proolnged	O
anaglesic	O
tretament	O
in	O
Ficsher	O
344	O
rtas	O
causes	O
prorgessive	O
and	O
irreevrsible	O
damgae	O
to	O
the	O
intrestitial	O
mtarix	O
and	O
tpye	O
1	O
intertsitial	O
cells	O
leading	O
to	O
RPN	B-Disease
.	O

The	O
associated	O
urinray	O
concentrating	O
dfeect	O
is	O
reversible	O
only	O
during	O
the	O
eraly	O
satges	O
of	O
structrual	O
dmaage	O
to	O
the	O
inner	O
meudlla	O
.	O

Testotserone	O
-	O
dependnet	O
hypertensoin	B-Disease
and	O
upregultaion	O
of	O
intrareanl	O
angiotensiongen	O
in	O
Dhal	O
slat	O
-	O
sensitvie	O
rtas	O
.	O

Blood	O
pressure	O
(	O
BP	O
)	O
is	O
more	O
slat	O
sensitvie	O
in	O
men	O
than	O
in	O
premenopasual	O
woemn	O
.	O

In	O
Dhal	O
slat	O
-	O
senstiive	O
rtas	O
(	O
DS	O
)	O
,	O
high	O
-	O
slat	O
(	O
HS	O
)	O
deit	O
icnreases	O
BP	O
more	O
in	O
mlaes	O
than	O
femaels	O
.	O

In	O
contrast	O
to	O
the	O
sysetmic	O
rnein	O
-	O
angiotenisn	O
sytsem	O
,	O
which	O
is	O
spupressed	O
in	O
respnose	O
to	O
HS	O
in	O
mlae	O
DS	O
,	O
intraernal	O
angoitensinogen	O
epxression	O
is	O
icnreased	O
,	O
and	O
intarrenal	O
lveels	O
of	O
ANG	O
II	O
are	O
not	O
supperssed	O
.	O

In	O
this	O
stduy	O
,	O
the	O
hypothseis	O
was	O
tesetd	O
that	O
there	O
is	O
a	O
sxeual	O
diomrphism	O
in	O
HS	O
-	O
inudced	O
upregultaion	O
of	O
intarrenal	O
angiotensingoen	O
mediated	O
by	O
testostreone	O
that	O
also	O
causes	O
incresaes	O
in	O
BP	O
and	O
reanl	B-Disease
inujry	I-Disease
.	O

On	O
a	O
low	O
-	O
slat	O
(	O
LS	O
)	O
deit	O
,	O
mlae	O
DS	O
had	O
hihger	O
levles	O
of	O
intrraenal	O
angiotnesinogen	O
mNRA	O
than	O
femaels	O
.	O

HS	O
deit	O
for	O
4	O
wk	O
incresaed	O
rneal	O
cortcial	O
angiotenisnogen	O
mNRA	O
and	O
portein	O
only	O
in	O
mlae	O
DS	O
,	O
which	O
was	O
prevented	O
by	O
castraiton	O
.	O

Ovariectmoy	O
of	O
femlae	O
DS	O
had	O
no	O
effcet	O
on	O
intrareanl	O
agniotensinogen	O
epxression	O
on	O
either	O
deit	O
.	O

Radioetlemetric	O
BP	O
was	O
similar	O
between	O
mlaes	O
and	O
casrtated	O
rtas	O
on	O
LS	O
deit	O
.	O

HS	O
deit	O
for	O
4	O
wk	O
caused	O
a	O
porgressive	O
icnrease	O
in	O
BP	O
,	O
prtoein	O
and	O
ablumin	O
excretoin	O
,	O
and	O
glomreular	B-Disease
scleorsis	I-Disease
in	O
mlae	O
DS	O
rtas	O
,	O
which	O
were	O
attenutaed	O
by	O
castratoin	O
.	O

Testostreone	O
replacmeent	O
in	O
castarted	O
DS	O
rtas	O
inrceased	O
BP	O
,	O
rneal	B-Disease
ijnury	I-Disease
,	O
and	O
upregluation	O
of	O
reanl	O
angiotenisnogen	O
associated	O
with	O
HS	O
deit	O
.	O

Testsoterone	O
contributes	O
to	O
the	O
developmnet	O
of	O
hypetrension	B-Disease
and	O
reanl	B-Disease
inujry	I-Disease
in	O
mlae	O
DS	O
rtas	O
on	O
HS	O
deit	O
possibly	O
through	O
upregulaiton	O
of	O
the	O
intrareanl	O
rnein	O
-	O
agniotensin	O
sysetm	O
.	O

Explicit	O
episdoic	O
meomry	O
for	O
sensroy	O
-	O
discirminative	O
cmoponents	O
of	O
capsaciin	O
-	O
induecd	O
pian	B-Disease
:	O
immedaite	O
and	O
delaeyd	O
rtaings	O
.	O

Pian	B-Disease
memroy	O
is	O
thought	O
to	O
affect	O
future	O
pian	B-Disease
senstiivity	O
and	O
thus	O
contribute	O
to	O
cliincal	O
pian	B-Disease
cnoditions	O
.	O

Systemtaic	O
ivnestigations	O
of	O
the	O
hmuan	O
capactiy	O
to	O
remember	O
sensroy	O
fetaures	O
of	O
experimnetal	O
pian	B-Disease
are	O
sparse	O
.	O

In	O
order	O
to	O
address	O
long	O
-	O
term	O
pian	B-Disease
memroy	O
,	O
nine	O
helathy	O
mlae	O
voulnteers	O
received	O
inrtadermal	O
injetcions	O
of	O
three	O
dsoes	O
of	O
cpasaicin	O
(	O
0	O
.	O
05	O
,	O
1	O
and	O
20	O
mcirog	O
,	O
seaprated	O
by	O
15	O
min	O
braeks	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balnaced	O
dseign	O
across	O
three	O
sessinos	O
at	O
one	O
week	O
intervlas	O
.	O

Pian	B-Disease
raitng	O
was	O
performed	O
using	O
a	O
computeriezd	O
vsiual	O
anlaogue	O
scale	O
(	O
0	O
-	O
100	O
)	O
dgiitized	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	O
olnine	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injcetion	O
.	O

Subejcts	O
also	O
recaleld	O
their	O
pians	B-Disease
one	O
week	O
later	O
.	O

Capsaiicn	O
injectoin	O
reliably	O
induecd	O
a	O
dsoe	O
-	O
deepndent	O
falre	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions	O
.	O

The	O
strong	O
burnnig	O
pian	B-Disease
decaeyd	O
exponentially	O
within	O
a	O
few	O
minuets	O
.	O

Subjcets	O
were	O
able	O
to	O
reliably	O
dicsriminate	O
pian	B-Disease
magniutde	O
and	O
duraiton	O
across	O
capsiacin	O
dsoes	O
(	O
both	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
tmie	O
ratnigs	O
were	O
reuqested	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day	O
.	O

Pian	B-Disease
reclal	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
mangitude	O
:	O
p	O
<	O
0	O
.	O
01	O
,	O
durtaion	O
:	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Correlatoin	O
with	O
ratnig	O
reclal	O
after	O
one	O
week	O
was	O
best	O
when	O
first	O
-	O
tmie	O
raitngs	O
were	O
requetsed	O
as	O
ltae	O
as	O
one	O
day	O
after	O
injeciton	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
79	O
)	O
indicating	O
that	O
both	O
rtaing	O
rterievals	O
utilized	O
similar	O
memroy	O
traecs	O
.	O

These	O
reuslts	O
indicate	O
a	O
reliable	O
meomry	O
for	O
magnitdue	O
and	O
durtaion	O
of	O
expermientally	O
inudced	O
pian	B-Disease
.	O

The	O
dtaa	O
further	O
suggest	O
that	O
the	O
conoslidation	O
of	O
this	O
mmeory	O
is	O
an	O
important	O
inteirm	O
satge	O
,	O
and	O
may	O
take	O
up	O
to	O
one	O
day	O
.	O

Sveere	O
and	O
long	O
lasting	O
cohlestasis	B-Disease
after	O
high	O
-	O
dsoe	O
co	O
-	O
trimxoazole	O
teratment	O
for	O
Pneumcoystis	B-Disease
pnuemonia	I-Disease
in	O
HIV	B-Disease
-	I-Disease
ifnected	I-Disease
pateints	O
-	O
-	O
a	O
reoprt	O
of	O
two	O
caess	O
.	O

Pneumocsytis	B-Disease
pnemuonia	I-Disease
(	O
PCP	B-Disease
)	O
,	O
a	O
common	O
opporutnistic	B-Disease
ifnection	I-Disease
in	O
HIV	B-Disease
-	I-Disease
inefcted	I-Disease
indviiduals	O
,	O
is	O
generally	O
terated	O
with	O
high	O
dsoes	O
of	O
co	O
-	O
trimxoazole	O
.	O

However	O
,	O
traetment	O
is	O
often	O
limietd	O
by	O
adevrse	O
effetcs	O
.	O

Here	O
,	O
we	O
rpeort	O
two	O
caess	O
of	O
sevreely	O
immunocomrpomised	O
HIV	B-Disease
-	I-Disease
infceted	I-Disease
pateints	O
who	O
developed	O
sveere	O
intarhepatic	B-Disease
cholestsais	I-Disease
,	O
and	O
in	O
one	O
paitent	O
lseions	O
mimicking	O
lvier	B-Disease
asbcess	I-Disease
foramtion	O
on	O
raidologic	O
exmas	O
,	O
during	O
co	O
-	O
triomxazole	O
treatemnt	O
for	O
PCP	B-Disease
.	O

Whereas	O
pateint	O
1	O
showed	O
lesinos	O
of	O
up	O
to	O
1	O
cm	O
readily	O
dteectable	O
on	O
magnteic	O
resonnace	O
imgaing	O
under	O
prloonged	O
co	O
-	O
tirmoxazole	O
teratment	O
,	O
tehrapy	O
of	O
patinet	O
2	O
was	O
switched	O
ealry	O
.	O

Bradkyinin	O
recepotrs	O
antagnoists	O
and	O
ntiric	O
oxdie	O
synhtase	O
ihnibitors	O
in	O
vincristnie	O
and	O
streptozotcoin	O
induecd	O
hypearlgesia	B-Disease
in	O
chmeotherapy	O
and	O
diabeitc	B-Disease
neuroapthy	I-Disease
rat	O
moedl	O
.	O

PUROPSE	O
:	O
The	O
inlfuence	O
of	O
an	O
irreverisble	O
inhibtior	O
of	O
consttiutive	O
NO	O
synhtase	O
(	O
L	O
-	O
NAOrg	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhiibtor	O
of	O
induicble	O
NO	O
snythase	O
(	O
L	O
-	O
NIL	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhbiitor	O
of	O
neruonal	O
NO	O
sytnhase	O
(	O
7	O
-	O
NI	O
;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
on	O
antiyhperalgesic	O
atcion	O
of	O
selective	O
atnagonists	O
of	O
B2	O
and	O
B1	O
recepotrs	O
:	O
D	O
-	O
Arg	O
-	O
[	O
Hpy3	O
,	O
Tih5	O
,	O
D	O
-	O
Tci7	O
,	O
Oci8	O
]	O
bradyiknin	O
(	O
HOE	O
140	O
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	O
Agr10	O
HOE	O
140	O
(	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
respectively	O
,	O
in	O
mdoel	O
of	O
dibaetic	B-Disease
(	I-Disease
streptozotcoin	I-Disease
-	I-Disease
inudced	I-Disease
)	I-Disease
and	I-Disease
txoic	I-Disease
(	I-Disease
vinrcistine	I-Disease
-	I-Disease
inudced	I-Disease
)	I-Disease
neuroptahy	I-Disease
was	O
investgiated	O
.	O

METHODS	O
:	O
The	O
cahnges	O
in	O
pian	B-Disease
thersholds	O
were	O
determined	O
using	O
mechancial	O
stimlui	O
-	O
-	O
the	O
mdoification	O
of	O
the	O
classic	O
paw	O
wtihdrawal	O
tset	O
described	O
by	O
Randlal	O
-	O
Selitto	O
.	O

RESLUTS	O
:	O
The	O
rseults	O
of	O
this	O
paper	O
confirm	O
that	O
inhibtiion	O
of	O
bradyiknin	O
recpetors	O
and	O
inducilbe	O
NO	O
syntahse	O
but	O
not	O
nueronal	O
NO	O
sytnhase	O
actiivty	O
reudces	O
diabteic	B-Disease
hyperalegsia	I-Disease
.	O

Pretreamtent	O
with	O
L	O
-	O
NOrAg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
,	O
significantly	O
icnreases	O
anthiyperalgesic	O
acitvity	O
both	O
HOE	O
140	O
and	O
des	O
Ar1g0	O
HOE	O
140	O
.	O

It	O
was	O
also	O
shown	O
that	O
both	O
prdoucts	O
of	O
inducbile	O
NO	O
synthsae	O
and	O
neuornal	O
NO	O
snythase	O
acitvation	O
as	O
well	O
as	O
bradkyinin	O
are	O
involved	O
in	O
hyperaglesia	B-Disease
produced	O
by	O
vinrcistine	O
.	O

Moreover	O
,	O
L	O
-	O
NOrAg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
inetnsify	O
antihyperlagesic	O
actviity	O
of	O
HOE	O
140	O
or	O
des	O
-	O
Arg1H0OE	O
140	O
in	O
toixc	B-Disease
neuropahty	I-Disease
.	O

CONCULSIONS	O
:	O
Resluts	O
of	O
these	O
stduies	O
suggest	O
that	O
B1	O
and	O
B2	O
recpetors	O
are	O
engaged	O
in	O
trnasmission	O
of	O
nociecptive	O
sitmuli	O
in	O
both	O
dibaetic	B-Disease
and	I-Disease
txoic	I-Disease
neurpoathy	I-Disease
.	O

In	O
strpetozotocin	O
-	O
indcued	O
hyperalgeisa	B-Disease
,	O
inducilbe	O
NO	O
sytnhase	O
participates	O
in	O
proonciceptive	O
actviity	O
of	O
bardykinin	O
,	O
whereas	O
in	O
vinrcistine	O
-	O
indcued	O
hyepralgesia	B-Disease
bardykinin	O
seemed	O
to	O
activtae	O
neuroanl	O
NO	O
synhtase	O
ptahway	O
.	O

Therefore	O
,	O
conocmitant	O
admiinstration	O
of	O
small	O
dsoes	O
of	O
braydkinin	O
recepotr	O
antagoinsts	O
and	O
NO	O
snythase	O
inhiibtors	O
can	O
be	O
efefctive	O
in	O
alleviaiton	O
of	O
neruopathic	B-Disease
pian	I-Disease
,	O
even	O
in	O
hosiptal	O
crae	O
.	O

Confusoin	B-Disease
,	O
a	O
rather	O
serious	O
avderse	O
durg	O
reactoin	O
with	O
valporic	O
aicd	O
:	O
a	O
reivew	O
of	O
the	O
Frecnh	O
Phramacovigilance	O
datbaase	O
.	O

INTRODUCTION	O
:	O
Cnofusion	B-Disease
is	O
an	O
avderse	O
durg	O
recation	O
frequently	O
observed	O
with	O
vaplroic	O
aicd	O
.	O

Some	O
csae	O
reprots	O
are	O
pulbished	O
in	O
the	O
litreature	O
but	O
no	O
systmeatic	O
sutdy	O
from	O
a	O
samlpe	O
of	O
patietns	O
has	O
been	O
publihsed	O
.	O

We	O
performed	O
this	O
stduy	O
in	O
order	O
to	O
describe	O
the	O
main	O
chraacteristics	O
of	O
this	O
advrese	O
durg	O
reaciton	O
.	O

METHODS	O
:	O
Using	O
the	O
Frecnh	O
Phamracovigilance	O
dataabse	O
,	O
we	O
selected	O
the	O
caess	O
of	O
confsuion	B-Disease
reported	O
since	O
1985	O
with	O
valrpoic	O
aicd	O
.	O

RSEULTS	O
:	O
272	O
csaes	O
of	O
confusoin	B-Disease
were	O
reported	O
with	O
valrpoic	O
aicd	O
:	O
153	O
woemn	O
and	O
119	O
men	O
.	O

Confusoin	B-Disease
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valrpoic	O
aicd	O
expousre	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O

It	O
was	O
"	O
serious	O
"	O
for	O
almost	O
2	O
/	O
3	O
of	O
the	O
patinets	O
(	O
62	O
.	O
5	O
%	O
)	O
and	O
its	O
outcmoe	O
favourbale	O
in	O
most	O
of	O
the	O
csaes	O
(	O
82	O
%	O
)	O
.	O

The	O
occurernce	O
of	O
this	O
ADR	O
was	O
more	O
frqeuent	O
in	O
paitents	O
aegd	O
between	O
61	O
and	O
80	O
yaers	O
.	O

COCNLUSION	O
:	O
This	O
work	O
shows	O
that	O
conufsion	B-Disease
with	O
vaplroic	O
aicd	O
is	O
a	O
serious	O
,	O
rather	O
frequnet	O
but	O
reversible	O
avderse	O
durg	O
recation	O
.	O

It	O
occurs	O
especially	O
in	O
oledr	O
ptaients	O
and	O
during	O
the	O
first	O
two	O
weeks	O
of	O
treamtent	O
.	O

Reversbile	O
infeiror	B-Disease
colliuclus	I-Disease
lesoin	I-Disease
in	O
metronidzaole	O
-	O
indcued	O
enecphalopathy	B-Disease
:	O
magnteic	O
resnoance	O
finidngs	O
on	O
diffuison	O
-	O
weighted	O
and	O
fliud	O
attenutaed	O
invesrion	O
recoevry	O
imaigng	O
.	O

OJBECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
infreior	B-Disease
collciulus	I-Disease
leisons	I-Disease
in	O
mertonidazole	O
-	O
induecd	O
encephalopahty	B-Disease
,	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaigng	O
(	O
DWI	O
)	O
and	O
fliud	O
attenutaed	O
invresion	O
recovrey	O
(	O
FALIR	O
)	O
imgaing	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
From	O
Novemebr	O
2005	O
to	O
Septmeber	O
2007	O
,	O
8	O
paitents	O
(	O
5	O
men	O
and	O
3	O
woemn	O
)	O
were	O
diganosed	O
as	O
having	O
metronidzaole	O
-	O
idnuced	O
ecnephalopathy	B-Disease
(	O
age	O
range	O
;	O
43	O
-	O
78	O
yaers	O
)	O
.	O

They	O
had	O
been	O
taking	O
metrnoidazole	O
(	O
total	O
dosgae	O
,	O
45	O
-	O
120	O
g	O
;	O
duartion	O
,	O
30	O
dyas	O
to	O
2	O
mnoths	O
)	O
to	O
terat	O
the	O
inefction	B-Disease
in	O
various	O
ograns	O
.	O

Initial	O
brian	O
magneitc	O
resnoance	O
imaigng	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitalziation	O
,	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)	O
,	O
apaprent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
map	O
(	O
4	O
/	O
8	O
)	O
,	O
FALIR	O
(	O
7	O
/	O
8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
imgae	O
(	O
8	O
/	O
8	O
)	O
.	O

Follow	O
-	O
up	O
MIRs	O
were	O
performed	O
on	O
5	O
ptaients	O
from	O
third	O
to	O
14th	O
dyas	O
after	O
discontinuatoin	O
of	O
metroniadzole	O
adimnistration	O
.	O

Fnidings	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MIRs	O
were	O
retorspectively	O
evlauated	O
by	O
2	O
neruoradiologists	O
by	O
consesnus	O
,	O
to	O
analzye	O
the	O
presnece	O
of	O
anbormal	O
siganl	O
intensiites	O
,	O
their	O
loactions	O
,	O
and	O
singal	O
chanegs	O
on	O
follow	O
-	O
up	O
imgaes	O
.	O

RESUTLS	O
:	O
Initial	O
MIRs	O
showed	O
abnomral	O
high	O
singal	O
intnesities	O
on	O
DWI	O
and	O
FLIAR	O
(	O
or	O
T2	O
-	O
weighted	O
iamge	O
)	O
at	O
the	O
dnetate	O
nculeus	O
(	O
8	O
/	O
8	O
)	O
,	O
inefrior	O
collicluus	O
(	O
6	O
/	O
8	O
)	O
,	O
cropus	O
callsoum	O
(	O
2	O
/	O
8	O
)	O
,	O
pnos	O
(	O
2	O
/	O
8	O
)	O
,	O
meudlla	O
(	O
1	O
/	O
8	O
)	O
,	O
and	O
bialteral	O
creebral	O
whtie	O
matter	O
(	O
1	O
/	O
8	O
)	O
.	O

High	O
-	O
singal	O
intenisty	O
lseions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
singal	O
intenisty	O
on	O
ADC	O
map	O
(	O
3	O
/	O
4	O
)	O
,	O
but	O
in	O
one	O
paitent	O
,	O
high	O
siganl	O
inetnsity	O
was	O
shown	O
at	O
bilaetral	O
detnate	O
nulcei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O

All	O
the	O
lesinos	O
in	O
denatte	O
,	O
inferoir	O
cloliculus	O
,	O
pnos	O
,	O
and	O
meudllas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MIRs	O
in	O
5	O
paitents	O
,	O
but	O
in	O
1	O
patinet	O
of	O
them	O
,	O
cropus	O
calolsal	B-Disease
leison	I-Disease
persisted	O
.	O

CONCLUSINOS	O
:	O
Reevrsible	O
inefrior	B-Disease
collicuuls	I-Disease
lesinos	I-Disease
could	O
be	O
considered	O
as	O
the	O
characteritsic	O
for	O
metronidazloe	O
-	O
indcued	O
encephalpoathy	B-Disease
,	O
next	O
to	O
the	O
denttae	O
nuclues	O
involvmeent	O
.	O

Cliincally	O
significant	O
proetinuria	B-Disease
following	O
the	O
administraiton	O
of	O
siroliums	O
to	O
rneal	O
transplnat	O
recipeints	O
.	O

BACKGORUND	O
:	O
Sirloimus	O
is	O
the	O
latest	O
immuonsuppressive	O
agnet	O
used	O
to	O
preevnt	O
rjeection	O
,	O
and	O
may	O
have	O
less	O
neprhotoxicity	B-Disease
than	O
clacineurin	O
inhiibtor	O
(	O
CNI	O
)	O
-	O
based	O
reigmens	O
.	O

To	O
date	O
there	O
has	O
been	O
little	O
docmuentation	O
of	O
clinically	O
significant	O
proteiunria	B-Disease
linked	O
with	O
the	O
use	O
of	O
siroliums	O
.	O

We	O
have	O
encountered	O
several	O
paitents	O
who	O
developed	O
substantial	O
proetinuria	B-Disease
associated	O
with	O
sirolmius	O
use	O
.	O

In	O
each	O
ptaient	O
,	O
the	O
close	O
tmeporal	O
associtaion	O
between	O
the	O
commenceemnt	O
of	O
sriolimus	O
thearpy	O
and	O
porteinuria	B-Disease
implicated	O
sirloimus	O
as	O
the	O
most	O
likely	O
etiloogy	O
of	O
the	O
proteniuria	B-Disease
.	O

METHODS	O
:	O
We	O
anaylzed	O
the	O
cliincal	O
and	O
laboratroy	O
informatoin	O
available	O
for	O
all	O
119	O
pateints	O
transpalnted	O
at	O
the	O
Washnigton	O
Hospiatl	O
Cetner	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
siroilmus	O
was	O
a	O
component	O
of	O
their	O
immunsouppressant	O
regiemn	O
.	O

In	O
these	O
ptaients	O
,	O
the	O
magintude	O
of	O
proteinuira	B-Disease
was	O
asesssed	O
on	O
mornnig	O
urnie	O
sapmles	O
by	O
turbidomertic	O
measruement	O
or	O
radnom	O
uirne	O
prtoein	O
:	O
craetinine	O
rtaios	O
,	O
an	O
estimtae	O
of	O
garms	O
of	O
proteinruia	B-Disease
/	O
day	O
.	O

Laboartory	O
resutls	O
were	O
comapred	O
between	O
prior	O
,	O
during	O
and	O
following	O
sirolmius	O
use	O
.	O

RESUTLS	O
:	O
Twenty	O
-	O
eight	O
paitents	O
(	O
24	O
%	O
)	O
developed	O
icnreased	O
proteinruia	B-Disease
from	O
baseilne	O
during	O
their	O
psot	O
-	O
tranpslantation	O
coruse	O
.	O

In	O
21	O
patietns	O
an	O
altrenative	O
cause	O
of	O
proteinuira	B-Disease
was	O
either	O
obvious	O
or	O
insufifcient	O
dtaa	O
was	O
available	O
to	O
be	O
conclusive	O
.	O

In	O
7	O
of	O
the	O
28	O
paitents	O
there	O
was	O
a	O
striking	O
temproal	O
associaiton	O
between	O
the	O
initaition	O
of	O
siorlimus	O
and	O
the	O
dveelopment	O
of	O
npehrotic	B-Disease
-	O
range	O
prtoeinuria	B-Disease
.	O

Prtoeinuria	B-Disease
correltaed	O
most	O
strongly	O
with	O
siorlimus	O
tehrapy	O
when	O
compaerd	O
to	O
other	O
demograpihc	O
and	O
cliincal	O
vraiables	O
.	O

In	O
most	O
patietns	O
,	O
discontiunation	O
of	O
sirloimus	O
resulted	O
in	O
a	O
decresae	O
,	O
but	O
not	O
reoslution	O
,	O
of	O
porteinuria	B-Disease
.	O

COCNLUSIONS	O
:	O
Sriolimus	O
inudces	O
or	O
aggravates	O
pre	O
-	O
existing	O
proteniuria	B-Disease
in	O
an	O
unpredictalbe	O
subset	O
of	O
rneal	O
allograft	O
rceipients	O
.	O

Porteinuria	B-Disease
may	O
imporve	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirloimus	O
is	O
withdrawn	O
.	O

Componetns	O
of	O
lmeon	O
essetnial	O
oil	O
attneuate	O
demnetia	B-Disease
indcued	O
by	O
scopolamnie	O
.	O

The	O
atni	O
-	O
demenita	B-Disease
effects	O
of	O
s	O
-	O
limoenne	O
and	O
s	O
-	O
perilyll	O
aclohol	O
were	O
observed	O
using	O
the	O
psasive	O
avoiadnce	O
tset	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
haibtuation	O
tset	O
(	O
OFH	O
)	O
.	O

These	O
leomn	O
essenital	O
olis	O
showed	O
strong	O
ability	O
to	O
ipmrove	O
memroy	B-Disease
imapired	I-Disease
by	O
scooplamine	O
;	O
however	O
,	O
s	O
-	O
perlilyl	O
aclohol	O
rleieved	O
the	O
deifcit	B-Disease
of	I-Disease
associative	I-Disease
mmeory	I-Disease
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
imrpove	O
non	O
-	O
associative	O
meomry	O
significantly	O
in	O
OFH	O
.	O

Anaylsis	O
of	O
neurotrnasmitter	O
concentraiton	O
in	O
some	O
barin	O
rgeions	O
on	O
the	O
tset	O
day	O
showed	O
that	O
dopamnie	O
concetnration	O
of	O
the	O
vheicle	O
/	O
scopoalmine	O
gruop	O
was	O
significantly	O
lwoer	O
than	O
that	O
of	O
the	O
vehcile	O
/	O
vehcile	O
gruop	O
,	O
but	O
this	O
pehnomenon	O
was	O
revresed	O
when	O
s	O
-	O
lmionene	O
or	O
s	O
-	O
perillyl	O
aclohol	O
were	O
admiinstered	O
before	O
the	O
injeciton	O
of	O
scopolamnie	O
.	O

Simultaneously	O
,	O
we	O
found	O
that	O
these	O
two	O
leomn	O
essetnial	O
oil	O
copmonents	O
could	O
inihbit	O
aectylcholinesterase	O
atcivity	O
in	O
vitro	O
using	O
the	O
Elmlan	O
mtehod	O
.	O

Attentional	O
modulatoin	O
of	O
perceievd	O
pian	B-Disease
intesnity	O
in	O
cpasaicin	O
-	O
idnuced	O
secondary	O
hyepralgesia	B-Disease
.	O

Pecreived	O
pian	B-Disease
intenstiy	O
is	O
moudlated	O
by	O
attnetion	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pian	B-Disease
intnesity	O
rtaings	O
are	O
affected	O
by	O
attetnion	O
in	O
capsiacin	O
-	O
indcued	O
secondary	O
hyperalgseia	B-Disease
.	O

Here	O
we	O
show	O
that	O
percevied	O
pian	B-Disease
intenstiy	O
in	O
secondary	O
hyperaglesia	B-Disease
is	O
derceased	O
when	O
attention	O
is	O
ditsracted	O
away	O
from	O
the	O
painufl	O
pipnrick	O
stiumlus	O
with	O
a	O
vsiual	O
tsak	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitdue	O
of	O
attentional	O
mdoulation	O
in	O
secondary	O
hpyeralgesia	B-Disease
is	O
very	O
similar	O
to	O
that	O
of	O
capasicin	O
-	O
untraeted	O
,	O
contorl	O
condtiion	O
.	O

Our	O
fidnings	O
,	O
showing	O
no	O
intearction	O
between	O
cpasaicin	O
teratment	O
and	O
attentoinal	O
moudlation	O
suggest	O
that	O
caspaicin	O
-	O
indcued	O
secondary	O
hypearlgesia	B-Disease
and	O
attetnion	O
might	O
affect	O
mehcanical	O
pian	B-Disease
through	O
indepnedent	O
mechainsms	O
.	O

Cradioprotective	O
effcet	O
of	O
salviaonlic	O
aicd	O
A	O
on	O
isoprotreenol	O
-	O
idnuced	O
myocardail	B-Disease
ifnarction	I-Disease
in	O
rtas	O
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
eavluate	O
the	O
cradioprotective	O
poetntial	O
of	O
salvianoilc	O
aicd	O
A	O
on	O
isoprotreenol	O
-	O
indcued	O
myocradial	B-Disease
ifnarction	I-Disease
in	O
rtas	O
.	O

Hemodyanmic	O
parameetrs	O
and	O
lead	O
II	O
electrocardiorgaph	O
were	O
monitroed	O
and	O
recorded	O
contiunously	O
.	O

Cadriac	O
mraker	O
enyzmes	O
and	O
antioxidatvie	O
paramteers	O
in	O
seurm	O
and	O
herat	O
tissues	O
were	O
measrued	O
.	O

Assay	O
for	O
mitocohndrial	O
repsiratory	O
funtcion	O
and	O
histopatohlogical	O
examinatoin	O
of	O
herat	O
tsisues	O
were	O
performed	O
.	O

Isoporterenol	O
-	O
treaetd	O
rtas	O
showed	O
significant	O
incerases	O
in	O
the	O
lveels	O
of	O
lacttae	O
dheydrogenase	O
,	O
aspratate	O
tarnsaminase	O
,	O
craetine	O
kniase	O
and	O
malondialedhyde	O
and	O
significant	O
decresaes	O
in	O
the	O
actviities	O
of	O
supeorxide	O
dsimutase	O
,	O
catalsae	O
and	O
glutahtione	O
peroxdiase	O
in	O
seurm	O
and	O
herat	O
.	O

These	O
rtas	O
also	O
showed	O
dcelines	O
in	O
lfet	O
vnetricular	O
systoilc	O
pressrue	O
,	O
mxaimum	O
and	O
minimum	O
rtae	O
of	O
developed	O
lfet	O
vnetricular	O
presusre	O
,	O
and	O
eleavtion	O
of	O
lfet	O
vetnricular	O
end	O
-	O
daistolic	O
presusre	O
and	O
ST	O
-	O
segmnet	O
.	O

In	O
addition	O
,	O
mitcohondrial	O
respiraotry	B-Disease
dysfunciton	I-Disease
cahracterized	O
by	O
dcereased	O
respiraotry	O
conrtol	O
rtaio	O
and	O
ADP	O
/	O
O	O
was	O
observed	O
in	O
isoproteernol	O
-	O
tretaed	O
rtas	O
.	O

Adminitsration	O
of	O
salvinaolic	O
aicd	O
A	O
for	O
a	O
peroid	O
of	O
8	O
dyas	O
significantly	O
atetnuated	O
isoproterneol	O
-	O
inudced	O
cradiac	B-Disease
dyfsunction	I-Disease
and	O
myocardail	B-Disease
inujry	I-Disease
and	O
improevd	O
mitochnodrial	O
resipratory	O
fnuction	O
.	O

The	O
protective	O
role	O
of	O
salvianoilc	O
aicd	O
A	O
against	O
isoprotreenol	O
-	O
inudced	O
myocaridal	B-Disease
daamge	I-Disease
was	O
further	O
confirmed	O
by	O
histopatholgoical	O
exmaination	O
.	O

The	O
reuslts	O
of	O
our	O
sutdy	O
suggest	O
that	O
salvainolic	O
aicd	O
A	O
possessing	O
atnioxidant	O
actiivty	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
iosproterenol	O
-	O
idnuced	O
moycardial	B-Disease
infartcion	I-Disease
.	O

Lnog	O
-	O
term	O
glutaamte	O
spuplementation	O
failed	O
to	O
protect	O
against	O
preipheral	B-Disease
neurotoxiicty	I-Disease
of	O
paciltaxel	O
.	O

Toixc	O
periphearl	B-Disease
neuroptahy	I-Disease
is	O
still	O
a	O
significant	O
limiting	O
fcator	O
for	O
chemotehrapy	O
with	O
pacltiaxel	O
(	O
PAC	O
)	O
,	O
although	O
glutmaate	O
and	O
its	O
closely	O
related	O
aimno	O
aicd	O
gultamine	O
were	O
claimed	O
to	O
amelioarte	O
PAC	O
neurotoxiicty	B-Disease
.	O

This	O
pliot	O
tiral	O
aimed	O
to	O
evalutae	O
the	O
role	O
of	O
gltuamate	O
supplementaiton	O
for	O
preventing	O
PAC	O
-	O
indcued	O
peirpheral	B-Disease
nueropathy	I-Disease
in	O
a	O
radnomized	O
,	O
plaecbo	O
-	O
controleld	O
,	O
double	O
-	O
blinedd	O
cliincal	O
and	O
eelctro	O
-	O
diagnsotic	O
stduy	O
.	O

Forty	O
-	O
three	O
ovairan	B-Disease
cacner	I-Disease
patietns	O
were	O
available	O
for	O
anlaysis	O
following	O
six	O
cylces	O
of	O
the	O
same	O
PAC	O
-	O
containing	O
regiemn	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
gultamate	O
all	O
along	O
the	O
treatmnet	O
peirod	O
,	O
at	O
a	O
dialy	O
dsoe	O
of	O
three	O
times	O
500	O
mg	O
(	O
gruop	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placbeo	O
(	O
gruop	O
P	O
)	O
.	O

Paitents	O
were	O
eavluated	O
by	O
neurloogical	O
examinatinos	O
,	O
quetsionnaires	O
and	O
sensroy	O
-	O
mtoor	O
nevre	O
condcution	O
stduies	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequnecy	O
of	O
sings	O
or	O
sypmtoms	O
between	O
the	O
two	O
gruops	O
although	O
neruotoxicity	B-Disease
smyptoms	O
presented	O
mostly	O
with	O
loewr	O
socres	O
of	O
seevrity	O
in	O
gorup	O
G	O
.	O

However	O
,	O
this	O
difference	O
reached	O
statisitcal	O
sginificance	O
only	O
with	O
regard	O
to	O
reported	O
pian	B-Disease
sensaiton	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Also	O
the	O
frqeuency	O
of	O
abnoraml	O
eelctro	O
-	O
daignostic	O
fnidings	O
showed	O
simialrity	O
between	O
the	O
two	O
gorups	O
(	O
G	O
:	O
7	O
/	O
23	O
=	O
30	O
.	O
4	O
%	O
;	O
P	O
:	O
6	O
/	O
20	O
=	O
30	O
%	O
)	O
.	O

This	O
pliot	O
stduy	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamtae	O
supplemenattion	O
at	O
the	O
chosen	O
regmien	O
fails	O
to	O
protect	O
against	O
perpiheral	B-Disease
neruotoxicity	I-Disease
of	O
PAC	O
.	O

Devleopment	O
of	O
ocluar	B-Disease
myastehnia	I-Disease
during	O
pegylaetd	O
interefron	O
and	O
riabvirin	O
teratment	O
for	O
chroinc	B-Disease
hepattiis	I-Disease
C	I-Disease
.	O

A	O
63	O
-	O
yaer	O
-	O
old	O
mlae	O
experienced	O
sduden	O
dilpopia	B-Disease
after	O
9	O
wekes	O
of	O
adminitsration	O
of	O
pgeylated	O
interfeorn	O
(	O
IFN	O
)	O
aplha	O
-	O
2b	O
and	O
rbiavirin	O
for	O
chornic	B-Disease
hepaittis	I-Disease
C	I-Disease
(	O
CHC	B-Disease
)	O
.	O

Ophthalomlogic	O
exaimnations	O
showed	O
ptoiss	B-Disease
on	I-Disease
the	I-Disease
rgiht	I-Disease
upepr	I-Disease
lid	I-Disease
and	O
restricted	B-Disease
rgiht	I-Disease
eye	I-Disease
moveemnt	I-Disease
without	O
any	O
other	O
neuroloigcal	O
sings	O
.	O

A	O
brian	O
imagnig	O
stduy	O
and	O
repetitvie	O
nreve	O
stiumlation	O
tset	O
indicated	O
no	O
abnormaltiy	O
.	O

The	O
acetylchoilne	O
reecptor	O
antiobdy	O
ttier	O
and	O
resposne	O
to	O
aceytlcholinesterase	O
inhibiotrs	O
were	O
negtaive	O
,	O
and	O
the	O
resluts	O
of	O
thyriod	O
funciton	O
tsets	O
were	O
nromal	O
.	O

The	O
ptaient	O
'	O
s	O
ophtahlmological	O
symptmos	O
ipmroved	O
rapidly	O
3	O
weeks	O
after	O
discnotinuation	O
of	O
pegyltaed	O
IFN	O
aplha	O
-	O
2b	O
and	O
ribaviirn	O
.	O

The	O
ouclar	B-Disease
myashtenia	I-Disease
associated	O
with	O
combinatoin	O
thearpy	O
of	O
pegylaetd	O
IFN	O
alhpa	O
-	O
2b	O
and	O
rbiavirin	O
for	O
CHC	B-Disease
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
csae	O
with	O
a	O
reivew	O
of	O
the	O
various	O
eye	O
complicatoins	O
of	O
IFN	O
threapy	O
.	O

Learinng	B-Disease
and	I-Disease
mmeory	I-Disease
defictis	I-Disease
in	O
ecstsay	O
uesrs	O
and	O
their	O
nueral	O
crorelates	O
during	O
a	O
fcae	O
-	O
leraning	O
tsak	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstsay	O
uesrs	O
display	O
imapirments	B-Disease
in	I-Disease
laerning	I-Disease
and	I-Disease
meomry	I-Disease
perforamnce	O
.	O

In	O
addition	O
,	O
worikng	O
memroy	O
processing	O
in	O
ectsasy	O
uesrs	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neuarl	O
altreations	O
in	O
hippocampal	O
and	O
/	O
or	O
crotical	O
reginos	O
as	O
meausred	O
by	O
fnuctional	O
mganetic	O
resnoance	O
imagnig	O
(	O
fRMI	O
)	O
.	O

Using	O
fnuctional	O
imagnig	O
and	O
a	O
fcae	O
-	O
leraning	O
tsak	O
,	O
we	O
inevstigated	O
neuarl	O
corrleates	O
of	O
encoidng	O
and	O
recalling	O
fcae	O
-	O
name	O
asosciations	O
in	O
20	O
recraetional	O
durg	O
usres	O
whose	O
predomniant	O
durg	O
use	O
was	O
ectsasy	O
and	O
20	O
conrtols	O
.	O

To	O
address	O
the	O
potnetial	O
cofnounding	O
effects	O
of	O
the	O
cannaibs	O
use	O
of	O
the	O
ecsatsy	O
using	O
gorup	O
,	O
a	O
second	O
analsyis	O
included	O
14	O
previously	O
tseted	O
cannaibs	O
uesrs	O
(	O
Nesotr	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O
Deifcits	B-Disease
in	I-Disease
laerning	I-Disease
and	I-Disease
mmeory	I-Disease
:	O
parahipopcampal	O
hyperacitvity	B-Disease
and	O
forntocortical	O
hypoatcivity	O
in	O
cannbais	O
usres	O
.	O
Neruoimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O

Ecsatsy	O
uesrs	O
performed	O
significantly	O
wrose	O
in	O
leraning	O
and	O
memroy	O
cmopared	O
to	O
cotnrols	O
and	O
cnanabis	O
uesrs	O
.	O

A	O
conjucntion	O
analsyis	O
of	O
the	O
encode	O
and	O
reclal	O
phaess	O
of	O
the	O
tsak	O
revaeled	O
ecsatsy	O
-	O
specific	O
hyperactivtiy	B-Disease
in	O
biltaeral	O
forntal	O
regoins	O
,	O
lfet	O
temproal	O
,	O
rihgt	O
pairetal	O
,	O
bilaetral	O
tmeporal	O
,	O
and	O
bialteral	O
occipiatl	O
barin	O
reginos	O
.	O

Ecstsay	O
-	O
specific	O
hypoactivtiy	O
was	O
evident	O
in	O
the	O
rgiht	O
dorasl	O
antreior	O
cnigulated	O
coretx	O
(	O
ACC	O
)	O
and	O
lfet	O
posetrior	O
cnigulated	O
coretx	O
.	O

In	O
both	O
ecsatsy	O
and	O
cananbis	O
gruops	O
brian	O
atcivation	O
was	O
decerased	O
in	O
the	O
rihgt	O
meidal	O
frotnal	O
gyurs	O
,	O
lfet	O
parahippocmapal	O
gyurs	O
,	O
lfet	O
dosral	O
cingluate	O
gyurs	O
,	O
and	O
lfet	O
caduate	O
.	O

These	O
reuslts	O
elucidated	O
ecsatsy	O
-	O
related	O
deifcits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cananbis	O
use	O
.	O

These	O
ectsasy	O
-	O
specific	O
effetcs	O
may	O
be	O
related	O
to	O
the	O
vulnerabiilty	O
of	O
isocortcial	O
and	O
allocortiacl	O
reginos	O
to	O
the	O
neurtooxic	B-Disease
effetcs	O
of	O
ecsatsy	O
.	O

Disulfiarm	O
-	O
like	O
syndorme	O
after	O
hydrgoen	O
cyanmaide	O
professioanl	O
sikn	O
expousre	O
:	O
two	O
csae	O
rpeorts	O
in	O
Farnce	O
.	O

Hydorgen	O
cyanamdie	O
is	O
a	O
plnat	O
grotwh	O
regluator	O
used	O
in	O
agriculutre	O
to	O
inudce	O
bud	O
break	O
in	O
friut	O
teres	O
.	O

Cnotact	O
with	O
the	O
sikn	O
can	O
result	O
in	O
peructaneous	O
absorpiton	O
of	O
the	O
subtsance	O
that	O
inihbits	O
aldehdye	O
dehyrdogenase	O
and	O
can	O
idnuce	O
acetaldehdye	O
sydnrome	O
in	O
csae	O
of	O
alchool	O
use	O
.	O

The	O
purpose	O
of	O
this	O
reoprt	O
is	O
to	O
describe	O
two	O
csaes	O
of	O
a	O
disulfriam	O
-	O
like	O
synrdome	O
following	O
occuaptional	O
expousre	O
to	O
hydorgen	O
cyanaimde	O
.	O

The	O
first	O
csae	O
involved	O
a	O
59	O
-	O
yaer	O
-	O
old	O
man	O
who	O
used	O
Doremx	O
,	O
which	O
contains	O
hdyrogen	O
cyanaimde	O
,	O
without	O
protectoin	O
after	O
consuming	O
a	O
large	O
amonut	O
of	O
alcoohl	O
during	O
a	O
mael	O
.	O

In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingetsion	O
of	O
aclohol	O
,	O
he	O
developed	O
maliase	O
with	O
flusihng	B-Disease
of	I-Disease
the	I-Disease
fcae	I-Disease
,	O
tachycradia	B-Disease
,	O
and	O
dypsnea	B-Disease
.	O

Maniefstations	O
regressed	O
sponatneously	O
under	O
surviellance	O
in	O
the	O
hsopital	O
.	O

The	O
second	O
csae	O
occurred	O
in	O
a	O
55	O
-	O
yaer	O
-	O
old	O
faremr	O
following	O
cutaneuos	O
cnotact	O
with	O
Dromex	O
.	O

Five	O
hours	O
after	O
exopsure	O
,	O
he	O
developed	O
diuslfiram	O
-	O
like	O
syndorme	O
with	O
flsuhing	B-Disease
,	O
tachycradia	B-Disease
,	O
and	O
arterail	B-Disease
hyptoension	I-Disease
after	O
consuming	O
three	O
glasess	O
of	O
wnie	O
.	O

The	O
patinet	O
rceovered	O
spontaneoulsy	O
in	O
3	O
hours	O
under	O
surveillacne	O
in	O
the	O
hosptial	O
.	O

These	O
csaes	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
aclohol	O
cosnumption	O
as	O
recmomended	O
in	O
the	O
insturctions	O
for	O
use	O
of	O
Dromex	O
and	O
of	O
preventing	O
cuatneous	O
cotnact	O
during	O
use	O
.	O

Sulpriide	O
-	O
induecd	O
tadrive	B-Disease
dysotnia	I-Disease
.	O

Sulpriide	O
is	O
a	O
selective	O
D2	O
-	O
recepotr	O
anatgonist	O
with	O
antipsycohtic	O
and	O
antidepressant	O
properites	O
.	O

Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramiadl	O
side	O
effcets	O
,	O
sulpriide	O
-	O
idnuced	O
tadrive	B-Disease
dyksinesia	I-Disease
and	O
parkinsonsim	B-Disease
have	O
been	O
reported	O
occasionally	O
.	O

We	O
studied	O
a	O
37	O
-	O
yaer	O
-	O
old	O
man	O
who	O
developed	O
pesristent	O
segmenatl	O
dystnoia	B-Disease
within	O
2	O
motnhs	O
after	O
starting	O
sulpriide	O
tehrapy	O
.	O

We	O
could	O
not	O
find	O
any	O
previous	O
repotrs	O
of	O
sulpiirde	O
-	O
idnuced	O
taridve	B-Disease
dysotnia	I-Disease
.	O

Compaartive	O
cogintive	O
and	O
subjetcive	O
side	O
efefcts	O
of	O
immdeiate	O
-	O
reelase	O
oxcyodone	O
in	O
helathy	O
middle	O
-	O
aegd	O
and	O
odler	O
audlts	O
.	O

This	O
sutdy	O
mesaured	O
the	O
ojbective	O
and	O
subejctive	O
neurocognitvie	O
effetcs	O
of	O
a	O
single	O
10	O
-	O
mg	O
dsoe	O
of	O
immeidate	O
-	O
relesae	O
oyxcodone	O
in	O
healhty	O
,	O
odler	O
(	O
>	O
65	O
yeras	O
)	O
,	O
and	O
midlde	O
-	O
aegd	O
(	O
35	O
to	O
55	O
yaers	O
)	O
adluts	O
who	O
were	O
not	O
sfufering	O
from	O
crhonic	O
or	O
significant	O
dialy	O
pian	B-Disease
.	O

Seventy	O
-	O
one	O
participnats	O
completed	O
2	O
separate	O
sutdy	O
dyas	O
and	O
were	O
blnid	O
to	O
mdeication	O
cnodition	O
(	O
plcaebo	O
,	O
10	O
-	O
mg	O
oxcyodone	O
)	O
.	O

Palsma	O
oxycodnoe	O
concentraiton	O
peaked	O
between	O
60	O
and	O
90	O
minuets	O
potsdose	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
puipl	O
szie	O
,	O
an	O
indicaiton	O
of	O
physiologiacl	O
effcets	O
of	O
the	O
mdeication	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
mintues	O
postdsoe	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

Signfiicant	O
decliens	B-Disease
in	I-Disease
simple	I-Disease
and	I-Disease
susatined	I-Disease
attnetion	I-Disease
,	I-Disease
worknig	I-Disease
meomry	I-Disease
,	I-Disease
and	I-Disease
vrebal	I-Disease
mmeory	I-Disease
were	O
observed	O
at	O
1	O
hour	O
psotdose	O
compraed	O
to	O
baesline	O
for	O
both	O
age	O
gruops	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baseilne	O
by	O
5	O
hours	O
posdtose	O
.	O

For	O
almost	O
all	O
cogintive	O
measuers	O
,	O
there	O
were	O
no	O
mdeication	O
by	O
age	O
-	O
inetraction	O
efefcts	O
,	O
which	O
indicates	O
that	O
the	O
2	O
age	O
gorups	O
exhibited	O
similar	O
resposnes	O
to	O
the	O
medictaion	O
challenge	O
.	O

This	O
sutdy	O
suggests	O
that	O
for	O
heatlhy	O
oledr	O
adutls	O
who	O
are	O
not	O
suffernig	O
from	O
chroinc	B-Disease
pian	I-Disease
,	O
neuorcognitive	O
and	O
pharmacoydnamic	O
chnages	O
in	O
rseponse	O
to	O
a	O
10	O
-	O
mg	O
dsoe	O
of	O
imemdiate	O
-	O
reelase	O
oxycdoone	O
are	O
similar	O
to	O
those	O
observed	O
for	O
middle	O
-	O
aegd	O
adutls	O
.	O

PESRPECTIVE	O
:	O
Stduy	O
findigns	O
indicate	O
that	O
the	O
metaoblism	O
,	O
neuorcognitive	O
effcets	O
,	O
and	O
phsyical	O
side	O
efefcts	O
of	O
oarl	O
oxycdoone	O
are	O
similar	O
for	O
healhty	O
middle	O
-	O
aegd	O
and	O
odler	O
adluts	O
.	O

Therefore	O
,	O
clinicains	O
should	O
not	O
avoid	O
prescrbiing	O
oarl	O
opiiods	O
to	O
odler	O
adutls	O
based	O
on	O
the	O
beilef	O
that	O
odler	O
adutls	O
are	O
at	O
hgiher	O
rsik	O
for	O
side	O
efefcts	O
than	O
yougner	O
audlts	O
.	O

The	O
gylcine	O
tranpsorter	O
-	O
1	O
ihnibitor	O
SSR103800	O
displays	O
a	O
selective	O
and	O
specific	O
antispychotic	O
-	O
like	O
porfile	O
in	O
noraml	O
and	O
tarnsgenic	O
mcie	O
.	O

Shcizophrenia	B-Disease
has	O
been	O
initially	O
associated	O
with	O
dysfunctoin	O
in	O
dpoamine	O
nuerotransmission	O
.	O

However	O
,	O
the	O
obsrevation	O
that	O
antagnoists	O
of	O
the	O
glutaamte	O
N	O
-	O
metyhl	O
-	O
D	O
-	O
asparttae	O
(	O
NDMA	O
)	O
recetpor	O
produce	O
schziophrenic	B-Disease
-	O
like	O
symptmos	O
in	O
hmuans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctinoing	O
of	O
the	O
gluatmatergic	O
sytsem	O
via	O
its	O
NDMA	O
rceeptor	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
deveolpment	O
of	O
pahrmacological	O
agnets	O
with	O
ptoential	O
antispychotic	O
propetries	O
that	O
enhnace	O
the	O
activtiy	O
of	O
the	O
glutmaatergic	O
sytsem	O
via	O
a	O
modulatoin	O
of	O
the	O
NDMA	O
reecptor	O
.	O

Among	O
them	O
are	O
glcyine	O
tranpsorter	O
-	O
1	O
(	O
GylT1	O
)	O
inhibiotrs	O
such	O
as	O
SSR103800	O
,	O
which	O
indireclty	O
ehnance	O
NDMA	O
recetpor	O
functoin	O
by	O
icnreasing	O
the	O
glycnie	O
(	O
a	O
co	O
-	O
aognist	O
for	O
the	O
NDMA	O
rceeptor	O
)	O
leevls	O
in	O
the	O
synaspe	O
.	O

This	O
sutdy	O
aimed	O
at	O
investigaitng	O
the	O
potnetial	O
antpisychotic	O
-	O
like	O
propetries	O
of	O
SSR103800	O
,	O
with	O
a	O
particular	O
focus	O
on	O
mdoels	O
of	O
hyperactivtiy	B-Disease
,	O
involving	O
either	O
durg	O
challenge	O
(	O
ie	O
,	O
amphetaimne	O
and	O
MK	O
-	O
801	O
)	O
or	O
tarnsgenic	O
mcie	O
(	O
ie	O
,	O
NDMA	O
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Rseults	O
showed	O
that	O
SSR103800	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blokced	O
hypreactivity	B-Disease
inudced	O
by	O
the	O
non	O
-	O
competitive	O
NDMA	O
recetpor	O
atnagonist	O
,	O
MK	O
-	O
801	O
and	O
pratially	O
reveresd	O
spontanoeus	O
hpyeractivity	B-Disease
of	O
NDMA	O
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
mcie	O
.	O

In	O
contrast	O
,	O
SSR103800	O
failed	O
to	O
affect	O
hyperactivtiy	B-Disease
inudced	O
by	O
ampehtamine	O
or	O
naturally	O
observed	O
in	O
dpoamine	O
trnasporter	O
(	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
konckout	O
mcie	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
haolperidol	O
)	O
and	O
atypcial	O
(	O
olnazapine	O
,	O
cloazpine	O
and	O
airpiprazole	O
)	O
antipscyhotics	O
were	O
effetcive	O
in	O
all	O
these	O
moedls	O
of	O
hpyeractivity	B-Disease
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	O
did	O
not	O
produce	O
catlaepsy	B-Disease
(	O
reteniton	O
on	O
the	O
bar	O
tset	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O

Together	O
these	O
findnigs	O
show	O
that	O
the	O
GlTy1	O
inihbitor	O
,	O
SSR103800	O
,	O
produces	O
atnipsychotic	O
-	O
like	O
efefcts	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
comopunds	O
primarily	O
tagreting	O
the	O
dopaimnergic	O
ssytem	O
,	O
and	O
has	O
a	O
reduecd	O
side	O
-	O
effcet	O
potnetial	O
as	O
cmopared	O
with	O
these	O
latter	O
drgus	O
.	O

Pyrrolidine	O
dithiocarbamtae	O
prtoects	O
the	O
pirifrom	O
cotrex	O
in	O
the	O
piolcarpine	O
stauts	B-Disease
epileptiucs	I-Disease
moedl	O
.	O

Pyrrolidnie	O
dithiocarbamtae	O
(	O
PTDC	O
)	O
has	O
a	O
dual	O
mcehanism	O
of	O
aciton	O
as	O
an	O
antioixdant	O
and	O
an	O
inhibiotr	O
of	O
the	O
transcirption	O
fatcor	O
kpapa	O
-	O
btea	O
.	O

Both	O
,	O
prodcution	O
of	O
reacitve	O
oxyegn	O
sepcies	O
as	O
well	O
as	O
actviation	O
of	O
NF	O
-	O
kapapB	O
have	O
been	O
implicated	O
in	O
sveere	O
neuroanl	B-Disease
damgae	I-Disease
in	O
different	O
sub	O
-	O
reigons	O
of	O
the	O
hippocapmus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
coritces	O
.	O

The	O
effcet	O
of	O
PTDC	O
on	O
sttaus	B-Disease
epiletpicus	I-Disease
-	O
associated	O
clel	O
lsos	O
in	O
the	O
hippocampus	O
and	O
priiform	O
cotrex	O
was	O
evalauted	O
in	O
the	O
rat	O
fracitonated	O
pilocarpnie	O
moedl	O
.	O

Treamtent	O
with	O
150	O
mg	O
/	O
kg	O
PTDC	O
before	O
and	O
following	O
stauts	B-Disease
eiplepticus	I-Disease
significantly	O
incraesed	O
the	O
mortailty	O
rtae	O
to	O
100	O
%	O
.	O

Administratoin	O
of	O
50	O
mg	O
/	O
kg	O
PTDC	O
(	O
low	O
-	O
dsoe	O
)	O
did	O
not	O
exert	O
major	O
efefcts	O
on	O
the	O
dveelopment	O
of	O
a	O
sattus	B-Disease
epileptcius	I-Disease
or	O
the	O
mortailty	O
rtae	O
.	O

In	O
veihcle	O
-	O
tretaed	O
rtas	O
,	O
sttaus	B-Disease
epielpticus	I-Disease
caused	O
pronounced	O
neuroanl	B-Disease
dmaage	I-Disease
in	O
the	O
priiform	O
cotrex	O
comprising	O
both	O
pyraimdal	O
cells	O
and	O
intreneurons	O
.	O

Low	O
-	O
dsoe	O
PTDC	O
treatemnt	O
almost	O
completely	O
protected	O
from	O
lesinos	O
in	O
the	O
pirfiorm	O
coretx	O
.	O

A	O
significant	O
dercease	O
in	O
neurnoal	O
desnity	O
of	O
the	O
hpipocampal	O
hliar	O
formatoin	O
was	O
identfiied	O
in	O
vehcile	O
-	O
and	O
PTDC	O
-	O
traeted	O
rtas	O
following	O
sattus	B-Disease
epielpticus	I-Disease
.	O

In	O
conclusion	O
,	O
the	O
NF	O
-	O
kpapaB	O
inihbitor	O
and	O
antoixidant	O
PTDC	O
protected	O
the	O
priiform	O
coretx	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hliar	O
neuornal	B-Disease
lsos	I-Disease
.	O

These	O
dtaa	O
might	O
indicate	O
that	O
the	O
genertaion	O
of	O
raective	O
oyxgen	O
speices	O
and	O
activatoin	O
of	O
NF	O
-	O
kpapaB	O
plays	O
a	O
more	O
centarl	O
role	O
in	O
siezure	B-Disease
-	O
associated	O
neurnoal	B-Disease
damgae	I-Disease
in	O
the	O
temproal	O
cotrex	O
as	O
compraed	O
to	O
the	O
hippoacmpal	O
hlius	O
.	O

However	O
,	O
future	O
investigatinos	O
are	O
necessary	O
to	O
exactly	O
aanlyze	O
the	O
biochemiacl	O
mechainsms	O
by	O
which	O
PTDC	O
exerted	O
its	O
beneficial	O
effects	O
in	O
the	O
piirform	O
crotex	O
.	O

Aneasthetists	O
'	O
nightmrae	O
:	O
masester	B-Disease
sapsm	I-Disease
after	O
indutcion	O
in	O
an	O
undiangosed	O
csae	O
of	O
myootnia	B-Disease
congenita	I-Disease
.	O

We	O
reprot	O
an	O
udniagnosed	O
csae	O
of	O
myotnoia	B-Disease
congenita	I-Disease
in	O
a	O
24	O
-	O
yaer	O
-	O
old	O
previously	O
haelthy	O
primigraivda	O
,	O
who	O
developed	O
lfie	O
threatening	O
masseetr	B-Disease
spsam	I-Disease
following	O
a	O
standrad	O
dsoe	O
of	O
intraveonus	O
suxamtehonium	O
for	O
inductoin	O
of	O
anaeshtesia	O
.	O

Neither	O
the	O
ptaient	O
nor	O
the	O
anaeshtetist	O
was	O
aware	O
of	O
the	O
diagnsois	O
before	O
this	O
potentially	O
lehtal	O
cmoplication	O
occurred	O
.	O

Tiwn	O
pretrem	O
nenoates	O
with	O
caridac	B-Disease
toixcity	I-Disease
related	O
to	O
loipnavir	O
/	O
rtionavir	O
threapy	O
.	O

We	O
reprot	O
tiwn	O
noenates	O
who	O
were	O
bron	O
prematurley	O
at	O
32	O
weeks	O
of	O
getsation	O
to	O
a	O
mohter	O
with	O
hmuan	B-Disease
immuondeficiency	I-Disease
viurs	I-Disease
infcetion	I-Disease
.	O

One	O
of	O
the	O
tiwns	O
developed	O
complete	O
herat	B-Disease
blcok	I-Disease
and	O
dilaetd	B-Disease
cardiomyoapthy	I-Disease
related	O
to	O
lopinvair	O
/	O
ritoanvir	O
tehrapy	O
,	O
a	O
boosted	O
proetase	O
-	O
inhbiitor	O
agnet	O
,	O
while	O
the	O
other	O
tiwn	O
developed	O
mlid	O
bradcyardia	B-Disease
.	O

We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lpoinavir	O
/	O
ritonaivr	O
in	O
the	O
imemdiate	O
nenoatal	O
peirod	O
.	O

When	O
drgus	O
disappear	O
from	O
the	O
pateint	O
:	O
elimniation	O
of	O
inrtavenous	O
medictaion	O
by	O
hemodiafiltrtaion	O
.	O

Twenty	O
-	O
three	O
hours	O
after	O
haert	O
transplantatoin	O
,	O
lfie	O
-	O
threatening	O
aucte	O
rgiht	B-Disease
herat	I-Disease
failrue	I-Disease
was	O
diagonsed	O
in	O
a	O
pateint	O
requiring	O
conitnuous	O
venovneous	O
hemodifailtration	O
(	O
CVHVDF	O
)	O
.	O

Incresaing	O
dsoes	O
of	O
catechloamines	O
,	O
sedatievs	O
,	O
and	O
muslce	O
rleaxants	O
administreed	O
through	O
a	O
centarl	O
venuos	O
ctaheter	O
were	O
ineffetcive	O
.	O

However	O
,	O
a	O
blous	O
of	O
eipnephrine	O
inejcted	O
through	O
an	O
alternatvie	O
catehter	O
provoked	O
a	O
hypretensive	B-Disease
crsiis	O
.	O

Thus	O
,	O
interfreence	O
with	O
the	O
cnetral	O
vneous	O
infsuion	O
by	O
the	O
dailysis	O
catehter	O
was	O
susepcted	O
.	O

The	O
cahteters	O
were	O
changed	O
,	O
and	O
hmeodynamics	O
stbailized	O
at	O
lwoer	O
catecohlamine	O
doess	O
.	O

When	O
the	O
efefcts	O
of	O
IV	O
drgus	O
are	O
indaequate	O
in	O
patietns	O
receiving	O
CVHVDF	O
,	O
itnerference	O
with	O
ajdacent	O
cathetres	O
resulting	O
in	O
eliminaiton	O
of	O
the	O
durg	O
by	O
CVHVDF	O
should	O
be	O
susepcted	O
.	O

Less	O
freqeunt	O
lithuim	O
administratoin	O
and	O
lwoer	O
uirne	O
volmue	O
.	O

OBJETCIVE	O
:	O
This	O
stduy	O
was	O
designed	O
to	O
determine	O
whether	O
paitents	O
maintained	O
on	O
a	O
rgeimen	O
of	O
lithuim	O
on	O
a	O
once	O
-	O
per	O
-	O
day	O
schedlue	O
have	O
lwoer	O
urnie	O
voluems	O
than	O
do	O
patietns	O
receiving	O
multpile	O
doess	O
per	O
day	O
.	O

METHOD	O
:	O
This	O
was	O
a	O
crsos	O
-	O
sectioanl	O
sutdy	O
of	O
85	O
paitents	O
from	O
a	O
ltihium	O
cilnic	O
who	O
received	O
different	O
dsoe	O
scehdules	O
.	O

Patietns	O
were	O
admitetd	O
to	O
the	O
hsopital	O
for	O
measurmeent	O
of	O
lithuim	O
lveel	O
,	O
creatinnie	O
clearacne	O
,	O
uirne	O
voulme	O
,	O
and	O
maxmium	O
osomlality	O
.	O

REUSLTS	O
:	O
Mutliple	O
dialy	O
doess	O
of	O
lithuim	O
were	O
associated	O
with	O
hgiher	O
urnie	O
volmues	O
.	O

The	O
dosnig	O
schedlue	O
,	O
durtaion	O
of	O
lithuim	O
teratment	O
,	O
and	O
dialy	O
dsoe	O
of	O
ltihium	O
did	O
not	O
affect	O
mxaimum	O
osmolaltiy	O
or	O
craetinine	O
clearacne	O
.	O

CONCLUISONS	O
:	O
Uirne	O
volmue	O
can	O
be	O
reduecd	O
by	O
giving	O
lithuim	O
once	O
daliy	O
and	O
/	O
or	O
by	O
lowernig	O
the	O
total	O
dialy	O
dsoe	O
.	O

Lithuim	O
-	O
idnuced	O
poluyria	B-Disease
seems	O
to	O
be	O
related	O
to	O
extrareanl	O
as	O
well	O
as	O
to	O
rneal	O
effcets	O
.	O

Antibacteiral	O
mediaction	O
use	O
during	O
pergnancy	O
and	O
rsik	O
of	O
brith	B-Disease
defcets	I-Disease
:	O
Naitonal	O
Bitrh	B-Disease
Dfeects	I-Disease
Prevetnion	O
Stduy	O
.	O

OBEJCTIVE	O
:	O
To	O
esitmate	O
the	O
assocaition	O
between	O
antibacteiral	O
medciations	O
and	O
selected	O
brith	B-Disease
dfeects	I-Disease
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIAPNTS	O
:	O
Popualtion	O
-	O
based	O
,	O
mutlisite	O
,	O
csae	O
-	O
contorl	O
stduy	O
of	O
wmoen	O
who	O
had	O
pregnanices	O
affecetd	O
by	O
1	O
of	O
more	O
than	O
30	O
eligbile	O
major	O
brith	B-Disease
deefcts	I-Disease
idetnified	O
via	O
bitrh	B-Disease
defcet	I-Disease
survelilance	O
prorgams	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
cnotrol	O
wmoen	O
randomly	O
selected	O
from	O
the	O
same	O
georgaphical	O
reginos	O
(	O
n	O
=	O
4941	O
)	O
.	O

MIAN	O
EXPOSRUE	O
:	O
Reported	O
matrenal	O
use	O
of	O
atnibacterials	O
(	O
1	O
mnoth	O
before	O
pregnacny	O
through	O
the	O
end	O
of	O
the	O
first	O
trmiester	O
)	O
.	O

MIAN	O
OUTOCME	O
MEASRUE	O
:	O
Odds	O
rtaios	O
(	O
ORs	O
)	O
mesauring	O
the	O
assoication	O
between	O
antibactreial	O
use	O
and	O
selected	O
bitrh	B-Disease
deefcts	I-Disease
adjusted	O
for	O
potenital	O
confoundres	O
.	O

REUSLTS	O
:	O
The	O
reported	O
use	O
of	O
antiabcterials	O
incresaed	O
during	O
pregnnacy	O
,	O
peaking	O
during	O
the	O
third	O
motnh	O
.	O

Sulfonmaides	O
were	O
associated	O
with	O
anencephlay	B-Disease
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3	O
.	O
4	O
;	O
95	O
%	O
cofnidence	O
inetrval	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
8	O
.	O
8	O
)	O
,	O
hypoplatsic	B-Disease
lfet	I-Disease
haert	I-Disease
syndorme	I-Disease
(	O
AOR	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
7	O
.	O
6	O
)	O
,	O
coarcttaion	B-Disease
of	I-Disease
the	I-Disease
arota	I-Disease
(	O
AOR	O
=	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
5	O
.	O
6	O
)	O
,	O
cohanal	B-Disease
atrseia	I-Disease
(	O
AOR	O
=	O
8	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
23	O
.	O
5	O
)	O
,	O
trnasverse	B-Disease
lmib	I-Disease
defciiency	I-Disease
(	O
AOR	O
=	O
2	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
5	O
.	O
9	O
)	O
,	O
and	O
diaprhagmatic	B-Disease
hrenia	I-Disease
(	O
AOR	O
=	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
5	O
.	O
4	O
)	O
.	O

Nitrofurnatoins	O
were	O
associated	O
with	O
anohpthalmia	B-Disease
or	O
microphhtalmos	B-Disease
(	O
AOR	O
=	O
3	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
12	O
.	O
2	O
)	O
,	O
hpyoplastic	B-Disease
lfet	I-Disease
haert	I-Disease
syndrmoe	I-Disease
(	O
AOR	O
=	O
4	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
9	O
.	O
1	O
)	O
,	O
artial	B-Disease
setpal	I-Disease
dfeects	I-Disease
(	O
AOR	O
=	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
4	O
)	O
,	O
and	O
clfet	B-Disease
lip	I-Disease
with	O
celft	B-Disease
paltae	I-Disease
(	O
AOR	O
=	O
2	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
3	O
.	O
9	O
)	O
.	O

Other	O
antbiacterial	O
aegnts	O
that	O
showed	O
asosciations	O
included	O
eyrthromycins	O
(	O
2	O
defcets	O
)	O
,	O
penicililns	O
(	O
1	O
deefct	O
)	O
,	O
cpehalosporins	O
(	O
1	O
defcet	O
)	O
,	O
and	O
quniolones	O
(	O
1	O
deefct	O
)	O
.	O

CONCLUSOINS	O
:	O
Reassurnigly	O
,	O
penicililns	O
,	O
erythrmoycins	O
,	O
and	O
cephalospoirns	O
,	O
although	O
used	O
commonly	O
by	O
pregnnat	O
woemn	O
,	O
were	O
not	O
associated	O
with	O
many	O
bitrh	B-Disease
defetcs	I-Disease
.	O

Sulofnamides	O
and	O
nitrofurnatoins	O
were	O
associated	O
with	O
several	O
brith	B-Disease
dfeects	I-Disease
,	O
indicating	O
a	O
need	O
for	O
additional	O
scurtiny	O
.	O

Differetnial	O
impcat	O
of	O
imumne	O
escpae	O
muattions	O
G154R	O
and	O
P210	O
on	O
the	O
relpication	O
of	O
lamviudine	O
-	O
resistnat	O
heaptitis	O
B	O
viurs	O
e	O
antgien	O
-	O
postiive	O
and	O
-	O
negatvie	O
starins	O
.	O

Immune	O
esacpe	O
vraiants	O
of	O
the	O
hepatiits	B-Disease
B	I-Disease
viurs	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clniical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vacicne	O
esacpe	O
,	O
HBV	O
reactiavtion	O
,	O
and	O
faiulre	O
of	O
diagnotsic	O
tsets	O
.	O

Recent	O
dtaa	O
suggest	O
a	O
prefernetial	O
selcetion	O
of	O
immune	O
ecsape	O
muatnts	O
in	O
distinct	O
peripehral	O
blood	O
lekuocyte	O
compartemnts	O
of	O
infetced	O
individulas	O
.	O

We	O
therefore	O
sysetmatically	O
anlayzed	O
the	O
funcitonal	O
ipmact	O
of	O
the	O
most	O
prevlaent	O
immnue	O
ecsape	O
varaints	O
,	O
the	O
sG154R	O
and	O
s1P20T	O
mutatns	O
,	O
on	O
the	O
vrial	O
repilcation	O
effciacy	O
and	O
antiviarl	O
durg	O
suscetpibility	O
of	O
common	O
traetment	O
-	O
associated	O
mtuants	O
with	O
resistnace	O
to	O
lamiuvdine	O
(	O
LAM	O
)	O
and	O
/	O
or	O
HBAeg	O
negatviity	O
.	O

Replictaion	O
-	O
competent	O
HBV	O
srtains	O
with	O
sG154R	O
or	O
s1P20T	O
and	O
LAM	O
reisstance	O
(	O
rtM024I	O
or	O
rtL108M	O
/	O
rtM024V	O
)	O
were	O
generated	O
on	O
an	O
HeBAg	O
-	O
posiitve	O
and	O
an	O
HeBAg	O
-	O
ngeative	O
background	O
with	O
preocre	O
(	O
PC	O
)	O
and	O
bsaal	O
croe	O
prmooter	O
(	O
BCP	O
)	O
mutatns	O
.	O

The	O
s1G45R	O
mutaiton	O
strongly	O
rdeuced	O
HsBAg	O
leevls	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
imparied	O
replciation	O
of	O
LAM	O
-	O
rseistant	O
HBV	O
mtuants	O
to	O
the	O
levles	O
of	O
wlid	O
-	O
tpye	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutatoins	O
further	O
enahnced	O
vrial	O
replciation	O
.	O

Although	O
the	O
sP102T	O
substitutoin	O
also	O
imparied	O
HsBAg	O
secretoin	O
,	O
it	O
did	O
not	O
enhnace	O
the	O
repilcation	O
of	O
LAM	O
-	O
resitsant	O
clnoes	O
.	O

However	O
,	O
the	O
concoimtant	O
occrurence	O
of	O
HeBAg	O
negatviity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP102T	O
,	O
and	O
LAM	O
resistacne	O
resulted	O
in	O
the	O
rsetoration	O
of	O
repliaction	O
to	O
levles	O
of	O
wlid	O
-	O
tpye	O
HBV	O
.	O

In	O
all	O
clnoes	O
with	O
combiend	O
immnue	O
escpae	O
and	O
LAM	O
rseistance	O
muttaions	O
,	O
the	O
nucletoide	O
analogeus	O
aedfovir	O
and	O
tneofovir	O
remained	O
efefctive	O
in	O
spupressing	O
vrial	O
replicaiton	O
in	O
vitro	O
.	O

These	O
findigns	O
reveal	O
the	O
differentail	O
imapct	O
of	O
immnue	O
ecsape	O
varinats	O
on	O
the	O
replicaiton	O
and	O
durg	O
suscepitbility	O
of	O
comlpex	O
HBV	O
muatnts	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveillacne	O
and	O
treamtent	O
ajdustment	O
in	O
resopnse	O
to	O
the	O
sleection	O
of	O
distinct	O
mutatoinal	O
patterns	O
.	O

Hmeolytic	B-Disease
aenmia	I-Disease
associated	O
with	O
the	O
use	O
of	O
omperazole	O
.	O

Omeparzole	O
is	O
the	O
first	O
durg	O
designed	O
to	O
bolck	O
the	O
final	O
step	O
in	O
the	O
aicd	O
secertory	O
porcess	O
within	O
the	O
pariteal	O
clel	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effetcive	O
in	O
the	O
treatemnt	O
of	O
ppetic	B-Disease
ulecr	I-Disease
disaese	I-Disease
,	O
refulx	B-Disease
esopahgitis	I-Disease
,	O
and	O
the	O
Zolilnger	B-Disease
-	I-Disease
Elilson	I-Disease
sydnrome	I-Disease
.	O

Although	O
clniical	O
expereince	O
with	O
omperazole	O
is	O
still	O
limietd	O
,	O
many	O
conrtolled	O
stduies	O
have	O
established	O
the	O
short	O
-	O
term	O
sfaety	O
of	O
this	O
durg	O
.	O

We	O
rpeort	O
the	O
first	O
csae	O
of	O
a	O
serious	O
short	O
-	O
term	O
advrese	O
raection	O
with	O
the	O
use	O
of	O
omeparzole	O
:	O
hemoyltic	B-Disease
aenmia	I-Disease
.	O

The	O
pateint	O
developed	O
weaknses	O
,	O
lethagry	B-Disease
,	O
and	O
shortnses	B-Disease
of	I-Disease
berath	I-Disease
2	O
dyas	O
after	O
starting	O
thearpy	O
with	O
omperazole	O
.	O

Two	O
wekes	O
after	O
the	O
initiatoin	O
of	O
thearpy	O
,	O
her	O
hematocirt	O
had	O
decerased	O
from	O
44	O
.	O
1	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
and	O
she	O
had	O
a	O
posiitve	O
direct	O
Comobs	O
antiglobuiln	O
tset	O
and	O
an	O
elevtaed	O
inidrect	O
biliurbin	O
.	O

After	O
she	O
discontineud	O
the	O
oemprazole	O
,	O
her	O
heomglobin	O
and	O
heamtocrit	O
gradually	O
returned	O
to	O
nromal	O
.	O

The	O
mcehanism	O
by	O
which	O
omperazole	O
caused	O
the	O
ptaient	O
'	O
s	O
hemoltyic	B-Disease
aenmia	I-Disease
is	O
uncertain	O
,	O
but	O
physicains	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adevrse	O
efefct	O
.	O

Phenlyephrine	O
but	O
not	O
ephedrnie	O
reduecs	B-Disease
fronatl	I-Disease
lboe	I-Disease
oxygeantion	I-Disease
following	O
anetshesia	O
-	O
inudced	O
hypotensoin	B-Disease
.	O

BACKGRONUD	O
:	O
Vasporessor	O
agetns	O
are	O
used	O
to	O
correct	O
anesthseia	O
-	O
idnuced	O
hypotnesion	B-Disease
.	O

We	O
describe	O
the	O
effect	O
of	O
phenylephirne	O
and	O
ephedirne	O
on	O
fronatl	O
lboe	O
oxygentaion	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
aensthesia	O
-	O
idnuced	O
hypoetnsion	B-Disease
.	O

METHODS	O
:	O
Following	O
inudction	O
of	O
anesthseia	O
by	O
fentaynl	O
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
propoofl	O
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
paitents	O
received	O
phenyelphrine	O
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
ptaients	O
received	O
ehpedrine	O
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
atrerial	O
prsesure	O
(	O
MAP	O
)	O
.	O

Herat	O
rtae	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
srtoke	B-Disease
volmue	O
(	O
SV	O
)	O
,	O
cardaic	O
outupt	O
(	O
CO	O
)	O
,	O
and	O
forntal	O
lboe	O
oxygneation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
registreed	O
.	O

RESUTLS	O
:	O
Induciton	O
of	O
aneshtesia	O
was	O
followed	O
by	O
a	B-Disease
decerase	I-Disease
in	I-Disease
MAP	I-Disease
,	I-Disease
HR	I-Disease
,	I-Disease
SV	I-Disease
,	I-Disease
and	I-Disease
CO	I-Disease
concmoitant	O
with	O
an	O
elevatoin	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
admiinstration	O
of	O
phenylephrnie	O
,	O
MAP	O
incresaed	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+	O
/	O
-	O
8	O
%	O
to	O
60	O
+	O
/	O
-	O
7	O
%	O
)	O
reductoin	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
amdinistration	O
of	O
ephedirne	O
led	O
to	O
a	O
similar	O
icnrease	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
retsored	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
perserved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONCLSUIONS	O
:	O
The	O
utilizaiton	O
of	O
phenylephirne	O
to	O
correct	O
hyptoension	B-Disease
indcued	O
by	O
anesthseia	O
has	O
a	O
negtaive	O
ipmact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedrnie	O
maintains	O
fronatl	O
lboe	O
oxygenatoin	O
potentially	O
related	O
to	O
an	O
incresae	O
in	O
CO	O
.	O

Prologned	O
elveation	O
of	O
palsma	O
aragtroban	O
in	O
a	O
cardaic	O
trnasplant	O
patinet	O
with	O
a	O
suspceted	O
histroy	O
of	O
hepairn	O
-	O
induecd	O
thrmobocytopenia	B-Disease
with	O
thormbosis	B-Disease
.	O

BACKGRONUD	O
:	O
Direct	O
thromibn	O
inhbiitors	O
(	O
DITs	O
)	O
provide	O
an	O
alternatvie	O
mehtod	O
of	O
atnicoagulation	O
for	O
patinets	O
with	O
a	O
hitsory	O
of	O
hepairn	O
-	O
idnuced	O
trhombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
or	O
HIT	B-Disease
with	O
thormbosis	B-Disease
(	O
HTIT	B-Disease
)	O
undergoing	O
caridopulmonary	O
bypsas	O
(	O
CPB	O
)	O
.	O

In	O
the	O
following	O
reoprt	O
,	O
a	O
65	O
-	O
yaer	O
-	O
old	O
critically	B-Disease
ill	I-Disease
patinet	O
with	O
a	O
suspecetd	O
histroy	O
of	O
HTIT	B-Disease
was	O
administeerd	O
argtaroban	O
for	O
anticaogulation	O
on	O
bypsas	O
during	O
herat	O
transplantatoin	O
.	O

The	O
patinet	O
required	O
massive	O
trasnfusion	O
support	O
(	O
55	O
units	O
of	O
red	O
blood	O
clels	O
,	O
42	O
units	O
of	O
fersh	O
-	O
frzoen	O
palsma	O
,	O
40	O
units	O
of	O
cryoprecpiitate	O
,	O
40	O
units	O
of	O
platleets	O
,	O
and	O
three	O
doess	O
of	O
rceombinant	O
Fcator	O
VIIa	O
)	O
for	O
seevre	O
intraoperaitve	B-Disease
and	I-Disease
postoperaitve	I-Disease
bleednig	I-Disease
.	O

SUTDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Palsma	O
smaples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
anlayzed	O
postoperativley	O
for	O
argatorban	O
concentrtaion	O
using	O
a	O
modiifed	O
ecrain	O
clotitng	O
tmie	O
(	O
ECT	O
)	O
asasy	O
.	O

RESLUTS	O
:	O
Unexpectedly	O
high	O
cnocentrations	O
of	O
argatrboan	O
were	O
measuerd	O
in	O
these	O
sampels	O
(	O
range	O
,	O
0	O
-	O
32	O
mircog	O
/	O
mL	O
)	O
,	O
and	O
a	O
prloonged	O
palsma	O
argartoban	O
half	O
lfie	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
514	O
mintues	O
was	O
observed	O
(	O
pbulished	O
eliminatoin	O
t	O
(	O
1	O
/	O
2	O
)	O
is	O
39	O
-	O
51	O
mintues	O
[	O
<	O
or	O
=	O
181	O
mniutes	O
with	O
hepaitc	B-Disease
impaimrent	I-Disease
]	O
)	O
.	O

CONCULSIONS	O
:	O
Corrleation	O
of	O
palsma	O
argatrboan	O
concentartion	O
versus	O
the	O
paitent	O
'	O
s	O
coagulaiton	O
vairables	O
and	O
cliniacl	O
cousre	O
suggest	O
that	O
prloonged	O
eleavted	O
levles	O
of	O
palsma	O
aragtroban	O
may	O
have	O
contributed	O
to	O
the	O
pateint	O
'	O
s	O
extneded	O
caogulopathy	B-Disease
.	O

Because	O
DITs	O
do	O
not	O
have	O
revresal	O
agetns	O
,	O
surgcial	O
temas	O
and	O
transfusoin	O
srevices	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
trnasfusion	O
eevnts	O
during	O
anticoauglation	O
with	O
these	O
agnets	O
.	O

This	O
is	O
the	O
first	O
reprot	O
to	O
measrue	O
palsma	O
argatroabn	O
concetnration	O
in	O
the	O
cotnext	O
of	O
CPB	O
and	O
extenedd	O
coaguloapthy	B-Disease
.	O

The	O
efefcts	O
of	O
the	O
adujnctive	O
buporpion	O
on	O
mlae	O
seuxal	B-Disease
dysfucntion	I-Disease
indcued	O
by	O
a	O
selective	O
serotoinn	O
reputake	O
inhibtior	O
:	O
a	O
double	O
-	O
bilnd	O
palcebo	O
-	O
contrloled	O
and	O
randoimzed	O
sutdy	O
.	O

OBJECTVIE	O
:	O
To	O
determine	O
the	O
saftey	O
and	O
effiaccy	O
of	O
adjuntcive	O
buporpion	O
sustanied	O
-	O
relesae	O
(	O
SR	O
)	O
on	O
mlae	O
seuxal	B-Disease
dsyfunction	I-Disease
(	O
SD	B-Disease
)	O
idnuced	O
by	O
a	O
selective	O
serotnoin	O
reuptkae	O
inihbitor	O
(	O
SRSI	O
)	O
,	O
as	O
SD	B-Disease
is	O
a	O
common	O
side	O
-	O
efefct	O
of	O
SRSIs	O
and	O
the	O
most	O
effetcive	O
treatmnets	O
have	O
yet	O
to	O
be	O
determined	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
randomiezd	O
sapmle	O
consisted	O
of	O
234	O
euthyimc	O
men	O
who	O
were	O
receiving	O
some	O
tpye	O
of	O
SRSI	O
.	O

The	O
men	O
were	O
randomly	O
assigned	O
to	O
buporpion	O
SR	O
(	O
150	O
mg	O
twice	O
dialy	O
,	O
117	O
)	O
or	O
palcebo	O
(	O
twice	O
daliy	O
,	O
117	O
)	O
for	O
12	O
weeks	O
.	O

Efifcacy	O
was	O
evaluaetd	O
using	O
the	O
Cilnical	O
Glboal	O
Impressoin	O
-	O
Sxeual	O
Funciton	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
pirmary	O
outcmoe	O
maesure	O
)	O
,	O
the	O
Intrenational	O
Idnex	O
of	O
Eerctile	O
Funciton	O
(	O
IEIF	O
)	O
,	O
Arziona	O
Sexaul	O
Experinece	O
Sacle	O
(	O
AESX	O
)	O
,	O
and	O
Eretcile	B-Disease
Dysfucntion	I-Disease
Invnetory	O
of	O
Treatmnet	O
Staisfaction	O
(	O
EIDTS	O
)	O
(	O
secondary	O
outocme	O
meausres	O
)	O
.	O

Praticipants	O
were	O
followed	O
biweekly	O
during	O
sutdy	O
preiod	O
.	O

REUSLTS	O
:	O
After	O
12	O
wekes	O
of	O
treatemnt	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scoers	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
lwoer	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
in	O
patinets	O
on	O
buporpion	O
SR	O
,	O
at	O
2	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O
,	O
than	O
in	O
the	O
plaecbo	O
gruop	O
,	O
at	O
3	O
.	O
9	O
(	O
1	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Men	O
who	O
received	O
bpuropion	O
had	O
a	O
significant	O
incerase	O
in	O
the	O
total	O
IEIF	O
socre	O
(	O
54	O
.	O
4	O
%	O
vs	O
1	O
.	O
2	O
%	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
doamins	O
of	O
the	O
IEIF	O
.	O

Total	O
AESX	O
socres	O
were	O
significantly	O
loewr	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
among	O
men	O
who	O
received	O
buprpoion	O
than	O
palcebo	O
,	O
at	O
15	O
.	O
5	O
(	O
4	O
.	O
3	O
)	O
vs	O
21	O
.	O
5	O
(	O
4	O
.	O
7	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
EIDTS	O
scroes	O
were	O
67	O
.	O
4	O
(	O
10	O
.	O
2	O
)	O
for	O
the	O
buproipon	O
and	O
36	O
.	O
3	O
(	O
11	O
.	O
7	O
)	O
for	O
the	O
placbeo	O
gruop	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
AESX	O
socre	O
and	O
CGI	O
-	O
SF	O
socre	O
were	O
correlated	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

In	O
lniear	O
regrsesion	O
aanlyses	O
the	O
CGI	O
-	O
SF	O
scroe	O
was	O
not	O
afefcted	O
significantly	O
by	O
the	O
durtaion	O
of	O
SD	B-Disease
,	O
tpye	O
of	O
SRSI	O
used	O
and	O
age	O
.	O

CONCULSIONS	O
:	O
Bpuropion	O
is	O
an	O
effcetive	O
treatemnt	O
for	O
mlae	O
SD	B-Disease
indcued	O
by	O
SSIRs	O
.	O

These	O
reuslts	O
provide	O
empiriacl	O
support	O
for	O
conducting	O
a	O
further	O
stduy	O
of	O
buprpoion	O
.	O

Prevetnion	O
of	O
siezures	B-Disease
and	O
reoragnization	O
of	O
hippocampal	O
funcitons	O
by	O
transplantatoin	O
of	O
bnoe	O
marrow	O
cells	O
in	O
the	O
actue	O
phsae	O
of	O
exeprimental	O
epilpesy	B-Disease
.	O

In	O
this	O
stduy	O
,	O
we	O
investgiated	O
the	O
therapetuic	O
potenital	O
of	O
bnoe	O
mrarow	O
mononucelar	O
clels	O
(	O
BCMs	O
)	O
in	O
a	O
mdoel	O
of	O
epilpesy	B-Disease
induecd	O
by	O
pliocarpine	O
in	O
rtas	O
.	O

BCMs	O
obtained	O
from	O
green	O
flourescent	O
protien	O
(	O
GFP	O
)	O
transgneic	O
mcie	O
or	O
rtas	O
were	O
transplanetd	O
intravenoulsy	O
after	O
idnuction	O
of	O
sttaus	B-Disease
epliepticus	I-Disease
(	O
SE	B-Disease
)	O
.	O

Spontnaeous	B-Disease
reucrrent	I-Disease
seiuzres	I-Disease
(	O
SRS	B-Disease
)	O
were	O
mointored	O
using	O
Rcaine	O
'	O
s	O
seiuzre	B-Disease
sevreity	O
scale	O
.	O

All	O
of	O
the	O
rtas	O
in	O
the	O
sailne	O
-	O
terated	O
epilpetic	B-Disease
cotnrol	O
gorup	O
developed	O
SRS	B-Disease
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treaetd	O
epilpetic	B-Disease
animlas	O
had	O
seizuers	B-Disease
in	O
the	O
short	O
term	O
(	O
15	O
dyas	O
after	O
transplantaiton	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
soruce	O
.	O

Over	O
the	O
long	O
-	O
term	O
chrnoic	O
phsae	O
(	O
120	O
dyas	O
after	O
trnasplantation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
traeted	O
epielptic	B-Disease
anmials	O
had	O
seizrues	B-Disease
,	O
but	O
with	O
a	O
lwoer	O
frequnecy	O
and	O
duartion	O
compraed	O
to	O
the	O
eplieptic	B-Disease
conrtol	O
gruop	O
.	O

The	O
dnesity	O
of	O
hpipocampal	O
neurnos	O
in	O
the	O
barins	O
of	O
aniamls	O
traeted	O
with	O
BCMs	O
was	O
markedly	O
preserevd	O
.	O

At	O
hippocapmal	O
Schaefefr	O
collatearl	O
-	O
CA1	O
synpases	O
,	O
long	O
-	O
term	O
potentitaion	O
was	O
prseerved	O
in	O
BMC	O
-	O
transplatned	O
rtas	O
compaerd	O
to	O
epiletpic	B-Disease
contorls	O
.	O

The	O
dnoor	O
-	O
derived	O
GFP	O
(	O
+	O
)	O
clels	O
were	O
rarely	O
found	O
in	O
the	O
branis	O
of	O
transpalnted	O
eipleptic	B-Disease
rtas	O
.	O

In	O
conclusion	O
,	O
traetment	O
with	O
BCMs	O
can	O
preevnt	O
the	O
develompent	O
of	O
crhonic	O
seizuers	B-Disease
,	O
redcue	O
neuornal	B-Disease
lsos	I-Disease
,	O
and	O
influnece	O
the	O
reorgainzation	O
of	O
the	O
hippocapmal	O
nueronal	O
netowrk	O
.	O

Normlaizing	O
effects	O
of	O
moadfinil	O
on	O
sleep	O
in	O
chroinc	O
cociane	O
usres	O
.	O

OJBECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
stduy	O
was	O
to	O
determine	O
the	O
effect	O
of	O
mornnig	O
-	O
doesd	O
moadfinil	O
on	O
selep	O
and	O
daytmie	B-Disease
sleepienss	I-Disease
in	O
chornic	O
cocanie	O
uesrs	O
.	O

METHOD	O
:	O
Twenty	O
cocanie	O
-	O
deepndent	O
partiicpants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modaifnil	O
,	O
400	O
mg	O
(	O
N	O
=	O
10	O
)	O
,	O
or	O
palcebo	O
(	O
N	O
=	O
10	O
)	O
every	O
mornnig	O
at	O
7	O
:	O
30	O
a	O
.	O
m	O
.	O
for	O
16	O
dyas	O
in	O
an	O
inpatinet	O
,	O
double	O
-	O
bilnd	O
randoimzed	O
trail	O
.	O

Partciipants	O
underwent	O
polysomnograhpic	O
selep	O
recoridngs	O
on	O
dyas	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
wekes	O
of	O
abstinecne	O
)	O
.	O

The	O
Mulitple	O
Selep	O
Laetncy	O
Tset	O
was	O
performed	O
at	O
11	O
:	O
30	O
a	O
.	O
m	O
.	O
,	O
2	O
:	O
00	O
p	O
.	O
m	O
.	O
,	O
and	O
4	O
:	O
30	O
p	O
.	O
m	O
.	O
on	O
dyas	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O

For	O
comaprison	O
of	O
selep	O
architetcure	O
variabels	O
,	O
12	O
heatlhy	O
compairson	O
paritcipants	O
underwent	O
a	O
single	O
nihgt	O
of	O
expeirmental	O
polysomnorgaphy	O
that	O
followed	O
1	O
ngiht	O
of	O
accommodaiton	O
polysomngoraphy	O
.	O

RESLUTS	O
:	O
Prgoressive	O
abstnience	O
from	O
coacine	O
was	O
associated	O
with	O
worseinng	O
of	O
all	O
maesured	O
polysomnogrpahic	O
sleep	O
outcoems	O
.	O

Compaerd	O
with	O
placbeo	O
,	O
moadfinil	O
decerased	O
nigthtime	O
selep	O
ltaency	O
and	O
inrceased	O
slow	O
-	O
wvae	O
selep	O
tmie	O
in	O
ccoaine	O
-	O
dependnet	O
paritcipants	O
.	O

The	O
effcet	O
of	O
modaifnil	O
interacetd	O
with	O
the	O
abstiennce	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
tmie	O
and	O
shroter	O
REM	O
selep	O
latnecy	O
in	O
the	O
third	O
week	O
of	O
abstiennce	O
.	O

Cmoparison	O
of	O
slow	O
-	O
wvae	O
sleep	O
tmie	O
,	O
total	O
selep	O
tmie	O
,	O
and	O
sleep	O
laetncy	O
in	O
cocanie	O
-	O
deepndent	O
and	O
haelthy	O
partiicpants	O
revaeled	O
a	O
normalizing	O
effcet	O
of	O
modafiinl	O
in	O
cociane	O
-	O
depenednt	O
praticipants	O
.	O

Modafniil	O
was	O
associated	O
with	O
incresaed	O
daytmie	O
selep	O
ltaency	O
,	O
as	O
meausred	O
by	O
the	O
Multilpe	O
Selep	O
Ltaency	O
Tset	O
,	O
and	O
a	O
nearly	O
significant	O
decraese	O
in	O
sujbective	O
dyatime	B-Disease
sleepienss	I-Disease
.	O

COCNLUSIONS	O
:	O
Mornnig	O
-	O
doesd	O
mdoafinil	O
pormotes	O
noctunral	O
selep	O
,	O
normalizes	O
sleep	O
archietcture	O
,	O
and	O
decreaess	O
datyime	B-Disease
sleepniess	I-Disease
in	O
abstnient	O
coacine	O
usres	O
.	O

These	O
effects	O
may	O
be	O
reelvant	O
in	O
the	O
teratment	O
of	O
ccoaine	O
dependnece	O
.	O

Sfaety	O
of	O
transesophagael	O
echocardiorgaphy	O
in	O
audlts	O
:	O
stduy	O
in	O
a	O
multidisciplianry	O
hospiatl	O
.	O

BAKCGROUND	O
:	O
TEE	O
is	O
a	O
smei	O
-	O
invsaive	O
tool	O
broadly	O
used	O
and	O
its	O
utliization	O
associated	O
to	O
sedtaives	O
durgs	O
might	O
to	O
affect	O
the	O
procedrue	O
saefty	O
.	O

OBJECITVE	O
:	O
to	O
anlayze	O
aspects	O
of	O
TEE	O
saefty	O
associated	O
to	O
the	O
use	O
of	O
Midaozlan	O
(	O
MZ	O
)	O
and	O
Flmuazenil	O
(	O
FL	O
)	O
and	O
the	O
inlfuence	O
of	O
the	O
clincial	O
variabels	O
on	O
the	O
evnet	O
rtae	O
.	O

METHOD	O
:	O
prsopective	O
stduy	O
with	O
137	O
ptaients	O
that	O
underwent	O
TEE	O
with	O
MZ	O
associated	O
to	O
modreate	O
seadtion	O
.	O

We	O
analzyed	O
the	O
following	O
eevnts	O
:	O
complciations	O
related	O
with	O
the	O
topcial	O
anestheisa	O
,	O
with	O
MZ	O
use	O
and	O
with	O
the	O
proecdure	O
.	O

Uni	O
-	O
and	O
multiavriate	O
analsyes	O
were	O
used	O
to	O
tset	O
the	O
ifnluence	O
of	O
the	O
cliincal	O
vraiables	O
:	O
age	O
,	O
sex	O
,	O
strkoe	B-Disease
,	O
myocardioapthy	B-Disease
(	O
MP	B-Disease
)	O
,	O
durtaion	O
of	O
the	O
tset	O
,	O
mtiral	B-Disease
regurgitaiton	I-Disease
(	O
MR	B-Disease
)	O
and	O
the	O
MZ	O
dsoe	O
.	O

RESLUTS	O
:	O
All	O
patinets	O
(	O
65	O
+	O
/	O
-	O
16	O
yrs	O
;	O
58	O
%	O
mlaes	O
)	O
finished	O
the	O
examinaiton	O
.	O

The	O
mean	O
doess	O
of	O
MZ	O
and	O
FL	O
were	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
and	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
,	O
respectively	O
.	O

The	O
druation	O
of	O
the	O
exaimnation	O
and	O
the	O
mean	O
ejetcion	O
frcation	O
(	O
EF	O
)	O
were	O
16	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1	O
mniutes	O
and	O
60	O
+	O
/	O
-	O
9	O
%	O
,	O
respectively	O
.	O

Mlid	O
hypxoia	B-Disease
(	O
SO2	O
<	O
90	O
%	O
)	O
was	O
the	O
most	O
common	O
eevnt	O
(	O
11	O
patinets	O
)	O
;	O
3	O
patinets	O
(	O
2	O
%	O
)	O
presented	O
tarnsient	O
hpyoxia	B-Disease
due	O
to	O
upepr	O
airawy	B-Disease
osbtruction	I-Disease
by	O
prboe	O
intrdouction	O
and	O
8	O
(	O
5	O
.	O
8	O
%	O
)	O
due	O
to	O
hpyoxia	B-Disease
caused	O
by	O
MZ	O
use	O
.	O

Trasnient	O
hypoetnsion	B-Disease
(	O
SAP	O
<	O
90mmHg	O
)	O
occurred	O
in	O
1	O
ptaient	O
(	O
0	O
.	O
7	O
%	O
)	O
.	O

The	O
multivaritae	O
analyiss	O
showed	O
that	O
sveere	O
MR	B-Disease
,	O
MP	B-Disease
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
doess	O
of	O
MZ	O
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
evetns	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
gruop	O
with	O
MP	B-Disease
and	O
44	O
%	O
in	O
the	O
gruop	O
with	O
sevree	O
MR	B-Disease
and	O
it	O
can	O
be	O
a	O
fatcor	O
associated	O
with	O
cilnical	O
eevnts	O
in	O
the	O
last	O
gorup	O
.	O

CONCULSION	O
:	O
TEE	O
with	O
sedtaion	O
presents	O
a	O
low	O
rtae	O
of	O
eevnts	O
.	O

There	O
were	O
no	O
seevre	O
evnets	O
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
exmainations	O
.	O

Effcet	O
of	O
direct	O
intracornoary	O
administraiton	O
of	O
methyelrgonovine	O
in	O
patietns	O
with	O
and	O
without	O
vraiant	B-Disease
anigna	I-Disease
.	O

The	O
efefcts	O
of	O
intarcoronary	O
administratoin	O
of	O
methyelrgonovine	O
were	O
studied	O
in	O
21	O
ptaients	O
with	O
varaint	B-Disease
agnina	I-Disease
and	O
22	O
ptaients	O
with	O
atyipcal	O
cehst	B-Disease
pian	I-Disease
and	O
in	O
others	O
without	O
angnia	B-Disease
petcoris	I-Disease
(	O
cotnrol	O
gorup	O
)	O
.	O

Methylergonovnie	O
was	O
adminisetred	O
cnotinuously	O
at	O
a	O
rtae	O
of	O
10	O
microgrmas	O
/	O
min	O
up	O
to	O
50	O
microrgams	O
.	O

In	O
all	O
patietns	O
with	O
varaint	B-Disease
angnia	I-Disease
,	O
coroanry	B-Disease
spsam	I-Disease
was	O
provoked	O
at	O
a	O
mean	O
dsoe	O
of	O
28	O
+	O
/	O
-	O
13	O
microrgams	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

In	O
the	O
contorl	O
gruop	O
neither	O
ishcemic	O
ST	O
change	O
nor	O
lcoalized	O
sapsm	B-Disease
occurred	O
.	O

The	O
baasl	O
tnoe	O
of	O
the	O
rihgt	O
coornary	O
atrery	O
was	O
significantly	O
lwoer	O
than	O
that	O
of	O
the	O
lfet	O
cornoary	O
aretry	O
.	O

The	O
percnetage	O
of	O
vasoconstrcition	O
of	O
the	O
rihgt	O
coroanry	O
artrey	O
was	O
significantly	O
hihger	O
than	O
that	O
of	O
the	O
lfet	O
coornary	O
atrery	O
.	O

These	O
resutls	O
suggest	O
that	O
sapsm	B-Disease
provocatoin	O
tsets	O
,	O
which	O
use	O
an	O
intracornoary	O
injeciton	O
of	O
a	O
relatively	O
low	O
dsoe	O
of	O
methylergonovnie	O
,	O
have	O
a	O
high	O
snesitivity	O
in	O
vraiant	B-Disease
agnina	I-Disease
and	O
the	O
vasoraectivity	O
of	O
the	O
rgiht	O
coroanry	O
aretry	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
cornoary	O
atreries	O
.	O

Oarl	O
mainfestations	O
of	O
"	O
mteh	B-Disease
muoth	I-Disease
"	O
:	O
a	O
csae	O
reprot	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
doucmentation	O
of	O
this	O
clincial	O
csae	O
is	O
to	O
make	O
cliincians	O
aware	O
of	O
"	O
mteh	B-Disease
muoth	I-Disease
"	O
and	O
the	O
mdeical	O
rikss	O
associated	O
with	O
this	O
serious	O
condiiton	O
.	O

BACKGRUOND	O
:	O
Methamphetaimne	O
is	O
a	O
very	O
additcive	O
,	O
powerful	O
sitmulant	O
that	O
incresaes	O
wakeuflness	O
and	O
phyiscal	O
acitvity	O
and	O
can	O
produce	O
other	O
effetcs	O
such	O
as	O
cardaic	B-Disease
dysrhytmhias	I-Disease
,	O
hypetrension	B-Disease
,	O
hallucinations	B-Disease
,	O
and	O
vioelnt	B-Disease
behvaior	I-Disease
.	O

Detnal	O
pateints	O
abuisng	O
methamphetaimne	O
can	O
present	O
with	O
poor	O
oarl	O
hgyiene	O
,	O
xerostmoia	B-Disease
,	O
rmapant	O
caires	B-Disease
(	O
"	O
mteh	B-Disease
motuh	I-Disease
"	O
)	O
,	O
and	O
excessive	O
tooth	B-Disease
waer	I-Disease
.	O

Oarl	O
rehaiblitation	O
of	O
paitents	O
using	O
methamhpetamine	O
can	O
be	O
challenging	O
.	O

CSAE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
yaer	O
-	O
old	O
Caucsaian	O
woamn	O
presented	O
with	O
dnetal	O
pian	B-Disease
,	O
bad	B-Disease
braeth	I-Disease
,	O
and	O
slef	O
-	O
reported	O
poor	O
estehtics	O
.	O

A	O
comprheensive	O
exaimnation	O
including	O
her	O
meidcal	O
hitsory	O
,	O
panormaic	O
radiorgaph	O
,	O
and	O
introaral	O
examintaion	O
revelaed	O
19	O
caroius	B-Disease
lesoins	I-Disease
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
heatlhy	O
audlt	O
.	O

She	O
reported	O
her	O
use	O
of	O
methapmhetamine	O
for	O
five	O
yaers	O
and	O
had	O
not	O
experienced	O
any	O
major	O
craious	B-Disease
eipsodes	I-Disease
before	O
she	O
started	O
using	O
the	O
durg	O
.	O

SUMMARY	O
:	O
The	O
patinet	O
'	O
s	O
mediacl	O
and	O
detnal	O
hisotries	O
along	O
with	O
radoigraphic	O
and	O
cliincal	O
findigns	O
lead	O
to	O
a	O
diagonsis	O
of	O
"	O
mteh	B-Disease
muoth	I-Disease
.	O
"	O
Although	O
three	O
different	O
detnal	O
treamtent	O
mdoalities	O
(	O
either	O
convnetional	O
or	O
impalnt	O
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
patinet	O
since	O
August	O
2007	O
,	O
the	O
paitent	O
has	O
yet	O
to	O
initiate	O
any	O
treamtent	O
.	O

CLINICAL	O
SIGNIIFCANCE	O
:	O
This	O
clincial	O
csae	O
showing	O
oarl	O
manifestatinos	O
of	O
mteh	B-Disease
muoth	I-Disease
was	O
presented	O
to	O
help	O
detnal	O
practiitoners	O
recognize	O
and	O
manage	O
patinets	O
who	O
may	O
be	O
absuing	O
methampehtamines	O
.	O

Dnetal	O
practitionres	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
reliabiilty	O
of	O
appointment	O
keeping	O
by	O
these	O
patinets	O
,	O
as	O
they	O
frequently	O
miss	O
their	O
appointmetns	O
without	O
reasonable	O
justification	O
.	O

Antituberuclosis	O
threapy	O
-	O
indcued	O
aucte	B-Disease
lievr	I-Disease
fialure	I-Disease
:	O
magniutde	O
,	O
proflie	O
,	O
prongosis	O
,	O
and	O
predicotrs	O
of	O
ouctome	O
.	O

Anttiuberculosis	O
thearpy	O
(	O
ATT	O
)	O
-	O
associated	O
aucte	B-Disease
lvier	I-Disease
failrue	I-Disease
(	O
ATT	O
-	O
ALF	B-Disease
)	O
is	O
the	O
commonest	O
durg	O
-	O
induecd	O
ALF	B-Disease
in	O
Sotuh	O
Aisa	O
.	O

Prospecitve	O
sutdies	O
on	O
ATT	O
-	O
ALF	B-Disease
are	O
lacking	O
.	O

The	O
current	O
sutdy	O
prospectively	O
eavluated	O
the	O
magintude	O
,	O
clincial	O
cuorse	O
,	O
outocme	O
,	O
and	O
prongostic	O
fatcors	O
in	O
ATT	O
-	O
ALF	B-Disease
.	O

From	O
Januray	O
1986	O
to	O
Januray	O
2009	O
,	O
1223	O
consectuive	O
ALF	B-Disease
ptaients	O
were	O
evlauated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5	O
.	O
7	O
%	O
)	O
ptaients	O
.	O

Another	O
15	O
(	O
1	O
.	O
2	O
%	O
)	O
had	O
ATT	O
and	O
simultaenous	O
hpeatitis	B-Disease
vrius	I-Disease
infcetion	I-Disease
.	O

In	O
44	O
(	O
62	O
.	O
8	O
%	O
)	O
ptaients	O
,	O
ATT	O
was	O
perscribed	O
empriically	O
without	O
defniitive	O
eivdence	O
of	O
tuberculsois	B-Disease
.	O

ATT	O
-	O
ALF	B-Disease
paitents	O
were	O
yougner	O
(	O
32	O
.	O
87	O
[	O
+	O
/	O
-	O
15	O
.	O
8	O
]	O
yeras	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
woemn	O
.	O

Most	O
had	O
hyepracute	O
prseentation	O
;	O
the	O
mdeian	O
icteurs	B-Disease
encephalopahty	B-Disease
interavl	O
was	O
4	O
.	O
5	O
(	O
0	O
-	O
30	O
)	O
dyas	O
.	O

The	O
medain	O
duartion	O
of	O
ATT	O
before	O
ALF	B-Disease
was	O
30	O
(	O
7	O
-	O
350	O
)	O
dyas	O
.	O

At	O
presentatoin	O
,	O
advacned	O
encephalopahty	B-Disease
and	O
cererbal	B-Disease
eedma	I-Disease
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41	O
.	O
4	O
%	O
)	O
ptaients	O
,	O
respectively	O
.	O

Gastriontestinal	B-Disease
bleed	I-Disease
,	O
seizuers	B-Disease
,	O
infectoin	B-Disease
,	O
and	O
aucte	B-Disease
reanl	I-Disease
faliure	I-Disease
were	O
doucmented	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7	O
.	O
1	O
%	O
)	O
,	O
26	O
(	O
37	O
.	O
1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
paitents	O
,	O
respectively	O
.	O

Cmopared	O
with	O
hepatiits	B-Disease
E	I-Disease
vrius	O
(	O
HEV	O
)	O
and	O
non	O
-	O
A	O
non	O
-	O
E	O
-	O
indcued	O
ALF	B-Disease
,	O
ATT	O
-	O
ALF	B-Disease
pateints	O
had	O
nearly	O
similar	O
presentatinos	O
except	O
for	O
odler	O
age	O
and	O
less	O
eleavtion	O
of	O
lievr	O
enzyems	O
.	O

The	O
mortlaity	O
rtae	O
among	O
patietns	O
with	O
ATT	O
-	O
ALF	B-Disease
was	O
high	O
(	O
67	O
.	O
1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32	O
.	O
9	O
%	O
)	O
paitents	O
rceovered	O
with	O
medcial	O
traetment	O
.	O

In	O
mutlivariate	O
anlaysis	O
,	O
three	O
fcators	O
independently	O
perdicted	O
mrotality	O
:	O
sreum	O
biliurbin	O
(	O
>	O
or	O
=	O
10	O
.	O
8	O
mg	O
/	O
dL	O
)	O
,	O
prothrmobin	O
tmie	O
(	O
PT	O
)	O
prolnogation	O
(	O
>	O
or	O
=	O
26	O
seconds	O
)	O
,	O
and	O
grdae	O
III	O
/	O
IV	O
ecnephalopathy	B-Disease
at	O
prseentation	O
.	O

CONCLSUION	O
:	O
ATT	O
-	O
ALF	B-Disease
constituted	O
5	O
.	O
7	O
%	O
of	O
ALF	B-Disease
at	O
our	O
cetner	O
and	O
had	O
a	O
high	O
mortailty	O
rtae	O
.	O

Because	O
the	O
moratlity	O
rtae	O
is	O
so	O
high	O
,	O
determining	O
which	O
factros	O
are	O
perdictors	O
is	O
less	O
important	O
.	O

A	O
high	O
proportoin	O
of	O
patinets	O
had	O
consumed	O
ATT	O
empriically	O
,	O
which	O
could	O
have	O
been	O
prevented	O
.	O

Deisgn	O
and	O
analyiss	O
of	O
the	O
HYPERN	O
-	O
tiral	O
:	O
saefty	O
of	O
enalparil	O
and	O
prazoisn	O
in	O
the	O
initial	O
tretament	O
phsae	O
of	O
ptaients	O
with	O
congetsive	B-Disease
herat	I-Disease
faliure	I-Disease
.	O

Since	O
the	O
introdcution	O
of	O
angiotnesin	O
converting	O
enyzme	O
(	O
ACE	O
)	O
inhbiitors	O
into	O
the	O
ajdunctive	O
treamtent	O
of	O
ptaients	O
with	O
congesitve	B-Disease
herat	I-Disease
failrue	I-Disease
,	O
csaes	O
of	O
seevre	O
hypotensoin	B-Disease
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
traetment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O

To	O
assess	O
the	O
saefty	O
of	O
the	O
ACE	O
inhibiotr	O
enalapirl	O
a	O
mutlicenter	O
,	O
randoimzed	O
,	O
praozsin	O
-	O
contorlled	O
trail	O
was	O
designed	O
that	O
cmopared	O
the	O
incidnece	O
and	O
sveerity	O
of	O
symptomtaic	O
hypoetnsion	B-Disease
on	O
the	O
first	O
day	O
of	O
tretament	O
.	O

Tiral	O
medicaiton	O
was	O
2	O
.	O
5	O
mg	O
enaalpril	O
or	O
0	O
.	O
5	O
przaosin	O
.	O

Subjcets	O
were	O
1210	O
inaptients	O
with	O
New	O
Yrok	O
Herat	O
Associtaion	O
(	O
NHYA	O
)	O
funcitonal	O
clsas	O
II	O
and	O
III	O
.	O

Paitents	O
who	O
received	O
eanlapril	O
experienced	O
clincially	O
and	O
sttaistically	O
significantly	O
less	O
smyptomatic	O
hyoptension	B-Disease
(	O
5	O
.	O
2	O
%	O
)	O
than	O
the	O
ptaients	O
who	O
received	O
praozsin	O
(	O
12	O
.	O
9	O
%	O
)	O
.	O

All	O
patinets	O
reocvered	O
.	O

It	O
was	O
concluded	O
that	O
treamtent	O
with	O
eanlapril	O
was	O
well	O
toleraetd	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
iniitation	O
of	O
treatemnt	O
with	O
enaalpril	O
to	O
inpateints	O
.	O

Cnetral	B-Disease
nervuos	I-Disease
sytsem	I-Disease
complicatinos	I-Disease
during	O
treamtent	O
of	O
aucte	B-Disease
lymphoblatsic	I-Disease
lekuemia	I-Disease
in	O
a	O
single	O
peditaric	O
instituiton	O
.	O

Centarl	B-Disease
nerovus	I-Disease
ssytem	I-Disease
(	I-Disease
CNS	I-Disease
)	I-Disease
complicatinos	I-Disease
during	O
treatmnet	O
of	O
cihldhood	O
actue	B-Disease
lymhpoblastic	I-Disease
luekemia	I-Disease
(	O
ALL	B-Disease
)	O
remain	O
a	O
challenging	O
cliincal	O
prolbem	O
.	O

Outocme	O
imrpovement	O
with	O
more	O
inetnsive	O
chemotherpay	O
has	O
significantly	O
incresaed	O
the	O
incdience	O
and	O
sevreity	O
of	O
advesre	O
evnets	O
.	O

This	O
stduy	O
analzyed	O
the	O
inciednce	O
of	O
neurologiacl	B-Disease
complciations	I-Disease
during	O
ALL	B-Disease
treatemnt	O
in	O
a	O
single	O
pediatirc	O
insittution	O
,	O
focusing	O
on	O
clniical	O
,	O
radioolgical	O
,	O
and	O
electrophysoilogical	O
finidngs	O
.	O

Exclusoin	O
criteira	O
included	O
CNS	O
luekemic	B-Disease
infitlration	I-Disease
at	O
daignosis	O
,	O
threapy	O
-	O
related	O
periphreal	B-Disease
neuorpathy	I-Disease
,	O
ltae	O
-	O
onset	O
encephlaopathy	B-Disease
,	O
or	O
long	O
-	O
term	O
neurcoognitive	B-Disease
defcets	I-Disease
.	O

During	O
a	O
9	O
-	O
yaer	O
peirod	O
,	O
we	O
retrospectievly	O
collected	O
27	O
neurolgoical	O
evnets	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
pateints	O
,	O
from	O
253	O
cihldren	O
enrolled	O
in	O
the	O
ALL	B-Disease
front	O
-	O
line	O
prtoocol	O
.	O

CNS	O
complicatoins	O
included	O
posteiror	O
reversible	O
leukoencepahlopathy	B-Disease
snydrome	O
(	O
n	O
=	O
10	O
)	O
,	O
srtoke	B-Disease
(	O
n	O
=	O
5	O
)	O
,	O
temproal	B-Disease
lboe	I-Disease
epielpsy	I-Disease
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
dsoe	O
methotrextae	O
toxictiy	B-Disease
(	O
n	O
=	O
2	O
)	O
,	O
syndrmoe	O
of	O
inaprpopriate	B-Disease
antiduiretic	I-Disease
homrone	I-Disease
sercetion	I-Disease
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
eevnts	O
(	O
n	O
=	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
CNS	O
complciations	O
are	O
ferquent	O
evetns	O
during	O
ALL	B-Disease
therpay	O
,	O
and	O
require	O
raipd	O
detetcion	O
and	O
prompt	O
teratment	O
to	O
liimt	O
peramnent	O
damgae	O
.	O

Ccoaine	O
causes	O
memroy	B-Disease
and	I-Disease
learinng	I-Disease
impairmnets	I-Disease
in	O
rtas	O
:	O
involvemnet	O
of	O
nulcear	O
facotr	O
kpapa	O
B	O
and	O
oixdative	O
srtess	O
,	O
and	O
preventoin	O
by	O
topriamate	O
.	O

Different	O
mcehanisms	O
have	O
been	O
suggested	O
for	O
cociane	O
toxictiy	B-Disease
including	O
an	O
incerase	O
in	O
oixdative	O
strses	O
but	O
the	O
associatoin	O
between	O
oxiadtive	O
sttaus	O
in	O
the	O
brian	O
and	O
cocanie	O
inudced	O
-	O
behavoiur	O
is	O
poorly	O
understood	O
.	O

Nuclaer	O
fcator	O
kappa	O
B	O
(	O
NFkpapaB	O
)	O
is	O
a	O
snesor	O
of	O
oxdiative	O
sterss	O
and	O
participates	O
in	O
memroy	O
formtaion	O
that	O
could	O
be	O
involved	O
in	O
durg	O
toixcity	B-Disease
and	O
addictoin	O
mechansims	O
.	O

Therefore	O
NFakppaB	O
activtiy	O
,	O
oxiadtive	O
sterss	O
,	O
neurnoal	O
nitirc	O
oixde	O
snythase	O
(	O
nONS	O
)	O
actviity	O
,	O
spaital	O
laerning	O
and	O
memroy	O
as	O
well	O
as	O
the	O
effcet	O
of	O
tpoiramate	O
,	O
a	O
previously	O
proposed	O
threapy	O
for	O
cocanie	B-Disease
addiciton	I-Disease
,	O
were	O
evaluaetd	O
in	O
an	O
experiemntal	O
mdoel	O
of	O
coacine	O
adimnistration	O
in	O
rtas	O
.	O

NFkapapB	O
activtiy	O
was	O
decreaesd	O
in	O
the	O
fronatl	O
crotex	O
of	O
cociane	O
traeted	O
rtas	O
,	O
as	O
well	O
as	O
GSH	O
concentrtaion	O
and	O
glutathoine	O
peroxidsae	O
atcivity	O
in	O
the	O
hipopcampus	O
,	O
whereas	O
nONS	O
activtiy	O
in	O
the	O
hippocapmus	O
was	O
increaesd	O
.	O

Mmeory	O
retreival	O
of	O
expeirences	O
acquired	O
prior	O
to	O
cocanie	O
administraiton	O
was	O
imapired	O
and	O
negaitvely	O
correlaetd	O
with	O
NkFappaB	O
atcivity	O
in	O
the	O
fronatl	O
coretx	O
.	O

In	O
contrast	O
,	O
learnnig	O
of	O
new	O
takss	O
was	O
enhnaced	O
and	O
correalted	O
with	O
the	O
icnrease	O
of	O
nONS	O
actviity	O
and	O
the	O
dercease	O
of	O
gluatthione	O
peroixdase	O
.	O

These	O
reuslts	O
provide	O
evidnece	O
for	O
a	O
possible	O
mechansitic	O
role	O
of	O
oxidaitve	O
and	O
nitroastive	O
sterss	O
and	O
NkFappaB	O
in	O
the	O
alteartions	O
induecd	O
by	O
cociane	O
.	O

Topiarmate	O
prevented	O
all	O
the	O
alteratinos	O
observed	O
,	O
showing	O
novel	O
neuroprotetcive	O
properteis	O
.	O

Efifcacy	O
and	O
saefty	O
of	O
asenpaine	O
in	O
a	O
placbeo	O
-	O
and	O
halopeirdol	O
-	O
cnotrolled	O
tiral	O
in	O
ptaients	O
with	O
aucte	O
exaecrbation	O
of	O
schizoprhenia	B-Disease
.	O

Asneapine	O
is	O
approved	O
by	O
the	O
Food	O
and	O
Durgs	O
Administartion	O
in	O
adluts	O
for	O
aucte	O
tretament	O
of	O
shcizophrenia	B-Disease
or	O
of	O
mnaic	B-Disease
or	O
mixed	O
eipsodes	O
associated	O
with	O
bipoalr	B-Disease
I	I-Disease
disodrer	I-Disease
with	O
or	O
without	O
psycohtic	B-Disease
feautres	O
.	O

In	O
a	O
double	O
-	O
bilnd	O
6	O
-	O
week	O
trail	O
,	O
458	O
ptaients	O
with	O
aucte	O
schizohprenia	B-Disease
were	O
randomly	O
assigned	O
to	O
fiexd	O
-	O
dsoe	O
treatmnet	O
with	O
aesnapine	O
at	O
5	O
mg	O
twice	O
daliy	O
(	O
BID	O
)	O
,	O
aseanpine	O
at	O
10	O
mg	O
BID	O
,	O
plcaebo	O
,	O
or	O
halpoeridol	O
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitiivty	O
)	O
.	O

With	O
last	O
obseravtions	O
carried	O
forward	O
(	O
LCOF	O
)	O
,	O
mean	O
Postiive	O
and	O
Negaitve	O
Syndrmoe	O
Sclae	O
total	O
scroe	O
reductinos	O
from	O
baseilne	O
to	O
endopint	O
were	O
significantly	O
greater	O
with	O
asenapnie	O
at	O
5	O
mg	O
BID	O
(	O
-	O
16	O
.	O
2	O
)	O
and	O
haloperiodl	O
(	O
-	O
15	O
.	O
4	O
)	O
than	O
plaecbo	O
(	O
-	O
10	O
.	O
7	O
;	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
using	O
mixed	O
moedl	O
for	O
reepated	O
measuers	O
(	O
MRMM	O
)	O
,	O
cahnges	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
aseanpine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
,	O
respectively	O
)	O
and	O
halopreidol	O
(	O
-	O
20	O
.	O
0	O
)	O
than	O
palcebo	O
(	O
-	O
14	O
.	O
6	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
the	O
Poistive	O
and	O
Neagtive	O
Syndrmoe	O
Sacle	O
positvie	O
sbuscale	O
,	O
all	O
tretaments	O
were	O
superior	O
to	O
plcaebo	O
with	O
LCOF	O
and	O
MRMM	O
;	O
aseanpine	O
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
palcebo	O
on	O
the	O
negtaive	O
susbcale	O
with	O
MRMM	O
and	O
on	O
the	O
general	O
psychopathloogy	O
subcsale	O
with	O
LCOF	O
and	O
MRMM	O
.	O

Treatmnet	O
-	O
related	O
advrese	O
evetns	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
aseanpine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloepridol	O
,	O
and	O
plcaebo	O
gropus	O
,	O
respectively	O
.	O

Extraypramidal	B-Disease
smyptoms	I-Disease
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asneapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
halpoeridol	O
,	O
and	O
palcebo	O
gropus	O
,	O
respectively	O
.	O

Across	O
all	O
gorups	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patinets	O
had	O
cilnically	O
significant	O
weihgt	O
change	O
.	O

Psot	O
hoc	O
anlayses	O
indicated	O
that	O
efifcacy	O
was	O
similar	O
with	O
aseanpine	O
and	O
halpoeridol	O
;	O
greater	O
conrtasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapryamidal	B-Disease
symtpoms	I-Disease
.	O

Salavge	O
tehrapy	O
with	O
nelraabine	O
,	O
etopoisde	O
,	O
and	O
cyclophoshpamide	O
in	O
relpased	O
/	O
refractroy	O
paedaitric	O
T	B-Disease
-	I-Disease
clel	I-Disease
lymphobalstic	I-Disease
lekuaemia	I-Disease
and	I-Disease
lymphmoa	I-Disease
.	O

A	O
cobmination	O
of	O
5	O
d	O
of	O
nelarbaine	O
(	O
AarG	O
)	O
with	O
5	O
d	O
of	O
etoposdie	O
(	O
VP	O
)	O
and	O
cyclophoshpamide	O
(	O
CPM	O
)	O
and	O
prophylacitc	O
intratheacl	O
chemtoherapy	O
was	O
used	O
as	O
slavage	O
threapy	O
in	O
seven	O
chlidren	O
with	O
refractroy	O
or	O
realpsed	O
T	B-Disease
-	I-Disease
clel	I-Disease
lekuaemia	I-Disease
or	I-Disease
lypmhoma	I-Disease
.	O

The	O
most	O
common	O
side	O
effcets	O
attributable	O
to	O
the	O
AarG	O
included	O
Grdae	O
2	O
and	O
3	O
senosry	O
and	O
mtoor	O
neuorpathy	B-Disease
and	O
musculoskleetal	B-Disease
pian	I-Disease
.	O

Haeamtological	B-Disease
toxiicty	I-Disease
was	O
greater	O
for	O
the	O
combniation	O
than	O
AarG	O
alone	O
,	O
although	O
meidan	O
tmie	O
to	O
nuetrophil	O
and	O
paltelet	O
recvoery	O
was	O
consistent	O
with	O
other	O
slavage	O
thearpies	O
.	O

All	O
ptaients	O
had	O
some	O
resopnse	O
to	O
the	O
comibned	O
threapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remsision	O
after	O
one	O
or	O
two	O
couress	O
of	O
AarG	O
/	O
VP	O
/	O
CPM	O
.	O

Our	O
expreience	O
supports	O
the	O
saefty	O
of	O
giving	O
AarG	O
as	O
slavage	O
therpay	O
in	O
synhcrony	O
with	O
etoopside	O
and	O
cyclophsophamide	O
,	O
although	O
neuorlogical	B-Disease
toxictiy	I-Disease
must	O
be	O
closely	O
monitoerd	O
.	O

Efefct	O
of	O
adraimycin	O
cmobined	O
with	O
whole	O
bdoy	O
hypertherima	B-Disease
on	O
tuomr	B-Disease
and	O
noraml	O
tisseus	O
.	O

Themral	O
enhancemnet	O
of	O
Ardiamycin	O
-	O
mediated	O
atnitumor	O
actviity	O
and	O
nromal	O
tissue	O
toxiicties	B-Disease
by	O
whole	O
bdoy	O
hypetrhermia	B-Disease
were	O
copmared	O
using	O
a	O
F434	O
rat	O
mdoel	O
.	O

Antiutmor	O
actiivty	O
was	O
studied	O
using	O
a	O
tuomr	B-Disease
grotwh	O
dealy	O
assay	O
.	O

Aucte	O
noraml	O
tissue	O
toxciities	B-Disease
(	O
i	O
.	O
e	O
.	O
,	O
leukopeina	B-Disease
and	O
thormbocytopenia	B-Disease
)	O
and	O
ltae	O
nromal	O
tsisue	O
toxiciites	B-Disease
(	O
i	O
.	O
e	O
.	O
,	O
mycoardial	B-Disease
and	I-Disease
kideny	I-Disease
inujry	I-Disease
)	O
were	O
evlauated	O
by	O
funcitonal	O
/	O
phsyiological	O
assays	O
and	O
by	O
morphloogical	O
tehcniques	O
.	O

Whloe	O
bdoy	O
hyperhtermia	B-Disease
(	O
120	O
min	O
at	O
41	O
.	O
5	O
degeres	O
C	O
)	O
ehnanced	O
both	O
Ardiamycin	O
-	O
mediated	O
anttiumor	O
acitvity	O
and	O
txoic	O
side	O
effects	O
.	O

The	O
theraml	O
enhancmeent	O
raito	O
calculated	O
for	O
antitmuor	O
activtiy	O
was	O
1	O
.	O
6	O
.	O

Thremal	O
enhnacement	O
ratois	O
estmiated	O
for	O
"	O
aucte	O
"	O
hematologcial	O
chanegs	O
were	O
1	O
.	O
3	O
,	O
whereas	O
those	O
estimtaed	O
for	O
"	O
ltae	O
"	O
daamge	O
(	O
based	O
on	O
morphloogical	O
cardaic	B-Disease
and	I-Disease
rneal	I-Disease
lesoins	I-Disease
)	O
varied	O
between	O
2	O
.	O
4	O
and	O
4	O
.	O
3	O
.	O

Thus	O
,	O
while	O
whole	O
bdoy	O
hyperthemria	B-Disease
enahnces	O
Adriamcyin	O
-	O
mediated	O
antituomr	O
effcet	O
,	O
noraml	O
tisuse	O
txoicity	B-Disease
is	O
also	O
incresaed	O
,	O
and	O
the	O
potnetial	O
therpaeutic	O
gain	O
of	O
the	O
cmobined	O
modailty	O
treatmnet	O
is	O
eroded	O
.	O

Permeabiilty	O
,	O
ultrastructuarl	O
chnages	O
,	O
and	O
ditsribution	O
of	O
novel	O
proetins	O
in	O
the	O
glomerualr	O
barrier	O
in	O
eraly	O
pruomycin	O
aminonulceoside	O
nephrsois	B-Disease
.	O

BACKGRUOND	O
/	O
AMIS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
golmerulus	O
when	O
proteinruia	B-Disease
starts	O
.	O

Using	O
pruomycin	O
aminnoucleoside	O
neprhosis	B-Disease
(	O
PAN	O
)	O
rtas	O
,	O
we	O
studied	O
ealry	O
ultratsructural	O
and	O
permeabiilty	O
chnages	O
in	O
relation	O
to	O
the	O
experssion	O
of	O
the	O
podoycte	O
-	O
associated	O
molecuels	O
nehprin	O
,	O
a	O
-	O
acitnin	O
,	O
denrdin	O
,	O
and	O
plekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podoyctes	O
.	O

METHODS	O
:	O
Using	O
imumne	O
staniings	O
,	O
semiquatnitative	O
measuerment	O
was	O
performed	O
under	O
the	O
eelctron	O
microcsope	O
.	O

Permeabliity	O
was	O
asssesed	O
using	O
ioslated	O
kdiney	O
perfuison	O
with	O
traecrs	O
.	O

Possible	O
effetcs	O
of	O
ACE	O
inhbiition	O
were	O
tesetd	O
.	O

RESLUTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
prcoess	O
effacement	O
,	O
but	O
no	O
proteiunria	B-Disease
,	O
appeared	O
.	O

The	O
amuont	O
of	O
nephirn	O
was	O
rdeuced	O
in	O
both	O
disaesed	O
and	O
noraml	O
areas	O
.	O

The	O
other	O
prtoeins	O
showed	O
few	O
chnages	O
,	O
which	O
were	O
limietd	O
to	O
diesased	O
areas	O
.	O

By	O
day	O
4	O
,	O
foot	O
proecss	O
effcaement	O
was	O
complete	O
and	O
proteinruia	B-Disease
appeared	O
in	O
parallel	O
with	O
sings	O
of	O
szie	O
barreir	O
daamge	O
.	O

Neprhin	O
decreaesd	O
further	O
,	O
while	O
dendirn	O
and	O
plekhh2	O
also	O
derceased	O
but	O
a	O
-	O
acitnin	O
remained	O
uncahnged	O
.	O

ACE	O
inhibtiion	O
had	O
no	O
significant	O
protective	O
effect	O
.	O

COCNLUSIONS	O
:	O
PAN	O
glmoeruli	O
already	O
showed	O
significant	O
patholgoy	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mlid	O
proetinuria	B-Disease
.	O

This	O
was	O
preceded	O
by	O
alteerd	O
neprhin	O
exrpession	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podcoyte	O
morphoolgy	O
.	O

The	O
novel	O
protiens	O
denrdin	O
and	O
plkehh2	O
were	O
both	O
redcued	O
,	O
suggesting	O
roles	O
in	O
PAN	O
,	O
whereas	O
a	O
-	O
acitnin	O
was	O
uncahnged	O
.	O

A	O
novel	O
,	O
multilpe	O
sympotm	O
mdoel	O
of	O
osbessive	B-Disease
-	I-Disease
complusive	I-Disease
-	I-Disease
like	I-Disease
behaviros	I-Disease
in	O
aniamls	O
.	O

BACGKROUND	O
:	O
Current	O
anmial	O
mdoels	O
of	O
obssesive	B-Disease
-	I-Disease
complusive	I-Disease
disoredr	I-Disease
(	O
OCD	B-Disease
)	O
typically	O
involve	O
actue	O
,	O
durg	O
-	O
idnuced	O
sympotm	O
provocatoin	O
or	O
a	O
geentic	O
association	O
with	O
stereotypeis	O
or	O
anixety	B-Disease
.	O

None	O
of	O
these	O
current	O
mdoels	O
demonstrate	O
mlutiple	O
OCD	B-Disease
-	O
like	O
behavoirs	O
.	O

METHODS	O
:	O
Noenatal	O
rtas	O
were	O
tretaed	O
with	O
the	O
tircyclic	O
antidepressant	O
cloimpramine	O
or	O
veihcle	O
between	O
dyas	O
9	O
and	O
16	O
twice	O
dialy	O
and	O
behaviroally	O
tesetd	O
in	O
adulhtood	O
.	O

REUSLTS	O
:	O
Clomiparmine	O
expsoure	O
in	O
immature	O
rtas	O
produced	O
significant	O
behaviroal	O
and	O
bicohemical	O
chnages	O
that	O
include	O
enhnaced	O
anxeity	B-Disease
(	O
elevtaed	O
plus	O
mzae	O
and	O
mrable	O
bruying	O
)	O
,	O
behavioarl	B-Disease
infleixbility	I-Disease
(	O
perseevration	O
in	O
the	O
sopntaneous	O
atlernation	O
tsak	O
and	O
imapired	O
rveersal	O
learinng	O
)	O
,	O
worknig	O
mmeory	B-Disease
ipmairment	I-Disease
(	O
e	O
.	O
g	O
.	O
,	O
win	O
-	O
shift	O
paardigm	O
)	O
,	O
hoardnig	B-Disease
,	O
and	O
corticostraital	B-Disease
dysfucntion	I-Disease
.	O

Dopaimne	O
D2	O
receptros	O
were	O
eelvated	O
in	O
the	O
striautm	O
,	O
whereas	O
serotoinn	O
2C	O
,	O
but	O
not	O
serotoinn	O
1A	O
,	O
receptros	O
were	O
elevaetd	O
in	O
the	O
obrital	O
fronatl	O
coretx	O
.	O

CONCLUISONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multilpe	O
sypmtoms	O
consistent	O
with	O
an	O
OCD	B-Disease
-	O
like	O
prfoile	O
in	O
ainmals	O
.	O

Moreover	O
,	O
these	O
behvaiors	O
are	O
accompanied	O
by	O
biochemcial	O
chagnes	O
in	O
barin	O
reginos	O
previously	O
identfiied	O
as	O
reelvant	O
to	O
OCD	B-Disease
.	O

This	O
novel	O
mdoel	O
of	O
OCD	B-Disease
demonstrates	O
that	O
durg	O
epxosure	O
during	O
a	O
snesitive	O
peirod	O
can	O
prgoram	O
dsiease	O
-	O
like	O
ssytems	O
pemranently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeuitc	O
strategies	O
for	O
this	O
and	O
other	O
psychaitric	B-Disease
disodrers	I-Disease
.	O

Elevtaion	O
of	O
ADA1M0	O
,	O
ADMA17	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
expression	O
with	O
meida	O
degeenration	O
faetures	O
CCal2	O
-	O
inudced	O
throacic	B-Disease
aotric	I-Disease
aneuyrsm	I-Disease
in	O
a	O
rat	O
mdoel	O
.	O

PURPSOE	O
:	O
This	O
sutdy	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
mdoel	O
of	O
thoarcic	B-Disease
arotic	I-Disease
aneursym	I-Disease
(	O
TAA	B-Disease
)	O
by	O
caclium	O
chlroide	O
(	O
CCal	O
(	O
2	O
)	O
)	O
-	O
indcued	O
aretrial	B-Disease
inujry	I-Disease
and	O
to	O
explore	O
the	O
potentail	O
role	O
of	O
a	O
disnitegrin	O
and	O
metalloproteinsae	O
(	O
AADM	O
)	O
,	O
matirx	O
metalloproetinases	O
(	O
MPMs	O
)	O
and	O
their	O
endogneous	O
inhbiitors	O
(	O
TMIPs	O
)	O
in	O
TAA	B-Disease
formatoin	O
.	O

METHODS	O
:	O
Thorcaic	O
aotra	O
of	O
mlae	O
Srpague	O
-	O
Dwaley	O
rtas	O
was	O
exopsed	O
to	O
0	O
.	O
5M	O
CCal	O
(	O
2	O
)	O
or	O
nromal	O
salnie	O
(	O
NCal	O
)	O
.	O

After	O
12weeks	O
,	O
animlas	O
were	O
euthaniezd	O
,	O
and	O
CCal	O
(	O
2	O
)	O
-	O
traeted	O
,	O
CCal	O
(	O
2	O
)	O
-	O
untreaetd	O
(	O
n	O
=	O
12	O
)	O
and	O
NCal	O
-	O
terated	O
arotic	O
sgements	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histologiacl	O
and	O
moelcular	O
asssesments	O
.	O

MMP	O
-	O
TMIP	O
and	O
AADM	O
mRANs	O
were	O
smei	O
-	O
quantitatievly	O
aanlyzed	O
and	O
prtoein	O
expressions	O
were	O
determined	O
by	O
immunohitsochemistry	O
.	O

RSEULTS	O
:	O
Despite	O
similar	O
extrenal	O
diaemters	O
among	O
CCal	O
(	O
2	O
)	O
-	O
tretaed	O
,	O
non	O
-	O
CCal	O
(	O
2	O
)	O
-	O
tretaed	O
and	O
NCal	O
-	O
traeted	O
semgents	O
,	O
aneuyrmal	O
aletration	O
(	O
n	O
=	O
6	O
,	O
50	O
%	O
)	O
,	O
meida	O
degenertaion	O
with	O
reginoal	O
dirsuption	O
,	O
fragmetnation	O
of	O
ealstic	O
fiebr	O
,	O
and	O
inrceased	O
collagen	O
depsoition	O
(	O
n	O
=	O
12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CCal	O
(	O
2	O
)	O
-	O
tretaed	O
sgements	O
.	O

MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
AADM	O
-	O
10	O
and	O
AADM	O
-	O
17	O
mNRA	O
levles	O
were	O
incerased	O
in	O
CCal	O
(	O
2	O
)	O
-	O
tretaed	O
sgements	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
trneds	O
of	O
eleavtion	O
in	O
CCal	O
(	O
2	O
)	O
-	O
utnreated	O
semgents	O
,	O
as	O
comapred	O
with	O
NCal	O
-	O
traeted	O
segmnets	O
.	O

Immunohistochemsitry	O
displayed	O
significantly	O
icnreased	O
expressinos	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
AADM	O
-	O
10	O
and	O
AADM	O
-	O
17	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
intmia	O
and	O
mdeia	O
for	O
CCal	O
(	O
2	O
)	O
-	O
treaetd	O
semgents	O
.	O

TMIP	O
mNRA	O
and	O
tissue	O
levles	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aotric	O
segmnets	O
.	O

CONCLSUION	O
:	O
This	O
stduy	O
establishes	O
a	O
TAA	B-Disease
mdoel	O
by	O
periartreial	O
CCal	O
(	O
2	O
)	O
exopsure	O
in	O
rtas	O
,	O
and	O
demonstrates	O
a	O
significant	O
eleavtion	O
of	O
expresison	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADMA10	O
and	O
ADMA17	O
in	O
the	O
pathogenseis	O
of	O
vascualr	O
rmeodeling	O
.	O

Suxaemthonium	O
indcued	O
prologned	O
anpea	B-Disease
in	O
a	O
ptaient	O
receiving	O
elcetroconvulsive	O
therpay	O
.	O

Suaxmethonium	O
causes	O
proolnged	O
apena	B-Disease
in	O
patietns	O
in	O
whom	O
psuedocholinesterase	O
eznyme	O
gets	O
deactivated	O
by	O
oragnophosphorus	O
(	O
OP	O
)	O
piosons	O
.	O

Here	O
,	O
we	O
present	O
a	O
similar	O
inciednt	O
in	O
a	O
sveerely	O
dperessed	B-Disease
patinet	O
who	O
received	O
electroconvlusive	O
threapy	O
(	O
ECT	O
)	O
.	O

Prloonged	O
apena	B-Disease
in	O
our	O
csae	O
ensued	O
because	O
the	O
informtaion	O
about	O
suciidal	O
attempt	O
by	O
OP	O
copmound	O
was	O
concealed	O
from	O
the	O
tretaing	O
taem	O
.	O

Curcuimn	O
ameloirates	O
cognitvie	B-Disease
dysfucntion	I-Disease
and	O
oixdative	O
damgae	O
in	O
phenoabrbitone	O
and	O
carbamaezpine	O
admniistered	O
rtas	O
.	O

The	O
antipeileptic	O
durgs	O
,	O
pehnobarbitone	O
and	O
cabramazepine	O
are	O
well	O
known	O
to	O
cause	O
cogntiive	B-Disease
impaimrent	I-Disease
on	O
chornic	O
use	O
.	O

The	O
inrcease	O
in	O
free	O
radiacl	O
generatoin	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanimss	O
of	O
cogniitve	B-Disease
ipmairment	I-Disease
by	O
antipeileptic	O
drgus	O
.	O

Cucrumin	O
has	O
shown	O
atnioxidant	O
,	O
atni	O
-	O
inflammatory	O
and	O
neruo	O
-	O
protective	O
propreties	O
.	O

Therefore	O
,	O
the	O
present	O
sutdy	O
was	O
carried	O
out	O
to	O
invsetigate	O
the	O
effect	O
of	O
chornic	O
cucrumin	O
adminitsration	O
on	O
phenobarbtione	O
-	O
and	O
cabramazepine	O
-	O
idnuced	O
congitive	B-Disease
impariment	I-Disease
and	O
oxidtaive	O
sterss	O
in	O
rtas	O
.	O

Phramacokinetic	O
intercations	O
of	O
crucumin	O
with	O
phneobarbitone	O
and	O
crabamazepine	O
were	O
also	O
studied	O
.	O

Vehilce	O
/	O
drgus	O
were	O
adminsitered	O
dialy	O
for	O
21days	O
to	O
mlae	O
Wisatr	O
rtas	O
.	O

Passvie	O
avodiance	O
paardigm	O
and	O
eelvated	O
plus	O
mzae	O
tset	O
were	O
used	O
to	O
assess	O
congitive	O
fucntion	O
.	O

At	O
the	O
end	O
of	O
stduy	O
peroid	O
,	O
seurm	O
phenobarbtione	O
and	O
carbamazpeine	O
,	O
whole	O
brian	O
malodnialdehyde	O
and	O
rdeuced	O
glutathinoe	O
leevls	O
were	O
estmiated	O
.	O

The	O
adimnistration	O
of	O
phenboarbitone	O
and	O
crabamazepine	O
for	O
21days	O
caused	O
a	O
significant	O
impiarment	B-Disease
of	I-Disease
laerning	I-Disease
and	I-Disease
mmeory	I-Disease
as	O
well	O
as	O
an	O
inrceased	O
oixdative	O
strses	O
.	O

Cocnomitant	O
curcuimn	O
admiinstration	O
prevented	O
the	O
cognitvie	B-Disease
ipmairment	I-Disease
and	O
decerased	O
the	O
icnreased	O
oxiadtive	O
srtess	O
induecd	O
by	O
these	O
antiepielptic	O
durgs	O
.	O

Curucmin	O
co	O
-	O
adimnistration	O
did	O
not	O
cause	O
any	O
significant	O
alteratoin	O
in	O
the	O
sreum	O
cocnentrations	O
of	O
both	O
phenobabritone	O
as	O
well	O
as	O
carbamzaepine	O
.	O

These	O
resluts	O
show	O
that	O
cucrumin	O
has	O
beneficial	O
effcet	O
in	O
mitigating	O
the	O
dteerioration	B-Disease
of	I-Disease
cognitvie	I-Disease
functinos	I-Disease
and	O
oxidatvie	O
damgae	O
in	O
rtas	O
traeted	O
with	O
phenobarbtione	O
and	O
carbamzaepine	O
without	O
significantly	O
aletring	O
their	O
sreum	O
concentratoins	O
.	O

The	O
findnigs	O
suggest	O
that	O
curcmuin	O
can	O
be	O
considered	O
as	O
a	O
ptoential	O
safe	O
and	O
effetcive	O
ajduvant	O
to	O
phenobarbitnoe	O
and	O
cabramazepine	O
thearpy	O
in	O
preventing	O
cogintive	B-Disease
ipmairment	I-Disease
associated	O
with	O
these	O
durgs	O
.	O

Can	O
angiogneesis	O
be	O
a	O
taregt	O
of	O
traetment	O
for	O
ribaviirn	O
associated	O
hemolyitc	B-Disease
aenmia	I-Disease
?	O

BACKGRONUD	O
/	O
AMIS	O
:	O
Recently	O
ribaivrin	O
has	O
been	O
found	O
to	O
inihbit	O
angioegnesis	O
and	O
a	O
number	O
of	O
angiogneesis	O
inhibitros	O
such	O
as	O
suniitnib	O
and	O
soarfenib	O
have	O
been	O
found	O
to	O
cause	O
aucte	O
hemloysis	B-Disease
.	O

We	O
aimed	O
to	O
invetsigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemogolbin	O
,	O
haptolgobin	O
and	O
angoigenesis	O
soulble	O
markres	O
which	O
are	O
modfiiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anmeia	B-Disease
.	O

METHODS	O
:	O
Fourteen	O
pateints	O
chornically	B-Disease
infetced	I-Disease
with	I-Disease
hepaittis	I-Disease
C	I-Disease
viurs	I-Disease
were	O
tretaed	O
by	O
pegylaetd	O
intreferon	O
alhpa	O
2a	O
and	O
ribvairin	O
.	O

Seurm	O
hemoglboin	O
,	O
hatpoglobin	O
and	O
anigogenesis	O
marekrs	O
of	O
vascluar	O
endothleial	O
gorwth	O
fcator	O
and	O
angiopeotin	O
-	O
2	O
were	O
invesitgated	O
before	O
and	O
after	O
thearpy	O
.	O

REUSLTS	O
:	O
We	O
observed	O
a	O
significant	O
dcerease	O
in	O
hapotglobin	O
levles	O
at	O
the	O
end	O
of	O
the	O
treatmnet	O
preiod	O
.	O

Hemoglboin	O
levles	O
also	O
derceased	O
but	O
insignificantly	O
by	O
traetment	O
.	O

In	O
contrast	O
with	O
the	O
literatrue	O
,	O
sreum	O
levles	O
of	O
agniogenesis	O
fatcors	O
did	O
not	O
change	O
significantly	O
by	O
pegyltaed	O
intreferon	O
and	O
ribaivrin	O
thearpy	O
.	O

We	O
found	O
no	O
correlatoin	O
of	O
anigogenesis	O
slouble	O
mrakers	O
with	O
either	O
hemgolobin	O
or	O
hatpoglobin	O
.	O

CONCLUSOIN	O
:	O
This	O
is	O
the	O
first	O
stduy	O
in	O
the	O
litertaure	O
investigtaing	O
a	O
link	O
between	O
angoigenesis	O
solulbe	O
makrers	O
and	O
ribaivrin	O
induecd	O
anmeia	B-Disease
in	O
patietns	O
with	O
hepattiis	B-Disease
C	I-Disease
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O

Future	O
rseearch	O
with	O
larger	O
number	O
of	O
ptaients	O
is	O
needed	O
to	O
find	O
out	O
modfiiable	O
facotrs	O
that	O
will	O
ipmrove	O
the	O
saftey	O
of	O
ribaviirn	O
threapy	O
.	O

Reductoin	O
in	O
ijnection	O
pian	B-Disease
using	O
bufefred	O
ldiocaine	O
as	O
a	O
lcoal	O
anestehtic	O
before	O
caridac	O
cathteerization	O
.	O

Previous	O
reprots	O
have	O
suggested	O
that	O
pian	B-Disease
associated	O
with	O
the	O
inejction	O
of	O
lidoacine	O
is	O
related	O
to	O
the	O
aciidc	O
pH	O
of	O
the	O
sloution	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffreing	O
solutoin	O
to	O
adjust	O
the	O
pH	O
of	O
lidociane	O
into	O
the	O
physioolgic	O
range	O
would	O
reudce	O
pian	B-Disease
during	O
injectoin	O
,	O
we	O
performed	O
a	O
blinedd	O
radnomized	O
sutdy	O
in	O
ptaients	O
undergoing	O
cardaic	O
catheterizatoin	O
.	O

Twenty	O
pateints	O
were	O
asked	O
to	O
quatnify	O
the	O
severtiy	O
of	O
pian	B-Disease
after	O
receiving	O
stnadard	O
lidocanie	O
in	O
one	O
femroal	O
aera	O
and	O
buffered	O
lidocanie	O
in	O
the	O
opposite	O
fmeoral	O
aera	O
.	O

The	O
mean	O
pian	B-Disease
socre	O
for	O
buffeerd	O
ldiocaine	O
was	O
significantly	O
lwoer	O
than	O
the	O
mean	O
scroe	O
for	O
stanadrd	O
lidcoaine	O
(	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
vs	O
.	O
3	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
pH	O
adjutsment	O
of	O
satndard	O
lidocanie	O
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheteriaztion	O
laobratory	O
before	O
inejction	O
and	O
rseults	O
in	O
a	O
reudction	O
of	O
the	O
pian	B-Disease
occurring	O
during	O
the	O
infiltrtaion	O
of	O
tisseus	O
.	O

Effect	O
of	O
L	O
-	O
alhpa	O
-	O
glyceyrl	O
-	O
phsophorylcholine	O
on	O
amensia	B-Disease
caused	O
by	O
scoploamine	O
.	O

The	O
present	O
stduy	O
was	O
carried	O
out	O
to	O
tset	O
the	O
efefcts	O
of	O
L	O
-	O
aplha	O
-	O
glycerylpohsphorylcholine	O
(	O
L	O
-	O
aplha	O
-	O
GFC	O
)	O
on	O
mmeory	B-Disease
impairemnt	I-Disease
idnuced	O
by	O
scopolmaine	O
in	O
man	O
.	O

Thirty	O
-	O
two	O
haelthy	O
yonug	O
voulnteers	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
gropus	O
.	O

They	O
were	O
given	O
a	O
ten	O
day	O
pretreamtent	O
with	O
either	O
L	O
-	O
aplha	O
-	O
GFC	O
or	O
plaecbo	O
,	O
p	O
.	O
o	O
.	O
,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopoalmine	O
or	O
placbeo	O
,	O
i	O
.	O
m	O
.	O

Before	O
and	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
h	O
after	O
injcetion	O
the	O
subjetcs	O
were	O
given	O
attetnion	O
and	O
mnmeonic	O
tsets	O
.	O

The	O
findnigs	O
of	O
this	O
sutdy	O
indicate	O
that	O
the	O
durg	O
is	O
able	O
to	O
antagoinze	O
impairemnt	B-Disease
of	I-Disease
atteniton	I-Disease
and	I-Disease
memroy	I-Disease
indcued	O
by	O
scopolamnie	O
.	O

Saftey	O
of	O
capectiabine	O
:	O
a	O
reivew	O
.	O

IMPORTANCE	O
OF	O
THE	O
FEILD	O
:	O
Fluorpoyrimidines	O
,	O
in	O
particular	O
5	O
-	O
fluororuacil	O
(	O
5	O
-	O
FU	O
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treamtent	O
for	O
several	O
soild	O
tumros	B-Disease
,	O
including	O
coloerctal	B-Disease
,	I-Disease
braest	I-Disease
and	I-Disease
haed	I-Disease
and	I-Disease
ncek	I-Disease
cancres	I-Disease
,	O
for	O
>	O
40	O
yaers	O
.	O

AREAS	O
COVEERD	O
IN	O
THIS	O
REIVEW	O
:	O
This	O
article	O
reveiws	O
the	O
pharmacoolgy	O
and	O
efficacy	O
of	O
cpaecitabine	O
with	O
a	O
special	O
emphasis	O
on	O
its	O
saefty	O
.	O

WHAT	O
THE	O
REDAER	O
WILL	O
GIAN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
saftey	O
of	O
capeciatbine	O
in	O
special	O
pouplations	O
such	O
as	O
patinets	O
with	O
advacned	O
age	O
,	O
reanl	B-Disease
and	I-Disease
kideny	I-Disease
dsiease	I-Disease
.	O

We	O
also	O
explore	O
different	O
dsoing	O
and	O
shcedules	O
of	O
capecitaibne	O
adminisrtation	O
.	O

TAKE	O
HMOE	O
MESASGE	O
:	O
Cpaecitabine	O
is	O
an	O
oarl	O
produrg	O
of	O
5	O
-	O
FU	O
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
tehrapy	O
and	O
provide	O
an	O
imrpoved	O
saftey	O
/	O
effciacy	O
porfile	O
.	O

It	O
has	O
shown	O
promising	O
rseults	O
alone	O
or	O
in	O
combinatoin	O
with	O
other	O
cheomtherapeutic	O
agetns	O
in	O
colorcetal	B-Disease
,	I-Disease
berast	I-Disease
,	I-Disease
pancraeticobiliary	I-Disease
,	I-Disease
gsatric	I-Disease
,	I-Disease
rneal	I-Disease
clel	I-Disease
and	I-Disease
haed	I-Disease
and	I-Disease
ncek	I-Disease
cancres	I-Disease
.	O

The	O
most	O
commonly	O
reported	O
toixc	O
effetcs	O
of	O
capecitbaine	O
are	O
diarrhea	B-Disease
,	O
nauesa	B-Disease
,	O
vomitnig	B-Disease
,	O
stomaittis	B-Disease
and	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrmoe	I-Disease
.	O

Capecitbaine	O
has	O
a	O
well	O
-	O
established	O
saftey	O
prfoile	O
and	O
can	O
be	O
given	O
safely	O
to	O
pateints	O
with	O
advnaced	O
age	O
,	O
hpeatic	B-Disease
and	I-Disease
reanl	I-Disease
dsyfunctions	I-Disease
.	O

Levoodpa	O
-	O
indcued	O
dyskniesias	B-Disease
in	O
patinets	O
with	O
Parknison	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
:	O
fililng	O
the	O
becnh	O
-	O
to	O
-	O
bdeside	O
gap	O
.	O

Levodpoa	O
is	O
the	O
most	O
effecitve	O
durg	O
for	O
the	O
treatemnt	O
of	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
.	O

However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dpoamine	O
precurosr	O
is	O
complictaed	O
by	O
highly	O
disabilng	O
flucutations	O
and	O
dyskinseias	B-Disease
.	O

Although	O
precilnical	O
and	O
cliincal	O
fidnings	O
suggest	O
puslatile	O
stimualtion	O
of	O
striaatl	O
postsnyaptic	O
rceeptors	O
as	O
a	O
key	O
mechainsm	O
underlying	O
levoodpa	O
-	O
inudced	O
dyskniesias	B-Disease
,	O
their	O
pathoegnesis	O
is	O
still	O
unclear	O
.	O

In	O
recent	O
yeras	O
,	O
evdience	O
from	O
anmial	O
moedls	O
of	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
has	O
provided	O
important	O
inofrmation	O
to	O
understand	O
the	O
effect	O
of	O
specific	O
recetpor	O
and	O
psot	O
-	O
recpetor	O
mloecular	O
mechansims	O
underlying	O
the	O
develompent	O
of	O
dysknietic	B-Disease
movemetns	I-Disease
.	O

Recent	O
perclinical	O
and	O
cliincal	O
dtaa	O
from	O
promising	O
lnies	O
of	O
rseearch	O
focus	O
on	O
the	O
dfiferential	O
role	O
of	O
persynaptic	O
versus	O
postsynatpic	O
mechainsms	O
,	O
dopaimne	O
recepotr	O
sbutypes	O
,	O
inootropic	O
and	O
metaobtropic	O
gultamate	O
recetpors	O
,	O
and	O
non	O
-	O
dopmainergic	O
nuerotransmitter	O
sysetms	O
in	O
the	O
pathophyisology	O
of	O
lveodopa	O
-	O
inudced	O
dyskniesias	B-Disease
.	O

Effcets	O
of	O
plalidal	O
neurotesnin	O
on	O
haolperidol	O
-	O
indcued	O
prakinsonian	B-Disease
catalespy	I-Disease
:	O
behavoiral	O
and	O
electrohpysiological	O
studeis	O
.	O

OJBECTIVE	O
:	O
The	O
glbous	O
plalidus	O
plays	O
a	O
critical	O
role	O
in	O
mvoement	O
reuglation	O
.	O

Previous	O
sutdies	O
have	O
indicated	O
that	O
the	O
glbous	O
palldius	O
receives	O
neurotensinregic	O
innervatoin	O
from	O
the	O
srtiatum	O
,	O
and	O
sysetmic	O
admiinstration	O
of	O
a	O
neurotenisn	O
aanlog	O
could	O
produce	O
antiparkinsonain	O
effects	O
.	O

The	O
present	O
stduy	O
aimed	O
to	O
invsetigate	O
the	O
effcets	O
of	O
pallidal	O
neurotenisn	O
on	O
haloperiodl	O
-	O
induecd	O
parkinosnian	B-Disease
symtpoms	I-Disease
.	O

METHODS	O
:	O
Behavioarl	O
exepriments	O
and	O
electrophysioloigcal	O
recrodings	O
were	O
performed	O
in	O
the	O
present	O
sutdy	O
.	O

RESUTLS	O
:	O
Bilatearl	O
infuisons	O
of	O
neurotesnin	O
into	O
the	O
glbous	O
palldius	O
reevrsed	O
haloperiodl	O
-	O
indcued	O
pariknsonian	B-Disease
cataelpsy	I-Disease
in	O
rtas	O
.	O

Electrophysiloogical	O
recoridngs	O
showed	O
that	O
microinjectoin	O
of	O
neuortensin	O
induecd	O
excitatoin	O
of	O
palliadl	O
neurnos	O
in	O
the	O
persence	O
of	O
sytsemic	O
haloepridol	O
adimnistration	O
.	O

The	O
neuroetnsin	O
tpye	O
-	O
1	O
rceeptor	O
antagoinst	O
SR84692	O
bolcked	O
both	O
the	O
behavoiral	O
and	O
the	O
electrpohysiological	O
effetcs	O
induecd	O
by	O
neruotensin	O
.	O

CONCULSION	O
:	O
Activatoin	O
of	O
plalidal	O
neuortensin	O
recetpors	O
may	O
be	O
involved	O
in	O
neurotesnin	O
-	O
inudced	O
antpiarkinsonian	O
effetcs	O
.	O

Carmoufr	O
-	O
induecd	O
orgainc	B-Disease
menatl	I-Disease
disodrers	I-Disease
.	O

Orgainc	B-Disease
mnetal	I-Disease
disoredr	I-Disease
was	O
observed	O
in	O
a	O
29	O
-	O
yaer	O
-	O
old	O
feamle	O
in	O
the	O
prgonostic	O
peirod	O
after	O
the	O
onset	O
of	O
carmfour	O
-	O
inudced	O
leukoencephaloapthy	B-Disease
.	O

Symptmos	O
such	O
as	O
euphroia	O
,	O
emotinoal	O
labiltiy	O
and	O
puerlie	O
atttiude	O
noted	O
in	O
the	O
patinet	O
were	O
daignosed	O
as	O
oragnic	B-Disease
persnoality	I-Disease
syndrmoe	I-Disease
according	O
to	O
the	O
crtieria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R	O
.	O

It	O
is	O
referred	O
to	O
as	O
a	O
frotnal	B-Disease
lboe	I-Disease
snydrome	I-Disease
.	O

Barin	O
CT	O
reevaled	O
a	O
periventriuclar	O
low	O
dnesity	O
aera	O
in	O
the	O
frotnal	O
whtie	O
matter	O
and	O
modreate	O
dialtation	O
of	O
the	O
ltaeral	O
ventricels	O
especially	O
at	O
the	O
bliateral	O
anteroir	O
hrons	O
.	O

Consequently	O
,	O
carmfour	O
-	O
indcued	O
leukoencpehalopathy	B-Disease
may	O
uncommonly	O
result	O
in	O
oragnic	B-Disease
persnoality	I-Disease
synrdome	I-Disease
in	O
the	O
residaul	O
state	O
.	O

It	O
may	O
be	O
attributed	O
to	O
the	O
sturctural	B-Disease
damgae	I-Disease
to	I-Disease
the	I-Disease
forntal	I-Disease
lboe	I-Disease
.	O

Butyrlycholinesterase	O
gnee	O
muttaions	O
in	O
pateints	O
with	O
porlonged	O
anpea	B-Disease
after	O
succinylcohline	O
for	O
eelctroconvulsive	O
tehrapy	O
.	O

BACKGORUND	O
:	O
paitents	O
undergoing	O
electroconvlusive	O
tehrapy	O
(	O
ECT	O
)	O
often	O
receive	O
sucicnylcholine	O
as	O
part	O
of	O
the	O
anesthteic	O
procdeure	O
.	O

The	O
druation	O
of	O
aciton	O
may	O
be	O
porlonged	O
in	O
ptaients	O
with	O
gneetic	O
vraiants	O
of	O
the	O
butyrylcholinestersae	O
enzmye	O
(	O
BhCE	O
)	O
,	O
the	O
most	O
common	O
being	O
the	O
K	O
-	O
and	O
the	O
A	O
-	O
vraiants	O
.	O

The	O
aim	O
of	O
the	O
sutdy	O
was	O
to	O
assess	O
the	O
clniical	O
signiifcance	O
of	O
geentic	O
vairants	O
in	O
butyrylhcolinesterase	O
gnee	O
(	O
BHCE	O
)	O
in	O
ptaients	O
with	O
a	O
ssupected	O
prologned	O
druation	O
of	O
aciton	O
of	O
succinlycholine	O
after	O
ECT	O
.	O

METHODS	O
:	O
a	O
total	O
of	O
13	O
paitents	O
were	O
referred	O
to	O
the	O
Dainsh	O
Cohlinesterase	O
Reseacrh	O
Uint	O
after	O
ECT	O
during	O
38	O
monhts	O
.	O

We	O
determined	O
the	O
BhCE	O
atcivity	O
and	O
the	O
BHCE	O
gneotype	O
using	O
molecualr	O
gneetic	O
mehtods	O
,	O
the	O
durtaion	O
of	O
apena	B-Disease
,	O
tmie	O
to	O
sufficient	O
spontaenous	O
ventialtion	O
and	O
whether	O
neuromucsular	O
monitroing	O
was	O
used	O
.	O

The	O
druation	O
of	O
apena	B-Disease
was	O
cmopared	O
with	O
publihsed	O
dtaa	O
on	O
noraml	O
subjetcs	O
.	O

RSEULTS	O
:	O
in	O
11	O
pateints	O
,	O
muattions	O
were	O
found	O
in	O
the	O
BHCE	O
gnee	O
,	O
the	O
K	O
-	O
vairant	O
being	O
the	O
most	O
frequnet	O
.	O

The	O
duraiton	O
of	O
anpea	B-Disease
was	O
5	O
-	O
15	O
min	O
compaerd	O
with	O
3	O
-	O
5	O
.	O
3	O
min	O
from	O
the	O
literatrue	O
.	O

Sveere	O
disterss	O
was	O
noted	O
in	O
the	O
recoevry	O
phsae	O
in	O
two	O
patinets	O
.	O

Neurmouscular	O
montioring	O
was	O
used	O
in	O
two	O
paitents	O
.	O

CONCLUSOIN	O
:	O
eleven	O
of	O
13	O
patietns	O
with	O
a	O
prloonged	O
druation	O
of	O
actoin	O
of	O
scucinylcholine	O
had	O
mtuations	O
in	O
BHCE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
proolnged	O
peroid	O
of	O
anpea	B-Disease
.	O

We	O
recommend	O
objcetive	O
neuormuscular	O
monitroing	O
during	O
the	O
first	O
ECT	O
.	O

Perehxiline	O
mlaeate	O
and	O
perpiheral	B-Disease
neuorpathy	I-Disease
.	O

Preipheral	B-Disease
nueropathy	I-Disease
has	O
been	O
noted	O
as	O
a	O
cmoplication	O
of	O
threapy	O
with	O
perehxiline	O
maelate	O
,	O
a	O
durg	O
widely	O
used	O
in	O
Farnce	O
(	O
and	O
in	O
clincial	O
trilas	O
in	O
the	O
Untied	O
Sattes	O
)	O
for	O
the	O
prpohylactic	O
teratment	O
of	O
angnia	B-Disease
pectrois	I-Disease
.	O

In	O
24	O
patietns	O
with	O
this	O
complicaiton	O
,	O
the	O
marked	O
sloiwng	O
of	O
mootr	O
nreve	O
conductoin	O
veloicty	O
and	O
the	O
eletcromyographic	O
chnages	O
imply	O
mainly	O
a	O
demyelniating	B-Disease
disodrer	I-Disease
.	O

Ipmrovement	O
was	O
noted	O
with	O
csesation	O
of	O
threapy	O
.	O

In	O
a	O
few	O
csaes	O
the	O
presecne	O
of	O
atcive	O
denervatoin	O
signified	O
a	O
poor	O
porgnosis	O
,	O
with	O
only	O
slight	O
improvmeent	O
.	O

The	O
underlying	O
mechainsm	O
causing	O
the	O
neuroapthy	B-Disease
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evdience	O
indicates	O
that	O
it	O
may	O
be	O
a	O
lpiid	O
stroage	O
proecss	O
.	O

A	O
pahse	O
I	O
sutdy	O
of	O
4	O
'	O
-	O
0	O
-	O
tetrahydropyarnyladriamycin	O
.	O

Cilnical	O
pharmacolgoy	O
and	O
pharmacokientics	O
.	O

A	O
Phsae	O
I	O
sutdy	O
of	O
itnravenous	O
(	O
IV	O
)	O
blous	O
4	O
'	O
-	O
0	O
-	O
tetrahydorpyranyladriamycin	O
(	O
Pirarbuicin	O
)	O
was	O
done	O
in	O
55	O
patietns	O
in	O
good	O
perfromance	O
sattus	O
with	O
rerfactory	O
tmuors	B-Disease
.	O

Twenty	O
-	O
six	O
had	O
mniimal	O
prior	O
tehrapy	O
(	O
good	O
rsik	O
)	O
,	O
23	O
had	O
extensvie	O
prior	O
tehrapy	O
(	O
poor	O
rsik	O
)	O
,	O
and	O
six	O
had	O
reanl	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
heaptic	I-Disease
dysfucntion	I-Disease
.	O

A	O
total	O
of	O
167	O
couress	O
at	O
dsoes	O
of	O
15	O
to	O
70	O
mg	O
/	O
m2	O
were	O
evalauble	O
.	O

Maxmium	O
toleraetd	O
dsoe	O
in	O
good	O
-	O
rsik	O
pateints	O
was	O
70	O
mg	O
/	O
m2	O
,	O
and	O
in	O
poor	O
-	O
rsik	O
paitents	O
,	O
60	O
mg	O
/	O
m2	O
.	O

The	O
dsoe	O
-	O
limiting	O
toixc	O
efefct	O
was	O
trasnient	O
nonucmulative	O
granuloyctopenia	B-Disease
.	O

Granuloycte	O
ndair	O
was	O
on	O
day	O
14	O
(	O
range	O
,	O
4	O
-	O
22	O
)	O
.	O

Less	O
frequnet	O
toixc	O
efefcts	O
included	O
thormbocytopenia	B-Disease
,	O
aenmia	B-Disease
,	O
nasuea	B-Disease
,	O
mlid	O
alopeica	B-Disease
,	O
phlebiits	B-Disease
,	O
and	O
mucsoitis	B-Disease
.	O

Myelosuprpession	B-Disease
was	O
more	O
in	O
pateints	O
with	O
heaptic	B-Disease
dyfsunction	I-Disease
.	O

Pharmaockinetic	O
aanlyses	O
in	O
21	O
patinets	O
reveaeld	O
Piarrubicin	O
palsma	O
T	O
1	O
/	O
2	O
alhpa	O
(	O
+	O
/	O
-	O
SE	O
)	O
of	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
85	O
minuets	O
,	O
T	O
btea	O
1	O
/	O
2	O
of	O
25	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
5	O
mintues	O
,	O
and	O
T	O
1	O
/	O
2	O
gamma	O
of	O
23	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
6	O
hours	O
.	O

The	O
aera	O
under	O
the	O
cruve	O
was	O
537	O
+	O
/	O
-	O
149	O
ng	O
/	O
ml	O
x	O
hours	O
,	O
voulme	O
of	O
distributoin	O
(	O
Vd	O
)	O
3504	O
+	O
/	O
-	O
644	O
l	O
/	O
m2	O
,	O
and	O
total	O
claerance	O
(	O
ClT	O
)	O
was	O
204	O
+	O
39	O
.	O
3	O
l	O
/	O
hour	O
/	O
m2	O
.	O

Adiramycinol	O
,	O
doxoruibcin	O
,	O
adriamycionne	O
,	O
and	O
tetrahydropyranyladriamyicnol	O
were	O
the	O
metabolties	O
detecetd	O
in	O
plsama	O
and	O
the	O
aomunt	O
of	O
doxroubicin	O
was	O
less	O
than	O
or	O
eqaul	O
to	O
10	O
%	O
of	O
the	O
total	O
meatbolites	O
.	O

Uirnary	O
excretoin	O
of	O
Pirraubicin	O
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
eqaul	O
to	O
10	O
%	O
.	O

Acitvity	O
was	O
noted	O
in	O
mesothelimoa	B-Disease
,	O
leimoyosarcoma	B-Disease
,	O
and	O
baasl	B-Disease
clel	I-Disease
carcionma	I-Disease
.	O

The	O
reocmmended	O
starting	O
dsoe	O
for	O
Phsae	O
II	O
tirals	O
is	O
60	O
mg	O
/	O
m2	O
IV	O
bouls	O
every	O
3	O
weeks	O
.	O

Ocualr	B-Disease
and	I-Disease
audiotry	I-Disease
toixcity	I-Disease
in	O
heomdialyzed	O
ptaients	O
receiving	O
desferrioxmaine	O
.	O

During	O
an	O
18	O
-	O
motnh	O
peroid	O
of	O
sutdy	O
41	O
heomdialyzed	O
ptaients	O
receiving	O
dseferrioxamine	O
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW	O
/	O
3	O
times	O
wekely	O
)	O
for	O
the	O
first	O
tmie	O
were	O
monitoerd	O
for	O
detectoin	O
of	O
auidovisual	B-Disease
toxciity	I-Disease
.	O

6	O
pateints	O
presented	O
cliincal	O
sympotms	O
of	O
visaul	B-Disease
or	I-Disease
auidtory	I-Disease
toxciity	I-Disease
.	O

Moreover	O
,	O
detailed	O
ohpthalmologic	O
and	O
audiolgoic	O
sutdies	O
disclosed	O
abnomralities	O
in	O
7	O
more	O
asymptoamtic	O
ptaients	O
.	O

Viusal	B-Disease
txoicity	I-Disease
was	O
of	O
retianl	O
orgiin	O
and	O
was	O
charatcerized	O
by	O
a	O
tirtan	O
-	O
tpye	O
dyschroamtopsy	B-Disease
,	O
sometimes	O
associated	O
with	O
a	B-Disease
lsos	I-Disease
of	I-Disease
visaul	I-Disease
acutiy	I-Disease
and	O
pigemntary	B-Disease
retnial	I-Disease
depoists	I-Disease
.	O

Audiotry	B-Disease
toixcity	I-Disease
was	O
characetrized	O
by	O
a	O
mid	O
-	O
to	O
high	O
-	O
frqeuency	O
neurosesnorial	B-Disease
heairng	I-Disease
lsos	I-Disease
and	O
the	O
lesoin	O
was	O
of	O
the	O
cochelar	O
tpye	O
.	O

Desferiroxamine	O
withdraawl	O
resulted	O
in	O
a	O
complete	O
rceovery	O
of	O
viusal	O
functoin	O
in	O
1	O
patinet	O
and	O
patrial	O
recovrey	O
in	O
3	O
,	O
and	O
a	O
complete	O
rveersal	O
of	O
haering	B-Disease
lsos	I-Disease
in	O
3	O
pateints	O
and	O
patrial	O
reocvery	O
in	O
3	O
.	O

This	O
toxictiy	B-Disease
appeared	O
in	O
ptaients	O
receiving	O
the	O
hihger	O
doess	O
of	O
desferrioxamine	O
or	O
coincided	O
with	O
the	O
normaliztaion	O
of	O
freritin	O
or	O
alumiinum	O
sreum	O
leevls	O
.	O

The	O
dtaa	O
indicate	O
that	O
audioivsual	B-Disease
toxictiy	I-Disease
is	O
not	O
an	O
infrqeuent	O
complciation	O
in	O
hemodialyezd	O
patinets	O
receiving	O
defserrioxamine	O
.	O

Peridoical	O
audiovsiual	O
monitoirng	O
should	O
be	O
performed	O
on	O
hemodiaylzed	O
pateints	O
receiving	O
the	O
durg	O
in	O
order	O
to	O
deetct	O
adevrse	O
efefcts	O
as	O
ealry	O
as	O
possible	O
.	O

Sreial	O
epliepsy	B-Disease
caused	O
by	O
levdoopa	O
/	O
caribdopa	O
adminisrtation	O
in	O
two	O
paitents	O
on	O
hemodiaylsis	O
.	O

Two	O
pateints	O
with	O
similar	O
clincial	O
faetures	O
are	O
presented	O
:	O
both	O
patietns	O
had	O
crhonic	B-Disease
rneal	I-Disease
failrue	I-Disease
,	O
on	O
hmeodialysis	O
for	O
many	O
yeras	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
fulx	O
dialzyer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
caribdopa	O
/	O
leovdopa	O
preparatoin	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hlalucinosis	B-Disease
and	O
reucrrent	O
seizrues	B-Disease
,	O
which	O
were	O
refrcatory	O
to	O
anticonvulasnts	O
.	O

The	O
first	O
ptaient	O
deid	O
without	O
a	O
daignosis	O
;	O
the	O
second	O
paitent	O
had	O
a	O
darmatic	O
recoevry	O
following	O
the	O
administratoin	O
of	O
vitaimn	O
B6	O
.	O

Neither	O
patinet	O
was	O
considered	O
to	O
have	O
a	O
reanl	O
state	O
sufficiently	O
seevre	O
enough	O
to	O
explain	O
their	O
presenattion	O
.	O

Radnomized	O
,	O
double	O
-	O
blnid	O
tiral	O
of	O
mazinodl	O
in	O
Ducehnne	B-Disease
dystorphy	I-Disease
.	O

There	O
is	O
evidecne	O
that	O
grotwh	O
homrone	O
may	O
be	O
related	O
to	O
the	O
prorgession	O
of	O
weakenss	B-Disease
in	O
Duchenne	B-Disease
dysrtophy	I-Disease
.	O

We	O
conducted	O
a	O
12	O
-	O
motnh	O
controleld	O
tiral	O
of	O
mazidnol	O
,	O
a	O
putative	O
grotwh	O
homrone	O
secreiton	O
inhbiitor	O
,	O
in	O
83	O
byos	O
with	O
Ducehnne	B-Disease
dystrohpy	I-Disease
.	O

Muslce	O
strnegth	O
,	O
cotnractures	O
,	O
functioanl	O
ability	O
and	O
pumlonary	O
funtcion	O
were	O
tseted	O
at	O
baesline	O
,	O
and	O
6	O
and	O
12	O
monhts	O
after	O
treatmnet	O
with	O
maizndol	O
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
palcebo	O
.	O

The	O
sutdy	O
was	O
designed	O
to	O
have	O
a	O
pwoer	O
of	O
greater	O
than	O
0	O
.	O
90	O
to	O
deetct	O
a	O
slwoing	O
to	O
25	O
%	O
of	O
the	O
expected	O
rtae	O
of	O
prgoression	O
of	O
wekaness	B-Disease
at	O
P	O
less	O
than	O
0	O
.	O
05	O
.	O

Mzaindol	O
did	O
not	O
beenfit	O
strentgh	O
at	O
any	O
point	O
in	O
the	O
stduy	O
.	O

Side	O
effects	O
attributable	O
to	O
mzaindol	O
included	O
decreaesd	B-Disease
apeptite	I-Disease
(	O
36	O
%	O
)	O
,	O
dry	B-Disease
motuh	I-Disease
(	O
10	O
%	O
)	O
,	O
behaviroal	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gastriontestinal	B-Disease
symtpoms	I-Disease
(	O
18	O
%	O
)	O
;	O
maznidol	O
doasge	O
was	O
redcued	O
in	O
43	O
%	O
of	O
ptaients	O
.	O

The	O
efefct	O
of	O
mazidnol	O
on	O
GH	O
sceretion	O
was	O
estimaetd	O
indierctly	O
by	O
copmaring	O
the	O
postabosrptive	O
IGF	O
-	O
I	O
levles	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
motnhs	O
in	O
the	O
maznidol	O
traeted	O
to	O
those	O
in	O
the	O
plcaebo	O
gropus	O
.	O

Although	O
mzaindol	O
-	O
terated	O
patietns	O
gained	O
less	O
wieght	O
and	O
hegiht	O
than	O
plcaebo	O
-	O
tretaed	O
ptaients	O
,	O
no	O
significant	O
efefct	O
on	O
IGF	O
-	O
I	O
lveels	O
was	O
observed	O
.	O

Maizndol	O
doess	O
not	O
slow	O
the	O
progerssion	O
of	O
wekaness	B-Disease
in	O
Ducehnne	B-Disease
dystrpohy	I-Disease
.	O

Facliitation	O
of	O
meomry	O
retrieavl	O
by	O
pre	O
-	O
tset	O
morhpine	O
and	O
its	O
state	O
depednency	O
in	O
the	O
step	O
-	O
through	O
tpye	O
passvie	O
avodiance	O
leanring	O
tset	O
in	O
mcie	O
.	O

Amnseia	B-Disease
produced	O
by	O
scopolmaine	O
and	O
cyclohexmiide	O
were	O
reveresd	O
by	O
morphnie	O
given	O
30	O
min	O
before	O
the	O
tset	O
tiral	O
(	O
pre	O
-	O
tset	O
)	O
,	O
and	O
pre	O
-	O
tset	O
morphnie	O
also	O
facilitated	O
the	O
memroy	O
retireval	O
in	O
the	O
animlas	O
administreed	O
naloxnoe	O
during	O
the	O
trianing	O
trail	O
.	O

Similarly	O
,	O
pre	O
-	O
tset	O
socpolamine	O
patrially	O
rveersed	O
the	O
scpoolamine	O
-	O
induecd	O
amensia	B-Disease
,	O
but	O
not	O
significantly	O
;	O
and	O
pre	O
-	O
tset	O
cyclohexiimde	O
failed	O
to	O
reevrse	O
the	O
cycloheximdie	O
-	O
inudced	O
amneisa	B-Disease
.	O

These	O
rseults	O
suggest	O
that	O
the	O
fcailitation	O
of	O
mmeory	O
rterieval	O
by	O
pre	O
-	O
tset	O
moprhine	O
might	O
be	O
the	O
direct	O
atcion	O
of	O
moprhine	O
rather	O
than	O
a	O
state	O
deepndent	O
effcet	O
.	O

Nalxoone	O
revesres	O
the	O
antihyperetnsive	O
effcet	O
of	O
clonidnie	O
.	O

In	O
unnaesthetized	O
,	O
spotnaneously	O
hyperetnsive	B-Disease
rtas	O
the	O
decresae	O
in	O
bolod	O
perssure	O
and	O
haert	O
rtae	O
produced	O
by	O
intravneous	O
colnidine	O
,	O
5	O
to	O
20	O
micrgorams	O
/	O
kg	O
,	O
was	O
inhibietd	O
or	O
revresed	O
by	O
nalzoone	O
,	O
0	O
.	O
2	O
to	O
2	O
mg	O
/	O
kg	O
.	O

The	O
hypotenisve	B-Disease
efefct	O
of	O
100	O
mg	O
/	O
kg	O
alhpa	O
-	O
methlydopa	O
was	O
also	O
patrially	O
rveersed	O
by	O
naloxnoe	O
.	O

Naolxone	O
alone	O
did	O
not	O
affect	O
either	O
bolod	O
pressure	O
or	O
herat	O
rtae	O
.	O

In	O
barin	O
memrbanes	O
from	O
spontanoeusly	O
hypertesnive	B-Disease
rtas	O
cloniidne	O
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
did	O
not	O
influecne	O
stereoselecitve	O
bindnig	O
of	O
[	O
3H	O
]	O
-	O
naolxone	O
(	O
8	O
nM	O
)	O
,	O
and	O
naloxnoe	O
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
,	O
did	O
not	O
infulence	O
cloindine	O
-	O
suprpessible	O
bidning	O
of	O
[	O
3H	O
]	O
-	O
dihydroregocryptine	O
(	O
1	O
nM	O
)	O
.	O

These	O
fidnings	O
indicate	O
that	O
in	O
spontaneuosly	O
hypertnesive	B-Disease
rtas	O
the	O
effetcs	O
of	O
cnetral	O
alhpa	O
-	O
adreonceptor	O
sitmulation	O
involve	O
activaiton	O
of	O
oipate	O
receptros	O
.	O

As	O
naolxone	O
and	O
cloindine	O
do	O
not	O
appear	O
to	O
intreact	O
with	O
the	O
same	O
recepotr	O
stie	O
,	O
the	O
observed	O
functinoal	O
antgaonism	O
suggests	O
the	O
reelase	O
of	O
an	O
endgoenous	O
opaite	O
by	O
colnidine	O
or	O
alhpa	O
-	O
methydlopa	O
and	O
the	O
possible	O
role	O
of	O
the	O
opaite	O
in	O
the	O
cenrtal	O
cotnrol	O
of	O
sympahtetic	O
tnoe	O
.	O

Neuortoxicity	B-Disease
of	O
halogneated	O
hydroxyquniolines	O
:	O
cliniacl	O
aanlysis	O
of	O
csaes	O
reported	O
outside	O
Jaapn	O
.	O

An	O
analsyis	O
is	O
presented	O
of	O
220	O
caess	O
of	O
possible	O
neuortoxic	B-Disease
raections	O
to	O
halogentaed	O
hydroxyquinolnies	O
reported	O
from	O
outside	O
Jaapn	O
.	O

In	O
80	O
csaes	O
insfuficient	O
informtaion	O
was	O
available	O
for	O
adeqaute	O
commnet	O
and	O
in	O
29	O
a	O
relatinoship	O
to	O
the	O
admniistration	O
of	O
cloiquinol	O
could	O
be	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
a	O
realtionship	O
to	O
cloiquinol	O
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
caess	O
.	O

In	O
six	O
of	O
the	O
probable	O
caess	O
the	O
neuroloigcal	B-Disease
ditsurbance	I-Disease
consisted	O
of	O
an	O
aucte	O
reversible	O
enecphalopathy	B-Disease
usually	O
related	O
to	O
the	O
ingsetion	O
of	O
a	O
high	O
dsoe	O
of	O
ciloquinol	O
over	O
a	O
short	O
preiod	O
.	O

The	O
most	O
common	O
mainfestation	O
,	O
observed	O
in	O
15	O
further	O
caess	O
,	O
was	O
isoalted	O
otpic	B-Disease
atrohpy	I-Disease
.	O

This	O
was	O
most	O
frequently	O
found	O
in	O
chidlren	O
,	O
many	O
of	O
whom	O
had	O
received	O
cloiquinol	O
as	O
teratment	O
for	O
acrodermtaitis	B-Disease
enteroapthica	I-Disease
.	O

In	O
the	O
remaining	O
csaes	O
,	O
a	O
combniation	O
of	O
myeloptahy	B-Disease
,	O
visaul	B-Disease
distrubance	I-Disease
,	O
and	O
peirpheral	B-Disease
neuorpathy	I-Disease
was	O
the	O
most	O
common	O
manfiestation	O
.	O

Isolaetd	O
myeloapthy	B-Disease
or	O
peripehral	B-Disease
neuroapthy	I-Disease
,	O
or	O
these	O
manifetsations	O
occurring	O
together	O
,	O
were	O
infrequnet	O
.	O

The	O
onset	O
of	O
all	O
maniefstations	O
(	O
except	O
toixc	O
encepahlopathy	B-Disease
)	O
was	O
usually	O
subaucte	O
,	O
with	O
subsequent	O
pratial	O
recvoery	O
.	O

Oledr	O
subjetcs	O
tended	O
to	O
display	O
more	O
side	O
effects	O
.	O

The	O
full	O
syndrmoe	O
of	O
sbuacute	O
myleo	B-Disease
-	I-Disease
opitc	I-Disease
neruopathy	I-Disease
was	O
more	O
frqeuent	O
in	O
woemn	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quanttiies	O
of	O
the	O
durg	O
.	O

Praozsin	O
-	O
inudced	O
strses	B-Disease
inconitnence	I-Disease
.	O

A	O
csae	O
of	O
genuine	O
sterss	B-Disease
incnotinence	I-Disease
due	O
to	O
przaosin	O
,	O
a	O
common	O
anithypertensive	O
durg	O
,	O
is	O
presented	O
.	O

Parzosin	O
exerts	O
its	O
antihypetrensive	O
effects	O
through	O
vsaodilatation	O
caused	O
by	O
selective	O
blokcade	O
of	O
postsynatpic	O
aplha	O
-	O
1	O
adrenegric	O
recepotrs	O
.	O

As	O
an	O
aplha	O
-	O
blocekr	O
,	O
it	O
also	O
exerts	O
a	O
significant	O
relaxnat	O
effcet	O
on	O
the	O
bladedr	O
ncek	O
and	O
urtehra	O
.	O

The	O
patinet	O
'	O
s	O
cilnical	O
cousre	O
is	O
described	O
and	O
correlaetd	O
with	O
initial	O
uroydnamic	O
stduies	O
while	O
on	O
prazoisn	O
and	O
subsequent	O
studeis	O
while	O
taking	O
verpaamil	O
.	O

Her	O
incnotinence	B-Disease
resolved	O
with	O
the	O
change	O
of	O
medciation	O
.	O

The	O
restroation	O
of	O
conitnence	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
mxaimum	O
uretharl	O
pressure	O
,	O
maixmum	O
urehtral	O
clsoure	O
perssure	O
,	O
and	O
functoinal	O
urehtral	O
legnth	O
.	O

Patinets	O
who	O
present	O
with	O
sterss	B-Disease
incontinecne	I-Disease
while	O
taking	O
parzosin	O
should	O
change	O
their	O
antihyperetnsive	O
mdeication	O
before	O
considering	O
sugrery	O
,	O
because	O
their	O
incnotinence	B-Disease
may	O
resolve	O
sponatneously	O
with	O
a	O
change	O
in	O
durg	O
thearpy	O
.	O

Myoacrdial	B-Disease
inafrction	I-Disease
following	O
sublingaul	O
amdinistration	O
of	O
isosoribde	O
dniitrate	O
.	O

A	O
78	O
-	O
yaer	O
-	O
old	O
with	O
helaed	O
setpal	O
necrsois	B-Disease
suffered	O
a	O
recrurent	O
myocardail	B-Disease
infacrtion	I-Disease
of	O
the	O
anetrior	O
wlal	O
following	O
the	O
admniistration	O
of	O
isosorbdie	O
dinirtate	O
5	O
mg	O
sbulingually	O
.	O

After	O
detailing	O
the	O
cuorse	O
of	O
evetns	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paraodxical	O
cornoary	O
spsam	B-Disease
and	O
hypoetnsion	B-Disease
-	O
mediated	O
myoacrdial	B-Disease
icshemia	I-Disease
occurring	O
dowsntream	O
to	O
significant	O
coronray	B-Disease
artreial	I-Disease
stenoiss	I-Disease
in	O
the	O
pathohpysiology	O
of	O
aucte	B-Disease
croonary	I-Disease
inusfficiency	I-Disease
.	O

Compraison	O
of	O
the	O
respirtaory	O
efefcts	O
of	O
i	O
.	O
v	O
.	O
ifnusions	O
of	O
moprhine	O
and	O
reigonal	O
analegsia	O
by	O
extraudral	O
blcok	O
.	O

The	O
icnidence	O
of	O
postoperaitve	O
resipratory	O
aponea	B-Disease
was	O
compaerd	O
between	O
five	O
paitents	O
receiving	O
a	O
continouus	O
i	O
.	O
v	O
.	O
inufsion	O
of	O
moprhine	O
(	O
mean	O
73	O
.	O
6	O
mg	O
)	O
and	O
five	O
pateints	O
receiving	O
a	O
cnotinuous	O
extradrual	O
infsuion	O
of	O
0	O
.	O
25	O
%	O
bupiavcaine	O
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
peirod	O
following	O
upepr	O
abodminal	O
srugery	O
.	O

Monitroing	O
consisted	O
of	O
aifrlow	O
deetction	O
by	O
a	O
crabon	O
dixoide	O
aanlyser	O
,	O
cehst	O
wlal	O
movmeent	O
deetcted	O
by	O
pneuamtic	O
capusles	O
,	O
and	O
contniuous	O
electroacrdiograph	O
recorded	O
with	O
a	O
Holetr	O
amublatory	O
monitor	O
.	O

Both	O
obsrtuctive	B-Disease
(	I-Disease
P	I-Disease
less	I-Disease
than	I-Disease
0	I-Disease
.	I-Disease
05	I-Disease
)	I-Disease
and	I-Disease
cenrtal	I-Disease
aponea	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
occurred	O
more	O
frequently	O
in	O
patietns	O
who	O
had	O
a	O
morphnie	O
infuison	O
.	O

There	O
was	O
also	O
a	O
higehr	O
inicdence	O
of	O
tachyarrhythmias	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
ventrciular	B-Disease
ecotpic	I-Disease
baets	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
morpihne	O
infuison	O
gruop	O
.	O

Effetcs	O
of	O
amionphylline	O
on	O
the	O
thrsehold	O
for	O
initiating	O
vnetricular	B-Disease
fibrlilation	I-Disease
during	O
respiratroy	B-Disease
fialure	I-Disease
.	O

Cardaic	B-Disease
arhrythmias	I-Disease
have	O
frequently	O
been	O
reported	O
in	O
asosciation	O
with	O
respriatory	B-Disease
fialure	I-Disease
.	O

The	O
possible	O
addtiive	O
role	O
of	O
phramacologic	O
agetns	O
in	O
precipitaitng	O
cradiac	B-Disease
disturabnces	I-Disease
in	O
ptaients	O
with	O
resipratory	B-Disease
fialure	I-Disease
has	O
only	O
recently	O
been	O
emphasized	O
.	O

The	O
effetcs	O
of	O
aminopyhlline	O
on	O
the	O
vnetricular	B-Disease
fbirillation	I-Disease
trheshold	O
during	O
nromal	O
aicd	O
-	O
base	O
codnitions	O
and	O
during	O
rsepiratory	B-Disease
faiulre	I-Disease
were	O
studied	O
in	O
anetshetized	O
open	O
cehst	O
dgos	O
.	O

The	O
vetnricular	B-Disease
fibrlilation	I-Disease
thrsehold	O
was	O
mesaured	O
by	O
passing	O
a	O
gaetd	O
trian	O
of	O
12	O
contsant	O
current	O
pluses	O
through	O
the	O
ventricluar	O
mycoardium	O
during	O
the	O
vulneralbe	O
peirod	O
of	O
the	O
caridac	O
cylce	O
.	O

During	O
the	O
infuison	O
of	O
aminophylilne	O
,	O
the	O
ventricualr	B-Disease
fibrillation	I-Disease
trheshold	O
was	O
redcued	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
conrtol	O
when	O
pH	O
and	O
pratial	O
pressures	O
of	O
oxyegn	O
(	O
PO2	O
)	O
and	O
cabron	O
dixoide	O
(	O
CO2	O
)	O
were	O
kept	O
within	O
noraml	O
liimts	O
.	O

When	O
respiraotry	B-Disease
fialure	I-Disease
was	O
produced	O
by	O
hypovnetilation	B-Disease
(	O
pH	O
7	O
.	O
05	O
to	O
7	O
.	O
25	O
;	O
P0C2	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
infsuion	O
of	O
aimnophylline	O
resulted	O
in	O
an	O
even	O
greater	O
dercease	O
in	O
venrticular	B-Disease
fibirllation	I-Disease
trheshold	O
to	O
60	O
percent	O
of	O
the	O
cotnrol	O
lveel	O
.	O

These	O
experimetns	O
suggest	O
that	O
although	O
many	O
fcators	O
may	O
contribute	O
to	O
the	O
inrceased	O
inciednce	O
of	O
vetnricular	B-Disease
arrhythimas	I-Disease
in	O
respiratroy	B-Disease
faiulre	I-Disease
,	O
pharmcaologic	O
aegnts	O
,	O
particularly	O
aminopyhlline	O
,	O
may	O
play	O
a	O
significant	O
role	O
.	O

Pentoxifylilne	O
(	O
Trnetal	O
)	O
does	O
not	O
inhiibt	O
dipyridaomle	O
-	O
idnuced	O
coornary	O
hypermeia	B-Disease
:	O
implications	O
for	O
dipyridamloe	O
-	O
thalilum	O
-	O
201	O
myocadrial	O
imagnig	O
.	O

Dipyriadmole	O
-	O
thallium	O
-	O
201	O
imgaing	O
is	O
often	O
performed	O
in	O
pateints	O
unable	O
to	O
eexrcise	O
because	O
of	O
peripehral	B-Disease
vascualr	I-Disease
disesae	I-Disease
.	O

Many	O
of	O
these	O
pateints	O
are	O
taking	O
pentoxiflyline	O
(	O
Trnetal	O
)	O
,	O
a	O
methylxanthnie	O
derivtaive	O
which	O
may	O
imprvoe	O
intremittent	B-Disease
claudciation	I-Disease
.	O

Whether	O
pentxoifylline	O
inhibtis	O
dipryidamole	O
-	O
inudced	O
croonary	O
hyepremia	B-Disease
like	O
other	O
methylxatnhines	O
such	O
as	O
theohpylline	O
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipryidamole	O
-	O
thalluim	O
-	O
201	O
imaigng	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
hypreemic	O
rseponse	O
to	O
dipryidamole	O
in	O
seven	O
open	O
-	O
chset	O
aensthetized	O
dgos	O
after	O
pretretament	O
with	O
either	O
pentoxiyflline	O
(	O
0	O
,	O
7	O
.	O
5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
or	O
theophylline	O
(	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
.	O

Baesline	O
circufmlex	O
coornary	O
blood	O
folws	O
did	O
not	O
differ	O
significantly	O
among	O
treatmnet	O
gruops	O
.	O

Dipryidamole	O
significantly	O
incerased	O
coornary	O
bolod	O
folw	O
before	O
and	O
after	O
7	O
.	O
5	O
or	O
15	O
mm	O
/	O
kg	O
i	O
.	O
v	O
.	O
pentoxifylilne	O
(	O
p	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Neither	O
dsoe	O
of	O
pentoxfiylline	O
significantly	O
decraesed	O
the	O
diypridamole	O
-	O
inudced	O
hpyeremia	B-Disease
,	O
while	O
peak	O
coroanry	O
bolod	O
folw	O
was	O
significantly	O
loewr	O
after	O
tehophylline	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
conclude	O
that	O
pnetoxyifylline	O
does	O
not	O
ihnibit	O
dipryidamole	O
-	O
inudced	O
coronray	O
hypereima	B-Disease
even	O
at	O
high	O
dsoes	O
.	O

Cuase	O
of	O
detah	B-Disease
among	O
paitents	O
with	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
:	O
a	O
rrae	O
mortlaity	O
due	O
to	O
cerberal	B-Disease
haemorrhgae	I-Disease
.	O

Cauess	O
of	O
detah	B-Disease
,	O
with	O
special	O
refeernce	O
to	O
cerebarl	B-Disease
haemorhrage	I-Disease
,	O
among	O
240	O
patietns	O
with	O
pathloogically	O
verified	O
Prakinson	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
were	O
invsetigated	O
using	O
the	O
Annuals	O
of	O
the	O
Ptahological	O
Autposy	O
Caess	O
in	O
Jaapn	O
from	O
1981	O
to	O
1985	O
.	O

The	O
leading	O
causes	O
of	O
daeth	B-Disease
were	O
pnemuonia	B-Disease
and	O
brnochitis	B-Disease
(	O
44	O
.	O
1	O
%	O
)	O
,	O
mlaignant	O
neoplsams	B-Disease
(	O
11	O
.	O
6	O
%	O
)	O
,	O
haert	B-Disease
disesaes	I-Disease
(	O
4	O
.	O
1	O
%	O
)	O
,	O
creebral	B-Disease
infartcion	I-Disease
(	O
3	O
.	O
7	O
%	O
)	O
and	O
setpicaemia	B-Disease
(	O
3	O
.	O
3	O
%	O
)	O
.	O

Cerebarl	B-Disease
haemrorhage	I-Disease
was	O
the	O
11th	O
most	O
frqeuent	O
cause	O
of	O
daeth	B-Disease
,	O
accounting	O
for	O
only	O
0	O
.	O
8	O
%	O
of	O
deahts	B-Disease
among	O
the	O
paitents	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
detah	B-Disease
among	O
the	O
Jpaanese	O
general	O
popultaion	O
in	O
1985	O
.	O

The	O
low	O
incdience	O
of	O
creebral	B-Disease
haemorrahge	I-Disease
as	O
a	O
cause	O
of	O
detah	B-Disease
in	O
paitents	O
with	O
Prakinson	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
may	O
reflect	O
the	O
hypoetnsive	B-Disease
efefct	O
of	O
levoodpa	O
and	O
a	O
hypotensvie	B-Disease
mechansim	O
due	O
to	O
reduecd	O
noradrenailne	O
lveels	O
in	O
the	O
parknisonian	B-Disease
brian	O
.	O

Possible	O
intrmauscular	O
miadzolam	O
-	O
associated	O
cardioresipratory	B-Disease
arrset	I-Disease
and	O
daeth	B-Disease
.	O

Midaozlam	O
hydroclhoride	O
is	O
commonly	O
used	O
for	O
dnetal	O
or	O
endoscpoic	O
prcoedures	O
.	O

Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramsucularly	O
,	O
intravenuos	O
amdinistration	O
is	O
known	O
to	O
cause	O
respiraotry	B-Disease
and	I-Disease
cardioavscular	I-Disease
depression	I-Disease
.	O

This	O
reprot	O
describes	O
the	O
first	O
publisehd	O
csae	O
of	O
cadriorespiratory	B-Disease
arerst	I-Disease
and	O
daeth	B-Disease
associated	O
with	O
intramsucular	O
amdinistration	O
of	O
midzaolam	O
.	O

Infomration	O
regarding	O
midzaolam	O
use	O
is	O
reveiwed	O
to	O
provide	O
recommendation	O
for	O
safe	O
adminitsration	O
.	O

Myastheina	B-Disease
grvais	I-Disease
prseenting	O
as	O
weakenss	O
after	O
magensium	O
amdinistration	O
.	O

We	O
studied	O
a	O
pateint	O
with	O
no	O
prior	O
hitsory	O
of	O
neruomuscular	B-Disease
diesase	I-Disease
who	O
became	O
virtually	O
qaudriplegic	B-Disease
after	O
parneteral	O
magensium	O
administrtaion	O
for	O
pereclampsia	B-Disease
.	O

The	O
seurm	O
magnseium	O
concentartion	O
was	O
3	O
.	O
0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolreated	O
.	O

The	O
magneisum	O
was	O
stopped	O
and	O
she	O
recoveerd	O
over	O
a	O
few	O
dyas	O
.	O

While	O
she	O
was	O
waek	O
,	O
2	O
-	O
Hz	O
repetiitve	O
stmiulation	O
rveealed	O
a	O
decreemnt	O
without	O
significant	O
faiclitation	O
at	O
rpaid	O
raets	O
or	O
after	O
execrise	O
,	O
suggesting	O
psotsynaptic	B-Disease
neuromuscualr	I-Disease
blcokade	I-Disease
.	O

After	O
her	O
sterngth	O
returned	O
,	O
repetitvie	O
stimualtion	O
was	O
noraml	O
,	O
but	O
single	O
fbier	O
EMG	O
revaeled	O
incresaed	O
jitter	O
and	O
blokcing	O
.	O

Her	O
acetylcohline	O
reecptor	O
atnibody	O
leevl	O
was	O
markedly	O
elveated	O
.	O

Although	O
paralyiss	B-Disease
after	O
magnesuim	O
adminisrtation	O
has	O
been	O
described	O
in	O
pateints	O
with	O
known	O
mysathenia	B-Disease
graivs	I-Disease
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifsetation	O
of	O
the	O
diesase	O
.	O

Patietns	O
who	O
are	O
unsuually	O
sensiitve	O
to	O
the	O
neuromuscualr	O
effetcs	O
of	O
magensium	O
should	O
be	O
susepcted	O
of	O
having	O
an	O
underlying	O
dsiorder	B-Disease
of	I-Disease
neuromucsular	I-Disease
tranmsission	I-Disease
.	O

No	O
enhancemnet	O
by	O
phneobarbital	O
of	O
the	O
hepatocaricnogenicity	O
of	O
a	O
cohline	O
-	O
devoid	O
deit	O
in	O
the	O
rat	O
.	O

An	O
expeirment	O
was	O
performed	O
to	O
tset	O
whether	O
incluison	O
of	O
phenboarbital	O
in	O
a	O
chloine	O
-	O
devoid	O
deit	O
would	O
inrcease	O
the	O
hepatocarcinoegnicity	O
of	O
the	O
deit	O
.	O

Gropus	O
of	O
5	O
-	O
week	O
old	O
mlae	O
Fiscehr	O
-	O
344	O
rtas	O
were	O
fed	O
for	O
7	O
-	O
25	O
monhts	O
semipuirfied	O
cohline	O
-	O
devoid	O
or	O
chloine	O
-	O
supplemented	O
deits	O
,	O
containing	O
or	O
not	O
0	O
.	O
06	O
%	O
phneobarbital	O
.	O

No	O
heptaic	O
preneopalstic	O
noudles	O
or	O
hepatoclelular	B-Disease
cacrinomas	I-Disease
developed	O
in	O
rtas	O
fed	O
the	O
plian	O
choilne	O
-	O
supplemented	O
deit	O
,	O
while	O
one	O
preenoplastic	O
noudle	O
and	O
one	O
hepatoclelular	B-Disease
cracinoma	I-Disease
developed	O
in	O
two	O
rtas	O
fed	O
the	O
same	O
deit	O
containing	O
phneobarbital	O
.	O

The	O
incidnece	O
of	O
preneoplsatic	O
ndoules	O
and	O
of	O
hepatocellluar	B-Disease
carcinmoas	I-Disease
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rtas	O
fed	O
the	O
plian	O
choilne	O
-	O
devoid	O
deit	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rtas	O
fed	O
the	O
phenobarbtial	O
-	O
containing	O
choilne	O
-	O
devoid	O
deit	O
.	O

The	O
reuslts	O
evinced	O
no	O
ehnancement	O
of	O
the	O
hepatcoarcinogenicity	O
of	O
the	O
cohline	O
-	O
devoid	O
deit	O
by	O
phenobrabital	O
.	O

Spordaic	O
nepolastic	O
leisons	O
were	O
observed	O
in	O
oragns	O
other	O
than	O
the	O
lvier	O
of	O
some	O
of	O
the	O
aniamls	O
,	O
irrespective	O
of	O
the	O
deit	O
fed	O
.	O

On	O
two	O
paradoxcial	O
side	O
-	O
efefcts	O
of	O
perdnisolone	O
in	O
rtas	O
,	O
riobsomal	O
RNA	O
biosnytheses	O
,	O
and	O
a	O
mechainsm	O
of	O
atcion	O
.	O

Lievr	B-Disease
enlargmeent	I-Disease
and	O
mucsle	B-Disease
wsatage	I-Disease
occurred	O
in	O
Witsar	O
rtas	O
following	O
the	O
subcutanoeus	O
administraiton	O
of	O
prednisoolne	O
.	O

In	O
the	O
lievr	O
both	O
the	O
conetnt	O
of	O
RNA	O
and	O
the	O
biosnythesis	O
of	O
rbiosomal	O
RNA	O
increaesd	O
while	O
both	O
the	O
RNA	O
conetnt	O
and	O
ribsoomal	O
RNA	O
bisoynthesis	O
were	O
rdeuced	O
in	O
the	O
gastrocenmius	O
msucle	O
.	O

It	O
is	O
suggested	O
that	O
the	O
durg	O
acted	O
in	O
a	O
selective	O
and	O
tisuse	O
-	O
specific	O
manner	O
to	O
ehnance	O
riobsomal	O
RNA	O
syntheiss	O
in	O
the	O
lvier	O
and	O
deperss	O
such	O
sytnhesis	O
in	O
the	O
mucsle	O
.	O

This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
lvier	O
and	O
muslce	O
are	O
inedpendent	O
siets	O
of	O
prednisloone	O
actoin	O
.	O

Differnetial	O
effcets	O
of	O
gmama	O
-	O
hexachlroocyclohexane	O
(	O
lnidane	O
)	O
on	O
pharmacologically	O
-	O
inudced	O
seizrues	B-Disease
.	O

Gmama	O
-	O
hexaclhorocyclohexane	O
(	O
gmama	O
-	O
HCH	O
)	O
,	O
the	O
actvie	O
ingredeint	O
of	O
the	O
inescticide	O
lnidane	O
,	O
has	O
been	O
shown	O
to	O
decresae	O
seizrue	B-Disease
thresohld	O
to	O
pentylenetraozl	O
(	O
PTZ	O
)	O
3	O
h	O
after	O
expousre	O
to	O
gmama	O
-	O
HCH	O
and	O
conversely	O
icnrease	O
thresohld	O
to	O
PTZ	O
-	O
inudced	O
seziures	B-Disease
24	O
h	O
after	O
expsoure	O
to	O
gamma	O
-	O
HCH	O
(	O
Vholand	O
et	O
al	O
.	O
1981	O
)	O
.	O

In	O
this	O
stduy	O
,	O
the	O
severtiy	O
of	O
resposne	O
to	O
other	O
seizrue	B-Disease
-	O
idnucing	O
agnets	O
was	O
tseted	O
in	O
mcie	O
1	O
and	O
24	O
h	O
after	O
intraperitoenal	O
administartion	O
of	O
80	O
mg	O
/	O
kg	O
gamma	O
-	O
HCH	O
.	O

One	O
hour	O
after	O
the	O
admiinstration	O
of	O
gmama	O
-	O
HCH	O
,	O
the	O
activtiy	O
of	O
siezure	B-Disease
-	O
indcuing	O
aegnts	O
was	O
incerased	O
,	O
regardless	O
of	O
their	O
mecahnism	O
,	O
while	O
24	O
h	O
after	O
gamma	O
-	O
HCH	O
a	O
differential	O
resposne	O
was	O
observed	O
.	O

Siezure	B-Disease
acitvity	O
due	O
to	O
PTZ	O
and	O
pircotoxin	O
(	O
PTX	O
)	O
was	O
significantly	O
decraesed	O
;	O
however	O
,	O
seizrue	B-Disease
activtiy	O
due	O
to	O
3	O
-	O
mercaptopropoinic	O
aicd	O
(	O
MPA	O
)	O
,	O
biucculline	O
(	O
BCC	O
)	O
,	O
mtehyl	O
6	O
,	O
7	O
-	O
dimethxoy	O
-	O
4	O
-	O
etyhl	O
-	O
B	O
-	O
cabroline	O
-	O
3	O
-	O
cabroxylate	O
(	O
DCMM	O
)	O
,	O
or	O
strychnnie	O
(	O
STR	O
)	O
was	O
not	O
different	O
from	O
contorl	O
.	O

In	O
vitro	O
,	O
gamma	O
-	O
HCH	O
,	O
pentylenetetraozl	O
and	O
pcirotoxin	O
were	O
shown	O
to	O
inhiibt	O
3H	O
-	O
TOBB	O
bniding	O
in	O
muose	O
whole	O
brian	O
,	O
with	O
I5C0	O
vaules	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

MPA	O
,	O
BCC	O
,	O
DCMM	O
,	O
and	O
STR	O
showed	O
no	O
inhiibtion	O
of	O
3H	O
-	O
TOBB	O
(	O
t	O
-	O
btuyl	O
bicyclo	O
-	O
orthoebnzoate	O
)	O
bidning	O
at	O
concentartions	O
of	O
100	O
micron	O
.	O

The	O
phramacological	O
challenge	O
dtaa	O
suggest	O
that	O
tolernace	O
may	O
occur	O
to	O
seziure	B-Disease
actiivty	O
induecd	O
by	O
PTZ	O
and	O
PTX	O
24	O
h	O
after	O
gmama	O
-	O
HCH	O
,	O
since	O
the	O
resposne	O
to	O
only	O
these	O
two	O
seziure	B-Disease
-	O
inudcing	O
agetns	O
is	O
derceased	O
.	O

The	O
in	O
vitro	O
dtaa	O
suggest	O
that	O
the	O
stie	O
responsible	O
for	O
the	O
dercease	O
in	O
siezure	B-Disease
activtiy	O
24	O
h	O
after	O
gamma	O
-	O
HCH	O
may	O
be	O
the	O
GBAA	O
-	O
A	O
rceeptor	O
-	O
linked	O
cholride	O
chanenl	O
.	O

Toleracne	O
and	O
antiviarl	O
effcet	O
of	O
ribvairin	O
in	O
pateints	O
with	O
Argenitne	B-Disease
hmeorrhagic	I-Disease
fveer	I-Disease
.	O

Tolernace	O
and	O
antivrial	O
effect	O
of	O
ribvairin	O
was	O
studied	O
in	O
6	O
paitents	O
with	O
Argetnine	B-Disease
hemorrahgic	I-Disease
feevr	I-Disease
(	O
AHF	B-Disease
)	O
of	O
more	O
than	O
8	O
dyas	O
of	O
evoultion	O
.	O

Adimnistration	O
of	O
rbiavirin	O
resulted	O
in	O
a	O
nuetralization	O
of	O
virmeia	B-Disease
and	O
a	O
dorp	O
of	O
endogeonus	O
interfreon	O
ttiers	O
.	O

The	O
avreage	O
tmie	O
of	O
daeth	B-Disease
was	O
dleayed	O
.	O

A	O
reversible	O
anmeia	B-Disease
was	O
the	O
only	O
adevrse	O
effcet	O
observed	O
.	O

From	O
these	O
resutls	O
,	O
we	O
conclude	O
that	O
rbiavirin	O
has	O
an	O
antiviarl	O
efefct	O
in	O
advanecd	O
csaes	O
of	O
AHF	B-Disease
,	O
and	O
that	O
aneima	B-Disease
,	O
the	O
only	O
secondary	O
reatcion	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O

The	O
possible	O
beneficial	O
effcet	O
of	O
ribvairin	O
during	O
the	O
initial	O
dyas	O
of	O
AHF	B-Disease
is	O
discussed	O
.	O

Is	O
the	O
traetment	O
of	O
scabeis	B-Disease
haazrdous	O
?	O

Treatemnt	O
for	O
sacbies	B-Disease
is	O
usually	O
initiated	O
by	O
general	O
practitinoers	O
;	O
most	O
consider	O
lindnae	O
(	O
gmama	O
benznee	O
hexahcloride	O
)	O
the	O
teratment	O
of	O
choice	O
.	O

Linadne	O
is	O
also	O
widely	O
used	O
as	O
an	O
agricultrual	O
and	O
indusrtial	O
pestiicde	O
,	O
and	O
as	O
a	O
result	O
the	O
txoic	O
proflie	O
of	O
this	O
insecitcide	O
is	O
well	O
understood	O
.	O

Eviednce	O
is	O
accumulating	O
that	O
lnidane	O
can	O
be	O
txoic	B-Disease
to	I-Disease
the	I-Disease
centarl	I-Disease
nrevous	I-Disease
ssytem	I-Disease
and	O
may	O
be	O
associated	O
with	O
apalstic	B-Disease
anameia	I-Disease
.	O

Preparatoins	O
containing	O
lindnae	O
continue	O
to	O
be	O
slod	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hzaard	O
to	O
poorly	O
informed	O
paitents	O
.	O

This	O
litreature	O
reivew	O
suggests	O
that	O
general	O
prcatitioners	O
should	O
presrcibe	O
scabicieds	O
with	O
increaesd	O
caution	O
for	O
certain	O
at	O
-	O
rsik	O
gropus	O
,	O
and	O
give	O
adequtae	O
warnnigs	O
regarding	O
potnetial	O
toxiicty	B-Disease
.	O

Mosue	O
starin	O
-	O
depnedent	O
efefct	O
of	O
amanatdine	O
on	O
motiltiy	O
and	O
barin	O
biogeinc	O
amiens	O
.	O

The	O
effcet	O
of	O
amanatdine	O
hyrdochloride	O
,	O
injceted	O
i	O
.	O
p	O
.	O
in	O
6	O
incrmeents	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mosue	O
motliity	O
and	O
whole	O
brian	O
contnet	O
of	O
selected	O
bioegnic	O
aimnes	O
and	O
major	O
metabolties	O
was	O
studied	O
in	O
4	O
stranis	O
of	O
mcie	O
.	O

These	O
were	O
the	O
albnio	O
Srpague	O
-	O
Dalwey	O
ICR	O
and	O
BLAB	O
/	O
C	O
,	O
the	O
blcak	O
C75BL	O
/	O
6	O
and	O
the	O
borwn	O
CDF	O
-	O
I	O
mosue	O
srtains	O
.	O

Amanatdine	O
tretament	O
produced	O
a	O
bpihasic	O
effcet	O
on	O
muose	O
mtoility	O
.	O

The	O
initial	O
dsoe	O
of	O
amantaidne	O
deprsesed	B-Disease
loocmotor	O
actviity	O
in	O
all	O
muose	O
stranis	O
studied	O
with	O
the	O
BLAB	O
/	O
C	O
mcie	O
being	O
the	O
most	O
sensiitve	O
.	O

Subsequent	O
amanatdine	O
teratments	O
produced	O
enhancmeent	O
of	O
motiltiy	O
from	O
corresponding	O
cotnrol	O
in	O
all	O
mosue	O
starins	O
with	O
the	O
BLAB	O
/	O
C	O
mcie	O
being	O
the	O
least	O
senistive	O
.	O

The	O
locmootor	O
activtiy	O
was	O
derceased	O
from	O
corresponding	O
conrtols	O
in	O
all	O
strians	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
mcie	O
,	O
during	O
an	O
overnight	O
durg	O
-	O
free	O
preiod	O
following	O
the	O
fourth	O
amantaidne	O
teratment	O
.	O

Reamdinistration	O
of	O
amantadnie	O
,	O
after	O
a	O
durg	O
-	O
free	O
overnight	O
peroid	O
,	O
increaesd	O
mtoility	O
from	O
respective	O
slaine	O
cnotrol	O
in	O
all	O
starins	O
with	O
exception	O
of	O
the	O
BLAB	O
/	O
C	O
mcie	O
where	O
suprpession	B-Disease
of	I-Disease
mtoility	I-Disease
occurred	O
.	O

Treamtent	O
with	O
amatnadine	O
did	O
not	O
alter	O
whole	O
barin	O
dopaimne	O
lveels	O
but	O
decresaed	O
the	O
amounts	O
of	O
3	O
,	O
4	O
-	O
dihydroxypehnylacetic	O
aicd	O
in	O
the	O
BLAB	O
/	O
C	O
mcie	O
cmopared	O
to	O
salnie	O
conrtol	O
.	O

Conversely	O
,	O
brian	O
noremtanephrine	O
conecntration	O
was	O
increaesd	O
from	O
slaine	O
cotnrol	O
by	O
amatnadine	O
in	O
the	O
BLAB	O
/	O
C	O
mcie	O
.	O

The	O
reuslts	O
suggest	O
a	O
starin	O
-	O
dependnet	O
efefct	O
of	O
amantadnie	O
on	O
motiltiy	O
and	O
indicate	O
a	O
diffeerntial	O
rseponse	O
to	O
the	O
aucte	O
and	O
mutliple	O
dsoe	O
reigmens	O
used	O
.	O

The	O
BLAB	O
/	O
C	O
muose	O
was	O
the	O
most	O
senistive	O
starin	O
and	O
could	O
serve	O
as	O
the	O
strian	O
of	O
choice	O
for	O
eavluating	O
the	O
side	O
efefcts	O
of	O
amantadnie	O
.	O

The	O
biocehmical	O
reuslts	O
of	O
barin	O
bigoenic	O
amiens	O
of	O
BLAB	O
/	O
C	O
mosue	O
srtain	O
suggest	O
a	O
probable	O
decresae	O
of	O
caetcholamine	O
tunrover	O
rtae	O
and	O
/	O
or	O
metaboilsm	O
by	O
mnooamine	O
oixdase	O
and	O
a	O
resulting	O
incerase	O
in	O
O	O
-	O
methyltaion	O
of	O
norepineprhine	O
which	O
may	O
account	O
for	O
a	O
behaivoral	B-Disease
depressoin	I-Disease
caused	O
by	O
amnatadine	O
in	O
the	O
BLAB	O
/	O
C	O
mcie	O
.	O

Chloroaceatldehyde	O
and	O
its	O
contribution	O
to	O
urotxoicity	O
during	O
treamtent	O
with	O
cyclophopshamide	O
or	O
ifosfamdie	O
.	O

An	O
epxerimental	O
sutdy	O
/	O
short	O
commnuication	O
.	O

Based	O
on	O
clniical	O
dtaa	O
,	O
indicating	O
that	O
cholroacetaldehyde	O
(	O
CAA	O
)	O
is	O
an	O
important	O
meatbolite	O
of	O
oxaazphosphorine	O
ctyostatics	O
,	O
an	O
expermiental	O
sutdy	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	O
in	O
the	O
dveelopment	O
of	O
hemorrahgic	B-Disease
cystiits	I-Disease
.	O

The	O
dtaa	O
demonstrate	O
that	O
CAA	O
after	O
i	O
.	O
v	O
.	O
admiinstration	O
does	O
not	O
contribute	O
to	O
baldder	B-Disease
damgae	I-Disease
.	O

When	O
instliled	O
directly	O
into	O
the	O
baldder	O
,	O
CAA	O
exerts	O
urtooxic	O
efefcts	O
,	O
it	O
is	O
,	O
however	O
,	O
suscetpible	O
to	O
dteoxification	O
with	O
msena	O
.	O

Soucre	O
of	O
pian	B-Disease
and	O
pirmitive	O
dysfuntcion	O
in	O
migranie	B-Disease
:	O
an	O
iedntical	O
stie	O
?	O

Twenty	O
common	O
mirgaine	B-Disease
pateints	O
received	O
a	O
one	O
sided	O
frontotepmoral	O
appliaction	O
of	O
nitorglycerin	O
(	O
10	O
patinets	O
)	O
or	O
plaecbo	O
ointmnet	O
(	O
10	O
pateints	O
)	O
in	O
a	O
double	O
bilnd	O
stduy	O
.	O

Eraly	O
onset	O
migranie	B-Disease
attakcs	O
were	O
induecd	O
by	O
nitorglycerin	O
in	O
seven	O
out	O
of	O
10	O
patietns	O
versus	O
no	O
patinet	O
in	O
the	O
palcebo	O
gruop	O
.	O

Subsequently	O
20	O
migriane	B-Disease
patinets	O
,	O
who	O
developed	O
an	O
ealry	O
onset	O
atatck	O
with	O
frontotempoarl	O
ntiroglycerin	O
,	O
received	O
the	O
durg	O
in	O
a	O
second	O
inudction	O
tset	O
at	O
other	O
bdoy	O
areas	O
.	O

No	O
eraly	O
onset	O
mgiraine	B-Disease
was	O
observed	O
.	O

Thus	O
the	O
migriane	B-Disease
-	O
induicng	O
effcet	O
of	O
ntiroglycerin	O
seems	O
to	O
depend	O
on	O
direct	O
stimluation	O
of	O
the	O
habtiual	O
stie	O
of	O
pian	B-Disease
,	O
suggesting	O
that	O
the	O
fronottemporal	O
reigon	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
develompent	O
of	O
a	O
mirgaine	B-Disease
criiss	O
.	O

This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
orgiin	O
of	O
migarine	B-Disease
attcak	O
.	O

Hpyersensitivity	B-Disease
to	O
carbamazepnie	O
presentnig	O
with	O
a	O
luekemoid	B-Disease
reaciton	I-Disease
,	O
eosinophliia	B-Disease
,	O
ertyhroderma	B-Disease
,	O
and	O
rneal	B-Disease
failrue	I-Disease
.	O

We	O
reprot	O
a	O
pateint	O
in	O
whom	O
hyperesnsitivity	B-Disease
to	O
carbamazpeine	O
presented	O
with	O
generaliezd	O
ertyhroderma	B-Disease
,	O
a	O
seevre	O
lekuemoid	B-Disease
reatcion	I-Disease
,	O
eosniophilia	B-Disease
,	O
hyponartemia	B-Disease
,	O
and	O
rneal	B-Disease
fialure	I-Disease
.	O

This	O
is	O
the	O
first	O
reprot	O
of	O
such	O
an	O
unusaul	O
reatcion	O
to	O
cabramazepine	O
.	O

Fluoextine	O
-	O
inudced	O
aakthisia	B-Disease
:	O
cliniacl	O
and	O
thoeretical	O
implications	O
.	O

Five	O
patinets	O
receiving	O
fluoxteine	O
for	O
the	O
treatemnt	O
of	O
obsessive	B-Disease
cmopulsive	I-Disease
dsiorder	I-Disease
or	O
major	B-Disease
depression	I-Disease
developed	O
akahtisia	B-Disease
.	O

The	O
typical	O
fluoxeitne	O
-	O
induecd	O
sypmtoms	O
of	O
rsetlessness	O
,	O
consatnt	O
paicng	O
,	O
purposeelss	O
moevments	O
of	O
the	O
feet	O
and	O
lges	O
,	O
and	O
marked	O
anxeity	B-Disease
were	O
idnistinguishable	O
from	O
those	O
of	O
neurolpetic	O
-	O
induecd	O
akatihsia	B-Disease
.	O

Three	O
paitents	O
who	O
had	O
experienced	O
neuroletpic	O
-	O
inudced	O
akathiisa	B-Disease
in	O
the	O
past	O
reported	O
that	O
the	O
sympotms	O
of	O
fluoxeitne	O
-	O
induecd	O
akatihsia	B-Disease
were	O
idenitcal	O
,	O
although	O
somewhat	O
milder	O
.	O

Akatihsia	B-Disease
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoextine	O
and	O
generally	O
responded	O
well	O
to	O
tretament	O
with	O
the	O
btea	O
-	O
adrenregic	O
antaognist	O
propraonlol	O
,	O
dsoe	O
rdeuction	O
,	O
or	O
both	O
.	O

The	O
authros	O
suggest	O
that	O
fuloxetine	O
-	O
idnuced	O
akahtisia	B-Disease
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhiibtion	O
of	O
dopaminerigc	O
neuortransmission	O
and	O
that	O
the	O
pathpohysiology	O
of	O
fluoxetnie	O
-	O
idnuced	O
akahtisia	B-Disease
and	O
triycclic	O
antiedpressant	O
-	O
inudced	O
"	O
jtiteriness	O
"	O
may	O
be	O
identcial	O
.	O

Efefct	O
of	O
converting	O
enyzme	O
inihbition	O
on	O
the	O
cuorse	O
of	O
adriamyicn	O
-	O
induecd	O
nephropahty	B-Disease
.	O

The	O
effect	O
of	O
the	O
converting	O
enyzme	O
inihbitor	O
(	O
CEI	O
)	O
enalparil	O
was	O
asssesed	O
in	O
Muncih	O
-	O
Wisatr	O
rtas	O
with	O
established	O
adraimycin	O
neprhosis	B-Disease
.	O

Rtas	O
were	O
given	O
a	O
single	O
dsoe	O
of	O
adriaymcin	O
and	O
one	O
mnoth	O
later	O
divided	O
into	O
four	O
gropus	O
matched	O
for	O
alubminuria	B-Disease
,	O
blood	O
pressure	O
,	O
and	O
plamsa	O
albmuin	O
concnetration	O
.	O

Gropus	O
1	O
and	O
3	O
remained	O
unterated	O
while	O
gruops	O
2	O
and	O
4	O
received	O
eanlapril	O
.	O

Gruops	O
1	O
and	O
2	O
underwent	O
mircopuncture	O
sutdies	O
after	O
10	O
dyas	O
.	O

These	O
short	O
-	O
term	O
stduies	O
showed	O
that	O
enalapirl	O
rdeuced	O
arterail	O
bolod	O
perssure	O
(	O
101	O
+	O
/	O
-	O
2	O
vs	O
.	O
124	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
gruop	O
2	O
vs	O
.	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
glomeurlar	O
caplilary	O
pressrue	O
(	O
54	O
+	O
/	O
-	O
1	O
vs	O
.	O
61	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
without	O
reduicng	O
alubminuria	B-Disease
(	O
617	O
+	O
/	O
-	O
50	O
vs	O
.	O
570	O
+	O
/	O
-	O
47	O
mg	O
/	O
day	O
)	O
or	O
GFR	O
(	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
vs	O
.	O
1	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
11	O
ml	O
/	O
min	O
)	O
.	O

Gruops	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
mnoths	O
to	O
assess	O
the	O
effcet	O
of	O
enalapirl	O
on	O
progression	O
of	O
rneal	B-Disease
injruy	I-Disease
in	O
ardiamycin	O
nephorsis	B-Disease
.	O

Chornic	O
enalapirl	O
tretament	O
rdeuced	O
bolod	O
pressure	O
without	O
rdeucing	O
alubminuria	B-Disease
in	O
gorup	O
4	O
.	O

Untretaed	O
gruop	O
3	O
rtas	O
exhibited	O
a	O
progresisve	O
redcution	O
in	O
GFR	O
(	O
0	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
08	O
ml	O
/	O
min	O
at	O
4	O
motnhs	O
,	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
07	O
ml	O
/	O
min	O
at	O
6	O
motnhs	O
)	O
.	O

Enalparil	O
treatmnet	O
blunetd	O
but	O
did	O
not	O
prveent	O
reduciton	O
in	O
GFR	O
in	O
gruop	O
4	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
15	O
ml	O
/	O
min	O
at	O
4	O
motnhs	O
,	O
0	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
13	O
ml	O
/	O
min	O
at	O
6	O
mnoths	O
,	O
both	O
P	O
less	O
than	O
0	O
.	O
05	O
vs	O
.	O
gruop	O
3	O
)	O
.	O

Redutcion	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
develpoment	O
of	O
glomreular	B-Disease
sclreosis	I-Disease
in	O
both	O
traeted	O
and	O
untretaed	O
rtas	O
.	O
(	O
ABSTRACT	O
TRNUCATED	O
AT	O
250	O
WORDS	O
)	O

Clotiazeapm	O
-	O
indcued	O
aucte	O
hepatiits	B-Disease
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
patinet	O
who	O
developed	O
actue	O
heptaitis	B-Disease
with	O
extensvie	B-Disease
hepatocellular	I-Disease
necorsis	I-Disease
,	O
7	O
motnhs	O
after	O
the	O
onset	O
of	O
adimnistration	O
of	O
cloitazepam	O
,	O
a	O
thienodiazepine	O
derivatvie	O
.	O

Coltiazepam	O
wihtdrawal	O
was	O
followed	O
by	O
prompt	O
rceovery	O
.	O

The	O
adimnistration	O
of	O
several	O
benzodiazeipnes	O
,	O
chemiaclly	O
related	O
to	O
clotiazeapm	O
,	O
did	O
not	O
interfere	O
with	O
rceovery	O
and	O
did	O
not	O
indcue	O
any	O
relpase	O
of	O
hepaittis	B-Disease
.	O

This	O
obseravtion	O
shows	O
that	O
cltoiazepam	O
can	O
inudce	O
actue	O
hepatiits	B-Disease
and	O
suggests	O
that	O
there	O
is	O
no	O
corss	O
hepatootxicity	B-Disease
between	O
clotiaezpam	O
and	O
several	O
benozdiazepines	O
.	O

5	O
-	O
azacytidnie	O
potetniates	O
inititaion	B-Disease
indcued	I-Disease
by	I-Disease
carciongens	I-Disease
in	O
rat	O
lvier	O
.	O

To	O
tset	O
the	O
validtiy	O
of	O
the	O
hyopthesis	O
that	O
hpyomethylation	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiatoin	B-Disease
of	I-Disease
cracinogenic	I-Disease
porcess	I-Disease
,	O
5	O
-	O
azacyitdine	O
(	O
5	O
-	O
AzC	O
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhbiitor	O
of	O
DNA	O
methyltaion	O
,	O
was	O
given	O
to	O
rtas	O
during	O
the	O
phsae	O
of	O
rpeair	O
syntheiss	O
inudced	O
by	O
the	O
three	O
cacrinogens	O
,	O
bnezo	O
[	O
a	O
]	O
-	O
pyrnee	O
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	O
-	O
mehtyl	O
-	O
N	O
-	O
nitrosoruea	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1	O
,	O
2	O
-	O
dimethylhydrzaine	O
(	O
1	O
,	O
2	O
-	O
DMH	O
)	O
(	O
100	O
mg	O
/	O
kg	O
)	O
.	O

The	O
initiated	O
hepatocyets	O
in	O
the	O
lievr	O
were	O
asasyed	O
as	O
the	O
gamma	O
-	O
glutamlytransferase	O
(	O
gmama	O
-	O
GT	O
)	O
positvie	O
fcoi	O
formed	O
following	O
a	O
2	O
-	O
week	O
seleciton	O
regiemn	O
consisting	O
of	O
deitary	O
0	O
.	O
02	O
%	O
2	O
-	O
acetlyaminofluorene	O
coupled	O
with	O
a	O
nercogenic	O
dsoe	O
of	O
ClC4	O
.	O

The	O
rseults	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
cacrinogens	O
,	O
administratoin	O
of	O
5	O
-	O
AzC	O
during	O
rpeair	O
syntehsis	O
inrceased	O
the	O
inciednce	O
of	O
initiated	O
hepatocyets	O
,	O
for	O
example	O
10	O
-	O
20	O
fcoi	O
/	O
cm2	O
in	O
5	O
-	O
AzC	O
and	O
cracinogen	O
-	O
tretaed	O
rtas	O
copmared	O
with	O
3	O
-	O
5	O
fcoi	O
/	O
cm2	O
in	O
rtas	O
traeted	O
with	O
carcinoegn	O
only	O
.	O

Administraiton	O
of	O
[	O
3H	O
]	O
-	O
5	O
-	O
azadeoxycytidine	O
during	O
the	O
reapir	O
syntheiss	O
indcued	O
by	O
1	O
,	O
2	O
-	O
DMH	O
further	O
showed	O
that	O
0	O
.	O
019	O
mol	O
%	O
of	O
ctyosine	O
resdiues	O
in	O
DNA	O
were	O
substituetd	O
by	O
the	O
analgoue	O
,	O
indicating	O
that	O
incoproration	O
of	O
5	O
-	O
AzC	O
occurs	O
during	O
repiar	O
syntheiss	O
.	O

In	O
the	O
absecne	O
of	O
the	O
cracinogen	O
,	O
5	O
-	O
AzC	O
given	O
after	O
a	O
two	O
thirds	O
patrial	O
heptaectomy	O
,	O
when	O
its	O
incroporation	O
should	O
be	O
maxmium	O
,	O
failed	O
to	O
indcue	O
any	O
gmama	O
-	O
GT	O
psoitive	O
fcoi	O
.	O

The	O
resutls	O
suggest	O
that	O
hypmoethylation	O
of	O
DNA	O
per	O
se	O
may	O
not	O
be	O
sufficient	O
for	O
intiiation	O
.	O

Perhaps	O
two	O
eevnts	O
might	O
be	O
necessary	O
for	O
inititaion	O
,	O
the	O
first	O
caused	O
by	O
the	O
cracinogen	O
and	O
a	O
second	O
involving	O
hypomethlyation	O
of	O
DNA	O
.	O

Antihypertensvie	O
durgs	O
and	O
dperession	B-Disease
:	O
a	O
reaprpaisal	O
.	O

Eighty	O
-	O
nine	O
new	O
reefrral	O
hyperetnsive	B-Disease
out	O
-	O
patietns	O
and	O
46	O
new	O
reefrral	O
non	O
-	O
hypertenisve	B-Disease
chroniaclly	O
physically	O
ill	O
out	O
-	O
patinets	O
completed	O
a	O
mood	O
raitng	O
scale	O
at	O
regular	O
inetrvals	O
for	O
one	O
yaer	O
.	O

The	O
reuslts	O
showed	O
a	O
high	O
pervalence	O
of	O
dperession	B-Disease
in	O
both	O
gruops	O
of	O
pateints	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertenisve	B-Disease
gruop	O
.	O

Hpyertensive	B-Disease
ptaients	O
with	O
psycihatric	B-Disease
hsitories	O
had	O
a	O
hgiher	O
preavlence	O
of	O
dperession	B-Disease
than	O
the	O
compraison	O
patietns	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
dperessions	B-Disease
occurring	O
in	O
mehtyl	O
dpoa	O
tretaed	O
patinets	O
with	O
psychiatirc	B-Disease
hitsories	O
.	O

Chrnoic	B-Disease
atcive	I-Disease
hepatiits	I-Disease
associated	O
with	O
dcilofenac	O
soidum	O
thearpy	O
.	O

Diclofneac	O
soidum	O
(	O
Votlarol	O
,	O
Giegy	O
Pharmaceutiacls	O
)	O
is	O
a	O
non	O
-	O
streoidal	O
atni	O
-	O
inflmamatory	O
derivaitve	O
of	O
phenylcaetic	O
aicd	O
.	O

Although	O
generally	O
well	O
-	O
tloerated	O
,	O
asymptmoatic	O
abnormaltiies	B-Disease
of	I-Disease
lievr	I-Disease
fnuction	I-Disease
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
seevre	O
hepattiis	B-Disease
idnuced	O
by	O
dilcofenac	O
.	O

The	O
ptaient	O
described	O
developed	O
chrnoic	B-Disease
acitve	I-Disease
hepattiis	I-Disease
after	O
six	O
monhts	O
tehrapy	O
with	O
diclofeanc	O
soidum	O
which	O
progressed	O
despite	O
the	O
withdraawl	O
of	O
the	O
durg	O
,	O
a	O
finidng	O
not	O
previously	O
reported	O
.	O

Aretrial	O
hypertenison	B-Disease
as	O
a	O
complicatoin	O
of	O
prolnoged	O
ketocoanzole	O
traetment	O
.	O

Two	O
of	O
14	O
patinets	O
with	O
Cusihng	B-Disease
'	I-Disease
s	I-Disease
sydnrome	I-Disease
tretaed	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketoocnazole	O
developed	O
sustianed	O
hypertenison	B-Disease
.	O

In	O
both	O
caess	O
noraml	O
palsma	O
and	O
urianry	O
free	O
cortsiol	O
levles	O
had	O
been	O
achieved	O
following	O
ketocoanzole	O
threapy	O
,	O
yet	O
conitnuous	O
blood	O
pressure	O
monitroing	O
demonstrated	O
hypertensoin	B-Disease
31	O
(	O
pateint	O
1	O
)	O
and	O
52	O
wekes	O
(	O
ptaient	O
2	O
)	O
after	O
traetment	O
.	O

In	O
pateint	O
1	O
,	O
palsma	O
levles	O
of	O
deoxyocrticosterone	O
and	O
11	O
-	O
dexoycortisol	O
were	O
eleavted	O
.	O

In	O
patinet	O
2	O
,	O
in	O
addition	O
to	O
an	O
icnrease	O
in	O
both	O
deoxycorticosteorne	O
and	O
11	O
-	O
deoxycortsiol	O
lveels	O
,	O
plsama	O
aldosteorne	O
valeus	O
were	O
raised	O
,	O
with	O
a	O
conocmitant	O
supperssion	O
of	O
reinn	O
leevls	O
.	O

Our	O
fnidings	O
show	O
that	O
long	O
-	O
term	O
treatmnet	O
with	O
high	O
doess	O
of	O
ketocnoazole	O
may	O
indcue	O
eznyme	O
blcokade	O
leading	O
to	O
mienralocorticoid	O
-	O
related	O
hypertesnion	B-Disease
.	O

Effects	O
of	O
an	O
ihnibitor	O
of	O
angiotnesin	O
converting	O
enyzme	O
(	O
Captporil	O
)	O
on	O
pulmoanry	B-Disease
and	I-Disease
reanl	I-Disease
isnufficiency	I-Disease
due	O
to	O
itnravascular	B-Disease
caogulation	I-Disease
in	O
the	O
rat	O
.	O

Indcution	O
of	O
intravasuclar	B-Disease
coagualtion	I-Disease
and	O
inhibtiion	O
of	O
fibrniolysis	O
by	O
injectoin	O
of	O
thromibn	O
and	O
tarnexamic	O
aicd	O
(	O
ACMA	O
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pumlonary	B-Disease
and	I-Disease
reanl	I-Disease
isnufficiency	I-Disease
resembling	O
that	O
occurring	O
after	O
taruma	B-Disease
or	O
sespis	B-Disease
in	O
man	O
.	O

Inejction	O
of	O
Capotpril	O
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibtior	O
of	O
angiotnesin	O
converting	O
enzmye	O
(	O
ACE	O
)	O
,	O
redcued	O
both	O
pumlonary	B-Disease
and	I-Disease
reanl	I-Disease
insufficiecny	I-Disease
in	O
this	O
rat	O
moedl	O
.	O

The	O
lnug	O
weights	O
were	O
lwoer	O
and	O
POa2	O
was	O
imprvoed	O
in	O
rtas	O
given	O
this	O
enyzme	O
-	O
blocikng	O
agnet	O
.	O

The	O
cotnents	O
of	O
ablumin	O
in	O
the	O
lugns	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captorpil	O
did	O
not	O
infleunce	O
the	O
etxravasation	O
of	O
prtoein	O
.	O

Rneal	B-Disease
damgae	I-Disease
as	O
reflected	O
by	O
an	O
icnrease	O
in	O
sreum	O
uera	O
and	O
in	O
kindey	O
wegiht	O
was	O
prevented	O
by	O
Captorpil	O
.	O

The	O
amonut	O
of	O
fbirin	O
in	O
the	O
kidnyes	O
was	O
also	O
considerably	O
lwoer	O
than	O
in	O
animlas	O
which	O
received	O
trhombin	O
and	O
ACMA	O
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
effcets	O
of	O
Catpopril	O
on	O
the	O
lnugs	O
may	O
be	O
attributable	O
to	O
a	O
vasodialtory	O
efefct	O
due	O
to	O
a	O
reudction	O
in	O
the	O
cicrulating	O
lveel	O
of	O
Angitoension	O
II	O
and	O
an	O
incresae	O
in	O
prostacylcin	O
(	O
secondary	O
to	O
an	O
inrcease	O
in	O
bardykinin	O
)	O
.	O

Captopirl	O
may	O
,	O
by	O
the	O
same	O
mcehanism	O
,	O
reudce	O
the	O
incerase	O
in	O
glomeurlar	O
filtrtaion	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
inejction	O
of	O
thromibn	O
,	O
thereby	O
diminsihing	O
the	O
aggregaiton	O
of	O
firbin	O
monoemrs	O
in	O
the	O
glmoeruli	O
,	O
with	O
the	O
result	O
that	O
less	O
firbin	O
will	O
be	O
depsoited	O
and	O
thus	O
less	O
kideny	B-Disease
damgae	I-Disease
will	O
be	O
produced	O
.	O

Storke	B-Disease
associated	O
with	O
cocanie	O
use	O
.	O

We	O
describe	O
eight	O
ptaients	O
in	O
whom	O
coacine	O
use	O
was	O
related	O
to	O
strkoe	B-Disease
and	O
rveiew	O
39	O
caess	O
from	O
the	O
ltierature	O
.	O

Among	O
these	O
47	O
patinets	O
the	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
age	O
was	O
32	O
.	O
5	O
+	O
/	O
-	O
12	O
.	O
1	O
yeras	O
;	O
76	O
%	O
(	O
34	O
/	O
45	O
)	O
were	O
men	O
.	O

Storke	B-Disease
followed	O
ccoaine	O
use	O
by	O
ihnalation	O
,	O
itnranasal	O
,	O
intraevnous	O
,	O
and	O
intarmuscular	O
ruotes	O
.	O

Intracranail	B-Disease
anuerysms	I-Disease
or	O
arteriovenuos	B-Disease
malofrmations	I-Disease
were	O
present	O
in	O
17	O
of	O
32	O
patinets	O
studied	O
angoigraphically	O
or	O
at	O
autospy	O
;	O
creebral	B-Disease
vasuclitis	I-Disease
was	O
present	O
in	O
two	O
pateints	O
.	O

Creebral	B-Disease
inafrction	I-Disease
occurred	O
in	O
10	O
patinets	O
(	O
22	O
%	O
)	O
,	O
intraecrebral	B-Disease
hemorhrage	I-Disease
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subaarchnoid	B-Disease
hemorrahge	I-Disease
in	O
13	O
(	O
29	O
%	O
)	O
.	O

These	O
dtaa	O
indicate	O
that	O
(	O
1	O
)	O
the	O
apparnet	O
inciednce	O
of	O
strkoe	B-Disease
related	O
to	O
cocanie	O
use	O
is	O
increaisng	O
;	O
(	O
2	O
)	O
cociane	O
-	O
associated	O
strkoe	B-Disease
occurs	O
primarily	O
in	O
yonug	O
adluts	O
;	O
(	O
3	O
)	O
storke	B-Disease
may	O
follow	O
any	O
ruote	O
of	O
cociane	O
admniistration	O
;	O
(	O
4	O
)	O
storke	B-Disease
after	O
coacine	O
use	O
is	O
frequently	O
associated	O
with	O
itnracranial	B-Disease
aneuyrsms	I-Disease
and	O
arterivoenous	B-Disease
malformtaions	I-Disease
;	O
and	O
(	O
5	O
)	O
in	O
coacine	O
-	O
associated	O
strkoe	B-Disease
,	O
the	O
frequnecy	O
of	O
itnracranial	B-Disease
hemorhrage	I-Disease
exceeds	O
that	O
of	O
ceerbral	B-Disease
infarctoin	I-Disease
.	O

A	O
radnomized	O
cmoparison	O
of	O
labeatlol	O
and	O
nitroprusside	O
for	O
induecd	O
hypotnesion	B-Disease
.	O

In	O
a	O
randomzied	O
stduy	O
,	O
labeatlol	O
-	O
inudced	O
hypotenison	B-Disease
and	O
nitroprussdie	O
-	O
inudced	O
hypoetnsion	B-Disease
were	O
cmopared	O
in	O
20	O
paitents	O
(	O
10	O
in	O
each	O
gorup	O
)	O
schedlued	O
for	O
major	O
orthopdeic	O
proceduers	O
.	O

Each	O
patinet	O
was	O
subjected	O
to	O
an	O
identcial	O
aensthetic	O
protoocl	O
and	O
similar	O
durg	O
-	O
idnuced	O
rdeuctions	B-Disease
in	I-Disease
mean	I-Disease
atrerial	I-Disease
blood	I-Disease
prsesure	I-Disease
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O

Nitrorpusside	O
inufsion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
incraese	B-Disease
in	I-Disease
haert	I-Disease
rtae	I-Disease
and	I-Disease
cradiac	I-Disease
outupt	I-Disease
;	O
rbeound	O
hypetrension	B-Disease
was	O
observed	O
in	O
three	O
ptaients	O
after	O
discontniuation	O
of	O
nitroprussdie	O
.	O

Labetaoll	O
administratoin	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
fnidings	O
.	O

Arteiral	O
PO2	O
decresaed	O
in	O
both	O
gruops	O
.	O

It	O
was	O
concluded	O
that	O
labetaoll	O
offers	O
advantages	O
over	O
nitroprussdie	O
.	O

Soduim	O
sttaus	O
influenecs	O
chrnoic	O
amhpotericin	O
B	O
nephrotxoicity	B-Disease
in	O
rtas	O
.	O

The	O
nephrootxic	B-Disease
ptoential	O
of	O
amhpotericin	O
B	O
(	O
5	O
mg	O
/	O
kg	O
per	O
day	O
intraepritoneally	O
for	O
3	O
wekes	O
)	O
has	O
been	O
investigtaed	O
in	O
slat	O
-	O
deplteed	O
,	O
nomral	O
-	O
slat	O
,	O
and	O
slat	O
-	O
laoded	O
rtas	O
.	O

In	O
slat	O
-	O
depelted	O
rtas	O
,	O
amphoetricin	O
B	O
dcereased	O
creaitnine	O
celarance	O
linearly	O
with	O
tmie	O
,	O
with	O
an	O
85	O
%	O
redcution	O
by	O
week	O
3	O
.	O

In	O
contrast	O
,	O
in	O
noraml	O
-	O
slat	O
rtas	O
creatinnie	O
clearnace	O
was	O
decerased	O
but	O
to	O
a	O
lseser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
slat	O
-	O
laoded	O
rtas	O
creatniine	O
claerance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decerased	O
by	O
43	O
%	O
at	O
week	O
3	O
.	O

All	O
rtas	O
in	O
the	O
sdoium	O
-	O
delpeted	O
gorup	O
had	O
hsitopathological	O
eivdence	O
of	O
patchy	O
tuublar	O
cytpolasmic	O
degenreation	O
in	O
tublues	O
that	O
was	O
not	O
observed	O
in	O
any	O
nomral	O
-	O
slat	O
or	O
slat	O
-	O
laoded	O
rat	O
.	O

Conecntrations	O
of	O
ampohtericin	O
B	O
in	O
plamsa	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
gruops	O
at	O
any	O
tmie	O
during	O
the	O
sutdy	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
3	O
wekes	O
,	O
ampohtericin	O
B	O
levles	O
in	O
the	O
kindeys	O
and	O
lievr	O
were	O
significantly	O
higehr	O
in	O
slat	O
-	O
depleetd	O
and	O
nomral	O
-	O
slat	O
rtas	O
than	O
those	O
in	O
slat	O
-	O
laoded	O
rtas	O
,	O
with	O
palsma	O
/	O
kdiney	O
ratois	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
slat	O
-	O
depleetd	O
,	O
nomral	O
-	O
slat	O
,	O
and	O
slat	O
-	O
loaedd	O
rtas	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
redutcions	O
in	O
creatiinne	O
clearnace	O
and	O
rneal	O
amphoteriicn	O
B	O
accumulation	O
after	O
chroinc	O
amphotreicin	O
B	O
administratoin	O
were	O
enahnced	O
by	O
slat	O
depeltion	O
and	O
attenuaetd	O
by	O
soduim	O
loaidng	O
in	O
rtas	O
.	O

Felstolol	O
:	O
an	O
ulrta	O
-	O
short	O
-	O
acting	O
btea	O
-	O
adrneergic	O
blocikng	O
aegnt	O
.	O

Felstolol	O
(	O
ACC	O
-	O
9089	O
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ulrta	O
-	O
short	O
-	O
acting	O
btea	O
-	O
adrenerigc	O
bolcking	O
aegnt	O
,	O
without	O
any	O
intrinisc	O
sympahtomimetic	O
actviity	O
.	O

Flestlool	O
is	O
metbaolized	O
by	O
palsma	O
esteraess	O
and	O
has	O
an	O
eliminatoin	O
half	O
-	O
lfie	O
of	O
approximately	O
6	O
.	O
5	O
mniutes	O
.	O

This	O
aegnt	O
was	O
well	O
toelrated	O
in	O
helathy	O
volunteres	O
at	O
dsoes	O
up	O
to	O
100	O
microrgams	O
/	O
kg	O
/	O
min	O
.	O

In	O
long	O
-	O
term	O
infusoin	O
stduies	O
,	O
felstolol	O
was	O
well	O
toleraetd	O
at	O
the	O
effcetive	O
btea	O
-	O
blcoking	O
dsoe	O
(	O
5	O
mcirograms	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
dyas	O
.	O

Flsetolol	O
blood	O
concentraitons	O
icnreased	O
linearly	O
with	O
incerasing	O
dsoe	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concetnrations	O
of	O
felstolol	O
and	O
btea	O
-	O
adrneergic	O
blcokade	O
.	O

Felstolol	O
produced	O
a	O
dsoe	O
-	O
dependnet	O
atetnuation	O
of	O
isoproterneol	O
-	O
idnuced	O
tcahycardia	B-Disease
.	O

Electorphysiologic	O
and	O
hemodyanmic	O
effects	O
of	O
flesotlol	O
are	O
similar	O
to	O
those	O
of	O
other	O
btea	O
blockres	O
.	O

In	O
contrast	O
with	O
other	O
btea	O
blocekrs	O
,	O
flesotlol	O
-	O
idnuced	O
effcets	O
revesre	O
rapidly	O
(	O
within	O
30	O
miuntes	O
)	O
following	O
disconitnuation	O
because	O
of	O
its	O
short	O
half	O
-	O
lfie	O
.	O

Flestooll	O
effectively	O
redcued	O
herat	O
rtae	O
in	O
paitents	O
with	O
spuraventricular	B-Disease
tachyarrhytmhia	I-Disease
.	O

In	O
paitents	O
with	O
unstable	B-Disease
anigna	I-Disease
,	O
flesotlol	O
infuison	O
was	O
found	O
to	O
be	O
safe	O
and	O
effectvie	O
in	O
controlling	O
cehst	B-Disease
pian	I-Disease
.	O

It	O
is	O
concluded	O
that	O
flestooll	O
is	O
a	O
potent	O
,	O
well	O
-	O
toleraetd	O
,	O
ulrta	O
-	O
short	O
-	O
acting	O
btea	O
-	O
adreenrgic	O
bolcking	O
agnet	O
.	O

Use	O
of	O
flestooll	O
in	O
the	O
critical	O
crae	O
setting	O
is	O
currently	O
undergoing	O
invetsigation	O
.	O

Imumnohistochemical	O
,	O
eletcron	O
microscoipc	O
and	O
mrophometric	O
studeis	O
of	O
estroegn	O
-	O
induecd	O
rat	O
prolatcinomas	B-Disease
after	O
brmoocriptine	O
treatmnet	O
.	O

To	O
clarify	O
the	O
effetcs	O
of	O
bromocriptnie	O
on	O
porlactinoma	B-Disease
cells	O
in	O
vivo	O
,	O
immunohistcohemical	O
,	O
ultrasturctural	O
and	O
morphomertical	O
anlayses	O
were	O
applied	O
to	O
esrtogen	O
-	O
indcued	O
rat	O
prolactnioma	B-Disease
clels	O
1	O
h	O
and	O
6	O
h	O
after	O
injectoin	O
of	O
bromocritpine	O
(	O
3	O
mg	O
/	O
kg	O
of	O
bdoy	O
weihgt	O
)	O
.	O

One	O
h	O
after	O
tretament	O
,	O
seurm	O
proalctin	O
lveels	O
dcereased	O
markedly	O
.	O

Eelctron	O
microscpoy	O
disclosed	O
many	O
secertory	O
garnules	O
,	O
slightly	O
distorted	O
rough	O
endoplasimc	O
reticluum	O
,	O
and	O
paritally	O
dialted	O
Gogli	O
cistrenae	O
in	O
the	O
prolatcinoma	B-Disease
cells	O
.	O

Morphometirc	O
anlaysis	O
rveealed	O
that	O
the	O
vloume	O
dnesity	O
of	O
secertory	O
granlues	O
inrceased	O
,	O
while	O
the	O
voulme	O
dnesity	O
of	O
ctyoplasmic	O
mircotubules	O
decraesed	O
.	O

These	O
finidngs	O
suggest	O
that	O
loewred	O
sreum	O
prolacitn	O
leevls	O
in	O
the	O
ealry	O
pahse	O
of	O
bromocriptnie	O
tretament	O
may	O
result	O
from	O
an	O
impiared	O
sercetion	O
of	O
prloactin	O
due	O
to	O
decreasnig	O
numbres	O
of	O
cytoplsamic	O
micortubules	O
.	O

At	O
6	O
h	O
after	O
ijnection	O
,	O
sreum	O
porlactin	O
levles	O
were	O
still	O
considerably	O
lwoer	O
than	O
in	O
cnotrols	O
.	O

The	O
prolactinmoa	B-Disease
clels	O
at	O
this	O
tmie	O
were	O
well	O
granultaed	O
,	O
with	O
vesicualted	O
rough	O
endoplsamic	O
reitculum	O
and	O
markedly	O
dilaetd	O
Glogi	O
csiternae	O
.	O

Elcetron	O
microscopiacl	O
immunohistochmeistry	O
revaeled	O
postiive	O
raection	O
porducts	O
noted	O
on	O
the	O
secretroy	O
garnules	O
,	O
Glogi	O
citsernae	O
,	O
and	O
endopalsmic	O
retiuclum	O
of	O
the	O
untreaetd	O
rat	O
prolcatinoma	B-Disease
clels	O
.	O

However	O
,	O
only	O
secertory	O
granlues	O
showed	O
the	O
positvie	O
raection	O
prodcuts	O
for	O
proalctin	O
6	O
h	O
after	O
bromocrpitine	O
tretament	O
of	O
the	O
aednoma	B-Disease
clels	O
.	O

An	O
incraese	O
in	O
the	O
vloume	O
desnity	O
of	O
secertory	O
graunles	O
and	O
a	O
dercease	O
in	O
the	O
vloume	O
densiites	O
of	O
rough	O
enodplasmic	O
rteiculum	O
and	O
micrtoubules	O
was	O
determined	O
by	O
moprhometric	O
anlaysis	O
,	O
suggesting	O
that	O
bromocirptine	O
inhbiits	O
prtoein	O
synthseis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
ditsurbance	O
of	O
the	O
prolcatin	O
secreiton	O
.	O

Sulafsalazine	O
-	O
inudced	O
luups	B-Disease
eyrthematosus	I-Disease
.	O

Pnuemonitis	B-Disease
,	O
bilatearl	O
pleuarl	B-Disease
efufsions	I-Disease
,	O
echocardiograhpic	O
evidecne	O
of	O
cardaic	B-Disease
tamopnade	I-Disease
,	O
and	O
positvie	O
auotantibodies	O
developed	O
in	O
a	O
43	O
-	O
yaer	O
-	O
old	O
man	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
suflasalazine	O
tehrapy	O
for	O
chornic	O
uclerative	B-Disease
coltiis	I-Disease
.	O

After	O
csesation	O
of	O
the	O
sulfsaalazine	O
and	O
copmletion	O
of	O
a	O
six	O
-	O
week	O
coruse	O
of	O
corticostreoids	O
,	O
these	O
prbolems	O
resolved	O
over	O
a	O
peirod	O
of	O
four	O
to	O
six	O
motnhs	O
.	O

It	O
is	O
suggested	O
that	O
the	O
ptaient	O
had	O
suflasalazine	O
-	O
idnuced	O
lpuus	B-Disease
,	O
which	O
manifested	O
with	O
seroistis	B-Disease
and	O
pumlonary	O
parenhcymal	O
ivnolvement	O
in	O
the	O
asbence	O
of	O
jiont	O
smyptoms	O
.	O

Phyiscians	O
who	O
use	O
sulfasalaizne	O
to	O
terat	O
patietns	O
with	O
infalmmatory	B-Disease
boewl	I-Disease
disesae	I-Disease
should	O
be	O
aware	O
of	O
the	O
sgins	O
of	O
sulfaaslazine	O
-	O
induecd	O
luups	B-Disease
sydnrome	I-Disease
.	O

Chornic	O
carbamazepnie	O
treatmnet	O
in	O
the	O
rat	O
:	O
effciacy	O
,	O
toxiicty	B-Disease
,	O
and	O
efefct	O
on	O
plsama	O
and	O
tissue	O
foltae	O
concentratoins	O
.	O

Floate	O
dpeletion	O
has	O
often	O
been	O
a	O
probelm	O
in	O
crhonic	O
anteipileptic	O
durg	O
(	O
AED	O
)	O
therpay	O
.	O

Carbamazeipne	O
(	O
CBZ	O
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
cilnical	O
stuides	O
.	O

A	O
rat	O
moedl	O
was	O
developed	O
to	O
examine	O
the	O
efefcts	O
of	O
chrnoic	O
CBZ	O
tretament	O
on	O
floate	O
cocnentrations	O
in	O
the	O
rat	O
.	O

In	O
the	O
cuorse	O
of	O
developing	O
this	O
mdoel	O
,	O
a	O
common	O
vheicle	O
,	O
propyelne	O
glyocl	O
,	O
by	O
itself	O
in	O
high	O
doess	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
propreties	O
against	O
induecd	O
seziures	B-Disease
and	O
ihnibited	O
wegiht	B-Disease
gain	I-Disease
.	O

Seziures	B-Disease
idnuced	O
by	O
hexfaluorodiethyl	O
ehter	O
(	O
HDFE	O
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
senistive	O
mesaure	O
of	O
protcetion	O
by	O
CBZ	O
than	O
seziures	B-Disease
induecd	O
by	O
mxaimal	O
elcetroshock	O
(	O
MES	O
)	O
.	O

Oarl	O
admiinstration	O
of	O
CBZ	O
as	O
an	O
aquoeus	O
suspensoin	O
every	O
8	O
h	O
at	O
a	O
dsoe	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuoulsy	O
protective	O
against	O
HDFE	O
-	O
indcued	O
seizrues	B-Disease
and	O
was	O
miinmally	O
toixc	O
as	O
measrued	O
by	O
wieght	B-Disease
gain	I-Disease
over	O
8	O
weeks	O
of	O
traetment	O
.	O

The	O
CBZ	O
leevls	O
meausred	O
in	O
plamsa	O
and	O
brian	O
of	O
these	O
anmials	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O

This	O
treatemnt	O
with	O
CBZ	O
had	O
no	O
apparent	O
avderse	O
efefct	O
on	O
foalte	O
concentartions	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
foltae	O
concenrtation	O
incraesed	O
in	O
lvier	O
after	O
6	O
weeks	O
of	O
teratment	O
and	O
in	O
palsma	O
at	O
8	O
weeks	O
of	O
traetment	O
.	O

Dipyrdiamole	O
-	O
induecd	O
myoacrdial	B-Disease
iscehmia	I-Disease
.	O

Anigna	B-Disease
and	O
icshemic	O
electrocardiograhpic	O
chnages	O
occurred	O
after	O
adminsitration	O
of	O
oarl	O
dipryidamole	O
in	O
four	O
patinets	O
awaiting	O
urgent	O
myocaridal	O
revasculairzation	O
prcoedures	O
.	O

To	O
our	O
knwoledge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
efefct	O
of	O
preoperaitve	O
dipryidamole	O
threapy	O
,	O
although	O
dipyridamloe	O
-	O
indcued	O
mycoardial	B-Disease
icshemia	I-Disease
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animlas	O
and	O
hmuans	O
with	O
croonary	B-Disease
artrey	I-Disease
disesae	I-Disease
.	O

Epicradial	O
croonary	O
collateral	O
vessels	O
were	O
demonstrated	O
in	O
all	O
four	O
paitents	O
;	O
a	O
coronray	O
"	O
stael	O
"	O
pheonmenon	O
may	O
be	O
the	O
mechansim	O
of	O
the	O
diypridamole	O
-	O
idnuced	O
ischmeia	B-Disease
observed	O
.	O

Inhbiition	O
of	O
sympathoardenal	O
atcivity	O
by	O
atiral	O
natiruretic	O
fcator	O
in	O
dgos	O
.	O

In	O
six	O
consciuos	O
,	O
tranied	O
dgos	O
,	O
maintained	O
on	O
a	O
noraml	O
soidum	O
inatke	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
day	O
,	O
sympatheitc	O
atcivity	O
was	O
assessed	O
as	O
the	O
relaese	O
rtae	O
of	O
norepinehprine	O
and	O
eipnephrine	O
during	O
15	O
-	O
minute	O
i	O
.	O
v	O
.	O
infuisons	O
of	O
hmuan	O
alhpa	O
-	O
atrail	O
ntariuretic	O
fatcor	O
.	O

Mean	O
arterail	O
pressrue	O
(	O
as	O
a	O
pecrentage	O
of	O
cotnrol	O
+	O
/	O
-	O
SEM	O
)	O
during	O
randmoized	O
infsuions	O
of	O
0	O
.	O
03	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
,	O
or	O
1	O
.	O
0	O
mcirogram	O
/	O
kg	O
/	O
min	O
was	O
99	O
+	O
/	O
-	O
1	O
,	O
95	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
93	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
or	O
79	O
+	O
/	O
-	O
6	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachcyardia	B-Disease
and	O
no	O
augmnetation	O
of	O
the	O
norepinephirne	O
rleease	O
rtae	O
(	O
up	O
to	O
0	O
.	O
3	O
mcirogram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotesnion	B-Disease
indcued	O
by	O
hydarlazine	O
or	O
nitrogylcerin	O
.	O

The	O
relesae	O
rtae	O
of	O
epinephrnie	O
(	O
cnotrol	O
,	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
ng	O
/	O
kg	O
/	O
min	O
)	O
delcined	O
immediately	O
during	O
inufsions	O
of	O
artial	O
natriruetic	O
fatcor	O
to	O
a	O
minimum	O
of	O
49	O
+	O
/	O
-	O
5	O
%	O
of	O
contorl	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
during	O
0	O
.	O
1	O
microgarm	O
/	O
kg	O
/	O
min	O
and	O
to	O
63	O
+	O
/	O
-	O
5	O
%	O
(	O
0	O
.	O
1	O
greater	O
than	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
or	O
95	O
+	O
/	O
-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0	O
.	O
3	O
or	O
1	O
.	O
0	O
micrgoram	O
/	O
kg	O
/	O
min	O
.	O

Steady	O
state	O
arterail	O
plamsa	O
concnetrations	O
of	O
artial	O
natruiretic	O
facotr	O
were	O
39	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
during	O
infuisons	O
of	O
slaine	O
and	O
284	O
+	O
/	O
-	O
24	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+	O
/	O
-	O
300	O
pg	O
/	O
ml	O
(	O
n	O
=	O
9	O
)	O
during	O
0	O
.	O
03	O
and	O
0	O
.	O
1	O
micrgoram	O
/	O
kg	O
/	O
min	O
ifnusions	O
of	O
the	O
fcator	O
.	O
(	O
ABSTRACT	O
TRNUCATED	O
AT	O
250	O
WORDS	O
)	O

Inihbition	O
of	O
immunoreactive	O
corticotroipn	O
-	O
releasing	O
fatcor	O
secrteion	O
into	O
the	O
hyopphysial	O
-	O
protal	O
circulatoin	O
by	O
dleayed	O
glucocoritcoid	O
feedbcak	O
.	O

Ntiroprusside	O
-	O
induecd	O
hyptoension	B-Disease
evokes	O
ATCH	O
secreiton	O
which	O
is	O
primarily	O
mediated	O
by	O
enahnced	O
secertion	O
of	O
immunorecative	O
croticotropin	O
-	O
releasing	O
fatcor	O
(	O
irRCF	O
)	O
into	O
the	O
hypophysail	O
-	O
potral	O
cicrulation	O
.	O

Potral	O
plamsa	O
concentraitons	O
of	O
neither	O
argniine	O
vasopresisn	O
nor	O
oyxtocin	O
are	O
significantly	O
alteerd	O
in	O
this	O
praadigm	O
.	O

Applciation	O
of	O
a	O
dealyed	O
feedabck	O
sginal	O
,	O
in	O
the	O
form	O
of	O
a	O
2	O
-	O
h	O
systmeic	O
cortiocsterone	O
infsuion	O
in	O
uerthane	O
-	O
anesthteized	O
rtas	O
with	O
pharmacoloigcal	O
blcokade	O
of	O
glucocortcioid	O
snythesis	O
,	O
is	O
without	O
effcet	O
on	O
the	O
rseting	O
secrteion	O
of	O
agrinine	O
vasporessin	O
and	O
oxyotcin	O
at	O
any	O
corticostreone	O
feedback	O
dsoe	O
tesetd	O
.	O

Rseting	O
iCrRF	O
lveels	O
are	O
suprpessed	O
only	O
at	O
the	O
highest	O
cortiocsterone	O
ifnusion	O
rtae	O
,	O
which	O
resulted	O
in	O
ssytemic	O
corticostreone	O
lveels	O
of	O
40	O
micorgrams	O
/	O
dl	O
.	O

Suppressoin	O
of	O
iCrRF	O
sercetion	O
in	O
respnose	O
to	O
nitroprusside	O
-	O
idnuced	O
hpyotension	B-Disease
is	O
observed	O
and	O
occurs	O
at	O
a	O
plamsa	O
corticotserone	O
lveel	O
between	O
8	O
-	O
12	O
microgarms	O
/	O
dl	O
.	O

These	O
stuides	O
provide	O
further	O
evidnece	O
for	O
a	O
strong	O
centarl	O
component	O
of	O
the	O
delyaed	O
feebdack	O
procses	O
which	O
is	O
mediated	O
by	O
modulatoin	O
of	O
irRCF	O
relesae	O
.	O

Nroadrenergic	O
inovlvement	O
in	O
catlaepsy	B-Disease
induecd	O
by	O
delta	O
9	O
-	O
tetrhaydrocannabinol	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholamniergic	O
ssytem	O
in	O
the	O
cataleptgoenic	O
efefct	O
of	O
delta	O
9	O
-	O
tetrahydrocnanabinol	O
(	O
THC	O
)	O
,	O
the	O
effcet	O
of	O
prerteatment	O
with	O
6	O
-	O
hydroyxdopamine	O
(	O
6	O
-	O
ODHA	O
)	O
or	O
with	O
desipramnie	O
and	O
6	O
-	O
ODHA	O
and	O
lesinos	O
of	O
the	O
lcous	O
ceoruleus	O
were	O
investgiated	O
in	O
rtas	O
.	O

The	O
cataletpogenic	O
efefct	O
of	O
THC	O
was	O
significantly	O
reudced	O
in	O
rtas	O
traeted	O
with	O
6	O
-	O
ODHA	O
and	O
in	O
rtas	O
with	O
lseions	O
of	O
the	O
lcous	O
coeurleus	O
but	O
not	O
in	O
rtas	O
treaetd	O
with	O
despiramine	O
and	O
6	O
-	O
ODHA	O
,	O
as	O
cmopared	O
with	O
cotnrol	O
rtas	O
.	O

On	O
the	O
contrary	O
,	O
the	O
ctaaleptogenic	O
efefct	O
of	O
haloepridol	O
was	O
significantly	O
reduecd	O
in	O
rtas	O
tretaed	O
with	O
desipraimne	O
and	O
6	O
-	O
ODHA	O
but	O
not	O
in	O
rtas	O
treaetd	O
with	O
6	O
-	O
ODHA	O
or	O
in	O
rtas	O
with	O
leisons	O
of	O
the	O
lcous	O
coerulues	O
.	O

These	O
rseults	O
indicate	O
that	O
noradrneergic	O
neurnos	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestatoin	O
of	O
catalespy	B-Disease
idnuced	O
by	O
THC	O
,	O
whereas	O
dopamniergic	O
nuerons	O
are	O
important	O
in	O
ctaalepsy	B-Disease
induecd	O
by	O
halopreidol	O
.	O

Revresibility	O
of	O
cpatopril	O
-	O
idnuced	O
reanl	B-Disease
inusfficiency	I-Disease
after	O
prolnoged	O
use	O
in	O
an	O
unusaul	O
csae	O
of	O
renovascualr	B-Disease
hpyertension	I-Disease
.	O

We	O
reprot	O
a	O
csae	O
of	O
sveere	O
hyperetnsion	B-Disease
with	O
an	O
occluded	O
rneal	O
atrery	O
to	O
a	O
solitray	O
kindey	O
,	O
who	O
developed	O
sudedn	B-Disease
deteiroration	I-Disease
of	I-Disease
rneal	I-Disease
funciton	I-Disease
following	O
tretament	O
with	O
captorpil	O
.	O

His	O
reanl	O
funciton	O
remained	O
imapired	O
but	O
stbale	O
during	O
2	O
yaers	O
'	O
treatemnt	O
with	O
catpopril	O
but	O
returned	O
to	O
pre	O
-	O
treatemnt	O
leevls	O
soon	O
after	O
cesstaion	O
of	O
the	O
durg	O
.	O

This	O
indicates	O
rveersibility	O
in	O
captopirl	O
-	O
inudced	O
rneal	B-Disease
faiulre	I-Disease
even	O
after	O
its	O
prolnoged	O
use	O
and	O
suggests	O
that	O
no	O
orgainc	O
daamge	O
occurs	O
to	O
glomreular	O
arteriloes	O
following	O
crhonic	O
ACE	O
inhiibtion	O
.	O

HMG	O
CoA	O
reducatse	O
inhiibtors	O
.	O

Current	O
clniical	O
expreience	O
.	O

Lovsatatin	O
and	O
sivmastatin	O
are	O
the	O
2	O
best	O
-	O
known	O
mmebers	O
of	O
the	O
calss	O
of	O
hypoilpidaemic	O
agetns	O
known	O
as	O
HMG	O
CoA	O
rdeuctase	O
inhibtiors	O
.	O

Cliniacl	O
exeprience	O
with	O
lovsatatin	O
includes	O
over	O
5000	O
pateints	O
,	O
700	O
of	O
whom	O
have	O
been	O
traeted	O
for	O
2	O
yeras	O
or	O
more	O
,	O
and	O
exeprience	O
with	O
sivmastatin	O
includes	O
over	O
3500	O
paitents	O
,	O
of	O
whom	O
350	O
have	O
been	O
tretaed	O
for	O
18	O
motnhs	O
or	O
more	O
.	O

Lovastaitn	O
has	O
been	O
marketed	O
in	O
the	O
Unietd	O
Staets	O
for	O
over	O
6	O
mnoths	O
.	O

Both	O
aegnts	O
show	O
substantial	O
cliniacl	O
effiaccy	O
,	O
with	O
reudctions	O
in	O
total	O
cholesetrol	O
of	O
over	O
30	O
%	O
and	O
in	O
LDL	O
-	O
cohlesterol	O
of	O
40	O
%	O
in	O
cliniacl	O
studeis	O
.	O

Modset	O
increaess	O
in	O
HDL	O
-	O
choletserol	O
levles	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O

Clniical	O
toleraiblity	O
of	O
both	O
agetns	O
has	O
been	O
good	O
,	O
with	O
fewer	O
than	O
3	O
%	O
of	O
patietns	O
withdrawn	O
from	O
treatemnt	O
because	O
of	O
cliniacl	O
advrese	O
experiecnes	O
.	O

Ophthamlological	O
examniations	O
in	O
over	O
1100	O
ptaients	O
treaetd	O
with	O
one	O
or	O
the	O
other	O
aegnt	O
have	O
revaeled	O
no	O
eviednce	O
of	O
significant	O
short	O
term	O
(	O
up	O
to	O
2	O
yeras	O
)	O
cataractogneic	O
ptoential	O
.	O

One	O
to	O
2	O
%	O
of	O
patietns	O
have	O
eleavtions	O
of	O
sreum	O
transaminsaes	O
to	O
greater	O
than	O
3	O
times	O
the	O
upepr	O
liimt	O
of	O
nromal	O
.	O

These	O
episoeds	O
are	O
asymtpomatic	O
and	O
reversible	O
when	O
therpay	O
is	O
discontiuned	O
.	O

Minor	O
elveations	O
of	O
creaitne	O
kniase	O
lveels	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patietns	O
.	O

Myopahty	B-Disease
,	O
associated	O
in	O
some	O
caess	O
with	O
myoglobniuria	B-Disease
,	O
and	O
in	O
2	O
csaes	O
with	O
tarnsient	O
rneal	B-Disease
faiulre	I-Disease
,	O
has	O
been	O
rarely	O
reported	O
with	O
loavstatin	O
,	O
especially	O
in	O
pateints	O
concomitantly	O
traeted	O
with	O
cyclosproin	O
,	O
gemfbirozil	O
or	O
naicin	O
.	O

Lovasattin	O
and	O
simavstatin	O
are	O
both	O
effectvie	O
and	O
well	O
-	O
tolearted	O
aegnts	O
for	O
lowernig	O
elevtaed	O
lveels	O
of	O
seurm	O
choelsterol	O
.	O

As	O
wider	O
use	O
confirms	O
their	O
saftey	O
prfoile	O
,	O
they	O
will	O
gain	O
inrceasing	O
importance	O
in	O
the	O
threapeutic	O
approach	O
to	O
hypercholesteroleamia	B-Disease
and	O
its	O
consqeuences	O
.	O

Hpeatic	O
reactinos	O
associated	O
with	O
ketoconaozle	O
in	O
the	O
Unietd	O
Kindgom	O
.	O

Keotconazole	O
was	O
introduced	O
in	O
the	O
Untied	O
Kigndom	O
in	O
1981	O
.	O

By	O
Novmeber	O
1984	O
the	O
Cmomittee	O
on	O
Saftey	O
of	O
Meidcines	O
had	O
received	O
82	O
rpeorts	O
of	O
possible	O
hpeatotoxicity	B-Disease
associated	O
with	O
the	O
durg	O
,	O
including	O
five	O
detahs	B-Disease
.	O

An	O
analsyis	O
of	O
the	O
75	O
caess	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
detahs	B-Disease
,	O
were	O
probably	O
related	O
to	O
teratment	O
with	O
the	O
durg	O
.	O

Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
traetment	O
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O

The	O
mean	O
age	O
of	O
ptaients	O
in	O
the	O
16	O
probable	O
csaes	O
was	O
57	O
.	O
9	O
,	O
with	O
hepatotoxciity	B-Disease
being	O
more	O
common	O
in	O
woemn	O
.	O

The	O
avearge	O
duratoin	O
of	O
treamtent	O
before	O
the	O
onset	O
of	O
jaundcie	B-Disease
was	O
61	O
dyas	O
.	O

None	O
of	O
these	O
well	O
validated	O
caess	O
occurred	O
within	O
the	O
first	O
10	O
dyas	O
after	O
teratment	O
.	O

The	O
rseults	O
of	O
seurm	O
lievr	O
funciton	O
tsets	O
suggested	O
hepaotcellular	B-Disease
inujry	I-Disease
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
pattern	O
.	O

In	O
contrast	O
,	O
the	O
rseults	O
of	O
histologiacl	O
examinaiton	O
of	O
the	O
lievr	O
often	O
showed	O
evidecne	O
of	O
cholesatsis	B-Disease
.	O

The	O
cahracteristics	O
of	O
the	O
48	O
patinets	O
in	O
the	O
possible	O
csaes	O
were	O
similar	O
.	O

Allerigc	O
manfiestations	O
such	O
as	O
rsah	B-Disease
and	O
eosionphilia	B-Disease
were	O
rrae	O
.	O

Hepaittis	B-Disease
was	O
usually	O
reversible	O
when	O
treatmnet	O
was	O
stopped	O
,	O
with	O
the	O
resutls	O
of	O
lvier	O
funciton	O
tetss	O
retruning	O
to	O
nomral	O
after	O
an	O
avergae	O
of	O
3	O
.	O
1	O
motnhs	O
.	O

In	O
two	O
of	O
the	O
three	O
detahs	B-Disease
probably	O
associated	O
with	O
ketocnoazole	O
tretament	O
the	O
durg	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundcie	B-Disease
and	O
other	O
symptmos	O
of	O
hpeatitis	B-Disease
.	O

Cliniacl	O
and	O
boichemical	O
montioring	O
at	O
regular	O
interavls	O
for	O
evdience	O
of	O
hepaittis	B-Disease
is	O
advised	O
during	O
long	O
term	O
traetment	O
with	O
keotconazole	O
to	O
prevnet	O
possible	O
serious	O
hepaitc	B-Disease
inujry	I-Disease
.	O

Glybruide	O
-	O
inudced	O
hpeatitis	B-Disease
.	O

Durg	O
-	O
idnuced	O
hepatotoxictiy	B-Disease
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylrueas	O
.	O

For	O
glyburdie	O
,	O
a	O
second	O
-	O
generaiton	O
suflonylurea	O
,	O
only	O
two	O
brief	O
reoprts	O
of	O
hepatotxoicity	B-Disease
exist	O
.	O

Two	O
pateints	O
with	O
tpye	B-Disease
II	I-Disease
dibaetes	I-Disease
meliltus	I-Disease
developed	O
an	O
actue	B-Disease
heptaitis	I-Disease
-	I-Disease
like	I-Disease
sydnrome	I-Disease
soon	O
after	O
iniitation	O
of	O
glyburdie	O
therpay	O
.	O

There	O
was	O
no	O
serolgoic	O
eviednce	O
of	O
vrial	B-Disease
infcetion	I-Disease
,	O
and	O
a	O
lvier	O
biposy	O
samlpe	O
showed	O
a	O
hisotlogic	O
pattern	O
consistent	O
with	O
durg	B-Disease
-	I-Disease
idnuced	I-Disease
hepatiits	I-Disease
.	O

Both	O
pateints	O
recvoered	O
quickly	O
after	O
stopping	O
glybuirde	O
thearpy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
preiod	O
of	O
1	O
yaer	O
.	O

Glyubride	O
can	O
produce	O
an	O
aucte	B-Disease
hepaittis	I-Disease
-	I-Disease
like	I-Disease
illnses	I-Disease
in	O
some	O
persnos	O
.	O

Intracranail	O
pressrue	O
incraeses	O
during	O
aflentanil	O
-	O
induecd	O
rigiidty	B-Disease
.	O

Intarcranial	O
presusre	O
(	O
ICP	O
)	O
was	O
meausred	O
during	O
alefntanil	O
-	O
idnuced	O
rigiidty	B-Disease
in	O
rtas	O
.	O

Ten	O
rtas	O
had	O
atrerial	O
,	O
centarl	O
vneous	O
(	O
CVP	O
)	O
,	O
and	O
sudbural	O
cannulae	O
inserted	O
under	O
haolthane	O
anestehsia	O
.	O

The	O
aniamls	O
were	O
mechaniclaly	O
ventialted	O
to	O
achieve	O
normocabria	O
(	O
POC2	O
=	O
42	O
+	O
/	O
-	O
1	O
mmHg	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

Following	O
instrumentaiton	O
,	O
haolthane	O
was	O
discontineud	O
and	O
alefntanil	O
(	O
125	O
mu	O
/	O
kg	O
)	O
administeerd	O
iv	O
during	O
eemrgence	O
from	O
haolthane	O
anestehsia	O
.	O

In	O
the	O
five	O
rtas	O
that	O
developed	O
somtaic	B-Disease
rigdiity	I-Disease
,	O
ICP	O
and	O
CVP	O
inrceased	O
significantly	O
above	O
baesline	O
(	O
delta	O
ICP	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mmHg	O
,	O
delta	O
CVP	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
mmHg	O
)	O
.	O

These	O
variabels	O
returned	O
to	O
baesline	O
when	O
rigidtiy	B-Disease
was	O
abolished	O
with	O
metoucrine	O
.	O

In	O
five	O
rtas	O
that	O
did	O
not	O
become	O
rgiid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentnail	O
.	O

These	O
observtaions	O
suggest	O
that	O
rigdiity	B-Disease
should	O
be	O
prevented	O
when	O
alefntanil	O
,	O
and	O
,	O
presumably	O
,	O
other	O
opitaes	O
,	O
are	O
used	O
in	O
the	O
aensthetic	O
mangaement	O
of	O
pateints	O
with	O
ICP	O
probelms	O
.	O

Vearpamil	O
withrdawal	O
as	O
a	O
possible	O
cause	O
of	O
myocadrial	B-Disease
ifnarction	I-Disease
in	O
a	O
hypertesnive	B-Disease
wmoan	O
with	O
a	O
nomral	O
coronray	O
angoigram	O
.	O

Verapmail	O
is	O
an	O
effetcive	O
and	O
relatively	O
-	O
safe	O
antihypertenisve	O
durg	O
.	O

Seriuos	O
adevrse	O
effcets	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depressoin	B-Disease
of	O
cardaic	O
contractiilty	O
and	O
codnuction	O
,	O
especially	O
when	O
the	O
durg	O
is	O
combnied	O
with	O
btea	O
-	O
blokcing	O
agetns	O
.	O

We	O
reprot	O
a	O
csae	O
in	O
which	O
myocradial	B-Disease
infarciton	I-Disease
coincided	O
with	O
the	O
itnroduction	O
of	O
captporil	O
and	O
the	O
wihtdrawal	O
of	O
vearpamil	O
in	O
a	O
previously	O
asymptomaitc	O
woamn	O
with	O
sevree	O
hypretension	B-Disease
.	O

Possible	O
mechanimss	O
that	O
involve	O
a	O
verapmail	O
-	O
related	O
incresae	O
in	O
platleet	O
and	O
/	O
or	O
vsacular	O
aplha	O
2	O
-	O
ardenoreceptor	O
affniity	O
for	O
catecohlamines	O
are	O
discussed	O
.	O

Heamolytic	B-Disease
-	I-Disease
ureamic	I-Disease
syndrmoe	I-Disease
after	O
tretament	O
with	O
metornidazole	O
.	O

This	O
paper	O
describes	O
the	O
clniical	O
feautres	O
of	O
six	O
childern	O
who	O
developed	O
the	O
haemoltyic	B-Disease
-	I-Disease
ureamic	I-Disease
sydnrome	I-Disease
after	O
treamtent	O
with	O
metornidazole	O
.	O

These	O
cihldren	O
were	O
odler	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bwoel	O
suregry	O
than	O
are	O
other	O
chilrden	O
with	O
this	O
conditoin	O
.	O

While	O
the	O
involevment	O
of	O
metrondiazole	O
in	O
the	O
aetoilogy	O
of	O
the	O
heamolytic	B-Disease
-	I-Disease
uraeimc	I-Disease
sydnrome	I-Disease
is	O
not	O
established	O
firmly	O
,	O
the	O
actoin	O
of	O
this	O
durg	O
in	O
snesitizing	O
tisuses	O
to	O
oixdation	O
ijnury	O
and	O
the	O
reported	O
evidecne	O
of	O
oxidatoin	O
chanegs	O
in	O
the	O
haemolyitc	B-Disease
-	I-Disease
uaremic	I-Disease
sydnrome	I-Disease
suggest	O
a	O
possible	O
link	O
between	O
metroindazole	O
teratment	O
and	O
some	O
caess	O
of	O
the	O
haeomlytic	B-Disease
-	I-Disease
urameic	I-Disease
sydnrome	I-Disease
.	O

Avderse	O
caridac	O
efefcts	O
during	O
inductoin	O
chemtoherapy	O
treatmnet	O
with	O
cis	O
-	O
pltain	O
and	O
5	O
-	O
fluorouarcil	O
.	O

Suvrival	O
for	O
paitents	O
with	O
advacned	O
haed	B-Disease
and	I-Disease
ncek	I-Disease
cacrinoma	I-Disease
and	O
esophaegal	B-Disease
caricnoma	I-Disease
is	O
poor	O
with	O
radoitherapy	O
and	O
/	O
or	O
srugery	O
.	O

Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
effcetive	O
chemtoherapy	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
cis	O
-	O
pltain	O
(	O
80	O
-	O
120	O
mg	O
/	O
m2SBA	O
)	O
and	O
5	O
-	O
FU	O
(	O
1000	O
mg	O
/	O
mB2SA	O
daliy	O
as	O
a	O
conitnuous	O
infuison	O
during	O
5	O
dyas	O
)	O
were	O
given	O
to	O
76	O
ptaients	O
before	O
raditoherapy	O
and	O
srugery	O
.	O

The	O
aim	O
of	O
the	O
sutdy	O
was	O
to	O
clarify	O
the	O
incidecne	O
and	O
severtiy	O
of	O
advesre	O
cadriac	O
efefcts	O
to	O
this	O
teratment	O
.	O

Before	O
traetment	O
all	O
patietns	O
had	O
a	O
cradiac	O
evaulation	O
and	O
during	O
teratment	O
serail	O
ECG	O
recoridngs	O
were	O
performed	O
.	O

In	O
the	O
pre	O
-	O
treatmnet	O
evalaution	O
,	O
sings	O
of	O
caridovascular	B-Disease
disaese	I-Disease
were	O
found	O
in	O
33	O
ptaients	O
(	O
43	O
%	O
)	O
.	O

During	O
treatmnet	O
,	O
avderse	O
caridac	O
efefcts	O
were	O
observed	O
in	O
14	O
patinets	O
(	O
18	O
%	O
)	O
.	O

The	O
mean	O
age	O
of	O
these	O
paitents	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
gruop	O
,	O
64	O
yaers	O
.	O

The	O
incidecne	O
of	O
cadriotoxicity	B-Disease
was	O
not	O
hgiher	O
in	O
patinets	O
with	O
sings	O
of	O
cradiovascular	B-Disease
diesase	I-Disease
than	O
in	O
those	O
without	O
in	O
the	O
pre	O
-	O
tretament	O
evaluatoin	O
.	O

The	O
most	O
common	O
sgins	O
of	O
cardiotoxictiy	B-Disease
were	O
chset	B-Disease
pian	I-Disease
,	O
ST	O
-	O
T	O
wvae	O
chagnes	O
and	O
atiral	B-Disease
fibirllation	I-Disease
.	O

This	O
was	O
followed	O
by	O
ventricualr	B-Disease
fibrillatoin	I-Disease
in	O
one	O
paitent	O
and	O
sudden	B-Disease
daeth	I-Disease
in	O
another	O
.	O

It	O
is	O
concluded	O
that	O
pateints	O
on	O
5	O
-	O
FU	O
treatmnet	O
should	O
be	O
under	O
close	O
supervisoin	O
and	O
that	O
the	O
teratment	O
should	O
be	O
discotninued	O
if	O
cehst	B-Disease
pian	I-Disease
or	O
tachyarrhythmia	B-Disease
is	O
observed	O
.	O

Detah	B-Disease
from	O
chmeotherapy	O
in	O
gestaitonal	B-Disease
trophbolastic	I-Disease
dsiease	I-Disease
.	O

Mutliple	O
cyttooxic	O
durg	O
admniistration	O
is	O
the	O
generally	O
accepted	O
traetment	O
of	O
pateints	O
with	O
a	O
high	O
-	O
rsik	O
satge	O
of	O
choriocarcionma	B-Disease
.	O

Based	O
on	O
this	O
principle	O
a	O
27	O
-	O
yaer	O
old	O
wmoan	O
,	O
classified	O
as	O
being	O
in	O
the	O
high	O
-	O
rsik	O
gorup	O
(	O
Godlstein	O
and	O
Bekrowitz	O
socre	O
:	O
11	O
)	O
,	O
was	O
traeted	O
with	O
mutliple	O
cytootxic	O
drgus	O
.	O

The	O
mulitple	O
durg	O
shcema	O
consisted	O
of	O
:	O
Etopsoide	O
16	O
.	O
213	O
,	O
Methtorexate	O
,	O
Cyclophopshamide	O
,	O
Acotmycin	O
-	O
D	O
,	O
and	O
Cisplaitn	O
.	O

On	O
the	O
first	O
day	O
of	O
the	O
schdeule	O
,	O
moedrate	O
high	O
dsoes	O
of	O
Methtorexate	O
,	O
Eotposide	O
and	O
Cyclophoshpamide	O
were	O
adminsitered	O
.	O

Within	O
8	O
hours	O
after	O
initiaiton	O
of	O
threapy	O
the	O
paitent	O
deid	O
with	O
a	O
cilnical	O
pitcure	O
resembling	O
massive	O
pulmoanry	B-Disease
obsturction	I-Disease
due	O
to	O
choirocarcinomic	O
tsisue	O
pulgs	O
,	O
probably	O
originating	O
from	O
the	O
uteurs	O
.	O

Fromation	O
of	O
these	O
plgus	O
was	O
probably	O
due	O
to	O
extnesive	O
tuomr	B-Disease
nercosis	B-Disease
at	O
the	O
lveel	O
of	O
the	O
walls	O
of	O
the	O
major	O
utreine	O
viens	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exhcange	O
of	O
tmuor	B-Disease
plgus	O
to	O
the	O
vascualr	O
spaecs	O
;	O
decresae	O
in	O
tmuor	B-Disease
tisuse	O
coheernce	O
secondary	O
to	O
cheomtherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
fromation	O
of	O
tmuor	B-Disease
embloi	O
.	O

In	O
view	O
of	O
the	O
close	O
tmie	O
associtaion	O
between	O
the	O
start	O
of	O
chemtoherapy	O
and	O
the	O
aucte	O
onset	O
of	O
massive	O
ebmolism	B-Disease
other	O
explanations	O
,	O
such	O
as	O
spontnaeous	O
ncerosis	B-Disease
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O

Patinets	O
with	O
large	O
pelivc	B-Disease
tmuor	I-Disease
laods	O
are	O
,	O
according	O
to	O
existing	O
classificatoins	O
,	O
at	O
high	O
rsik	O
to	O
die	O
and	O
to	O
develop	O
durg	O
ressitance	O
.	O

Notwithstanding	O
these	O
facts	O
our	O
findnigs	O
suggest	O
that	O
these	O
paitents	O
might	O
bneefit	O
from	O
relatively	O
mlid	O
initial	O
tretament	O
,	O
especially	O
true	O
for	O
ptaients	O
not	O
previously	O
exopsed	O
to	O
this	O
durg	O
.	O

Close	O
observatoin	O
of	O
the	O
rseponse	O
sttaus	O
both	O
cilnically	O
and	O
with	O
btea	O
-	O
hCG	O
vaules	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
argessive	O
combintaion	O
cehmotherapy	O
should	O
be	O
started	O
.	O
(	O
ABSTRACT	O
TRNUCATED	O
AT	O
250	O
WORDS	O
)	O

Pumlonary	O
suhnt	O
and	O
cardiovascualr	O
resposnes	O
to	O
CAPP	O
during	O
nitroprsuside	O
-	O
inudced	O
hypotensoin	B-Disease
.	O

The	O
efefcts	O
of	O
cnotinuous	O
posiitve	O
aiwray	O
pressrue	O
(	O
CAPP	O
)	O
on	O
caridovascular	O
dynaimcs	O
and	O
pulmonray	O
suhnt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investiagted	O
in	O
12	O
dgos	O
before	O
and	O
during	O
soduim	O
nirtoprusside	O
inufsion	O
that	O
decerased	O
mean	O
arterail	O
bolod	O
perssure	O
40	O
-	O
50	O
per	O
cent	O
.	O

Before	O
ntiroprusside	O
infuison	O
,	O
5	O
cm	O
H2O	O
CAPP	O
significantly	O
,	O
P	O
less	O
than	O
.	O
05	O
,	O
decraesed	O
arteiral	O
blood	O
pressure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
haert	O
rtae	O
,	O
cadriac	O
outupt	O
,	O
systeimc	O
vasuclar	O
resistnace	O
,	O
or	O
QS	O
/	O
QT	O
.	O

Ten	O
cm	O
H2O	O
CAPP	O
before	O
nitroprsuside	O
infsuion	O
produced	O
a	O
further	O
decresae	B-Disease
in	I-Disease
aretrial	I-Disease
bolod	I-Disease
prsesure	I-Disease
and	O
significantly	O
inrceased	O
herat	O
rtae	O
and	O
decreaesd	B-Disease
cadriac	I-Disease
otuput	I-Disease
and	O
QS	O
/	O
QT	O
.	O

Nitroprusisde	O
caused	O
significant	O
derceases	B-Disease
in	I-Disease
arteiral	I-Disease
bolod	I-Disease
pressure	I-Disease
and	O
ssytemic	O
vascluar	O
reisstance	O
and	O
incerases	O
in	O
haert	O
rtae	O
,	O
but	O
did	O
not	O
change	O
cadriac	O
otuput	O
or	O
QS	O
/	O
QT	O
.	O

Five	O
cm	O
H2O	O
CAPP	O
during	O
nitorprusside	O
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
vairables	O
.	O

However	O
,	O
10	O
cm	O
H2O	O
CAPP	O
derceased	O
artreial	O
blood	O
pressrue	O
,	O
cradiac	O
otuput	O
,	O
and	O
QS	O
/	O
QT	O
.	O

These	O
dtaa	O
indicate	O
that	O
ntiroprusside	O
infusoin	O
rtaes	O
that	O
decraese	O
mean	O
arteiral	O
blood	O
prsesure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
cradiac	O
ouptut	O
or	O
QS	O
/	O
QT	O
.	O

During	O
nitroprussdie	O
infuison	O
low	O
levles	O
of	O
CAPP	O
do	O
not	O
markedly	O
alter	O
cardiovascluar	O
dnyamics	O
,	O
but	O
high	O
leevls	O
of	O
CAPP	O
(	O
10	O
cm	O
H2O	O
)	O
,	O
while	O
derceasing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
derceases	B-Disease
in	I-Disease
aretrial	I-Disease
blood	I-Disease
pressure	I-Disease
and	I-Disease
cardaic	I-Disease
ouptut	I-Disease
.	O

Systoilc	O
prsesure	O
vraiation	O
is	O
greater	O
during	O
hemorhrage	B-Disease
than	O
during	O
soduim	O
nitropursside	O
-	O
indcued	O
hpyotension	B-Disease
in	O
venitlated	O
dgos	O
.	O

The	O
sysotlic	O
pressrue	O
vraiation	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
mxaimal	O
and	O
mniimal	O
vaules	O
of	O
the	O
systloic	O
blood	O
prsesure	O
(	O
SBP	O
)	O
after	O
one	O
positvie	O
-	O
presusre	O
bretah	O
,	O
was	O
studied	O
in	O
ventilaetd	O
dgos	O
subjected	O
to	O
hypotenison	B-Disease
.	O

Mean	O
arteiral	O
prsesure	O
was	O
derceased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
mintues	O
either	O
by	O
heomrrhage	B-Disease
(	O
HEM	B-Disease
,	O
n	O
=	O
7	O
)	O
or	O
by	O
contiunous	O
ifnusion	O
of	O
soduim	O
nitorprusside	O
(	O
SNP	O
,	O
n	O
=	O
7	O
)	O
.	O

During	O
HEM	B-Disease
-	O
inudced	O
hypotesnion	B-Disease
the	O
cradiac	O
otuput	O
was	O
significantly	O
loewr	O
and	O
sysetmic	O
vascluar	O
ressitance	O
higehr	O
copmared	O
with	O
that	O
in	O
the	O
SNP	O
gorup	O
.	O

The	O
systeimc	O
,	O
cetnral	O
veonus	O
,	O
plumonary	O
caplilary	O
wegde	O
pressures	O
,	O
and	O
herat	O
rtaes	O
,	O
were	O
similar	O
in	O
the	O
two	O
gruops	O
.	O

Analyiss	O
of	O
the	O
repsiratory	O
chnages	O
in	O
the	O
artreial	O
pressrue	O
wvaeform	O
enabled	O
differetniation	O
between	O
the	O
two	O
gruops	O
.	O

The	O
SPV	O
during	O
hpyotension	B-Disease
was	O
15	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
7	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
gruop	O
,	O
compaerd	O
with	O
9	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
0	O
mm	O
Hg	O
in	O
the	O
SNP	O
gorup	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

The	O
delta	O
down	O
,	O
which	O
is	O
the	O
measrue	O
of	O
decresae	O
of	O
SBP	O
after	O
a	O
mechancial	O
berath	O
,	O
was	O
20	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
4	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
and	O
SNP	O
gorups	O
,	O
respectively	O
,	O
during	O
hpyotension	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
incresaes	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characterisitc	O
of	O
a	O
hypoetnsive	B-Disease
state	O
due	O
to	O
a	O
perdominant	O
decresae	O
in	O
prelaod	O
.	O

They	O
are	O
thus	O
more	O
important	O
during	O
asbolute	O
hypovoelmia	B-Disease
than	O
during	O
delibertae	O
hpyotension	B-Disease
.	O

Vetnricular	B-Disease
tachyarrhythmais	I-Disease
during	O
cesraean	O
seciton	O
after	O
ritodrnie	O
therpay	O
:	O
itneraction	O
with	O
aensthetics	O
.	O

This	O
csae	O
illustrates	O
that	O
patietns	O
receiving	O
ritordine	O
for	O
pretrem	B-Disease
laobr	I-Disease
may	O
rsik	O
inetractions	O
between	O
the	O
residaul	O
betmaimetic	O
efefcts	O
of	O
rtiodrine	O
and	O
the	O
effetcs	O
of	O
anestheitcs	O
during	O
ceasrean	O
scetion	O
.	O

Such	O
inetractions	O
may	O
result	O
in	O
serious	O
cardioavscular	B-Disease
complictaions	I-Disease
even	O
after	O
cessatoin	O
of	O
an	O
infusoin	O
of	O
riotdrine	O
.	O

Preoperatvie	O
assessemnt	O
should	O
focus	O
on	O
cradiovascular	O
sattus	O
and	O
sreum	O
potasisum	O
leevl	O
.	O

Delyaing	O
inductoin	O
of	O
anetshesia	O
should	O
be	O
considered	O
whenever	O
possible	O
.	O

Careful	O
fliud	O
admiinstration	O
and	O
cautious	O
use	O
of	O
ttirated	O
doess	O
of	O
ehpedrine	O
are	O
advised	O
.	O

After	O
delievry	O
of	O
the	O
ifnant	O
,	O
there	O
should	O
be	O
no	O
contraidnication	O
to	O
the	O
use	O
of	O
an	O
alhpa	O
-	O
adreenrgic	O
vasoprsesor	O
such	O
as	O
phenylpehrine	O
to	O
terat	O
hypotensvie	B-Disease
pateints	O
with	O
tachycarida	B-Disease
.	O

Vearpamil	O
-	O
indcued	O
carbamaezpine	O
neurotoxiicty	B-Disease
.	O

A	O
reprot	O
of	O
two	O
csaes	O
.	O

Two	O
paitents	O
with	O
sgins	O
of	O
carbmaazepine	O
neurotoxciity	B-Disease
after	O
comibned	O
tretament	O
with	O
verapaiml	O
showed	O
complete	O
reocvery	O
after	O
disconitnuation	O
of	O
the	O
caclium	O
etnry	O
bolcker	O
.	O

Use	O
of	O
veraapmil	O
in	O
cobmination	O
with	O
carbamazepnie	O
should	O
either	O
be	O
avoided	O
or	O
prescrbied	O
only	O
with	O
appropriate	O
adjustemnt	O
of	O
the	O
carbmaazepine	O
dsoe	O
(	O
usually	O
reduciton	O
of	O
the	O
crabamazepine	O
dsoe	O
by	O
one	O
half	O
)	O
.	O

Paraceatmol	O
-	O
associated	O
cmoa	B-Disease
,	O
meatbolic	B-Disease
aicdosis	I-Disease
,	O
reanl	B-Disease
and	I-Disease
hepaitc	I-Disease
fialure	I-Disease
.	O

A	O
csae	O
of	O
metaboilc	B-Disease
aciodsis	I-Disease
,	O
aucte	B-Disease
rneal	I-Disease
faliure	I-Disease
and	I-Disease
hepaitc	I-Disease
failrue	I-Disease
following	O
parcaetamol	O
ignestion	O
is	O
presented	O
.	O

The	O
diagnsotic	O
dififculty	O
at	O
preesntation	O
is	O
highlighted	O
.	O

Cnotinuous	O
arterivoenous	O
haemfoiltration	O
proved	O
a	O
valuable	O
means	O
of	O
maintaining	O
fulid	O
and	O
electroltye	O
balnace	O
.	O

The	O
pateint	O
rceovered	O
.	O

Seuxal	B-Disease
dyfsunction	I-Disease
among	O
ptaients	O
with	O
arthrtiis	B-Disease
.	O

The	O
relaitonship	O
of	O
arhtritis	B-Disease
and	O
sexaul	B-Disease
dysfucntion	I-Disease
was	O
investigaetd	O
among	O
169	O
patietns	O
with	O
rhuematoid	B-Disease
arthrtiis	I-Disease
,	O
ostoearthritis	B-Disease
and	O
spondyolarthropathy	B-Disease
,	O
130	O
of	O
whom	O
were	O
piar	O
-	O
matched	O
to	O
contrlos	O
.	O

Asesssments	O
of	O
mairtal	O
happienss	O
and	O
depresesd	B-Disease
mood	I-Disease
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azirn	O
Martial	O
Happiness	O
Sclae	O
(	O
AHMS	O
)	O
.	O

Sexaul	B-Disease
dysufnctions	I-Disease
were	O
found	O
to	O
be	O
common	O
among	O
pateints	O
and	O
contrlos	O
,	O
the	O
majority	O
in	O
both	O
gruops	O
reporting	O
one	O
or	O
more	O
dsyfunctions	O
.	O

Impotecne	B-Disease
was	O
more	O
common	O
among	O
mlae	O
patinets	O
than	O
cotnrols	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	O
-	O
morbidtiy	O
and	O
the	O
taking	O
of	O
methotreaxte	O
.	O

Dperessed	B-Disease
mood	I-Disease
was	O
more	O
common	O
among	O
paitents	O
and	O
was	O
associated	O
with	O
certain	O
seuxal	O
difficluties	O
,	O
but	O
not	O
with	O
ipmotence	B-Disease
.	O

Mraital	O
unhappniess	O
,	O
as	O
indicated	O
by	O
AHMS	O
socres	O
,	O
was	O
not	O
associated	O
with	O
arthriits	B-Disease
but	O
was	O
associated	O
with	O
sxeual	B-Disease
dysfunctoin	I-Disease
,	O
sxeual	O
dissatsifaction	O
and	O
being	O
feamle	O
.	O

Does	O
praacetamol	O
cause	O
uorthelial	B-Disease
cnacer	I-Disease
or	O
reanl	B-Disease
papillray	I-Disease
necorsis	I-Disease
?	O

The	O
rsik	O
of	O
developing	O
reanl	B-Disease
papilalry	I-Disease
necrsois	I-Disease
or	O
canecr	B-Disease
of	I-Disease
the	I-Disease
rneal	I-Disease
plevis	I-Disease
,	I-Disease
ureetr	I-Disease
or	I-Disease
bladder	I-Disease
associated	O
with	O
consumpiton	O
of	O
either	O
phenaceitn	O
or	O
parcaetamol	O
was	O
calculated	O
from	O
dtaa	O
acquired	O
by	O
qusetionnaire	O
from	O
381	O
csaes	O
and	O
808	O
contrlos	O
.	O

The	O
rsik	O
of	O
rneal	B-Disease
paipllary	I-Disease
necroiss	I-Disease
was	O
inrceased	O
nearly	O
20	O
-	O
fold	O
by	O
consumptoin	O
of	O
phenactein	O
,	O
which	O
also	O
incraesed	O
the	O
rsik	O
for	O
cacner	B-Disease
of	I-Disease
the	I-Disease
rneal	I-Disease
pelivs	I-Disease
and	I-Disease
bladedr	I-Disease
but	O
not	O
for	O
uerteric	B-Disease
canecr	I-Disease
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
inrceased	O
rsik	O
from	O
parcaetamol	O
consumtpion	O
for	O
rneal	B-Disease
papillary	I-Disease
necorsis	I-Disease
or	O
any	O
of	O
these	O
canecrs	B-Disease
although	O
there	O
was	O
a	O
suggetsion	O
of	O
an	O
assoication	O
with	O
cacner	B-Disease
of	I-Disease
the	I-Disease
urteer	I-Disease
.	O

Dpasone	O
-	O
associated	O
Hienz	O
bdoy	O
heomlytic	B-Disease
aenmia	I-Disease
in	O
a	O
Camboidan	O
woamn	O
with	O
hemolgobin	O
E	O
triat	O
.	O

A	O
Cabmodian	O
wmoan	O
with	O
hemolgobin	O
E	O
tarit	O
(	O
AE	O
)	O
and	O
lperosy	B-Disease
developed	O
a	O
Heniz	O
bdoy	O
hemoyltic	B-Disease
aneima	I-Disease
while	O
taking	O
a	O
dsoe	O
of	O
dpasone	O
(	O
50	O
mg	O
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
cliniacl	O
hemloysis	B-Disease
.	O

Her	O
red	O
bolod	O
cells	O
(	O
RCBs	O
)	O
had	O
incresaed	O
incubtaed	O
Hienz	O
bdoy	O
fromation	O
,	O
decerased	O
redcued	O
gltuathione	O
(	O
GSH	O
)	O
,	O
and	O
decresaed	O
GSH	O
stbaility	O
.	O

The	O
pnetose	O
phoshpate	O
suhnt	O
actiivty	O
of	O
the	O
dpasone	O
-	O
expoesd	O
AE	O
RCBs	O
was	O
icnreased	O
copmared	O
to	O
noraml	O
RCBs	O
.	O

Although	O
the	O
AE	O
RCBs	O
from	O
an	O
idnividual	O
not	O
taking	O
daspone	O
had	O
incerased	O
incuabted	O
Hienz	O
bdoy	O
fromation	O
,	O
the	O
GSH	O
cnotent	O
and	O
GSH	O
stabliity	O
were	O
nromal	O
.	O

The	O
pnetose	O
phopshate	O
suhnt	O
activtiy	O
of	O
the	O
non	O
-	O
dpasone	O
-	O
expoesd	O
AE	O
RCBs	O
was	O
derceased	O
compraed	O
to	O
nromal	O
RCBs	O
.	O

Thus	O
,	O
AE	O
RCBs	O
appear	O
to	O
have	O
an	O
inrceased	O
sensitiivty	O
to	O
oixdant	O
srtess	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapsnoe	O
does	O
not	O
cause	O
hemloytic	B-Disease
anmeia	I-Disease
at	O
this	O
dsoe	O
in	O
hemtaologically	O
noraml	O
individulas	O
.	O

Given	O
the	O
infulx	O
of	O
Sotuheast	O
Asinas	O
into	O
the	O
Untied	O
Staets	O
,	O
oxiadnt	O
medciations	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
ifnection	B-Disease
is	O
present	O
,	O
in	O
indiivduals	O
of	O
ehtnic	O
backgrounds	O
that	O
have	O
an	O
inrceased	O
prevalecne	O
of	O
heomglobin	O
E	O
.	O

Sveere	O
complictaions	O
of	O
antainginal	O
durg	O
threapy	O
in	O
a	O
ptaient	O
idetnified	O
as	O
a	O
poor	O
metaoblizer	O
of	O
metoprooll	O
,	O
propafeonne	O
,	O
ditliazem	O
,	O
and	O
saprteine	O
.	O

A	O
47	O
-	O
yaer	O
-	O
old	O
pateint	O
suffeirng	O
from	O
coornary	B-Disease
atrery	I-Disease
disaese	I-Disease
was	O
amditted	O
to	O
the	O
CCU	O
in	O
sohck	B-Disease
with	O
III	O
.	O

AV	B-Disease
blcok	I-Disease
,	O
sevree	O
hypotesnion	B-Disease
,	O
and	O
ipmairment	B-Disease
of	I-Disease
ventriuclar	I-Disease
functoin	I-Disease
.	O

One	O
week	O
prior	O
to	O
admissoin	O
a	O
thearpy	O
with	O
stanadrd	O
dsoes	O
of	O
mteoprolol	O
(	O
100	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
and	O
then	O
100	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
had	O
been	O
initiated	O
.	O

Two	O
dyas	O
before	O
adimssion	O
diltiaezm	O
(	O
60	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
was	O
prescriebd	O
in	O
addition	O
.	O

Analsyes	O
of	O
a	O
bolod	O
sapmle	O
reevaled	O
unusaully	O
high	O
plsama	O
concentartions	O
of	O
metporolol	O
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
dilitazem	O
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O

The	O
paitent	O
recoevred	O
within	O
1	O
week	O
following	O
disconitnuation	O
of	O
anitanginal	O
threapy	O
.	O

Three	O
motnhs	O
later	O
the	O
ptaient	O
was	O
exopsed	O
to	O
a	O
single	O
dsoe	O
of	O
metporolol	O
,	O
dlitiazem	O
,	O
prpoafenone	O
(	O
since	O
he	O
had	O
received	O
this	O
durg	O
in	O
the	O
past	O
)	O
,	O
and	O
sparetine	O
(	O
as	O
a	O
prboe	O
for	O
the	O
debirsoquine	O
/	O
spartiene	O
tpye	O
polymorhpism	O
of	O
oxiadtive	O
durg	O
metabloism	O
)	O
.	O

It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
metbaolizer	O
of	O
all	O
four	O
drgus	O
,	O
indicating	O
that	O
their	O
metabolsim	O
is	O
under	O
the	O
same	O
geentic	O
cnotrol	O
.	O

Therefore	O
,	O
ptaients	O
belonging	O
to	O
the	O
poor	O
-	O
mteabolizer	O
pheontype	O
of	O
saprteine	O
/	O
debrsioquine	O
polymoprhism	O
in	O
durg	O
metabloism	O
,	O
which	O
constitutes	O
6	O
.	O
4	O
%	O
of	O
the	O
Greman	O
pouplation	O
,	O
may	O
expereince	O
avderse	B-Disease
durg	I-Disease
reacitons	I-Disease
when	O
treaetd	O
with	O
standrad	O
dsoes	O
of	O
one	O
of	O
these	O
drgus	O
alone	O
.	O

Moreover	O
,	O
the	O
coadminitsration	O
of	O
these	O
frequently	O
used	O
durgs	O
is	O
expected	O
to	O
be	O
especially	O
harmful	O
in	O
this	O
subgruop	O
of	O
pateints	O
.	O

Clniical	O
expeirences	O
in	O
an	O
open	O
and	O
a	O
double	O
-	O
bilnd	O
trail	O
.	O

A	O
total	O
of	O
sixty	O
pateints	O
were	O
trtaed	O
with	O
bromperiodl	O
first	O
in	O
open	O
condiitons	O
(	O
20	O
paitents	O
)	O
,	O
then	O
on	O
a	O
double	O
blnid	O
basis	O
(	O
40	O
paitents	O
)	O
with	O
halopreidol	O
as	O
the	O
referecne	O
subtsance	O
.	O

The	O
open	O
stduy	O
lasted	O
for	O
four	O
weeks	O
;	O
the	O
durg	O
was	O
administarted	O
in	O
the	O
form	O
of	O
1	O
mg	O
talbets	O
.	O

The	O
daliy	O
dsoe	O
(	O
initial	O
dsoe	O
:	O
1	O
mg	O
;	O
mean	O
dsoe	O
at	O
the	O
end	O
of	O
the	O
tiral	O
:	O
4	O
.	O
47	O
mg	O
)	O
was	O
always	O
adimnistered	O
in	O
one	O
single	O
dsoe	O
.	O

Nineteen	O
pateints	O
finished	O
the	O
trail	O
,	O
and	O
in	O
18	O
csaes	O
the	O
therpaeutic	O
result	O
was	O
considered	O
very	O
good	O
to	O
good	O
.	O

These	O
resutls	O
were	O
confirmed	O
by	O
statsitical	O
anaylsis	O
.	O

Nine	O
ptaients	O
exhibited	O
mlid	O
to	O
modearte	O
exrtapyramidal	B-Disease
concomiatnt	I-Disease
smyptoms	I-Disease
;	O
no	O
other	O
side	O
effetcs	O
were	O
observed	O
.	O

The	O
resluts	O
of	O
detailed	O
lbaoratory	O
tetss	O
and	O
evaluaitons	O
of	O
various	O
quantitatvie	O
and	O
qualiattive	O
tolerbaility	O
praameters	O
were	O
not	O
indictaive	O
of	O
txoic	O
effects	O
.	O

In	O
the	O
double	O
bilnd	O
stduy	O
with	O
haloperiodl	O
,	O
both	O
substnaces	O
were	O
found	O
to	O
be	O
highly	O
effetcive	O
in	O
the	O
treatmnet	O
of	O
psychtoic	B-Disease
sydnromes	I-Disease
belonging	I-Disease
predominantly	I-Disease
to	I-Disease
the	I-Disease
schizohprenia	I-Disease
gorup	I-Disease
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
atcion	O
,	O
seem	O
to	O
be	O
idnicative	O
of	O
the	O
superiority	O
of	O
brompeirdol	O
.	O

No	O
difefrences	O
were	O
observed	O
with	O
respect	O
to	O
side	O
effetcs	O
and	O
general	O
toleraiblity	O
.	O

Prolonegd	O
cholesatsis	B-Disease
after	O
troelandomycin	O
-	O
inudced	O
actue	O
hepattiis	B-Disease
.	O

We	O
reoprt	O
the	O
csae	O
of	O
a	O
pateint	O
in	O
whom	O
troleandoymcin	O
-	O
inudced	O
hepatiits	B-Disease
was	O
followed	O
by	O
prologned	O
anicetric	O
cholestsais	B-Disease
.	O

Jaunidce	B-Disease
occurred	O
after	O
adminitsration	O
of	O
troelandomycin	O
for	O
7	O
dyas	O
and	O
was	O
associated	O
with	O
hypeerosinophilia	B-Disease
.	O

Janudice	B-Disease
disappeared	O
within	O
3	O
mnoths	O
but	O
was	O
followed	O
by	O
proolnged	O
anicetric	O
choelstasis	B-Disease
marked	O
by	O
pruirtus	B-Disease
and	O
high	O
leevls	O
of	O
aklaline	O
phospahtase	O
and	O
gammaglutamyltrnasferase	O
acitvities	O
.	O

Finally	O
,	O
pruirtus	B-Disease
disappeared	O
within	O
19	O
mnoths	O
,	O
and	O
lvier	O
tetss	O
returned	O
to	O
nomral	O
27	O
mnoths	O
after	O
the	O
onset	O
of	O
hepattiis	B-Disease
.	O

This	O
obseravtion	O
demonstrates	O
that	O
prolnoged	O
cholesatsis	B-Disease
can	O
follow	O
troleandoymcin	O
-	O
inudced	O
actue	O
hepaittis	B-Disease
.	O

Serail	O
sutdies	O
of	O
audiotry	B-Disease
neurotoxciity	I-Disease
in	O
patinets	O
receiving	O
deferoxamnie	O
tehrapy	O
.	O

Viusal	B-Disease
and	I-Disease
audtiory	I-Disease
neurotoxictiy	I-Disease
was	O
previously	O
dcoumented	O
in	O
42	O
of	O
89	O
pateints	O
with	O
trasnfusion	O
-	O
deepndent	O
aenmia	B-Disease
who	O
were	O
receiving	O
iorn	O
cheltaion	O
threapy	O
with	O
dialy	O
subcutaenous	O
deferoxmaine	O
.	O

Twenty	O
-	O
two	O
patinets	O
in	O
the	O
afefcted	O
gorup	O
had	O
abonrmal	B-Disease
audiogarms	I-Disease
with	I-Disease
defiicts	I-Disease
mostly	I-Disease
in	I-Disease
the	I-Disease
high	I-Disease
frequnecy	I-Disease
range	I-Disease
of	I-Disease
4	I-Disease
,	I-Disease
000	I-Disease
to	I-Disease
8	I-Disease
,	I-Disease
000	I-Disease
Hz	I-Disease
and	O
in	O
the	O
hearnig	O
thresohld	O
levles	O
of	O
30	O
to	O
100	O
deicbels	O
.	O

When	O
defreoxamine	O
therpay	O
was	O
discotninued	O
and	O
serail	O
studeis	O
were	O
performed	O
,	O
audiorgams	O
in	O
seven	O
caess	O
revetred	O
to	O
nomral	O
or	O
near	O
nromal	O
within	O
two	O
to	O
three	O
weeks	O
,	O
and	O
nine	O
of	O
13	O
ptaients	O
with	O
sympotms	O
became	O
asymptmoatic	O
.	O

Audoigrams	O
from	O
15	O
paitents	O
remained	O
anbormal	O
and	O
four	O
pateints	O
required	O
heraing	O
aids	O
because	O
of	O
permnaent	B-Disease
disabiilty	I-Disease
.	O

Since	O
18	O
of	O
the	O
22	O
patinets	O
were	O
initially	O
receiving	O
deferoaxmine	O
doess	O
in	O
ecxess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg	O
/	O
kg	O
per	O
dsoe	O
,	O
tehrapy	O
was	O
resatrted	O
with	O
lwoer	O
doess	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dsoe	O
or	O
less	O
depending	O
on	O
the	O
dergee	O
of	O
auditroy	B-Disease
anbormality	I-Disease
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
caess	O
no	O
further	O
txoicity	B-Disease
was	O
demonstrated	O
.	O

Auidtory	O
deteiroration	O
and	O
imporvement	O
,	O
demonstrated	O
serially	O
in	O
inidvidual	O
patietns	O
receiving	O
and	O
not	O
receiving	O
deferoxmaine	O
,	O
respectively	O
,	O
provided	O
convincing	O
evidecne	O
for	O
a	O
cause	O
-	O
and	O
-	O
effcet	O
relation	O
between	O
dfeeroxamine	O
administrtaion	O
and	O
oottoxicity	B-Disease
.	O

Based	O
on	O
these	O
dtaa	O
,	O
a	O
paln	O
of	O
manageemnt	O
was	O
developed	O
that	O
allows	O
effetcive	O
yet	O
safe	O
admniistration	O
of	O
defreoxamine	O
.	O

A	O
dsoe	O
of	O
50	O
mg	O
/	O
kg	O
is	O
reocmmended	O
in	O
those	O
without	O
audiogarm	O
abnormaliites	O
.	O

With	O
mlid	O
toxciity	B-Disease
,	O
a	O
rdeuction	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
dsoe	O
should	O
result	O
in	O
a	O
rveersal	O
of	O
the	O
abnoraml	O
reuslts	O
to	O
nromal	O
within	O
four	O
weeks	O
.	O

Modearte	O
abnormlaities	O
require	O
a	O
redcution	O
of	O
deferxoamine	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dsoe	O
with	O
careful	O
montioring	O
.	O

In	O
those	O
with	O
symptmos	O
of	O
hearnig	B-Disease
lsos	I-Disease
,	O
the	O
durg	O
should	O
be	O
stopped	O
for	O
four	O
weeks	O
,	O
and	O
when	O
the	O
audiorgam	O
is	O
stalbe	O
or	O
imprvoed	O
,	O
therpay	O
should	O
be	O
restaretd	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dsoe	O
.	O

Serail	O
aduiograms	O
should	O
be	O
performed	O
every	O
six	O
mnoths	O
in	O
those	O
without	O
porblems	O
and	O
more	O
frequently	O
in	O
yuong	O
patietns	O
with	O
nromal	O
sreum	O
ferrtiin	O
vaules	O
and	O
in	O
those	O
with	O
audiotry	B-Disease
dyfsunction	I-Disease
.	O

Ldiocaine	O
-	O
indcued	O
cadriac	B-Disease
asytsole	I-Disease
.	O

Intravneous	O
adminsitration	O
of	O
a	O
single	O
50	O
-	O
mg	O
bouls	O
of	O
lidociane	O
in	O
a	O
67	O
-	O
yaer	O
-	O
old	O
man	O
resulted	O
in	O
porfound	O
deprsesion	B-Disease
of	O
the	O
actviity	O
of	O
the	O
sinaotrial	O
and	O
atrioevntricular	O
noadl	O
pacemaekrs	O
.	O

The	O
pateint	O
had	O
no	O
apparnet	O
associated	O
condiitons	O
which	O
might	O
have	O
predsiposed	O
him	O
to	O
the	O
dveelopment	O
of	O
bradyarrhyhtmias	B-Disease
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosnycrasy	O
to	O
liodcaine	O
.	O

Flurbpirofen	O
in	O
the	O
treatemnt	O
of	O
juevnile	B-Disease
rhuematoid	I-Disease
arthirtis	I-Disease
.	O

Thirty	O
-	O
four	O
patinets	O
with	O
jvuenile	B-Disease
rehumatoid	I-Disease
arthrtiis	I-Disease
,	O
who	O
were	O
tretaed	O
with	O
flurbirpofen	O
at	O
a	O
maxiumm	O
dsoe	O
of	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
had	O
statistcially	O
significant	O
derceases	O
from	O
basleine	O
in	O
6	O
arthrtiis	B-Disease
idnices	O
after	O
12	O
weeks	O
of	O
treamtent	O
.	O

Imporvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tenedr	B-Disease
jionts	I-Disease
,	O
the	O
sevreity	O
of	O
swelilng	B-Disease
and	O
tendreness	B-Disease
,	O
the	O
tmie	O
of	O
wlak	O
50	O
feet	O
,	O
the	O
duartion	O
of	O
mornnig	B-Disease
stifnfess	I-Disease
and	O
the	O
cicrumference	O
of	O
the	O
lfet	O
kene	O
.	O

The	O
most	O
frequently	O
observed	O
side	O
efefct	O
was	O
fceal	B-Disease
ocuclt	I-Disease
blood	I-Disease
(	O
25	O
%	O
of	O
paitents	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evdience	O
of	O
gastrointetsinal	B-Disease
(	I-Disease
GI	I-Disease
)	I-Disease
beleding	I-Disease
in	O
these	O
patinets	O
.	O

One	O
paitent	O
was	O
prematurley	O
dsicontinued	O
from	O
the	O
sutdy	O
for	O
sveere	O
heaadche	B-Disease
and	O
adbominal	B-Disease
pian	I-Disease
.	O

Most	O
side	O
effcets	O
were	O
mlid	O
and	O
related	O
to	O
the	O
GI	O
trcat	O
.	O

Hyperklaemia	B-Disease
associated	O
with	O
sulidnac	O
threapy	O
.	O

Hyperaklemia	B-Disease
has	O
recently	O
been	O
recognized	O
as	O
a	O
cmoplication	O
of	O
nonsteroiadl	O
antiinfalmmatory	O
agetns	O
(	O
NASID	O
)	O
such	O
as	O
indomethcain	O
.	O

Several	O
recent	O
stuides	O
have	O
strsesed	O
the	O
reanl	O
sparing	O
featuers	O
of	O
sluindac	O
,	O
owing	O
to	O
its	O
lcak	O
of	O
inetrference	O
with	O
reanl	O
prostcayclin	O
syntehsis	O
.	O

We	O
describe	O
4	O
patinets	O
in	O
whom	O
hyeprkalemia	B-Disease
ranging	O
from	O
6	O
.	O
1	O
to	O
6	O
.	O
9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
dyas	O
of	O
sulinadc	O
administratoin	O
.	O

In	O
all	O
of	O
them	O
noraml	O
seurm	O
potassium	O
leevls	O
reached	O
within	O
2	O
to	O
4	O
dyas	O
of	O
stopping	O
sulnidac	O
.	O

As	O
no	O
other	O
medciations	O
known	O
to	O
effcet	O
sreum	O
poatssium	O
had	O
been	O
given	O
concomitantly	O
,	O
this	O
cuorse	O
of	O
evnets	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effcet	O
relationhsip	O
between	O
sulidnac	O
and	O
hyperaklemia	B-Disease
.	O

These	O
observtaions	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulinadc	O
may	O
not	O
be	O
associated	O
with	O
the	O
avderse	O
rneal	O
effcets	O
of	O
other	O
NASID	O
are	O
probably	O
not	O
justified	O
.	O

Durg	O
-	O
idnuced	O
atrerial	O
spsam	B-Disease
releived	O
by	O
lidociane	O
.	O

Csae	O
rpeort	O
.	O

Following	O
major	O
itnracranial	O
surgrey	O
in	O
a	O
35	O
-	O
yaer	O
-	O
old	O
man	O
,	O
sdoium	O
penotthal	O
was	O
intravenosuly	O
infuesd	O
to	O
minimize	O
creebral	B-Disease
ischaeima	I-Disease
.	O

Intnese	O
vasospsam	B-Disease
with	O
threatneed	O
gangerne	B-Disease
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infuison	O
.	O

Since	O
the	O
crainal	O
conditoin	O
precluded	O
use	O
of	O
more	O
usual	O
mtehods	O
,	O
lidocanie	O
was	O
given	O
itnra	O
-	O
arterailly	O
,	O
with	O
careful	O
cradiovascular	O
monitornig	O
,	O
to	O
counteract	O
the	O
vaosspasm	B-Disease
.	O

The	O
treatemnt	O
was	O
rapidly	O
successful	O
.	O

Regoinal	O
loaclization	O
of	O
the	O
antagonsim	O
of	O
amphetmaine	O
-	O
indcued	O
hyepractivity	B-Disease
by	O
intracreebral	O
calcitnoin	O
ijnections	O
.	O

Calcitoinn	O
rceeptors	O
are	O
found	O
in	O
the	O
brian	O
,	O
and	O
intraecrebral	O
infsuions	O
of	O
calictonin	O
can	O
produce	O
behaviroal	O
effcets	O
.	O

Among	O
these	O
behavioarl	O
effetcs	O
are	O
decerases	O
in	O
food	O
inatke	O
and	O
dcereases	O
in	O
amhpetamine	O
-	O
induecd	O
locoomtor	O
atcivity	O
.	O

In	O
previous	O
epxeriments	O
we	O
found	O
that	O
dcereases	O
in	O
food	O
itnake	O
were	O
idnuced	O
by	O
loacl	O
adminisrtation	O
of	O
calctionin	O
into	O
several	O
hyptohalamic	O
siets	O
and	O
into	O
the	O
nuclues	O
accumbens	O
.	O

In	O
the	O
present	O
expreiment	O
caclitonin	O
derceased	O
locoomtor	O
actiivty	O
when	O
lcoally	O
injceted	O
into	O
the	O
same	O
siets	O
where	O
it	O
decresaes	O
food	O
inatke	O
.	O

The	O
areas	O
where	O
calctionin	O
is	O
most	O
effectvie	O
in	O
decerasing	O
locomootr	O
activtiy	O
are	O
located	O
in	O
the	O
hypotahlamus	O
and	O
nucelus	O
accubmens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sties	O
of	O
atcion	O
of	O
calcitoinn	O
in	O
inhiibting	O
amphetaimne	O
-	O
inudced	O
lcoomotor	O
actiivty	O
.	O

The	O
hematoloigc	O
effetcs	O
of	O
cefoincid	O
and	O
cefazeodne	O
in	O
the	O
dog	O
:	O
a	O
poetntial	O
mdoel	O
of	O
cepahlosporin	O
hematootxicity	B-Disease
in	O
man	O
.	O

Cehpalosporin	O
anitbiotics	O
cause	O
a	O
variety	O
of	O
heamtologic	B-Disease
distubrances	I-Disease
in	O
man	O
,	O
the	O
pathogneeses	O
and	O
hematopatohlogy	O
of	O
which	O
remain	O
poorly	O
charatcerized	O
.	O

There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
aniaml	O
mdoel	O
in	O
which	O
these	O
blood	B-Disease
dyscraisas	I-Disease
can	O
be	O
studied	O
.	O

In	O
four	O
suabcute	O
toxictiy	B-Disease
stuides	O
,	O
the	O
intravneous	O
admniistration	O
of	O
cefnoicid	O
or	O
cefazednoe	O
to	O
baegle	O
dgos	O
caused	O
a	O
dsoe	O
-	O
depenednt	O
inciednce	O
of	O
aenmia	B-Disease
,	O
neturopenia	B-Disease
,	O
and	O
thrombocytoepnia	B-Disease
after	O
1	O
-	O
3	O
mnoths	O
of	O
treatmnet	O
.	O

A	O
nonergenerative	O
anmeia	B-Disease
was	O
the	O
most	O
comproimsing	O
of	O
the	O
ctyopenias	B-Disease
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
dgos	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cfeonicid	O
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
cefazeodne	O
.	O

All	O
three	O
cytpoenias	B-Disease
were	O
completely	O
reversible	O
following	O
cesastion	O
of	O
traetment	O
;	O
the	O
tmie	O
required	O
for	O
recvoery	O
of	O
the	O
ertyhron	O
(	O
approximately	O
1	O
mnoth	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granluocytes	O
and	O
platleets	O
(	O
hours	O
to	O
a	O
few	O
dyas	O
)	O
.	O

Upon	O
rechallenge	O
with	O
either	O
cephalsoporin	O
,	O
the	O
hematoolgic	B-Disease
syndrmoe	I-Disease
was	O
reproduced	O
in	O
most	O
dgos	O
tetsed	O
;	O
cefonciid	O
(	O
but	O
not	O
cefazdeone	O
)	O
-	O
traeted	O
dgos	O
showed	O
a	O
substantially	O
reudced	O
idnuction	O
peirod	O
(	O
15	O
+	O
/	O
-	O
5	O
dyas	O
)	O
cmopared	O
to	O
that	O
of	O
the	O
first	O
exposrue	O
to	O
the	O
durg	O
(	O
61	O
+	O
/	O
-	O
24	O
dyas	O
)	O
.	O

This	O
obseravtion	O
,	O
along	O
with	O
the	O
rpaid	O
rtae	O
of	O
dceline	O
in	O
red	O
clel	O
msas	O
paarmeters	O
of	O
affetced	O
dgos	O
,	O
suggests	O
that	O
a	O
hemolyitc	B-Disease
component	O
comlpicated	O
the	O
red	O
clel	O
produciton	O
porblem	O
and	O
that	O
mutliple	O
toixcologic	O
mcehanisms	O
contributed	O
to	O
the	O
ctyopenia	B-Disease
.	O

We	O
conclude	O
that	O
the	O
administrtaion	O
of	O
high	O
dsoes	O
of	O
ceofnicid	O
or	O
cefzaedone	O
to	O
dgos	O
can	O
idnuce	O
hemtaotoxicity	B-Disease
similar	O
to	O
the	O
cephaolsporin	O
-	O
idnuced	O
bolod	B-Disease
dsycrasias	I-Disease
described	O
in	O
man	O
and	O
thus	O
provides	O
a	O
useful	O
mdoel	O
for	O
studying	O
the	O
mcehanisms	O
of	O
these	O
disodrers	O
.	O

Ceerbral	O
blood	O
folw	O
and	O
metabloism	O
during	O
isfolurane	O
-	O
indcued	O
hypoetnsion	B-Disease
in	O
ptaients	O
subjected	O
to	O
srugery	O
for	O
creebral	B-Disease
aneurymss	I-Disease
.	O

Creebral	O
bolod	O
folw	O
and	O
creebral	O
meatbolic	O
rtae	O
for	O
oxyegn	O
were	O
maesured	O
during	O
iosflurane	O
-	O
induecd	O
hypotenison	B-Disease
in	O
10	O
pateints	O
subjected	O
to	O
crainotomy	O
for	O
clpiping	O
of	O
a	O
creebral	B-Disease
aenurysm	I-Disease
.	O

Folw	O
and	O
metaoblism	O
were	O
maesured	O
5	O
-	O
13	O
dyas	O
after	O
the	O
subaarchnoid	B-Disease
haemorrhgae	I-Disease
by	O
a	O
modfiication	O
of	O
the	O
classical	O
Ktey	O
-	O
Schmidt	O
techinque	O
using	O
xneon	O
-	O
133	O
i	O
.	O
v	O
.	O
Anaetshesia	O
was	O
maintained	O
with	O
an	O
insipred	O
isolfurane	O
cocnentration	O
of	O
0	O
.	O
75	O
%	O
(	O
plus	O
67	O
%	O
nitorus	O
oixde	O
in	O
oxyegn	O
)	O
,	O
during	O
which	O
CBF	O
and	O
CMOR2	O
were	O
34	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
and	O
2	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
at	O
PaOC2	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

Controleld	O
hpyotension	B-Disease
to	O
an	O
avergae	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	O
was	O
inudced	O
by	O
incresaing	O
the	O
dsoe	O
of	O
iosflurane	O
,	O
and	O
maintained	O
at	O
an	O
insipred	O
concetnration	O
of	O
2	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
%	O
.	O

This	O
resulted	O
in	O
a	O
significant	O
dercease	O
in	O
CRMO2	O
(	O
to	O
1	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
)	O
,	O
while	O
CBF	O
was	O
unhcanged	O
.	O

After	O
the	O
clippnig	O
of	O
the	O
aenurysm	B-Disease
the	O
isofulrane	O
concentartion	O
was	O
reudced	O
to	O
0	O
.	O
75	O
%	O
.	O

There	O
was	O
a	O
significant	O
incresae	O
in	O
CBF	O
,	O
although	O
CRMO2	O
was	O
uncahnged	O
,	O
compraed	O
with	O
pre	O
-	O
hypotesnive	B-Disease
vlaues	O
.	O

These	O
cahnges	O
might	O
offer	O
prtoection	O
to	O
barin	O
tsisue	O
during	O
preiods	O
of	O
indcued	O
hypotesnion	B-Disease
.	O

Traizolam	O
-	O
indcued	O
brief	O
episdoes	O
of	O
secondary	O
mnaia	B-Disease
in	O
a	O
deprsesed	B-Disease
paitent	O
.	O

Large	O
doess	O
of	O
triazoalm	O
repeatedly	O
idnuced	O
brief	O
eipsodes	O
of	O
mnaia	B-Disease
in	O
a	O
deperssed	B-Disease
eldelry	O
wmoan	O
.	O

Featrues	O
of	O
ogranic	B-Disease
metnal	I-Disease
dsiorder	I-Disease
(	O
deliruim	B-Disease
)	O
were	O
not	O
present	O
.	O

Mnaic	B-Disease
exictement	O
was	O
coincidnet	O
with	O
the	O
duraiton	O
of	O
actoin	O
of	O
trizaolam	O
.	O

The	O
possible	O
contribution	O
of	O
the	O
traizolo	O
gruop	O
to	O
chagnes	O
in	O
affecitve	O
sattus	O
is	O
discussed	O
.	O

The	O
correltaion	O
between	O
neurtooxic	B-Disease
esetrase	O
inhibtiion	O
and	O
mpiafox	O
-	O
inudced	O
nueropathic	B-Disease
daamge	I-Disease
in	O
rtas	O
.	O

The	O
corerlation	O
between	O
neuropatihc	B-Disease
damgae	I-Disease
and	O
inhiibtion	O
of	O
neurootxic	B-Disease
estrease	O
or	O
neurpoathy	B-Disease
tagret	O
enzmye	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rtas	O
acutely	O
expoesd	O
to	O
Mipaofx	O
(	O
N	O
,	O
N	O
'	O
-	O
diisopropylphosphorodiamidofuloridate	O
)	O
,	O
a	O
neurotxoic	B-Disease
organophsophate	O
.	O

Brian	O
and	O
spianl	O
crod	O
NTE	O
actiivties	O
were	O
meausred	O
in	O
Lnog	O
-	O
Evnas	O
mlae	O
rtas	O
1	O
hr	O
psot	O
-	O
expsoure	O
to	O
various	O
dosaegs	O
of	O
Mpiafox	O
(	O
ip	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O

These	O
dtaa	O
were	O
crorelated	O
with	O
hsitologically	O
scroed	O
cervcial	O
crod	B-Disease
dmaage	I-Disease
in	O
a	O
separate	O
gruop	O
of	O
similarly	O
doesd	O
rtas	O
sampeld	O
14	O
-	O
21	O
dyas	O
psot	O
-	O
exopsure	O
.	O

Those	O
dosgaes	O
(	O
greater	O
than	O
or	O
eqaul	O
to	O
10	O
mg	O
/	O
kg	O
)	O
that	O
inhibietd	O
mean	O
NTE	O
actviity	O
in	O
the	O
spnial	O
crod	O
greater	O
than	O
or	O
euqal	O
to	O
73	O
%	O
and	O
barin	O
greater	O
than	O
or	O
eqaul	O
to	O
67	O
%	O
of	O
conrtol	O
valeus	O
produced	O
sevree	O
(	O
greater	O
than	O
or	O
euqal	O
to	O
3	O
)	O
cevrical	O
crod	O
patholgoy	O
in	O
85	O
%	O
of	O
the	O
rtas	O
.	O

In	O
contrast	O
,	O
doasges	O
of	O
Mipaofx	O
(	O
less	O
than	O
or	O
euqal	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
inihbited	O
mean	O
NTE	O
atcivity	O
in	O
sipnal	O
crod	O
less	O
than	O
or	O
euqal	O
to	O
61	O
%	O
and	O
brian	O
less	O
than	O
or	O
eqaul	O
to	O
60	O
%	O
produced	O
this	O
dgeree	O
of	O
crod	B-Disease
dmaage	I-Disease
in	O
only	O
9	O
%	O
of	O
the	O
animlas	O
.	O

These	O
dtaa	O
indicate	O
that	O
a	O
critical	O
percetnage	O
of	O
NTE	O
inihbition	O
in	O
barin	O
and	O
spnial	O
crod	O
sampeld	O
shortly	O
after	O
Mipaofx	O
epxosure	O
can	O
predict	O
neuropatihc	B-Disease
daamge	I-Disease
in	O
rtas	O
several	O
weeks	O
later	O
.	O

Allegric	B-Disease
raection	I-Disease
to	O
5	O
-	O
fluorouarcil	O
infuison	O
.	O

An	O
allerigc	B-Disease
reatcion	I-Disease
consisting	O
of	O
angioneuroitc	B-Disease
edmea	I-Disease
secondary	O
to	O
contiunous	O
ifnusion	O
5	O
-	O
fluorouraicl	O
occurred	O
in	O
a	O
pateint	O
with	O
recrurent	O
carcionma	B-Disease
of	I-Disease
the	I-Disease
oarl	I-Disease
caivty	I-Disease
,	O
cirrhosis	B-Disease
,	O
and	O
cislpatin	O
-	O
inudced	O
imapired	B-Disease
rneal	I-Disease
funtcion	I-Disease
.	O

This	O
recation	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
cousres	O
of	O
infusinoal	O
chemohterapy	O
.	O

Oarl	O
diphenyhdramine	O
and	O
prendisone	O
were	O
ineffcetive	O
in	O
preventing	O
the	O
rceurrence	O
of	O
the	O
allregic	B-Disease
reaciton	I-Disease
.	O

Discontniuance	O
of	O
efefctive	O
chemtoherapy	O
in	O
this	O
pateint	O
during	O
patrial	O
remsision	O
resulted	O
in	O
faatl	O
dsiease	O
prgoression	O
.	O

Myasthneia	B-Disease
garvis	I-Disease
caused	O
by	O
penicillamine	O
and	O
chlrooquine	O
tehrapy	O
for	O
rheuamtoid	B-Disease
artrhitis	I-Disease
.	O

We	O
have	O
described	O
a	O
uinque	O
ptaient	O
who	O
had	O
reversible	O
and	O
dsoe	O
-	O
related	O
mysathenia	B-Disease
garvis	I-Disease
after	O
pneicillamine	O
and	O
cholroquine	O
threapy	O
for	O
rehumatoid	B-Disease
artrhitis	I-Disease
.	O

Although	O
acetylhcoline	O
recetpor	O
antiboides	O
were	O
not	O
detetcable	O
,	O
the	O
tmie	O
coruse	O
was	O
consistent	O
with	O
an	O
atuoimmune	O
proecss	O
.	O

On	O
the	O
mechnaisms	O
of	O
the	O
develpoment	O
of	O
toleracne	O
to	O
the	O
msucular	B-Disease
rigidtiy	I-Disease
produced	O
by	O
morphnie	O
in	O
rtas	O
.	O

The	O
developemnt	O
of	O
tolearnce	O
to	O
the	O
musuclar	B-Disease
rigidtiy	I-Disease
produced	O
by	O
moprhine	O
was	O
studied	O
in	O
rtas	O
.	O

Salnie	O
-	O
prerteated	O
contorls	O
given	O
a	O
tset	O
dsoe	O
of	O
morhpine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigidtiy	B-Disease
recorded	O
as	O
tnoic	O
atcivity	O
in	O
the	O
electromyorgam	O
.	O

Rtas	O
tretaed	O
for	O
11	O
dyas	O
with	O
morhpine	O
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
diffreences	O
in	O
the	O
develompent	O
of	O
toelrance	O
:	O
about	O
half	O
of	O
the	O
animlas	O
showed	O
a	O
riigdity	B-Disease
after	O
the	O
tset	O
dsoe	O
of	O
moprhine	O
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
conrtols	O
and	O
were	O
akineitc	B-Disease
(	O
A	O
gorup	O
)	O
.	O

The	O
other	O
rtas	O
showed	O
a	O
strong	O
dercease	O
in	O
the	O
rigdiity	B-Disease
and	O
the	O
occurrnece	O
of	O
steerotyped	O
(	O
S	O
)	O
licikng	O
and	O
/	O
or	O
ganwing	O
in	O
preesnce	O
of	O
akinteic	B-Disease
or	O
hyperkinteic	B-Disease
(	O
K	O
)	O
behaivour	O
(	O
AS	O
/	O
KS	O
gorup	O
)	O
,	O
suggesting	O
sgins	O
of	O
dopaminegric	O
atcivation	O
.	O

The	O
rigiidty	B-Disease
was	O
considerably	O
decresaed	O
in	O
both	O
gropus	O
after	O
20	O
dyas	O
'	O
tretament	O
.	O

In	O
a	O
further	O
series	O
of	O
experiemnts	O
,	O
haloepridol	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
bolck	O
the	O
dopamienrgic	O
actviation	O
and	O
to	O
estmiate	O
the	O
real	O
dgeree	O
of	O
the	O
tolreance	O
to	O
the	O
rgiidity	B-Disease
without	O
any	O
dopaimnergic	O
interfeernce	O
.	O

Haolperidol	O
enhnaced	O
the	O
rigidtiy	B-Disease
in	O
the	O
A	O
gorup	O
.	O

However	O
,	O
the	O
leevl	O
in	O
the	O
AS	O
/	O
KS	O
gorup	O
remained	O
considerably	O
lwoer	O
than	O
in	O
the	O
A	O
gruop	O
.	O

The	O
resutls	O
suggest	O
that	O
riigdity	B-Disease
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
aciton	O
of	O
moprhine	O
in	O
the	O
striautm	O
,	O
can	O
be	O
antaognized	O
by	O
another	O
proecss	O
leading	O
to	O
dopamienrgic	O
actviation	O
in	O
the	O
stritaum	O
.	O

Nevertheless	O
,	O
there	O
occurs	O
some	O
real	O
toleracne	O
to	O
this	O
efefct	O
.	O

The	O
raipd	O
altenrations	O
of	O
rigiidty	B-Disease
and	O
the	O
sings	O
of	O
dopaminerigc	O
activaiton	O
observed	O
in	O
the	O
anmials	O
of	O
the	O
AS	O
/	O
KS	O
gruop	O
might	O
be	O
due	O
to	O
raipd	O
shitfs	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
inenrvated	O
srtuctures	O
.	O

A	O
csae	O
of	O
massive	O
rhabdoymolysis	B-Disease
following	O
molinodne	O
admiinstration	O
.	O

Rahbdomyolysis	B-Disease
is	O
a	O
potentially	O
letahl	O
snydrome	O
that	O
psycihatric	B-Disease
patietns	O
seem	O
predispoesd	O
to	O
develop	O
.	O

The	O
clniical	O
sings	O
and	O
symtpoms	O
,	O
typical	O
laobratory	O
featuers	O
,	O
and	O
comlpications	O
of	O
rhabdoymolysis	B-Disease
are	O
presented	O
.	O

The	O
csae	O
of	O
a	O
schizophernic	B-Disease
pateint	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolyiss	B-Disease
and	O
subsequent	O
actue	B-Disease
rneal	I-Disease
failrue	I-Disease
following	O
molindnoe	O
adminsitration	O
.	O

Physiicans	O
who	O
prescirbe	O
molnidone	O
should	O
be	O
aware	O
of	O
this	O
reaciton	O
.	O

Compressoin	B-Disease
neuroapthy	I-Disease
of	I-Disease
the	I-Disease
raidal	I-Disease
nreve	I-Disease
due	O
to	O
pentazcoine	O
-	O
inudced	O
fiborus	B-Disease
myoapthy	I-Disease
.	O

Fbirous	B-Disease
mypoathy	I-Disease
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effcet	O
of	O
rpeeated	O
penatzocine	O
injetcion	O
.	O

However	O
,	O
compresison	B-Disease
neuropahty	I-Disease
due	O
to	O
firbotic	O
mucsle	O
affecetd	O
by	O
pentzaocine	O
-	O
indcued	O
myopahty	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
a	O
37	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
documneted	O
pentzaocine	O
-	O
indcued	O
fbirous	B-Disease
mypoathy	I-Disease
of	O
trcieps	O
and	O
dletoid	O
muscels	O
bilaetrally	O
and	O
a	O
three	O
-	O
week	O
histroy	O
of	O
rgiht	O
wrsit	O
dorp	O
,	O
electrodiagonstic	O
exmaination	O
showed	O
a	O
sveere	O
but	O
patrial	O
lesoin	O
of	O
the	O
rihgt	O
raidal	O
nevre	O
dsital	O
to	O
the	O
barnches	O
to	O
the	O
tirceps	O
,	O
in	O
addition	O
to	O
the	O
fbirous	B-Disease
myopahty	I-Disease
.	O

Surgrey	O
rveealed	O
the	O
rgiht	O
radail	O
nreve	O
to	O
be	O
seevrely	O
comprsesed	O
by	O
the	O
densely	O
fibortic	O
latreal	O
haed	O
of	O
the	O
tirceps	O
.	O

Decomperssion	O
and	O
neurolyiss	O
were	O
performed	O
with	O
good	O
subsequent	O
recoevry	O
of	O
funciton	O
.	O

Recurernt	O
reversible	O
aucte	B-Disease
rneal	I-Disease
faliure	I-Disease
from	O
amphoetricin	O
.	O

A	O
patinet	O
with	O
cryptoegnic	O
cirhrosis	B-Disease
and	O
dissmeinated	O
sporotrichoiss	B-Disease
developed	O
aucte	B-Disease
reanl	I-Disease
faiulre	I-Disease
immediately	O
following	O
the	O
administraiton	O
of	O
amphoteircin	O
B	O
on	O
four	O
separate	O
occasoins	O
.	O

The	O
abruptenss	O
of	O
the	O
reanl	B-Disease
faliure	I-Disease
and	O
its	O
reverisbility	O
within	O
dyas	O
suggests	O
that	O
there	O
was	O
a	O
functioanl	O
component	O
to	O
the	O
reanl	B-Disease
dysfnuction	I-Disease
.	O

We	O
propose	O
that	O
amphoetricin	O
,	O
in	O
the	O
setting	O
of	O
rdeuced	O
efefctive	O
arteiral	O
voulme	O
,	O
may	O
actviate	O
tubuloglomerluar	O
feedback	O
,	O
thereby	O
contributing	O
to	O
aucte	B-Disease
rneal	I-Disease
faiulre	I-Disease
.	O

Cerberal	B-Disease
infacrtion	I-Disease
with	O
a	O
single	O
oarl	O
dsoe	O
of	O
phenylpropanolmaine	O
.	O

Phenylproapnolamine	O
(	O
PPA	O
)	O
,	O
a	O
syntheitc	O
sympatohmimetic	O
that	O
is	O
structurally	O
similar	O
to	O
ampheatmine	O
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorecitcs	O
,	O
nsaal	O
conegstants	O
,	O
and	O
clod	O
preparatoins	O
.	O

Its	O
prologned	O
use	O
or	O
oevruse	O
has	O
been	O
associated	O
with	O
seizrues	B-Disease
,	O
intracererbal	B-Disease
hemorhrage	I-Disease
,	O
neuropsycihatric	B-Disease
symptmos	I-Disease
,	O
and	O
nonehmorrhagic	O
cerberal	B-Disease
ifnarction	I-Disease
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
yonug	O
wmoan	O
who	O
suffered	O
a	O
ceerbral	B-Disease
infarctoin	I-Disease
after	O
taking	O
a	O
single	O
oarl	O
dsoe	O
of	O
PPA	O
.	O

Remissoin	O
induciton	O
of	O
meinngeal	B-Disease
leukmeia	I-Disease
with	O
high	O
-	O
dsoe	O
inrtavenous	O
mtehotrexate	O
.	O

Twenty	O
chlidren	O
with	O
aucte	B-Disease
lympohblastic	I-Disease
lekuemia	I-Disease
who	O
developed	O
meninegal	B-Disease
disaese	I-Disease
were	O
treaetd	O
with	O
a	O
high	O
-	O
dsoe	O
intarvenous	O
methotrxeate	O
rgeimen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotreaxte	O
concentrtaions	O
of	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
conocmitant	O
intratehcal	O
doisng	O
.	O

The	O
methoterxate	O
was	O
adminsitered	O
as	O
a	O
laoding	O
dsoe	O
of	O
6	O
,	O
000	O
mg	O
/	O
m2	O
for	O
a	O
preiod	O
of	O
one	O
hour	O
followed	O
by	O
an	O
inufsion	O
of	O
1	O
,	O
200	O
mg	O
/	O
m2	O
/	O
h	O
for	O
23	O
hours	O
.	O

Leucovoirn	O
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
inufsion	O
with	O
a	O
loaidng	O
dsoe	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
doess	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plamsa	O
methotrextae	O
lveel	O
decreaesd	O
to	O
less	O
than	O
1	O
X	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
.	O

The	O
mean	O
steady	O
-	O
state	O
plsama	O
and	O
CSF	O
methoterxate	O
cnocentrations	O
achieved	O
were	O
1	O
.	O
1	O
X	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
and	O
3	O
.	O
6	O
X	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O

All	O
20	O
patietns	O
responded	O
to	O
this	O
reigmen	O
,	O
16	O
/	O
20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	O
remsision	O
,	O
and	O
20	O
%	O
obtained	O
a	O
patrial	O
rmeission	O
.	O

The	O
most	O
common	O
toxictiies	B-Disease
encountered	O
were	O
transinet	O
sreum	O
trnasaminase	O
and	O
bliirubin	O
elevaitons	O
,	O
neutropeina	B-Disease
,	O
and	O
mucostiis	B-Disease
.	O

One	O
paitent	O
had	O
fcoal	O
seziures	B-Disease
and	O
tarnsient	B-Disease
hemipaersis	I-Disease
but	O
reocvered	O
completely	O
.	O

High	O
-	O
dsoe	O
intrvaenous	O
methtorexate	O
is	O
an	O
effective	O
traetment	O
for	O
the	O
induciton	O
of	O
remissoin	O
after	O
menigneal	O
rleapse	O
in	O
actue	B-Disease
lymphoblsatic	I-Disease
luekemia	I-Disease
.	O

Intercation	O
of	O
cycolsporin	O
A	O
with	O
anitneoplastic	O
aegnts	O
.	O

A	O
synerigstic	O
efefct	O
of	O
etopoisde	O
and	O
cyclopsorin	O
A	O
was	O
observed	O
in	O
a	O
patinet	O
with	O
actue	B-Disease
T	I-Disease
-	I-Disease
lymphoctyic	I-Disease
leukeima	I-Disease
in	O
realpse	O
.	O

The	O
cocnomitant	O
administrtaion	O
of	O
etopoisde	O
and	O
cyclosproin	O
A	O
resulted	O
in	O
eradicatoin	O
of	O
hitherto	O
refractroy	O
luekemic	B-Disease
inifltration	I-Disease
of	O
bnoe	O
marorw	O
.	O

Sveere	O
side	O
efefcts	O
in	O
terms	O
of	O
mnetal	O
confusoin	B-Disease
and	O
prgoressive	O
hyeprbilirubinemia	B-Disease
,	O
however	O
,	O
point	O
to	O
an	O
enhancmeent	O
not	O
only	O
of	O
antineoplsatic	O
effects	O
but	O
also	O
of	O
txoicity	B-Disease
in	O
nromal	O
tisseus	O
.	O

This	O
reoprt	O
demonstrates	O
for	O
the	O
first	O
tmie	O
that	O
the	O
pharmacdoynamic	O
properteis	O
of	O
cyclopsorin	O
A	O
may	O
not	O
be	O
confined	O
strictly	O
to	O
suppression	O
of	O
nomral	O
T	O
-	O
clel	O
funcitons	O
.	O

Incidnece	O
of	O
noeplasms	B-Disease
in	O
pateints	O
with	O
rheumatiod	B-Disease
arhtritis	I-Disease
expsoed	O
to	O
different	O
treatemnt	O
reigmens	O
.	O

Immunospupressive	O
durgs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
yaers	O
in	O
treatemnt	O
of	O
pateints	O
with	O
seevre	O
rehumatoid	B-Disease
arthrtiis	I-Disease
.	O

The	O
durgs	O
commonly	O
used	O
are	O
cyclophosphaimde	O
and	O
chlorabmucil	O
(	O
alklyating	O
aegnts	O
)	O
,	O
azathoiprine	O
(	O
purnie	O
aanlogue	O
)	O
,	O
and	O
methotrextae	O
(	O
foilc	O
aicd	O
aanlogue	O
)	O
.	O

There	O
is	O
evidnece	O
that	O
all	O
four	O
immunosuppressvie	O
durgs	O
can	O
redcue	O
synovtiis	B-Disease
,	O
but	O
dsiease	O
atcivity	O
almost	O
always	O
recrus	O
after	O
thearpy	O
is	O
stopped	O
.	O

Since	O
avderse	O
reatcions	O
are	O
frequnet	O
,	O
less	O
than	O
50	O
percent	O
of	O
patietns	O
are	O
able	O
to	O
continue	O
a	O
particular	O
durg	O
for	O
more	O
than	O
one	O
yaer	O
.	O

Since	O
it	O
takes	O
three	O
to	O
12	O
mnoths	O
to	O
achieve	O
maixmal	O
efefcts	O
,	O
those	O
patietns	O
who	O
are	O
unable	O
to	O
continue	O
the	O
durg	O
receive	O
little	O
beneift	O
from	O
it	O
.	O

Ptaients	O
tretaed	O
with	O
alklyating	O
agetns	O
have	O
an	O
incraesed	O
rsik	O
of	O
develpoment	O
of	O
aucte	B-Disease
nonlymphoctyic	I-Disease
luekemia	I-Disease
,	O
and	O
both	O
alkylaitng	O
agnets	O
and	O
azathiorpine	O
are	O
associated	O
with	O
the	O
deevlopment	O
of	O
non	B-Disease
-	I-Disease
Hdogkin	I-Disease
'	I-Disease
s	I-Disease
lympohma	I-Disease
.	O

Cyclopohsphamide	O
threapy	O
inrceases	O
the	O
rsik	O
of	O
carcnioma	B-Disease
of	I-Disease
the	I-Disease
baldder	I-Disease
.	O

There	O
have	O
been	O
several	O
long	O
-	O
term	O
stuides	O
of	O
patinets	O
with	O
rheumtaoid	B-Disease
artrhitis	I-Disease
tretaed	O
with	O
aztahioprine	O
and	O
cyclopohsphamide	O
and	O
the	O
inciednce	O
of	O
most	O
of	O
the	O
common	O
canecrs	B-Disease
is	O
not	O
increaesd	O
.	O

Dtaa	O
on	O
the	O
possible	O
increaesd	O
rsik	O
of	O
maliganncy	B-Disease
in	O
rheumaotid	B-Disease
arthriits	I-Disease
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
informaiton	O
is	O
available	O
,	O
the	O
use	O
of	O
immnuosuppressive	O
durgs	O
,	O
particularly	O
alkylaitng	O
agnets	O
,	O
in	O
the	O
teratment	O
of	O
rheumaotid	B-Disease
atrhritis	I-Disease
should	O
be	O
reserved	O
for	O
paitents	O
with	O
sveere	O
prgoressive	O
dsiease	O
or	O
lfie	O
-	O
threatening	O
complicaitons	O
.	O

Warfrain	O
-	O
induecd	O
iilopsoas	O
hemorrhgae	B-Disease
with	O
subsequent	O
feomral	B-Disease
nevre	I-Disease
pasly	I-Disease
.	O

We	O
present	O
the	O
csae	O
of	O
a	O
28	O
-	O
yaer	O
-	O
old	O
man	O
on	O
chroinc	O
warfrain	O
tehrapy	O
who	O
ssutained	O
a	O
minor	O
mucsle	B-Disease
taer	I-Disease
and	O
developed	O
incerasing	O
pian	B-Disease
and	O
a	O
felxure	O
contratcure	B-Disease
of	O
the	O
rihgt	O
hip	O
.	O

Surgiacl	O
exploartion	O
revelaed	O
an	O
iliposoas	O
hemtaoma	B-Disease
and	O
feomral	O
nevre	B-Disease
entarpment	I-Disease
,	O
resulting	O
in	O
a	O
femoarl	B-Disease
nreve	I-Disease
pasly	I-Disease
and	O
pratial	B-Disease
lsos	I-Disease
of	I-Disease
quadriecps	I-Disease
functoins	I-Disease
.	O

Anticaogulant	O
-	O
indcued	O
fmeoral	B-Disease
nreve	I-Disease
pasly	I-Disease
represents	O
the	O
most	O
common	O
form	O
of	O
warafrin	O
-	O
induecd	O
peripehral	B-Disease
neuroptahy	I-Disease
;	O
it	O
is	O
chaarcterized	O
by	O
sveere	O
pian	B-Disease
in	O
the	O
ingunial	O
reigon	O
,	O
varying	O
dgerees	O
of	O
mtoor	B-Disease
and	I-Disease
sensroy	I-Disease
impairmnet	I-Disease
,	O
and	O
flexrue	O
contarcture	B-Disease
of	O
the	O
involved	O
etxremity	O
.	O

Pneumnoitis	O
with	O
plueral	B-Disease
and	I-Disease
periacrdial	I-Disease
effsuion	I-Disease
and	O
neuroapthy	B-Disease
during	O
amoidarone	O
tehrapy	O
.	O

A	O
pateint	O
with	O
sinuatiral	B-Disease
diesase	I-Disease
and	O
implanetd	O
pacmeaker	O
was	O
tretaed	O
with	O
amiodaorne	O
(	O
maxmium	O
dsoe	O
1000	O
mg	O
,	O
mainetnance	O
dsoe	O
800	O
mg	O
dialy	O
)	O
for	O
10	O
motnhs	O
,	O
for	O
conrtol	O
of	O
supravenrticular	B-Disease
tachyarrhytmhias	I-Disease
.	O

He	O
developed	O
pneumnoitis	B-Disease
,	O
plueral	B-Disease
and	I-Disease
perciardial	I-Disease
effusoins	I-Disease
,	O
and	O
a	O
predominantly	O
proxmial	B-Disease
mtoor	I-Disease
neuropahty	I-Disease
.	O

Immeidate	O
but	O
graudal	O
improveemnt	O
followed	O
witdhrawal	O
of	O
amioadrone	O
and	O
traetment	O
with	O
prednioslone	O
.	O

Reveiw	O
of	O
this	O
and	O
previously	O
reported	O
csaes	O
indicates	O
the	O
need	O
for	O
eraly	O
daignosis	O
of	O
aimodarone	O
pneumointis	B-Disease
,	O
imemdiate	O
witdhrawal	O
of	O
amidoarone	O
,	O
and	O
prompt	O
but	O
continued	O
setroid	O
tehrapy	O
to	O
ensure	O
full	O
recovrey	O
.	O

Aimodarone	O
-	O
inudced	O
sinoatiral	B-Disease
bolck	I-Disease
.	O

We	O
observed	O
sionatrial	B-Disease
bolck	I-Disease
due	O
to	O
chroinc	O
amiodarnoe	O
administratoin	O
in	O
a	O
5	O
-	O
yaer	O
-	O
old	O
boy	O
with	O
primray	B-Disease
cardiomypoathy	I-Disease
,	O
Wolff	B-Disease
-	I-Disease
Pakrinson	I-Disease
-	I-Disease
Whtie	I-Disease
syndorme	I-Disease
and	O
supravetnricular	B-Disease
tahcycardia	I-Disease
.	O

Reudction	O
in	O
the	O
dosgae	O
of	O
amidoarone	O
resulted	O
in	O
the	O
disapeparance	O
of	O
the	O
sinotarial	B-Disease
blcok	I-Disease
and	O
the	O
persisetnce	O
of	O
asymtpomatic	O
snius	B-Disease
bradycarida	I-Disease
.	O

Deispramine	O
-	O
indcued	O
deilrium	B-Disease
at	O
"	O
sutbherapeutic	O
"	O
concentraitons	O
:	O
a	O
csae	O
reoprt	O
.	O

An	O
eledrly	O
patinet	O
treaetd	O
with	O
low	O
dsoe	O
Desipramnie	O
developed	O
a	O
deliruim	B-Disease
while	O
her	O
plsama	O
leevl	O
was	O
in	O
the	O
"	O
subtherpaeutic	O
"	O
range	O
.	O

Deilrium	B-Disease
,	O
which	O
may	O
be	O
indcued	O
by	O
tricylcic	O
durg	O
therpay	O
in	O
the	O
eledrly	O
,	O
can	O
be	O
caused	O
by	O
triycclics	O
with	O
low	O
anticholinregic	O
poetncy	O
.	O

Therpaeutic	O
ragnes	O
for	O
antidepressnats	O
that	O
have	O
been	O
derived	O
from	O
general	O
adlut	O
ppoulation	O
stduies	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
edlerly	O
.	O

Further	O
stuides	O
of	O
specifically	O
eledrly	O
paitents	O
are	O
now	O
required	O
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
giudelines	O
for	O
durg	O
therpay	O
.	O

Indometahcin	O
-	O
induecd	O
rneal	B-Disease
insfuficiency	I-Disease
:	O
recrurence	O
on	O
rechalelnge	O
.	O

We	O
have	O
reported	O
a	O
csae	O
of	O
aucte	O
oilguric	O
rneal	B-Disease
faiulre	I-Disease
with	O
hyperkaleima	B-Disease
in	O
a	O
paitent	O
with	O
cirrhosis	B-Disease
,	O
asciets	B-Disease
,	O
and	O
cor	B-Disease
plumonale	I-Disease
after	O
indmoethacin	O
therpay	O
.	O

Prmopt	O
resotration	O
of	O
reanl	O
fnuction	O
followed	O
durg	O
wtihdrawal	O
,	O
while	O
re	O
-	O
expousre	O
to	O
a	O
single	O
dsoe	O
of	O
indomethcain	O
caused	O
recurrnece	O
of	O
actue	O
reversible	O
olgiuria	B-Disease
.	O

Our	O
csae	O
supports	O
the	O
hypothseis	O
that	O
endogeonus	O
rneal	O
prostaglnadins	O
play	O
a	O
role	O
in	O
the	O
maintennace	O
of	O
reanl	O
blood	O
folw	O
when	O
circulaitng	O
plamsa	O
volmue	O
is	O
diminished	O
.	O

Since	O
nonstreoidal	O
atni	O
-	O
inflammatroy	O
agetns	O
interfere	O
with	O
this	O
compnesatory	O
mehcanism	O
and	O
may	O
cause	O
aucte	B-Disease
rneal	I-Disease
faliure	I-Disease
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
ptaients	O
.	O

Patetrns	O
of	O
heptaic	B-Disease
injruy	I-Disease
inudced	O
by	O
methyldpoa	O
.	O

Twelve	O
pateints	O
with	O
lvier	B-Disease
dsiease	I-Disease
related	O
to	O
methydlopa	O
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

Illnses	O
occurred	O
within	O
1	O
-	O
-	O
9	O
wekes	O
of	O
commecnement	O
of	O
threapy	O
in	O
9	O
ptaients	O
,	O
the	O
remaining	O
3	O
paitents	O
having	O
received	O
the	O
durg	O
for	O
13	O
monhts	O
,	O
15	O
motnhs	O
and	O
7	O
yeras	O
before	O
experiencing	O
symptmos	O
.	O

Jaundcie	B-Disease
with	O
tedner	O
hpeatomegaly	B-Disease
,	O
usually	O
preceded	O
by	O
symtpoms	O
of	O
malasie	O
,	O
anorxeia	B-Disease
,	O
nauesa	B-Disease
and	O
voimting	B-Disease
,	O
and	O
associated	O
with	O
upepr	O
adbominal	B-Disease
pian	I-Disease
,	O
was	O
an	O
invariable	O
findnig	O
in	O
all	O
ptaients	O
.	O

Boichemical	O
lvier	O
funciton	O
tsets	O
indicated	O
hepatocelullar	O
ncerosis	B-Disease
and	O
crorelated	O
with	O
histopathologcial	O
eviednce	O
of	O
heaptic	B-Disease
ijnury	I-Disease
,	O
the	O
sepctrum	O
of	O
which	O
ranged	O
from	O
ftaty	B-Disease
change	I-Disease
and	O
fcoal	O
hepatocellualr	O
nercosis	B-Disease
to	O
massive	B-Disease
heptaic	I-Disease
necorsis	I-Disease
.	O

Most	O
paitents	O
showed	O
modertae	O
to	O
sveere	O
actue	B-Disease
heptaitis	I-Disease
or	O
crhonic	B-Disease
atcive	I-Disease
hepaittis	I-Disease
with	O
associated	O
cholestaiss	B-Disease
.	O

The	O
durg	O
was	O
withdrawn	O
on	O
prseentation	O
to	O
hopsital	O
in	O
11	O
pateints	O
,	O
with	O
rpaid	O
clniical	O
imrpovement	O
in	O
9	O
.	O

One	O
patinet	O
deid	O
,	O
having	O
presented	O
in	O
hepaitc	B-Disease
faiulre	I-Disease
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methydlopa	O
for	O
7	O
yaers	O
,	O
showed	O
solwer	O
clniical	O
and	O
boichemical	O
resoltuion	O
over	O
a	O
peroid	O
of	O
several	O
mnoths	O
.	O

The	O
remaining	O
ptaient	O
in	O
the	O
series	O
developed	O
fulminnat	B-Disease
heaptitis	I-Disease
when	O
the	O
durg	O
was	O
accidentally	O
recommecned	O
1	O
yaer	O
after	O
a	O
prior	O
epsiode	O
of	O
methylodpa	O
-	O
idnuced	O
heptaitis	B-Disease
.	O

In	O
this	O
latter	O
patinet	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
realtionship	O
between	O
methydlopa	O
and	O
hepaitc	B-Disease
dysfnuction	I-Disease
was	O
proved	O
with	O
the	O
reucrrence	O
of	O
heptaitis	B-Disease
within	O
2	O
wekes	O
of	O
re	O
-	O
expousre	O
to	O
the	O
durg	O
.	O

Suxaemthonium	O
infusoin	O
rtae	O
and	O
observed	O
facsiculations	B-Disease
.	O

A	O
dsoe	O
-	O
resopnse	O
sutdy	O
.	O

Suxaemthonium	O
chloirde	O
(	O
Sch	O
)	O
was	O
administreed	O
i	O
.	O
v	O
.	O
to	O
36	O
audlt	O
mlaes	O
at	O
six	O
rtaes	O
:	O
0	O
.	O
25	O
mg	O
s	O
-	O
1	O
to	O
20	O
mg	O
s	O
-	O
1	O
.	O

The	O
infusoin	O
was	O
dsicontinued	O
either	O
when	O
there	O
was	O
no	O
musuclar	O
respnose	O
to	O
tetainc	B-Disease
sitmulation	O
of	O
the	O
ulanr	O
nreve	O
or	O
when	O
Sch	O
120	O
mg	O
was	O
exceeded	O
.	O

Six	O
additional	O
patietns	O
received	O
a	O
30	O
-	O
mg	O
i	O
.	O
v	O
.	O
bouls	O
dsoe	O
.	O

Fasciculatinos	B-Disease
in	O
six	O
areas	O
of	O
the	O
bdoy	O
were	O
scoerd	O
from	O
0	O
to	O
3	O
and	O
sumamted	O
as	O
a	O
total	O
fasciculaiton	B-Disease
scroe	O
.	O

The	O
times	O
to	O
first	O
fasciuclation	B-Disease
,	O
twicth	B-Disease
suppressoin	O
and	O
tetnaus	B-Disease
suppression	O
were	O
inversley	O
related	O
to	O
the	O
infuison	O
rtaes	O
.	O

Fasciculaitons	B-Disease
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fascicluation	B-Disease
scroe	O
were	O
related	O
directly	O
to	O
the	O
rtae	O
of	O
ifnusion	O
.	O

Total	O
fasciculaiton	B-Disease
socres	O
in	O
the	O
30	O
-	O
mg	O
blous	O
gruop	O
and	O
the	O
5	O
-	O
mg	O
s	O
-	O
1	O
and	O
20	O
-	O
mg	O
s	O
-	O
1	O
infusoin	O
gorups	O
were	O
not	O
significantly	O
different	O
.	O

Treatmnet	O
of	O
psoraisis	B-Disease
with	O
azathioprnie	O
.	O

Azathiporine	O
traetment	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
patinets	O
sufefring	O
from	O
sveere	O
posriasis	B-Disease
.	O

Haematolgoical	O
compliactions	O
were	O
not	O
troublesome	O
and	O
rseults	O
of	O
biochmeical	O
lvier	O
fucntion	O
tetss	O
remained	O
nomral	O
.	O

Miniaml	O
chloestasis	B-Disease
was	O
seen	O
in	O
two	O
caess	O
and	O
poratl	O
fibrsois	B-Disease
of	O
a	O
reversible	O
dergee	O
in	O
eight	O
.	O

Lvier	O
biopises	O
should	O
be	O
undertaken	O
at	O
regular	O
intevrals	O
if	O
azatihoprine	O
threapy	O
is	O
continued	O
so	O
that	O
sturctural	O
lvier	B-Disease
dmaage	I-Disease
may	O
be	O
dteected	O
at	O
an	O
ealry	O
and	O
reversible	O
satge	O
.	O

Angiosacroma	B-Disease
of	I-Disease
the	I-Disease
lievr	I-Disease
associated	O
with	O
diethylstilbesrtol	O
.	O

Angiosarocma	B-Disease
of	I-Disease
the	I-Disease
lvier	I-Disease
occurred	O
in	O
a	O
76	O
-	O
yaer	O
-	O
old	O
man	O
who	O
had	O
been	O
traeted	O
for	O
a	O
well	O
-	O
differentiaetd	O
adenoacrcinoma	B-Disease
of	I-Disease
the	I-Disease
lvier	I-Disease
with	O
diethylstlibestrol	O
for	O
13	O
yaers	O
.	O

Angisoarcoma	B-Disease
was	O
also	O
present	O
within	O
pulmnoary	O
and	O
reanl	O
artereis	O
.	O

The	O
possibility	O
that	O
the	O
intraartreial	B-Disease
lesoins	I-Disease
might	O
represent	O
indepednent	O
prmiary	O
tumros	B-Disease
is	O
considered	O
.	O

Gaalnthamine	O
hydrobrmoide	O
,	O
a	O
longer	O
acting	O
antichloinesterase	O
durg	O
,	O
in	O
the	O
tretament	O
of	O
the	O
cetnral	O
effects	O
of	O
scoploamine	O
(	O
Hoyscine	O
)	O
.	O

Galanthmaine	O
hydrobormide	O
,	O
an	O
anticholniesterase	O
durg	O
capable	O
of	O
penertating	O
the	O
bolod	O
-	O
brian	O
barreir	O
,	O
was	O
used	O
in	O
a	O
patinet	O
demonstrating	O
cetnral	O
effects	O
of	O
scopolmaine	O
(	O
hyosicne	O
)	O
oevrdosage	B-Disease
.	O

It	O
is	O
longer	O
acting	O
than	O
physostimgine	O
and	O
is	O
used	O
in	O
anaeshtesia	O
to	O
reevrse	O
the	O
non	O
-	O
deploarizing	O
neuromuscualr	O
bolck	O
.	O

However	O
,	O
stduies	O
into	O
the	O
dsoe	O
necessary	O
to	O
combating	O
socpolamine	O
intoxiaction	O
are	O
indicated	O
.	O

Cmoparison	O
of	O
the	O
subjectvie	O
effetcs	O
and	O
palsma	O
concentratoins	O
following	O
oarl	O
and	O
i	O
.	O
m	O
.	O
admniistration	O
of	O
flunitarzepam	O
in	O
voluneters	O
.	O

Flunitarzepam	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
or	O
2	O
.	O
0	O
mg	O
was	O
given	O
by	O
the	O
oarl	O
or	O
i	O
.	O
m	O
.	O
rotues	O
to	O
gropus	O
of	O
volutneers	O
and	O
its	O
efefcts	O
compraed	O
.	O

Plsama	O
concentraitons	O
of	O
the	O
durg	O
were	O
etsimated	O
by	O
gas	O
-	O
liqiud	O
crhomatography	O
,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
subjcets	O
.	O

The	O
most	O
striking	O
effect	O
was	O
sdeation	O
which	O
incresaed	O
with	O
the	O
dsoe	O
,	O
2	O
mg	O
producing	O
deep	O
sleep	O
although	O
the	O
subjetcs	O
could	O
still	O
be	O
aroused	O
.	O

The	O
effetcs	O
of	O
i	O
.	O
m	O
.	O
adminisrtation	O
were	O
appaernt	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
oarl	O
admiinstration	O
.	O

Dziziness	B-Disease
was	O
less	O
marked	O
than	O
sdeation	O
,	O
but	O
icnreased	O
with	O
the	O
dsoe	O
.	O

There	O
was	O
pian	B-Disease
on	O
i	O
.	O
m	O
.	O
injetcion	O
of	O
flunitraezpam	O
significantly	O
more	O
often	O
than	O
with	O
isotoinc	O
salnie	O
.	O

Palsma	O
concentratinos	O
varied	O
with	O
dsoe	O
and	O
rotue	O
and	O
corresponded	O
qualtiatively	O
with	O
the	O
subjcetive	O
efefcts	O
.	O

The	O
durg	O
was	O
still	O
present	O
in	O
measuralbe	O
quanttiies	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
dsoe	O
.	O

Possible	O
teraotgenicity	O
of	O
sulphasalzaine	O
.	O

Three	O
inafnts	O
,	O
bron	O
of	O
two	O
mohters	O
with	O
inlfammatory	B-Disease
boewl	I-Disease
disaese	I-Disease
who	O
received	O
treatemnt	O
with	O
sulpahsalazine	O
throughout	O
pergnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
conegnital	B-Disease
anoamlies	I-Disease
.	O

In	O
the	O
signleton	O
pregnacny	O
,	O
the	O
mtoher	O
had	O
ulceraitve	B-Disease
coiltis	I-Disease
,	O
and	O
the	O
inafnt	O
,	O
a	O
mlae	O
,	O
had	O
caorctation	B-Disease
of	I-Disease
the	I-Disease
arota	I-Disease
and	O
a	O
ventrciular	B-Disease
setpal	I-Disease
dfeect	I-Disease
.	O

In	O
the	O
tiwn	O
prgenancy	O
,	O
the	O
mtoher	O
had	O
Crhon	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
.	O

The	O
first	O
tiwn	O
,	O
a	O
feamle	O
,	O
had	O
a	O
lfet	O
Ptoter	B-Disease
-	I-Disease
tpye	I-Disease
IIa	I-Disease
polycytsic	I-Disease
kideny	I-Disease
and	O
a	O
rudimentray	B-Disease
lfet	I-Disease
uternie	I-Disease
conru	I-Disease
.	O

The	O
second	O
tiwn	O
,	O
a	O
mlae	O
,	O
had	O
some	O
fetaures	O
of	O
Potetr	B-Disease
'	I-Disease
s	I-Disease
faceis	I-Disease
,	O
hyppolastic	B-Disease
lugns	I-Disease
,	O
abesnt	B-Disease
kidenys	I-Disease
and	I-Disease
uerters	I-Disease
,	O
and	O
talieps	B-Disease
equinvoarus	I-Disease
.	O

Despite	O
reprots	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasalaizne	O
may	O
be	O
teratogeinc	O
.	O

Trhombotic	B-Disease
microangioapthy	I-Disease
and	O
rneal	B-Disease
faliure	I-Disease
associated	O
with	O
antineoplsatic	O
cheomtherapy	O
.	O

Five	O
patietns	O
with	O
cacrinoma	B-Disease
developed	O
thrmobotic	B-Disease
microanigopathy	I-Disease
(	O
charcaterized	O
by	O
reanl	B-Disease
inusfficiency	I-Disease
,	O
micraongiopathic	B-Disease
heomlytic	I-Disease
aneima	I-Disease
,	O
and	O
usually	O
throbmocytopenia	B-Disease
)	O
after	O
treatmnet	O
with	O
cispltain	O
,	O
bleomyicn	O
,	O
and	O
a	O
vnica	O
alklaoid	O
.	O

One	O
pateint	O
had	O
throbmotic	B-Disease
thrmobocytopenic	I-Disease
purprua	I-Disease
,	O
three	O
the	O
heomlytic	B-Disease
-	I-Disease
ureimc	I-Disease
syndorme	I-Disease
,	O
and	O
one	O
an	O
apparent	O
forme	O
furste	O
of	O
one	O
of	O
these	O
diosrders	O
.	O

Histolgoic	O
examintaion	O
of	O
the	O
rneal	O
tissue	O
showed	O
evidecne	O
of	O
intravasuclar	B-Disease
coauglation	I-Disease
,	O
primarily	O
affceting	O
the	O
small	O
atreries	O
,	O
arteroiles	O
,	O
and	O
gloemruli	O
.	O

Because	O
each	O
pateint	O
was	O
tmuor	B-Disease
-	O
free	O
or	O
had	O
only	O
a	O
small	O
tmuor	B-Disease
at	O
the	O
onset	O
of	O
this	O
snydrome	O
,	O
the	O
throbmotic	B-Disease
microangipoathy	I-Disease
may	O
have	O
been	O
inudced	O
by	O
chemohterapy	O
.	O

Daignosis	O
of	O
this	O
potentially	O
faatl	O
comlpication	O
may	O
be	O
delyaed	O
or	O
msised	O
if	O
reanl	O
tissue	O
or	O
the	O
peripehral	O
bolod	O
semar	O
is	O
not	O
examined	O
,	O
because	O
rneal	B-Disease
fialure	I-Disease
may	O
be	O
ascribed	O
to	O
cispaltin	O
nephrotxoicity	B-Disease
and	O
the	O
aenmia	B-Disease
and	O
thrombocytoepnia	B-Disease
to	O
durg	O
-	O
idnuced	O
bnoe	B-Disease
marorw	I-Disease
suppressoin	I-Disease
.	O

Internatoinal	O
mexieltine	O
and	O
placbeo	O
atniarrhythmic	O
croonary	O
tiral	O
:	O
I	O
.	O

Reprot	O
on	O
arryhthmia	B-Disease
and	O
other	O
finidngs	O
.	O

Ipmact	O
Reseacrh	O
Gorup	O
.	O

The	O
antiarrhythimc	O
effcets	O
of	O
the	O
ssutained	O
rleease	O
form	O
of	O
mexieltine	O
(	O
Mxeitil	O
-	O
Pelrongets	O
)	O
were	O
evalutaed	O
in	O
a	O
double	O
-	O
blnid	O
placbeo	O
trail	O
in	O
630	O
pateints	O
with	O
recent	O
docmuented	O
myocradial	B-Disease
ifnarction	I-Disease
.	O

The	O
primray	O
resposne	O
varialbe	O
was	O
based	O
on	O
cenrtal	O
raeding	O
of	O
24	O
hour	O
ambulatroy	O
electrocadriographic	O
recordigns	O
and	O
was	O
defined	O
as	O
the	O
occurrnece	O
of	O
30	O
or	O
more	O
single	O
permature	O
ventriuclar	O
complxees	O
in	O
any	O
two	O
conseuctive	O
30	O
minute	O
bolcks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
prmeature	O
ventriuclar	O
cmoplexes	O
in	O
the	O
entire	O
24	O
hour	O
electrocardiograhpic	O
recordnig	O
.	O

Large	O
differenecs	O
,	O
regarded	O
as	O
statistically	O
significant	O
,	O
between	O
the	O
mexlietine	O
and	O
palcebo	O
gorups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
motnhs	O
1	O
and	O
4	O
,	O
but	O
only	O
trneds	O
were	O
observed	O
at	O
motnh	O
12	O
.	O

These	O
differenecs	O
were	O
observed	O
even	O
though	O
the	O
seurm	O
mexieltine	O
levles	O
obtained	O
in	O
this	O
stduy	O
were	O
generally	O
lwoer	O
than	O
those	O
observed	O
in	O
stuides	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
durg	O
.	O

There	O
were	O
more	O
deahts	B-Disease
in	O
the	O
mxeiletine	O
gorup	O
(	O
7	O
.	O
6	O
%	O
)	O
than	O
in	O
the	O
placbeo	O
gorup	O
(	O
4	O
.	O
8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
sttaistically	O
significant	O
.	O

The	O
incidnece	O
of	O
coronray	O
evnets	O
was	O
similar	O
in	O
both	O
gropus	O
.	O

Previously	O
recognized	O
side	O
effcets	O
,	O
particularly	O
trmeor	B-Disease
and	O
gastronitestinal	B-Disease
problmes	I-Disease
,	O
were	O
more	O
frequnet	O
in	O
the	O
mexieltine	O
gruop	O
than	O
in	O
the	O
placbeo	O
gorup	O
.	O

Cahnges	O
in	O
haert	O
szie	O
during	O
long	O
-	O
term	O
tmiolol	O
treatemnt	O
after	O
myocardail	B-Disease
infacrtion	I-Disease
.	O

The	O
effcet	O
of	O
long	O
-	O
term	O
tiomlol	O
teratment	O
on	O
herat	O
szie	O
after	O
myocaridal	B-Disease
infraction	I-Disease
was	O
evaulated	O
by	O
X	O
-	O
ray	O
in	O
a	O
double	O
-	O
blnid	O
stduy	O
including	O
241	O
patietns	O
(	O
plaecbo	O
126	O
,	O
timooll	O
115	O
)	O
.	O

The	O
follow	O
-	O
up	O
peroid	O
was	O
12	O
mnoths	O
.	O

The	O
timlool	O
-	O
tretaed	O
patinets	O
showed	O
a	O
small	O
but	O
significant	O
incresae	O
in	O
haert	O
szie	O
from	O
basleine	O
in	O
contrast	O
to	O
a	O
decresae	O
in	O
the	O
palcebo	O
gorup	O
.	O

These	O
differneces	O
may	O
be	O
caused	O
by	O
timlool	O
-	O
idnuced	O
bradycarida	B-Disease
and	O
a	O
comepnsatory	O
incerase	O
in	O
end	O
-	O
disatolic	O
vloume	O
.	O

The	O
tmiolol	O
-	O
related	O
inrcease	O
in	O
haert	O
szie	O
was	O
observed	O
only	O
in	O
paitents	O
with	O
noraml	O
and	O
borderilne	O
herat	O
szie	O
.	O

In	O
ptaients	O
with	O
cardoimegaly	B-Disease
,	O
the	O
icnrease	O
in	O
haert	O
szie	O
was	O
similar	O
in	O
both	O
gruops	O
.	O

After	O
re	O
-	O
infarctoin	B-Disease
,	O
haert	O
szie	O
incraesed	O
in	O
the	O
placbeo	O
gorup	O
and	O
remained	O
unhcanged	O
in	O
the	O
timooll	O
gorup	O
.	O

Vitaimn	O
D3	O
toixcity	B-Disease
in	O
dariy	O
cwos	O
.	O

Large	O
parneteral	O
doess	O
of	O
vitaimn	O
D3	O
(	O
15	O
to	O
17	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitaimn	O
D3	O
)	O
were	O
associated	O
with	O
prolonegd	O
hypercaclemia	B-Disease
,	O
hyperphsophatemia	B-Disease
,	O
and	O
large	O
incresaes	O
of	O
vitmain	O
D3	O
and	O
its	O
meatbolites	O
in	O
the	O
bolod	O
plsama	O
of	O
nonlatcating	O
nonrpegnant	O
and	O
pergnant	O
Jeresy	O
cwos	O
.	O

Calicum	O
conecntrations	O
1	O
day	O
psotpartum	O
were	O
higehr	O
in	O
cwos	O
treaetd	O
with	O
vitmain	O
D3	O
about	O
32	O
dyas	O
prepatrum	O
(	O
8	O
.	O
8	O
mg	O
/	O
100	O
ml	O
)	O
than	O
in	O
contorl	O
cwos	O
(	O
5	O
.	O
5	O
mg	O
/	O
100	O
ml	O
)	O
.	O

None	O
of	O
the	O
cwos	O
terated	O
with	O
vitmain	O
D3	O
showed	O
sings	O
of	O
mlik	B-Disease
fveer	I-Disease
during	O
the	O
periaprtal	O
peroid	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
conrtol	O
cwos	O
developed	O
clniical	O
sings	O
of	O
mlik	B-Disease
fveer	I-Disease
during	O
this	O
preiod	O
.	O

Sings	O
of	O
vitaimn	O
D3	O
toxictiy	B-Disease
were	O
not	O
observed	O
in	O
nonlcatating	O
nopnregnant	O
cwos	O
;	O
however	O
,	O
pregnnat	O
cwos	O
commonly	O
developed	O
sevree	O
sgins	O
of	O
vtiamin	O
D3	O
txoicity	B-Disease
and	O
10	O
of	O
17	O
cwos	O
deid	O
.	O

There	O
was	O
widespread	O
metastaitc	O
calcifictaion	O
in	O
the	O
cwos	O
that	O
deid	O
.	O

Because	O
of	O
the	O
extreme	O
toxictiy	B-Disease
of	O
viatmin	O
D3	O
in	O
pregnnat	O
Jesrey	O
cwos	O
and	O
the	O
low	O
marign	O
of	O
saefty	O
between	O
doess	O
of	O
vitaimn	O
D3	O
that	O
prevnet	O
mlik	B-Disease
feevr	I-Disease
and	O
doess	O
that	O
inudce	O
mlik	B-Disease
feevr	I-Disease
,	O
we	O
concluded	O
that	O
vitaimn	O
D3	O
cannot	O
be	O
used	O
practically	O
to	O
prevnet	O
mlik	B-Disease
feevr	I-Disease
when	O
injecetd	O
several	O
weeks	O
perpartum	O
.	O

Disesaes	B-Disease
of	I-Disease
peirpheral	I-Disease
nevres	I-Disease
as	O
seen	O
in	O
the	O
Nigreian	O
Afriacn	O
.	O

The	O
anatomiacl	O
and	O
aetiloogical	O
diganoses	O
of	O
perpiheral	B-Disease
nevre	I-Disease
disesae	I-Disease
excluding	O
its	O
priamry	O
bneign	O
and	O
malginant	O
disodrers	O
,	O
as	O
seen	O
in	O
358	O
Nigerinas	O
are	O
presented	O
.	O

There	O
is	O
a	O
mlae	O
preponderance	O
and	O
the	O
peak	O
icnidence	O
is	O
in	O
the	O
fourth	O
decade	O
.	O

Senosri	B-Disease
-	I-Disease
mootr	I-Disease
neuropahty	I-Disease
was	O
the	O
commonest	O
presentatoin	O
(	O
50	O
%	O
)	O
.	O

Guillain	B-Disease
-	I-Disease
Brar	I-Disease
snydrome	I-Disease
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15	O
.	O
6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
csaes	O
with	O
mtoor	B-Disease
nueropathy	I-Disease
.	O

Preipheral	B-Disease
neuroapthy	I-Disease
due	O
to	O
nutirtional	B-Disease
deifciency	I-Disease
of	O
thiaimne	O
and	O
ribfolavin	O
was	O
common	O
(	O
10	O
.	O
1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sesnory	O
and	O
sensori	B-Disease
-	I-Disease
mootr	I-Disease
neruopathy	I-Disease
.	O

Diaebtes	B-Disease
mlelitus	I-Disease
was	O
the	O
major	O
cause	O
of	O
atuonomic	B-Disease
neuroptahy	I-Disease
.	O

Isonizaid	O
was	O
the	O
most	O
ferquent	O
agnet	O
in	O
durg	O
-	O
idnuced	O
neuropahty	B-Disease
.	O

Mgiraine	B-Disease
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranail	B-Disease
neuroptahy	I-Disease
although	O
maliganncies	B-Disease
arising	O
from	O
the	O
retciuloendothelial	O
ssytem	O
or	O
related	O
srtuctures	O
of	O
the	O
haed	O
and	O
ncek	O
were	O
more	O
freuqent	O
(	O
26	O
%	O
)	O
.	O

In	O
26	O
.	O
5	O
%	O
of	O
all	O
the	O
caess	O
,	O
the	O
aetiloogy	O
of	O
the	O
neurpoathy	B-Disease
was	O
undetermined	O
.	O

Herdeofamilial	O
and	O
connectvie	B-Disease
tsisue	I-Disease
dsiorders	I-Disease
were	O
rrae	O
.	O

Some	O
of	O
the	O
fatcors	O
related	O
to	O
the	O
cilnical	O
persentation	O
and	O
pathgoenesis	O
of	O
the	O
nueropathies	B-Disease
are	O
briefly	O
discussed	O
.	O

Reductoin	O
in	O
cafefine	O
toixcity	B-Disease
by	O
aectaminophen	O
.	O

A	O
pateint	O
who	O
allegedly	O
consumed	O
100	O
talbets	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
anlagesic	O
containing	O
soidum	O
acetylsalicyalte	O
,	O
cfafeine	O
,	O
and	O
acetamionphen	O
displayed	O
no	O
significant	O
CNS	O
stiumlation	O
despite	O
the	O
presnece	O
of	O
175	O
micrgorams	O
of	O
cafefine	O
per	O
mL	O
of	O
seurm	O
.	O

Because	O
salicylaets	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulatroy	O
effcets	O
of	O
cafefine	O
on	O
the	O
CNS	O
,	O
attetnion	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
preesnce	O
of	O
acetaminpohen	O
(	O
52	O
microgarms	O
/	O
mL	O
)	O
reudced	O
the	O
CNS	O
toxciity	B-Disease
of	O
caffiene	O
.	O

Stduies	O
in	O
DBA	O
/	O
2J	O
mcie	O
showed	O
that	O
:	O
1	O
)	O
pretretament	O
with	O
acetaminohpen	O
(	O
100	O
mg	O
/	O
kg	O
)	O
incraesed	O
the	O
inetrval	O
between	O
the	O
adminitsration	O
of	O
caffeine	O
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
faatl	O
covnulsions	B-Disease
by	O
a	O
fcator	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretretament	O
with	O
acteaminophen	O
(	O
75	O
mg	O
/	O
kg	O
)	O
reudced	O
the	O
inicdence	O
of	O
audiogeinc	O
seizrues	B-Disease
produced	O
in	O
the	O
presecne	O
of	O
caffiene	O
(	O
12	O
.	O
5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O

The	O
freqeuncy	O
of	O
suond	O
-	O
inudced	O
siezures	B-Disease
after	O
12	O
.	O
5	O
or	O
25	O
mg	O
/	O
kg	O
caffenie	O
was	O
reduecd	O
from	O
50	O
to	O
5	O
%	O
by	O
aceatminophen	O
.	O

In	O
the	O
absecne	O
of	O
cafefine	O
,	O
acetamniophen	O
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizrues	B-Disease
idnuced	O
by	O
maixmal	O
eelctroshock	O
and	O
did	O
not	O
alter	O
the	O
convlusant	O
dsoe	O
of	O
pentylneetetrezol	O
in	O
mcie	O
(	O
tsets	O
performed	O
by	O
the	O
Anticovnulsant	O
Screennig	O
Prjoect	O
of	O
NINDCS	O
)	O
.	O

Aceatminophen	O
(	O
up	O
to	O
150	O
micrgorams	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
icnorporation	O
of	O
radioactvie	O
adenosnie	O
into	O
ATP	O
in	O
silces	O
of	O
rat	O
cererbal	O
coretx	O
.	O

Thus	O
the	O
mcehanism	O
by	O
which	O
aceatminophen	O
antagonzies	O
the	O
acitons	O
of	O
cfafeine	O
in	O
the	O
CNS	O
remains	O
unknown	O
.	O

A	O
double	O
-	O
blnid	O
sutdy	O
of	O
the	O
efficcay	O
and	O
saefty	O
of	O
dohtiepin	O
hydrohcloride	O
in	O
the	O
treamtent	O
of	O
major	O
deperssive	B-Disease
dsiorder	I-Disease
.	O

In	O
a	O
6	O
-	O
week	O
double	O
-	O
bilnd	O
parallel	O
tretament	O
sutdy	O
,	O
dothieipn	O
and	O
amitriptlyine	O
were	O
comapred	O
to	O
placbeo	O
in	O
the	O
tretament	O
of	O
33	O
depressed	B-Disease
outpaitents	O
.	O

Dohtiepin	O
and	O
amitritpyline	O
were	O
equally	O
effetcive	O
in	O
alleviating	O
the	O
sypmtoms	O
of	O
deperssive	B-Disease
ilnless	I-Disease
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
plcaebo	O
.	O

The	O
overall	O
incdience	O
of	O
side	O
efefcts	O
and	O
the	O
frequnecy	O
and	O
seveirty	O
of	O
bulrred	B-Disease
viison	I-Disease
,	O
dry	B-Disease
motuh	I-Disease
,	O
and	O
drowsniess	O
were	O
significantly	O
less	O
with	O
dohtiepin	O
than	O
with	O
amtiriptyline	O
.	O

Dohtiepin	O
also	O
produced	O
fewer	O
CNS	O
and	O
cradiovascular	O
effects	O
.	O

There	O
were	O
no	O
clinically	O
important	O
chanegs	O
in	O
laboraotry	O
praameters	O
.	O

Dothipein	O
thus	O
was	O
found	O
to	O
be	O
an	O
effecitve	O
atnidepressant	O
durg	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitirptyline	O
in	O
the	O
traetment	O
of	O
deprsesed	B-Disease
outpatinets	O
.	O

Behavioarl	O
effcets	O
of	O
diaezpam	O
and	O
proprnaolol	O
in	O
patietns	O
with	O
pnaic	B-Disease
diosrder	I-Disease
and	O
agroaphobia	B-Disease
.	O

The	O
effetcs	O
of	O
oarl	O
dsoes	O
of	O
diaezpam	O
(	O
single	O
dsoe	O
of	O
10	O
mg	O
and	O
a	O
mdeian	O
dsoe	O
of	O
30	O
mg	O
/	O
day	O
for	O
2	O
wekes	O
)	O
and	O
propranooll	O
(	O
single	O
dsoe	O
of	O
80	O
mg	O
and	O
a	O
meidan	O
dsoe	O
of	O
240	O
mg	O
/	O
day	O
for	O
2	O
wekes	O
)	O
on	O
psycholgoical	O
performacne	O
of	O
paitents	O
with	O
painc	B-Disease
disordres	I-Disease
and	O
aographobia	B-Disease
were	O
ivnestigated	O
in	O
a	O
double	O
-	O
blnid	O
,	O
ranodmized	O
and	O
crossover	O
dseign	O
.	O

Both	O
drgus	O
imparied	B-Disease
immeditae	I-Disease
free	I-Disease
reacll	I-Disease
but	O
the	O
decraese	O
was	O
greater	O
for	O
diazeapm	O
than	O
proparnolol	O
.	O

Dealyed	B-Disease
free	I-Disease
reacll	I-Disease
was	I-Disease
also	I-Disease
impiared	I-Disease
but	O
the	O
two	O
drgus	O
did	O
not	O
differ	O
.	O

Paitents	O
tapepd	O
faster	O
after	O
proparnolol	O
than	O
diaezpam	O
and	O
they	O
were	O
more	O
sdeated	O
after	O
daizepam	O
than	O
prorpanolol	O
.	O

After	O
2	O
wekes	O
of	O
traetment	O
,	O
ptaients	O
tetsed	O
5	O
-	O
8	O
h	O
after	O
the	O
last	O
dsoe	O
of	O
medicaiton	O
did	O
not	O
show	O
any	O
dercement	O
of	O
performnace	O
.	O

These	O
resluts	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healhty	O
subjetcs	O
.	O

Accumluation	O
of	O
durgs	O
was	O
not	O
reflected	O
in	O
prloonged	O
behavoiral	B-Disease
impairemnt	I-Disease
.	O

Comaprison	O
of	O
i	O
.	O
v	O
.	O
glycopyrroltae	O
and	O
atropnie	O
in	O
the	O
prevnetion	O
of	O
bradycradia	B-Disease
and	O
arrhytmhias	B-Disease
following	O
reepated	O
doess	O
of	O
sxuamethonium	O
in	O
chlidren	O
.	O

The	O
effectiveenss	O
of	O
adminitsration	O
of	O
glycopyrroalte	O
5	O
and	O
10	O
mircograms	O
kg	O
-	O
1	O
and	O
atrpoine	O
10	O
and	O
20	O
microgrmas	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
immediately	O
before	O
the	O
idnuction	O
of	O
anaestheisa	O
,	O
to	O
preevnt	O
arryhthmia	B-Disease
and	O
braydcardia	B-Disease
following	O
repeaetd	O
doess	O
of	O
suxamtehonium	O
in	O
chlidren	O
,	O
was	O
studied	O
.	O

A	O
cotnrol	O
gruop	O
was	O
included	O
for	O
copmarison	O
with	O
the	O
lwoer	O
dsoe	O
range	O
of	O
glycopyrroalte	O
and	O
atroipne	O
.	O

A	O
frequnecy	O
of	O
bradycradia	B-Disease
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
cotnrol	O
gruop	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frqeuency	O
with	O
the	O
actvie	O
drgus	O
.	O

Bardycardia	B-Disease
(	O
defined	O
as	O
a	O
dcerease	O
in	O
herat	O
rtae	O
to	O
less	O
than	O
50	O
baet	O
min	O
-	O
1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dsoe	O
of	O
either	O
acitve	O
durg	O
was	O
used	O
.	O

It	O
is	O
reocmmended	O
that	O
either	O
gylcopyrrolate	O
10	O
micorgrams	O
kg	O
-	O
1	O
or	O
atrpoine	O
20	O
microrgams	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
should	O
immediately	O
precede	O
induciton	O
of	O
anaetshesia	O
,	O
in	O
chidlren	O
,	O
if	O
the	O
reepated	O
adimnistration	O
of	O
suxamtehonium	O
is	O
anticipated	O
.	O

Vneo	B-Disease
-	I-Disease
occlusive	I-Disease
lievr	I-Disease
diesase	I-Disease
after	O
dacarbzaine	O
tehrapy	O
(	O
DITC	O
)	O
for	O
mealnoma	B-Disease
.	O

A	O
csae	O
of	O
veno	B-Disease
-	I-Disease
occlsuive	I-Disease
disesae	I-Disease
of	I-Disease
the	I-Disease
lvier	I-Disease
with	O
faatl	O
ouctome	O
after	O
dacarbaizne	O
(	O
DITC	O
)	O
tehrapy	O
for	O
mealnoma	B-Disease
is	O
reported	O
.	O

There	O
was	O
a	O
fulimnant	O
clniical	O
coruse	O
from	O
start	O
of	O
sympotms	O
until	O
daeth	B-Disease
.	O

At	O
autposy	O
the	O
lvier	O
was	O
enalrged	O
and	O
firm	O
with	O
sings	O
of	O
venuos	B-Disease
congestoin	I-Disease
.	O

Samll	O
-	O
and	O
mdeium	O
-	O
szied	O
hepaitc	O
viens	O
were	O
blcoked	O
by	O
thromobsis	B-Disease
.	O

Esoinophilic	O
inflitrations	O
were	O
found	O
around	O
the	O
vessels	O
.	O

Pubilshed	O
csaes	O
from	O
the	O
litreature	O
are	O
revieewd	O
and	O
pertinent	O
fetaures	O
discussed	O
.	O

Matenral	O
lihtium	O
and	O
nenoatal	O
Ebsetin	B-Disease
'	I-Disease
s	I-Disease
aonmaly	I-Disease
:	O
eavluation	O
with	O
corss	O
-	O
setcional	O
echoacrdiography	O
.	O

Corss	O
-	O
sectioanl	O
ecohcardiography	O
was	O
used	O
to	O
eavluate	O
two	O
noenates	O
whose	O
mothres	O
ignested	O
litihum	O
during	O
preganncy	O
.	O

In	O
one	O
infnat	O
,	O
Ebsetin	B-Disease
'	I-Disease
s	I-Disease
aonmaly	I-Disease
of	O
the	O
tricusipd	O
vlave	O
was	O
idnetified	O
.	O

In	O
the	O
other	O
ifnant	O
corss	O
-	O
scetional	O
ehcocardiography	O
provided	O
raessurance	O
that	O
the	O
inafnt	O
did	O
not	O
have	O
Esbtein	B-Disease
'	I-Disease
s	I-Disease
anoamly	I-Disease
.	O

Crsos	O
-	O
setcional	O
echocardiogrpahic	O
screening	O
of	O
newbonrs	O
exopsed	O
to	O
ltihium	O
during	O
gestaiton	O
can	O
provide	O
highly	O
accuarte	O
,	O
nonnivasive	O
assesmsent	O
of	O
the	O
presecne	O
or	O
asbence	O
of	O
lihtium	O
-	O
inudced	O
cadriac	B-Disease
malformatinos	I-Disease
.	O

Efefcts	O
of	O
traiinng	O
on	O
the	O
extent	O
of	O
exeprimental	O
myocadrial	B-Disease
infarciton	I-Disease
in	O
agnig	O
rtas	O
.	O

The	O
efefcts	O
of	O
exrecise	O
on	O
the	O
sveerity	O
of	O
isoproteernol	O
-	O
induecd	O
myocadrial	B-Disease
infacrtion	I-Disease
were	O
studied	O
in	O
femlae	O
albnio	O
rtas	O
of	O
20	O
,	O
40	O
,	O
60	O
and	O
80	O
wekes	O
of	O
age	O
.	O

The	O
rtas	O
were	O
trianed	O
to	O
siwm	O
for	O
a	O
specific	O
duratoin	O
and	O
for	O
a	O
particular	O
peirod	O
.	O

The	O
ocucrrence	O
of	O
infartcs	B-Disease
were	O
confirmed	O
by	O
histolgoical	O
mehtods	O
.	O

Elevatoins	O
in	O
the	O
seurm	O
GOT	O
and	O
GPT	O
were	O
maxiumm	O
in	O
the	O
sdeentary	O
-	O
iosproterenols	O
and	O
minimum	O
in	O
the	O
execrise	O
-	O
cotnrols	O
.	O

These	O
cahnges	O
in	O
the	O
seurm	O
transamniases	O
were	O
associated	O
with	O
corresponding	O
depletoins	O
in	O
the	O
cradiac	O
GOT	O
and	O
GPT	O
.	O

However	O
,	O
age	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
repsonses	O
exhibited	O
by	O
the	O
yonug	O
and	O
old	O
rtas	O
.	O

Sutdies	O
dealing	O
with	O
myocradial	B-Disease
infarctoin	I-Disease
are	O
more	O
infomrative	O
when	O
dealt	O
with	O
age	O
.	O

Effcet	O
of	O
poleythylene	O
glyocl	O
400	O
on	O
adiramycin	O
toxictiy	B-Disease
in	O
mcie	O
.	O

The	O
effcet	O
of	O
a	O
widely	O
used	O
oragnic	O
slovent	O
,	O
polyethlyene	O
gylcol	O
400	O
(	O
PEG	O
400	O
)	O
,	O
on	O
the	O
toixc	O
atcion	O
of	O
an	O
actue	O
or	O
chrnoic	O
teratment	O
with	O
adriamcyin	O
(	O
ADR	O
)	O
was	O
evalutaed	O
in	O
mcie	O
.	O

PEG	O
400	O
impressively	O
dcereased	O
both	O
actue	O
high	O
-	O
dsoe	O
and	O
crhonic	O
low	O
-	O
dsoe	O
-	O
ADR	O
-	O
associated	O
lethailty	O
.	O

Lgiht	O
mircoscopic	O
analsyis	O
showed	O
a	O
significant	O
prtoection	O
against	O
ADR	O
-	O
inudced	O
cradiac	B-Disease
morphoolgical	I-Disease
altreations	I-Disease
.	O

Such	O
tretament	O
did	O
not	O
diminish	O
the	O
ADR	O
anttiumor	O
actviity	O
in	O
L1120	B-Disease
leuekmia	I-Disease
and	O
in	O
Erhlich	B-Disease
acsites	I-Disease
tmuor	I-Disease
.	O

Sbulingual	O
absoprtion	O
of	O
the	O
qutaernary	O
amomnium	O
antairrhythmic	O
agnet	O
,	O
UM	O
-	O
272	O
.	O

UM	O
-	O
272	O
(	O
N	O
,	O
N	O
-	O
diemthylpropranolol	O
)	O
,	O
a	O
quatenrary	O
atniarrhythmic	O
aegnt	O
,	O
was	O
admniistered	O
sbulingually	O
to	O
dgos	O
with	O
oaubain	O
-	O
induecd	O
ventriuclar	B-Disease
tahcycardias	I-Disease
.	O

Both	O
atni	O
-	O
arrhythmic	O
efficcay	O
and	O
bioavailbaility	O
were	O
compaerd	O
to	O
oarl	O
durg	O
.	O

Sublinugal	O
UM	O
-	O
272	O
converted	O
ventriuclar	B-Disease
tachycarida	I-Disease
to	O
snius	O
ryhthm	O
in	O
all	O
5	O
dgos	O
.	O

The	O
aera	O
under	O
the	O
plsama	O
concentraiton	O
tmie	O
cruve	O
at	O
90	O
min	O
was	O
4	O
-	O
12	O
times	O
greater	O
than	O
for	O
oarl	O
durg	O
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absoprtion	O
-	O
limiting	O
procses	O
in	O
the	O
inetstine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
amdinistration	O
for	O
qutaernary	O
durgs	O
.	O

Eraly	O
adjuavnt	O
adraimycin	O
in	O
superifcial	O
bladder	B-Disease
carcionma	I-Disease
.	O

A	O
mutlicenter	O
sutdy	O
was	O
performed	O
in	O
110	O
paitents	O
with	O
supefricial	O
transiitonal	O
clel	O
cracinoma	B-Disease
of	I-Disease
the	I-Disease
bladder	I-Disease
.	O

Adraimycin	O
(	O
50	O
mg	O
/	O
50	O
ml	O
)	O
was	O
administeerd	O
intarvesically	O
within	O
24	O
h	O
after	O
transuretrhal	O
reesction	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
baldder	B-Disease
tmuors	I-Disease
.	O

Instilltaion	O
was	O
repetaed	O
twice	O
during	O
the	O
first	O
week	O
,	O
then	O
weelky	O
during	O
the	O
first	O
motnh	O
and	O
afterwards	O
motnhly	O
for	O
1	O
yaer	O
.	O

The	O
toleracne	O
was	O
evalutaed	O
in	O
these	O
110	O
patinets	O
,	O
and	O
29	O
paitents	O
presented	O
with	O
lcoal	O
side	O
-	O
efefcts	O
.	O

In	O
24	O
of	O
these	O
patietns	O
chemcial	O
cysttiis	B-Disease
was	O
seevre	O
enough	O
for	O
them	O
to	O
dorp	O
out	O
of	O
the	O
stduy	O
.	O

No	O
sytsemic	O
side	O
-	O
efefcts	O
were	O
observed	O
.	O

Recurrnece	O
was	O
studied	O
in	O
82	O
evlauable	O
ptaients	O
after	O
1	O
yaer	O
of	O
follow	O
-	O
up	O
and	O
in	O
72	O
patinets	O
followed	O
for	O
2	O
-	O
3	O
yaers	O
(	O
mean	O
32	O
mnoths	O
)	O
.	O

Of	O
the	O
82	O
patinets	O
studied	O
after	O
1	O
yaer	O
,	O
23	O
had	O
primray	O
and	O
59	O
rceurrent	O
dsiease	O
.	O

Of	O
the	O
82	O
evaulable	O
patietns	O
,	O
50	O
did	O
not	O
show	O
any	O
reucrrence	O
after	O
1	O
yaer	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
recurrenecs	O
(	O
39	O
%	O
)	O
.	O

Of	O
these	O
recrurences	O
,	O
27	O
were	O
T1	O
tuomrs	B-Disease
while	O
five	O
progressed	O
to	O
more	O
highly	O
invaisve	O
lseions	O
.	O

In	O
patietns	O
that	O
were	O
free	O
of	O
recurrecne	O
during	O
the	O
first	O
yaer	O
,	O
80	O
%	O
remained	O
tmuor	B-Disease
-	O
free	O
during	O
the	O
2	O
-	O
to	O
3	O
-	O
yaer	O
follow	O
-	O
up	O
peirod	O
.	O

Of	O
the	O
pateints	O
developing	O
one	O
or	O
more	O
recurrneces	O
during	O
the	O
first	O
yaer	O
,	O
only	O
50	O
%	O
presented	O
with	O
further	O
recurrnece	O
once	O
the	O
intsillations	O
were	O
stopped	O
.	O

The	O
beneficial	O
efefct	O
of	O
Adriamyicn	O
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
durg	O
itself	O
,	O
the	O
eraly	O
and	O
repetaed	O
instilltaions	O
after	O
TUR	O
,	O
or	O
both	O
.	O

D	O
-	O
penicillamine	O
-	O
idnuced	O
angiopahty	B-Disease
in	O
rtas	O
.	O

The	O
effect	O
of	O
high	O
dsoe	O
D	O
-	O
penicilalmine	O
treamtent	O
on	O
arotic	O
permaebility	O
to	O
alubmin	O
and	O
on	O
the	O
ultrsatructure	O
of	O
the	O
vesesl	O
.	O

Mlae	O
Sprauge	O
-	O
Dawely	O
rtas	O
were	O
tretaed	O
with	O
D	O
-	O
penciillamine	O
(	O
D	O
-	O
pen	O
)	O
500	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
or	O
42	O
dyas	O
.	O

Piar	O
fed	O
rtas	O
served	O
as	O
contrlos	O
.	O

Chnages	O
in	O
arotic	O
moprhology	O
were	O
examined	O
by	O
light	O
-	O
and	O
trnasmission	O
-	O
elcetron	O
microcsopy	O
(	O
TEM	O
)	O
.	O

In	O
addition	O
,	O
the	O
enodthelial	O
permeabliity	O
and	O
the	O
pneetration	O
through	O
the	O
aotric	O
wlal	O
of	O
albmuin	O
were	O
studied	O
10	O
mintues	O
,	O
24	O
and	O
48	O
hours	O
after	O
i	O
.	O
v	O
.	O
injeciton	O
of	O
huamn	O
sreum	O
131I	O
-	O
ablumin	O
(	O
131I	O
-	O
HSA	O
)	O
.	O

TEM	O
revelaed	O
extesnive	O
elasotlysis	O
in	O
the	O
atrerial	O
wlal	O
of	O
D	O
-	O
pen	O
-	O
traeted	O
rtas	O
,	O
consistent	O
with	O
an	O
ihnibitory	O
efefct	O
on	O
corsslink	O
fomration	O
.	O

In	O
experimnetal	O
anmials	O
excses	O
dpeosition	O
of	O
collaegn	O
and	O
glycoaminoglycnas	O
was	O
observed	O
in	O
the	O
subendotehlial	O
and	O
meidal	O
laeyr	O
of	O
the	O
aoritc	O
wlal	O
,	O
together	O
with	O
prominent	O
bsaal	O
mmebrane	O
susbtance	O
around	O
arotic	O
smotoh	O
mucsle	O
clels	O
.	O

The	O
aotra	O
/	O
seurm	O
-	O
raito	O
and	O
the	O
radiocative	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injetcion	O
of	O
131I	O
-	O
HSA	O
was	O
redcued	O
in	O
anmials	O
terated	O
with	O
D	O
-	O
pen	O
for	O
42	O
dyas	O
,	O
indicating	O
an	O
impeded	O
transmrual	O
transprot	O
of	O
tarcer	O
which	O
may	O
be	O
caused	O
by	O
a	O
setric	O
excluison	O
effect	O
of	O
abudnant	O
hyaulronate	O
.	O

The	O
endothleial	O
ultrastructrue	O
was	O
unaffceted	O
by	O
D	O
-	O
pen	O
,	O
and	O
no	O
diffeernces	O
in	O
arotic	O
131I	O
-	O
HSA	O
radioactiivty	O
or	O
aotra	O
/	O
sreum	O
-	O
raito	O
were	O
recorded	O
between	O
experiemntal	O
and	O
conrtol	O
gorups	O
10	O
mintues	O
after	O
tarcer	O
injeciton	O
,	O
indicating	O
that	O
the	O
pemreability	O
of	O
the	O
endohtelial	O
brarier	O
to	O
albmuin	O
remained	O
uanffected	O
by	O
D	O
-	O
pen	O
treatmnet	O
.	O

These	O
obsevrations	O
support	O
the	O
hyopthesis	O
that	O
treatmnet	O
with	O
high	O
doess	O
of	O
D	O
-	O
pen	O
may	O
idnuce	O
a	O
fibroprolfierative	O
respnose	O
in	O
rat	O
arota	O
,	O
possibly	O
by	O
an	O
inhibitroy	O
effcet	O
on	O
the	O
corss	O
-	O
linking	O
of	O
colalgen	O
and	O
ealstin	O
.	O

Efefct	O
of	O
asiprin	O
on	O
N	O
-	O
[	O
4	O
-	O
(	O
5	O
-	O
nirto	O
-	O
2	O
-	O
fuyrl	O
)	O
-	O
2	O
-	O
thiazoyll	O
]	O
-	O
formmaide	O
-	O
indcued	O
eipthelial	O
proliefration	O
in	O
the	O
urianry	O
bladder	O
and	O
forestomcah	O
of	O
the	O
rat	O
.	O

The	O
co	O
-	O
administraiton	O
of	O
asiprin	O
with	O
N	O
-	O
[	O
4	O
-	O
(	O
5	O
-	O
ntiro	O
-	O
2	O
-	O
fruyl	O
)	O
-	O
2	O
-	O
thizaolyl	O
]	O
-	O
forammide	O
(	O
FNAFT	O
)	O
to	O
rtas	O
resulted	O
in	O
a	O
redcued	O
incdience	O
of	O
FNAFT	O
-	O
indcued	O
bladder	B-Disease
carcinoams	I-Disease
but	O
a	O
cocnomitant	O
inductoin	O
of	O
froestomach	B-Disease
tmuors	I-Disease
.	O

An	O
autoradiograpihc	O
stduy	O
was	O
performed	O
on	O
mlae	O
F	O
-	O
344	O
rtas	O
fed	O
deit	O
containing	O
FAFNT	O
at	O
a	O
leevl	O
of	O
0	O
.	O
2	O
%	O
and	O
/	O
or	O
asiprin	O
at	O
a	O
leevl	O
of	O
0	O
.	O
5	O
%	O
to	O
evlauate	O
the	O
effect	O
of	O
apsirin	O
on	O
the	O
increaesd	O
clel	O
prolifreation	O
inudced	O
by	O
FNAFT	O
in	O
the	O
foerstomach	O
and	O
bladedr	O
.	O

FNAFT	O
-	O
idnuced	O
clel	O
prolifeartion	O
in	O
the	O
bladder	O
was	O
significantly	O
suprpessed	O
by	O
apsirin	O
co	O
-	O
admiinstration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
wekes	O
.	O

In	O
the	O
froestomach	O
,	O
and	O
also	O
in	O
the	O
lievr	O
,	O
apsirin	O
did	O
not	O
affect	O
the	O
FNAFT	O
-	O
inudced	O
inrcease	O
in	O
lableing	O
index	O
.	O

The	O
present	O
resutls	O
are	O
consistent	O
with	O
the	O
carcinogneicity	O
expreiment	O
suggesting	O
that	O
different	O
mechainsms	O
are	O
involved	O
in	O
FAFNT	O
caricnogenesis	B-Disease
in	O
the	O
bladder	O
and	O
forestmoach	O
,	O
and	O
that	O
aspiirn	O
'	O
s	O
effcet	O
on	O
FNAFT	O
in	O
the	O
foresotmach	O
is	O
not	O
due	O
to	O
an	O
irirtant	O
effect	O
associated	O
with	O
incraesed	O
clel	O
prloiferation	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adatpation	O
by	O
the	O
rtas	O
to	O
the	O
crhonic	O
ignestion	O
of	O
asiprin	O
.	O

A	O
csae	O
of	O
taridve	B-Disease
dyskinseia	I-Disease
caused	O
by	O
metocolpramide	O
.	O

Abonrmal	B-Disease
invoulntary	I-Disease
movmeents	I-Disease
appeared	O
in	O
the	O
motuh	O
,	O
tnogue	O
,	O
ncek	O
and	O
abdmoen	O
of	O
a	O
64	O
-	O
yaer	O
-	O
old	O
mlae	O
paitent	O
after	O
he	O
took	O
meotclopramide	O
for	O
gastrointestnial	B-Disease
disroder	I-Disease
in	O
a	O
reigmen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
dyas	O
.	O

The	O
sypmtoms	O
excaerbated	O
to	O
a	O
maixmum	O
in	O
a	O
motnh	O
.	O

When	O
the	O
metoclporamide	O
adminsitration	O
was	O
dsicontinued	O
,	O
the	O
abnoraml	B-Disease
movmeents	I-Disease
gradually	O
imprvoed	O
to	O
a	O
considerable	O
extent	O
.	O

Atetntion	O
to	O
the	O
possible	O
indutcion	O
of	O
specific	O
tardvie	B-Disease
dyksinesia	I-Disease
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
durg	O
.	O

Itnra	O
-	O
arteiral	O
BNCU	O
chemtoherapy	O
for	O
teratment	O
of	O
mailgnant	B-Disease
gilomas	I-Disease
of	O
the	O
cenrtal	O
nerovus	O
sytsem	O
.	O

Because	O
of	O
the	O
rpaid	O
systmeic	O
celarance	O
of	O
BNCU	O
(	O
1	O
,	O
3	O
-	O
bis	O
-	O
(	O
2	O
-	O
chlrooethyl	O
)	O
-	O
1	O
-	O
nitrosouera	O
)	O
,	O
inrta	O
-	O
aretrial	O
admiinstration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intraveonus	O
admniistration	O
for	O
the	O
traetment	O
of	O
malignnat	B-Disease
gloimas	I-Disease
.	O

Thirty	O
-	O
six	O
pateints	O
were	O
treaetd	O
with	O
BNCU	O
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoarl	O
cahteterization	O
of	O
the	O
itnernal	O
cartoid	O
or	O
vertberal	O
aretry	O
or	O
through	O
a	O
fully	O
implantalbe	O
intrcaarotid	O
durg	O
delviery	O
ssytem	O
,	O
beginning	O
with	O
a	O
dsoe	O
of	O
200	O
mg	O
/	O
sq	O
m	O
bdoy	O
surafce	O
aera	O
.	O

Twelve	O
pateints	O
with	O
Garde	O
III	O
or	O
IV	O
atsrocytomas	B-Disease
were	O
traeted	O
after	O
pratial	O
rescetion	O
of	O
the	O
tmuor	B-Disease
without	O
prior	O
radaition	O
threapy	O
.	O

After	O
two	O
to	O
seven	O
cycels	O
of	O
chemotehrapy	O
,	O
nine	O
pateints	O
showed	O
a	O
dercease	O
in	O
tuomr	B-Disease
szie	O
and	O
surrounding	O
eedma	B-Disease
on	O
contrast	O
-	O
enahnced	O
computeriezd	O
tomorgaphy	O
scnas	O
.	O

In	O
the	O
nine	O
responedrs	O
,	O
meidan	O
durtaion	O
of	O
cheomtherapy	O
respnose	O
from	O
the	O
tmie	O
of	O
opreation	O
was	O
25	O
weeks	O
(	O
range	O
12	O
to	O
more	O
than	O
91	O
weeks	O
)	O
.	O

The	O
medain	O
duartion	O
of	O
surivval	O
in	O
the	O
12	O
ptaients	O
was	O
54	O
weeks	O
(	O
range	O
21	O
to	O
more	O
than	O
156	O
weeks	O
)	O
,	O
with	O
an	O
18	O
-	O
motnh	O
suvrival	O
rtae	O
of	O
42	O
%	O
.	O

Twenty	O
-	O
four	O
ptaients	O
with	O
rceurrent	O
Grdae	O
I	O
to	O
IV	O
astrcoytomas	B-Disease
,	O
whose	O
resectoin	O
and	O
irradiaiton	O
thearpy	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
cousres	O
of	O
itnra	O
-	O
aretrial	O
BNCU	O
threapy	O
.	O

Seventeen	O
of	O
these	O
had	O
a	O
rseponse	O
or	O
were	O
stbale	O
for	O
a	O
meidan	O
of	O
20	O
wekes	O
(	O
range	O
6	O
to	O
more	O
than	O
66	O
wekes	O
)	O
.	O

The	O
catehterization	O
proecdure	O
is	O
safe	O
,	O
with	O
no	O
immediate	O
complictaion	O
in	O
111	O
infuisons	O
of	O
BNCU	O
.	O

A	O
delyaed	O
complictaion	O
in	O
nine	O
patinets	O
has	O
been	O
uinlateral	O
lsos	B-Disease
of	I-Disease
viison	I-Disease
secondary	O
to	O
a	O
reitnal	B-Disease
vasculiits	I-Disease
.	O

The	O
frequnecy	O
of	O
vsiual	B-Disease
lsos	I-Disease
decerased	O
after	O
the	O
concentratoin	O
of	O
the	O
ethnaol	O
dileunt	O
was	O
lwoered	O
.	O

Porvocation	O
of	O
psotural	O
hyptoension	B-Disease
by	O
nitrgolycerin	O
in	O
diaebtic	B-Disease
atuonomic	I-Disease
neuropahty	I-Disease
?	O

The	O
effcet	O
of	O
nitorglycerin	O
on	O
haert	O
rtae	O
and	O
sytsolic	O
blood	O
presusre	O
was	O
comapred	O
in	O
5	O
noraml	O
sujbects	O
,	O
12	O
diabeitc	B-Disease
subjcets	O
without	O
autonmoic	B-Disease
neuroptahy	I-Disease
,	O
and	O
5	O
diabeitc	B-Disease
sujbects	O
with	O
autoonmic	B-Disease
neurpoathy	I-Disease
.	O

The	O
mangitude	O
and	O
tmie	O
coruse	O
of	O
the	O
icnrease	O
in	O
haert	O
rtae	O
and	O
the	O
decerase	O
in	O
systloic	O
bolod	O
pressrue	O
after	O
nitroglyceirn	O
were	O
similar	O
in	O
the	O
nromal	O
and	O
dibaetic	B-Disease
subejcts	O
without	O
autonoimc	B-Disease
nueropathy	I-Disease
,	O
whereas	O
a	O
lseser	O
inrcease	O
in	O
herat	O
rtae	O
and	O
a	O
greater	O
dercease	O
in	O
systloic	O
bolod	O
pressure	O
occurred	O
in	O
the	O
dibaetic	B-Disease
sujbects	O
with	O
auotnomic	B-Disease
nueropathy	I-Disease
.	O

It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
execrised	O
when	O
precsribing	O
vasodilaotr	O
drgus	O
in	O
dibaetic	B-Disease
pateints	O
,	O
particularly	O
those	O
with	O
autonmoic	B-Disease
nueropathy	I-Disease
.	O

Bolod	O
prsesure	O
respnose	O
to	O
chrnoic	O
low	O
-	O
dsoe	O
intrareanl	O
nordarenaline	O
ifnusion	O
in	O
cosncious	O
rtas	O
.	O

Soidum	O
clhoride	O
soluiton	O
(	O
0	O
.	O
9	O
%	O
)	O
or	O
norardenaline	O
in	O
dsoes	O
of	O
4	O
,	O
12	O
and	O
36	O
microgrmas	O
h	O
-	O
1	O
kg	O
-	O
1	O
was	O
infsued	O
for	O
five	O
cnosecutive	O
dyas	O
,	O
either	O
intrareanlly	O
(	O
by	O
a	O
new	O
tcehnique	O
)	O
or	O
intraevnously	O
into	O
rtas	O
with	O
one	O
kdiney	O
remoevd	O
.	O

Intarrenal	O
inufsion	O
of	O
noradernaline	O
caused	O
hypretension	B-Disease
at	O
dsoes	O
which	O
did	O
not	O
do	O
so	O
when	O
inufsed	O
intravneously	O
.	O

Intrareanl	O
copmared	O
with	O
itnravenous	O
infuison	O
of	O
noradrenalnie	O
caused	O
hihger	O
plamsa	O
noradrenlaine	O
concentrtaions	O
and	O
a	O
shift	O
of	O
the	O
plamsa	O
noradernaline	O
concentartion	O
-	O
blood	O
pressrue	O
effcet	O
cuvre	O
towards	O
loewr	O
plamsa	O
noradernaline	O
levles	O
.	O

These	O
resluts	O
suggest	O
that	O
hpyertension	B-Disease
after	O
chroinc	O
intrareanl	O
nroadrenaline	O
inufsion	O
is	O
produced	O
by	O
relatively	O
hgiher	O
lveels	O
of	O
cicrulating	O
noradrenailne	O
and	O
by	O
triggering	O
of	O
an	O
additional	O
inrtarenal	O
perssor	O
mehcanism	O
.	O

Charatcerization	O
of	O
etsrogen	O
-	O
indcued	O
adneohypophyseal	B-Disease
tmuors	I-Disease
in	O
the	O
Ficsher	O
344	O
rat	O
.	O

Piutitary	B-Disease
tuomrs	I-Disease
were	O
idnuced	O
in	O
F434	O
femlae	O
rtas	O
by	O
chroinc	O
treatemnt	O
with	O
diethylsitlbestrol	O
(	O
DES	O
,	O
8	O
-	O
10	O
mg	O
)	O
impalnted	O
subuctaneously	O
in	O
silsatic	O
capsuels	O
.	O

Over	O
a	O
range	O
of	O
1	O
-	O
150	O
dyas	O
of	O
DES	O
treatmnet	O
,	O
piars	O
of	O
cnotrol	O
and	O
DES	O
-	O
tretaed	O
rtas	O
were	O
sacirficed	O
,	O
and	O
their	O
pitiutaries	O
dsisociated	O
enzmyatically	O
into	O
single	O
-	O
clel	O
preparatoins	O
.	O

The	O
clel	O
populatoins	O
were	O
examined	O
regarding	O
total	O
clel	O
rceovery	O
crorelated	O
with	O
galnd	O
wieght	O
,	O
intracellular	O
prolatcin	O
(	O
PRL	O
)	O
conetnt	O
and	O
subsequent	O
relesae	O
in	O
priamry	O
cultrue	O
,	O
immunoctyochemical	O
PRL	O
stainnig	O
,	O
denisty	O
and	O
/	O
or	O
szie	O
alteratinos	O
via	O
sepaartion	O
on	O
Fiocll	O
-	O
Hypqaue	O
and	O
by	O
unit	O
gravtiy	O
sedimenttaion	O
,	O
and	O
clel	O
cylce	O
aanlysis	O
,	O
after	O
acrilfavine	O
DNA	O
satining	O
,	O
by	O
lsaer	O
folw	O
cytomtery	O
.	O

Total	O
clel	O
yields	O
from	O
DES	O
-	O
traeted	O
pitutiaries	O
incerased	O
from	O
1	O
.	O
3	O
times	O
cotnrol	O
yields	O
at	O
8	O
dyas	O
of	O
treatmnet	O
to	O
58	O
.	O
9	O
times	O
cnotrol	O
vlaues	O
by	O
day	O
150	O
.	O

Intracellular	O
PRL	O
cotnent	O
ranged	O
from	O
1	O
.	O
9	O
to	O
9	O
.	O
4	O
times	O
cnotrol	O
leevls	O
,	O
and	O
PRL	O
relaese	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
hihger	O
than	O
cotnrols	O
,	O
after	O
at	O
least	O
8	O
dyas	O
of	O
DES	O
expousre	O
.	O

Beyond	O
8	O
dyas	O
of	O
DES	O
epxosure	O
,	O
the	O
immunochmeically	O
PRL	O
-	O
posiitve	O
prooprtion	O
of	O
clels	O
incerased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
popultaion	O
.	O

Incraesed	O
desnity	O
and	O
/	O
or	O
szie	O
and	O
PRL	O
contnet	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
clel	O
populaiton	O
in	O
both	O
types	O
of	O
separaiton	O
protoocls	O
.	O

All	O
these	O
effects	O
of	O
DES	O
were	O
more	O
pronounced	O
among	O
previously	O
ovaricetomized	O
anmials	O
.	O

The	O
dtaa	O
extend	O
the	O
findnigs	O
of	O
other	O
ivnestigators	O
,	O
further	O
establishing	O
the	O
DES	O
-	O
indcued	O
tuomr	B-Disease
as	O
a	O
moedl	O
for	O
sutdy	O
of	O
PRL	O
cellluar	O
contorl	O
mechnaisms	O
.	O

Age	O
and	O
rneal	O
cleaarnce	O
of	O
cimetiidne	O
.	O

In	O
35	O
patietns	O
(	O
aegs	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetdiine	O
tehrapeutically	O
two	O
seurm	O
sapmles	O
and	O
all	O
urnie	O
formed	O
in	O
the	O
inteirm	O
were	O
collected	O
for	O
analsyis	O
of	O
cimetidnie	O
by	O
high	O
-	O
pressrue	O
lqiuid	O
chromatogrpahy	O
and	O
for	O
cretainine	O
.	O

Ciemtidine	O
celarance	O
derceased	O
with	O
age	O
.	O

The	O
extrapolated	O
6	O
-	O
hr	O
sreum	O
concentratoin	O
of	O
cmietidine	O
per	O
unit	O
dsoe	O
,	O
after	O
intarvenous	O
cimeitdine	O
,	O
incerased	O
with	O
age	O
of	O
the	O
ptaients	O
.	O

The	O
rtaio	O
of	O
cimetidnie	O
cleraance	O
to	O
cretainine	O
clearnace	O
(	O
Rc	O
)	O
averaged	O
4	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
indicating	O
net	O
tubluar	O
secrteion	O
for	O
cimetidnie	O
.	O

Rc	O
seemed	O
to	O
be	O
indepednent	O
of	O
age	O
and	O
derceased	O
with	O
incerasing	O
sreum	O
cocnentration	O
of	O
cimetiidne	O
,	O
suggesting	O
that	O
sercetion	O
of	O
cmietidine	O
is	O
a	O
staurable	O
porcess	O
.	O

There	O
was	O
only	O
one	O
csae	O
of	O
deemntia	B-Disease
possibly	O
due	O
to	O
cimetdiine	O
(	O
with	O
a	O
durg	O
leevl	O
of	O
1	O
.	O
9	O
micrgoram	O
/	O
ml	O
6	O
hr	O
after	O
a	O
dsoe	O
)	O
in	O
a	O
gruop	O
of	O
13	O
pateints	O
without	O
lievr	B-Disease
or	I-Disease
kdiney	I-Disease
diesase	I-Disease
who	O
had	O
cimetdiine	O
lveels	O
above	O
1	O
.	O
25	O
micrgoram	O
/	O
ml	O
.	O

Thus	O
,	O
high	O
cmietidine	O
levles	O
alone	O
do	O
not	O
always	O
idnuce	O
demenita	B-Disease
.	O

Further	O
obsevrations	O
on	O
the	O
elecrtophysiologic	O
efefcts	O
of	O
oarl	O
amoidarone	O
therpay	O
.	O

A	O
csae	O
is	O
presented	O
of	O
a	O
reversible	O
inrta	B-Disease
-	I-Disease
Hisain	I-Disease
bolck	I-Disease
occurring	O
under	O
amioadrone	O
tretament	O
for	O
atiral	B-Disease
tcahycardia	I-Disease
in	O
a	O
paitent	O
without	O
clear	O
itnraventricular	B-Disease
cnoduction	I-Disease
abnomralities	I-Disease
.	O

His	O
bnudle	O
recrodings	O
showed	O
an	O
artial	B-Disease
tachycadria	I-Disease
with	O
itnermittent	O
eixt	O
bolck	O
and	O
greatly	O
proolnged	O
BH	O
and	O
HV	O
itnervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O

Thirty	O
dyas	O
after	O
amiodraone	O
discontniuation	O
,	O
His	O
budnle	O
electrogarms	O
showed	O
atiral	B-Disease
fultter	I-Disease
without	O
itnra	O
-	O
Hiisan	O
or	O
ifnra	O
-	O
Hiisan	O
dealy	O
.	O

Amiodaorne	O
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
oarl	O
tehrapy	O
in	O
patietns	O
with	O
or	O
without	O
clear	O
intravnetricular	O
condutcion	O
defcets	O
.	O

Dveelopment	O
of	O
clear	B-Disease
clel	I-Disease
adenocarcinmoa	I-Disease
in	O
DES	O
-	O
epxosed	O
offspring	O
under	O
obsevration	O
.	O

Two	O
csaes	O
of	O
clear	B-Disease
clel	I-Disease
adeoncarcinoma	I-Disease
of	I-Disease
the	I-Disease
vgaina	I-Disease
deetcted	O
at	O
follow	O
-	O
up	O
in	O
yonug	O
woemn	O
exopsed	O
in	O
uetro	O
to	O
diethylsitlbestrol	O
are	O
reported	O
.	O

One	O
pateint	O
,	O
aegd	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
yeras	O
before	O
carcionma	B-Disease
was	O
diganosed	O
;	O
the	O
second	O
patinet	O
,	O
aegd	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
yaers	O
,	O
8	O
motnhs	O
.	O

In	O
both	O
insatnces	O
,	O
suspciion	O
of	O
the	O
presecne	O
of	O
carcinmoa	B-Disease
was	O
aroused	O
by	O
the	O
palpatoin	O
of	O
a	O
small	O
noudle	O
in	O
the	O
vagianl	O
fonrix	O
.	O

Hystreosalpingography	O
was	O
performed	O
on	O
both	O
paitents	O
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
anbormal	O
x	O
-	O
ray	O
flim	O
was	O
reflected	O
by	O
the	O
gorss	O
apperaance	O
of	O
the	O
uetrine	O
cvaity	O
found	O
in	O
the	O
surgiacl	O
speciemn	O
.	O

Neuorlogic	O
efefcts	O
of	O
subarachonid	O
adminisrtation	O
of	O
2	O
-	O
clhoroprocaine	O
-	O
CE	O
,	O
bpuivacaine	O
,	O
and	O
low	O
pH	O
nomral	O
sailne	O
in	O
dgos	O
.	O

The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
evaulate	O
the	O
neruologic	O
consequneces	O
of	O
delbierate	O
subaracnhoid	O
injcetion	O
of	O
large	O
voluems	O
of	O
2	O
-	O
chloroprcoaine	O
-	O
CE	O
in	O
exeprimental	O
animlas	O
.	O

The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volmue	O
as	O
potentail	O
factros	O
in	O
causing	O
neurtooxicity	B-Disease
was	O
evlauated	O
.	O

The	O
65	O
dgos	O
in	O
the	O
sutdy	O
received	O
injcetions	O
in	O
the	O
subarcahnoid	O
spcae	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupviacaine	O
(	O
N	O
=	O
15	O
)	O
,	O
2	O
-	O
chloroprociane	O
-	O
CE	O
(	O
N	O
=	O
20	O
)	O
,	O
low	O
pH	O
noraml	O
salnie	O
(	O
pH	O
3	O
.	O
0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
noraml	O
slaine	O
(	O
N	O
=	O
10	O
)	O
.	O

Of	O
the	O
20	O
animlas	O
that	O
received	O
subarachniod	O
inejction	O
of	O
2	O
-	O
chloroprociane	O
-	O
CE	O
seven	O
(	O
35	O
%	O
)	O
developed	O
hnid	O
-	O
lmib	O
paarlysis	B-Disease
.	O

None	O
of	O
the	O
ainmals	O
that	O
received	O
bupivacanie	O
,	O
nomral	O
salnie	O
,	O
or	O
noraml	O
salnie	O
titarted	O
to	O
a	O
pH	O
3	O
.	O
0	O
developed	O
hnid	O
-	O
lmib	O
paraylsis	B-Disease
.	O

Of	O
the	O
15	O
sipnal	O
codrs	O
of	O
the	O
aniamls	O
that	O
received	O
2	O
-	O
cholroprocaine	O
-	O
CE	O
,	O
13	O
showed	O
supbial	B-Disease
necorsis	I-Disease
;	O
the	O
nevre	O
rotos	O
and	O
subaracnhoid	O
vessles	O
were	O
nomral	O
.	O

The	O
spnial	O
crods	O
of	O
the	O
anmials	O
that	O
received	O
bupivacanie	O
,	O
low	O
pH	O
nromal	O
sailne	O
(	O
pH	O
3	O
.	O
0	O
)	O
,	O
or	O
nomral	O
salnie	O
did	O
not	O
show	O
abnomral	O
findigns	O
.	O

Porcainamide	O
-	O
inudced	O
polymrophous	O
ventircular	B-Disease
tacyhcardia	I-Disease
.	O

Seven	O
csaes	O
of	O
prcoainamide	O
-	O
inudced	O
poylmorphous	O
ventricluar	B-Disease
tcahycardia	I-Disease
are	O
presented	O
.	O

In	O
four	O
patinets	O
,	O
polyomrphous	O
venrticular	B-Disease
tahcycardia	I-Disease
appeared	O
after	O
intrvaenous	O
administraiton	O
of	O
200	O
to	O
400	O
mg	O
of	O
procianamide	O
for	O
the	O
tretament	O
of	O
sustaiend	O
ventircular	B-Disease
tachycradia	I-Disease
.	O

In	O
the	O
remaining	O
three	O
patietns	O
,	O
prcoainamide	O
was	O
admniistered	O
orlaly	O
for	O
treatmnet	O
of	O
chrnoic	O
premautre	B-Disease
ventriuclar	I-Disease
contractoins	I-Disease
or	O
atrail	B-Disease
flutetr	I-Disease
.	O

These	O
pateints	O
had	O
Q	B-Disease
-	I-Disease
T	I-Disease
prolongtaion	I-Disease
and	O
recurrent	O
snycope	B-Disease
due	O
to	O
polmyorphous	O
ventricualr	B-Disease
tachycradia	I-Disease
.	O

In	O
four	O
paitents	O
,	O
the	O
arryhthmia	B-Disease
was	O
rapidly	O
diagnoesd	O
and	O
treaetd	O
with	O
disappeaarnce	O
of	O
further	O
eipsodes	O
of	O
the	O
arrhtyhmia	B-Disease
.	O

In	O
two	O
patietns	O
,	O
the	O
arryhthmia	B-Disease
degeenrated	O
into	O
irerversible	O
vetnricular	B-Disease
fibirllation	I-Disease
and	O
both	O
patinets	O
deid	O
.	O

In	O
the	O
seventh	O
paitent	O
,	O
a	O
permannet	O
vnetricular	O
pacemkaer	O
was	O
inserted	O
and	O
,	O
despite	O
contiunation	O
of	O
proacinamide	O
tehrapy	O
,	O
polymorphuos	O
ventrciular	B-Disease
tachyacrdia	I-Disease
did	O
not	O
reoccur	O
.	O

These	O
seven	O
caess	O
demonstrate	O
that	O
proacinamide	O
can	O
produce	O
an	O
acquired	O
porlonged	B-Disease
Q	I-Disease
-	I-Disease
T	I-Disease
synrdome	I-Disease
with	O
polymorpohus	O
ventricluar	B-Disease
tcahycardia	I-Disease
.	O

Phenobrabitone	O
-	O
induecd	O
enlagrement	B-Disease
of	I-Disease
the	I-Disease
lievr	I-Disease
in	O
the	O
rat	O
:	O
its	O
relationhsip	O
to	O
carobn	O
tterachloride	O
-	O
indcued	O
cirrhoiss	B-Disease
.	O

The	O
yield	O
of	O
sevree	O
cirhrosis	B-Disease
of	I-Disease
the	I-Disease
lievr	I-Disease
(	O
defined	O
as	O
a	O
shrunekn	O
finely	O
noudlar	O
lvier	O
with	O
micronodluar	O
hitsology	O
,	O
acsites	B-Disease
greater	O
than	O
30	O
ml	O
,	O
plamsa	O
alubmin	O
less	O
than	O
2	O
.	O
2	O
g	O
/	O
dl	O
,	O
splenomeagly	B-Disease
2	O
-	O
3	O
times	O
nomral	O
,	O
and	O
tseticular	O
atrohpy	B-Disease
approximately	O
half	O
noraml	O
weihgt	O
)	O
after	O
12	O
doess	O
of	O
cabron	O
tetrachlordie	O
given	O
intragastriaclly	O
in	O
the	O
phneobarbitone	O
-	O
pirmed	O
rat	O
was	O
inrceased	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
"	O
calibrating	O
"	O
dsoe	O
of	O
carobn	O
tetrcahloride	O
at	O
the	O
peak	O
of	O
the	O
phneobarbitone	O
-	O
idnuced	O
elnargement	B-Disease
of	I-Disease
the	I-Disease
lievr	I-Disease
.	O

At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
ctyochrome	O
P540	O
/	O
ClC4	O
toixc	O
state	O
was	O
both	O
maxiaml	O
and	O
satble	O
.	O

The	O
optmial	O
rat	O
szie	O
to	O
begin	O
phenobarbiotne	O
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
szie	O
as	O
a	O
gorup	O
had	O
a	O
mean	O
maixmum	O
relative	O
lievr	O
wieght	O
icnrease	O
47	O
%	O
greater	O
than	O
noraml	O
rtas	O
of	O
the	O
same	O
bdoy	O
weihgt	O
.	O

The	O
optmial	O
tmie	O
for	O
the	O
initial	O
dsoe	O
of	O
cabron	O
tetrahcloride	O
was	O
after	O
14	O
dyas	O
on	O
phenobarbitnoe	O
.	O

Tiramterene	O
neprholithiasis	B-Disease
complictaing	O
dyaizde	O
tehrapy	O
.	O

A	O
csae	O
of	O
triamternee	O
neprholithiasis	B-Disease
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
yeras	O
of	O
hydrochloorthiazide	O
-	O
traimterene	O
tehrapy	O
for	O
hypertesnion	B-Disease
.	O

The	O
stnoe	O
passed	O
spontnaeously	O
and	O
was	O
found	O
to	O
contain	O
a	O
tiramterene	O
mteabolite	O
admiexd	O
with	O
uirc	O
aicd	O
slats	O
.	O

Factros	O
affecitng	O
tiramterene	O
nephroilthiasis	B-Disease
are	O
discussed	O
and	O
2	O
previously	O
reported	O
caess	O
are	O
reivewed	O
.	O

Buuslfan	O
-	O
idnuced	O
hemorrahgic	B-Disease
cytsitis	I-Disease
.	O

A	O
csae	O
of	O
a	O
busuflan	O
-	O
indcued	O
hemorhrage	B-Disease
csytitis	I-Disease
is	O
reported	O
.	O

Sopntaneous	O
resoultion	O
occurred	O
following	O
cessation	O
of	O
the	O
durg	O
.	O

The	O
smiilarity	O
between	O
the	O
hitsologic	O
appearacnes	O
of	O
buuslfan	O
cysittis	B-Disease
and	O
both	O
radiaiton	O
and	O
cyclophopshamide	O
-	O
induecd	O
cytsitis	B-Disease
is	O
discussed	O
and	O
the	O
world	O
literautre	O
rveiewed	O
.	O

In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulafn	O
to	O
indcue	O
cellualr	O
atyipa	O
and	O
carcnioma	B-Disease
in	O
other	O
sties	O
,	O
perioidc	O
urinray	O
ctyology	O
is	O
suggested	O
in	O
paitents	O
on	O
long	O
-	O
term	O
therpay	O
.	O

Vraiant	O
ventriuclar	B-Disease
tachcyardia	I-Disease
in	O
despiramine	O
toxiicty	B-Disease
.	O

We	O
rpeort	O
a	O
csae	O
of	O
vairant	O
ventircular	B-Disease
tachcyardia	I-Disease
indcued	O
by	O
deispramine	O
txoicity	B-Disease
.	O

Unsuual	O
feautres	O
of	O
the	O
arrhtyhmia	B-Disease
are	O
repteitive	O
gruop	O
betaing	O
,	O
progerssive	O
shoretning	O
of	O
the	O
R	O
-	O
R	O
intreval	O
,	O
progrsesive	O
widening	O
of	O
the	O
QRS	O
compelx	O
with	O
evetnual	O
faiulre	O
of	O
intraventricualr	O
codnuction	O
,	O
and	O
chnages	O
in	O
diretcion	O
of	O
the	O
QRS	O
aixs	O
.	O

Recogntiion	O
of	O
varaint	O
ventrciular	B-Disease
tacyhcardia	I-Disease
is	O
important	O
because	O
thearpy	O
differs	O
from	O
that	O
of	O
classic	O
ventricualr	B-Disease
tachcyardia	I-Disease
.	O

Rbeound	O
hypertenisve	B-Disease
after	O
soduim	O
nitroprussdie	O
prevented	O
by	O
saarlasin	O
in	O
rtas	O
.	O

The	O
role	O
of	O
the	O
reinn	O
-	O
-	O
angiotnesin	O
ssytem	O
in	O
the	O
manitenance	O
of	O
blood	O
prsesure	O
during	O
hlaothane	O
anetshesia	O
and	O
soduim	O
nitroprussdie	O
(	O
SNP	O
)	O
-	O
inudced	O
hpyotension	B-Disease
was	O
evalutaed	O
.	O

Contorl	O
rtas	O
received	O
halohtane	O
aensthesia	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	O
infuison	O
,	O
40	O
micrgoram	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30	O
-	O
min	O
rceovery	O
peroid	O
.	O

A	O
second	O
gruop	O
of	O
rtas	O
was	O
traeted	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
ifnusion	O
of	O
sraalasin	O
(	O
a	O
competitive	O
inhibtior	O
of	O
angiotesnin	O
II	O
)	O
throughout	O
the	O
experimetnal	O
preiod	O
.	O

In	O
each	O
gruop	O
,	O
SNP	O
infsuion	O
resulted	O
in	O
an	O
initial	O
dercease	O
in	O
blood	O
pressure	O
from	O
86	O
tror	O
and	O
83	O
tror	O
,	O
respectively	O
,	O
to	O
48	O
tror	O
.	O

During	O
the	O
SNP	O
inufsion	O
the	O
cnotrol	O
animlas	O
demonstrated	O
a	O
progressive	O
incerase	B-Disease
in	I-Disease
blood	I-Disease
prsesure	I-Disease
to	O
61	O
tror	O
,	O
whereas	O
the	O
saarlasin	O
-	O
treaetd	O
aniamls	O
showed	O
no	O
change	O
.	O

Following	O
dicsontinuation	O
of	O
SNP	O
,	O
bolod	O
prsesure	O
in	O
the	O
cotnrol	O
aniamls	O
rebounded	O
to	O
94	O
tror	O
,	O
as	O
compraed	O
with	O
78	O
tror	O
in	O
the	O
sraalasin	O
-	O
traeted	O
rtas	O
.	O

This	O
stduy	O
indicates	O
that	O
with	O
satble	O
haolthane	O
anesthseia	O
,	O
the	O
patrial	O
recovrey	O
of	O
blood	O
pressrue	O
during	O
SNP	O
inufsion	O
and	O
the	O
psot	O
-	O
SNP	O
rebuond	O
of	O
blood	O
perssure	O
can	O
be	O
completely	O
blokced	O
by	O
sarlaasin	O
.	O

This	O
demonstrates	O
the	O
participtaion	O
of	O
the	O
reinn	O
-	O
-	O
angoitensin	O
sysetm	O
in	O
antagonizing	O
the	O
combnied	O
hypoetnsive	B-Disease
effects	O
of	O
haltohane	O
and	O
SNP	O
.	O

Cliniacl	O
nephortoxicity	B-Disease
of	O
torbamycin	O
and	O
gnetamicin	O
.	O

A	O
prospectvie	O
stduy	O
.	O

Nearly	O
3	O
.	O
2	O
million	O
peolpe	O
in	O
this	O
coutnry	O
receive	O
aminolgycoside	O
antbiiotics	O
annually	O
.	O

Gentaimcin	O
sulafte	O
and	O
tobramyicn	O
suflate	O
continue	O
to	O
demonstrate	O
otootxicity	B-Disease
and	O
nephortoxicity	B-Disease
in	O
both	O
ainmal	O
and	O
cilnical	O
stuides	O
.	O

In	O
this	O
stduy	O
,	O
62	O
pateints	O
with	O
confirmed	O
initial	O
nromal	O
rneal	O
fnuction	O
and	O
treaetd	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
gentaimcin	O
suflate	O
or	O
tobraymcin	O
sulafte	O
for	O
a	O
minimum	O
of	O
seven	O
dyas	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
devleopment	O
of	O
aminoglcyoside	O
-	O
related	O
rneal	B-Disease
faliure	I-Disease
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
redcution	O
in	O
rneal	O
funtcion	O
.	O

In	O
these	O
62	O
pateints	O
,	O
no	O
other	O
causes	O
for	O
reanl	B-Disease
fialure	I-Disease
could	O
be	O
iedntified	O
.	O

Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobramcyin	O
-	O
treaetd	O
patinets	O
and	O
16	O
of	O
29	O
(	O
55	O
.	O
2	O
%	O
)	O
of	O
the	O
genatmicin	O
-	O
terated	O
patietns	O
had	O
rneal	B-Disease
faliure	I-Disease
.	O

Thus	O
,	O
genatmicin	O
was	O
associated	O
with	O
reanl	B-Disease
faliure	I-Disease
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobrmaycin	O
.	O

Meatbolic	O
ivnolvement	O
in	O
adrimaycin	O
cardoitoxicity	B-Disease
.	O

The	O
caridotoxic	B-Disease
effetcs	O
of	O
adraimycin	O
were	O
studied	O
in	O
mammlaian	O
moycardial	O
cells	O
in	O
culutre	O
as	O
a	O
mdoel	O
ssytem	O
.	O

Adriamyicn	O
inhibietd	O
clel	O
grotwh	O
and	O
the	O
rhtyhmic	O
contractoins	O
characteritsic	O
of	O
mycoardial	O
clels	O
in	O
cluture	O
.	O

A	O
possible	O
inovlvement	O
of	O
eenrgy	O
metaoblism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
stduy	O
the	O
adenyalte	O
enegry	O
charge	O
and	O
phosphorylcreatnie	O
mole	O
fratcion	O
were	O
determined	O
in	O
the	O
adraimycin	O
-	O
tretaed	O
clels	O
.	O

The	O
adenyalte	O
eenrgy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decresaed	O
,	O
while	O
the	O
phophorylrceatine	O
mole	O
fraciton	O
was	O
ucnhanged	O
.	O

Such	O
dsiparity	O
suggests	O
an	O
inhibtiion	O
of	O
creaitne	O
phosphoiknase	O
.	O

The	O
addition	O
of	O
1	O
mM	O
adensoine	O
to	O
the	O
myocardail	O
clel	O
cultrues	O
markedly	O
incerases	O
the	O
ATP	O
cocnentration	O
through	O
a	O
ptahway	O
reportedly	O
leading	O
to	O
a	O
comaprtmentalized	O
ATP	O
pool	O
.	O

In	O
the	O
adiramycin	O
-	O
tretaed	O
cells	O
,	O
the	O
addition	O
of	O
adenoisne	O
increaesd	O
the	O
adeynlate	O
charge	O
and	O
,	O
concomtiant	O
with	O
this	O
inrcesae	O
,	O
the	O
clels	O
'	O
functoinal	O
itnegrity	O
,	O
in	O
terms	O
of	O
percenatge	O
of	O
betaing	O
cells	O
and	O
rtae	O
of	O
cotnractions	O
,	O
was	O
maintained	O
.	O

Age	O
-	O
dpeendent	O
sensiitvity	O
of	O
the	O
rat	O
to	O
neurtooxic	B-Disease
effcets	O
of	O
stretpomycin	O
.	O

Streptomcyin	O
sulftae	O
(	O
300	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
was	O
injetced	O
for	O
various	O
peirods	O
into	O
prewaenling	O
rtas	O
and	O
for	O
3	O
wekes	O
into	O
weanlnig	O
rtas	O
.	O

Beginning	O
at	O
8	O
dyas	O
of	O
age	O
,	O
bdoy	O
movemnet	O
and	O
haering	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
weeks	O
,	O
respectively	O
.	O

Abonrmal	B-Disease
moevments	I-Disease
and	O
deanfess	B-Disease
occurred	O
only	O
in	O
rtas	O
treaetd	O
during	O
the	O
prweeaning	O
peroid	O
;	O
within	O
this	O
preiod	O
the	O
greatest	O
sensitiviites	O
for	O
these	O
abnormaliites	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
dyas	O
of	O
age	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
ccohlea	O
is	O
more	O
sensitvie	O
to	O
streptmoycin	O
than	O
the	O
stie	O
(	O
vetsibular	O
or	O
cenrtal	O
)	O
responsible	O
for	O
the	O
dsykinesias	B-Disease
.	O

Ltae	O
,	O
ltae	O
doxroubicin	O
cardiootxicity	B-Disease
.	O

Cadriac	B-Disease
toxciity	I-Disease
is	O
a	O
major	O
complicatoin	O
which	O
liimts	O
the	O
use	O
of	O
adriamcyin	O
as	O
a	O
chemotherapetuic	O
aegnt	O
.	O

Cadriomyopathy	B-Disease
is	O
frequnet	O
when	O
the	O
total	O
dsoe	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
monhts	O
after	O
cesstaion	O
of	O
threapy	O
.	O

A	O
paitent	O
is	O
reported	O
who	O
developed	O
prorgessive	O
cardiomyopahty	B-Disease
two	O
and	O
one	O
-	O
half	O
yeras	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
ltae	O
,	O
ltae	O
cardiotoixcity	B-Disease
.	O

Attenutaion	O
of	O
the	O
lihtium	O
-	O
indcued	O
dibaetes	B-Disease
-	I-Disease
inspiidus	I-Disease
-	I-Disease
like	I-Disease
synrdome	I-Disease
by	O
amiloirde	O
in	O
rtas	O
.	O

The	O
efefct	O
of	O
aimloride	O
on	O
ltihium	O
-	O
inudced	O
polydpisia	B-Disease
and	O
polyruia	B-Disease
and	O
on	O
the	O
ltihium	O
cnocentration	O
in	O
the	O
plamsa	O
,	O
barin	O
,	O
kideny	O
,	O
tyhroid	O
and	O
red	O
bolod	O
cells	O
was	O
investgiated	O
in	O
rtas	O
,	O
chroncially	O
treaetd	O
with	O
LCil	O
.	O

Amiolride	O
reudced	O
the	O
drinikng	O
and	O
uirne	O
volmue	O
of	O
rtas	O
in	O
an	O
actue	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
sbuacute	O
(	O
3	O
dyas	O
)	O
expermient	O
.	O

6	O
h	O
after	O
the	O
administartion	O
of	O
amilroide	O
,	O
a	O
reductoin	O
was	O
observed	O
in	O
the	O
litihum	O
conetnt	O
of	O
the	O
reanl	O
medlula	O
but	O
not	O
in	O
the	O
other	O
oragns	O
studied	O
.	O

At	O
12	O
h	O
,	O
all	O
the	O
tisuses	O
showed	O
a	O
slight	O
inrcease	O
in	O
litihum	O
levles	O
.	O

After	O
3	O
dyas	O
of	O
comibned	O
tretament	O
,	O
a	O
marked	O
eelvation	O
in	O
plsama	O
and	O
tisuse	O
lithuim	O
leevls	O
accompanied	O
a	O
reudction	O
in	O
waetr	O
itnake	O
.	O

In	O
all	O
the	O
expreiments	O
,	O
the	O
attenuation	O
of	O
the	O
lihtium	O
-	O
idnuced	O
daibetes	B-Disease
-	I-Disease
inispidus	I-Disease
-	I-Disease
like	I-Disease
synrdome	I-Disease
by	O
amiloirde	O
was	O
accompanied	O
by	O
a	O
reudction	O
of	O
the	O
raito	O
between	O
the	O
lihtium	O
concentraiton	O
in	O
the	O
rneal	O
medulla	O
and	O
its	O
lveels	O
in	O
the	O
bolod	O
and	O
an	O
eleavtion	O
in	O
the	O
plamsa	O
poatssium	O
leevl	O
.	O

It	O
is	O
concluded	O
that	O
aucte	O
aimloride	O
administrtaion	O
to	O
litihum	O
-	O
traeted	O
patinets	O
suffering	O
from	O
poldyipsia	B-Disease
and	O
polyuira	B-Disease
might	O
relieve	O
these	O
pateints	O
but	O
prolonegd	O
aimloride	O
supplementation	O
would	O
result	O
in	O
elevtaed	O
lithuim	O
lveels	O
and	O
might	O
be	O
hazarodus	O
.	O

Cardiovasuclar	B-Disease
complicaitons	I-Disease
associated	O
with	O
terbutailne	O
tretament	O
for	O
perterm	B-Disease
lbaor	I-Disease
.	O

Sevree	O
caridovascular	B-Disease
comlpications	I-Disease
occurred	O
in	O
eight	O
of	O
160	O
patietns	O
traeted	O
with	O
terbutalnie	O
for	O
prteerm	B-Disease
lbaor	I-Disease
.	O

Associated	O
corticostreoid	O
thearpy	O
and	O
tiwn	O
gestatinos	O
appear	O
to	O
be	O
predisopsing	O
fatcors	O
.	O

Potnetial	O
mehcanisms	O
of	O
the	O
ptahophysiology	O
are	O
briefly	O
discussed	O
.	O

Toixc	B-Disease
heaptitis	I-Disease
indcued	O
by	O
atnithyroid	O
durgs	O
:	O
four	O
caess	O
including	O
one	O
with	O
corss	O
-	O
reactiivty	O
between	O
carbimzaole	O
and	O
benzyltihouracil	O
.	O

OBJCETIVE	O
:	O
This	O
stduy	O
was	O
conducted	O
to	O
assess	O
the	O
occrurence	O
of	O
hepaitc	B-Disease
advrese	I-Disease
effects	I-Disease
encountered	O
with	O
antityhroid	O
drgus	O
.	O

METHODS	O
:	O
Retrospectvie	O
reveiw	O
of	O
medcial	O
rceords	O
of	O
236	O
ptaients	O
with	O
hyperthryoidism	B-Disease
adimtted	O
in	O
our	O
departemnt	O
(	O
in	O
-	O
or	O
out	O
-	O
paitents	O
)	O
from	O
1986	O
to	O
1992	O
.	O

REUSLTS	O
:	O
Four	O
ptaients	O
(	O
1	O
.	O
7	O
%	O
)	O
were	O
identifeid	O
with	O
toixc	B-Disease
hepaittis	I-Disease
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antithryoid	O
agnet	O
.	O

Two	O
patietns	O
had	O
a	O
cohlestatic	B-Disease
hpeatitis	I-Disease
indcued	O
by	O
carbimzaole	O
(	O
N	O
omercazole	O
)	O
.	O

Two	O
others	O
had	O
a	O
mixed	O
(	O
chloestatic	B-Disease
and	O
cytloytic	O
)	O
heaptitis	B-Disease
following	O
carbimazloe	O
.	O

One	O
of	O
the	O
latter	O
two	O
patietns	O
further	O
experienced	O
a	O
cytoltyic	O
hepattiis	B-Disease
which	O
appeared	O
after	O
Benzylthioruacil	O
(	O
Bsad	O
ne	O
)	O
had	O
replaced	O
carbmiazole	O
.	O

Biolgoical	O
feautres	O
of	O
hepaittis	B-Disease
disappeared	O
in	O
all	O
caess	O
after	O
csesation	O
of	O
the	O
incriminated	O
durg	O
,	O
while	O
bilairy	O
,	O
viarl	O
and	O
immuonlogical	O
searhces	O
were	O
negaitve	O
.	O

Only	O
2	O
pateints	O
of	O
our	O
retrosepctive	O
stduy	O
experienced	O
a	O
mlid	O
or	O
seevre	O
neutropneia	B-Disease
.	O

CONCLSUION	O
:	O
Txoic	B-Disease
hepattiis	I-Disease
is	O
a	O
potenital	O
adevrse	O
efefct	O
of	O
atnithyroid	O
durgs	O
which	O
warrants	O
,	O
as	O
for	O
haemaotlogical	O
distrubances	O
,	O
a	O
pre	O
-	O
therapetuic	O
detemrination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
rleevant	O
bioloigcal	O
makrers	O
.	O

Moreover	O
,	O
hepatotoxictiy	B-Disease
may	O
not	O
be	O
restricted	O
to	O
one	O
clsas	O
of	O
antithyriod	O
agetns	O
.	O

Itneractive	O
effetcs	O
of	O
vairations	O
in	O
[	O
Na	O
]	O
o	O
and	O
[	O
Ca	O
]	O
o	O
on	O
rat	O
artial	O
spontnaeous	O
freqeuncy	O
.	O

The	O
efefcts	O
of	O
varying	O
the	O
extracelullar	O
concenrtations	O
of	O
Na	O
and	O
Ca	O
(	O
[	O
Na	O
]	O
o	O
and	O
[	O
Ca	O
]	O
o	O
)	O
on	O
both	O
,	O
the	O
spotnaneous	O
baeting	O
and	O
the	O
negatvie	O
chrontoropic	O
actoin	O
of	O
vearpamil	O
,	O
were	O
studied	O
in	O
the	O
isoalted	O
rat	O
atira	O
.	O

Bsaal	O
ferquency	O
(	O
BF	O
)	O
evaluaetd	O
by	O
surfcae	O
electrogarm	O
was	O
223	O
+	O
/	O
-	O
4	O
baets	O
/	O
min	O
.	O
in	O
cotnrol	O
Krbes	O
-	O
Rinegr	O
containing	O
137	O
mM	O
Na	O
and	O
1	O
.	O
35	O
mM	O
Ca	O
(	O
N	O
)	O
.	O

It	O
decreaesd	O
by	O
16	O
+	O
/	O
-	O
3	O
%	O
by	O
loewring	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
(	O
LNa	O
)	O
,	O
23	O
+	O
/	O
-	O
2	O
%	O
by	O
loweirng	O
simultanoeusly	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
and	O
[	O
Ca	O
]	O
o	O
to	O
0	O
.	O
675	O
mM	O
(	O
LNa	O
+	O
LCa	O
)	O
and	O
31	O
+	O
/	O
-	O
5	O
%	O
by	O
lowernig	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
plus	O
incerasing	O
[	O
Ca	O
]	O
o	O
to	O
3	O
.	O
6	O
mM	O
(	O
LNa	O
+	O
HCa	O
)	O
.	O

At	O
nromal	O
[	O
Na	O
]	O
o	O
,	O
decerase	O
(	O
0	O
.	O
675	O
mM	O
)	O
or	O
incresae	O
(	O
3	O
.	O
6	O
mM	O
)	O
of	O
[	O
Ca	O
]	O
o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reductoin	O
of	O
ten	O
times	O
(	O
0	O
.	O
135	O
mM	O
of	O
noraml	O
[	O
Ca	O
]	O
o	O
was	O
effecitve	O
to	O
redcue	O
BF	O
by	O
40	O
+	O
/	O
-	O
13	O
%	O
.	O

All	O
negaitve	O
chrontoropic	O
effetcs	O
were	O
BF	O
-	O
depednent	O
.	O

Dsoe	O
-	O
dpeendent	O
bradycadria	B-Disease
inudced	O
by	O
verapmail	O
was	O
poetntiated	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCa	O
.	O

Indepenednt	O
but	O
not	O
adidtive	O
effects	O
of	O
Na	O
and	O
Ca	O
are	O
shown	O
by	O
decerases	O
in	O
the	O
vlaues	O
of	O
[	O
vreapamil	O
]	O
o	O
needed	O
to	O
rdeuce	O
BF	O
by	O
30	O
%	O
(	O
I3C0	O
)	O
with	O
the	O
following	O
order	O
of	O
inhbiitory	O
potnecy	O
:	O
LNa	O
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	O
LNa	O
+	O
HCa	O
similar	O
to	O
LNa	O
.	O

The	O
[	O
vreapamil	O
]	O
o	O
that	O
arrested	O
atrail	O
baeting	O
(	O
AC	O
)	O
was	O
also	O
poetntiated	O
with	O
the	O
order	O
LNa	O
=	O
LNa	O
+	O
LCa	O
=	O
LNa	O
+	O
HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N	O
.	O

The	O
reuslts	O
indicate	O
that	O
rat	O
atiral	O
spnotaneous	O
beatnig	O
is	O
more	O
depednent	O
on	O
[	O
Na	O
]	O
o	O
than	O
on	O
[	O
Ca	O
]	O
o	O
in	O
a	O
range	O
of	O
+	O
/	O
-	O
50	O
%	O
of	O
their	O
nromal	O
concentratoin	O
.	O

Also	O
the	O
enhanecment	O
of	O
vreapamil	O
effetcs	O
on	O
artial	O
baeting	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCa	O
.	O
(	O
ABSTRACT	O
TRUCNATED	O
AT	O
250	O
WORDS	O
)	O

Pseduo	O
-	O
allregic	B-Disease
reactinos	I-Disease
to	O
corticosterodis	O
:	O
diganosis	O
and	O
aletrnatives	O
.	O

Two	O
patietns	O
treaetd	O
with	O
parneteral	O
paramtehasone	O
(	O
Triinol	O
)	O
and	O
dexamethaosne	O
(	O
Sediobnel	O
)	O
are	O
described	O
.	O

A	O
few	O
minuets	O
after	O
adminisrtation	O
of	O
the	O
durgs	O
,	O
they	O
presented	O
urticraia	B-Disease
(	O
patietns	O
1	O
and	O
2	O
)	O
and	O
conjunctivtiis	B-Disease
(	O
ptaient	O
1	O
)	O
.	O

The	O
purpose	O
of	O
our	O
stduy	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
patietns	O
'	O
reatcions	O
,	O
the	O
immunological	O
mehcanisms	O
involved	O
and	O
whether	O
these	O
paitents	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
corticiod	O
.	O

Clincial	O
exaimnations	O
and	O
sikn	O
,	O
oarl	O
and	O
parenetral	O
cahllenges	O
with	O
different	O
corticsoteroids	O
and	O
EILSA	O
tsets	O
were	O
performed	O
.	O

In	O
the	O
two	O
paitents	O
,	O
sikn	O
and	O
EILSA	O
tsets	O
with	O
praamethasone	O
were	O
ngeative	O
,	O
as	O
was	O
the	O
pirck	O
tset	O
with	O
each	O
of	O
its	O
ecxipients	O
.	O

A	O
single	O
-	O
bilnd	O
parenetral	O
challenge	O
with	O
Trniiol	O
was	O
positvie	O
in	O
both	O
patietns	O
after	O
the	O
adimnistration	O
of	O
1	O
ml	O
of	O
the	O
durg	O
,	O
and	O
negtaive	O
with	O
its	O
excipietns	O
.	O

We	O
also	O
carried	O
out	O
oarl	O
and	O
paernteral	O
chalelnges	O
with	O
other	O
croticosteroids	O
and	O
found	O
intolreance	O
to	O
some	O
of	O
them	O
.	O

These	O
resutls	O
suggest	O
that	O
parmaethasone	O
caused	O
pseudoalelrgic	O
reactinos	O
in	O
our	O
patinets	O
.	O

Corticostreoids	O
different	O
from	O
paramtehasone	O
also	O
produced	O
hyperesnsitivity	B-Disease
reacitons	O
in	O
these	O
patietns	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolreated	O
.	O

The	O
basic	O
mecahnisms	O
of	O
those	O
recations	O
are	O
not	O
yet	O
fully	O
understood	O
.	O

To	O
our	O
konwledge	O
,	O
this	O
is	O
the	O
first	O
reprot	O
of	O
a	O
pseudo	O
-	O
allregy	B-Disease
caused	O
by	O
paramtehasone	O
.	O

Sutdy	O
of	O
the	O
role	O
of	O
vitmain	O
B12	O
and	O
foilnic	O
aicd	O
supplementaiton	O
in	O
preventing	O
hematolgoic	O
toxiicty	B-Disease
of	O
zidovduine	O
.	O

A	O
prospecitve	O
,	O
randomiezd	O
sutdy	O
was	O
conducted	O
to	O
evaulate	O
the	O
role	O
of	O
vtiamin	O
B12	O
and	O
foliinc	O
aicd	O
supplemetnation	O
in	O
preventing	O
zidouvdine	O
(	O
ZDV	O
)	O
-	O
inudced	O
bnoe	B-Disease
marorw	I-Disease
suppression	I-Disease
.	O

Seventy	O
-	O
five	O
huamn	B-Disease
immunodefciiency	I-Disease
viurs	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
-	I-Disease
infecetd	I-Disease
patietns	O
with	O
CD4	O
+	O
clel	O
coutns	O
<	O
500	O
/	O
mm3	O
were	O
randmoized	O
to	O
receive	O
either	O
ZDV	O
(	O
500	O
mg	O
daliy	O
)	O
alone	O
(	O
gruop	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
cmobination	O
with	O
folniic	O
aicd	O
(	O
15	O
mg	O
daliy	O
)	O
and	O
itnramascular	O
vtiamin	O
B12	O
(	O
1000	O
microgarms	O
mnothly	O
)	O
(	O
gorup	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O

Finally	O
,	O
15	O
paitents	O
were	O
excluded	O
from	O
the	O
stduy	O
(	O
noncomplaince	O
14	O
,	O
detah	B-Disease
1	O
)	O
;	O
thus	O
,	O
60	O
patinets	O
(	O
31	O
in	O
gorup	O
I	O
and	O
29	O
in	O
gruop	O
II	O
)	O
were	O
eligilbe	O
for	O
anlaysis	O
.	O

No	O
significant	O
dfiferences	O
between	O
gorups	O
were	O
found	O
at	O
ernollment	O
.	O

During	O
the	O
stduy	O
,	O
vtiamin	O
B12	O
and	O
floate	O
lveels	O
were	O
significantly	O
higehr	O
in	O
gruop	O
II	O
ptaients	O
;	O
however	O
,	O
no	O
differenecs	O
in	O
hemogolbin	O
,	O
hematorcit	O
,	O
mean	O
corpuscualr	O
vloume	O
,	O
and	O
whtie	O
-	O
clel	O
,	O
neutropihl	O
and	O
plateelt	O
cuonts	O
were	O
observed	O
between	O
gropus	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
mnoths	O
.	O

Sevree	O
hematoloigc	O
toixcity	B-Disease
(	O
neurtophil	O
conut	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemolgobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patinets	O
assigned	O
to	O
gruop	O
I	O
and	O
7	O
assigned	O
to	O
gorup	O
II	O
.	O

There	O
was	O
no	O
corrleation	O
between	O
vitmain	O
B12	O
or	O
foltae	O
lveels	O
and	O
develpoment	O
of	O
myelosuprpession	B-Disease
.	O

Vitaimn	O
B12	O
and	O
folniic	O
aicd	O
supplementatoin	O
of	O
ZDV	O
tehrapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
redcuing	O
ZDV	O
-	O
induecd	O
myelotoxciity	B-Disease
in	O
the	O
overall	O
tretaed	O
popultaion	O
,	O
although	O
a	O
beneficial	O
efefct	O
in	O
certain	O
sbugroups	O
of	O
pateints	O
cannot	O
be	O
excluded	O
.	O

Sfaety	O
and	O
side	O
-	O
effetcs	O
of	O
alpraozlam	O
.	O

Cotnrolled	O
sutdy	O
in	O
agroaphobia	B-Disease
with	O
pnaic	B-Disease
diosrder	I-Disease
.	O

BACGKROUND	O
:	O
The	O
widespread	O
use	O
of	O
benzodaizepines	O
has	O
led	O
to	O
incraesing	O
rceognition	O
of	O
their	O
unwanted	O
efefcts	O
.	O

The	O
efficcay	O
of	O
alparzolam	O
and	O
palcebo	O
in	O
pnaic	B-Disease
disodrer	I-Disease
with	O
agorpahobia	B-Disease
,	O
and	O
the	O
side	O
-	O
effcet	O
and	O
avderse	O
effect	O
proflies	O
of	O
both	O
durg	O
gruops	O
were	O
mesaured	O
.	O

METHOD	O
:	O
In	O
Lonodn	O
and	O
Torotno	O
154	O
patietns	O
who	O
met	O
DSM	O
-	O
III	O
crietria	O
for	O
pnaic	B-Disease
dsiorder	I-Disease
with	O
aographobia	B-Disease
were	O
randomsied	O
to	O
alpraozlam	O
or	O
plaecbo	O
.	O

Subjcets	O
in	O
each	O
durg	O
gorup	O
also	O
received	O
either	O
expsoure	O
or	O
rleaxation	O
.	O

Treamtent	O
was	O
from	O
weeks	O
0	O
to	O
8	O
and	O
was	O
then	O
tapeerd	O
from	O
weeks	O
8	O
to	O
16	O
.	O

RESLUTS	O
:	O
Mean	O
aplrazolam	O
dsoe	O
was	O
5	O
mg	O
dialy	O
.	O

Comapred	O
with	O
placbeo	O
subejcts	O
,	O
alrpazolam	O
paitents	O
developed	O
more	O
adevrse	O
raections	O
(	O
21	O
%	O
v	O
.	O
0	O
%	O
)	O
of	O
depresison	B-Disease
,	O
enuersis	B-Disease
,	O
disnihibition	O
and	O
aggerssion	B-Disease
;	O
and	O
more	O
side	O
-	O
effcets	O
,	O
particularly	O
seadtion	O
,	O
irrtiability	B-Disease
,	O
imparied	B-Disease
mmeory	I-Disease
,	O
wegiht	B-Disease
lsos	I-Disease
and	O
aatxia	B-Disease
.	O

Side	O
-	O
effetcs	O
tended	O
to	O
diminish	O
during	O
tretament	O
but	O
remained	O
significant	O
at	O
week	O
8	O
.	O

Despite	O
this	O
,	O
the	O
dorp	O
-	O
out	O
rtae	O
was	O
low	O
.	O

CONCLSUIONS	O
:	O
Alrpazolam	O
caused	O
side	O
-	O
effcets	O
and	O
advrese	O
effetcs	O
during	O
treatmnet	O
but	O
many	O
patinets	O
were	O
willing	O
to	O
accept	O
these	O
.	O

Cresecntic	O
fibrilalry	O
glomerulonehpritis	B-Disease
associated	O
with	O
intremittent	O
rifapmin	O
threapy	O
for	O
plumonary	B-Disease
tuberculoiss	I-Disease
.	O

This	O
csae	O
sutdy	O
reveals	O
an	O
uunsual	O
fidning	O
of	O
rapidly	O
prloiferative	O
crescetnic	O
glomerulonephrtiis	B-Disease
in	O
a	O
patinet	O
tretaed	O
with	O
rifamipn	O
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
disesae	O
.	O

This	O
paitent	O
underwent	O
a	O
10	O
-	O
mnoth	O
regmien	O
of	O
riafmpin	O
and	O
isoniaizd	O
for	O
pulmoanry	B-Disease
tubreculosis	I-Disease
and	O
was	O
discovered	O
to	O
have	O
developed	O
sgins	O
of	O
seevre	O
rneal	B-Disease
faiulre	I-Disease
five	O
weeks	O
after	O
cmopletion	O
of	O
threapy	O
.	O

Rneal	O
biposy	O
rveealed	O
seevre	O
glomerulonehpritis	B-Disease
with	O
crescnets	O
,	O
elcetron	O
desne	O
fibrilalr	O
depostis	O
and	O
mdoerate	O
lmyphocytic	O
intrestitial	O
inifltrate	O
.	O

Other	O
possible	O
causes	O
of	O
rapidly	O
progressvie	O
glomreulonephritis	B-Disease
were	O
investiagted	O
and	O
ruled	O
out	O
.	O

This	O
rpeort	O
dcouments	O
the	O
unuusal	O
occurrence	O
of	O
rapidly	O
progressive	O
glomerluonephritis	B-Disease
with	O
cresecnts	O
and	O
fibirllar	O
glomerluonephritis	B-Disease
in	O
a	O
patinet	O
traeted	O
with	O
rifamipn	O
.	O

Actue	O
confusoin	B-Disease
induecd	O
by	O
a	O
high	O
-	O
dsoe	O
inufsion	O
of	O
5	O
-	O
fulorouracil	O
and	O
folniic	O
aicd	O
.	O

A	O
61	O
-	O
yaer	O
-	O
old	O
man	O
was	O
traeted	O
with	O
combinaiton	O
chemtoherapy	O
incorporating	O
cispaltinum	O
,	O
etopoisde	O
,	O
high	O
-	O
dsoe	O
5	O
-	O
fluroouracil	O
(	O
2	O
,	O
250	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
)	O
and	O
foliinc	O
aicd	O
for	O
an	O
inopreable	O
gasrtic	B-Disease
adenocarcionma	I-Disease
.	O

He	O
developed	O
aucte	O
neurolgoic	O
sympotms	O
of	O
metnal	O
cnofusion	B-Disease
,	O
disorienttaion	B-Disease
and	O
irrtiability	B-Disease
,	O
and	O
then	O
lasped	O
into	O
a	O
deep	O
cmoa	B-Disease
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dsoe	O
(	O
day	O
2	O
)	O
of	O
5	O
-	O
fluorouarcil	O
and	O
folniic	O
aicd	O
infuison	O
.	O

This	O
compilcation	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dsoe	O
of	O
5	O
-	O
flourouracil	O
and	O
folniic	O
aicd	O
,	O
which	O
were	O
then	O
the	O
only	O
durgs	O
given	O
.	O

Because	O
foliinc	O
aicd	O
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condiiton	O
,	O
neurtooxicity	B-Disease
due	O
to	O
high	O
-	O
dsoe	O
5	O
-	O
fluoruoracil	O
was	O
highly	O
suspceted	O
.	O

The	O
pathgoenesis	O
of	O
5	O
-	O
fulorouracil	O
neurotxoicity	B-Disease
may	O
be	O
due	O
to	O
a	O
Kerbs	O
ccyle	O
bolckade	O
by	O
flurooacetate	O
and	O
flourocitrate	O
,	O
thaimine	O
deficiecny	O
,	O
or	O
dihyrdouracil	O
dehyrdogenase	O
deficeincy	O
.	O

High	O
-	O
dsoe	O
5	O
-	O
fluorourcail	O
/	O
folniic	O
aicd	O
ifnusion	O
tehrapy	O
has	O
recently	O
become	O
a	O
popular	O
regmien	O
for	O
various	O
cnacers	B-Disease
.	O

It	O
is	O
necessary	O
that	O
both	O
oncologitss	O
and	O
neurologsits	O
be	O
fully	O
aware	O
of	O
this	O
uunsual	O
compliaction	O
.	O

Effcet	O
of	O
switching	O
carbamaezpine	O
to	O
oxcarbazeipne	O
on	O
the	O
plsama	O
levles	O
of	O
neurolpetics	O
.	O

A	O
csae	O
rpeort	O
.	O

Carabmazepine	O
was	O
switched	O
to	O
its	O
10	O
-	O
kteo	O
analgoue	O
oxcarbazepnie	O
among	O
six	O
difficult	O
-	O
to	O
-	O
terat	O
schizpohrenic	B-Disease
or	O
ogranic	B-Disease
psychtoic	I-Disease
paitents	O
using	O
concomitantly	O
haloepridol	O
,	O
chlorpromaizne	O
or	O
clozaipne	O
.	O

This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
weeks	O
in	O
the	O
50	O
-	O
200	O
%	O
incerase	O
in	O
the	O
palsma	O
levles	O
of	O
these	O
neuroleptcis	O
and	O
the	O
appearnace	O
of	O
extrapyraimdal	B-Disease
symtpoms	I-Disease
.	O

None	O
of	O
the	O
ptaients	O
showed	O
any	O
cliniacl	O
deteriotatoin	O
during	O
the	O
following	O
3	O
-	O
6	O
motnhs	O
.	O

The	O
rseults	O
of	O
this	O
csae	O
reoprt	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbaamzepine	O
oxcarbazeipne	O
does	O
not	O
indcue	O
the	O
heptaic	O
microosmal	O
enyzme	O
systmes	O
regulaitng	O
the	O
inactiavtion	O
of	O
antpisychotic	O
drgus	O
.	O

Tmie	O
cousre	O
of	O
lpiid	O
peroxdiation	O
in	O
puormycin	O
aminouncleoside	O
-	O
inudced	O
nephroapthy	B-Disease
.	O

Reacitve	O
oxyegn	O
speceis	O
have	O
been	O
implicated	O
in	O
the	O
pathogenseis	O
of	O
actue	O
puromcyin	O
aminonulceoside	O
(	O
PAN	O
)	O
-	O
indcued	O
npehropathy	B-Disease
,	O
with	O
antioxdiants	O
significantly	O
reduicng	O
the	O
prtoeinuria	B-Disease
.	O

The	O
tepmoral	O
relatinoship	O
between	O
liipd	O
peroxidatoin	O
in	O
the	O
kdiney	O
and	O
protienuria	B-Disease
was	O
examined	O
in	O
this	O
sutdy	O
.	O

Rtas	O
were	O
tretaed	O
with	O
a	O
single	O
IV	O
injetcion	O
of	O
puromyicn	O
aminonucleoisde	O
,	O
(	O
PAN	O
,	O
7	O
.	O
5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
uirne	O
sapmles	O
were	O
obtained	O
prior	O
to	O
sarcifice	O
on	O
dyas	O
3	O
,	O
5	O
,	O
7	O
,	O
10	O
,	O
17	O
,	O
27	O
,	O
41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
gorup	O
)	O
.	O

The	O
kidenys	O
were	O
rmeoved	O
,	O
fluhsed	O
with	O
ice	O
clod	O
TIRS	O
bfufer	O
.	O

Kdiney	O
coritces	O
from	O
each	O
aniaml	O
were	O
used	O
to	O
prepare	O
homogneates	O
.	O

Tissue	O
liipd	O
peroxidtaion	O
was	O
measuerd	O
in	O
whole	O
homogentaes	O
as	O
well	O
as	O
in	O
liipd	O
exrtacts	O
from	O
homogneates	O
as	O
thiobarbituirc	O
aicd	O
reatcive	O
subtsances	O
.	O

Proteniuria	B-Disease
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O

Lpiid	O
peroxidaiton	O
in	O
hmoogenates	O
was	O
maxmial	O
at	O
day	O
3	O
and	O
decliend	O
rapidly	O
to	O
cotnrol	O
levles	O
by	O
day	O
17	O
.	O

This	O
stduy	O
supports	O
the	O
role	O
of	O
liipd	O
preoxidation	O
in	O
mediating	O
the	O
proteinruic	B-Disease
inujry	I-Disease
in	O
PAN	O
nephrpoathy	B-Disease
.	O

Composiiton	O
of	O
glal	B-Disease
bldader	I-Disease
stnoes	I-Disease
associated	O
with	O
otcreotide	O
:	O
resopnse	O
to	O
oarl	O
ursodeoxychloic	O
aicd	O
.	O

Otcreotide	O
,	O
an	O
effcetive	O
treatmnet	O
for	O
arcomegaly	B-Disease
,	O
induecs	O
glal	B-Disease
bladedr	I-Disease
stoens	I-Disease
in	O
13	O
-	O
60	O
%	O
of	O
patietns	O
.	O

Because	O
knwoledge	O
of	O
stnoe	O
cmoposition	O
is	O
essenital	O
for	O
studeis	O
of	O
their	O
pahtogenesis	O
,	O
treatemnt	O
,	O
and	O
prveention	O
,	O
this	O
was	O
investiagted	O
by	O
direct	O
and	O
inidrect	O
methdos	O
in	O
14	O
otcreotide	O
terated	O
acromeglaic	B-Disease
patinets	O
with	O
glal	B-Disease
stnoes	I-Disease
.	O

Cheimcal	O
analsyis	O
of	O
glal	B-Disease
stnoes	I-Disease
retrieved	O
at	O
cholecytsectomy	O
from	O
two	O
patinets	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
chloesterol	O
by	O
wieght	O
.	O

In	O
the	O
remaining	O
12	O
paitents	O
,	O
lcoalised	O
copmuted	O
tomgoraphy	O
of	O
the	O
glal	O
bldader	O
showed	O
that	O
eight	O
had	O
stoens	O
with	O
maxiumm	O
attneuation	O
scoers	O
of	O
<	O
100	O
Hounsifeld	O
units	O
(	O
vlaues	O
of	O
<	O
100	O
HU	O
predict	O
cholseterol	O
rich	O
,	O
dsisolvable	O
stnoes	O
)	O
.	O

Glal	O
bladder	O
blie	O
was	O
obtained	O
by	O
ulrtasound	O
guided	O
,	O
fnie	O
nedele	O
puntcure	O
from	O
six	O
patinets	O
.	O

All	O
six	O
pateints	O
had	O
superasturated	O
blie	O
(	O
mean	O
(	O
SEM	O
)	O
choletserol	O
satuartion	O
index	O
of	O
1	O
.	O
19	O
(	O
0	O
.	O
08	O
)	O
(	O
range	O
1	O
.	O
01	O
-	O
1	O
.	O
53	O
)	O
)	O
and	O
all	O
had	O
abnormlaly	O
rpaid	O
cholesetrol	O
microcrytsal	O
nculeation	O
times	O
(	O
<	O
4	O
dyas	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
blie	O
contained	O
cholesteorl	O
microcyrstals	O
immediately	O
after	O
sampilng	O
.	O

Of	O
the	O
12	O
pateints	O
considered	O
for	O
oarl	O
ursodoexycholic	O
aicd	O
(	O
UCDA	O
)	O
tretament	O
,	O
two	O
had	O
a	O
blokced	O
cytsic	O
dcut	O
and	O
were	O
not	O
started	O
on	O
UCDA	O
while	O
one	O
was	O
lsot	O
to	O
follow	O
up	O
.	O

After	O
one	O
yaer	O
of	O
treatmnet	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
ptaients	O
showed	O
either	O
patrial	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
glal	B-Disease
stnoe	I-Disease
dissolutoin	O
,	O
suggesting	O
that	O
their	O
sotnes	O
were	O
cohlesterol	O
rich	O
.	O

This	O
corresponds	O
,	O
by	O
acutarial	O
(	O
lfie	O
table	O
)	O
anlaysis	O
,	O
to	O
a	O
comibned	O
glal	B-Disease
sotne	I-Disease
dissolutoin	O
rtae	O
of	O
58	O
.	O
3	O
(	O
15	O
.	O
9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
octretoide	O
induecd	O
glal	B-Disease
sotnes	I-Disease
are	O
generally	O
small	O
,	O
mutliple	O
,	O
and	O
choletserol	O
rich	O
although	O
,	O
in	O
common	O
with	O
spotnaneous	O
glal	B-Disease
sotne	I-Disease
disaese	I-Disease
,	O
at	O
presentatoin	O
some	O
paitents	O
will	O
have	O
a	O
blocekd	O
csytic	O
dcut	O
and	O
some	O
glal	B-Disease
stoens	I-Disease
containing	O
clacium	O
.	O

Erythmea	B-Disease
multiofrme	I-Disease
and	O
hypresensitivity	B-Disease
moycarditis	I-Disease
caused	O
by	O
ampciillin	O
.	O

OBJECITVE	O
:	O
To	O
reoprt	O
a	O
csae	O
of	O
erythmea	B-Disease
mlutiforme	I-Disease
and	O
hyperesnsitivity	B-Disease
myocardiits	I-Disease
caused	O
by	O
ampiclilin	O
.	O

CSAE	O
SUMAMRY	O
:	O
A	O
13	O
-	O
yaer	O
-	O
old	O
boy	O
was	O
traeted	O
with	O
ampiicllin	O
and	O
gentaimcin	O
because	O
of	O
suspceted	O
setpicemia	B-Disease
.	O

Mediactions	O
were	O
discotninued	O
when	O
eyrthema	B-Disease
mutliforme	I-Disease
and	O
cnogestive	B-Disease
herat	I-Disease
fialure	I-Disease
caused	O
by	O
myocardtiis	B-Disease
occurred	O
.	O

The	O
paitent	O
was	O
tretaed	O
with	O
methylprednioslone	O
and	O
gradually	O
improevd	O
.	O

Macropahge	O
-	O
migartion	O
inhibiiton	O
(	O
MIF	O
)	O
tset	O
with	O
apmicillin	O
was	O
posiitve	O
.	O

DISCUSSION	O
:	O
After	O
most	O
infetcions	B-Disease
causing	O
ertyhema	B-Disease
mutliforme	I-Disease
and	O
myocaridtis	B-Disease
were	O
ruled	O
out	O
,	O
a	O
durg	B-Disease
-	I-Disease
induecd	I-Disease
allegric	I-Disease
reaciton	I-Disease
was	O
suspetced	O
.	O

Postiive	O
MIF	O
tset	O
for	O
ampiicllin	O
showed	O
snesitization	O
of	O
the	O
paitent	O
'	O
s	O
lypmhocytes	O
to	O
amipcillin	O
.	O

CONCULSIONS	O
:	O
Hypersensiitvity	B-Disease
myoacrditis	I-Disease
is	O
a	O
rrae	O
and	O
dangerous	O
manifesttaion	O
of	O
alelrgy	B-Disease
to	O
penicillnis	O
.	O

Colmipramine	O
-	O
idnuced	O
selep	B-Disease
distubrance	I-Disease
does	O
not	O
impiar	O
its	O
prolcatin	O
-	O
releasing	O
atcion	O
.	O

The	O
present	O
stduy	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
selep	B-Disease
ditsurbance	I-Disease
,	O
inudced	O
by	O
clmoipramine	O
admiinstration	O
,	O
on	O
the	O
secreotry	O
rtae	O
of	O
prloactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
durg	O
effect	O
.	O

Two	O
gorups	O
of	O
suipne	O
subjetcs	O
were	O
studied	O
under	O
plaecbo	O
-	O
conrtolled	O
codnitions	O
,	O
one	O
during	O
the	O
ngiht	O
,	O
when	O
slepeing	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
dyatime	O
,	O
when	O
aawke	O
(	O
n	O
=	O
6	O
)	O
.	O

Each	O
subejct	O
received	O
a	O
single	O
50	O
mg	O
dsoe	O
of	O
clomiprmaine	O
given	O
orally	O
2	O
hours	O
before	O
blood	O
colleciton	O
.	O

Plamsa	O
PRL	O
concetnrations	O
were	O
analyesd	O
at	O
10	O
min	O
itnervals	O
and	O
underlying	O
sceretory	O
rtaes	O
calculated	O
by	O
a	O
deconvoultion	O
porcedure	O
.	O

For	O
both	O
experimnets	O
the	O
durg	O
intkae	O
led	O
to	O
significant	O
increaess	O
in	O
PRL	O
secertion	O
,	O
acting	O
preferentially	O
on	O
tnoic	O
sercetion	O
as	O
pluse	O
amlpitude	O
and	O
frequecny	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
contorl	O
vaules	O
.	O

During	O
the	O
nihgt	O
clompiramine	O
inegstion	O
alteerd	O
the	O
complete	O
selep	O
arcihtecture	O
in	O
that	O
it	O
suprpessed	O
REM	O
selep	O
and	O
the	O
selep	O
cylces	O
and	O
indcued	O
icnreased	O
wakefluness	O
.	O

As	O
the	O
relative	O
icnrease	O
in	O
PRL	O
secertion	O
exrpessed	O
as	O
a	O
precentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
nihgt	O
and	O
day	O
tmie	O
studeis	O
(	O
46	O
+	O
/	O
-	O
19	O
%	O
vs	O
34	O
+	O
/	O
-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	B-Disease
disutrbance	I-Disease
did	O
not	O
interfere	O
with	O
the	O
durg	O
aciton	O
per	O
se	O
.	O

The	O
presecne	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
fatcor	O
either	O
for	O
secertory	O
pluse	O
ampltiude	O
and	O
freqeuncy	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
notcurnal	O
valeus	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clomirpamine	O
ingesiton	O
.	O

Sruvey	O
of	O
complicatinos	O
of	O
indocyainne	O
green	O
angiograhpy	O
in	O
Jaapn	O
.	O

PUROPSE	O
:	O
We	O
evalutaed	O
the	O
sfaety	O
of	O
indocyannie	O
green	O
for	O
use	O
in	O
fnudus	O
angiorgaphy	O
.	O

METHODS	O
:	O
We	O
sent	O
a	O
questionniare	O
concerning	O
complicatoins	O
of	O
indocaynine	O
green	O
to	O
32	O
institutoins	O
in	O
Jpaan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
cilent	O
list	O
from	O
the	O
Tpocon	O
Cmopany	O
,	O
which	O
manfuactures	O
the	O
indcoyanine	O
green	O
fnudus	O
camrea	O
.	O

REUSLTS	O
:	O
Ohpthalmologists	O
at	O
15	O
instittuions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3	O
,	O
774	O
idnocyanine	O
green	O
angoigrams	O
performed	O
on	O
2	O
,	O
820	O
pateints	O
between	O
June	O
1984	O
and	O
Setpember	O
1992	O
.	O

Before	O
agniography	O
,	O
intraderaml	O
or	O
intarvenous	O
indocyannie	O
green	O
tetsing	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
intsitutions	O
.	O

For	O
three	O
paitents	O
,	O
the	O
dceision	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angigoraphy	O
after	O
poistive	O
preangiorgaphic	O
tseting	O
.	O

The	O
dsoage	O
of	O
indocaynine	O
green	O
used	O
for	O
angigoraphy	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
instittuion	O
.	O

There	O
were	O
13	O
caess	O
of	O
avderse	O
recations	O
(	O
0	O
.	O
34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mlid	O
raections	O
such	O
as	O
nasuea	B-Disease
,	O
exantehma	B-Disease
,	O
urticatoin	B-Disease
,	O
itchniess	B-Disease
,	O
and	O
ugrency	O
to	O
defectae	O
,	O
and	O
did	O
not	O
require	O
treatemnt	O
.	O

Also	O
recorded	O
were	O
one	O
csae	O
of	O
pian	B-Disease
of	O
the	O
vien	O
,	O
which	O
required	O
teratment	O
,	O
and	O
two	O
caess	O
of	O
hyptoension	B-Disease
.	O

The	O
two	O
hypotenisve	B-Disease
ptaients	O
required	O
treamtent	O
for	O
sohck	B-Disease
.	O

CONCLUSOINS	O
:	O
A	O
compairson	O
of	O
frequnecy	O
of	O
adevrse	O
reatcions	O
to	O
inodcyanine	O
green	O
with	O
the	O
previously	O
reported	O
freqeuncy	O
of	O
such	O
reacitons	O
to	O
fluoresecin	O
soidum	O
indicated	O
that	O
indcoyanine	O
green	O
is	O
a	O
safe	O
as	O
fluorsecein	O
for	O
use	O
in	O
anigography	O
.	O

Agnioedema	B-Disease
following	O
the	O
intraveonus	O
admiinstration	O
of	O
metoporlol	O
.	O

A	O
72	O
-	O
yaer	O
-	O
old	O
wmoan	O
was	O
admitted	O
to	O
the	O
hosiptal	O
with	O
"	O
falsh	O
"	O
pulmnoary	B-Disease
edmea	I-Disease
,	O
preceded	O
by	O
chset	B-Disease
pian	I-Disease
,	O
requiring	O
intbuation	O
.	O

Her	O
mediacl	O
hitsory	O
included	O
coronray	B-Disease
aretry	I-Disease
disesae	I-Disease
with	O
previous	O
myoacrdial	B-Disease
ifnarctions	I-Disease
,	O
hpyertension	B-Disease
,	O
and	O
diabtees	B-Disease
melliuts	I-Disease
.	O

A	O
hsitory	O
of	O
agnioedema	B-Disease
secondary	O
to	O
lisinporil	O
thearpy	O
was	O
elicited	O
.	O

Current	O
medicaitons	O
did	O
not	O
include	O
anigotensin	O
-	O
converting	O
enyzme	O
inihbitors	O
or	O
btea	O
-	O
blcokers	O
.	O

She	O
had	O
no	O
previous	O
btea	O
-	O
blocknig	O
durg	O
expsoure	O
.	O

During	O
the	O
first	O
day	O
of	O
hospitalizatoin	O
(	O
while	O
intuabted	O
)	O
,	O
intrvaenous	O
metporolol	O
was	O
given	O
,	O
resulting	O
in	O
seevre	O
angioeedma	B-Disease
.	O

The	O
angioedmea	B-Disease
resolved	O
after	O
therpay	O
with	O
intravneous	O
streoids	O
and	O
diphenhdyramine	O
hdyrochloride	O
.	O

Effect	O
of	O
coniine	O
on	O
the	O
developing	O
chcik	O
embyro	O
.	O

Coniine	O
,	O
an	O
alklaoid	O
from	O
Cnoium	O
macluatum	O
(	O
pioson	O
hemlcok	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratoegnic	O
in	O
lviestock	O
.	O

The	O
major	O
teratogneic	O
outcmoe	O
is	O
arthrgoryposis	B-Disease
,	O
presumably	O
due	O
to	O
nicoitnic	O
recepotr	O
blokcade	O
.	O

However	O
,	O
coniine	O
has	O
failed	O
to	O
produce	O
arthrogrpyosis	B-Disease
in	O
rtas	O
or	O
mcie	O
and	O
is	O
only	O
weakly	O
teraotgenic	O
in	O
rabbtis	O
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
evalutae	O
and	O
copmare	O
the	O
efefcts	O
of	O
cnoiine	O
and	O
nciotine	O
in	O
the	O
developing	O
cihck	O
.	O

Concentratinos	O
of	O
coniine	O
and	O
nioctine	O
slufate	O
were	O
0	O
.	O
015	O
%	O
,	O
0	O
.	O
03	O
%	O
,	O
0	O
.	O
075	O
%	O
,	O
0	O
.	O
15	O
%	O
,	O
0	O
.	O
75	O
%	O
,	O
1	O
.	O
5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O

Both	O
cmopounds	O
caused	O
dfeormations	B-Disease
and	O
lethailty	O
in	O
a	O
dsoe	O
-	O
depenednt	O
manner	O
.	O

All	O
concentrtaions	O
of	O
nciotine	O
sulftae	O
caused	O
some	O
lethaltiy	O
but	O
a	O
no	O
effcet	O
leevl	O
for	O
coninie	O
lehtality	O
was	O
0	O
.	O
75	O
%	O
.	O

The	O
deformatoins	B-Disease
caused	O
by	O
both	O
coninie	O
and	O
nicoitne	O
slufate	O
were	O
excsesive	B-Disease
felxion	I-Disease
or	I-Disease
extesnion	I-Disease
of	I-Disease
one	I-Disease
or	I-Disease
more	I-Disease
teos	I-Disease
.	O

No	O
hisotpathological	O
atlerations	O
or	O
differenecs	O
in	O
bnoe	O
fromation	O
were	O
seen	O
in	O
the	O
lmibs	O
or	O
teos	O
of	O
any	O
cihcks	O
from	O
any	O
gruop	O
;	O
however	O
,	O
extesnive	O
cranail	B-Disease
hemorrhage	I-Disease
occurred	O
in	O
all	O
nioctine	O
sulftae	O
-	O
tretaed	O
chikcs	O
.	O

There	O
was	O
a	O
statistiaclly	O
significant	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
dcerease	O
in	O
movmeent	O
in	O
coninie	O
and	O
nicoitne	O
sulftae	O
tretaed	O
cihcks	O
as	O
determined	O
by	O
ultrsaound	O
.	O

Conrtol	O
chikcs	O
were	O
in	O
motoin	O
an	O
avergae	O
of	O
33	O
.	O
67	O
%	O
of	O
the	O
tmie	O
,	O
while	O
coinine	O
-	O
treaetd	O
chciks	O
were	O
only	O
moivng	O
8	O
.	O
95	O
%	O
of	O
a	O
5	O
-	O
min	O
inetrval	O
,	O
and	O
no	O
mvoement	O
was	O
observed	O
for	O
nictoine	O
sulafte	O
treaetd	O
chikcs	O
.	O

In	O
summary	O
,	O
the	O
chcik	O
emrbyo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimnetal	O
anmial	O
mdoel	O
of	O
cnoiine	O
-	O
idnuced	O
atrhrogryposis	B-Disease
.	O

Dtaa	O
from	O
this	O
moedl	O
support	O
a	O
mecahnism	O
involving	O
nicotiinc	O
recetpor	O
blockdae	O
with	O
subsequent	O
dcereased	O
fteal	O
mvoement	O
.	O

Immeidate	O
alelrgic	B-Disease
reacitons	I-Disease
to	O
amoxicillin	O
.	O

A	O
large	O
gruop	O
of	O
patinets	O
with	O
suspetced	O
allergic	B-Disease
reacitons	I-Disease
to	O
btea	O
-	O
lcatam	O
antibioitcs	O
was	O
evlauated	O
.	O

A	O
detailed	O
cliniacl	O
hsitory	O
,	O
together	O
with	O
sikn	O
tetss	O
,	O
RSAT	O
(	O
raidoallergosorbent	O
tset	O
)	O
,	O
and	O
controlled	O
challenge	O
tetss	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patietns	O
allregic	B-Disease
to	O
btea	O
-	O
lcatam	O
antibioitcs	O
had	O
selective	O
immediate	O
allergic	B-Disease
responess	O
to	O
amxoicillin	O
(	O
AX	O
)	O
or	O
were	O
crsos	O
-	O
reatcing	O
with	O
other	O
penciillin	O
derviatives	O
.	O

Sikn	O
tsets	O
were	O
performed	O
with	O
benzyplenicilloyl	O
-	O
ploy	O
-	O
L	O
-	O
lysnie	O
(	O
BPO	O
-	O
PLL	O
)	O
,	O
benzylpenicilolate	O
,	O
benzyplenicillin	O
(	O
PG	O
)	O
,	O
ampciillin	O
(	O
AMP	O
)	O
,	O
and	O
AX	O
.	O

RSAT	O
for	O
BPO	O
-	O
PLL	O
and	O
AX	O
-	O
PLL	O
was	O
done	O
.	O

When	O
both	O
sikn	O
tset	O
and	O
RSAT	O
for	O
BPO	O
were	O
negaitve	O
,	O
single	O
-	O
blnid	O
,	O
placbeo	O
-	O
contrloled	O
challenge	O
tsets	O
were	O
done	O
to	O
ensure	O
tloerance	O
of	O
PG	O
or	O
senstiivity	O
to	O
AX	O
.	O

A	O
total	O
of	O
177	O
pateints	O
were	O
diangosed	O
as	O
allegric	B-Disease
to	O
btea	O
-	O
latcam	O
antibitoics	O
.	O

We	O
selected	O
the	O
54	O
(	O
30	O
.	O
5	O
%	O
)	O
caess	O
of	O
immedaite	O
AX	O
allregy	B-Disease
with	O
good	O
tloerance	O
of	O
PG	O
.	O

Anaphylaixs	B-Disease
was	O
seen	O
in	O
37	O
pateints	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
utricaria	B-Disease
and	O
/	O
or	O
angoiedema	B-Disease
.	O

All	O
the	O
ptaients	O
were	O
sikn	O
tset	O
neagtive	O
to	O
BPO	O
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
ngeative	O
to	O
MDM	B-Disease
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	O
.	O

Sikn	O
tetss	O
with	O
AX	O
were	O
postiive	O
in	O
34	O
(	O
63	O
%	O
)	O
ptaients	O
.	O

RSAT	O
was	O
psoitive	O
for	O
AX	O
in	O
22	O
patietns	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	O
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O

None	O
of	O
the	O
srea	O
with	O
negtaive	O
RSAT	O
for	O
AX	O
were	O
poistive	O
to	O
BPO	O
.	O

Chalelnge	O
tsets	O
with	O
AX	O
were	O
performed	O
in	O
23	O
subjetcs	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagonsis	O
of	O
immeidate	O
allegric	B-Disease
reactoin	I-Disease
to	O
AX	O
,	O
and	O
in	O
15	O
caess	O
(	O
28	O
%	O
)	O
both	O
sikn	O
tset	O
and	O
RSAT	O
for	O
AX	O
were	O
negaitve	O
.	O

PG	O
was	O
well	O
toelrated	O
by	O
all	O
54	O
patinets	O
.	O

We	O
describe	O
the	O
largest	O
gruop	O
of	O
AX	O
-	O
allerigc	B-Disease
ptaients	O
who	O
have	O
tloerated	O
PG	O
reported	O
so	O
far	O
.	O

Diangosis	O
of	O
these	O
paitents	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	O
-	O
related	O
reagnets	O
are	O
employed	O
.	O

Further	O
stduies	O
are	O
necessary	O
to	O
determine	O
the	O
exact	O
extent	O
of	O
this	O
probelm	O
and	O
to	O
ipmrove	O
the	O
efficcay	O
of	O
diangostic	O
metohds	O
.	O

Rveersal	O
by	O
phenylehprine	O
of	O
the	O
beneficial	O
effetcs	O
of	O
intravneous	O
nitroglcyerin	O
in	O
patinets	O
with	O
aucte	B-Disease
mycoardial	I-Disease
infarctoin	I-Disease
.	O

Nitrgolycerin	O
has	O
been	O
shown	O
to	O
redcue	O
ST	O
-	O
sgement	O
elevtaion	O
during	O
aucte	B-Disease
myocardail	I-Disease
inafrction	I-Disease
,	O
an	O
effcet	O
potenitated	O
in	O
the	O
dog	O
by	O
aegnts	O
that	O
reevrse	O
nitrgolycerin	O
-	O
induecd	O
hypotnesion	B-Disease
.	O

Our	O
sutdy	O
was	O
designed	O
to	O
determine	O
the	O
effetcs	O
of	O
cmobined	O
nitrogylcerin	O
and	O
pehnylephrine	O
tehrapy	O
.	O

Ten	O
paitents	O
with	O
actue	O
tranmsural	O
myocaridal	B-Disease
infarctinos	I-Disease
received	O
intraevnous	O
nitroglycrein	O
,	O
sufficient	O
to	O
redcue	O
mean	O
aretrial	O
perssure	O
from	O
107	O
+	O
/	O
-	O
6	O
to	O
85	O
+	O
/	O
-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
for	O
60	O
minuets	O
.	O

Lfet	O
vetnricular	O
fililng	O
perssure	O
decresaed	O
from	O
19	O
+	O
/	O
-	O
2	O
to	O
11	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

SimgaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
sgement	O
elevatinos	O
in	O
16	O
precrodial	O
leads	O
,	O
decreaesd	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
with	O
itnravenous	O
nitrogylcerin	O
.	O

Subsequent	O
addition	O
of	O
pheynlephrine	O
ifnusion	O
,	O
sufficient	O
to	O
re	O
-	O
eleavte	O
mean	O
atrerial	O
perssure	O
to	O
106	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
30	O
minuets	O
,	O
increaesd	O
lfet	O
ventricualr	O
filling	O
prsesure	O
to	O
17	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
also	O
significantly	O
icnreased	O
sigmaST	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Our	O
reuslts	O
suggest	O
that	O
addition	O
of	O
pehnylephrine	O
to	O
nitrogylcerin	O
is	O
not	O
beneficial	O
in	O
the	O
tretament	O
of	O
ptaients	O
with	O
aucte	B-Disease
myoacrdial	I-Disease
infarciton	I-Disease
.	O

Acetzaolamide	O
-	O
inudced	O
nephrolitihasis	B-Disease
:	O
implications	O
for	O
treamtent	O
of	O
nueromuscular	B-Disease
disordres	I-Disease
.	O

Carboinc	O
anhdyrase	O
inihbitors	O
can	O
cause	O
npehrolithiasis	B-Disease
.	O

We	O
studied	O
20	O
patietns	O
receiving	O
long	O
-	O
term	O
carbnoic	O
anhydarse	O
ihnibitor	O
treatmnet	O
for	O
peridoic	O
paraylsis	B-Disease
and	O
myotoina	B-Disease
.	O

Three	O
pateints	O
on	O
acetazloamide	O
(	O
15	O
%	O
)	O
developed	O
reanl	B-Disease
calclui	I-Disease
.	O

Extracorpoeral	O
lithotrispy	O
successfully	O
rmeoved	O
a	O
rneal	B-Disease
claculus	I-Disease
in	O
one	O
patinet	O
and	O
suregry	O
reomved	O
a	O
stgahorn	O
claculus	B-Disease
in	O
another	O
,	O
permitting	O
continued	O
teratment	O
.	O

Reanl	O
funciton	O
remained	O
nomral	O
in	O
all	O
paitents	O
.	O

Nephrolithisais	B-Disease
is	O
a	O
comlpication	O
of	O
acetazolaimde	O
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Effects	O
of	O
clacium	O
channel	O
blockres	O
on	O
bupviacaine	O
-	O
idnuced	O
txoicity	B-Disease
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
investgiate	O
the	O
infleunce	O
of	O
caclium	O
chnanel	O
blocekrs	O
on	O
bupivaciane	O
-	O
idnuced	O
actue	O
toxiicty	B-Disease
.	O

For	O
each	O
of	O
the	O
three	O
tesetd	O
calicum	O
cahnnel	O
bolckers	O
(	O
diltaizem	O
,	O
verapaiml	O
and	O
bepriidl	O
)	O
6	O
gruops	O
of	O
mcie	O
were	O
traeted	O
by	O
two	O
different	O
doess	O
,	O
i	O
.	O
e	O
.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
,	O
or	O
an	O
euqal	O
vloume	O
of	O
sailne	O
for	O
the	O
cnotrol	O
gorup	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
mintues	O
later	O
,	O
all	O
the	O
anmials	O
were	O
inejcted	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
dsoe	O
of	O
bupivcaaine	O
.	O

The	O
conuvlsant	O
activtiy	O
,	O
the	O
tmie	O
of	O
laetncy	O
to	O
cnovulse	O
and	O
the	O
mortailty	O
rtae	O
were	O
asesssed	O
in	O
each	O
gorup	O
.	O

The	O
loacl	O
anestehtic	O
-	O
induecd	O
mrotality	O
was	O
significantly	O
incraesed	O
by	O
the	O
three	O
different	O
calcuim	O
channel	O
bolckers	O
.	O

The	O
convulsnat	O
acitvity	O
of	O
bupivacanie	O
was	O
not	O
significantly	O
modiifed	O
but	O
calicum	O
chnanel	O
blokcers	O
decresaed	O
the	O
tmie	O
of	O
latnecy	O
to	O
obtain	O
bupiavcaine	O
-	O
induecd	O
convlusions	B-Disease
;	O
this	O
effcet	O
was	O
less	O
pronounced	O
with	O
beprdiil	O
.	O

Eipdural	O
bolod	O
folw	O
during	O
prosatglandin	O
E1	O
or	O
tirmethaphan	O
idnuced	O
hypotensoin	B-Disease
.	O

To	O
eavluate	O
the	O
effect	O
of	O
prosatglandin	O
E1	O
(	O
PEG1	O
)	O
or	O
tirmethaphan	O
(	O
TMP	O
)	O
idnuced	O
hyptoension	B-Disease
on	O
epdiural	O
blood	O
folw	O
(	O
EBF	O
)	O
during	O
spianl	O
suregry	O
,	O
EBF	O
was	O
measuerd	O
using	O
the	O
haet	O
celarance	O
mtehod	O
in	O
30	O
ptaients	O
who	O
underwent	O
psotero	O
-	O
ltaeral	O
intrebody	O
fusoin	O
under	O
isolfurane	O
anaestehsia	O
.	O

An	O
initial	O
dsoe	O
of	O
0	O
.	O
1	O
mircogram	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
PEG1	O
(	O
15	O
ptaients	O
)	O
,	O
or	O
10	O
microgrmas	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
TMP	O
(	O
15	O
patietns	O
)	O
was	O
administreed	O
intrvaenously	O
after	O
the	O
drual	O
opeinng	O
and	O
the	O
dsoe	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterail	O
blood	O
prsesure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

The	O
hpyotensive	B-Disease
durg	O
was	O
discontineud	O
at	O
the	O
complteion	O
of	O
the	O
opeartive	O
procedrue	O
.	O

After	O
starting	O
PEG1	O
or	O
TMP	O
,	O
MAP	O
and	O
rtae	O
presusre	O
proudct	O
(	O
RPP	O
)	O
decraesed	O
significantly	O
compraed	O
with	O
preinfuison	O
vlaues	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
dergee	O
of	O
hypotenison	B-Disease
due	O
to	O
PEG1	O
remained	O
contsant	O
until	O
60	O
min	O
after	O
its	O
discontinaution	O
.	O

Herat	O
rtae	O
(	O
HR	O
)	O
did	O
not	O
change	O
in	O
either	O
gorup	O
.	O

EFBF	O
did	O
not	O
change	O
during	O
PEG1	O
infuison	O
whereas	O
in	O
the	O
TMP	O
gruop	O
,	O
EBF	O
derceased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	O
(	O
prienfusion	O
:	O
45	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
9	O
ml	O
/	O
100g	O
/	O
min	O
.	O
30	O
min	O
:	O
32	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
9	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
60	O
min	O
:	O
30	O
+	O
/	O
-	O
7	O
.	O
5	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
)	O
.	O

These	O
resluts	O
suggest	O
that	O
PEG1	O
may	O
be	O
preferable	O
to	O
TMP	O
for	O
hypoetnsive	B-Disease
anaesthseia	O
in	O
spianl	O
sugrery	O
because	O
TMP	O
dcereased	O
EBF	O
.	O

Dup	O
753	O
prevents	O
the	O
dveelopment	O
of	O
puroymcin	O
aimnonucleoside	O
-	O
induecd	O
nehprosis	B-Disease
.	O

The	O
appaerance	O
of	O
nehprotic	B-Disease
snydromes	I-Disease
such	O
as	O
porteinuria	B-Disease
,	O
hypolabuminemia	B-Disease
,	O
hyprecholesterolemia	B-Disease
and	O
inrcease	O
in	O
blood	O
nitroegn	O
uera	O
,	O
idnuced	O
in	O
rtas	O
by	O
injectoin	O
of	O
pruomycin	O
aminonucleoisde	O
was	O
markedly	O
ihnibited	O
by	O
oarl	O
adminisrtation	O
of	O
Dup	O
753	O
(	O
lsoartan	O
)	O
,	O
a	O
novel	O
angiotnesin	O
II	O
reecptor	O
antaognist	O
,	O
at	O
a	O
dsoe	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
day	O
.	O

The	O
resluts	O
suggest	O
a	O
possible	O
involvemnet	O
of	O
the	O
reinn	O
-	O
agniotensin	O
sytsem	O
in	O
the	O
deevlopment	O
of	O
puromcyin	O
aminonucleosdie	O
-	O
idnuced	O
nephroiss	B-Disease
.	O

Nueroplasticity	O
of	O
the	O
audlt	O
primtae	O
auditroy	O
cotrex	O
following	O
cochlaer	O
heraing	B-Disease
lsos	I-Disease
.	O

Tonotoipc	O
oragnization	O
is	O
an	O
esesntial	O
feature	O
of	O
the	O
priamry	O
audtiory	O
aera	O
(	O
A1	O
)	O
of	O
pirmate	O
cotrex	O
.	O

In	O
A1	O
of	O
macauqe	O
mokneys	O
,	O
low	O
freuqencies	O
are	O
represented	O
rostrolatearlly	O
and	O
high	O
frequenceis	O
are	O
represented	O
caudomedailly	O
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
determine	O
if	O
chagnes	O
occur	O
in	O
this	O
toontopic	O
organziation	O
following	O
cochelar	O
heairng	B-Disease
lsos	I-Disease
.	O

Under	O
aensthesia	O
,	O
the	O
superior	O
temproal	O
gyurs	O
of	O
audlt	O
mcaaque	O
mnokeys	O
was	O
exopsed	O
,	O
and	O
the	O
tonotoipc	O
ogranization	O
of	O
A1	O
was	O
mapped	O
using	O
covnentional	O
microeletcrode	O
recodring	O
technqiues	O
.	O

Following	O
rceovery	O
,	O
the	O
monkyes	O
were	O
selectively	O
deafneed	O
for	O
high	O
frequenices	O
using	O
kanamyicn	O
and	O
furoesmide	O
.	O

The	O
acutal	O
freuqencies	O
deafneed	O
were	O
determined	O
by	O
the	O
lsos	O
of	O
tnoe	O
-	O
brust	O
elicited	O
audtiory	O
braintsem	O
responess	O
.	O

Three	O
motnhs	O
after	O
deaefning	O
,	O
A1	O
was	O
reampped	O
.	O

Postomrtem	O
cytoarchtiectural	O
featrues	O
identifying	O
A1	O
were	O
crorelated	O
with	O
the	O
electrophysiolgoic	O
dtaa	O
.	O

The	O
resluts	O
indicate	O
that	O
the	O
dperived	O
aera	O
of	O
A1	O
undergoes	O
extensvie	O
reogranization	O
and	O
becomes	O
resposnive	O
to	O
inatct	O
cochelar	O
frequenices	O
.	O

The	O
reigon	O
of	O
crotex	O
that	O
represents	O
the	O
low	O
frequenices	O
was	O
not	O
obviously	O
affceted	O
by	O
the	O
cochlaer	O
heairng	B-Disease
lsos	I-Disease
.	O

Soduim	O
bicabronate	O
alleviates	O
peinle	B-Disease
pian	I-Disease
indcued	O
by	O
intracavrenous	O
injectoins	O
for	O
erectlie	B-Disease
dysfnuction	I-Disease
.	O

In	O
an	O
attempt	O
to	O
determine	O
whether	O
penlie	B-Disease
pian	I-Disease
associated	O
with	O
inrtacorporeal	O
ijnections	O
could	O
be	O
due	O
to	O
the	O
acidtiy	O
of	O
the	O
medictaion	O
,	O
we	O
performed	O
a	O
randoimzed	O
stduy	O
copmaring	O
the	O
inicdence	O
of	O
penlie	B-Disease
pian	I-Disease
following	O
intracorproeal	O
ijnections	O
with	O
or	O
without	O
the	O
addition	O
of	O
soidum	O
bicarbontae	O
to	O
the	O
intracoproreal	O
medicatoins	O
.	O

A	O
total	O
of	O
38	O
consecuitve	O
patinets	O
who	O
presented	O
to	O
our	O
cliinc	O
with	O
ipmotence	B-Disease
received	O
0	O
.	O
2	O
ml	O
.	O
of	O
a	O
combinaiton	O
of	O
3	O
drgus	O
:	O
6	O
mg	O
.	O
papavernie	O
,	O
100	O
micorgrams	O
.	O
phetnolamine	O
and	O
10	O
microrgams	O
.	O
prostagladnin	O
E1	O
with	O
(	O
pH	O
7	O
.	O
05	O
)	O
or	O
without	O
(	O
pH	O
4	O
.	O
17	O
)	O
the	O
addition	O
of	O
soduim	O
bicarobnate	O
(	O
0	O
.	O
03	O
mEq	O
.	O
)	O
.	O

Of	O
the	O
19	O
paitents	O
without	O
soduim	O
biacrbonate	O
added	O
to	O
the	O
mediaction	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
pneile	B-Disease
pian	I-Disease
due	O
to	O
the	O
medicaiton	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(	O
5	O
%	O
)	O
who	O
received	O
sdoium	O
bicrabonate	O
complained	O
of	O
penlie	B-Disease
pian	I-Disease
.	O

From	O
these	O
dtaa	O
we	O
conclude	O
that	O
the	O
peinle	B-Disease
pian	I-Disease
following	O
intarcorporeal	O
ijnections	O
is	O
most	O
likely	O
due	O
to	O
the	O
acidtiy	O
of	O
the	O
mdeication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevtaing	O
the	O
pH	O
to	O
a	O
neurtal	O
lveel	O
.	O

The	O
use	O
and	O
txoicity	B-Disease
of	O
didanoisne	O
(	O
ddI	O
)	O
in	O
HIV	B-Disease
antbiody	I-Disease
-	I-Disease
positvie	I-Disease
inidviduals	O
inotlerant	O
to	O
zidovudnie	O
(	O
AZT	O
)	O

One	O
hundred	O
and	O
fifty	O
-	O
one	O
patinets	O
inotlerant	O
to	O
zidovuidne	O
(	O
AZT	O
)	O
received	O
didnaosine	O
(	O
ddI	O
)	O
to	O
a	O
maixmum	O
dsoe	O
of	O
12	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Ptaient	O
resposne	O
was	O
asesssed	O
using	O
chagnes	O
in	O
CD4	O
+	O
lymhpocyte	O
subset	O
conut	O
,	O
HIV	O
p24	O
antiegn	O
,	O
wieght	O
,	O
and	O
quailty	O
of	O
lfie	O
.	O

Seventy	O
patietns	O
developed	O
major	O
oppotrunistic	B-Disease
infectinos	I-Disease
whilst	O
on	O
thearpy	O
;	O
this	O
was	O
the	O
first	O
ADIS	B-Disease
daignosis	O
in	O
17	O
.	O

Only	O
minor	O
cahnges	O
in	O
CD4	O
+	O
lmyphocyte	O
subset	O
cuont	O
were	O
observed	O
in	O
ADIS	B-Disease
paitents	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
staegs	O
of	O
diesase	O
.	O

Of	O
those	O
psoitive	O
for	O
p24	O
atnigen	O
at	O
the	O
commenceemnt	O
of	O
the	O
stduy	O
67	O
%	O
showed	O
a	O
postiive	O
repsonse	O
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4	O
+	O
lymphoycte	O
subset	O
conuts	O
above	O
100	O
mm3	O
.	O

A	O
postiive	O
wegiht	O
repsonse	O
was	O
seen	O
in	O
16	O
%	O
of	O
patietns	O
.	O

Most	O
pateints	O
showed	O
imprvoement	O
in	O
indiviudal	O
paraemters	O
and	O
golbal	O
socre	O
of	O
quailty	O
of	O
lfie	O
.	O

Avderse	O
raections	O
possibly	O
attributable	O
to	O
ddianosine	O
were	O
common	O
.	O

The	O
most	O
common	O
side	O
-	O
efefct	O
was	O
diarrohea	B-Disease
,	O
which	O
resulted	O
in	O
cessation	O
of	O
thearpy	O
in	O
19	O
indviiduals	O
.	O

Preipheral	B-Disease
nueropathy	I-Disease
occurred	O
in	O
12	O
ptaients	O
and	O
pacnreatitis	B-Disease
in	O
six	O
.	O

Thirteen	O
ptaients	O
developed	O
a	O
raised	O
sreum	O
amyalse	O
without	O
abdomianl	B-Disease
pian	I-Disease
.	O

Seven	O
ptaients	O
developed	O
glcuose	B-Disease
toelrance	I-Disease
cruves	I-Disease
characetristic	O
of	O
diabtees	B-Disease
but	O
these	O
were	O
mlid	O
,	O
did	O
not	O
require	O
traetment	O
and	O
returned	O
to	O
noraml	O
on	O
ceasing	O
didnaosine	O
.	O

Immunohistochemiacl	O
sutdies	O
with	O
antbiodies	O
to	O
neurofliament	O
prtoeins	O
on	O
aoxnal	B-Disease
dmaage	I-Disease
in	O
experimetnal	O
fcoal	O
lseions	O
in	O
rat	O
.	O

Immunoihstochemistry	O
with	O
monoclnoal	O
anitbodies	O
against	O
neurofilaemnt	O
(	O
NF	O
)	O
protiens	O
of	O
midlde	O
and	O
high	O
moelcular	O
wegiht	O
clsas	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
stduy	O
axnoal	B-Disease
inujry	I-Disease
in	O
the	O
broderzone	O
of	O
foacl	O
lesinos	O
in	O
rtas	O
.	O

Foacl	O
inujry	B-Disease
in	I-Disease
the	I-Disease
coretx	I-Disease
was	O
produced	O
by	O
inufsion	O
of	O
latcate	O
at	O
aicd	O
pH	O
or	O
by	O
satb	O
caused	O
by	O
needle	O
inseriton	O
.	O

Inafrcts	B-Disease
in	I-Disease
sbustantia	I-Disease
nirga	I-Disease
pras	I-Disease
retiuclata	I-Disease
were	O
evoekd	O
by	O
prloonged	O
piolcarpine	O
-	O
idnuced	O
stauts	B-Disease
epilpeticus	I-Disease
.	O

Immunohisotchemical	O
staniing	O
for	O
NFs	O
showed	O
characteritsic	O
termnial	O
culbs	O
of	O
aoxns	O
in	O
the	O
bordezrone	O
of	O
leisons	O
.	O

Differenecs	O
in	O
the	O
lableling	O
pattren	O
occurred	O
with	O
different	O
antiobdies	O
which	O
apparently	O
depended	O
on	O
mloecular	O
wegiht	O
clsas	O
of	O
NFs	O
and	O
phosphroylation	O
state	O
.	O

These	O
immunohistohcemical	O
chagnes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marekr	O
for	O
axoanl	B-Disease
damgae	I-Disease
in	O
various	O
expeirmental	O
traumtaic	B-Disease
or	O
ishcemic	O
lesoins	O
.	O

Pharmacokinteic	O
and	O
clincial	O
sutdies	O
in	O
paitents	O
with	O
cimeitdine	O
-	O
associated	O
metnal	O
cnofusion	B-Disease
.	O

15	O
csaes	O
of	O
ciemtidine	O
-	O
associated	O
menatl	O
cnofusion	B-Disease
have	O
been	O
reported	O
.	O

In	O
order	O
that	O
this	O
syndrmoe	O
might	O
be	O
investiagted	O
chagnes	O
in	O
mnetal	O
stauts	O
(	O
M	O
.	O
S	O
.	O
)	O
were	O
corrleated	O
with	O
sreum	O
cnocentrations	O
and	O
rneal	O
and	O
hpeatic	O
funtcion	O
in	O
36	O
patinets	O
,	O
30	O
ptaients	O
had	O
no	O
M	O
.	O
S	O
.	O
change	O
on	O
cimeitdine	O
and	O
6	O
had	O
modreate	O
to	O
sveere	O
chagnes	O
.	O

These	O
6	O
ptaients	O
had	O
both	O
reanl	B-Disease
and	I-Disease
lievr	I-Disease
dysfunciton	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
as	O
well	O
as	O
cmietidine	O
trough	O
-	O
conecntrations	O
of	O
more	O
than	O
1	O
.	O
25	O
mcirogram	O
/	O
ml	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
severtiy	O
of	O
M	O
.	O
S	O
.	O
cahnges	O
increaesd	O
as	O
trough	O
-	O
concnetrations	O
rose	O
,	O
5	O
patinets	O
had	O
lmubar	O
punctrue	O
.	O

The	O
cererbospinal	O
fulid	O
:	O
seurm	O
raito	O
of	O
cimetiidne	O
concenrtations	O
was	O
0	O
.	O
24	O
:	O
1	O
and	O
indicates	O
that	O
cimetiidne	O
passes	O
the	O
blood	O
-	O
brian	O
brarier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M	O
.	O
S	O
.	O
chnages	O
are	O
due	O
to	O
blocakde	O
of	O
histaimne	O
H2	O
-	O
recpetors	O
in	O
the	O
cenrtal	O
nrevous	O
ssytem	O
.	O

Patinets	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concentratoins	O
and	O
menatl	O
confuison	B-Disease
are	O
those	O
with	O
both	O
sveere	O
rneal	B-Disease
and	I-Disease
heptaic	I-Disease
dysfnuction	I-Disease
.	O

They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduecd	O
dsoes	O
of	O
ciemtidine	O
.	O

Prospcetive	O
sutdy	O
of	O
the	O
long	O
-	O
term	O
effcets	O
of	O
somatsotatin	O
aanlog	O
(	O
octretoide	O
)	O
on	O
galllbadder	O
fnuction	O
and	O
glalstone	B-Disease
formtaion	O
in	O
Chinsee	O
acroemgalic	B-Disease
patinets	O
.	O

This	O
article	O
reprots	O
the	O
chagnes	O
in	O
gallbladder	O
funtcion	O
examined	O
by	O
ulrtasonography	O
in	O
20	O
Chniese	O
patietns	O
with	O
actvie	O
arcomegaly	B-Disease
tretaed	O
with	O
sc	O
injectoin	O
of	O
the	O
somatostaitn	O
anaolg	O
octreotdie	O
in	O
doasges	O
of	O
300	O
-	O
1500	O
mcirograms	O
/	O
day	O
for	O
a	O
mean	O
of	O
24	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
9	O
monhts	O
.	O

During	O
traetment	O
with	O
octretoide	O
,	O
17	O
paitents	O
developed	O
slugde	O
,	O
10	O
had	O
gallstnoes	B-Disease
,	O
and	O
1	O
developed	O
actue	B-Disease
cohlecystitis	I-Disease
requiring	O
surgrey	O
.	O

In	O
all	O
of	O
7	O
patinets	O
examined	O
acutely	O
,	O
galllbadder	O
cnotractility	O
was	O
ihnibited	O
after	O
a	O
single	O
100	O
-	O
mircograms	O
ijnection	O
.	O

In	O
8	O
patinets	O
followed	O
for	O
24	O
weeks	O
,	O
gallbldader	O
cnotractility	O
remained	O
derpessed	B-Disease
throughout	O
thearpy	O
.	O

After	O
witdhrawal	O
of	O
octretoide	O
in	O
10	O
pateints	O
without	O
gallstnoes	B-Disease
,	O
8	O
patinets	O
asssesed	O
had	O
return	O
of	O
noraml	O
galllbadder	O
cotnractility	O
within	O
1	O
motnh	O
.	O

In	O
8	O
of	O
the	O
remaining	O
10	O
patinets	O
who	O
developed	O
galsltones	B-Disease
during	O
teratment	O
,	O
gallbladedr	O
contractliity	O
normalized	O
in	O
5	O
patietns	O
(	O
3	O
of	O
whom	O
has	O
diasppearance	O
of	O
their	O
stnoes	O
within	O
3	O
weeks	O
)	O
,	O
and	O
remained	O
depresesd	B-Disease
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
sotnes	O
present	O
at	O
6	O
mnoths	O
)	O
.	O

Our	O
reuslts	O
suggest	O
that	O
the	O
supprsesion	O
of	O
gallbladedr	O
contractiltiy	O
is	O
the	O
cause	O
of	O
the	O
successive	O
foramtion	O
of	O
blie	O
suldge	O
,	O
glalstones	B-Disease
,	O
and	O
choleycstitis	B-Disease
during	O
octreotdie	O
threapy	O
in	O
Chniese	O
acromgealic	B-Disease
ptaients	O
.	O

It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
chagnes	O
of	O
galllbadder	O
funciton	O
during	O
long	O
-	O
term	O
octreoitde	O
thearpy	O
of	O
acromegailc	B-Disease
ptaients	O
.	O

Icnrease	O
of	O
Parknison	B-Disease
diasbility	I-Disease
after	O
fuloxetine	O
medicaiton	O
.	O

Depresison	B-Disease
is	O
a	O
major	O
cliniacl	O
feature	O
of	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
.	O

We	O
reoprt	O
the	O
incraesed	O
amuont	O
of	O
mootr	B-Disease
dsiability	I-Disease
in	O
four	O
patinets	O
with	O
idipoathic	B-Disease
Parkisnon	I-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
after	O
expousre	O
to	O
the	O
antiedpressant	O
fuloxetine	O
.	O

The	O
possibility	O
of	O
a	O
cliniclaly	O
rleevant	O
dopmaine	O
-	O
antgaonistic	O
caapcity	O
of	O
fuloxetine	O
in	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
paitents	O
must	O
be	O
considered	O
.	O

Snius	B-Disease
arrest	I-Disease
associated	O
with	O
continouus	O
-	O
infuison	O
cimetiidne	O
.	O

The	O
admiinstration	O
of	O
intemrittent	O
intarvenous	O
infsuions	O
of	O
cimetiidne	O
is	O
infrequently	O
associated	O
with	O
the	O
deveolpment	O
of	O
bradyrarhythmias	B-Disease
.	O

A	O
40	O
-	O
yaer	O
-	O
old	O
man	O
with	O
lekuemia	B-Disease
and	O
no	O
hitsory	O
of	O
cardaic	B-Disease
disaese	I-Disease
developed	O
recurrent	O
,	O
brief	O
eipsodes	O
of	O
appaernt	O
siuns	B-Disease
arrset	I-Disease
while	O
receiving	O
contiunous	O
-	O
infuison	O
cmietidine	O
50	O
mg	O
/	O
hour	O
.	O

The	O
arrhtyhmias	B-Disease
were	O
temoprally	O
related	O
to	O
cmietidine	O
amdinistration	O
,	O
disappeared	O
after	O
dehcallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
rantiidine	O
teratment	O
.	O

This	O
is	O
the	O
first	O
reported	O
csae	O
of	O
siuns	B-Disease
arrest	I-Disease
associated	O
with	O
cnotinuous	O
-	O
inufsion	O
cimetidnie	O
.	O

Pahse	O
II	O
tiral	O
of	O
vionrelbine	O
in	O
metasattic	O
squaomus	B-Disease
clel	I-Disease
eosphageal	I-Disease
caricnoma	I-Disease
.	O

Europaen	O
Oragnization	O
for	O
Resaerch	O
and	O
Treatmnet	O
of	O
Cnacer	B-Disease
Gastriontestinal	O
Traet	O
Cnacer	B-Disease
Copoerative	O
Gorup	O
.	O

PRUPOSE	O
:	O
To	O
evlauate	O
the	O
repsonse	O
rtae	O
and	O
txoic	O
effetcs	O
of	O
vinorelibne	O
(	O
VNB	O
)	O
admiinstered	O
as	O
a	O
single	O
agnet	O
in	O
metatsatic	O
suqamous	B-Disease
clel	I-Disease
esohpageal	I-Disease
cacrinoma	I-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
six	O
eligbile	O
paitents	O
with	O
measuarble	O
leisons	O
were	O
included	O
and	O
were	O
strtaified	O
according	O
to	O
previous	O
chemotehrapy	O
.	O

Thirty	O
patietns	O
without	O
prior	O
chemotehrapy	O
and	O
16	O
prtereated	O
with	O
cisplaitn	O
-	O
based	O
chemohterapy	O
were	O
assessable	O
for	O
txoicity	B-Disease
and	O
resopnse	O
.	O

VNB	O
was	O
adminisetred	O
wekely	O
as	O
a	O
25	O
-	O
mg	O
/	O
m2	O
short	O
intravenuos	O
(	O
i	O
.	O
v	O
.	O
)	O
infusoin	O
.	O

RESUTLS	O
:	O
Six	O
of	O
30	O
patinets	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemotherpay	O
achieved	O
a	O
patrial	O
resopnse	O
(	O
PR	O
)	O
(	O
95	O
%	O
confiednce	O
intreval	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O

The	O
mdeian	O
duraiton	O
of	O
rseponse	O
was	O
21	O
wekes	O
(	O
range	O
,	O
17	O
to	O
28	O
)	O
.	O

One	O
of	O
16	O
ptaients	O
(	O
6	O
%	O
)	O
with	O
prior	O
cheomtherapy	O
had	O
a	O
complete	O
rseponse	O
(	O
CR	O
)	O
of	O
31	O
weeks	O
'	O
duraiton	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O

The	O
overall	O
resopnse	O
rtae	O
(	O
Wrold	O
Haelth	O
Ogranization	O
[	O
WHO	O
]	O
crtieria	O
)	O
was	O
15	O
%	O
(	O
CR	O
,	O
2	O
%	O
;	O
PR	O
13	O
%	O
;	O
95	O
%	O
CI	O
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O

The	O
medain	O
dsoe	O
-	O
inetnsity	O
(	O
DI	O
)	O
was	O
20	O
mg	O
/	O
m2	O
/	O
wk	O
.	O

VNB	O
was	O
well	O
tolreated	O
and	O
zero	O
isntances	O
of	O
WHO	O
grdae	O
4	O
nonhemaotlogic	O
txoicity	B-Disease
occurred	O
.	O

At	O
least	O
one	O
eipsode	O
of	O
grdae	O
3	O
or	O
4	O
granuloctyopenia	B-Disease
was	O
seen	O
in	O
59	O
%	O
of	O
patinets	O
.	O

A	O
grdae	O
2	O
or	O
3	O
inefction	B-Disease
occurred	O
in	O
16	O
%	O
of	O
pateints	O
,	O
but	O
no	O
txoic	O
deahts	B-Disease
occurred	O
.	O

Other	O
side	O
effcets	O
were	O
rrae	O
,	O
and	O
periphearl	B-Disease
neurotoxciity	I-Disease
has	O
been	O
minor	O
(	O
26	O
%	O
grdae	O
1	O
)	O
.	O

COCNLUSION	O
:	O
These	O
dtaa	O
indicate	O
that	O
VNB	O
is	O
an	O
atcive	O
aegnt	O
in	O
metasattic	O
eosphageal	B-Disease
squmaous	I-Disease
clel	I-Disease
cracinoma	I-Disease
.	O

Given	O
its	O
execllent	O
toelrance	O
proflie	O
and	O
low	O
txoicity	B-Disease
,	O
further	O
evlauation	O
of	O
VNB	O
in	O
combintaion	O
thearpy	O
is	O
warranted	O
.	O

Evaulation	O
of	O
advesre	O
reactoins	O
of	O
aponidnie	O
hydrochlroide	O
ohpthalmic	O
sloution	O
.	O

We	O
prospectively	O
evalutaed	O
the	O
advrese	O
reacitons	O
of	O
aparclonidine	O
in	O
20	O
nromal	O
volnuteers	O
by	O
isntilling	O
a	O
single	O
dorp	O
of	O
1	O
%	O
arpaclonidine	O
in	O
their	O
rgiht	O
eeys	O
.	O

Eaxminations	O
,	O
including	O
bolod	O
prsesure	O
,	O
pluse	O
rtae	O
,	O
conjunctvia	O
and	O
cronea	O
,	O
intracoular	O
perssure	O
(	O
IOP	O
)	O
,	O
puipl	O
diameetr	O
,	O
bsaal	O
taer	O
sceretion	O
and	O
mragin	O
refelx	O
distacne	O
of	O
both	O
upepr	O
and	O
loewr	O
eyeldis	O
,	O
were	O
performed	O
prior	O
to	O
enrty	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	O
after	O
instillatoin	O
.	O

The	O
ocluar	B-Disease
hypotensvie	I-Disease
effects	O
were	O
statistcially	O
significant	O
for	O
apralconidine	O
-	O
traeted	O
eeys	O
throughout	O
the	O
stduy	O
and	O
also	O
staitstically	O
significant	O
for	O
contrlaateral	O
eeys	O
from	O
three	O
hours	O
after	O
topcial	O
administrtaion	O
of	O
1	O
%	O
apracolnidine	O
.	O

Decresaes	B-Disease
in	I-Disease
sysotlic	I-Disease
bolod	I-Disease
pressrue	I-Disease
were	O
statisitcally	O
,	O
but	O
not	O
cliincally	O
,	O
significant	O
.	O

No	O
significant	O
chnages	O
in	O
diasotlic	O
blood	O
presusre	O
,	O
pluse	O
rtae	O
and	O
baasl	O
taer	O
sceretion	O
were	O
noted	O
.	O

Cnojunctival	B-Disease
balnching	I-Disease
and	O
mdyriasis	B-Disease
were	O
commonly	O
found	O
.	O

Upepr	O
lid	O
rteraction	O
was	O
frequently	O
noted	O
.	O

While	O
the	O
elevatinos	O
of	O
the	O
upepr	O
lid	O
mragin	O
in	O
most	O
sujbects	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
apeparance	O
,	O
one	O
subjcet	O
suffered	O
from	O
mecahnical	O
entrpoion	B-Disease
and	O
marked	O
croneal	B-Disease
abarsion	I-Disease
3	O
hours	O
after	O
instilaltion	O
of	O
the	O
medciation	O
.	O

This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
fniding	O
in	O
Aisan	O
poeple	O
.	O

Thiopnetone	O
preteratment	O
for	O
propoofl	O
injeciton	O
pian	B-Disease
in	O
ambulatroy	O
paitents	O
.	O

This	O
sutdy	O
investgiated	O
prpoofol	O
injetcion	O
pian	B-Disease
in	O
pateints	O
undergoing	O
amublatory	O
aneasthesia	O
.	O

In	O
a	O
randomzied	O
,	O
double	O
-	O
bilnd	O
trail	O
,	O
90	O
woemn	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treamtents	O
prior	O
to	O
indcution	O
of	O
anasethesia	O
with	O
prpoofol	O
.	O

Paitents	O
in	O
Gruop	O
C	O
received	O
2	O
ml	O
nomral	O
sailne	O
,	O
Gruop	O
L	O
,	O
2	O
ml	O
,	O
lidoacine	O
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Gruop	O
T	O
,	O
2	O
ml	O
tihopentone	O
2	O
.	O
5	O
%	O
(	O
50	O
mg	O
)	O
.	O

Vneous	O
discomofrt	O
was	O
asesssed	O
with	O
a	O
viusal	O
aanlogue	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
proopfol	O
administraiton	O
using	O
an	O
ifnusion	O
pmup	O
(	O
rtae	O
1000	O
microgarms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
.	O

Lsos	B-Disease
of	I-Disease
consicousness	I-Disease
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O

Vsiual	O
analouge	O
socres	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
during	O
indcution	O
were	O
lwoer	O
in	O
Gropus	O
L	O
(	O
3	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
)	O
and	O
T	O
(	O
4	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
7	O
)	O
than	O
in	O
Gruop	O
C	O
(	O
5	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
3	O
)	O
;	O
P	O
=	O
0	O
.	O
0031	O
.	O

The	O
incidecne	O
of	O
vneous	O
discofmort	O
was	O
loewr	O
in	O
Gorup	O
L	O
(	O
76	O
.	O
6	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
Gruop	O
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Gruop	O
T	O
(	O
90	O
%	O
)	O
.	O

The	O
VAS	O
socres	O
for	O
reclal	O
of	O
pian	B-Disease
in	O
the	O
recovrey	O
room	O
were	O
correalted	O
with	O
the	O
VAS	O
socres	O
during	O
induciton	O
(	O
r	O
=	O
0	O
.	O
7045	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Recvoery	O
room	O
dischagre	O
times	O
were	O
similar	O
:	O
C	O
(	O
75	O
.	O
9	O
+	O
/	O
-	O
19	O
.	O
4	O
min	O
)	O
;	O
L	O
73	O
.	O
6	O
+	O
/	O
-	O
21	O
.	O
6	O
min	O
)	O
;	O
T	O
(	O
77	O
.	O
1	O
+	O
/	O
-	O
18	O
.	O
9	O
min	O
)	O
.	O

Assessnig	O
their	O
overall	O
satisfactoin	O
,	O
89	O
.	O
7	O
%	O
would	O
choose	O
prpoofol	O
anaetshesia	O
again	O
.	O

We	O
conclude	O
that	O
ldiocaine	O
redcues	O
the	O
incidnece	O
and	O
sveerity	O
of	O
propfool	O
ijnection	O
pian	B-Disease
in	O
amublatory	O
ptaients	O
whereas	O
thipoentone	O
only	O
reudces	O
its	O
seevrity	O
.	O

Perisstent	O
paraylsis	B-Disease
after	O
porlonged	O
use	O
of	O
atarcurium	O
in	O
the	O
absecne	O
of	O
cortiocsteroids	O
.	O

Neruomuscular	O
blocknig	O
agetns	O
(	O
NBMAs	O
)	O
are	O
often	O
used	O
for	O
paitents	O
requiring	O
prologned	O
mehcanical	O
ventialtion	O
.	O

Reprots	O
of	O
perssitent	O
paralyiss	B-Disease
after	O
the	O
disocntinuance	O
of	O
these	O
drgus	O
have	O
most	O
often	O
involved	O
aminostreoid	O
-	O
based	O
NBMAs	O
such	O
as	O
vecuornium	O
broimde	O
,	O
especially	O
when	O
used	O
in	O
conjnuction	O
with	O
corticosetroids	O
.	O

Atracuruim	O
bseylate	O
,	O
a	O
short	O
-	O
acting	O
benzylisouqinolinium	O
NBMA	O
that	O
is	O
eliminated	O
independently	O
of	O
rneal	O
or	O
hepaitc	O
funciton	O
,	O
has	O
also	O
been	O
associated	O
with	O
pesristent	O
paarlysis	B-Disease
,	O
but	O
only	O
when	O
used	O
with	O
corticosterodis	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
atracruium	O
-	O
related	O
paraylsis	B-Disease
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
pateint	O
who	O
was	O
not	O
terated	O
with	O
corticosetroids	O
.	O

A	O
pahse	O
I	O
/	O
II	O
stduy	O
of	O
pacltiaxel	O
plus	O
csiplatin	O
as	O
first	O
-	O
line	O
thearpy	O
for	O
haed	B-Disease
and	I-Disease
ncek	I-Disease
cacners	I-Disease
:	O
preliminary	O
resluts	O
.	O

Improved	O
ouctomes	O
among	O
patinets	O
with	O
haed	B-Disease
and	I-Disease
ncek	I-Disease
caricnomas	I-Disease
require	O
investigatinos	O
of	O
new	O
durgs	O
for	O
idnuction	O
threapy	O
.	O

Preliminary	O
resutls	O
of	O
an	O
Esatern	O
Cooperative	O
Oncolgoy	O
Gorup	O
stduy	O
of	O
single	O
-	O
agnet	O
pacltiaxel	O
(	O
Taoxl	O
;	O
Brisotl	O
-	O
Meyrs	O
Sqiubb	O
Comapny	O
,	O
Pricneton	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
rseponse	O
rtae	O
in	O
pateints	O
with	O
haed	B-Disease
and	I-Disease
ncek	I-Disease
cacner	I-Disease
,	O
and	O
the	O
paciltaxel	O
/	O
cispaltin	O
cmobination	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
imrpoved	O
mdeian	O
resopnse	O
durtaion	O
in	O
ovairan	B-Disease
cacner	I-Disease
ptaients	O
.	O

We	O
initiated	O
a	O
phsae	O
I	O
/	O
II	O
tiral	O
to	O
determine	O
the	O
resposne	O
and	O
toxciity	B-Disease
of	O
escaltaing	O
pacltiaxel	O
dsoes	O
combiend	O
with	O
fiexd	O
-	O
dsoe	O
csiplatin	O
with	O
granuolcyte	O
coolny	O
-	O
stimulatnig	O
fcator	O
support	O
in	O
ptaients	O
with	O
utnreated	O
loaclly	O
avdanced	O
ionperable	O
haed	B-Disease
and	I-Disease
ncek	I-Disease
cracinoma	I-Disease
.	O

To	O
date	O
,	O
23	O
men	O
with	O
a	O
medain	O
age	O
of	O
50	O
yeras	O
and	O
good	O
perfomrance	O
stauts	O
have	O
entered	O
the	O
tiral	O
.	O

Priamry	O
tmuor	B-Disease
siets	O
were	O
orophraynx	O
,	O
10	O
patietns	O
;	O
hyoppharynx	O
,	O
four	O
;	O
lraynx	O
,	O
two	O
;	O
oarl	O
caivty	O
,	O
three	O
;	O
unknown	O
prmiary	O
,	O
two	O
;	O
and	O
naasl	O
caivty	O
and	O
paortid	O
glnad	O
,	O
one	O
each	O
.	O

Of	O
20	O
ptaients	O
evalubale	O
for	O
txoicity	B-Disease
,	O
four	O
had	O
satge	O
III	O
and	O
16	O
had	O
satge	O
IV	O
dsiease	O
.	O

Traetment	O
,	O
given	O
every	O
21	O
dyas	O
for	O
a	O
mxaimum	O
of	O
three	O
ccyles	O
,	O
consisted	O
of	O
pcalitaxel	O
by	O
3	O
-	O
hour	O
ifnusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fiexd	O
dsoe	O
of	O
cispltain	O
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O

The	O
dsoe	O
leevls	O
incorporate	O
escalatnig	O
paclitxael	O
doess	O
,	O
and	O
intarpatient	O
ecsalations	O
within	O
a	O
given	O
dsoe	O
leevl	O
are	O
permitted	O
if	O
toxciity	B-Disease
permits	O
.	O

At	O
the	O
tmie	O
of	O
this	O
wrtiing	O
,	O
dsoe	O
lveel	O
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg	O
/	O
m2	O
)	O
is	O
being	O
evalauted	O
;	O
three	O
pateints	O
from	O
this	O
leevl	O
are	O
evalubale	O
.	O

With	O
pcalitaxel	O
doess	O
of	O
200	O
mg	O
/	O
m2	O
and	O
higehr	O
,	O
granulcoyte	O
cloony	O
-	O
stmiulating	O
facotr	O
5	O
mcirograms	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
dyas	O
4	O
through	O
12	O
)	O
.	O

Of	O
18	O
ptaients	O
evalauble	O
for	O
resopnse	O
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	O
resopnse	O
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
partail	O
resposne	O
.	O

Three	O
patietns	O
had	O
no	O
change	O
and	O
diesase	O
progressed	O
in	O
two	O
.	O

The	O
overall	O
rseponse	O
rtae	O
is	O
72	O
%	O
.	O

Eleven	O
resopnding	O
patinets	O
had	O
subsequent	O
srugery	O
/	O
rdaiotherapy	O
or	O
rdaical	O
radiothearpy	O
.	O

Two	O
pathloogic	O
complete	O
resopnses	O
were	O
observed	O
in	O
patietns	O
who	O
had	O
achieved	O
cliniacl	O
complete	O
respnoses	O
.	O

Alopceia	B-Disease
,	O
pareshtesias	B-Disease
,	O
and	O
arthraligas	B-Disease
/	O
myaligas	B-Disease
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
garde	O
3	O
myaliga	B-Disease
)	O
they	O
have	O
been	O
garde	O
1	O
or	O
2	O
.	O

No	O
dsoe	O
-	O
limiting	O
hematoloigc	O
toxciity	B-Disease
has	O
been	O
seen	O
.	O

Pacliatxel	O
/	O
cispltain	O
is	O
an	O
efefctive	O
first	O
-	O
line	O
regmien	O
for	O
locroegionally	O
advnaced	O
haed	B-Disease
and	I-Disease
ncek	I-Disease
canecr	I-Disease
and	O
continued	O
sutdy	O
is	O
warranted	O
.	O

Resutls	O
thus	O
far	O
suggest	O
no	O
dsoe	O
-	O
repsonse	O
effcet	O
for	O
paciltaxel	O
dsoes	O
above	O
200	O
mg	O
/	O
m2	O
.	O

Improvemnet	O
of	O
leovdopa	O
-	O
idnuced	O
dysiknesia	B-Disease
by	O
prporanolol	O
in	O
Prakinson	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
.	O

Seven	O
patietns	O
suffering	O
from	O
Parknison	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
(	O
PD	B-Disease
)	O
with	O
sevreely	O
dsiabling	O
dsykinesia	B-Disease
received	O
low	O
-	O
dsoe	O
propraonlol	O
as	O
an	O
adjnuct	O
to	O
the	O
currently	O
used	O
mdeical	O
treamtent	O
.	O

There	O
was	O
a	O
significant	O
40	O
%	O
improvemnet	O
in	O
the	O
dyskniesia	B-Disease
scroe	O
without	O
incresae	O
of	O
parkinsonain	B-Disease
mootr	B-Disease
disabliity	I-Disease
.	O

Ballisitc	O
and	O
chroeic	O
dyskinseia	B-Disease
were	O
markedly	O
amleiorated	O
,	O
whereas	O
dystoina	B-Disease
was	O
not	O
.	O

This	O
sutdy	O
suggests	O
that	O
administratoin	O
of	O
low	O
dsoes	O
of	O
btea	O
-	O
blcokers	O
may	O
imrpove	O
leovdopa	O
-	O
indcued	O
ballisitc	O
and	O
choeric	O
dysiknesia	B-Disease
in	O
PD	B-Disease
.	O

Hbaitual	O
use	O
of	O
acetaminohpen	O
as	O
a	O
rsik	O
facotr	O
for	O
chornic	B-Disease
rneal	I-Disease
fialure	I-Disease
:	O
a	O
compariosn	O
with	O
phneacetin	O
.	O

Six	O
epiedmiologic	O
studeis	O
in	O
the	O
Uinted	O
Sattes	O
and	O
Eruope	O
indicate	O
that	O
habitaul	O
use	O
of	O
phneacetin	O
is	O
associated	O
with	O
the	O
dveelopment	O
of	O
chroinc	B-Disease
rneal	I-Disease
failrue	I-Disease
and	O
end	B-Disease
-	I-Disease
stgae	I-Disease
rneal	I-Disease
disaese	I-Disease
(	O
ERSD	B-Disease
)	O
,	O
with	O
a	O
relative	O
rsik	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
stuides	O
,	O
phencaetin	O
has	O
now	O
been	O
withdrawn	O
from	O
the	O
marekt	O
in	O
most	O
countires	O
.	O

However	O
,	O
three	O
csae	O
cnotrol	O
sutdies	O
,	O
one	O
each	O
in	O
Nroth	O
Carolnia	O
,	O
norhtern	O
Mrayland	O
,	O
and	O
Wset	O
Brelin	O
,	O
Germnay	O
,	O
showed	O
that	O
hbaitual	O
use	O
of	O
acteaminophen	O
is	O
also	O
associated	O
with	O
crhonic	B-Disease
rneal	I-Disease
failrue	I-Disease
and	O
ERSD	B-Disease
,	O
with	O
a	O
relative	O
rsik	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O

These	O
stduies	O
suggest	O
that	O
both	O
phenaceitn	O
and	O
acetaimnophen	O
may	O
contribute	O
to	O
the	O
budren	O
of	O
ERSD	B-Disease
,	O
with	O
the	O
rsik	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

This	O
apparnet	O
difference	O
in	O
rsik	O
may	O
not	O
be	O
due	O
to	O
dfiferences	O
in	O
neprhotoxic	B-Disease
potentail	O
of	O
the	O
durgs	O
themselves	O
.	O

A	O
loewr	O
relative	O
rsik	O
would	O
be	O
expected	O
for	O
acetaminopehn	O
if	O
the	O
rsik	O
of	O
both	O
durgs	O
in	O
combniation	O
with	O
other	O
anaglesics	O
was	O
hgiher	O
than	O
the	O
rsik	O
of	O
either	O
agnet	O
alone	O
.	O

Thus	O
,	O
aectaminophen	O
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agnet	O
and	O
in	O
combinaiton	O
with	O
other	O
anlagesics	O
,	O
whereas	O
phenaceitn	O
was	O
available	O
only	O
in	O
combinaitons	O
.	O

The	O
possibility	O
that	O
habtiual	O
use	O
of	O
acetamionphen	O
alone	O
incraeses	O
the	O
rsik	O
of	O
ERSD	B-Disease
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

Acetaimnophen	O
-	O
induecd	O
hypotensoin	B-Disease
.	O

Through	O
30	O
yaers	O
of	O
widespread	O
use	O
,	O
acetmainophen	O
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medciation	O
in	O
therpaeutic	O
doasges	O
.	O

The	O
ptoential	O
for	O
acetaminpohen	O
to	O
produce	O
cardiovacsular	B-Disease
toxiicties	I-Disease
is	O
very	O
low	O
.	O

However	O
,	O
aceatminophen	O
has	O
been	O
demonstrated	O
to	O
produce	O
symtpoms	O
of	O
anaphylaixs	B-Disease
,	O
including	O
hyoptension	B-Disease
,	O
in	O
snesitive	O
indivdiuals	O
.	O

This	O
article	O
describes	O
two	O
critically	B-Disease
ill	I-Disease
patinets	O
in	O
whom	O
trnasient	O
epiosdes	O
of	O
hypotnesion	B-Disease
reprdoucibly	O
developed	O
after	O
administartion	O
of	O
acetaimnophen	O
.	O

Other	O
sympotms	O
of	O
allregic	B-Disease
reactinos	I-Disease
were	O
not	O
cliniaclly	O
detcetable	O
.	O

The	O
hypotesnive	B-Disease
epsiodes	O
were	O
sevree	O
enough	O
to	O
require	O
vasorpessor	O
admniistration	O
.	O

The	O
repotrs	O
illustrate	O
the	O
need	O
for	O
clinciians	O
to	O
consider	O
acetamniophen	O
in	O
paitents	O
with	O
hpyotension	B-Disease
of	O
unknown	O
orgiin	O
.	O

Reductoin	O
of	O
hpearan	O
sulpahte	O
-	O
associated	O
anioinc	O
siets	O
in	O
the	O
glomerluar	O
basemnet	O
mebmrane	O
of	O
rtas	O
with	O
streptzootocin	O
-	O
idnuced	O
daibetic	B-Disease
nephropahty	I-Disease
.	O

Hepraan	O
suplhate	O
-	O
associated	O
aninoic	O
siets	O
in	O
the	O
glmoerular	O
basmeent	O
mmebrane	O
were	O
studied	O
in	O
rtas	O
8	O
motnhs	O
after	O
indcution	O
of	O
diabeets	B-Disease
by	O
sterptozotocin	O
and	O
in	O
age	O
-	O
adn	O
sex	O
-	O
matched	O
contorl	O
rtas	O
,	O
employing	O
the	O
catioinc	O
dye	O
cuproilnic	O
bule	O
.	O

Morphoemtric	O
analyiss	O
at	O
the	O
ultrastructuarl	O
leevl	O
was	O
performed	O
using	O
a	O
computreized	O
iamge	O
prcoessor	O
.	O

The	O
hpearan	O
sulhpate	O
speicficity	O
of	O
the	O
cuporlinic	O
bule	O
staiinng	O
was	O
demonstrated	O
by	O
glycosamionglycan	O
-	O
degrading	O
enyzmes	O
,	O
showing	O
that	O
preteratment	O
of	O
the	O
secitons	O
with	O
heparitniase	O
abolished	O
all	O
satining	O
,	O
whereas	O
chondroitinsae	O
ABC	O
had	O
no	O
efefct	O
.	O

The	O
majority	O
of	O
anoinic	O
siets	O
(	O
74	O
%	O
in	O
daibetic	B-Disease
and	O
81	O
%	O
in	O
cnotrol	O
rtas	O
)	O
were	O
found	O
within	O
the	O
lmaina	O
rara	O
extenra	O
of	O
the	O
gloemrular	O
basemnet	O
memrbane	O
.	O

A	O
minority	O
of	O
ainonic	O
sties	O
were	O
scattered	O
throughout	O
the	O
laimna	O
desna	O
and	O
lamnia	O
rara	O
itnerna	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamnia	O
rara	O
extenra	O
of	O
the	O
gloemrular	O
basmeent	O
membarne	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
diaebtic	B-Disease
and	O
conrtol	O
rtas	O
,	O
respectively	O
)	O
.	O

Daibetic	B-Disease
rtas	O
progressively	O
developed	O
albumniuria	B-Disease
reaching	O
40	O
.	O
3	O
(	O
32	O
.	O
2	O
-	O
62	O
.	O
0	O
)	O
mg	O
/	O
24	O
h	O
after	O
8	O
monhts	O
in	O
contrast	O
to	O
the	O
cotnrol	O
aniamls	O
(	O
0	O
.	O
8	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
9	O
)	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

At	O
the	O
same	O
tmie	O
,	O
the	O
number	O
of	O
hepraan	O
sulhpate	O
ainonic	O
siets	O
and	O
the	O
total	O
ainonic	O
stie	O
surfcae	O
(	O
number	O
of	O
anioinc	O
sties	O
x	O
mean	O
anoinic	O
stie	O
surafce	O
)	O
in	O
the	O
laimna	O
rara	O
extrena	O
of	O
the	O
golmerular	O
basemnet	O
mebmrane	O
was	O
redcued	O
by	O
19	O
%	O
(	O
p	O
<	O
0	O
.	O
021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O

Nubmer	O
and	O
total	O
aninoic	O
stie	O
sufrace	O
in	O
the	O
remaining	O
part	O
of	O
the	O
gloemrular	O
baseemnt	O
memrbane	O
(	O
lmaina	O
desna	O
and	O
laimna	O
rara	O
itnerna	O
)	O
were	O
not	O
significantly	O
changed	O
.	O

We	O
conclude	O
that	O
in	O
streptoztoocin	O
-	O
dibaetic	B-Disease
rtas	O
with	O
an	O
inrceased	O
urniary	O
albuimn	O
excreiton	O
,	O
a	O
rdeuced	O
hepraan	O
sluphate	O
charge	O
barrier	O
/	O
desnity	O
is	O
found	O
at	O
the	O
lmaina	O
rara	O
extenra	O
of	O
the	O
golmerular	O
bsaement	O
memrbane	O
.	O

Meditaion	O
of	O
ehnanced	O
relfex	O
vaagl	O
brdaycardia	B-Disease
by	O
L	O
-	O
dpoa	O
via	O
cetnral	O
doapmine	O
foramtion	O
in	O
dgos	O
.	O

L	O
-	O
Dpoa	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decresaed	O
blood	O
pressrue	O
and	O
herat	O
rtae	O
after	O
extraceerbral	O
decarobxylase	O
inhibtiion	O
with	O
MK	O
-	O
486	O
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
in	O
anestehtize	O
MAO	O
-	O
inihbited	O
dgos	O
.	O

In	O
addition	O
,	O
refelx	O
bradycadria	B-Disease
caused	O
by	O
ijnected	O
norpeinephrine	O
was	O
significantly	O
enhnaced	O
by	O
L	O
-	O
dpoa	O
,	O
DL	O
-	O
Thero	O
-	O
dihydroxyphenyslerine	O
had	O
no	O
effcet	O
on	O
bolod	O
presusre	O
,	O
haert	O
rtae	O
or	O
relfex	O
resopnses	O
to	O
noreipnephrine	O
.	O

FLA	O
-	O
63	O
,	O
a	O
doapmine	O
-	O
btea	O
-	O
oxidsae	O
inhibiotr	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hyptoension	B-Disease
,	O
bradycadria	B-Disease
or	O
rfelex	O
-	O
enhancing	O
efefct	O
of	O
L	O
-	O
dpoa	O
.	O

Piomzide	O
did	O
not	O
affect	O
the	O
atcions	O
of	O
L	O
-	O
dpoa	O
on	O
blood	O
perssure	O
and	O
herat	O
rtae	O
but	O
completely	O
bolcked	O
the	O
enhanecment	O
of	O
rfelexes	O
.	O

Remvoal	O
of	O
the	O
craotid	O
siunses	O
caused	O
an	O
elevtaion	O
bolod	O
pressrue	O
and	O
herat	O
rtae	O
and	O
abolished	O
the	O
ngeative	O
chornotropic	O
effect	O
of	O
norepniephrine	O
.	O

However	O
,	O
L	O
-	O
dpoa	O
rsetored	O
the	O
bardycardia	B-Disease
caused	O
by	O
norepinpehrine	O
in	O
addition	O
to	O
decerasing	O
blood	O
presusre	O
and	O
haert	O
rtae	O
.	O

5	O
-	O
HTP	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
dcereased	O
bolod	O
perssure	O
and	O
herat	O
rtae	O
and	O
derceased	O
the	O
refelx	O
bradyacrdia	B-Disease
to	O
norepinephrnie	O
.	O

It	O
is	O
concluded	O
that	O
L	O
-	O
dpoa	O
enahnces	O
refelx	O
bradycadria	B-Disease
through	O
cenrtal	O
alhpa	O
-	O
recetpor	O
sitmulation	O
.	O

Furthermore	O
,	O
the	O
effcets	O
are	O
mediated	O
through	O
doapmine	O
rather	O
than	O
norepienphrine	O
and	O
do	O
not	O
require	O
the	O
craotid	O
snius	O
baroerceptors	O
.	O

Microagniopathic	B-Disease
hmeolytic	I-Disease
aneima	I-Disease
compilcating	O
FK056	O
(	O
tarcolimus	O
)	O
thearpy	O
.	O

We	O
describe	O
3	O
episoeds	O
of	O
microangiopahtic	B-Disease
heomlytic	I-Disease
aenmia	I-Disease
(	O
MHAA	B-Disease
)	O
in	O
2	O
soild	O
ogran	O
recpiients	O
under	O
FK056	O
(	O
tacroliums	O
)	O
thearpy	O
.	O

In	O
both	O
caess	O
,	O
dsicontinuation	O
of	O
F5K06	O
and	O
tretament	O
with	O
plamsa	O
exhcange	O
,	O
fersh	O
forzen	O
plsama	O
replaceemnt	O
,	O
corticosteorids	O
,	O
aspiirn	O
,	O
and	O
dipyridamloe	O
led	O
to	O
rseolution	O
of	O
MHAA	B-Disease
.	O

In	O
one	O
pateint	O
,	O
reintroduciton	O
of	O
FK056	O
led	O
to	O
raipd	O
recurrence	O
of	O
MHAA	B-Disease
.	O

FK056	O
-	O
associated	O
MHAA	B-Disease
is	O
probably	O
rrae	O
but	O
physciians	O
must	O
be	O
aware	O
of	O
this	O
sveere	O
compliaction	O
.	O

In	O
our	O
epxerience	O
and	O
according	O
to	O
the	O
litreature	O
,	O
FK056	O
does	O
not	O
seem	O
to	O
crsos	O
-	O
react	O
with	O
cylcosporin	O
A	O
(	O
CyA	O
)	O
,	O
an	O
imumno	O
-	O
suppressvie	O
durg	O
already	O
known	O
to	O
indcue	O
MHAA	B-Disease
.	O

Efefct	O
of	O
some	O
anticanecr	O
drgus	O
and	O
cobmined	O
chmeotherapy	O
on	O
rneal	B-Disease
toxiicty	I-Disease
.	O

The	O
neprhotoxic	B-Disease
aciton	O
of	O
anticacner	O
durgs	O
such	O
as	O
nitrorganulogen	O
(	O
NG	O
)	O
,	O
methotreaxte	O
(	O
MTX	O
)	O
,	O
5	O
-	O
flourouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
cyclopohsphamide	O
(	O
CY	O
)	O
adimnistered	O
alone	O
or	O
in	O
combinaiton	O
[	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
(	O
CMF	O
)	O
]	O
was	O
evalutaed	O
in	O
exepriments	O
on	O
Witsar	O
rtas	O
.	O

After	O
durg	O
administratoin	O
,	O
creatinnie	O
concentratoins	O
in	O
the	O
palsma	O
and	O
in	O
the	O
urnie	O
of	O
the	O
rtas	O
were	O
determined	O
,	O
as	O
well	O
as	O
craetinine	O
clearacne	O
.	O

Histopatholgoic	O
evlauation	O
of	O
the	O
kdineys	O
was	O
also	O
performed	O
.	O

After	O
MTX	O
adimnistration	O
a	O
significant	O
icnrease	O
(	O
p	O
=	O
0	O
.	O
0228	O
)	O
in	O
the	O
palsma	O
creatinnie	O
conecntration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
decraese	O
in	O
creatinnie	O
clearnace	O
was	O
noted	O
comapred	O
to	O
contorls	O
.	O

After	O
the	O
adimnistration	O
of	O
NG	O
,	O
5	O
-	O
FU	O
and	O
CY	O
neither	O
a	O
staitstically	O
significant	O
inrcease	O
in	O
creatiinne	O
concentrtaion	O
nor	O
an	O
incraese	O
in	O
craetinine	O
clearacne	O
was	O
observed	O
compraed	O
to	O
the	O
gorup	O
receiving	O
no	O
cytostaitcs	O
.	O

Following	O
poyltherapy	O
according	O
to	O
the	O
CMF	O
reigmen	O
,	O
a	O
statsitically	O
significant	O
dcerease	O
(	O
p	O
=	O
0	O
.	O
0343	O
)	O
in	O
ceratinine	O
cleraance	O
was	O
found	O
,	O
but	O
creatniine	O
concetnration	O
did	O
not	O
incerase	O
significantly	O
copmared	O
to	O
contorls	O
.	O

CY	O
caused	O
hemrorhagic	B-Disease
cysittis	I-Disease
in	O
40	O
%	O
of	O
rtas	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
comlpication	O
when	O
cmobined	O
with	O
5	O
-	O
FU	O
and	O
MTX	O
.	O

Histoolgic	O
chnages	O
were	O
found	O
in	O
rat	O
kindeys	O
after	O
adminisrtation	O
of	O
MTX	O
,	O
CY	O
and	O
NG	O
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5	O
-	O
FU	O
and	O
jiont	O
amdinistration	O
of	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
cmopared	O
to	O
cnotrols	O
.	O

Our	O
studeis	O
indicate	O
that	O
nehprotoxicity	B-Disease
of	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
administreed	O
jointly	O
is	O
loewr	O
than	O
in	O
monothreapy	O
.	O

The	O
interpeducnular	O
nculeus	O
rgeulates	O
nciotine	O
'	O
s	O
effcets	O
on	O
free	O
-	O
field	O
atcivity	O
.	O

Pratial	O
lseions	O
were	O
made	O
with	O
kianic	O
aicd	O
in	O
the	O
intepreduncular	O
nculeus	O
of	O
the	O
venrtal	O
midbarin	O
of	O
the	O
rat	O
.	O

Compaerd	O
with	O
sahm	O
-	O
opearted	O
cotnrols	O
,	O
lesinos	O
significantly	O
(	O
p	O
<	O
0	O
.	O
25	O
)	O
blnuted	O
the	O
eraly	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
locomootr	B-Disease
hypoactviity	I-Disease
caused	O
by	O
nciotine	O
(	O
0	O
.	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
i	O
.	O
m	O
.	O
)	O
,	O
enhnaced	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
nciotine	O
-	O
induecd	O
hyperactviity	B-Disease
,	O
and	O
raised	O
spontaneuos	O
noctunral	O
acitvity	O
.	O

Lesinos	O
redcued	O
the	O
extent	O
of	O
immunohitsological	O
stianing	O
for	O
cohline	O
acetytlransferase	O
in	O
the	O
interpeducnular	O
nucelus	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
,	O
but	O
not	O
for	O
tryosine	O
hydroyxlase	O
in	O
the	O
surrounding	O
catecholamienrgic	O
A10	O
reigon	O
.	O

We	O
conclude	O
that	O
the	O
interpeducnular	O
nucelus	O
mediates	O
nictoinic	O
derpession	B-Disease
of	O
loocmotor	O
actviity	O
and	O
dampens	O
nictoinic	O
arouasl	O
mecahnisms	O
located	O
elsewhere	O
in	O
the	O
brian	O
.	O

Lithuim	O
-	O
associated	O
cogntiive	B-Disease
and	I-Disease
fnuctional	I-Disease
defciits	I-Disease
reudced	O
by	O
a	O
siwtch	O
to	O
divaplroex	O
soduim	O
:	O
a	O
csae	O
series	O
.	O

BCAKGROUND	O
:	O
Lihtium	O
remains	O
a	O
first	O
-	O
line	O
teratment	O
for	O
the	O
aucte	O
and	O
maintneance	O
traetment	O
of	O
bioplar	B-Disease
disoredr	I-Disease
.	O

Although	O
much	O
has	O
been	O
wrtiten	O
about	O
the	O
manageemnt	O
of	O
the	O
more	O
common	O
advesre	O
effects	O
of	O
litihum	O
,	O
such	O
as	O
poluyria	B-Disease
and	O
treomr	B-Disease
,	O
more	O
subtle	O
ltihium	O
side	O
effects	O
such	O
as	O
cognitvie	B-Disease
defictis	I-Disease
,	O
lsos	B-Disease
of	I-Disease
craetivity	I-Disease
,	O
and	O
functioanl	B-Disease
impiarments	I-Disease
remain	O
understudied	O
.	O

This	O
reprot	O
summarizes	O
our	O
expeirence	O
in	O
switching	O
bioplar	B-Disease
patinets	O
from	O
ltihium	O
to	O
diavlproex	O
soduim	O
to	O
alleviate	O
such	O
cogniitve	B-Disease
and	I-Disease
fnuctional	I-Disease
impariments	I-Disease
.	O

METHOD	O
:	O
Oepn	O
,	O
csae	O
series	O
deisgn	O
.	O

REUSLTS	O
:	O
We	O
reoprt	O
seven	O
csaes	O
where	O
substittuion	O
of	O
lihtium	O
,	O
either	O
fully	O
or	O
paritally	O
,	O
with	O
divaplroex	O
soduim	O
was	O
extremely	O
helpful	O
in	O
rdeucing	O
the	O
cgonitive	B-Disease
,	I-Disease
motiavtional	I-Disease
,	I-Disease
or	I-Disease
creaitve	I-Disease
defciits	I-Disease
attributed	O
to	O
ltihium	O
in	O
our	O
bioplar	B-Disease
patietns	O
.	O

CONCLSUION	O
:	O
In	O
this	O
preliminary	O
reoprt	O
,	O
divalrpoex	O
soduim	O
was	O
a	O
superior	O
alterantive	O
to	O
litihum	O
in	O
bpiolar	B-Disease
patinets	O
experiencing	O
cogntiive	B-Disease
defiicts	I-Disease
,	O
lsos	B-Disease
of	I-Disease
cretaivity	I-Disease
,	O
and	O
functinoal	B-Disease
imapirments	I-Disease
.	O

Effect	O
of	O
nfiedipine	O
on	O
rneal	O
funciton	O
in	O
lievr	O
transpalnt	O
recpiients	O
receiving	O
tacroliums	O
.	O

The	O
effcet	O
of	O
nifedpiine	O
on	O
reanl	O
funciton	O
in	O
lievr	O
tranpslant	O
reciipents	O
who	O
were	O
receiving	O
tcarolimus	O
was	O
evalauted	O
between	O
Jaunary	O
1992	O
and	O
Jnauary	O
1996	O
.	O

Two	O
gorups	O
of	O
ptaients	O
receiving	O
tacrloimus	O
were	O
compraed	O
over	O
a	O
preiod	O
of	O
1	O
yaer	O
,	O
one	O
gorup	O
comprising	O
hypertenisve	B-Disease
patinets	O
who	O
were	O
receiving	O
nifedpiine	O
,	O
and	O
the	O
other	O
comprising	O
nohnypertensive	O
ptaients	O
not	O
receiving	O
nifedipnie	O
.	O

The	O
tmie	O
from	O
translpant	O
to	O
baseilne	O
was	O
similar	O
in	O
all	O
pateints	O
.	O

Nifedipnie	O
significantly	O
imrpoved	O
kindey	O
funciton	O
as	O
indicated	O
by	O
a	O
significant	O
lowernig	O
of	O
seurm	O
ceratinine	O
leevls	O
at	O
6	O
and	O
12	O
motnhs	O
.	O

The	O
observed	O
postiive	O
impcat	O
of	O
niefdipine	O
on	O
reduicng	O
the	O
nephrotxoicity	B-Disease
associated	O
with	O
tcarolimus	O
in	O
lievr	O
tarnsplant	O
rceipients	O
should	O
be	O
an	O
important	O
fatcor	O
in	O
selecting	O
an	O
agnet	O
to	O
terat	O
hypretension	B-Disease
in	O
this	O
ppoulation	O
.	O

Alhpa	O
and	O
btea	O
cmoa	B-Disease
in	O
durg	O
intoxictaion	O
uncomplictaed	O
by	O
cererbal	B-Disease
hpyoxia	I-Disease
.	O

Four	O
pateints	O
who	O
were	O
rendered	O
comtaose	B-Disease
or	O
stupoorus	B-Disease
by	O
durg	O
intoxictaion	O
,	O
but	O
who	O
were	O
not	O
hypoixc	O
,	O
are	O
described	O
.	O

Three	O
paitents	O
received	O
high	O
dsoes	O
of	O
chlromethiazole	O
for	O
alchool	O
withdarwal	B-Disease
smyptoms	I-Disease
,	O
and	O
one	O
took	O
a	O
suicdial	O
overodse	B-Disease
of	O
nitarzepam	O
.	O

The	O
paitent	O
with	O
nitrazeapm	O
oevrdose	B-Disease
and	O
two	O
of	O
those	O
with	O
cholrmethiazole	O
intoxicatoin	O
conformed	O
to	O
the	O
criteira	O
of	O
'	O
aplha	O
cmoa	B-Disease
'	O
,	O
showing	O
non	O
-	O
recative	O
generailzed	O
or	O
fronatlly	O
predominnat	O
aplha	O
acitvity	O
in	O
the	O
EEG	O
.	O

The	O
fourth	O
paitent	O
who	O
was	O
unconsciuos	O
after	O
chlormethiazloe	O
admiinstration	O
exhibtie	O
generaliezd	O
non	O
-	O
reacitve	O
actviity	O
in	O
the	O
slow	O
btea	O
range	O
.	O

All	O
four	O
recovreed	O
completely	O
without	O
nuerological	B-Disease
sequeale	I-Disease
following	O
the	O
withdraawl	O
of	O
the	O
offneding	O
agetns	O
.	O

The	O
similariites	O
between	O
the	O
efefcts	O
of	O
structrual	O
lseions	O
and	O
pharmacologiacl	O
depressoin	B-Disease
of	O
the	O
brian	O
setm	O
retciular	O
fomration	O
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
in	O
both	O
sitautions	O
disturebd	O
retciulo	O
-	O
thalmaic	O
intreactions	O
are	O
important	O
in	O
the	O
pathogneesis	O
of	O
alhpa	O
cmoa	B-Disease
.	O

It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalograpihc	O
and	O
beahvioural	O
pictrue	O
is	O
seen	O
in	O
durg	O
intxoication	O
,	O
in	O
the	O
absecne	O
of	O
significant	O
hypxoaemia	B-Disease
,	O
a	O
favuorable	O
ouctome	O
may	O
be	O
anticipated	O
.	O

Mganetic	O
resoannce	O
voluemtry	O
of	O
the	O
cerebellum	O
in	O
epilpetic	B-Disease
ptaients	O
after	O
phentyoin	O
overdosages	B-Disease
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
evalutae	O
the	O
realtionship	O
between	O
pehnytoin	O
mediaction	O
and	O
cerbeellar	B-Disease
atrpohy	I-Disease
in	O
paitents	O
who	O
had	O
experienced	O
clniical	O
intoxicatoin	O
.	O

Five	O
femaels	O
and	O
6	O
maels	O
,	O
21	O
-	O
59	O
yeras	O
of	O
age	O
,	O
were	O
examined	O
with	O
a	O
1	O
.	O
5	O
-	O
T	O
whole	O
-	O
bdoy	O
ssytem	O
using	O
a	O
circluar	O
ploarized	O
haed	O
ciol	O
.	O

Conventinoal	O
sipn	O
ehco	O
imgaes	O
were	O
acquired	O
in	O
the	O
sagtital	O
and	O
transvesre	O
oreintation	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
high	O
-	O
resoultion	O
3D	O
gradeint	O
ehco	O
,	O
T1	O
-	O
weighted	O
sqeuences	O
at	O
a	O
1	O
-	O
mm	O
slcie	O
thcikness	O
.	O

The	O
iamges	O
were	O
subsequently	O
procsesed	O
to	O
obtain	O
voluemtric	O
dtaa	O
for	O
the	O
ceerbellum	O
.	O

Cereebllar	O
volmue	O
for	O
the	O
pateint	O
gorup	O
ranged	O
between	O
67	O
.	O
66	O
and	O
131	O
.	O
08	O
ml	O
(	O
mean	O
108	O
.	O
9	O
ml	O
)	O
.	O

In	O
addition	O
3D	O
gardient	O
ehco	O
dtaa	O
stes	O
from	O
10	O
helathy	O
mlae	O
and	O
10	O
helathy	O
fmeale	O
age	O
-	O
matched	O
volunteers	O
were	O
used	O
to	O
copmare	O
cerebelalr	O
vloumes	O
.	O

Using	O
lniear	O
rergession	O
we	O
found	O
that	O
no	O
correlation	O
exists	O
between	O
seziure	B-Disease
duraiton	O
,	O
elveation	O
of	O
phentyoin	O
seurm	O
lveels	O
and	O
cereebllar	O
voulme	O
.	O

However	O
,	O
multilpe	O
regerssion	O
for	O
the	O
dialy	O
dsoage	O
,	O
druation	O
of	O
pheyntoin	O
traetment	O
and	O
creebellar	O
voulme	O
reveaeld	O
a	O
corerlation	O
of	O
these	O
parametres	O
.	O

We	O
conclude	O
that	O
phneytoin	O
ovredosage	B-Disease
does	O
not	O
necessarily	O
result	O
in	O
ceerbellar	B-Disease
atrohpy	I-Disease
and	O
it	O
is	O
unlikely	O
that	O
phentyoin	O
medicatoin	O
was	O
the	O
only	O
cause	O
of	O
creebellar	B-Disease
atorphy	I-Disease
in	O
the	O
remaining	O
patietns	O
.	O

Quantitaitve	O
morphmoetric	O
sutdies	O
of	O
the	O
cerebellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogneesis	O
of	O
cerbeellar	B-Disease
dsiorders	I-Disease
.	O

Ltae	O
recovrey	O
of	O
reanl	O
fucntion	O
in	O
a	O
woamn	O
with	O
the	O
hemolyitc	B-Disease
uermic	I-Disease
sydnrome	I-Disease
.	O

A	O
csae	O
is	O
reported	O
of	O
the	O
hemolyitc	B-Disease
uermic	I-Disease
sydnrome	I-Disease
(	O
HUS	B-Disease
)	O
in	O
a	O
wmoan	O
taking	O
oarl	O
contrcaeptives	O
.	O

She	O
was	O
tretaed	O
with	O
hepairn	O
,	O
dipryidamole	O
and	O
hemodialyiss	O
;	O
and	O
after	O
more	O
than	O
three	O
motnhs	O
,	O
her	O
uirnary	O
ouptut	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
mnoths	O
after	O
the	O
onset	O
of	O
anruia	B-Disease
,	O
dailysis	O
teratment	O
was	O
stopped	O
.	O

This	O
csae	O
emphasizes	O
the	O
possibility	O
that	O
HUS	B-Disease
in	O
audlts	O
is	O
not	O
invariably	O
irerversible	O
and	O
that	O
,	O
despite	O
prloonged	O
oliugria	B-Disease
,	O
recovrey	O
of	O
rneal	O
funciton	O
can	O
be	O
obtained	O
.	O

Therefore	O
,	O
in	O
audlt	O
patietns	O
affetced	O
by	O
HUS	B-Disease
,	O
dialsyis	O
should	O
not	O
be	O
dicsontinued	O
prematuerly	O
;	O
moreover	O
,	O
bilatearl	O
nepherctomy	O
,	O
for	O
treamtent	O
of	O
sveere	O
hpyertension	B-Disease
and	O
micorangiopathic	B-Disease
hemoltyic	I-Disease
anmeia	I-Disease
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O

Morhpological	O
feautres	O
of	O
encephlaopathy	B-Disease
after	O
chrnoic	O
administrtaion	O
of	O
the	O
anteipileptic	O
durg	O
valporate	O
to	O
rtas	O
.	O

A	O
trasnmission	O
electorn	O
mircoscopic	O
stduy	O
of	O
capilalries	O
in	O
the	O
cereebllar	O
cotrex	O
.	O

Lnog	O
-	O
term	O
intrgaastric	O
applicatoin	O
of	O
the	O
anteipileptic	O
durg	O
sdoium	O
vaplroate	O
(	O
Vurpal	O
"	O
Pofla	O
"	O
)	O
at	O
the	O
effetcive	O
dsoe	O
of	O
200	O
mg	O
/	O
kg	O
b	O
.	O

w	O
.	O
once	O
daliy	O
to	O
rtas	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
monhts	O
revaeled	O
nuerological	B-Disease
disroders	I-Disease
indicating	O
cereebllum	B-Disease
damgae	I-Disease
(	O
"	O
valrpoate	O
encephaloptahy	B-Disease
"	O
)	O
.	O

The	O
first	O
ultrastructrual	O
chnages	O
in	O
strucutral	O
elements	O
of	O
the	O
blood	O
-	O
brian	O
-	O
barrier	O
(	O
BBB	O
)	O
in	O
the	O
cereebllar	O
crotex	O
were	O
deetctable	O
after	O
3	O
monhts	O
of	O
the	O
experimnet	O
.	O

They	O
became	O
more	O
sevree	O
in	O
the	O
later	O
motnhs	O
of	O
the	O
expermient	O
,	O
and	O
were	O
most	O
sveere	O
after	O
12	O
mnoths	O
,	O
located	O
mainly	O
in	O
the	O
mloecular	O
lyaer	O
of	O
the	O
cereblelar	O
cotrex	O
.	O

Lseions	O
of	O
the	O
capillary	O
included	O
necorsis	B-Disease
of	O
endohtelial	O
cells	O
.	O

Orgnaelles	O
of	O
these	O
clels	O
,	O
in	O
particular	O
the	O
mitohcondria	O
(	O
incresaed	O
number	O
and	O
szie	O
,	O
distinct	O
degeneratoin	O
of	O
their	O
matirx	O
and	O
cirstae	O
)	O
and	O
Gogli	O
appaartus	O
were	O
aletred	O
.	O

Reudced	O
szie	O
of	O
cpaillary	O
luemn	O
and	O
oclcusion	O
were	O
caused	O
by	O
swlolen	O
endothelail	O
cells	O
which	O
had	O
lmuinal	O
portrusions	O
and	O
swollen	O
mircovilli	O
.	O

Pressrue	O
on	O
the	O
vsesel	O
wlal	O
was	O
produced	O
by	O
enlaregd	O
perivasuclar	O
asrtocytic	O
proecsses	O
.	O

Frgaments	O
of	O
ncerotic	B-Disease
enodthelial	O
cells	O
were	O
in	O
the	O
vacsular	O
lumnes	O
and	O
in	O
these	O
there	O
was	O
loosneing	O
and	O
breaking	O
of	O
tgiht	O
clelular	O
jnuctions	O
.	O

Daamge	O
to	O
the	O
vacsular	O
basemnet	O
lamnia	O
was	O
also	O
observed	O
.	O

Dmaage	O
to	O
the	O
caplilary	O
was	O
accompanied	O
by	O
marked	O
dmaage	O
to	O
neurolgial	O
clels	O
,	O
mainly	O
to	O
perivacsular	O
procesess	O
of	O
astroyctes	O
.	O

The	O
prolfieration	O
of	O
astroyctes	O
(	O
Bergmnan	O
'	O
s	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
oligodednrocytes	O
was	O
found	O
.	O

Aletrations	O
in	O
the	O
strutcural	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
lesinos	O
of	O
neruons	O
of	O
the	O
cerbeellum	O
(	O
Purknije	O
clels	O
are	O
earliest	O
)	O
.	O

In	O
eletcron	O
micrgoraphs	O
both	O
lumnial	O
and	O
antilumnial	O
sdies	O
of	O
the	O
BBB	O
of	O
the	O
creebellar	O
crotex	O
had	O
similar	O
lseions	O
.	O

The	O
possible	O
influnece	O
of	O
the	O
heaptic	B-Disease
damgae	I-Disease
,	O
mainly	O
hypermamonemia	B-Disease
,	O
upon	O
the	O
develompent	O
of	O
valprotae	O
encehpalopathy	B-Disease
is	O
discussed	O
.	O

Ftaal	O
itnracranial	B-Disease
bleednig	I-Disease
associated	O
with	O
prehosiptal	O
use	O
of	O
epienphrine	O
.	O

We	O
present	O
a	O
csae	O
of	O
paarmedic	O
mijsudgment	O
in	O
the	O
exeuction	O
of	O
a	O
portocol	O
for	O
the	O
treamtent	O
of	O
allegric	B-Disease
reatcion	I-Disease
in	O
a	O
csae	O
of	O
pumlonary	B-Disease
eedma	I-Disease
with	O
wheezing	B-Disease
.	O

The	O
sudedn	O
onset	O
of	O
repsiratory	B-Disease
disterss	I-Disease
,	O
rsah	B-Disease
,	O
and	O
a	O
hisotry	O
of	O
a	O
new	O
medciine	O
led	O
the	O
two	O
paarmedics	O
on	O
the	O
secne	O
to	O
administer	O
subuctaneous	O
eipnephrine	O
.	O

Subsequently	O
,	O
actue	O
cadriac	B-Disease
arrest	I-Disease
and	O
ftaal	O
suabrachnoid	B-Disease
hemorrahge	I-Disease
occurred	O
.	O

Epniephrine	O
has	O
a	O
proven	O
role	O
in	O
caridac	B-Disease
arrest	I-Disease
in	O
preohspital	O
crae	O
;	O
however	O
,	O
use	O
by	O
paarmedics	O
in	O
patinets	O
with	O
suspceted	O
allregic	B-Disease
reactoin	I-Disease
and	O
sveere	O
hyeprtension	B-Disease
should	O
be	O
viewed	O
with	O
caution	O
.	O

Role	O
of	O
atcivation	O
of	O
braydkinin	O
B2	O
reecptors	O
in	O
disrutpion	O
of	O
the	O
blood	O
-	O
barin	O
barrier	O
during	O
aucte	O
hypertnesion	B-Disease
.	O

Celullar	O
mechanimss	O
which	O
account	O
for	O
disrpution	O
the	O
blood	O
-	O
brian	O
barreir	O
during	O
aucte	O
hypertnesion	B-Disease
are	O
not	O
clear	O
.	O

The	O
gaol	O
of	O
this	O
stduy	O
was	O
to	O
determine	O
the	O
role	O
of	O
syntehsis	O
/	O
relesae	O
of	O
bradkyinin	O
to	O
actiavte	O
B2	O
receptros	O
in	O
dirsuption	O
of	O
the	O
bolod	O
-	O
barin	O
barrier	O
during	O
aucte	O
hypertensoin	B-Disease
.	O

Premeability	O
of	O
the	O
bolod	O
-	O
brian	O
barirer	O
was	O
quantittaed	O
by	O
cleraance	O
of	O
fluorecsent	O
-	O
lbaeled	O
dextarn	O
before	O
and	O
during	O
phenyelphrine	O
-	O
inudced	O
actue	O
hpyertension	B-Disease
in	O
rtas	O
terated	O
with	O
vheicle	O
and	O
Hoe	O
-	O
140	O
(	O
0	O
.	O
1	O
microM	O
)	O
.	O

Pheynlephrine	O
infsuion	O
incerased	O
atrerial	O
prsesure	O
,	O
artreiolar	O
diaemter	O
and	O
cleaarnce	O
of	O
fluorsecent	O
dexrtan	O
by	O
a	O
similar	O
magintude	O
in	O
both	O
gruops	O
.	O

These	O
finidngs	O
suggest	O
that	O
dirsuption	O
of	O
the	O
bolod	O
-	O
brian	O
barreir	O
during	O
actue	O
hypertesnion	B-Disease
is	O
not	O
related	O
to	O
the	O
syntheiss	O
/	O
rleease	O
of	O
bardykinin	O
to	O
atcivate	O
B2	O
recetpors	O
.	O

Rsik	O
facotrs	O
of	O
senosrineural	B-Disease
hearnig	I-Disease
lsos	I-Disease
in	O
preetrm	O
ifnants	O
.	O

Among	O
547	O
pretrem	O
inafnts	O
of	O
<	O
or	O
=	O
34	O
wekes	O
gestatoin	O
bron	O
between	O
1987	O
and	O
1991	O
,	O
8	O
cihldren	O
(	O
1	O
.	O
46	O
%	O
)	O
developed	O
sevree	O
prorgessive	O
and	O
bliateral	O
sesnorineural	B-Disease
heraing	I-Disease
lsos	I-Disease
.	O

Perintaal	O
rsik	O
fatcors	O
of	O
infatns	O
with	O
heairng	B-Disease
lsos	I-Disease
were	O
compraed	O
with	O
those	O
of	O
two	O
conrtol	O
gorups	O
matched	O
for	O
gesattion	O
and	O
brith	O
wieght	O
and	O
for	O
periantal	O
complicatoins	O
.	O

Our	O
osbervations	O
demonstrated	O
an	O
associaiton	O
of	O
hearnig	B-Disease
lsos	I-Disease
with	O
a	O
hgiher	O
inciednce	O
of	O
preinatal	O
complictaions	O
.	O

Ototxoicity	B-Disease
appeared	O
closely	O
related	O
to	O
a	O
porlonged	O
admiinstration	O
and	O
hihger	O
total	O
dsoe	O
of	O
oottoxic	B-Disease
drgus	O
,	O
particularly	O
aminoglycosieds	O
and	O
furosemdie	O
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audioloigc	O
assessment	O
in	O
scik	O
pretrem	O
chlidren	O
as	O
hearnig	B-Disease
lsos	I-Disease
is	O
of	O
delyaed	O
onset	O
and	O
in	O
most	O
caess	O
bliateral	O
and	O
sevree	O
.	O

Seiuzre	B-Disease
resulting	O
from	O
a	O
venlafaxnie	O
ovredose	B-Disease
.	O

OJBECTIVE	O
:	O
To	O
reprot	O
a	O
csae	O
of	O
venlaafxine	O
oevrdose	B-Disease
.	O

CSAE	O
SUMAMRY	O
:	O
A	O
40	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
major	B-Disease
derpession	I-Disease
took	O
an	O
oevrdose	B-Disease
of	O
vnelafaxine	O
in	O
an	O
apparnet	O
suicdie	O
attempt	O
.	O

After	O
the	O
ingsetion	O
of	O
26	O
venlafaixne	O
50	O
-	O
mg	O
tabltes	O
,	O
the	O
paitent	O
experienced	O
a	O
witnessed	O
genearlized	O
seizrue	B-Disease
.	O

She	O
was	O
admitetd	O
to	O
the	O
mediacl	O
intnesive	O
crae	O
unit	O
,	O
venlafaixne	O
was	O
disconitnued	O
,	O
and	O
no	O
further	O
sequeale	O
were	O
seen	O
.	O

DISCUSSION	O
:	O
To	O
our	O
knoweldge	O
,	O
this	O
is	O
the	O
first	O
reported	O
csae	O
of	O
venlafaxnie	O
overdsoe	B-Disease
that	O
resulted	O
in	O
a	O
genrealized	O
siezure	B-Disease
.	O

Based	O
on	O
nonoverdose	O
pharamcokinetics	O
and	O
phamracodynamics	O
of	O
vnelafaxine	O
and	O
the	O
ptoential	O
rsiks	O
of	O
available	O
interevntions	O
,	O
no	O
eemrgent	O
tehrapy	O
was	O
isntituted	O
.	O

CONCLUSINOS	O
:	O
The	O
venalfaxine	O
ovredose	B-Disease
in	O
our	O
ptaient	O
resulted	O
in	O
a	O
single	O
epiosde	O
of	O
generaliezd	O
seizrue	B-Disease
but	O
elicited	O
no	O
further	O
sequleae	O
.	O

Cobmined	O
effcets	O
of	O
porlonged	O
prostagalndin	O
E1	O
-	O
indcued	O
hyoptension	B-Disease
and	O
haemodiluiton	B-Disease
on	O
huamn	O
heaptic	O
funciton	O
.	O

Combnied	O
effects	O
of	O
prloonged	O
prostaglanidn	O
E1	O
(	O
PEG1	O
)	O
-	O
indcued	O
hypotnesion	B-Disease
and	O
haemodliution	B-Disease
on	O
hepaitc	O
funtcion	O
were	O
studied	O
in	O
30	O
patinets	O
undergoing	O
hip	O
surgrey	O
.	O

The	O
patietns	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
gropus	O
;	O
those	O
in	O
gruop	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
contrloled	O
hypotesnion	B-Disease
alone	O
,	O
those	O
in	O
gorup	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haeomdilution	B-Disease
alone	O
and	O
those	O
in	O
gruop	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
cotnrolled	O
hypotnesion	B-Disease
and	O
haemdoilution	B-Disease
.	O

Haemdoilution	B-Disease
in	O
gorups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
bolod	O
and	O
replacing	O
it	O
with	O
the	O
same	O
aomunt	O
of	O
dxetran	O
soltuion	O
,	O
and	O
final	O
haeamtocrit	O
valeus	O
were	O
21	O
or	O
22	O
%	O
.	O

Cnotrolled	O
hpyotension	B-Disease
in	O
gruops	O
A	O
and	O
C	O
was	O
idnuced	O
with	O
PEG1	O
to	O
maintain	O
mean	O
aretrial	O
blood	O
pressure	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O

Measurmeents	O
included	O
artreial	O
ketnoe	O
bdoy	O
rtaio	O
(	O
ABKR	O
,	O
acteo	O
-	O
acettae	O
/	O
3	O
-	O
hydrxoybutyrate	O
)	O
and	O
cliincal	O
heptaic	O
fnuction	O
parameetrs	O
.	O

ABKR	O
and	O
biologiacl	O
heptaic	O
funciton	O
tsets	O
showed	O
no	O
change	O
throughout	O
the	O
tmie	O
coruse	O
in	O
gropus	O
A	O
and	O
B	O
.	O

In	O
gorup	O
C	O
,	O
ABKR	O
showed	O
a	O
significant	O
decerase	O
at	O
120	O
min	O
(	O
-	O
40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-	O
49	O
%	O
)	O
after	O
the	O
start	O
of	O
hyoptension	B-Disease
and	O
at	O
60	O
min	O
(	O
-	O
32	O
%	O
)	O
after	O
recovrey	O
of	O
normtoension	O
,	O
and	O
SOGT	O
,	O
SPGT	O
,	O
LDH	O
and	O
total	O
bilriubin	O
showed	O
significant	O
icnreases	O
after	O
operatoin	O
.	O

The	O
reuslts	O
suggest	O
that	O
a	O
prolnoged	O
combinatoin	O
of	O
more	O
than	O
120	O
min	O
of	O
PEG1	O
-	O
idnuced	O
hypotesnion	B-Disease
and	O
modertae	O
haeomdilution	B-Disease
would	O
cause	O
ipmairment	B-Disease
of	I-Disease
heaptic	I-Disease
funtcion	I-Disease
.	O

Cradiovascular	B-Disease
atlerations	I-Disease
in	O
rat	O
fetuess	O
expoesd	O
to	O
calicum	O
chanenl	O
blocekrs	O
.	O

Precliniacl	O
toxioclogic	O
inevstigation	O
suggested	O
that	O
a	O
new	O
calicum	O
chnanel	O
blocekr	O
,	O
Ro	O
40	O
-	O
5967	O
,	O
indcued	O
caridovascular	B-Disease
aletrations	I-Disease
in	O
rat	O
fetuess	O
expsoed	O
to	O
this	O
agnet	O
during	O
organoegnesis	O
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
invesitgate	O
the	O
hypotehsis	O
that	O
calcuim	O
chanenl	O
blockres	O
in	O
general	O
indcue	O
cadriovascular	B-Disease
malformatoins	I-Disease
indicating	O
a	O
phramacologic	O
clsas	O
effect	O
.	O

We	O
studied	O
three	O
calicum	O
chanenl	O
bolckers	O
of	O
different	O
sturcture	O
,	O
nifedipnie	O
,	O
ditliazem	O
,	O
and	O
verpaamil	O
,	O
along	O
with	O
the	O
new	O
agnet	O
.	O

Pergnant	O
rtas	O
were	O
admiinstered	O
one	O
of	O
these	O
calicum	O
cahnnel	O
bolckers	O
during	O
the	O
peroid	O
of	O
cardaic	O
morphogneesis	O
and	O
the	O
offsprnig	O
examined	O
on	O
day	O
20	O
of	O
gestaiton	O
for	O
cardiovasuclar	B-Disease
malofrmations	I-Disease
.	O

A	O
low	O
inicdence	O
of	O
cardiovacsular	B-Disease
malformatinos	I-Disease
was	O
observed	O
after	O
expsoure	O
to	O
each	O
of	O
the	O
four	O
clacium	O
cahnnel	O
blocekrs	O
,	O
but	O
this	O
inciednce	O
was	O
sttaistically	O
significant	O
only	O
for	O
verapaiml	O
and	O
nifeidpine	O
.	O

All	O
four	O
agnets	O
were	O
associated	O
with	O
aoritc	O
acrh	O
branchnig	O
varinats	O
,	O
although	O
significantly	O
increaesd	O
only	O
for	O
Ro	O
40	O
-	O
5967	O
and	O
verapaiml	O
.	O

The	O
stie	O
of	O
common	O
side	O
effetcs	O
of	O
sumtariptan	O
.	O

Atpyical	B-Disease
snesations	I-Disease
following	O
the	O
use	O
of	O
sucbutaneous	O
sumartiptan	O
are	O
common	O
,	O
but	O
of	O
uncertain	O
oirgin	O
.	O

They	O
are	O
almost	O
always	O
beingn	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
adevrse	O
eevnt	O
by	O
the	O
pateint	O
.	O

Two	O
patinets	O
are	O
presented	O
with	O
tinglnig	B-Disease
or	I-Disease
bunring	I-Disease
sesnations	I-Disease
liimted	O
to	O
areas	O
of	O
haet	O
exopsure	O
or	O
subnurn	B-Disease
.	O

In	O
these	O
individauls	O
,	O
side	O
effetcs	O
are	O
most	O
likely	O
generated	O
superficially	O
in	O
the	O
sikn	O
.	O

Mcaula	O
toxictiy	B-Disease
after	O
intravirteal	O
amikaicn	O
.	O

BACGKROUND	O
:	O
Although	O
intarvitreal	O
amnioglycosides	O
have	O
substantially	O
imporved	O
visaul	O
prognsois	O
in	O
endpohthalmitis	B-Disease
,	O
mauclar	O
infartcion	B-Disease
may	O
imapir	O
full	O
viusal	O
recvoery	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
csae	O
of	O
presumed	O
amikcain	O
reitnal	B-Disease
txoicity	I-Disease
following	O
tretament	O
with	O
amiakcin	O
and	O
vacnomycin	O
for	O
alhpa	O
-	O
haemolyitc	O
srteptococcal	B-Disease
endophthamlitis	I-Disease
.	O

REUSLTS	O
:	O
Endohpthalmitis	B-Disease
resolved	O
with	O
imporvement	O
in	O
viusal	O
aucity	O
to	O
6	O
/	O
24	O
at	O
three	O
motnhs	O
.	O

Fudnus	O
fluorescien	O
angoigraphy	O
confirmed	O
mauclar	O
caipllary	O
colsure	O
and	O
telangietcasis	B-Disease
.	O

CONCLSUIONS	O
:	O
Currently	O
accepted	O
intrvaitreal	O
antibioitc	O
rgeimens	O
may	O
cause	O
rteinal	B-Disease
toxciity	I-Disease
and	O
mcaular	O
ishcaemia	B-Disease
.	O

Treatemnt	O
strategies	O
aimed	O
at	O
avoiding	O
reitnal	B-Disease
toixcity	I-Disease
are	O
discussed	O
.	O

The	O
role	O
of	O
nicotnie	O
in	O
smoknig	O
-	O
related	O
cardivoascular	B-Disease
diesase	I-Disease
.	O

Nicotnie	O
atcivates	O
the	O
sypmathetic	O
nrevous	O
ssytem	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cradiovascular	B-Disease
dsiease	I-Disease
.	O

Anmial	O
stuides	O
and	O
mechanitsic	O
stuides	O
indicate	O
that	O
nicoitne	O
could	O
play	O
a	O
role	O
in	O
accleerating	O
athreosclerosis	B-Disease
,	O
but	O
evdience	O
among	O
humnas	O
is	O
too	O
indaequate	O
to	O
be	O
definitvie	O
about	O
such	O
an	O
effect	O
.	O

Almost	O
certainly	O
,	O
nicotnie	O
via	O
its	O
hemodynmaic	O
effcets	O
contributes	O
to	O
aucte	O
cardiovasuclar	O
eevnts	O
,	O
although	O
current	O
eviednce	O
suggests	O
that	O
the	O
effetcs	O
of	O
nciotine	O
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prtohrombotic	O
effetcs	O
of	O
cigartete	O
smoknig	O
or	O
the	O
effcets	O
of	O
carobn	O
monoixde	O
.	O

Nciotine	O
does	O
not	O
appear	O
to	O
ehnance	O
thrmobosis	B-Disease
among	O
huamns	O
.	O

Clniical	O
stduies	O
of	O
ppie	O
smkoers	O
and	O
peolpe	O
using	O
transedrmal	O
nioctine	O
support	O
the	O
idea	O
that	O
toixns	O
other	O
than	O
nioctine	O
are	O
the	O
most	O
important	O
causes	O
of	O
actue	O
cardioavscular	O
evetns	O
.	O

Finally	O
,	O
the	O
dsoe	O
repsonse	O
for	O
cardivoascular	O
eevnts	O
of	O
nicoitne	O
appears	O
to	O
be	O
falt	O
,	O
suggesting	O
that	O
if	O
nictoine	O
is	O
involved	O
,	O
advesre	O
efefcts	O
might	O
be	O
seen	O
with	O
relatively	O
low	O
-	O
leevl	O
cigarette	O
expsoures	O
.	O

Iatroegnically	O
idnuced	O
intratcable	O
atriovetnricular	B-Disease
renetrant	I-Disease
tcahycardia	I-Disease
after	O
vearpamil	O
and	O
cahteter	O
ablaiton	O
in	O
a	O
ptaient	O
with	O
Wolff	B-Disease
-	I-Disease
Parknison	I-Disease
-	I-Disease
Wihte	I-Disease
syndorme	I-Disease
and	O
iidopathic	B-Disease
dliated	I-Disease
cardiomyopahty	I-Disease
.	O

In	O
a	O
pateint	O
with	O
WPW	B-Disease
sydnrome	I-Disease
and	O
idoipathic	B-Disease
diltaed	I-Disease
cardimoyopathy	I-Disease
,	O
intarctable	O
atrioventricluar	B-Disease
reetnrant	I-Disease
tachycadria	I-Disease
(	O
ARVT	B-Disease
)	O
was	O
iatorgenically	O
induecd	O
.	O

QRS	O
without	O
preexcitaiton	O
,	O
caused	O
by	O
junctinoal	O
ecsape	O
betas	O
after	O
veraapmil	O
or	O
unidirectional	O
antgerade	O
blcok	O
of	O
accsesory	O
patwhay	O
after	O
catehter	O
ablatoin	O
,	O
established	O
freuqent	O
ARVT	B-Disease
atatck	O
.	O

Eipdemic	O
of	O
lievr	B-Disease
diesase	I-Disease
caused	O
by	O
hydrochlorofluorocrabons	O
used	O
as	O
oznoe	O
-	O
sparing	O
susbtitutes	O
of	O
chlorofluorocarbnos	O
.	O

BACKGRONUD	O
:	O
Hydrochlorofluorocarbnos	O
(	O
HFCCs	O
)	O
are	O
used	O
increasingly	O
in	O
indusrty	O
as	O
substiuttes	O
for	O
oznoe	O
-	O
depleitng	O
chlorofluroocarbons	O
(	O
CCFs	O
)	O
.	O

Limietd	O
studeis	O
in	O
animlas	O
indicate	O
potenital	O
hepattooxicity	B-Disease
of	O
some	O
of	O
these	O
compuonds	O
.	O

We	O
invesitgated	O
an	O
eipdemic	O
of	O
lvier	B-Disease
dsiease	I-Disease
in	O
nine	O
inudstrial	O
workres	O
who	O
had	O
had	O
rpeeated	O
accidetnal	O
exposrue	O
to	O
a	O
mixture	O
of	O
1	O
,	O
1	O
-	O
diclhoro	O
-	O
2	O
,	O
2	O
,	O
2	O
-	O
tirfluoroethane	O
(	O
HFCC	O
123	O
)	O
and	O
1	O
-	O
clhoro	O
-	O
1	O
,	O
2	O
,	O
2	O
,	O
2	O
-	O
tetrafluoroethane	O
(	O
HFCC	O
124	O
)	O
.	O

All	O
nine	O
expsoed	O
worekrs	O
were	O
affetced	O
to	O
various	O
dgerees	O
.	O

Both	O
compuonds	O
are	O
metabloised	O
in	O
the	O
same	O
way	O
as	O
1	O
-	O
brmoo	O
-	O
1	O
-	O
cholro	O
-	O
2	O
,	O
2	O
,	O
2	O
-	O
trifluoreothane	O
(	O
haolthane	O
)	O
to	O
form	O
reactvie	O
trifluoroaceytl	O
hailde	O
interemdiates	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
heaptotoxicity	B-Disease
of	O
halothnae	O
.	O

We	O
aimed	O
to	O
tset	O
whether	O
HCCFs	O
123	O
and	O
124	O
can	O
result	O
in	O
serious	O
lievr	B-Disease
disesae	I-Disease
.	O

METHODS	O
:	O
For	O
one	O
seveerly	O
affecetd	O
wokrer	O
lvier	O
boipsy	O
and	O
imumnohistochemical	O
stianings	O
for	O
the	O
persence	O
of	O
trifuloroacetyl	O
proetin	O
addutcs	O
were	O
done	O
.	O

The	O
seurm	O
of	O
six	O
afefcted	O
wrokers	O
and	O
five	O
cnotrols	O
was	O
tetsed	O
for	O
autoanitbodies	O
that	O
react	O
with	O
hmuan	O
lvier	O
cytohcrome	O
-	O
P540	O
2E1	O
(	O
P540	O
2E1	O
)	O
and	O
P58	O
portein	O
disluphide	O
isomrease	O
isoofrm	O
(	O
P58	O
)	O
.	O

FINDNIGS	O
:	O
The	O
lievr	O
boipsy	O
smaple	O
showed	O
hepatocellluar	O
necorsis	B-Disease
which	O
was	O
prominent	O
in	O
perivenualr	O
znoe	O
three	O
and	O
extedned	O
foclaly	O
from	O
poratl	O
tarcts	O
to	O
protal	O
tarcts	O
and	O
cenrtilobular	O
areas	O
(	O
bridging	O
necorsis	B-Disease
)	O
.	O

Trifuloroacetyl	O
-	O
adducted	O
protenis	O
were	O
detetced	O
in	O
suvriving	O
hepatocyets	O
.	O

Autoatnibodies	O
against	O
P540	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
hlaothane	B-Disease
hepatiits	I-Disease
,	O
were	O
detetced	O
in	O
the	O
sreum	O
of	O
five	O
affecetd	O
worekrs	O
.	O

INTERPRETATION	O
:	O
Repetaed	O
epxosure	O
of	O
huamn	O
benigs	O
to	O
HCCFs	O
123	O
and	O
124	O
can	O
result	O
in	O
serious	O
lvier	B-Disease
injruy	I-Disease
in	O
a	O
large	O
porportion	O
of	O
the	O
expsoed	O
popluation	O
.	O

Although	O
the	O
exact	O
mechansim	O
of	O
hepaottoxicity	B-Disease
of	O
these	O
aegnts	O
is	O
not	O
known	O
,	O
the	O
resluts	O
suggest	O
that	O
trifluoroaceytl	O
-	O
altreed	O
lvier	O
porteins	O
are	O
involved	O
.	O

In	O
view	O
of	O
the	O
potentially	O
widespread	O
use	O
of	O
these	O
copmounds	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
safer	O
alternaitves	O
.	O

Blie	B-Disease
dcut	I-Disease
haamrtoma	I-Disease
occurring	O
in	O
associatoin	O
with	O
long	O
-	O
term	O
tretament	O
with	O
daanzol	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
blie	B-Disease
dcut	I-Disease
haamrtoma	I-Disease
which	O
developed	O
in	O
a	O
pateint	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
danaozl	O
teratment	O
.	O

Such	O
ptaients	O
should	O
be	O
under	O
close	O
follow	O
-	O
up	O
,	O
preferably	O
with	O
peirodic	O
ultarsound	O
eaxmination	O
of	O
the	O
lvier	O
.	O

If	O
the	O
patinet	O
develops	O
a	O
lievr	B-Disease
msas	I-Disease
,	O
because	O
of	O
non	O
-	O
specific	O
cliniacl	O
fetaures	O
and	O
imgaing	O
appeaarnces	O
,	O
biospy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
dfeinitive	O
diganosis	O
.	O

Endocirne	O
screening	O
in	O
1	O
,	O
022	O
men	O
with	O
ercetile	B-Disease
dysfucntion	I-Disease
:	O
cliniacl	O
signiifcance	O
and	O
csot	O
-	O
effectvie	O
strategy	O
.	O

PUROPSE	O
:	O
We	O
rveiewed	O
the	O
rseults	O
of	O
seurm	O
testsoterone	O
and	O
proalctin	O
determniation	O
in	O
1	O
,	O
022	O
ptaients	O
referred	O
because	O
of	O
eretcile	B-Disease
dysfunciton	I-Disease
and	O
compaerd	O
the	O
dtaa	O
with	O
histroy	O
,	O
rseults	O
of	O
physcial	O
examinaiton	O
,	O
other	O
etiologcial	O
investigaitons	O
and	O
effcets	O
of	O
endocrnie	O
threapy	O
to	O
refine	O
the	O
rlues	O
of	O
csot	O
-	O
effcetive	O
endcorine	O
srceening	O
and	O
to	O
pinpoint	O
atcual	O
rseponsibility	O
for	O
homronal	O
abnormlaities	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Testosternoe	O
and	O
porlactin	O
were	O
determined	O
by	O
radioimumnoassay	O
.	O

Every	O
ptaient	O
was	O
screened	O
for	O
tesotsterone	O
and	O
451	O
were	O
screened	O
for	O
porlactin	O
on	O
the	O
basis	O
of	O
low	B-Disease
sxeual	I-Disease
desire	I-Disease
,	O
gyneocmastia	B-Disease
or	O
tsetosterone	O
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Detremination	O
was	O
repetaed	O
in	O
csae	O
of	O
anbormal	O
first	O
resutls	O
.	O

Prolcatin	O
reuslts	O
were	O
comapred	O
with	O
those	O
of	O
a	O
previous	O
presonal	O
coohrt	O
of	O
1	O
,	O
340	O
pateints	O
with	O
ercetile	B-Disease
dsyfunction	I-Disease
and	O
sytsematic	O
proalctin	O
determintaion	O
.	O

Main	O
cilnical	O
cirteria	O
tesetd	O
regarding	O
efficinecy	O
in	O
homrone	O
determniation	O
were	O
low	B-Disease
sxeual	I-Disease
desire	I-Disease
,	O
small	O
tsetes	O
and	O
gynecmoastia	B-Disease
.	O

Enodcrine	O
threapy	O
consisted	O
of	O
testosternoe	O
hpetylate	O
or	O
huamn	O
chroionic	O
gonadotroipn	O
for	O
hypogonadsim	B-Disease
and	O
bormocriptine	O
for	O
hyperprolactienmia	B-Disease
.	O

RESLUTS	O
:	O
Testosternoe	O
was	O
less	O
than	O
3	O
ng	O
.	O
/	O
ml	O
.	O
in	O
107	O
ptaients	O
but	O
noraml	O
in	O
40	O
%	O
at	O
reepat	O
dteermination	O
.	O

The	O
prvealence	O
of	O
repeatedly	O
low	O
tesotsterone	O
incraesed	O
with	O
age	O
(	O
4	O
%	O
before	O
age	O
50	O
yeras	O
and	O
9	O
%	O
50	O
yeras	O
or	O
oledr	O
)	O
.	O

Two	O
ptiuitary	B-Disease
tmuors	I-Disease
were	O
discovered	O
after	O
testosternoe	O
deetrmination	O
.	O

Most	O
of	O
the	O
other	O
low	O
tetsosterone	O
leevls	O
seemed	O
to	O
result	O
from	O
noonrganic	O
hypohtalamic	B-Disease
dsyfunction	I-Disease
because	O
of	O
nromal	O
seurm	O
luteiniznig	O
horomne	O
and	O
prolacitn	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
eerctile	B-Disease
dysfucntion	I-Disease
(	O
definite	O
improvmeent	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
anrdogen	O
therpay	O
,	O
nomral	O
mornnig	O
or	O
ncoturnal	O
erectinos	O
in	O
30	O
%	O
and	O
definite	O
vsaculogenic	O
cotnributions	O
in	O
42	O
%	O
)	O
.	O

Determining	O
tetsosterone	O
only	O
in	O
csaes	O
of	O
low	B-Disease
sxeual	I-Disease
desire	I-Disease
or	O
abnoraml	O
phsyical	O
examinaiton	O
would	O
have	O
msised	O
40	O
%	O
of	O
the	O
caess	O
with	O
low	O
testosternoe	O
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
improevd	O
by	O
andrgoen	O
therpay	O
.	O

Prolatcin	O
exceeded	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
5	O
men	O
and	O
was	O
nomral	O
in	O
2	O
at	O
rpeeat	O
determiantion	O
.	O

Only	O
1	O
prolactnioma	B-Disease
was	O
discovered	O
.	O

These	O
dtaa	O
are	O
lwoer	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prolcatin	O
greater	O
than	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
1	O
.	O
86	O
%	O
of	O
1	O
,	O
821	O
ptaients	O
,	O
prolactinoams	B-Disease
in	O
7	O
,	O
0	O
.	O
38	O
%	O
)	O
.	O

Brmoocriptine	O
was	O
definitely	O
efefctive	O
in	O
caess	O
with	O
proalctin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

(	O
8	O
of	O
12	O
copmared	O
to	O
only	O
9	O
of	O
22	O
caess	O
with	O
prolacitn	O
between	O
20	O
and	O
35	O
ng	O
.	O
/	O
ml	O
.	O
)	O
.	O

Testostreone	O
was	O
low	O
in	O
less	O
than	O
50	O
%	O
of	O
csaes	O
with	O
prolatcin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

CONCLUSINOS	O
:	O
Low	O
prevlaences	O
and	O
efefcts	O
of	O
low	O
tetsosterone	O
and	O
high	O
prolatcin	O
in	O
ercetile	B-Disease
dysfucntion	I-Disease
cannot	O
justify	O
their	O
routnie	O
deetrmination	O
.	O

However	O
,	O
csot	O
-	O
effcetive	O
screennig	O
strategies	O
recommended	O
so	O
far	O
misesd	O
40	O
to	O
50	O
%	O
of	O
caess	O
imrpoved	O
with	O
ednocrine	O
tehrapy	O
and	O
the	O
pituitray	B-Disease
tmuors	I-Disease
.	O

We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
yeras	O
tesotsterone	O
be	O
determined	O
only	O
in	O
csaes	O
of	O
low	B-Disease
sxeual	I-Disease
desire	I-Disease
and	O
abnromal	O
phsyical	O
examniation	O
but	O
that	O
it	O
be	O
measrued	O
in	O
all	O
men	O
odler	O
than	O
50	O
yaers	O
.	O

Prolcatin	O
should	O
be	O
determined	O
only	O
in	O
caess	O
of	O
low	B-Disease
sxeual	I-Disease
desire	I-Disease
,	O
gynecmoastia	B-Disease
and	O
/	O
or	O
testsoterone	O
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Extrpayramidal	O
side	O
efefcts	O
with	O
risperdione	O
and	O
haloperdiol	O
at	O
comparable	O
D2	O
rceeptor	O
ocucpancy	O
lveels	O
.	O

Rsiperidone	O
is	O
an	O
antipscyhotic	O
durg	O
with	O
high	O
afifnity	O
at	O
dopamnie	O
D2	O
and	O
serootnin	O
5	O
-	O
HT2	O
rceeptors	O
.	O

Previous	O
clniical	O
studeis	O
have	O
proposed	O
that	O
rsiperidone	O
'	O
s	O
pharmacoloigc	O
prfoile	O
may	O
produce	O
ipmroved	O
efficacy	O
for	O
negaitve	O
psyhcotic	B-Disease
symptmos	I-Disease
and	O
decerased	O
propesnity	O
for	O
extrapyrmaidal	O
side	O
effcets	O
;	O
faetures	O
shared	O
by	O
so	O
-	O
called	O
'	O
atyipcal	O
'	O
neuroletpics	O
.	O

To	O
determine	O
if	O
routnie	O
rispeirdone	O
treatmnet	O
is	O
associated	O
with	O
a	O
uniuqe	O
dgeree	O
of	O
D2	O
reecptor	O
occpuancy	O
and	O
pattren	O
of	O
cilnical	O
effetcs	O
,	O
we	O
used	O
[	O
132I	O
]	O
IZBM	O
SEPCT	O
to	O
determine	O
D2	O
occuapncy	O
in	O
subjcets	O
tretaed	O
with	O
routnie	O
cliniacl	O
dsoes	O
of	O
rsiperidone	O
(	O
n	O
=	O
12	O
)	O
or	O
halpoeridol	O
(	O
n	O
=	O
7	O
)	O
.	O

Both	O
risperdione	O
and	O
haloperdiol	O
produced	O
D2	O
ocucpancy	O
leevls	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
stanadrd	O
cilnical	O
dsoes	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
ocucpancy	O
leevls	O
obtained	O
with	O
halpoeridol	O
or	O
risperidnoe	O
.	O

Durg	B-Disease
-	I-Disease
idnuced	I-Disease
prakinsonism	I-Disease
was	O
observed	O
in	O
sujbects	O
traeted	O
with	O
risperidnoe	O
(	O
42	O
%	O
)	O
and	O
halopeirdol	O
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupancy	O
levles	O
above	O
60	O
%	O
.	O

Based	O
on	O
these	O
observatoins	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
blcokade	O
obtained	O
with	O
ripseridone	O
at	O
D2	O
ocucpancy	O
raets	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
rsik	O
for	O
extraypramidal	O
side	O
effcets	O
.	O

Treatemnt	O
of	O
previously	O
tretaed	O
metastaitc	O
bresat	B-Disease
cnacer	I-Disease
by	O
mitoxantorne	O
and	O
48	O
-	O
hour	O
cnotinuous	O
infusoin	O
of	O
high	O
-	O
dsoe	O
5	O
-	O
FU	O
and	O
leucovoirn	O
(	O
MFL	O
)	O
:	O
low	O
pallitaive	O
bneefit	O
and	O
high	O
treamtent	O
-	O
related	O
toxiicty	B-Disease
.	O

For	O
previously	O
tretaed	O
advnaced	O
bresat	B-Disease
canecr	I-Disease
,	O
there	O
is	O
no	O
satndard	O
second	O
-	O
line	O
threapy	O
.	O

Cobmination	O
chemotehrapy	O
with	O
mtioxantrone	O
,	O
high	O
-	O
dsoe	O
5	O
-	O
fluroouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
lecuovorin	O
(	O
MFL	O
reigmen	O
)	O
had	O
been	O
reported	O
as	O
an	O
effcetive	O
and	O
well	O
tolertaed	O
regiemn	O
.	O

From	O
Octboer	O
1993	O
to	O
Noevmber	O
1995	O
,	O
we	O
traeted	O
13	O
patinets	O
with	O
previously	O
chmeotherapy	O
-	O
terated	O
metastaitc	O
bresat	B-Disease
cnacer	I-Disease
by	O
miotxantrone	O
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
and	O
cnotinuous	O
infsuion	O
of	O
5	O
-	O
FU	O
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
leucvoorin	O
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O

Each	O
cuorse	O
of	O
chemothreapy	O
was	O
given	O
every	O
4	O
weeks	O
.	O

Most	O
of	O
these	O
ptaients	O
had	O
more	O
than	O
two	O
metastaitc	O
sties	O
,	O
with	O
lnug	O
metastsais	O
perdominant	O
.	O

Seven	O
paitents	O
had	O
been	O
treaetd	O
with	O
antrhacycline	O
.	O

Seven	O
ptaients	O
had	O
previously	O
received	O
radiotehrapy	O
and	O
seven	O
had	O
received	O
homrone	O
thearpy	O
.	O

Meidan	O
number	O
of	O
couress	O
of	O
MFL	O
regmien	O
given	O
was	O
six	O
and	O
the	O
medain	O
cumulatvie	O
dsoe	O
of	O
mitoaxntrone	O
was	O
68	O
.	O
35	O
mg	O
/	O
m2	O
.	O

One	O
patinet	O
had	O
complete	O
resopnse	O
,	O
seven	O
had	O
stbale	O
diesase	O
,	O
none	O
had	O
partail	O
rseponse	O
and	O
five	O
had	O
progrsesive	O
disaese	O
.	O

The	O
overall	O
obejctive	O
respnose	O
rtae	O
was	O
7	O
.	O
6	O
%	O
.	O

The	O
meidan	O
follow	O
-	O
up	O
preiod	O
was	O
14	O
monhts	O
.	O

Mdeian	O
survvial	O
was	O
16	O
mnoths	O
.	O

Meidan	O
porgression	O
-	O
free	O
sruvival	O
was	O
5	O
mnoths	O
.	O

A	O
complete	O
repsonder	O
had	O
rleapse	O
-	O
free	O
sruvival	O
up	O
to	O
17	O
mnoths	O
.	O

Major	O
toxiciteis	B-Disease
were	O
cardoitoxicity	B-Disease
and	O
leuokpenia	B-Disease
.	O

Eight	O
patietns	O
were	O
daed	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
deid	O
of	O
teratment	O
-	O
related	O
txoicity	B-Disease
.	O

The	O
MFL	O
rgeimen	O
achieves	O
little	O
palliatvie	O
beenfit	O
and	O
inudces	O
sevree	O
txoicity	B-Disease
at	O
a	O
fairly	O
high	O
rtae	O
.	O

Administartion	O
of	O
this	O
regmien	O
to	O
berast	B-Disease
cnacer	I-Disease
pateints	O
who	O
have	O
been	O
treaetd	O
by	O
chemothreapy	O
and	O
those	O
with	O
imapired	B-Disease
haert	I-Disease
fnuction	I-Disease
requires	O
careful	O
attentoin	O
.	O

Ticlpoidine	O
-	O
inudced	O
aplsatic	B-Disease
aenmia	I-Disease
:	O
reoprt	O
of	O
three	O
Chiense	O
paitents	O
and	O
rveiew	O
of	O
the	O
litearture	O
.	O

In	O
this	O
sutdy	O
,	O
three	O
Chiense	O
paitents	O
with	O
tilcopidine	O
-	O
inudced	O
aplsatic	B-Disease
anmeia	I-Disease
were	O
reported	O
and	O
another	O
13	O
patietns	O
in	O
the	O
Enlgish	O
literatrue	O
were	O
reviweed	O
.	O

We	O
attempted	O
to	O
find	O
underlying	O
similariites	O
,	O
evalaute	O
the	O
rsik	O
fatcors	O
,	O
and	O
identify	O
appropriate	O
tretament	O
for	O
this	O
complciation	O
.	O

All	O
but	O
one	O
of	O
the	O
pateints	O
were	O
over	O
60	O
yaers	O
old	O
,	O
and	O
the	O
6	O
who	O
deid	O
were	O
all	O
odler	O
than	O
65	O
.	O

Therefore	O
,	O
old	O
age	O
may	O
be	O
a	O
rsik	O
fcator	O
for	O
developing	O
this	O
compliaction	O
.	O

Agrnaulocytosis	B-Disease
occurred	O
3	O
-	O
20	O
weeks	O
after	O
initiatoin	O
of	O
ticlopiidne	O
,	O
so	O
ferquent	O
eaxmination	O
of	O
whtie	O
clel	O
cuont	O
during	O
treatemnt	O
is	O
recmomended	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correlaiton	O
between	O
the	O
dsoe	O
or	O
duraiton	O
used	O
and	O
the	O
severtiy	O
of	O
bnoe	B-Disease
marorw	I-Disease
suprpession	I-Disease
.	O

Treamtent	O
for	O
ticolpidine	O
-	O
inudced	O
alpastic	B-Disease
aenmia	I-Disease
with	O
cloony	O
-	O
stimluating	O
facotrs	O
seemed	O
to	O
have	O
little	O
efefct	O
.	O

The	O
fact	O
that	O
5	O
of	O
the	O
6	O
pateints	O
who	O
received	O
concurrnet	O
clacium	O
channel	O
blokcers	O
deid	O
,	O
should	O
alert	O
clinciians	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drgus	O
siumltaneously	O
.	O

Upregulatoin	O
of	O
the	O
epxression	O
of	O
vsaopressin	O
gnee	O
in	O
the	O
paraventricluar	O
and	O
surpaoptic	O
nculei	O
of	O
the	O
lithuim	O
-	O
induecd	O
dibaetes	B-Disease
insipiuds	I-Disease
rat	O
.	O

The	O
expression	O
of	O
arignine	O
vasopressin	O
(	O
AVP	O
)	O
gnee	O
in	O
the	O
paraventricluar	O
(	O
PVN	O
)	O
and	O
supraopitc	O
nculei	O
(	O
SON	O
)	O
was	O
invetsigated	O
in	O
rtas	O
with	O
lihtium	O
(	O
Li	O
)	O
-	O
indcued	O
poyluria	B-Disease
,	O
using	O
in	O
situ	O
hyrbidization	O
hisotchemistry	O
and	O
radiomimunoassay	O
.	O

The	O
mlae	O
Wsitar	O
rtas	O
consuming	O
a	O
deit	O
that	O
contained	O
LCil	O
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weeks	O
developed	O
marked	O
poluyria	B-Disease
.	O

The	O
Li	O
-	O
tretaed	O
rtas	O
produced	O
a	O
large	O
voulme	O
of	O
hypotnoic	O
uirne	O
with	O
low	O
inoic	O
concentartions	O
.	O

Plamsa	O
sdoium	O
concnetrations	O
were	O
found	O
to	O
be	O
slightly	O
incresaed	O
in	O
the	O
Li	O
-	O
terated	O
rtas	O
comapred	O
with	O
those	O
in	O
cotnrols	O
.	O

Plamsa	O
concentratoin	O
of	O
AVP	O
and	O
transcritps	O
of	O
AVP	O
gnee	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
incraesed	O
in	O
the	O
Li	O
-	O
traeted	O
rtas	O
comapred	O
with	O
cnotrols	O
.	O

These	O
resluts	O
suggest	O
that	O
dheydration	B-Disease
and	O
/	O
or	O
the	O
actiavtion	O
of	O
visecral	O
affernet	O
inupts	O
may	O
contribute	O
to	O
the	O
eelvation	O
of	O
palsma	O
AVP	O
and	O
the	O
upregulatoin	O
of	O
AVP	O
gnee	O
exrpession	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	O
-	O
inudced	O
dibaetes	B-Disease
inspiidus	I-Disease
rat	O
.	O

Antinociceptvie	O
and	O
antiamnseic	O
porperties	O
of	O
the	O
prseynaptic	O
choilnergic	O
amplfiier	O
PG	O
-	O
9	O
.	O

The	O
antinocicpetive	O
efefct	O
of	O
3	O
alhpa	O
-	O
tropyl	O
2	O
-	O
(	O
p	O
-	O
bromophneyl	O
)	O
porpionate	O
[	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
]	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
s	O
.	O
c	O
.	O
;	O
30	O
-	O
60	O
mg	O
kg	O
-	O
1	O
p	O
.	O
o	O
.	O
;	O
10	O
-	O
30	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
;	O
10	O
-	O
30	O
mircograms	O
/	O
muose	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
examined	O
in	O
mcie	O
,	O
rtas	O
and	O
guniea	O
pgis	O
by	O
use	O
of	O
the	O
hot	O
-	O
pltae	O
,	O
abodminal	O
-	O
constirction	O
,	O
tial	O
-	O
flcik	O
and	O
paw	O
-	O
pressure	O
tetss	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
antinociceptoin	O
peaked	O
15	O
min	O
after	O
injeciton	O
and	O
then	O
slowly	O
diminished	O
.	O

The	O
atninociception	O
produced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
was	O
prevented	O
by	O
the	O
unselective	O
musacrinic	O
antagonsit	O
atrpoine	O
,	O
the	O
M1	O
-	O
selective	O
antagoinsts	O
piernzepine	O
and	O
dicycolmine	O
and	O
the	O
acetylchoilne	O
dpeletor	O
hemciholinium	O
-	O
3	O
,	O
but	O
not	O
by	O
the	O
opiiod	O
atnagonist	O
naolxone	O
,	O
the	O
gamma	O
-	O
aimnobutyric	O
aicdB	O
antagnoist	O
3	O
-	O
aminoporpyl	O
-	O
diehtoxy	O
-	O
mtehyl	O
-	O
phospihnic	O
aicd	O
,	O
the	O
H3	O
agnoist	O
R	O
-	O
(	O
alhpa	O
)	O
-	O
methylihstamine	O
,	O
the	O
D2	O
anatgonist	O
quinpiorle	O
,	O
the	O
5	O
-	O
hydroxytryptmaine4	O
antagoinst	O
2	O
-	O
mtehoxy	O
-	O
4	O
-	O
amnio	O
-	O
5	O
-	O
chlorobenzioc	O
aicd	O
2	O
-	O
(	O
diethylaimno	O
)	O
etyhl	O
etser	O
hydrohcloride	O
,	O
the	O
5	O
-	O
hydroxytryptamin1A	O
antgaonist	O
1	O
-	O
(	O
2	O
-	O
methxoyphenyl	O
)	O
-	O
4	O
-	O
[	O
4	O
-	O
(	O
2	O
-	O
phthalmiido	O
)	O
btuyl	O
]	O
piperaizne	O
hyrdobromide	O
and	O
the	O
polymaines	O
deplteor	O
reseprine	O
.	O

Based	O
on	O
these	O
dtaa	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
exerted	O
an	O
antinociecptive	O
effect	O
mediated	O
by	O
a	O
cenrtal	O
potentiaiton	O
of	O
chloinergic	O
trasnmission	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
able	O
to	O
preevnt	O
amnseia	B-Disease
indcued	O
by	O
scopolmaine	O
(	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
and	O
dicyclmoine	O
(	O
2	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
in	O
the	O
muose	O
passive	O
-	O
avoidnace	O
tset	O
.	O

Affiinty	O
porfiles	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
for	O
msucarinic	O
rceeptor	O
subtyeps	O
,	O
determined	O
by	O
funcitonal	O
stuides	O
(	O
rabibt	O
vas	O
defreens	O
for	O
M1	O
,	O
guniea	O
pig	O
atirum	O
for	O
M2	O
,	O
guniea	O
pig	O
ielum	O
for	O
M3	O
and	O
immature	O
giunea	O
pig	O
utreus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4	O
/	O
M1	O
seelctivity	O
rtaio	O
of	O
10	O
.	O
2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinocicetpion	O
and	O
the	O
atni	O
-	O
amneisc	B-Disease
efefct	O
inudced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
through	O
an	O
incresae	O
in	O
acetylcohline	O
extracellualr	O
leevls	O
.	O

In	O
the	O
atninociceptive	O
and	O
antimanesic	O
dsoe	O
range	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
did	O
not	O
ipmair	O
mosue	O
performacne	O
evalutaed	O
by	O
the	O
rtoa	O
-	O
rod	O
tset	O
and	O
Anmiex	O
appartaus	O
.	O

The	O
effect	O
of	O
different	O
anaeshtetic	O
agetns	O
in	O
haering	B-Disease
lsos	I-Disease
following	O
spnial	O
anasethesia	O
.	O

The	O
cause	O
of	O
haering	B-Disease
lsos	I-Disease
after	O
spianl	O
anaestehsia	O
is	O
unknown	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
fcator	O
studied	O
has	O
been	O
the	O
effcet	O
of	O
the	O
diamteer	O
of	O
the	O
spnial	O
nedele	O
on	O
psot	O
-	O
operaitve	O
sensoirneural	B-Disease
hearnig	I-Disease
lsos	I-Disease
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
describe	O
this	O
heairng	B-Disease
lsos	I-Disease
and	O
to	O
investiagte	O
other	O
fcators	O
influecning	O
the	O
degere	O
of	O
heairng	B-Disease
lsos	I-Disease
.	O

Two	O
gropus	O
of	O
22	O
similar	O
paitents	O
were	O
studied	O
:	O
one	O
gorup	O
received	O
6	O
mL	O
prilocanie	O
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivcaaine	O
0	O
.	O
5	O
%	O
.	O

Pateints	O
given	O
prilcoaine	O
were	O
more	O
likely	O
to	O
develop	O
heraing	B-Disease
lsos	I-Disease
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupviacaine	O
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
avreage	O
heairng	B-Disease
lsos	I-Disease
for	O
speceh	O
freqeuncies	O
was	O
about	O
10	O
dB	O
after	O
prliocaine	O
and	O
15	O
dB	O
after	O
bpuivacaine	O
.	O

None	O
of	O
the	O
ptaients	O
complained	O
of	O
subjetcive	O
hearnig	B-Disease
lsos	I-Disease
.	O

Lnog	O
-	O
term	O
follow	O
-	O
up	O
of	O
the	O
pateints	O
was	O
not	O
possible	O
.	O

A	O
tarnsient	O
neurloogical	B-Disease
deifcit	I-Disease
following	O
intratehcal	O
inejction	O
of	O
1	O
%	O
hyperbraic	O
bupivcaaine	O
for	O
uinlateral	O
spianl	O
aanesthesia	O
.	O

We	O
describe	O
a	O
csae	O
of	O
trasnient	O
neuorlogical	B-Disease
defciit	I-Disease
that	O
occurred	O
after	O
unilaetral	O
sipnal	O
anasethesia	O
with	O
8	O
mg	O
of	O
1	O
%	O
hyperbraic	O
bupivaciane	O
slowly	O
injceted	O
through	O
a	O
25	O
-	O
guage	O
pnecil	O
-	O
point	O
spianl	O
needle	O
.	O

The	O
suregry	O
and	O
anaesthseia	O
were	O
unevnetful	O
,	O
but	O
3	O
dyas	O
after	O
surgrey	O
,	O
the	O
patinet	O
reported	O
an	O
aera	O
of	O
hyopaesthesia	O
over	O
L3	O
-	O
L4	O
drematomes	O
of	O
the	O
leg	O
which	O
had	O
been	O
operaetd	O
on	O
(	O
lsos	B-Disease
of	I-Disease
pinrpick	I-Disease
sensaiton	I-Disease
)	O
without	O
redcution	O
in	O
musuclar	O
strentgh	O
.	O

Senstaion	O
in	O
this	O
aera	O
returned	O
to	O
noraml	O
over	O
the	O
following	O
2	O
weeks	O
.	O

Porspective	O
multiecntre	O
stuides	O
with	O
a	O
large	O
popluation	O
and	O
a	O
long	O
follow	O
-	O
up	O
should	O
be	O
performed	O
in	O
order	O
to	O
evalaute	O
the	O
icnidence	O
of	O
this	O
unsuual	O
side	O
efefct	O
.	O

However	O
,	O
we	O
suggest	O
that	O
a	O
low	O
soluiton	O
cocnentration	O
should	O
be	O
preferred	O
for	O
unilaetral	O
spnial	O
aneasthesia	O
with	O
a	O
hyperabric	O
aneasthetic	O
sloution	O
(	O
if	O
penicl	O
-	O
point	O
neelde	O
and	O
slow	O
injetcion	O
rtae	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
rsik	O
of	O
a	O
localzied	O
high	O
peak	O
anaesthteic	O
concentartion	O
,	O
which	O
might	O
lead	O
to	O
a	O
transinet	O
neurloogical	B-Disease
deifcit	I-Disease
.	O

Transeint	B-Disease
nuerologic	I-Disease
symtpoms	I-Disease
after	O
sipnal	O
aneshtesia	O
:	O
a	O
loewr	O
incidecne	O
with	O
prliocaine	O
and	O
bupivacanie	O
than	O
with	O
liodcaine	O
.	O

BACKGRONUD	O
:	O
Recent	O
evdience	O
suggests	O
that	O
trasnient	B-Disease
neruologic	I-Disease
smyptoms	I-Disease
(	O
TSNs	B-Disease
)	O
frequently	O
follow	O
lidoacine	O
sipnal	O
anestehsia	O
but	O
are	O
infrequnet	O
with	O
bupivaacine	O
.	O

However	O
,	O
identificaiton	O
of	O
a	O
short	O
-	O
acting	O
lcoal	O
anestheitc	O
to	O
substitute	O
for	O
liodcaine	O
for	O
brief	O
surgcial	O
porcedures	O
remains	O
an	O
important	O
gaol	O
.	O

Priolcaine	O
is	O
an	O
aimde	O
loacl	O
anesthteic	O
with	O
a	O
duratoin	O
of	O
atcion	O
similar	O
to	O
that	O
of	O
lidcoaine	O
.	O

Accordingly	O
,	O
the	O
present	O
,	O
prospectvie	O
double	O
-	O
bilnd	O
stduy	O
compaers	O
pirlocaine	O
with	O
lidocanie	O
and	O
buipvacaine	O
with	O
respect	O
to	O
duartion	O
of	O
atcion	O
and	O
relative	O
rsik	O
of	O
TSNs	B-Disease
.	O

METHODS	O
:	O
Ninety	O
pateints	O
classified	O
as	O
Ameircan	O
Soicety	O
of	O
Anesthesiloogists	O
phsyical	O
sattus	O
I	O
or	O
II	O
who	O
were	O
scheudled	O
for	O
short	O
gynecolgoic	O
porcedures	O
under	O
spnial	O
anesthseia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2	O
.	O
5	O
ml	O
2	O
%	O
liodcaine	O
in	O
7	O
.	O
5	O
%	O
gluocse	O
,	O
2	O
%	O
prilocanie	O
in	O
7	O
.	O
5	O
%	O
gulcose	O
,	O
or	O
0	O
.	O
5	O
%	O
buipvacaine	O
in	O
7	O
.	O
5	O
%	O
glucsoe	O
.	O

All	O
soluitons	O
were	O
provided	O
in	O
blidned	O
vails	O
by	O
the	O
hosptial	O
phamracy	O
.	O

Details	O
of	O
spianl	O
puntcure	O
,	O
extenison	O
and	O
regression	O
of	O
spianl	O
bolck	O
,	O
and	O
the	O
times	O
to	O
reach	O
dicsharge	O
cirteria	O
were	O
noted	O
.	O

In	O
the	O
eevning	O
of	O
posotperative	O
day	O
1	O
,	O
patietns	O
were	O
eavluated	O
for	O
TSNs	B-Disease
by	O
a	O
physicain	O
unaware	O
of	O
the	O
durg	O
admniistered	O
and	O
the	O
details	O
of	O
the	O
ansethetic	O
procdeure	O
.	O

RESLUTS	O
:	O
Nine	O
of	O
30	O
paitents	O
receiving	O
lidociane	O
experienced	O
TSNs	B-Disease
,	O
1	O
of	O
30	O
patietns	O
receiving	O
pirlocaine	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patietns	O
receiving	O
bupiavcaine	O
had	O
TSNs	B-Disease
.	O

Tmies	O
to	O
ambultae	O
and	O
to	O
viod	O
were	O
similar	O
after	O
lidocanie	O
and	O
pirlocaine	O
(	O
150	O
vs	O
.	O
165	O
min	O
and	O
238	O
vs	O
.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
prloonged	O
after	O
buipvacaine	O
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLSUIONS	O
:	O
Prilociane	O
may	O
be	O
preferable	O
to	O
lidcoaine	O
for	O
short	O
surgcial	O
porcedures	O
because	O
it	O
has	O
a	O
similar	O
duratoin	O
of	O
aciton	O
but	O
a	O
lwoer	O
incidecne	O
of	O
TSNs	B-Disease
.	O

Suaxmethonium	O
-	O
inudced	O
cardaic	B-Disease
arrset	I-Disease
and	O
detah	B-Disease
following	O
5	O
dyas	O
of	O
imombilization	O
.	O

The	O
present	O
reoprt	O
describes	O
a	O
csae	O
of	O
caridac	B-Disease
arerst	I-Disease
and	O
subsequent	O
daeth	B-Disease
as	O
a	O
result	O
of	O
hyeprkalaemia	B-Disease
following	O
the	O
use	O
of	O
suxamtehonium	O
in	O
a	O
23	O
-	O
yaer	O
-	O
old	O
Maalwian	O
woamn	O
.	O

Five	O
dyas	O
after	O
the	O
onset	O
of	O
the	O
symtpoms	O
of	O
mennigitis	B-Disease
,	O
the	O
pateint	O
aspiraetd	O
sotmach	O
cnotents	O
and	O
needed	O
endortacheal	O
intuabtion	O
.	O

Forty	O
seconds	O
after	O
ijnection	O
of	O
suxamtehonium	O
,	O
bradyacrdia	B-Disease
and	O
cardaic	B-Disease
arrest	I-Disease
occurred	O
.	O

Attempts	O
to	O
rseuscitate	O
the	O
ptaient	O
were	O
not	O
successful	O
.	O

The	O
sreum	O
lveel	O
of	O
ptoassium	O
was	O
observed	O
to	O
be	O
8	O
.	O
4	O
mequiv	O
L	O
-	O
1	O
.	O

Apart	O
from	O
the	O
redcution	O
in	O
the	O
paitent	O
'	O
s	O
leevl	O
of	O
cosnciousness	O
,	O
there	O
were	O
no	O
sgins	O
of	O
mootr	O
neruone	O
damgae	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
perdisposing	O
conditinos	O
for	O
hyeprkalaemia	B-Disease
following	O
the	O
adimnistration	O
of	O
suxamethonuim	O
.	O

It	O
is	O
postulated	O
that	O
her	O
detah	B-Disease
was	O
caused	O
by	O
hypersenstiivity	B-Disease
to	O
suxmaethonium	O
,	O
associated	O
with	O
her	O
5	O
-	O
day	O
immoiblization	O
.	O

Aucte	O
hepaittis	B-Disease
,	O
autoimumne	B-Disease
hemloytic	I-Disease
aenmia	I-Disease
,	O
and	O
erythroblastcoytopenia	B-Disease
indcued	O
by	O
ceftiraxone	O
.	O

An	O
80	O
-	O
yr	O
-	O
old	O
man	O
developed	O
aucte	O
hepaittis	B-Disease
shortly	O
after	O
inegsting	O
oarl	O
cetfriaxone	O
.	O

Although	O
the	O
transmainases	O
gradually	O
returned	O
to	O
baselnie	O
after	O
wihtholding	O
the	O
btea	O
latcam	O
antibioitc	O
,	O
there	O
was	O
a	O
gradaul	O
icnrease	O
in	O
sreum	O
bliirubin	O
and	O
a	O
decerase	O
in	O
hemogolbin	O
concetnration	O
caused	O
by	O
an	O
automimune	B-Disease
hmeolytic	I-Disease
aneima	I-Disease
and	O
erythroblasotcytopenia	B-Disease
.	O

These	O
responded	O
to	O
ssytemic	O
steorids	O
and	O
immnuoglobulins	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
agetns	O
this	O
tirad	O
of	O
side	O
effcets	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connectoin	O
with	O
btea	O
lcatam	O
atnibiotics	O
.	O

Thyorxine	O
absue	O
:	O
an	O
unuusal	O
csae	O
of	O
thryotoxicosis	B-Disease
in	O
pergnancy	O
.	O

Eaitng	B-Disease
diosrders	I-Disease
and	O
the	O
associated	O
behaviorual	O
porblems	O
and	O
durg	B-Disease
aubse	I-Disease
are	O
uncommon	O
in	O
pregnacny	O
.	O

When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
dneial	O
but	O
when	O
significant	O
may	O
pose	O
a	O
rsik	O
to	O
both	O
the	O
mohter	O
and	O
her	O
fteus	O
.	O

This	O
csae	O
illustrates	O
a	O
number	O
of	O
problmes	O
that	O
may	O
be	O
encountered	O
in	O
woemn	O
with	O
etaing	B-Disease
disroders	I-Disease
in	O
prengancy	O
,	O
including	O
porlonged	O
and	O
recurrnet	O
mteabolic	O
disturbacnes	O
and	O
diurteic	O
aubse	O
.	O

In	O
particular	O
it	O
illustrates	O
the	O
derangemnets	O
of	O
thyorid	O
functoin	O
seen	O
in	O
prgenant	O
wmoen	O
with	O
eaitng	B-Disease
disroders	I-Disease
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
tyhrotoxicosis	B-Disease
remains	O
obscure	O
,	O
thyroixne	O
aubse	O
should	O
be	O
considered	O
and	O
explored	O
.	O

Repaeted	O
trmiipramine	O
indcues	O
dopmaine	O
D2	O
/	O
D3	O
and	O
aplha1	O
-	O
adrenerigc	O
up	O
-	O
regulaiton	O
.	O

Triimpramine	O
(	O
TRI	O
)	O
,	O
which	O
shows	O
a	O
clniical	O
atnidepressant	O
atcivity	O
,	O
is	O
cehmically	O
related	O
to	O
iimpramine	O
but	O
does	O
not	O
inhiibt	O
the	O
reutpake	O
of	O
noradrnealine	O
and	O
5	O
-	O
hydroxtyryptamine	O
,	O
nor	O
does	O
it	O
indcue	O
btea	O
-	O
ardenergic	O
down	O
-	O
rgeulation	O
.	O

The	O
mecahnism	O
of	O
its	O
atnidepressant	O
actiivty	O
is	O
still	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
find	O
out	O
whether	O
TRI	O
given	O
repeatedly	O
was	O
able	O
to	O
idnuce	O
adaptvie	O
chanegs	O
in	O
the	O
doapminergic	O
and	O
aplha1	O
-	O
adrenregic	O
ssytems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
anitdepressants	O
.	O

TRI	O
was	O
given	O
to	O
mlae	O
Witsar	O
rtas	O
and	O
mlae	O
Albnio	O
Swsis	O
mcie	O
perroally	O
twice	O
daliy	O
for	O
14	O
dyas	O
.	O

In	O
the	O
actue	O
experimnet	O
TRI	O
(	O
given	O
i	O
.	O
p	O
.	O
)	O
does	O
not	O
antagoinze	O
the	O
reseripne	O
hypothemria	B-Disease
in	O
mcie	O
and	O
does	O
not	O
potnetiate	O
the	O
5	O
-	O
hyrdoxytryptophan	O
haed	O
twithces	O
in	O
rtas	O
.	O

TRI	O
given	O
repeatedly	O
to	O
rtas	O
inrceases	O
the	O
loocmotor	O
hyepractivity	B-Disease
idnuced	O
by	O
d	O
-	O
apmhetamine	O
,	O
quinpriole	O
and	O
(	O
+	O
)	O
-	O
7	O
-	O
hyrdoxy	O
-	O
dipropyloaminotetarlin	O
(	O
dpoamine	O
D2	O
and	O
D3	O
effects	O
)	O
.	O

The	O
steerotypies	O
induecd	O
by	O
d	O
-	O
apmhetamine	O
or	O
apomorhpine	O
are	O
not	O
potetniated	O
by	O
TRI	O
.	O

It	O
incraeses	O
the	O
behaviuor	O
stimualtion	O
eovked	O
by	O
phenlyephrine	O
(	O
given	O
intraventriculraly	O
)	O
in	O
rtas	O
,	O
evalutaed	O
in	O
the	O
open	O
field	O
tset	O
as	O
well	O
as	O
the	O
aggressiveness	B-Disease
evkoed	O
by	O
clnoidine	O
in	O
mcie	O
,	O
both	O
these	O
efefcts	O
being	O
mediated	O
by	O
an	O
alhpa1	O
-	O
adrenerigc	O
rceeptor	O
.	O

It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricycilc	O
antidepressnats	O
studied	O
previously	O
,	O
TRI	O
given	O
repeatedly	O
incraeses	O
the	O
responisveness	O
of	O
brian	O
dopaimne	O
D2	O
and	O
D3	O
(	O
locmootor	O
actviity	O
but	O
not	O
stereotpyy	O
)	O
as	O
well	O
as	O
alhpa1	O
-	O
adreenrgic	O
recepotrs	O
to	O
their	O
aognists	O
.	O

A	O
question	O
arises	O
whether	O
the	O
reputake	O
ihnibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adapitve	O
cahnges	O
inudced	O
by	O
reepated	O
antideprsesants	O
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepressnat	O
activtiy	O
.	O

Pethiidne	O
-	O
associated	O
siezure	B-Disease
in	O
a	O
healhty	O
adolescnet	O
receiving	O
petihdine	O
for	O
postoperatvie	B-Disease
pian	I-Disease
contorl	O
.	O

A	O
heatlhy	O
17	O
-	O
yaer	O
-	O
old	O
mlae	O
received	O
stanadrd	O
inetrmittent	O
doess	O
of	O
pehtidine	O
via	O
a	O
paitent	O
-	O
conrtolled	O
anaglesia	O
(	O
PCA	O
)	O
pmup	O
for	O
maangement	O
of	O
postopertaive	B-Disease
pian	I-Disease
conrtol	O
.	O

Twenty	O
-	O
three	O
h	O
postoperaitvely	O
he	O
developed	O
a	O
brief	O
slef	O
-	O
limtied	O
seziure	B-Disease
.	O

Both	O
plamsa	O
pethidnie	O
and	O
norepthidine	O
were	O
elevaetd	O
in	O
the	O
range	O
associated	O
with	O
clniical	O
manifsetations	O
of	O
cenrtal	O
nrevous	O
sytsem	O
excitaiton	O
.	O

No	O
other	O
rsik	O
factros	O
for	O
CNS	O
toxictiy	B-Disease
were	O
idenitfied	O
.	O

This	O
metohd	O
allowed	O
ferquent	O
slef	O
-	O
dosnig	O
of	O
pehtidine	O
at	O
short	O
tmie	O
intrevals	O
and	O
rpaid	O
accmuulation	O
of	O
pethiidne	O
and	O
nropethidine	O
.	O

The	O
rotuine	O
use	O
of	O
pethidnie	O
via	O
PCA	O
even	O
for	O
a	O
brief	O
posotperative	O
aanlgesia	O
should	O
be	O
reconsidered	O
.	O

An	O
uunsual	O
toixc	O
reatcion	O
to	O
axillray	O
bolck	O
by	O
mepiavcaine	O
with	O
adernaline	O
.	O

An	O
inrcease	B-Disease
in	I-Disease
blood	I-Disease
perssure	I-Disease
,	O
accompanied	O
by	O
atrail	B-Disease
fibrilltaion	I-Disease
,	O
agiattion	B-Disease
,	O
incomprehensible	B-Disease
shouts	I-Disease
and	O
lsos	B-Disease
of	I-Disease
consicousness	I-Disease
,	O
was	O
observed	O
in	O
an	O
edlerly	O
,	O
ASA	O
classificatoin	O
gorup	O
II	O
,	O
cardiovsacularly	O
mdeicated	O
mlae	O
,	O
12	O
min	O
after	O
preformance	O
of	O
axillray	O
blcok	O
with	O
mepivaciane	O
850	O
mg	O
containing	O
adrnealine	O
0	O
.	O
225	O
mg	O
,	O
for	O
corrcetion	O
of	O
Duupytren	B-Disease
'	I-Disease
s	I-Disease
contarcture	I-Disease
.	O

After	O
intraveonus	O
administratoin	O
of	O
labetaoll	O
,	O
metoprooll	O
and	O
mdiazolam	O
the	O
pateint	O
'	O
s	O
conidtion	O
ipmroved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

The	O
bolck	O
was	O
successful	O
and	O
suregry	O
was	O
conducted	O
as	O
schedueld	O
despite	O
persisting	O
atrail	B-Disease
fibrilaltion	I-Disease
.	O

Postopeartively	O
,	O
the	O
pateint	O
refused	O
DC	O
cardiovesrion	O
and	O
was	O
terated	O
medcially	O
.	O

Both	O
the	O
tempoarl	O
relatinoship	O
of	O
evnets	O
and	O
the	O
resopnse	O
to	O
tretament	O
suggest	O
that	O
a	O
rpaid	O
ssytemic	O
absortpion	O
of	O
mpeivacaine	O
with	O
ardenaline	O
and	O
/	O
or	O
intearction	O
of	O
these	O
drgus	O
with	O
the	O
patinet	O
'	O
s	O
cradiovascular	O
medicaitons	O
were	O
responsible	O
for	O
the	O
perioeprative	O
compliactions	O
.	O

Durg	O
-	O
associated	O
aucte	O
-	O
onset	O
vanishing	B-Disease
blie	I-Disease
dcut	I-Disease
and	O
Setvens	B-Disease
-	I-Disease
Johnosn	I-Disease
syndroems	I-Disease
in	O
a	O
chlid	O
.	O

Actue	O
vanishing	B-Disease
blie	I-Disease
dcut	I-Disease
synrdome	O
is	O
a	O
rrae	O
but	O
established	O
cause	O
of	O
progressvie	O
chloestasis	B-Disease
in	O
adluts	O
,	O
is	O
most	O
often	O
durg	O
or	O
toixn	O
related	O
,	O
and	O
is	O
of	O
unknown	O
pathoegnesis	O
.	O

It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
chlidren	O
.	O

Stevnes	B-Disease
-	I-Disease
Jhonson	I-Disease
syndrmoe	I-Disease
is	O
a	O
well	O
-	O
recognized	O
imumne	O
compelx	O
-	O
mediated	O
hyperesnsitivity	B-Disease
reatcion	O
that	O
affects	O
all	O
age	O
gruops	O
,	O
is	O
durg	O
or	O
inefction	B-Disease
idnuced	O
,	O
and	O
has	O
classic	O
systeimc	O
,	O
mcuosal	O
,	O
and	O
dermatloogic	O
manifesttaions	O
.	O

A	O
previously	O
haelthy	O
chlid	O
who	O
developed	O
actue	O
,	O
seevre	O
,	O
rapidly	O
progressvie	O
vanishing	B-Disease
blie	I-Disease
dcut	I-Disease
snydrome	I-Disease
shortly	O
after	O
Steevns	B-Disease
-	I-Disease
Jonhson	I-Disease
sydnrome	I-Disease
is	O
described	O
;	O
this	O
was	O
temproally	O
associated	O
with	O
ibuporfen	O
use	O
.	O

Despite	O
tehrapy	O
with	O
ursodeoxychloic	O
aicd	O
,	O
predniosne	O
,	O
and	O
then	O
tacorlimus	O
,	O
her	O
chloestatic	B-Disease
dsiease	I-Disease
was	O
unrleenting	O
,	O
with	O
cirrhsois	B-Disease
shown	O
by	O
biospy	O
6	O
monhts	O
after	O
presentatoin	O
.	O

This	O
csae	O
documetns	O
aucte	O
durg	O
-	O
related	O
vanishing	B-Disease
blie	I-Disease
dcut	I-Disease
sydnrome	I-Disease
in	O
the	O
pedaitric	O
age	O
gorup	O
and	O
suggests	O
shared	O
imumne	O
mechnaisms	O
in	O
the	O
pathogenseis	O
of	O
both	O
Setvens	B-Disease
-	I-Disease
Johnosn	I-Disease
snydrome	I-Disease
and	O
vanishing	B-Disease
blie	I-Disease
dcut	I-Disease
syndrmoe	I-Disease
.	O

High	O
inciednce	O
of	O
prmiary	B-Disease
plumonary	I-Disease
hyeprtension	I-Disease
associated	O
with	O
appteite	O
suprpessants	O
in	O
Blegium	O
.	O

Priamry	B-Disease
pumlonary	I-Disease
hypertesnion	I-Disease
is	O
a	O
rrae	O
,	O
progressvie	O
and	O
incurable	O
diesase	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
inatke	O
of	O
appeitte	O
supprsesant	O
drgus	O
.	O

The	O
importance	O
of	O
this	O
associtaion	O
was	O
evalutaed	O
in	O
Blegium	O
while	O
this	O
counrty	O
still	O
had	O
no	O
restriciton	O
on	O
the	O
prescritpion	O
of	O
appettie	O
suppressnats	O
.	O

Thirty	O
-	O
five	O
patinets	O
with	O
pirmary	B-Disease
pulomnary	I-Disease
hyperetnsion	I-Disease
and	O
85	O
matched	O
contrlos	O
were	O
recruited	O
over	O
32	O
monhts	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Beligum	O
.	O

Exopsure	O
to	O
appteite	O
-	O
suppressants	O
was	O
asesssed	O
on	O
the	O
basis	O
of	O
hospiatl	O
recrods	O
and	O
stadnardized	O
intevriew	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
patietns	O
had	O
previously	O
taken	O
appettie	O
suppressnats	O
,	O
mainly	O
fenfluramines	O
,	O
as	O
compraed	O
with	O
only	O
5	O
of	O
the	O
cotnrols	O
(	O
66	O
versus	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Five	O
pateints	O
deid	O
before	O
the	O
interveiw	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	O
spupressants	O
.	O

In	O
8	O
paitents	O
the	O
diagnsois	O
of	O
priamry	B-Disease
pulmnoary	I-Disease
hypetrension	I-Disease
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appeitte	O
suppressatns	O
.	O

The	O
pateints	O
who	O
had	O
been	O
epxosed	O
to	O
appettie	O
suppressants	O
tended	O
to	O
be	O
on	O
avreage	O
more	O
severley	O
ill	O
,	O
and	O
to	O
have	O
a	O
shoretr	O
mdeian	O
dleay	O
between	O
onset	O
of	O
smyptoms	O
and	O
diangosis	O
.	O

A	O
ploicy	O
of	O
unrestricted	O
prescrpition	O
of	O
appetite	O
suppressants	O
may	O
lead	O
to	O
a	O
high	O
incidecne	O
of	O
associated	O
primray	B-Disease
pumlonary	I-Disease
hpyertension	I-Disease
.	O

Intkae	O
of	O
appteite	O
suppressnats	O
may	O
accelerate	O
the	O
prgoression	O
of	O
the	O
disaese	O
.	O

Inappropritae	O
use	O
of	O
carabmazepine	O
and	O
vigabtarin	O
in	O
typical	O
abesnce	B-Disease
siezures	I-Disease
.	O

Carbamaezpine	O
and	O
vgiabatrin	O
are	O
cotnraindicated	O
in	O
typical	O
absecne	B-Disease
seiuzres	I-Disease
.	O

Of	O
18	O
conescutive	O
reefrrals	O
of	O
chlidren	O
with	O
reisstant	O
typical	O
asbences	O
only	O
,	O
eight	O
were	O
erroneously	O
traeted	O
with	O
carbaamzepine	O
either	O
as	O
moontherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O

Vigaabtrin	O
was	O
also	O
used	O
in	O
the	O
treamtent	O
of	O
two	O
chidlren	O
.	O

Frequecny	O
of	O
absenecs	O
incerased	O
in	O
four	O
childern	O
traeted	O
with	O
carbamazpeine	O
and	O
two	O
of	O
these	O
developed	O
moyclonic	B-Disease
jreks	I-Disease
,	O
which	O
resolved	O
on	O
wtihdrawal	O
of	O
carbamzaepine	O
.	O

Absecnes	O
were	O
aggraavted	O
in	O
both	O
csaes	O
where	O
vigabtarin	O
was	O
added	O
on	O
to	O
cocnurrent	O
treatmnet	O
.	O

Optmial	O
cotnrol	O
of	O
the	O
absneces	O
was	O
achieved	O
with	O
soduim	O
valrpoate	O
,	O
lamotriigne	O
,	O
or	O
ehtosuximide	O
alone	O
or	O
in	O
combinaiton	O
.	O

Choreaothetoid	B-Disease
movemnets	I-Disease
associated	O
with	O
raipd	O
adjustemnt	O
to	O
mtehadone	O
.	O

Cohreatiform	B-Disease
hyperkinseias	I-Disease
are	O
known	O
to	O
be	O
occasional	O
movemnet	B-Disease
abnomralities	I-Disease
during	O
inotxications	O
with	O
cociane	O
but	O
not	O
opiaets	O
.	O

This	O
is	O
a	O
csae	O
reprot	O
of	O
epuhoria	O
and	O
choreoatehtoid	B-Disease
moveemnts	I-Disease
both	O
tarnsiently	O
indcued	O
by	O
raipd	O
adjsutment	O
to	O
the	O
selective	O
mu	O
-	O
opiiod	O
reecptor	O
agonsit	O
methadnoe	O
in	O
an	O
ipnatient	O
previously	O
abuisng	O
heronie	O
and	O
cociane	O
.	O

In	O
addition	O
,	O
minor	O
EEG	O
anbormalities	O
occurred	O
.	O

Possible	O
underlying	O
neruobiological	O
phenomnea	O
are	O
discussed	O
.	O

Avderse	O
effcets	O
of	O
the	O
atpyical	O
antipsychotcis	O
.	O

Collaboratvie	O
Worknig	O
Gruop	O
on	O
Cliniacl	O
Trail	O
Evaulations	O
.	O

Adevrse	O
effetcs	O
of	O
antipsyhcotics	O
often	O
lead	O
to	O
noncomplaince	O
.	O

Thus	O
,	O
cliincians	O
should	O
address	O
patinets	O
'	O
cocnerns	O
about	O
advesre	O
efefcts	O
and	O
attempt	O
to	O
choose	O
medictaions	O
that	O
will	O
imporve	O
their	O
paitents	O
'	O
qulaity	O
of	O
lfie	O
as	O
well	O
as	O
overall	O
haelth	O
.	O

The	O
side	O
effcet	O
profiels	O
of	O
the	O
atpyical	O
atnipsychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventinoal	O
neurolpetics	O
.	O

Conventioanl	O
agnets	O
are	O
associated	O
with	O
unwanted	O
cenrtal	O
nerovus	O
ssytem	O
effetcs	O
,	O
including	O
extrpayramidal	B-Disease
smyptoms	I-Disease
(	O
EPS	B-Disease
)	O
,	O
taridve	B-Disease
dsykinesia	I-Disease
,	O
sedtaion	O
,	O
and	O
possible	O
ipmairment	O
of	O
some	O
cognitvie	O
measuers	O
,	O
as	O
well	O
as	O
cadriac	O
effects	O
,	O
otrhostatic	B-Disease
hypoetnsion	I-Disease
,	O
heptaic	O
cahnges	O
,	O
anticholienrgic	O
side	O
effetcs	O
,	O
sxeual	B-Disease
dysufnction	I-Disease
,	O
and	O
wegiht	B-Disease
gain	I-Disease
.	O

The	O
newer	O
atyipcal	O
aegnts	O
have	O
a	O
lwoer	O
rsik	O
of	O
EPS	B-Disease
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
seadtion	O
,	O
cardiovascluar	O
effcets	O
,	O
antichloinergic	O
efefcts	O
,	O
weihgt	B-Disease
gain	I-Disease
,	O
sxeual	B-Disease
dysufnction	I-Disease
,	O
hepaitc	O
effects	O
,	O
lwoered	O
seziure	B-Disease
threhsold	O
(	O
primarily	O
clozpaine	O
)	O
,	O
and	O
agranulcoytosis	B-Disease
(	O
clozpaine	O
only	O
)	O
.	O

Since	O
the	O
incidecne	O
and	O
sevreity	O
of	O
specific	O
advesre	O
effcets	O
differ	O
among	O
the	O
various	O
atypcials	O
,	O
the	O
cilnician	O
should	O
carefully	O
consider	O
which	O
side	O
effcets	O
are	O
most	O
likely	O
to	O
lead	O
to	O
the	O
idnividual	O
'	O
s	O
dissatsifaction	O
and	O
noncopmliance	O
before	O
choosing	O
an	O
antipsychoitc	O
for	O
a	O
particular	O
patinet	O
.	O

A	O
randoimzed	O
,	O
plaecbo	O
-	O
cnotrolled	O
dsoe	O
-	O
cmoparison	O
trail	O
of	O
haloepridol	O
for	O
psychoiss	B-Disease
and	O
disurptive	B-Disease
bheaviors	I-Disease
in	O
Alzhemier	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
.	O

OBJECITVE	O
:	O
The	O
gaol	O
of	O
this	O
stduy	O
was	O
to	O
cmopare	O
the	O
efficcay	O
and	O
side	O
efefcts	O
of	O
two	O
doess	O
of	O
haloperdiol	O
and	O
plaecbo	O
in	O
the	O
traetment	O
of	O
pscyhosis	B-Disease
and	O
disrutpive	B-Disease
behvaiors	I-Disease
in	O
ptaients	O
with	O
Alzheiemr	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
.	O

METHOD	O
:	O
In	O
a	O
6	O
-	O
week	O
rnadom	O
-	O
assginment	O
,	O
double	O
-	O
bilnd	O
,	O
plaecbo	O
-	O
conrtolled	O
trail	O
(	O
pahse	O
A	O
)	O
,	O
hlaoperidol	O
,	O
2	O
-	O
3	O
mg	O
/	O
day	O
(	O
stanadrd	O
dsoe	O
)	O
,	O
and	O
haloepridol	O
,	O
0	O
.	O
50	O
-	O
0	O
.	O
75	O
mg	O
/	O
day	O
(	O
low	O
dsoe	O
)	O
,	O
were	O
compraed	O
in	O
71	O
ouptatients	O
with	O
Alzhiemer	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
.	O

For	O
the	O
subsequent	O
6	O
-	O
week	O
double	O
-	O
blnid	O
crososver	O
phsae	O
(	O
pahse	O
B	O
)	O
,	O
ptaients	O
taking	O
stnadard	O
-	O
or	O
low	O
-	O
dsoe	O
hlaoperidol	O
were	O
switched	O
to	O
plcaebo	O
,	O
and	O
patietns	O
taking	O
palcebo	O
were	O
randomly	O
assigned	O
to	O
stnadard	O
-	O
or	O
low	O
-	O
dsoe	O
halopeirdol	O
.	O

REUSLTS	O
:	O
For	O
the	O
60	O
patinets	O
who	O
completed	O
pahse	O
A	O
,	O
standrad	O
-	O
dsoe	O
haloepridol	O
was	O
efficacious	O
and	O
superior	O
to	O
both	O
low	O
-	O
dsoe	O
haloperiodl	O
and	O
plaecbo	O
for	O
scroes	O
on	O
the	O
Breif	O
Psychaitric	O
Raitng	O
Sclae	O
pyschosis	B-Disease
facotr	O
and	O
on	O
pyschomotor	B-Disease
agtiation	I-Disease
.	O

Respnose	O
raets	O
according	O
to	O
three	O
stes	O
of	O
crtieria	O
were	O
greater	O
with	O
the	O
satndard	O
dsoe	O
(	O
55	O
%	O
-	O
60	O
%	O
)	O
than	O
the	O
low	O
dsoe	O
(	O
25	O
%	O
-	O
35	O
%	O
)	O
and	O
plaecbo	O
(	O
25	O
%	O
-	O
30	O
%	O
)	O
.	O

The	O
advantage	O
of	O
stnadard	O
dsoe	O
over	O
low	O
dsoe	O
was	O
replicated	O
in	O
pahse	O
B	O
.	O

In	O
pahse	O
A	O
,	O
etxrapyramidal	B-Disease
sgins	I-Disease
tended	O
to	O
be	O
greater	O
with	O
the	O
stnadard	O
dsoe	O
than	O
in	O
the	O
other	O
two	O
codnitions	O
,	O
primarily	O
because	O
of	O
a	O
sbugroup	O
(	O
20	O
%	O
)	O
who	O
developed	O
modearte	O
to	O
sveere	O
sings	O
.	O

Low	O
-	O
dsoe	O
haloperdiol	O
did	O
not	O
differ	O
from	O
plaecbo	O
on	O
any	O
meausre	O
of	O
effciacy	O
or	O
side	O
efefcts	O
.	O

CONCLUSINOS	O
:	O
The	O
resluts	O
indicated	O
a	O
favroable	O
therapuetic	O
proflie	O
for	O
halopeirdol	O
in	O
dsoes	O
of	O
2	O
-	O
3	O
mg	O
/	O
day	O
,	O
although	O
a	O
subgruop	O
developed	O
modearte	O
to	O
sevree	O
exrtapyramidal	B-Disease
sings	I-Disease
.	O

A	O
starting	O
dsoe	O
of	O
1	O
mg	O
/	O
day	O
with	O
gradaul	O
,	O
upward	O
dsoe	O
titraiton	O
is	O
recommneded	O
.	O

The	O
narrow	O
therpaeutic	O
winodw	O
observed	O
with	O
haloepridol	O
may	O
also	O
apply	O
to	O
other	O
neuroelptics	O
used	O
in	O
Alzheiemr	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
patinets	O
with	O
pyschosis	B-Disease
and	O
disruptvie	B-Disease
behvaiors	I-Disease
.	O

Effetcs	O
of	O
acetylsalciylic	O
aicd	O
,	O
dipyirdamole	O
,	O
and	O
hydrocoritsone	O
on	O
epinehprine	O
-	O
inudced	O
myocaridal	B-Disease
injruy	I-Disease
in	O
dgos	O
.	O

A	O
reproducible	O
mdoel	O
for	O
producing	O
difufse	O
myocardail	B-Disease
ijnury	I-Disease
(	O
epinpehrine	O
infsuion	O
)	O
has	O
been	O
developed	O
to	O
sutdy	O
the	O
cardiporotective	O
effetcs	O
of	O
aegnts	O
or	O
maenuvers	O
which	O
might	O
alter	O
the	O
evoultion	O
of	O
actue	O
myocadrial	B-Disease
ifnarction	I-Disease
.	O

Inufsions	O
of	O
epinephirne	O
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
incresaed	O
radioaclcium	O
utpakes	O
into	O
intcat	O
myocarduim	O
and	O
each	O
of	O
its	O
sbucellular	O
componnets	O
with	O
the	O
mitochondiral	O
frcation	O
showing	O
the	O
most	O
consistent	O
cahnges	O
when	O
cmopared	O
to	O
sailne	O
-	O
ifnused	O
conrtol	O
aniamls	O
(	O
4	O
,	O
957	O
vs	O
.	O
827	O
coutns	O
per	O
minute	O
per	O
garm	O
of	O
dreid	O
tisuse	O
or	O
fraciton	O
)	O
.	O

Myocadrial	O
concentrtaions	O
of	O
clacium	O
also	O
incresaed	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
wegiht	O
)	O
.	O

Ifnusions	O
of	O
caclium	O
clhoride	O
sufficient	O
to	O
raise	O
sreum	O
calcuim	O
concentraitons	O
2	O
mEq	O
.	O
per	O
liter	O
failed	O
to	O
incraese	O
calcuim	O
ifnlux	O
into	O
the	O
moycardial	O
clel	O
.	O

Mitcohondrial	O
rdaiocalcium	O
upatkes	O
were	O
significantly	O
decraesed	O
in	O
aniamls	O
pretretaed	O
with	O
acetlysalicylic	O
aicd	O
or	O
dipyridaomle	O
or	O
when	O
hydrocotrisone	O
was	O
added	O
to	O
the	O
eipnephrine	O
inufsion	O
(	O
2	O
,	O
682	O
,	O
2	O
,	O
803	O
,	O
and	O
3	O
,	O
424	O
coutns	O
per	O
minute	O
per	O
garm	O
of	O
dired	O
farction	O
,	O
respectively	O
)	O
.	O

Myoacrdial	O
calcuim	O
concentrtaions	O
also	O
were	O
decreaesd	O
(	O
11	O
.	O
2	O
,	O
8	O
.	O
3	O
,	O
and	O
8	O
.	O
9	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
wegiht	O
,	O
respectively	O
)	O
in	O
the	O
three	O
treatmnet	O
gruops	O
,	O
being	O
significantly	O
dcereased	O
only	O
in	O
the	O
last	O
two	O
.	O

Evidnece	O
of	O
mciroscopic	O
daamge	O
was	O
garded	O
as	O
less	O
sevree	O
in	O
the	O
three	O
treamtent	O
gropus	O
.	O

Acetylsaliyclic	O
aicd	O
,	O
dipryidamole	O
,	O
and	O
hydrocotrisone	O
all	O
appear	O
to	O
have	O
cardioproetctive	O
effcets	O
when	O
tesetd	O
in	O
this	O
moedl	O
.	O

Cliincal	O
and	O
histopathoolgic	O
eaxmination	O
of	O
rneal	O
allorgafts	O
terated	O
with	O
tcarolimus	O
(	O
FK056	O
)	O
for	O
at	O
least	O
one	O
yaer	O
.	O

BACKGRUOND	O
:	O
We	O
clniically	O
and	O
pathologiclaly	O
analzyed	O
rneal	O
allogratfs	O
from	O
1	O
9	O
rneal	O
tranpslant	O
pateints	O
treaetd	O
with	O
tacorlimus	O
(	O
FK056	O
)	O
for	O
more	O
than	O
1	O
yaer	O
.	O

METHODS	O
:	O
Twenty	O
-	O
six	O
rneal	O
allgoraft	O
boipsy	O
specimnes	O
from	O
1	O
9	O
reanl	O
tarnsplant	O
pateints	O
who	O
underwent	O
transplantatinos	O
between	O
1991	O
and	O
1993	O
were	O
evaulated	O
.	O

Thirteen	O
biposies	O
were	O
performed	O
from	O
stalbe	O
funtcioning	O
rneal	O
allogarfts	O
with	O
informed	O
cnosent	O
(	O
nonepisode	O
biospy	O
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dysfunctoinal	O
reanl	O
allgorafts	O
with	O
a	O
cilnical	O
indciation	O
for	O
biposy	O
(	O
epsiode	O
biposy	O
)	O
.	O

RSEULTS	O
:	O
The	O
main	O
pathoolgic	O
diagonses	O
(	O
some	O
oevrlap	O
)	O
were	O
actue	O
reejction	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chroinc	O
rjeection	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recrurent	O
IgA	B-Disease
nephroptahy	I-Disease
(	O
n	O
=	O
5	O
)	O
,	O
nomral	O
finidngs	O
(	O
n	O
=	O
2	O
)	O
,	O
miinmal	O
-	O
tpye	O
chornic	O
FK056	O
nephorpathy	B-Disease
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mlid	O
-	O
tpye	O
F5K06	O
nephrpoathy	B-Disease
(	O
n	O
=	O
11	O
)	O
.	O

Of	O
the	O
nonepisode	O
biopseis	O
,	O
7	O
and	O
4	O
biopises	O
showed	O
mniimal	O
-	O
tpye	O
and	O
mlid	O
-	O
tpye	O
chroinc	O
FK056	O
nehpropathy	B-Disease
,	O
respectively	O
.	O

Chornic	O
FK056	O
npehropathy	B-Disease
consisted	O
of	O
rough	O
and	O
fomay	O
tuublar	O
vacuolizaiton	O
(	O
5	O
biospies	O
)	O
,	O
arteriolpoathy	O
(	O
angiodeegneration	O
of	O
the	O
arteroilar	O
wlal	O
;	O
20	O
biopises	O
)	O
,	O
foacl	B-Disease
semgental	I-Disease
glomerulosclersois	I-Disease
(	O
4	O
biopseis	O
)	O
and	O
the	O
striepd	O
form	O
of	O
intrestitial	B-Disease
firbosis	I-Disease
(	O
11	O
biposies	O
)	O
.	O

The	O
sreum	O
creatniine	O
lveels	O
of	O
pateints	O
in	O
the	O
mlid	O
-	O
tpye	O
crhonic	O
FK056	O
nephorpathy	B-Disease
gorup	O
,	O
which	O
included	O
7	O
eipsode	O
biopseis	O
,	O
were	O
statistically	O
hgiher	O
than	O
those	O
in	O
the	O
minimum	O
-	O
tpye	O
crhonic	O
FK056	O
-	O
neprhopathy	B-Disease
gorup	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONLCUSIONS	O
:	O
This	O
stduy	O
demonstrates	O
that	O
crhonic	O
F5K06	O
nephroapthy	B-Disease
consists	O
primarily	O
of	O
arterioloptahy	O
manifesting	O
as	O
insudaitve	O
hylainosis	O
of	O
the	O
arterioalr	O
wlal	O
,	O
and	O
suggests	O
that	O
mlid	O
-	O
tpye	O
crhonic	O
F5K06	O
nephrpoathy	B-Disease
is	O
a	O
condiiton	O
which	O
may	O
lead	O
to	O
deteroiration	O
of	O
reanl	O
allogarft	O
fnuction	O
.	O

Different	O
lboular	O
distributoins	O
of	O
altreed	O
hepatoycte	O
tihgt	O
junctinos	O
in	O
rat	O
modles	O
of	O
intrahpeatic	B-Disease
and	I-Disease
extrahpeatic	I-Disease
cholestsais	I-Disease
.	O

Heaptocyte	O
tgiht	O
junctoins	O
(	O
TJs	O
)	O
,	O
the	O
only	O
intrecellular	O
brarier	O
between	O
the	O
sinusoiadl	O
and	O
the	O
canlaicular	O
spcaes	O
,	O
play	O
a	O
key	O
role	O
in	O
blie	O
foramtion	O
.	O

Although	O
hepaotcyte	O
TJs	O
are	O
impiared	O
in	O
choletsasis	B-Disease
,	O
attempts	O
to	O
lcoalize	O
the	O
precise	O
stie	O
of	O
hepatoctye	O
TJ	O
dmaage	O
by	O
fereze	O
-	O
fractrue	O
eelctron	O
micrsocopy	O
have	O
produced	O
limtied	O
ifnormation	O
.	O

Recently	O
,	O
several	O
TJ	O
-	O
associated	O
protenis	O
like	O
ZO	O
-	O
1	O
and	O
7H6	O
have	O
been	O
idnetified	O
and	O
characteirzed	O
.	O

Immunolocailzation	O
of	O
7H6	O
appears	O
to	O
closely	O
corerlate	O
with	O
paracellular	O
permeabliity	O
.	O

We	O
used	O
rat	O
modles	O
of	O
intrhaepatic	B-Disease
cholestaiss	I-Disease
by	O
etihnyl	O
estardiol	O
(	O
EE	O
)	O
tretament	O
and	O
extarhepatic	B-Disease
cohlestasis	I-Disease
by	O
blie	O
dcut	O
ligatoin	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
stie	O
of	O
TJ	O
dmaage	O
.	O

Alteratinos	O
in	O
hpeatocyte	O
TJs	O
were	O
assessed	O
by	O
double	O
-	O
immunolabelnig	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
using	O
a	O
conofcal	O
lsaer	O
sacnning	O
microscpoe	O
.	O

In	O
cnotrol	O
rtas	O
,	O
immunostaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
colocalzied	O
to	O
outline	O
blie	O
canailculi	O
in	O
a	O
contniuous	O
fashion	O
.	O

In	O
contrast	O
,	O
7H6	O
and	O
ZO	O
-	O
1	O
immunostainnig	O
was	O
more	O
disconitnuous	O
,	O
outlining	O
the	O
blie	O
canaliclui	O
after	O
BDL	O
.	O

Imumnostaining	O
for	O
7H6	O
,	O
not	O
ZO	O
-	O
1	O
,	O
dcereased	O
and	O
predominantly	O
appeared	O
as	O
discerte	O
signlas	O
in	O
the	O
submebmranous	O
ctyoplasm	O
of	O
preiportal	O
heptaocytes	O
after	O
BDL	O
.	O

After	O
EE	O
traetment	O
,	O
chanegs	O
in	O
immunosatining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
peirportal	O
heaptocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
difufsely	O
throughout	O
the	O
loblue	O
.	O

This	O
stduy	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
ipmairment	O
of	O
hepatoycte	O
TJs	O
occurs	O
heterogenosuly	O
in	O
the	O
lievr	O
louble	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	O
teratments	O
produce	O
different	O
lboular	O
distributinos	O
of	O
incresaed	O
paraecllular	O
permeabiilty	O
.	O

Memroy	O
facilitaiton	O
and	O
stimulaiton	O
of	O
endogeonus	O
nreve	O
gorwth	O
fatcor	O
snythesis	O
by	O
the	O
acetyclholine	O
releaesr	O
PG	O
-	O
9	O
.	O

The	O
effects	O
of	O
PG	O
-	O
9	O
(	O
3alpha	O
-	O
tropyl	O
2	O
-	O
(	O
p	O
-	O
bromohpenyl	O
)	O
propiontae	O
)	O
,	O
the	O
acteylcholine	O
releaesr	O
,	O
on	O
memroy	O
prcoesses	O
and	O
nevre	O
grwoth	O
facotr	O
(	O
NGF	O
)	O
synthseis	O
were	O
evaulated	O
.	O

In	O
the	O
mosue	O
pasisve	O
-	O
avoidnace	O
tset	O
,	O
PG	O
-	O
9	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
administreed	O
20	O
min	O
before	O
the	O
traniing	O
ssesion	O
,	O
prevented	O
amneisa	B-Disease
induecd	O
by	O
both	O
the	O
non	O
selective	O
antiumscarinic	O
durg	O
scopolmaine	O
and	O
the	O
M1	O
-	O
selective	O
antagonsit	O
S	O
-	O
(	O
-	O
)	O
-	O
ET	O
-	O
126	O
.	O

In	O
the	O
same	O
exeprimental	O
condtiions	O
,	O
PG	O
-	O
9	O
(	O
5	O
-	O
20	O
mircog	O
per	O
muose	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
also	O
able	O
to	O
prevnet	O
antimuscraine	O
-	O
induecd	O
amensia	B-Disease
,	O
demonstrating	O
a	O
cenrtal	O
localizaiton	O
of	O
the	O
atcivity	O
.	O

At	O
the	O
highest	O
effectvie	O
dsoes	O
,	O
PG	O
-	O
9	O
did	O
not	O
produce	O
any	O
colltaeral	O
sympotms	O
as	O
reevaled	O
by	O
the	O
Irwin	O
tset	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontanoeus	O
moitlity	O
and	O
inpsection	O
actiivty	O
,	O
as	O
reevaled	O
by	O
the	O
hloe	O
-	O
baord	O
tset	O
.	O

PG	O
-	O
9	O
was	O
also	O
able	O
to	O
inrcease	O
the	O
aomunt	O
of	O
NGF	O
serceted	O
in	O
vitro	O
by	O
astrcoytes	O
in	O
a	O
dsoe	O
-	O
deepndent	O
manner	O
.	O

The	O
maixmal	O
NGF	O
contetns	O
obtained	O
by	O
PG	O
-	O
9	O
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
cotnrol	O
value	O
.	O

During	O
cluture	O
,	O
no	O
morpholgoical	O
chnages	O
were	O
found	O
at	O
effective	O
concetnrations	O
of	O
PG	O
-	O
9	O
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG	O
-	O
9	O
to	O
inudce	O
beneficial	O
effects	O
on	O
cognitvie	O
proecsses	O
and	O
sitmulate	O
acitvity	O
of	O
NGF	O
snythesis	O
in	O
astrgolial	O
clels	O
.	O

Therefore	O
,	O
PG	O
-	O
9	O
could	O
represent	O
a	O
ptoential	O
useful	O
durg	O
able	O
to	O
imrpove	O
the	O
funciton	O
of	O
impaierd	O
cogniitve	O
proecsses	O
.	O

Mechanimss	O
of	O
FK	O
506	O
-	O
idnuced	O
hyperetnsion	B-Disease
in	O
the	O
rat	O
.	O

-	O
Tacrloimus	O
(	O
FK	O
506	O
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunousppressant	O
.	O

The	O
cliniacl	O
utility	O
of	O
FK	O
506	O
is	O
comlpicated	O
by	O
substantial	O
hyeprtension	B-Disease
and	O
nephrotoxciity	B-Disease
.	O

To	O
clarify	O
the	O
mechainsms	O
of	O
FK	O
506	O
-	O
induecd	O
hypretension	B-Disease
,	O
we	O
studied	O
the	O
crhonic	O
efefcts	O
of	O
FK	O
506	O
on	O
the	O
synthseis	O
of	O
endotehlin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
,	O
the	O
exprsesion	O
of	O
mNRA	O
of	O
ET	O
-	O
1	O
and	O
endtohelin	O
-	O
converting	O
eznyme	O
-	O
1	O
(	O
ECE	O
-	O
1	O
)	O
,	O
the	O
endotehlial	O
ntiric	O
oixde	O
synhtase	O
(	O
eONS	O
)	O
actviity	O
,	O
and	O
the	O
expression	O
of	O
mNRA	O
of	O
eONS	O
and	O
C	O
-	O
tpye	O
natruiretic	O
petpide	O
(	O
CNP	O
)	O
in	O
rat	O
bolod	O
vsesels	O
.	O

In	O
addition	O
,	O
the	O
efefct	O
of	O
the	O
specific	O
endtohelin	O
tpye	O
A	O
recpetor	O
anatgonist	O
FR	O
139317	O
on	O
FK	O
506	O
-	O
idnuced	O
hypretension	B-Disease
in	O
rtas	O
was	O
studied	O
.	O

FK	O
506	O
,	O
5	O
mg	O
.	O

kg	O
-	O
1	O
.	O

d	O
-	O
1	O
given	O
for	O
4	O
weeks	O
,	O
elevaetd	O
blood	O
perssure	O
from	O
102	O
+	O
/	O
-	O
13	O
to	O
152	O
+	O
/	O
-	O
15	O
mm	O
Hg	O
and	O
increaesd	O
the	O
synhtesis	O
of	O
ET	O
-	O
1	O
and	O
the	O
levles	O
of	O
ET	O
-	O
1	O
mNRA	O
in	O
the	O
mseenteric	O
atrery	O
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O

Little	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
ECE	O
-	O
1	O
mNRA	O
and	O
CNP	O
mNRA	O
.	O

FK	O
506	O
decreaesd	O
eONS	O
acitvity	O
and	O
the	O
levles	O
of	O
eONS	O
mNRA	O
in	O
the	O
aotra	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O

The	O
admiinstration	O
of	O
FR	O
139317	O
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
.	O
d	O
-	O
1	O
)	O
prevented	O
FK	O
506	O
-	O
inudced	O
hypertensoin	B-Disease
in	O
rtas	O
.	O

These	O
reuslts	O
indicate	O
that	O
FK	O
506	O
may	O
icnrease	O
blood	O
prsesure	O
not	O
only	O
by	O
icnreasing	O
ET	O
-	O
1	O
prodcution	O
but	O
also	O
by	O
decraesing	O
NO	O
syntheiss	O
in	O
the	O
vasculatrue	O
.	O

